Publications
2026
76770
IP6F4TRX
2026
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22SP67MJAP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Zeoli%20et%20al.%22%2C%22parsedDate%22%3A%222026-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZeoli%20A%2C%20Ranadive%20P%2C%20Ville%20R%2C%20Castillo-Rozas%20G%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Veloso%20VG%2C%20et%20al.%20Trends%20in%20Incidence%20and%20Risk%20Factors%20of%20HIV-Associated%20Disseminated%20Histoplasmosis%20in%20the%20Americas%3A%20An%20Observational%20Cohort%20Study.%20J%20Int%20AIDS%20Soc.%202026%20Jul%3B29%287%29%3Ae70160.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70160%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70160%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042427064%3B%20PubMed%20Central%20PMCID%3A%20PMC13351113.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Trends%20in%20Incidence%20and%20Risk%20Factors%20of%20HIV-Associated%20Disseminated%20Histoplasmosis%20in%20the%20Americas%3A%20An%20Observational%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashley%22%2C%22lastName%22%3A%22Zeoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paridhi%22%2C%22lastName%22%3A%22Ranadive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Ville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Castillo-Rozas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juli%5Cu00e1n%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Histoplasmosis%20remains%20a%20significant%20cause%20of%20morbidity%20and%20mortality%20in%20people%20with%20HIV%20.%20We%20examined%20disseminated%20histoplasmosis%20incidence%2C%20risk%20factors%2C%20and%20outcomes%20from%20North%20and%20South%20American%20HIV%20clinical%20sites.%5CnMETHODS%3A%20Cohorts%20from%20Brazil%2C%20Chile%2C%20Honduras%2C%20Mexico%2C%20Peru%20and%20the%20United%20States%20%28Tennessee%29%20contributed%20data%20on%20PLWH%20%5Cu226518%20years%20old%20from%202000%20to%202021.%20Stratifying%20by%20US%20and%20Latin%20American%20cohorts%2C%20we%20examined%20diagnosed%20disseminated%20histoplasmosis%20incidence%20and%20risk%20factors%20with%20modified%20Poisson%20regression%20models.%20Cox%20proportional%20hazard%20models%20examined%20factors%20associated%20with%20mortality%20after%20histoplasmosis.%5CnRESULTS%3A%20Of%2026%2C672%20people%20with%20HIV%20%28Latin%20America%20n%20%3D%2019%2C836%3B%20United%20States%20n%20%3D%206836%29%2C%20214%20had%20incident%20histoplasmosis%28Latin%20America%5Cu00a0n%20%3D%20140%3B%20United%20States%20n%20%3D%2074%29.%20From%202000%20to%202021%2C%20histoplasmosis%20incidence%20decreased%20from%2016.08%20to%200.93%20in%20Latin%20America%20and%2013.4%20to%200.67%20per%201000%20person-years%20in%20the%20United%20States.%20In%20Latin%20America%2C%20histoplasmosis%20risk%20was%20higher%20for%20males%20%28aRR%20%3D%202.50%20%5B95%25%20CI%3A%201.62-3.86%5D%29%2C%20pre-antiretroviral%20therapy%20initiation%20%28aRR%20%3D%207.76%20%5B95%25%20CI%3A%205.05-11.90%5D%29%20and%20those%20who%20had%20migrated%20from%20a%20histoplasma-endemic%20country%20%28aRR%20%3D%206.12%20%5B95%25%20CI%3A%201.81-20.69%5D%29.%20Risk%20was%20also%20higher%20for%20older%20people%20with%20HIV%2C%20those%20with%20low%20CD4%2C%20earlier%20calendar%20year%20and%20differed%20by%20site.%20In%20the%20United%20States%2C%20risk%20was%20higher%20in%20people%20with%20HIV%20with%20low%20CD4%2C%20higher%20HIV%20viral%20load%2C%20earlier%20calendar%20year%20and%20pre-antiretroviral%20therapy%20initiation%20%28aRR%20%3D%202.65%20%5B95%25%20CI%3A%201.11-6.36%5D%29.%20Mortality%20after%20histoplasmosis%20was%20higher%20in%20people%20with%20HIV%20with%20an%20earlier%20year%20of%20histoplasmosis%202000%20versus%202010%20%28aHR%20%3D%202.00%20%5B95%25%20CI%3A%201.26-3.17%5D%29%20and%20among%20those%20who%20developed%20histoplasmosis%20after%20antiretroviral%20therapy%20initiation%20compared%20to%20before%20antiretroviral%20therapy%20%28aHR%20%3D%202.66%20%5B95%25%20CI%3A%201.43-4.95%5D%29.%5CnCONCLUSIONS%3A%20Despite%20concern%20for%20underdiagnosis%20of%20disseminated%20histoplasmosis%20in%20Latin%20America%2C%20its%20incidence%20in%20people%20with%20HIV%20decreased%2C%20as%20it%20did%20in%20the%20United%20States.%20Low%20CD4%20cell%20count%20and%20time%20before%20antiretroviral%20therapy%20initiation%20remain%20strongly%20associated%20with%20histoplasmosis%20risk.%20Further%20attention%20to%20early%20HIV%20diagnosis%20and%20treatment%20is%20needed.%22%2C%22date%22%3A%222026-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.70160%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242427064%22%2C%22PMCID%22%3A%22PMC13351113%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A42%3A01Z%22%7D%7D%2C%7B%22key%22%3A%225J584U46%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castilho%20et%20al.%22%2C%22parsedDate%22%3A%222026-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastilho%20JL%2C%20Duda%20SN%2C%20Shepherd%20BE%2C%20Sterling%20TR%2C%20Person%20AK%2C%20Rebeiro%20PF%2C%20et%20al.%20The%20Caribbean%2C%20Central%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%3A%2020%20Years%20of%20HIV%20Research%20in%20the%20Region.%20J%20Int%20AIDS%20Soc.%202026%20Jul%3B29%20Suppl%203%28Suppl%203%29%3Ae70169.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70169%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70169%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042502244%3B%20PubMed%20Central%20PMCID%3A%20PMC13401697.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Caribbean%2C%20Central%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%3A%2020%20Years%20of%20HIV%20Research%20in%20the%20Region%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20C.%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20R.%22%2C%22lastName%22%3A%22Koethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesse%22%2C%22lastName%22%3A%22Carlson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachael%20A.%22%2C%22lastName%22%3A%22Pellegrino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karu%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hilary%20Vansell%22%2C%22lastName%22%3A%22Riley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20Garcia%20De%20Matos%22%2C%22lastName%22%3A%22Amaral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20Cruvinel%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paridhi%22%2C%22lastName%22%3A%22Ranadive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vickie%22%2C%22lastName%22%3A%22Myers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%22%2C%22lastName%22%3A%22Burgess%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengxin%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liping%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danni%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhouhui%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaixing%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronaldo%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%20Derrico%22%2C%22lastName%22%3A%22Pedrosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Pia%20Diniz%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20Sergio%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20Moreira%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thiago%20Silva%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%22%2C%22lastName%22%3A%22Coutinho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayara%20Secco%20Torres%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flaviana%20Pavan%22%2C%22lastName%22%3A%22Victoriano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavia%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelle%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Bocardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Caporali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavia%22%2C%22lastName%22%3A%22Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateus%22%2C%22lastName%22%3A%22Westin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20C%5Cu00e9lia%20de%20Menezes%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aida%20de%20F%5Cu00e1tima%20Barbosa%22%2C%22lastName%22%3A%22Gouv%5Cu00eaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabiana%22%2C%22lastName%22%3A%22Bononi%20do%20Carmo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Fernanda%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Castillo-Rozas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabio%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgina%22%2C%22lastName%22%3A%22Estadella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20William%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adias%22%2C%22lastName%22%3A%22Marcelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jodany%22%2C%22lastName%22%3A%22Bernadin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%22%2C%22lastName%22%3A%22Cadet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magda%22%2C%22lastName%22%3A%22Chavez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ada%22%2C%22lastName%22%3A%22Mailhot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20Nu%5Cu00f1ez%22%2C%22lastName%22%3A%22Mochizaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20Crabtree%22%2C%22lastName%22%3A%22Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Sierra%22%2C%22lastName%22%3A%22Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%20Caro%22%2C%22lastName%22%3A%22Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c1lvaro%20L%5Cu00f3pez%22%2C%22lastName%22%3A%22I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Fernanda%20Ramos%22%2C%22lastName%22%3A%22Menchelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20Alarc%5Cu00f3n%22%2C%22lastName%22%3A%22Murra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geovanna%22%2C%22lastName%22%3A%22Coello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guadalupe%20Mu%5Cu00f1uzuri%22%2C%22lastName%22%3A%22N%5Cu00e1jera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%20Ville%22%2C%22lastName%22%3A%22Benavides%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Mej%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T%5Cu00e1vata%22%2C%22lastName%22%3A%22Bejarano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Sierra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florencia%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Aristegui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Ines%22%2C%22lastName%22%3A%22Figueroa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Doudtchitzky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Mariani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariela%22%2C%22lastName%22%3A%22Ceschel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gissella%22%2C%22lastName%22%3A%22Mernies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agustin%22%2C%22lastName%22%3A%22Nava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Latin%20America%20is%20a%20key%20region%20in%20advancing%20efforts%20to%20end%20the%20HIV%20epidemic%20globally.%20Despite%20breakthroughs%20in%20HIV%20treatment%20and%20prevention%20in%20the%20last%2020%20years%2C%20as%20well%20as%20region-wide%20improvements%20in%20health%20infrastructure%20and%20policies%2C%20there%20has%20been%20a%2013%25%20increase%20in%20new%20acquisitions%20in%20Latin%20America%20from%202010%20to%202024.%20The%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%2C%20established%20in%202006%2C%20is%20one%20of%20seven%20regions%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29.%20CCASAnet%20contributes%20substantially%20to%20regional%20science%20and%20the%20development%20of%20national%20and%20region-wide%20policies.%20Here%2C%20we%20describe%20data%20sources%20and%20operational%20methodologies%20employed%20by%20CCASAnet%2C%20as%20well%20as%20the%20current%20state%20of%20the%20cohort.%5CnMETHODS%3A%20CCASAnet%20data%20are%20collected%20using%20standardized%20data%20elements%2C%20including%20demographic%20information%2C%20HIV%20disease%20history%2C%20laboratory%20data%2C%20antiretroviral%20regimens%2C%20co-infections%20and%20comorbidities.%20Data%20collection%20has%20expanded%20to%20include%20prospective%20data%20such%20as%20substance%20use%2C%20antiretroviral%20therapy%20adherence%2C%20geriatric%20syndromes%20and%20tuberculosis%20treatment.%20All%20clinical%20sites%20retain%20ownership%20of%20their%20data%2C%20and%20CCASAnet%20data%20contribute%20as%20able%20to%20global%20IeDEA-level%20projects.%20Robust%20data%20quality%20initiatives%20and%20statistical%20methods%20have%20strengthened%20the%20cohort.%5CnRESULTS%3A%20CCASAnet%20consists%20of%20nine%20clinics%20across%20seven%20countries%20%28Argentina%2C%20Brazil%2C%20Chile%2C%20Haiti%2C%20Honduras%2C%20Mexico%20and%20Peru%29.%20Over%2061%2C000%20adults%20and%20children%20living%20with%20HIV%20have%20contributed%20observational%20data%20through%20December%202023.%20While%20CD4%20at%20enrolment%20has%20remained%20largely%20unchanged%2C%20time%20to%20antiretroviral%20therapy%20initiation%20has%20decreased%2C%20retention%20in%20care%20has%20improved%20and%20the%20proportion%20with%20undetectable%20HIV%20RNA%20has%20dramatically%20increased.%20Co-infections%20and%20AIDS-defining%20malignancies%20remain%20a%20cause%20of%20morbidity%20and%20mortality%2C%20but%20non-communicable%20diseases%20have%20also%20increased.%20Overall%20mortality%20trends%20in%20the%20region%20have%20improved%20over%20time%2C%20with%20some%20notable%20exceptions.%5CnCONCLUSIONS%3A%20Underscoring%20the%20importance%20of%20maintaining%20longitudinal%20collaborations%20and%20data%20collection%2C%20CCASAnet%20remains%20the%20largest%20source%20of%20high-quality%20data%20for%20HIV%20epidemiology%20in%20Latin%20America%20and%20serves%20as%20an%20important%20evidence%20base%20for%20informing%20global%20and%20regional%20policy%20and%20stakeholder%20decisions%20related%20to%20the%20HIV%20epidemic.%22%2C%22date%22%3A%222026-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.70169%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242502244%22%2C%22PMCID%22%3A%22PMC13401697%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-27T19%3A03%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22JV6XYH8W%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Liang%20et%20al.%22%2C%22parsedDate%22%3A%222026-06-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLiang%20ZJ%2C%20Li%20Z%2C%20Jackson%20NJ%2C%20Guo%20KH%2C%20Caro-Vega%20Y%2C%20Moreira%20RI%2C%20et%20al.%20Generating%20synthetic%20multi-national%20longitudinal%20cohorts%20for%20clinically%20grounded%20HIV%20research.%20Nat%20Commun.%202026%20Jun%2022.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-026-74492-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-026-74492-0%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042331823.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Generating%20synthetic%20multi-national%20longitudinal%20cohorts%20for%20clinically%20grounded%20HIV%20research%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuohui%20J.%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuohang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20J.%22%2C%22lastName%22%3A%22Jackson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20H.%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronaldo%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabio%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordany%22%2C%22lastName%22%3A%22Bernadin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Blasimme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20M.%22%2C%22lastName%22%3A%22Perkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amir%22%2C%22lastName%22%3A%22Asiaee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20A.%22%2C%22lastName%22%3A%22Malin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Yan%22%7D%5D%2C%22abstractNote%22%3A%22High-quality%2C%20widely%20accessible%20international%20longitudinal%20cohort%20data%20for%20people%20living%20with%20HIV%20%28PWH%29%20have%20long%20been%20needed%20for%20advancing%20open%20science%20and%20data-driven%20innovation%2C%20yet%20stringent%20and%20incongruent%20privacy%20regulations%20have%20made%20data%20sharing%20difficult.%20Synthetic%20data%20generation%20offers%20a%20promising%20privacy-preserving%20alternative%2C%20but%20producing%20realistic%20synthetic%20cohorts%20of%20PWH%20remains%20challenging%20due%20to%20complex%20temporal%20dynamics%2C%20interdependent%20clinical%20variables%2C%20long%20follow-up%20periods%2C%20and%20high%20missingness%20inherent%20in%20such%20data.%20Here%2C%20we%20introduce%20Medical%20Longitudinal%20latent%20Diffusion%20%28MeLD%29%2C%20a%20generative%20model%20designed%20to%20synthesize%20variable-length%2C%20decades-spanning%2C%20mixed-type%20clinical%20trajectories%20with%20missingness.%20Using%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%20cohort%2C%20one%20of%20the%20world%26%23039%3Bs%20largest%20international%20HIV%20datasets%20with%20over%2030%20years%20of%20follow-up%20on%20nearly%2050%2C000%20PWH%2C%20we%20show%20that%20MeLD%20consistently%20outperforms%20state-of-the-art%20methods%20across%20data%20utility%2C%20fidelity%2C%20and%20privacy.%20Notably%2C%20MeLD%20excels%20in%20longitudinal%20inference%20utility%2C%20accurately%20reproducing%20time-to-death%20estimates%20and%20risk%20factor%20effects%2C%20while%20maintaining%20strong%20privacy%20protection.%20This%20work%20delivers%20an%20in-depth%2C%20large-scale%2C%20and%20openly%20accessible%20synthetic%20longitudinal%20cohort%20of%20PWH%20that%20faithfully%20preserves%20the%20distributional%20patterns%20and%20clinical%20associations%20observed%20in%20real%20data%2C%20offering%20an%20immediately%20deployable%20resource%20for%20hypothesis%20generation%2C%20methods%20innovation%2C%20training%2C%20and%20reproducible%20HIV%20research.%22%2C%22date%22%3A%222026-06-22%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41467-026-74492-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242331823%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222041-1723%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A41%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22JAPWNS7E%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Luque%20et%20al.%22%2C%22parsedDate%22%3A%222026-05-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLuque%20MT%2C%20Du%20L%2C%20Rouzier%20V%2C%20Machado%20DM%2C%20Pinto%20J%2C%20Shepherd%20BE%2C%20et%20al.%20Use%20of%20Integrase%20Strand%20Transfer%20Inhibitors%20Among%20Children%20Living%20With%20HIV%20in%20Latin%20America%20and%20the%20Caribbean.%20Pediatr%20Infect%20Dis%20J.%202026%20May%2022.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000005281%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000005281%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042168824.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20Integrase%20Strand%20Transfer%20Inhibitors%20Among%20Children%20Living%20With%20HIV%20in%20Latin%20America%20and%20the%20Caribbean%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liping%22%2C%22lastName%22%3A%22Du%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Limited%20data%20exist%20on%20integrase%20strand%20transfer%20inhibitor%20%28INSTI%29%20use%20among%20children.%20We%20assessed%20dolutegravir%20%28DTG%29%20and%20raltegravir%20%28RAL%29%20use%20and%20outcomes%20among%20Latin%20American%20and%20Caribbean%20children%20with%20HIV.%5CnMETHODS%3A%20Cohorts%20from%20Brazil%2C%20Haiti%20and%20Honduras%20contributed%20data%20for%20children%20%28age%20%26lt%3B18%20years%29%20receiving%20care%20since%20the%20widespread%20availability%20of%20DTG%20and%20RAL%20%28approximately%202013-2022%29.%20Trends%20and%20factors%20associated%20with%20INSTI%20%28DTG%5C%2FRAL%29%20initiation%20were%20examined%20using%20multivariable%20logistic%20and%20Cox%20regression%20models%20among%20antiretroviral%20therapy%20%28ART%29-na%5Cu00efve%20and%20-experienced%20children%2C%20respectively.%20We%20compared%20viral%20and%20treatment%20outcomes%20among%20ART-na%5Cu00efve%20children%20by%20INSTI%20use%20with%20log-rank%20tests.%5CnRESULTS%3A%20Among%20ART-na%5Cu00efve%20children%2C%2077%5C%2F110%20started%20DTG%2C%205%5C%2F109%20started%20RAL%20and%2091%20started%20other%20ART.%20The%20proportion%20of%20ART-na%5Cu00efve%20children%20initiating%20DTG%20increased%20from%200%25%20in%202016%20to%2093%25%20%2813%5C%2F14%29%20in%202022.%20Starting%20DTG%20was%20more%20likely%20in%20older%20ART-na%5Cu00efve%20children%20and%20in%20more%20recent%20calendar%20years%20%28P%20%5Cu2264%200.01%29.%20Among%20ART-experienced%20children%2C%20122%5C%2F273%20switched%20to%20DTG%2C%20and%2025%5C%2F288%20switched%20to%20RAL.%20More%20recent%20calendar%20year%20and%20a%20greater%20number%20of%20prior%20ART%20regimens%20were%20associated%20with%20a%20higher%20incidence%20of%20switch%20to%20DTG%20and%20RAL%20%28P%20%26lt%3B%200.01%29.%20There%20was%20no%20statistical%20difference%20in%20virologic%20suppression%20among%20ART-na%5Cu00efve%20children%20by%20use%20or%20non-use%20of%20DTG%3B%20however%2C%20children%20started%20on%20DTG%20had%20a%20longer%20duration%20of%20the%20first%20regimen%20than%20those%20started%20on%20other%20ART%20%28P%20%26lt%3B%200.01%29.%5CnCONCLUSIONS%3A%20INSTI%20use%20among%20children%20has%20increased%20in%20parts%20of%20Latin%20American%20And%20Caribbean.%20As%20more%20children%20start%20INSTI%20regimens%2C%20further%20research%20is%20needed%20on%20their%20clinical%20impact.%22%2C%22date%22%3A%222026-05-22%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FINF.0000000000005281%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242168824%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-0987%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A41%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22ZPMKIG2Y%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Caro-Vega%20et%20al.%22%2C%22parsedDate%22%3A%222026-05-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCaro-Vega%20Y%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Hern%26%23xE1%3Bndez-Ruiz%20V%2C%20Mosqueda%20JL%2C%20Avila-Funes%20JA.%20Sex%20disparities%20in%20geriatric%20syndromes%20among%20people%2050%20years%20or%20older%20receiving%20care%20for%20HIV%20infection%20in%20Mexico%20%282012-2017%29%3A%20a%20cross-sectional%2C%20observational%20study.%20J%20Gerontol%20A%20Biol%20Sci%20Med%20Sci.%202026%20May%207%3B81%286%29%3Aglag107.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fgerona%5C%2Fglag107%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fgerona%5C%2Fglag107%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042018736.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex%20disparities%20in%20geriatric%20syndromes%20among%20people%2050%20years%20or%20older%20receiving%20care%20for%20HIV%20infection%20in%20Mexico%20%282012-2017%29%3A%20a%20cross-sectional%2C%20observational%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virgilio%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez-Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Luis%22%2C%22lastName%22%3A%22Mosqueda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20A.%22%2C%22lastName%22%3A%22Avila-Funes%22%7D%5D%2C%22abstractNote%22%3A%22We%20compared%20the%20frequency%20of%20geriatric%20syndromes%20and%20comorbidities%20between%20women%20and%20men%20over%2050%5Cu2009years%20of%20age%20receiving%20HIV%20care%20in%20Mexico%20and%20explore%20their%20associated%20characteristics.%20This%20cross-sectional%20study%20was%20conducted%20from%202012%20to%202017%20in%20Mexico.%20We%20assessed%20non-communicable%20diseases%20%28NCDs%29%2C%20disability%2C%20depressive%20symptoms%2C%20neurocognitive%20impairment%2C%20frailty%2C%20polypharmacy%2C%20falls%2C%20and%20visual%20and%20hearing%20impairment.%20We%20compared%20the%20prevalence%20of%20these%20syndromes%20by%20sex.%20We%20fitted%20multivariate%20logistic%20models%20to%20identify%20the%20association%20of%20sex%20with%20the%20presence%20of%20NCDs%20and%20geriatric%20syndromes.%20We%20enrolled%20616%20participants%2C%20including%20114%20%2818.5%25%29%20women.%20Women%20were%20older%20%28median%2057%20vs%2056%20years%20old%2C%20p%5Cu2009%3D%5Cu2009.032%29%20and%20had%20lower%20educational%20attainment%20%286%20vs%2012%5Cu2009years%2C%20p%5Cu2009%26lt%3B%5Cu2009.001%29%20than%20men.%20There%20were%20no%20sex%20differences%20in%20current%20viral%20suppression%20%2886%25%20vs%2085%25%2C%20p%5Cu2009%3D%5Cu2009.78%29%20and%20median%20CD4%20cell%20counts%20%28508%20vs%20458%2C%20p%5Cu2009%3D%5Cu2009.27%29.%20Women%20had%20a%20higher%20prevalence%20of%20any%20NCDs%20%2867%25%20vs%2055%25%2C%20p%5Cu2009%3D%5Cu2009.02%29%2C%20falls%3A%20%2844%25%20vs%2026%25%2C%20p%5Cu2009%26lt%3B%5Cu2009.001%29%2C%20depressive%20symptoms%20%2815%25%20vs%207.6%25%2C%20p%5Cu2009%3D%5Cu2009.02%29%2C%20and%20frailty%20%289.6%25%20vs%203.2%25%2C%20p%5Cu2009%3D%5Cu2009.047%29%20than%20men.%20In%20adjusted%20analyses%2C%20women%20had%20higher%20odds%20of%20frailty%20%28aOR%204.38%2C%2095%25%20CI%2C%201.7-11.0%2C%20p%5Cu2009%3D%5Cu2009.01%29%2C%20falls%20%28aOR%3A%201.97%2C%2095%25%20CI%2C%201.18-3.28%2C%20p%5Cu2009%26lt%3B%5Cu2009.01%29%2C%20NCDs%20%28aOR%3A%202.03%2C%2095%25%20CI%2C%201.27-3.23%2C%20p%5Cu2009%26lt%3B%5Cu2009.01%29%20and%20depression%20%28aOR%3A%202.35%2C%2095%25%20CI%2C%201.17-4.61%2C%20p%5Cu2009%26lt%3B%5Cu2009.01%29.%20Older%20women%20living%20with%20HIV%20in%20Mexico%20experience%20a%20high%20prevalence%20of%20overweight%5C%2Fobesity%2C%20falls%2C%20comorbidity%2C%20depressive%20symptoms%2C%20frailty%2C%20and%20disability%20disproportionately%20affect%20women.%20Women%20were%20at%20higher%20risk%20of%20frailty%2C%20falls%2C%20comorbidity%2C%20and%20depressive%20symptoms%2C%20independently%20of%20age%2C%20current%20CD4%20cell%20counts%2C%20and%20education%20level.%22%2C%22date%22%3A%222026-05-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fgerona%5C%2Fglag107%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242018736%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221758-535X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A41%3A41Z%22%7D%7D%2C%7B%22key%22%3A%229SZ7IAPW%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Kuniholm%20et%20al.%22%2C%22parsedDate%22%3A%222026-05-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKuniholm%20MH%2C%20Murenzi%20G%2C%20Samala%20N%2C%20Yunihastuti%20E%2C%20Wandeler%20G%2C%20Kim%20HN%2C%20et%20al.%20Hepatitis%20B%20and%20C%20Prevention%2C%20Screening%20and%20Diagnostic%20Services%20at%20HIV%20Treatment%20Sites%3A%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS.%20J%20Acquir%20Immune%20Defic%20Syndr.%202026%20May%205.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003896%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003896%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042086340%3B%20PubMed%20Central%20PMCID%3A%20PMC13334928.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hepatitis%20B%20and%20C%20Prevention%2C%20Screening%20and%20Diagnostic%20Services%20at%20HIV%20Treatment%20Sites%3A%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niharika%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evy%22%2C%22lastName%22%3A%22Yunihastuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Nina%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohan%22%2C%22lastName%22%3A%22Bopage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Lo%20Re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22L%5Cu00f3pez-I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20M.%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dewi%20K.%22%2C%22lastName%22%3A%22Wati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20P.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20D.%22%2C%22lastName%22%3A%22Kirk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20V.%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20A.%22%2C%22lastName%22%3A%22Yendewa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20C.%20M.%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Prevention%2C%20screening%20and%20diagnostic%20services%20for%20hepatitis%20B%20virus%20%28HBV%29%20and%20hepatitis%20C%20virus%20%28HCV%29%20can%20prevent%20morbidity%20and%20mortality%20in%20people%20receiving%20HIV%20care.%20However%2C%20there%20is%20limited%20information%20about%20the%20availability%20of%20HBV%20and%20HCV%20services%20at%20HIV%20clinics%20globally.%5CnMETHODS%3A%20The%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20conducted%20surveys%20of%20service%20delivery%20and%20practices%20at%20participating%20HIV%20treatment%20centers%20from%20seven%20regions.%20We%20used%202023%20survey%20data%20to%20measure%20availability%20of%20HBV%20vaccination%2C%20HBV%20and%20HCV%20screening%2C%20HBV%20surface%20antigen%20%28HBsAg%29%2C%20HBV%20DNA%2C%20HCV%20antibody%2C%20HCV%20RNA%20testing.%20Multivariable%20logistic%20regression%20models%20were%20used%20to%20test%20associations%20of%20site%20characteristics%20with%20HBV%20and%20HCV%20services.%5CnRESULTS%3A%20HBV%20vaccination%20was%20available%20on-site%20at%2067.7%25%20of%20204%20HIV%20treatment%20sites.%20Screening%20for%20HBV%20and%20HCV%20at%20HIV%20care%20enrollment%20was%20reported%20by%2072.1%25%20and%2050%25%20of%20sites%2C%20respectively.%20HBsAg%2C%20HBV%20DNA%2C%20HCV%20antibody%20and%20HCV%20RNA%20testing%20were%20available%20on-site%20at%2077%25%2C%2047.6%25%2C%2061.8%25%20and%2044.6%25%20of%20sites%2C%20respectively.%20Sites%20serving%20predominately%20rural%20%28vs.%20urban%29%20populations%20were%20less%20likely%20to%20report%20on-site%20availability%20of%20HBV%20DNA%20%28odds%20ratio%20%28OR%29%3A0.07%3B%2095%25%20confidence%20interval%20%28CI%29%3A0.01-0.68%3BP%3D0.02%29%2C%20HCV%20antibody%20%28OR%3D0.18%3B%2095%25%20CI%3A0.04-0.92%3BP%3D0.04%29%20and%20HCV%20RNA%20%28OR%3D0.10%3B%2095%25%20CI%3A0.01-0.90%3BP%3D0.04%29%20testing.%5CnCONCLUSION%3A%20Life-saving%20services%20such%20as%20HBV%20vaccination%2C%20HBsAg%20and%20HCV%20antibody%20testing%20were%20available%20on-site%20at%20most%20HIV%20treatment%20sites%20participating%20in%20the%20IeDEA%20network.%20Lower%20availability%20at%20rural%20sites%20suggests%20that%20expansion%20of%20services%20is%20important%20to%20eliminate%20HBV%20and%20HCV%20as%20public%20health%20problems%20in%20people%20receiving%20HIV%20care.%22%2C%22date%22%3A%222026-05-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003896%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242086340%22%2C%22PMCID%22%3A%22PMC13334928%22%2C%22ISSN%22%3A%221944-7884%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A40%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22R9QW7RQ4%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22van%20Dongen%20et%20al.%22%2C%22parsedDate%22%3A%222026-04-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3Bvan%20Dongen%20N%2C%20Technau%20KG%2C%20Jaguga%20F%2C%20Murenzi%20G%2C%20Machado%20DM%2C%20Amorissani-Folquet%20M%2C%20et%20al.%20Under%20the%20Influence%3A%20Alcohol%2C%20Substance%20Use%20and%20Treatment%20Adherence%20in%20Youth%20Living%20with%20HIV%20in%20the%20Global%20Adolescent%20and%20Young%20Adult%20Network%20of%20IeDEA%20%28AYANI%29%20Cohort.%20AIDS%20Behav.%202026%20Apr%2021.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-026-05127-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-026-05127-0%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2042012631.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Under%20the%20Influence%3A%20Alcohol%2C%20Substance%20Use%20and%20Treatment%20Adherence%20in%20Youth%20Living%20with%20HIV%20in%20the%20Global%20Adolescent%20and%20Young%20Adult%20Network%20of%20IeDEA%20%28AYANI%29%20Cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22van%20Dongen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Jaguga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%22%2C%22lastName%22%3A%22Ditango%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fiona%22%2C%22lastName%22%3A%22Mureithi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brittany%22%2C%22lastName%22%3A%22McCoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thanyawee%22%2C%22lastName%22%3A%22Phuthanakit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batya%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gladis%22%2C%22lastName%22%3A%22Oka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tukiya%22%2C%22lastName%22%3A%22Kanguya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Ryumugabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevieve%22%2C%22lastName%22%3A%22Hilaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%22%2C%22lastName%22%3A%22Brehm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22Alcohol%20and%20substance%20use%20in%20youth%20living%20with%20HIV%20%28YLHIV%29%20can%20influence%20health%20and%20treatment%20outcomes.%20We%20assessed%20substance%20use%20and%20associations%20with%20antiretroviral%20therapy%20%28ART%29%20adherence%20among%20YLHIV.%20The%20Adolescent%20and%20Young%20Adult%20Network%20of%20IeDEA%20enrolled%20YLHIV%20%2815%5Cu201324%20years%20old%29%20receiving%20ART%20%282021%5Cu20132024%29%20from%206%20global%20regions.%20We%20assessed%20biopsychosocial%20experiences%20with%20validated%20tools%3B%20adherence%20with%20self-reported%20missed%20medication%20doses%20and%20unsuppressed%20viral%20load%20%28VL%5Cu2009%26gt%3B%5Cu20091%2C000%20copies%5C%2Fml%29%3B%20and%20substance%20use%20by%20point-of-care%20urine%20tests%20and%20Alcohol%2C%20Smoking%20and%20Substance%20Involvement%20Screening%20Test%20%28ASSIST%29%20tool.%20Among%20694%20YLHIV%2C%2053%25%20female%2C%20median%20enrolment%2020%20years%20old%20%28IQR%2018%5Cu201322%29%2C%2083%25%20had%20perinatally-acquired%20HIV%2C%20and%2071%25%20received%20Integrase%20Inhibitor-based%20ART.%20Half%20%2849%25%29%20reported%20missing%20medication%20doses%20and%2014%25%20had%20unsuppressed%20VL.%20Any%20prior%20alcohol%20use%20%2847%25%29%20was%20more%20common%20than%20other%20substances%2C%20where%20cannabis%20%2812%25%29%20and%20sedatives%5C%2Fbenzodiazepines%20%283.9%25%29%20contributed.%20Recent%20moderate%5C%2Fhigh-risk%20alcohol%20and%20other%20substance%20use%20were%20reported%20by%209.1%25%20of%20YLHIV.%20YLHIV%20with%20positive%20urine%20tests%20had%20not%20reported%20recent%20use%20of%20alcohol%20%28n%5Cu2009%3D%5Cu200917%5C%2F46%3B%2037%25%29%2C%20cannabis%20%28n%5Cu2009%3D%5Cu200912%5C%2F32%3B%2038%25%29%20and%20benzodiazepines%20%28n%5Cu2009%3D%5Cu200913%5C%2F13%2C%20100%25%29.%20Moderate%5C%2Fhigh-risk%20alcohol%20and%20other%20substance%20use%20were%20associated%20with%20self-reported%20adherence%20difficulties%20%28adjusted%20odds%20ratio%28aOR%29%202.37%2C%2095%25%20CI%201.28%5Cu20134.38%3B%20and%20aOR%202.13%2C%2095%25%20CI%201.18%5Cu20133.85%29%20but%20not%20unsuppressed%20VL%20%28aOR%200.80%2C%2095%25%20CI%200.34%5Cu20131.88%3B%20and%20aOR%201.61%2C%2095%25%20CI%200.79%5Cu20133.29%29.%20Moderate%5C%2Fhigh-risk%20alcohol%20and%5C%2For%20substance%20use%20was%20reported%20by%2015%25%20of%20YLHIV%20and%20was%20associated%20with%20self-reported%20adherence%20difficulties.%20Discrepancies%20between%20point-of-care%20tests%20and%20self-reported%20use%20suggest%20alcohol%5C%2Fsubstance%20use%20is%20underestimated.%20Enhanced%20screening%20and%20interventions%20targeting%20substance%20use%20are%20recommended.%22%2C%22date%22%3A%222026-04-21%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-026-05127-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2242012631%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221573-3254%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A40%3A56Z%22%7D%7D%2C%7B%22key%22%3A%2298WS27P9%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pellegrino%20et%20al.%22%2C%22parsedDate%22%3A%222026-04-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPellegrino%20RA%2C%20Shepherd%20BE%2C%20Pujari%20S%2C%20Fink%20V%2C%20Murenzi%20G%2C%20Nakalembe%20M%2C%20et%20al.%20Availability%20of%20Cancer%20Screening%20Across%20HIV%20Treatment%20Sites%20in%20the%20IeDEA%20Consortium.%20Int%20J%20Cancer.%202026%20Apr%2016.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70503%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70503%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041992467.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20of%20Cancer%20Screening%20Across%20HIV%20Treatment%20Sites%20in%20the%20IeDEA%20Consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachael%20A.%22%2C%22lastName%22%3A%22Pellegrino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Nakalembe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%20B.%22%2C%22lastName%22%3A%22Coburn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Lade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lesley%20S.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Limpho%22%2C%22lastName%22%3A%22Mokone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%20Ketut%20Agus%22%2C%22lastName%22%3A%22Somia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omenge%22%2C%22lastName%22%3A%22Orang%27o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumbirai%20Pise%22%2C%22lastName%22%3A%22Quarter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chad%20J.%22%2C%22lastName%22%3A%22Achenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22Cancer%20remains%20a%20leading%20cause%20of%20morbidity%20and%20mortality%20in%20people%20with%20HIV%2C%20and%20the%20importance%20of%20cancer%20screening%20increases%20as%20this%20population%20ages.%20In%202017%2C%202020%2C%20and%202023%2C%20cross-sectional%20surveys%20were%20conducted%20at%20HIV%20care%20sites%20across%205%20continents%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20We%20described%20cancer%20screening%20availability%20in%202023%20and%20over%20time%20for%20cervical%20and%20anal%20cancer%20screening%20using%20generalized%20estimating%20equations%20with%20a%20logit%20link%20function%20to%20account%20for%20site%20clustering%2C%20rurality%2C%20and%20country%20income.%20Of%20the%20220%20sites%20in%20the%202023%20survey%2C%2061%25%20%28134%5C%2F220%29%20reported%20cervical%20cancer%20screening%20by%20cytology%20or%20human%20papillomavirus%20%28HPV%29%20testing%20on-site%2C%20and%2088%25%20%28194%5C%2F220%29%20reported%20cervical%20cancer%20screening%20by%20any%20method%2C%20including%20visual%20inspection.%20At%20sites%20serving%20predominantly%20rural%20populations%2C%2062%25%20%2829%5C%2F47%29%20exclusively%20performed%20screening%20by%20visual%20inspection.%20Overall%2C%2023%25%20%2850%5C%2F220%29%20of%20sites%20performed%20cytology-based%20anal%20cancer%20screening%20on-site%2C%20and%2016%25%20%2835%5C%2F220%29%20had%20availability%20of%20high-resolution%20anoscopy%2C%20either%20on-site%20or%20by%20referral.%20Screening%20for%20cancer%20of%20the%20liver%2C%20colon%2C%20lung%2C%20prostate%2C%20or%20breast%20%28by%20imaging%29%20were%20each%20available%20at%20less%20than%2043%25%20of%20sites.%20The%20odds%20of%20cervical%20cancer%20screening%20availability%20increased%20by%2016%25%20annually%20from%202017%20through%202023%20%28aOR%5Cu2009%3D%5Cu20091.16%2C%2095%25%20CI%3A%201.07-1.27%2C%20p%5Cu2009%3D%5Cu20090.001%29%2C%20while%20the%20relative%20odds%20of%20anal%20cancer%20screening%20availability%20decreased%20by%209%25%20annually%20%28aOR%5Cu2009%3D%5Cu20090.91%2C%2095%25%20CI%3A%200.84-0.99%2C%20p%5Cu2009%3D%5Cu20090.023%29.%20Lack%20of%20trained%20staff%20was%20the%20most%20frequently%20reported%20barrier%2C%20followed%20by%20lack%20of%20equipment.%20Understanding%20current%20practices%20and%20capacity%20is%20essential%20for%20the%20continued%20integration%20of%20cancer%20prevention%20in%20HIV%20care.%22%2C%22date%22%3A%222026-04-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.70503%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241992467%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A40%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22ZEMH96WV%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Jackson%20et%20al.%22%2C%22parsedDate%22%3A%222026-03-27%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJackson%20NJ%2C%20Yan%20C%2C%20Caro-Vega%20Y%2C%20Paredes%20F%2C%20Moreira%20RI%2C%20Cadet%20S%2C%20et%20al.%20Federated%20Learning%20Performance%20Depends%20on%20Site%20Variation%20in%20Global%20HIV%20Data%20Consortia.%20medRxiv.%202026%20Mar%2027%3B2026.03.25.26349286.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.64898%5C%2F2026.03.25.26349286%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.64898%5C%2F2026.03.25.26349286%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041929305%3B%20PubMed%20Central%20PMCID%3A%20PMC13042089.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Federated%20Learning%20Performance%20Depends%20on%20Site%20Variation%20in%20Global%20HIV%20Data%20Consortia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20J.%22%2C%22lastName%22%3A%22Jackson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Yan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabio%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronaldo%20Ismerio%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%22%2C%22lastName%22%3A%22Cadet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20A.%22%2C%22lastName%22%3A%22Malin%22%7D%5D%2C%22abstractNote%22%3A%22Digital%20health%20technologies%2C%20including%20machine%20learning%20%28ML%29%2C%20are%20transforming%20infectious%20disease%20management%2C%20however%20ML%20models%20for%20HIV%20care%20have%20been%20limited%20by%20data%20sharing%20restrictions%20that%20prevent%20multi-site%20collaboration.%20Federated%20Learning%20%28FL%29%20offers%20a%20privacy-preserving%20solution%2C%20enabling%20cross-site%20model%20training%20without%20sharing%20patient-level%20data.%20We%20evaluated%20FL%20for%20developing%20clinical%20prediction%20models%20using%20data%20from%2022%2C234%20people%20living%20with%20HIV%20%28PLWH%29%20across%20six%20sites%20in%20five%20countries%20within%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29.%20Across%20four%20prediction%20tasks%20-%201-year%20mortality%2C%203-year%20mortality%2C%20tuberculosis%20incidence%2C%20and%20AIDS-defining%20cancer%20incidence%20-%20FL%20algorithms%20achieved%20near-centralized%20performance%20while%20substantially%20outperforming%20site-specific%20models.%20Performance%20gains%20varied%20across%20sites%2C%20driven%20by%20both%20site%20size%20and%20between-site%20heterogeneity.%20Local%20fine-tuning%20often%20improved%20FL%20performance%2C%20though%20benefits%20were%20task%20dependent.%20These%20findings%20support%20FL%20as%20a%20scalable%2C%20privacy-preserving%20infrastructure%20for%20multi-site%20ML%20in%20international%20HIV%20research.%22%2C%22date%22%3A%222026-03-27%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.64898%5C%2F2026.03.25.26349286%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241929305%22%2C%22PMCID%22%3A%22PMC13042089%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A41%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22YKWLW3MP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222026-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Duda%20SN%2C%20Ross%20J%2C%20Semeere%20AS%2C%20Tiendrebeogo%20T%2C%20Chimbetete%20C%2C%20et%20al.%20Impact%20of%20US%20government%20funding%20freezes%20on%20the%20HIV%20response%3A%20findings%20from%20a%20rapid%20survey%20in%2032%20countries.%20Health%20Aff%20Sch.%202026%20Feb%3B4%282%29%3Aqxag020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fhaschl%5C%2Fqxag020%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fhaschl%5C%2Fqxag020%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041732341%3B%20PubMed%20Central%20PMCID%3A%20PMC12925645.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20US%20government%20funding%20freezes%20on%20the%20HIV%20response%3A%20findings%20from%20a%20rapid%20survey%20in%2032%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20S.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20After%20the%20freezing%20of%20US%20foreign%20assistance%20in%20January%202025%2C%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20conducted%20a%20rapid%20survey%20among%20clinics%20and%20programs%20actively%20participating%20in%20the%20research%20consortium%20to%20assess%20the%20status%20of%20HIV-related%20service%20delivery%20in%20mid-2025.%5CnMETHODS%3A%20In%20June-July%202025%2C%20an%20online%20survey%20was%20distributed%20to%20103%20IeDEA-participating%20clinics%5C%2Fprograms%20in%2041%20countries%20in%20sub-Saharan%20Africa%2C%20Latin%20America%20and%20the%20Caribbean%2C%20and%20Asia-Pacific.%20Survey%20domains%20included%20US%20funding-related%20disruptions%20in%20service%20delivery%2C%20medication%20availability%2C%20laboratory%20services%2C%20clinic%20operations%2C%20and%20attendant%20mitigation%20strategies.%20Responses%20were%20received%20from%2076%5C%2F103%20%2874%25%29%20clinics%5C%2Fprograms%20in%2032%5C%2F41%20%2878%25%29%20countries.%20Descriptive%20statistics%20were%20used%20to%20characterize%20disruptions%20in%20HIV-related%20care%20and%20mitigation%20measures.%5CnRESULTS%3A%20Almost%20half%20of%20responding%20sites%20reported%20disruptions%20in%20HIV-related%20services%20%2847%25%29%20since%20January%202025%2C%20along%20with%20disruptions%20in%20medication%20availability%20%2828%25%29%2C%20laboratory%20services%20%2834%25%29%2C%20and%20non-research%20clinic%20operations%20%2847%25%29.%20Among%20those%20reporting%20disruptions%20in%20HIV-related%20services%2C%20only%2014%25%20reported%20that%20all%20disruptions%20were%20fully%20resolved%20at%20the%20time%20of%20the%20survey.%5CnCONCLUSION%3A%20Given%20anticipated%20reductions%20in%20global%20HIV%20funding%2C%20government-%20and%20community-led%20monitoring%20of%20HIV%20prevention%20and%20treatment%20services%20and%20care%20outcomes%20are%20critical%20for%20informing%20national%20responses%20and%20averting%20reversal%20of%20progress%20in%20ending%20the%20epidemic.%22%2C%22date%22%3A%222026-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fhaschl%5C%2Fqxag020%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241732341%22%2C%22PMCID%22%3A%22PMC12925645%22%2C%22ISSN%22%3A%222976-5390%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22FF5LPAML%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Schmutz%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-27%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSchmutz%20R%2C%20Banholzer%20N%2C%20Shearer%20K%2C%20Golub%20JE%2C%20Cortes%20CP%2C%20Messou%20E%2C%20et%20al.%20The%20implementation%20of%20tuberculosis%20preventive%20therapy%20in%20HIV%20care%20clinics%20in%20Africa%2C%20Asia%20and%20Latin%20America%3A%20a%20multiregional%20site%20survey.%20BMJ%20Glob%20Health.%202026%20Jan%2027%3B11%281%29%3Ae018469.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2024-018469%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2024-018469%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041592909%3B%20PubMed%20Central%20PMCID%3A%20PMC12853508.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20implementation%20of%20tuberculosis%20preventive%20therapy%20in%20HIV%20care%20clinics%20in%20Africa%2C%20Asia%20and%20Latin%20America%3A%20a%20multiregional%20site%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remo%22%2C%22lastName%22%3A%22Schmutz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Banholzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kate%22%2C%22lastName%22%3A%22Shearer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20E.%22%2C%22lastName%22%3A%22Golub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nana%22%2C%22lastName%22%3A%22Mbonze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Musaazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anggraini%22%2C%22lastName%22%3A%22Alam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cordelia%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Zannou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dickman%22%2C%22lastName%22%3A%22Gareta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Komena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20Sarita%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samyra%20R.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20global%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Towards%20the%20%26%23039%3BEnd%20TB%20Strategy%26%23039%3B%20targets%2C%20the%20WHO%20recommends%20the%20provision%20of%20tuberculosis%20%28TB%29%20preventive%20therapy%20%28TPT%29%20for%20high-risk%20groups%20including%20people%20living%20with%20HIV%20%28PLWH%29.%203%20years%20after%20the%20release%20of%20the%20updated%202020%20WHO%20guidelines%2C%20we%20investigated%20the%20implementation%20of%20TPT%20services%20at%20HIV%20clinics%20in%20low-income%20and%20middle-income%20countries%20%28LMICs%29%2C%20focusing%20on%20TB%20screening%2C%20populations%20eligible%20for%20TPT%20and%20available%20TPT%20regimens.%5CnMETHODS%3A%20In%202023%2C%20we%20surveyed%20HIV%20care%20clinics%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%20in%20Africa%2C%20the%20Asia-Pacific%20and%20Latin%20America%20and%20the%20Caribbean.%20We%20used%20descriptive%20statistics%20to%20summarise%20TPT%20implementation%20according%20to%20WHO%20guidelines%20and%20multivariable%20logistic%20regression%20models%20to%20estimate%20associations%20with%20clinic%20characteristics.%5CnRESULTS%3A%20Of%20172%20HIV%20clinics%20included%2C%20142%20%2883%25%29%20were%20in%20Africa%2C%2022%20%2813%25%29%20in%20the%20Asia-Pacific%20and%208%20%285%25%29%20in%20Latin%20America%3B%20108%20%2863%25%29%20were%20located%20in%20urban%20areas.%20After%20ruling%20out%20active%20TB%2C%20TPT%20was%20reportedly%20offered%20to%20PLWH%20%28122%20clinics%2C%2071%25%29%2C%20household%20contacts%20of%20individuals%20with%20active%20TB%20%28120%20clinics%2C%2070%25%29%20and%20other%20high-risk%20populations.%20TPT%20for%20PLWH%20was%20more%20frequently%20available%20in%20clinics%20in%20lower-income%20and%20low-middle-income%20countries%2C%20in%20high%20TB%20burden%20countries%2C%20and%20in%20district%20hospitals%20compared%20with%20other%20facility%20types.%20Clinics%20reported%20use%20of%20isoniazid-based%20%28160%20clinics%2C%2093%25%29%20and%20shorter%20rifamycin-based%20%28129%20clinics%2C%2075%25%29%20TPT%20regimens.%20Reported%20barriers%20to%20TPT%20initiation%20included%20patient%20refusal%20at%2071%20%2841%25%29%20and%20drug%20shortages%20at%2067%20%2839%25%29%20clinics.%5CnCONCLUSIONS%3A%20TPT%20was%20available%20at%20most%20HIV%20care%20clinics%20in%20LMICs%20but%20further%20efforts%20are%20needed%20to%20reinforce%20WHO%20recommendations%20and%20ensure%20that%20TPT%20is%20consistently%20accessible%20to%20people%20at%20higher%20risk%20of%20developing%20active%20TB%2C%20especially%20PLWH.%22%2C%22date%22%3A%222026-01-27%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgh-2024-018469%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241592909%22%2C%22PMCID%22%3A%22PMC12853508%22%2C%22ISSN%22%3A%222059-7908%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-07-23T18%3A41%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22ZXZQD82H%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Slone%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSlone%20J%2C%20Amorim%20G%2C%20Semeere%20A%2C%20Diero%20L%2C%20Otero%20L%2C%20Crabtree-Ramirez%20B%2C%20et%20al.%20Analysis%20approaches%20to%20combine%20error-prone%20data%20with%20a%20subset%20of%20validated%20data%3A%20an%20application%20to%20a%20multinational%20study%20of%20Kaposi%20sarcoma%20and%20HIV.%20Am%20J%20Epidemiol.%202026%20Jan%2022%3Bkwag015.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwag015%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwag015%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041571459.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Analysis%20approaches%20to%20combine%20error-prone%20data%20with%20a%20subset%20of%20validated%20data%3A%20an%20application%20to%20a%20multinational%20study%20of%20Kaposi%20sarcoma%20and%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%22%2C%22lastName%22%3A%22Slone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larissa%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222026-01-22%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwag015%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241571459%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221476-6256%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A37Z%22%7D%7D%5D%7D
1.
Zeoli A, Ranadive P, Ville R, Castillo-Rozas G, Belaunzarán-Zamudio PF, Veloso VG, et al. Trends in Incidence and Risk Factors of HIV-Associated Disseminated Histoplasmosis in the Americas: An Observational Cohort Study. J Int AIDS Soc. 2026 Jul;29(7):e70160. http://doi.org/10.1002/jia2.70160 PubMed PMID: 42427064; PubMed Central PMCID: PMC13351113.
1.
Castilho JL, Duda SN, Shepherd BE, Sterling TR, Person AK, Rebeiro PF, et al. The Caribbean, Central and South America Network for HIV Epidemiology: 20 Years of HIV Research in the Region. J Int AIDS Soc. 2026 Jul;29 Suppl 3(Suppl 3):e70169. http://doi.org/10.1002/jia2.70169 PubMed PMID: 42502244; PubMed Central PMCID: PMC13401697.
1.
Liang ZJ, Li Z, Jackson NJ, Guo KH, Caro-Vega Y, Moreira RI, et al. Generating synthetic multi-national longitudinal cohorts for clinically grounded HIV research. Nat Commun. 2026 Jun 22. http://doi.org/10.1038/s41467-026-74492-0 PubMed PMID: 42331823.
1.
Luque MT, Du L, Rouzier V, Machado DM, Pinto J, Shepherd BE, et al. Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean. Pediatr Infect Dis J. 2026 May 22. http://doi.org/10.1097/INF.0000000000005281 PubMed PMID: 42168824.
1.
Caro-Vega Y, Belaunzarán-Zamudio PF, Hernández-Ruiz V, Mosqueda JL, Avila-Funes JA. Sex disparities in geriatric syndromes among people 50 years or older receiving care for HIV infection in Mexico (2012-2017): a cross-sectional, observational study. J Gerontol A Biol Sci Med Sci. 2026 May 7;81(6):glag107. http://doi.org/10.1093/gerona/glag107 PubMed PMID: 42018736.
1.
Kuniholm MH, Murenzi G, Samala N, Yunihastuti E, Wandeler G, Kim HN, et al. Hepatitis B and C Prevention, Screening and Diagnostic Services at HIV Treatment Sites: International epidemiology Databases to Evaluate AIDS. J Acquir Immune Defic Syndr. 2026 May 5. http://doi.org/10.1097/QAI.0000000000003896 PubMed PMID: 42086340; PubMed Central PMCID: PMC13334928.
1.
van Dongen N, Technau KG, Jaguga F, Murenzi G, Machado DM, Amorissani-Folquet M, et al. Under the Influence: Alcohol, Substance Use and Treatment Adherence in Youth Living with HIV in the Global Adolescent and Young Adult Network of IeDEA (AYANI) Cohort. AIDS Behav. 2026 Apr 21. http://doi.org/10.1007/s10461-026-05127-0 PubMed PMID: 42012631.
1.
Pellegrino RA, Shepherd BE, Pujari S, Fink V, Murenzi G, Nakalembe M, et al. Availability of Cancer Screening Across HIV Treatment Sites in the IeDEA Consortium. Int J Cancer. 2026 Apr 16. http://doi.org/10.1002/ijc.70503 PubMed PMID: 41992467.
1.
Jackson NJ, Yan C, Caro-Vega Y, Paredes F, Moreira RI, Cadet S, et al. Federated Learning Performance Depends on Site Variation in Global HIV Data Consortia. medRxiv. 2026 Mar 27;2026.03.25.26349286. http://doi.org/10.64898/2026.03.25.26349286 PubMed PMID: 41929305; PubMed Central PMCID: PMC13042089.
1.
Brazier E, Duda SN, Ross J, Semeere AS, Tiendrebeogo T, Chimbetete C, et al. Impact of US government funding freezes on the HIV response: findings from a rapid survey in 32 countries. Health Aff Sch. 2026 Feb;4(2):qxag020. http://doi.org/10.1093/haschl/qxag020 PubMed PMID: 41732341; PubMed Central PMCID: PMC12925645.
1.
Schmutz R, Banholzer N, Shearer K, Golub JE, Cortes CP, Messou E, et al. The implementation of tuberculosis preventive therapy in HIV care clinics in Africa, Asia and Latin America: a multiregional site survey. BMJ Glob Health. 2026 Jan 27;11(1):e018469. http://doi.org/10.1136/bmjgh-2024-018469 PubMed PMID: 41592909; PubMed Central PMCID: PMC12853508.
1.
Slone J, Amorim G, Semeere A, Diero L, Otero L, Crabtree-Ramirez B, et al. Analysis approaches to combine error-prone data with a subset of validated data: an application to a multinational study of Kaposi sarcoma and HIV. Am J Epidemiol. 2026 Jan 22;kwag015. http://doi.org/10.1093/aje/kwag015 PubMed PMID: 41571459.
2025
76770
IP6F4TRX
2025
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22DVW5BFB9%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Plaisy%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPlaisy%20MK%2C%20Mondoka%20C%2C%20Moreira%20R%2C%20Samala%20N%2C%20Borse%20R%2C%20Kuniholm%20MH%2C%20et%20al.%20Diagnostic%20value%20of%20serological%20scores%20for%20the%20detection%20of%20liver%20steatosis%20in%20people%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries.%20AIDS.%202025%20Dec%2030.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004434%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004434%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041467701.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20value%20of%20serological%20scores%20for%20the%20detection%20of%20liver%20steatosis%20in%20people%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlotta%22%2C%22lastName%22%3A%22Mondoka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niha%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohidas%22%2C%22lastName%22%3A%22Borse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez-I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denna%22%2C%22lastName%22%3A%22Michael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinei%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fiona%22%2C%22lastName%22%3A%22Mureithi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20P.%22%2C%22lastName%22%3A%22Mivumbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dung%20T.%20H.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Sentinel%20Research%20Network%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20accuracy%20of%20Fatty%20Liver%20Index%20%28FLI%29%20and%20Hepatic%20Steatosis%20Index%20%28HSI%29%20to%20predict%20liver%20steatosis%20in%20people%20living%20with%20HIV%20%28PLWH%29%20remains%20poorly%20studied%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29.%20We%20assessed%20their%20diagnostic%20performances%20in%20a%20multiregional%20cohort.%5CnMETHODS%3A%20This%20cross-sectional%20analysis%20included%20PLWH%20aged%20%5Cu226540%5Cu200ayears%20on%20antiretroviral%20therapy%20for%20%5Cu22656%5Cu200amonths%20at%20enrolment%20%282020-2023%29%20in%20the%20Sentinel%20Research%20Network%20%28SRN%29%20of%20IeDEA%20consortium%2C%20across%2012%20HIV%20clinics%20in%20Asia-Pacific%2C%20Americas%2C%20and%20central%2C%20East%2C%20southern%20and%20West%20Africa%20regions.%20Liver%20steatosis%20was%20defined%20based%20on%20Controlled%20Attenuation%20Parameter%20%28CAP%29%20%5Cu2265248%5Cu200adB%5C%2Fm%20using%20vibration-controlled%20transient%20elastography.%20HSI%20was%20evaluated%20in%20the%20overall%20population%2C%20while%20FLI%20was%20assessed%20and%20compared%20to%20HSI%20in%20a%20subset%20of%20participants%20with%20available%20data.%20Model%20discrimination%20was%20assessed%20using%20area%20under%20the%20receiver%20operating%20characteristic%20curve%20%28AUROC%29%20and%20model%20calibration%20with%20calibration%20plots.%20A%20decision%20curve%20analysis%20was%20performed%20to%20compare%20their%20clinical%20utility.%5CnRESULTS%3A%20Among%202%2C195%20PLWH%20assessed%20using%20CAP%2C%20624%20%2828.4%25%29%20presented%20with%20liver%20steatosis.%20HSI%20showed%20acceptable%20discriminative%20ability%20%28AUROC%5Cu200a%3D%5Cu200a0.74%29%20but%20poor%20calibration%2C%20generally%20overestimating%20the%20risk%2C%20except%20in%20Asia-Pacific%20region.%20FLI%20performed%20better%20than%20HSI%20%28AUROC%5Cu200a%3D%5Cu200a0.80%2C%20p%20%5Cu200a%26lt%3B%5Cu200a0.001%29%2C%20and%20demonstrated%20good%20calibration%20except%20in%20sub-Saharan%20Africa.%20Both%20scores%20showed%20high%20clinical%20utility%2C%20with%20FLI%20demonstrating%20a%20greater%20net%20benefit%20when%20compared%20with%20HSI.%5CnCONCLUSION%3A%20FLI%20demonstrated%20higher%20accuracy%20and%20clinical%20utility%20within%20a%20subgroup%20of%20regions.%20However%2C%20the%20limited%20performance%20of%20FLI%20and%20HSI%20in%20sub-Saharan%20populations%20highlights%20the%20need%20to%20adapt%20existing%20tools%20or%20develop%20new%20predictive%20models%20tailored%20to%20regional%20contexts.%22%2C%22date%22%3A%222025-12-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000004434%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241467701%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22GAQY4PDG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Sobral%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-22%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSobral%20L%2C%20Arriaga%20MB%2C%20Souza%20AB%2C%20Barreto-Duarte%20B%2C%20Garcia-Rosa%20BS%2C%20Fernandes%20CD%2C%20et%20al.%20Mycobacterium%20tuberculosis%20transmission%20among%20child%20and%20adolescent%20contacts%20of%20people%20with%20pulmonary%20tuberculosis%20in%20Brazil%3A%20a%20multi-center%20prospective%20cohort%20study.%20BMC%20Infect%20Dis.%202025%20Dec%2022%3B25%281%29%3A1789.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-025-12268-5%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12879-025-12268-5%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041430120%3B%20PubMed%20Central%20PMCID%3A%20PMC12750610.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20tuberculosis%20transmission%20among%20child%20and%20adolescent%20contacts%20of%20people%20with%20pulmonary%20tuberculosis%20in%20Brazil%3A%20a%20multi-center%20prospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciana%22%2C%22lastName%22%3A%22Sobral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%20S.%22%2C%22lastName%22%3A%22Garcia-Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catarina%20D.%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Cristina%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Children%20who%20are%20contacts%20of%20individuals%20with%20active%20pulmonary%20tuberculosis%20%28PTB%29%20are%20at%20risk%20of%20acquiring%20Mycobacterium%20tuberculosis%20infection%20%28TBI%29.%20We%20evaluated%20the%20determinants%20of%20TBI%20in%20child%20and%20adolescent%20contacts.%5CnMETHODS%3A%20Pediatric%20%28%5Cu2264%5Cu200918%20years%20old%29%20close%20contacts%20of%20PTB%20patients%20enrolled%20in%20a%20multi-center%20Brazilian%20observational%20cohort%20were%20followed%20up%20to%206%20months.%20Clinical%20evaluation%2C%20radiographic%20examination%2C%20and%20interferon%20gamma%20release%20assay%20%28IGRA%29%20were%20performed.%20Positive%20IGRA%20result%20at%20baseline%20or%20month%206%20%28IGRA-conversion%29%20was%20considered%20an%20indicator%20of%20TBI.%20Multivariable%20mixed-effects%20logistic%20regressions%20were%20performed%20to%20identify%20factors%20associated%20with%20TBI.%5CnRESULTS%3A%20Among%20562%20close%20contacts%20enrolled%2C%20171%20%2830.4%25%29%20had%20a%20positive%20IGRA%20at%20baseline%2C%20and%2037%20%289.5%25%29%20converted%20at%20month%206.%20Positive%20AFB%2C%20persistent%20cough%20and%20cavity%20on%20chest%20X-ray%20of%20TB%20index%20were%20independently%20associated%20with%20a%20positive%20IGRA%20result%20at%20baseline.%20IGRA-conversion%20was%20independently%20associated%20with%20older%20age%20among%20contacts%20and%20chest%20X-ray%20cavitations%20in%20the%20index%20cases.%20Contacts%5Cu2009%5Cu2265%5Cu200915.9%20years%20old%20had%203.4%20%2895%25CI%3A%201.49%5Cu20137.78%2C%20p%5Cu2009%3D%5Cu20090.004%29%20adjusted%20odds%20ratio%20of%20IGRA-conversion%20than%20those%5Cu2009%26lt%3B%5Cu200915.9%20years%20old.%5CnCONCLUSION%3A%20Among%20pediatric%20close%20TB%20contacts%2C%20the%20prevalence%20of%20IGRA%20positivity%20increased%20with%20age.%20Older%20children%20have%20substantially%20higher%20susceptibility%20to%20TBI%20upon%20exposure.%5CnSUPPLEMENTARY%20INFORMATION%3A%20The%20online%20version%20contains%20supplementary%20material%20available%20at%2010.1186%5C%2Fs12879-025-12268-5.%22%2C%22date%22%3A%222025-12-22%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12879-025-12268-5%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241430120%22%2C%22PMCID%22%3A%22PMC12750610%22%2C%22ISSN%22%3A%221471-2334%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22IY6J6BBL%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pan%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPan%20Z%2C%20Brazier%20E%2C%20Duda%20SN%2C%20Ross%20J%2C%20Templeton%20DJ%2C%20Pujari%20S%2C%20et%20al.%20Limited%20user%20fees%20for%20adult%20HIV%20diagnosis%20and%20routine%20laboratory%20monitoring%20in%20the%20global%20IeDEA%20consortium%3A%20analysis%20in%2042%20countries.%20medRxiv.%202025%20Dec%207%3B2025.12.05.25341715.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.64898%5C%2F2025.12.05.25341715%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.64898%5C%2F2025.12.05.25341715%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041404269%3B%20PubMed%20Central%20PMCID%3A%20PMC12704637.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20user%20fees%20for%20adult%20HIV%20diagnosis%20and%20routine%20laboratory%20monitoring%20in%20the%20global%20IeDEA%20consortium%3A%20analysis%20in%2042%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhongzhe%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Templeton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Pujari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20C.%22%2C%22lastName%22%3A%22Zalla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20M.%22%2C%22lastName%22%3A%22Galiwango%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romanee%22%2C%22lastName%22%3A%22Chaiwarith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raynell%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chido%22%2C%22lastName%22%3A%22Chinogurei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%20O.%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22van%20Dongen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cordoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathleen%22%2C%22lastName%22%3A%22McGinnis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethel%22%2C%22lastName%22%3A%22Rambiki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20D.%22%2C%22lastName%22%3A%22Kimmel%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20While%20HIV%20services%20have%20scaled%20up%20dramatically%20under%20universal%20treatment%20recommendations%2C%20availability%20of%20routine%20laboratory%20services%20for%20HIV%20diagnosis%20and%20management%2C%20and%20the%20extent%20to%20which%20user%20fees%20are%20charged%20for%20these%20services%2C%20are%20not%20well%20documented.%20We%20described%20site-level%20availability%20and%20user%20fees%20for%20adult%20HIV%20laboratory%20testing%20among%20238%20sites%20in%2042%20countries%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20global%20consortium%2C%20and%20contextualized%20practices%20by%20site-%20and%20country-level%20characteristics%2C%20including%20country%20income%20level%20and%20receipt%20of%20Global%20Fund%20or%20PEPFAR%20support.%5CnMETHODS%3A%20Availability%20of%20HIV-related%20laboratory%20services%20and%20charging%20of%20user%20fees%2C%20were%20examined%20via%20an%20IeDEA%20site%20assessment%20survey%20conducted%20September%202020-March%202021%2C%20with%20responses%20reflecting%20practices%20in%202019.%20Laboratory%20services%20examined%20included%3A%20HIV-1%5C%2FHIV-2%20antigen%5C%2Fantibody%20immunoassay%20test%20%28HIV-1%5C%2F2%20Ag%5C%2FAb%29%2C%20HIV-1%20p24%20antigen%20test%20%28p24%29%2C%20supplemental%20HIV-1%5C%2FHIV-2%20antibody%20differentiation%20immunoassay%20%28HIV-1%5C%2F2%20Ab%20suppl%29%2C%20quantitative%20PCR%20for%20HIV%20viral%20load%20%28VL%29%2C%20HIV-1%20genotypic%20drug%20resistance%20testing%20%28genotyping%29%2C%20and%20CD4%20count%20testing%20%28CD4%29.%20Availability%20was%20defined%20as%20provided%20on-site%20in%20the%20HIV%20clinic%20or%20within%20the%20same%20health%20facility.%20User%20fees%20were%20fees%20other%20than%20insurance%20co-pays%20paid%20for%20a%20given%20test%2C%20conditional%20on%20their%20on-site%20availability.%20We%20reported%20frequencies%20and%20percentages%20of%20site-level%20availability%20and%20user%20fees%2C%20overall%20and%20by%20site-%20and%20country-level%20characteristics.%5CnRESULTS%3A%20Most%20sites%20%2888%25%29%20reported%20HIV-1%5C%2FHIV-2%20Ag%5C%2FAb%20availability%20on-site%2C%20while%20fewer%20than%20half%20of%20sites%20reported%20having%20p24%20and%20HIV-1%5C%2F2%20Ab%20suppl%20available.%20Approximately%20half%20of%20sites%20reported%20VL%20and%20CD4%20testing%20availability%2C%20while%20less%20than%20one-third%20of%20sites%20%2828%25%29%20reported%20genotyping%20availability.%20The%20percentage%20of%20sites%20reporting%20user%20fees%20ranged%20from%206.5%25%20%28HIV-1%5C%2F2%20Ag%5C%2FAb%29%20to%2010.5%25%20%28CD4%29.%20A%20higher%20percentage%20of%20sites%20reporting%20user%20fees%20were%20from%20upper-middle%20income%20countries%2C%20countries%20receiving%20any%20Global%20Fund%20or%20any%20PEPFAR%20country%20support%2C%20and%20the%20Asia-Pacific%20region.%5CnCONCLUSIONS%3A%20While%20most%20HIV%20care%20sites%20participating%20in%20IeDEA%20did%20not%20charge%20user%20fees%20for%20HIV-related%20laboratory%20tests%20in%202019%2C%20on-site%20availability%20of%20such%20tests%20was%20limited.%20Continued%20action%20to%20identify%20and%20address%20constraints%20in%20the%20routine%20provision%20of%20these%20laboratory%20services%20is%20critical%20for%20appropriate%20management%20of%20HIV.%22%2C%22date%22%3A%222025-12-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.64898%5C%2F2025.12.05.25341715%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241404269%22%2C%22PMCID%22%3A%22PMC12704637%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22BK3EAG8U%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Amorim%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAmorim%20G%2C%20Slone%20J%2C%20Semeere%20A%2C%20Diero%20L%2C%20Otero%20L%2C%20Crabtree-Ramirez%20B%2C%20et%20al.%20Data%20validation%20in%20multinational%20observational%20studies%20with%20error-prone%20data%3A%20applying%20an%20optimal%20validation%20sampling%20strategy%20in%20a%20study%20of%20Kaposi%20sarcoma%20and%20HIV.%20Am%20J%20Epidemiol.%202025%20Nov%2025%3Bkwaf264.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwaf264%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwaf264%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041288120.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Data%20validation%20in%20multinational%20observational%20studies%20with%20error-prone%20data%3A%20applying%20an%20optimal%20validation%20sampling%20strategy%20in%20a%20study%20of%20Kaposi%20sarcoma%20and%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%22%2C%22lastName%22%3A%22Slone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larissa%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22A%20large%20multi-center%20study%20was%20conducted%20to%20investigate%20factors%20associated%20with%20Kaposi%20sarcoma%20%28KS%29%20among%20people%20with%20HIV%20%28PWH%29.%20The%20study%20used%20routinely%20collected%20%28eg%2C%20electronic%20health%20record%29%20data%20from%20257%5Cu2009429%20PWH%20in%20Latin%20America%20and%20East%20Africa.%20Although%20the%20routinely%20collected%20data%20contain%20rich%20information%20on%20key%20clinical%20and%20demographic%20variables%2C%20previous%20chart%20reviews%20of%20these%20datasets%20have%20raised%20some%20concerns%20about%20their%20accuracy.%20While%20validating%20all%20data%20is%20impractical%2C%20a%20subset%20of%20participants%26%23039%3B%20records%20can%20be%20validated%20and%20then%20combined%20with%20the%20error-prone%20data%20using%20techniques%20developed%20for%20measurement%20error%20and%20missing%20data%20problems%20to%20obtain%20consistent%20estimators%20and%20valid%20inference.%20A%20key%20step%20is%20thus%20choosing%20which%20records%20to%20validate%2C%20particularly%20with%20a%20rare%20outcome%20such%20as%20KS.%20Validated%20records%20should%20be%20informative%20for%20the%20research%20questions%2C%20while%20keeping%20the%20selection%20probabilistic%20to%20have%20results%20generalizable%20for%20the%20study%20population.%20We%20describe%20an%20optimal%20multi-wave%20validation%20procedure%20to%20internally%20validate%201000%20patient%20records%20to%20maximize%20precision%20of%20parameters%20of%20interest%20and%20better%20understand%20the%20incidence%20and%20prevalence%20of%20KS%20among%20PWH.%20We%20also%20describe%20challenges%20encountered%20with%20implementing%20the%20optimal%20validation%20design%20in%20a%20complex%20setting%20with%20a%20rare%20outcome%20and%20multiple%20study%20sites%20across%20two%20continents.%22%2C%22date%22%3A%222025-11-25%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwaf264%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241288120%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221476-6256%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22B5GSGLHM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Liang%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLiang%20ZJ%2C%20Li%20Z%2C%20Jackson%20NJ%2C%20Caro-Vega%20Y%2C%20Moreira%20RI%2C%20Paredes%20F%2C%20et%20al.%20Generating%20Synthetic%20Multi-national%20Longitudinal%20Cohorts%20for%20Clinically%20Grounded%20HIV%20Research.%20medRxiv.%202025%20Nov%2017%3B2025.11.14.25340245.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.11.14.25340245%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.11.14.25340245%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041332815%3B%20PubMed%20Central%20PMCID%3A%20PMC12668065.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Generating%20Synthetic%20Multi-national%20Longitudinal%20Cohorts%20for%20Clinically%20Grounded%20HIV%20Research%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuohui%20J.%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuohang%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%20J.%22%2C%22lastName%22%3A%22Jackson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronaldo%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabio%22%2C%22lastName%22%3A%22Paredes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordany%22%2C%22lastName%22%3A%22Bernadin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Blasimme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20M.%22%2C%22lastName%22%3A%22Perkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amir%22%2C%22lastName%22%3A%22Asiaee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20A.%22%2C%22lastName%22%3A%22Malin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chao%22%2C%22lastName%22%3A%22Yan%22%7D%5D%2C%22abstractNote%22%3A%22High-quality%2C%20widely%20accessible%20international%20longitudinal%20cohort%20data%20for%20people%20living%20with%20HIV%20%28PWH%29%20have%20long%20been%20needed%20for%20advancing%20open%20science%20and%20data-driven%20innovation%2C%20yet%20stringent%20and%20incongruent%20privacy%20regulations%20have%20made%20data%20sharing%20difficult.%20Synthetic%20data%20generation%20offers%20a%20promising%20privacy-preserving%20alternative%2C%20but%20producing%20realistic%20synthetic%20cohorts%20of%20PWH%20remains%20challenging%20due%20to%20complex%20temporal%20dynamics%2C%20interdependent%20clinical%20variables%2C%20long%20follow-up%20periods%2C%20and%20high%20missingness%20inherent%20in%20such%20data.%20Here%2C%20we%20introduce%20Medical%20Longitudinal%20latent%20Diffusion%20%28MeLD%29%2C%20a%20generative%20model%20designed%20to%20synthesize%20variable-length%2C%20decades-spanning%2C%20mixed-type%20clinical%20trajectories%20with%20missingness.%20Using%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%20cohort%2C%20one%20of%20the%20world%26%23039%3Bs%20largest%20international%20HIV%20datasets%20with%20over%2030%20years%20of%20follow-up%20on%20nearly%2050%2C000%20PWH%2C%20we%20show%20that%20MeLD%20consistently%20outperforms%20state-of-the-art%20methods%20across%20data%20utility%2C%20fidelity%2C%20and%20privacy.%20Notably%2C%20MeLD%20excels%20in%20longitudinal%20inference%20utility%2C%20accurately%20reproducing%20time-to-death%20estimates%20and%20risk%20factor%20effects%2C%20while%20maintaining%20strong%20privacy%20protection.%20This%20work%20delivers%20the%20first%20in-depth%2C%20large-scale%2C%20and%20openly%20accessible%20synthetic%20longitudinal%20cohort%20of%20PWH%20that%20faithfully%20preserves%20the%20distributional%20patterns%20and%20clinical%20associations%20observed%20in%20real%20data%2C%20offering%20an%20immediately%20deployable%20resource%20for%20hypothesis%20generation%2C%20methods%20innovation%2C%20medical%20training%2C%20and%20reproducible%20HIV%20research.%22%2C%22date%22%3A%222025-11-17%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1101%5C%2F2025.11.14.25340245%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241332815%22%2C%22PMCID%22%3A%22PMC12668065%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22N5F9J6ZS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arabadjis%20et%20al.%22%2C%22parsedDate%22%3A%222025-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArabadjis%20SD%2C%20Davenport%20F%2C%20Vecedo%20Cabrera%20AM%2C%20Shahn%20Z%2C%20Brazier%20E%2C%20Maroko%20A%2C%20et%20al.%20Modeling%20the%20Burden%20of%20Extreme%20Weather%20Events%20in%20a%20Large%20Network%20of%20International%20HIV%20Care%20Cohorts.%20Geohealth.%202025%20Nov%3B9%2811%29%3Ae2025GH001514.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1029%5C%2F2025GH001514%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1029%5C%2F2025GH001514%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041195258%3B%20PubMed%20Central%20PMCID%3A%20PMC12583239.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Modeling%20the%20Burden%20of%20Extreme%20Weather%20Events%20in%20a%20Large%20Network%20of%20International%20HIV%20Care%20Cohorts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophia%20D.%22%2C%22lastName%22%3A%22Arabadjis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Davenport%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Maria%22%2C%22lastName%22%3A%22Vecedo%20Cabrera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%22%2C%22lastName%22%3A%22Shahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Maroko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Avantika%22%2C%22lastName%22%3A%22Srivastava%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20John%22%2C%22lastName%22%3A%22Dizon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20S.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro%20Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20K.%20U.%22%2C%22lastName%22%3A%22Pasayan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheri%20D.%22%2C%22lastName%22%3A%22Weiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22Extreme%20weather%20events%20%28EWEs%29%20continue%20to%20threaten%20the%20health%20and%20well-being%20of%20populations%20across%20the%20globe.%20However%2C%20risk%20from%20drought%20and%20floods%20is%20not%20evenly%20distributed%20spatially%20nor%20are%20all%20populations%20equally%20at%20risk%20for%20poor%20health%20outcomes.%20Globally%2C%20people%20living%20with%20HIV%5C%2FAIDS%20%28PLHIV%29%20face%20a%20particular%20set%20of%20challenges%20with%20EWE%20exposure%20including%20increased%20susceptibility%20to%20disease%20progression%20from%20care%20disruptions%20and%20medication%20adherence%2C%20and%20general%20population%20concentration%20in%20areas%20where%20rainfall%20is%20both%20highly%20variable%20and%20key%20to%20economic%20well-being.%20To%20mitigate%20the%20impacts%20of%20EWE%20exposure%20on%20PLHIV%2C%20it%20is%20necessary%20to%20understand%20the%20historical%20EWE%20exposure%20patterns%20at%20HIV%20care%20clinics.%20In%20this%20paper%2C%20we%20link%20open-source%20measures%20of%20drought%20and%20flood%20events%20to%20clinic%20locations%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20network%2C%20a%20longitudinal%20study%20of%20over%202%20million%20people%20living%20with%20and%20at%20risk%20for%20HIV%20in%2044%20different%20countries%20around%20the%20globe%20enrolling%20in%20HIV%20care%20from%202006%20to%20present.%20Using%20generalized%20additive%20models%20fit%20to%20clinic-level%20drought%20and%20flood%20exposures%2C%20we%20show%20how%20exposures%20vary%20across%20and%20within%20countries%2C%20model%20each%20clinic%26%23039%3Bs%20probability%20of%20exposure%20to%20a%20drought%20or%20flood%20to%20identify%20high-risk%20areas%2C%20and%20describe%20how%20this%20historical%20exposure%20record%20could%20ultimately%20be%20used%20to%20identify%20at-risk%20populations%20for%20a%20wide%20variety%20of%20study%20designs.%20While%20EWEs%20occurred%20at%20HIV%20care%20clinics%20around%20the%20globe%2C%20we%20found%20that%20clinic%20locations%20in%20Southern%20Africa%20are%20particularly%20vulnerable%20to%20flood%20and%20drought%20events%20as%20compared%20to%20other%20IeDEA%20clinic%20regions%20and%20locations.%22%2C%22date%22%3A%222025-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1029%5C%2F2025GH001514%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241195258%22%2C%22PMCID%22%3A%22PMC12583239%22%2C%22ISSN%22%3A%222471-1403%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A37Z%22%7D%7D%2C%7B%22key%22%3A%222XGQE3IP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22He%20et%20al.%22%2C%22parsedDate%22%3A%222025-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHe%20J%2C%20Brewer%20E%2C%20Novotney%20A%2C%20Carter%20A%2C%20Paul%20H%2C%20Walters%20MK%2C%20et%20al.%20HIV-related%20mortality%20time%20trends%20among%20children%20and%20young%20adolescents%20on%20antiretroviral%20therapy%20by%20age%2C%20treatment%20duration%2C%20and%20region%3A%20a%20systematic%20review%20and%20meta-regression%20analysis.%20Lancet%20HIV.%202025%20Nov%3B12%2811%29%3Ae774%26%23×2013%3B88.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2825%2900168-7%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2825%2900168-7%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040912259%3B%20PubMed%20Central%20PMCID%3A%20PMC12774562.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-related%20mortality%20time%20trends%20among%20children%20and%20young%20adolescents%20on%20antiretroviral%20therapy%20by%20age%2C%20treatment%20duration%2C%20and%20region%3A%20a%20systematic%20review%20and%20meta-regression%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jiawei%22%2C%22lastName%22%3A%22He%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edmond%22%2C%22lastName%22%3A%22Brewer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Novotney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Austin%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hilary%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magdalene%20K.%22%2C%22lastName%22%3A%22Walters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kemal%22%2C%22lastName%22%3A%22Sherefa%20Oumer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joycelyn%22%2C%22lastName%22%3A%22Dame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reed%20J.%20D.%22%2C%22lastName%22%3A%22Sorensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%20L.%22%2C%22lastName%22%3A%22Murray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20I.%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aleksandr%22%2C%22lastName%22%3A%22Aravkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abraham%22%2C%22lastName%22%3A%22Flaxman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Zheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hmwe%20H.%22%2C%22lastName%22%3A%22Kyu%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Past%20cohort%20studies%20have%20examined%20mortality%20among%20children%20and%20young%20adolescents%20%28aged%200-14%20years%29%20who%20have%20received%20antiretroviral%20therapy%20%28ART%29%2C%20but%20no%20systematic%20reviews%20have%20been%20undertaken%20to%20synthesise%20these%20findings.%20Our%20study%20aims%20to%20provide%20the%20most%20comprehensive%20global%20estimates%20of%20paediatric%20mortality%20among%20children%20and%20adolescents%20receiving%20ART.%5CnMETHODS%3A%20For%20this%20systematic%20review%20and%20meta-regression%20analysis%2C%20we%20searched%20PubMed%20and%20Embase%20from%20Jan%201%2C%201990%20to%20July%2031%2C%202024%20for%20studies%20reporting%20mortality%20among%20children%20and%20young%20adolescents%20living%20with%20HIV%20who%20were%20on%20ART.%20We%20employed%20the%20meta-regression%20with%20Bayesian%20priors%2C%20regularisation%2C%20and%20trimming%20tool%2C%20developed%20for%20the%20Global%20Burden%20of%20Disease%20study%202019%2C%20for%20meta-regression%20analysis%20to%20estimate%20on-ART%20mortality%20by%20region%2C%20CD4%20cell%20count%20or%20percentage%2C%20age%2C%20sex%2C%20and%20treatment%20duration.%20We%20assessed%20the%20robustness%20of%20our%20results%20by%20doing%20a%20sensitivity%20analysis%2C%20restricting%20it%20to%20studies%20of%20good%20quality%20using%20the%20quality%20assessment%20tool%20adapted%20from%20the%20Newcastle-Ottawa%20Scale%20and%20the%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute.%20This%20study%20has%20been%20registered%20with%20PROSPERO%20%28CRD42022382702%29.%5CnFINDINGS%3A%20Our%20literature%20search%20identified%207588%20records%2C%20of%20which%205853%20were%20determined%20relevant%20for%20title%20and%20abstract%20review.%20Following%20screening%2C%201068%20records%20were%20selected%20for%20full-text%20assessment.%20We%20included%2084%20studies%20in%20our%20systematic%20review%2C%20of%20which%2066%20were%20included%20in%20the%20meta-regression%20analysis.%20Our%20analysis%20indicated%20that%20HIV-related%20mortality%20for%20all%20children%20and%20young%20adolescents%20%28aged%200-14%20years%29%20decreased%20over%20time%2C%20between%202000%20and%202020%20globally%2C%20after%20adjusting%20for%20region%2C%20baseline%20CD4%20cell%20count%2C%20age%2C%20treatment%20duration%2C%20and%20sex.%20Additionally%2C%20HIV-related%20mortality%20decreased%20with%20increasing%20CD4%20cell%20count%20at%20ART%20initiation%20and%20longer%20treatment%20duration.%20There%20have%20been%20considerable%20geographical%20variations%20in%20the%20risk%20of%20mortality.%20Among%20the%20high-mortality%20group%20in%202020%20%28ART%20duration%20%26lt%3B6%20months%2C%20age%20%26lt%3B1%20year%2C%20male%2C%20and%20the%20lowest%20CD4%20cell%20counts%29%2C%20HIV-related%20mortality%20across%20regions%20ranged%20from%2011%5Cu00b77%20deaths%20%2895%25%20CI%208%5Cu00b73-15%5Cu00b74%29%20per%20100%20person-years%20in%20eastern%20Sub-Saharan%20Africa%20to%2072%5Cu00b70%20deaths%20%2847%5Cu00b71-98%5Cu00b71%29%20per%20100%20person-years%20in%20Asia-Pacific.%20Among%20the%20low-mortality%20group%20in%202020%20%28ART%20duration%20%5Cu22651%20year%2C%20age%205-9%20years%2C%20female%2C%20and%20the%20highest%20CD4%20cell%20counts%29%2C%20HIV-related%20mortality%20ranged%20from%200%5Cu00b709%20deaths%20%280%5Cu00b707-0%5Cu00b710%29%20per%20100%20person-years%20in%20eastern%20Sub-Saharan%20Africa%20to%200%5Cu00b720%20deaths%20%280%5Cu00b703-0%5Cu00b780%29%20per%20100%20person-years%20in%20Latin%20America%20and%20the%20Caribbean.%5CnINTERPRETATION%3A%20A%20comprehensive%20approach%20to%20paediatric%20HIV%20care%20is%20essential%20to%20improving%20outcomes%20for%20children%20and%20young%20adolescents%20living%20with%20HIV.%20Clinically%2C%20this%20approach%20includes%20strengthening%20the%20prevention%20of%20vertical%20transmission%2C%20ensuring%20early%20diagnosis%20in%20infants%2C%20and%20initiating%20treatment%20promptly-ideally%20at%20higher%20CD4%20cell%20counts.%20From%20a%20policy%20perspective%2C%20health%20systems%20need%20to%20address%20disparities%20in%20treatment%20access%20and%20outcomes%20across%20regions%2C%20age%20groups%2C%20and%20sex.%20Efforts%20should%20also%20prioritise%20minimising%20treatment%20dropout%20and%20expanding%20access%20to%20high-quality%20HIV%20services.%20These%20strategies%20could%20collectively%20support%20global%20goals%20to%20reduce%20the%20burden%20of%20paediatric%20HIV.%5CnFUNDING%3A%20The%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%20and%20the%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%222025-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2825%2900168-7%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240912259%22%2C%22PMCID%22%3A%22PMC12774562%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22PFUL28AX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Mendelsohn%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMendelsohn%20SC%2C%20Andrade%20BB%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Amorim%20GC%2C%20Erasmus%20M%2C%20Andrade%20AM%2C%20et%20al.%20Blood%20transcriptomic%20signatures%20predict%20poor%20treatment%20outcomes%20in%20drug-susceptible%20pulmonary%20TB%20in%20Brazil.%20medRxiv.%202025%20Oct%208%3B2025.10.07.25337480.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.10.07.25337480%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.10.07.25337480%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041282706%3B%20PubMed%20Central%20PMCID%3A%20PMC12632667.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Blood%20transcriptomic%20signatures%20predict%20poor%20treatment%20outcomes%20in%20drug-susceptible%20pulmonary%20TB%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20C.%22%2C%22lastName%22%3A%22Mendelsohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20C.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mzwandile%22%2C%22lastName%22%3A%22Erasmus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20Ms%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%22%2C%22lastName%22%3A%22Muwanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Hatherill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20J.%22%2C%22lastName%22%3A%22Scriba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22members%20of%20the%20RePORT%20South%20Africa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20Consortia%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Non-sputum%20biomarkers%20to%20monitor%20tuberculosis%20%28TB%29%20treatment%20and%20predict%20poor%20outcomes%20are%20lacking.%20We%20evaluated%20host-blood%20transcriptomic%20signatures%20for%20treatment%20monitoring%20and%20prognosis%20%28death%2C%20treatment%20failure%2C%20recurrence%29%20in%20adults%20with%20pulmonary%20TB.%5CnMETHODS%3A%20Adults%20with%20culture-confirmed%2C%20drug-susceptible%20pulmonary%20TB%20were%20enrolled%20at%20five%20Brazilian%20sites.%20Whole-blood%20PAXgene%20samples%20were%20collected%20at%20baseline%2C%20month%202%20%28M2%29%2C%20and%20end%20of%20treatment%20%28EoT%29.%20Treatment%20failure%20was%20defined%20as%20sputum%20culture%20positivity%20at%20month%205%20or%20later.%20Participants%20were%20followed%20for%2024%20months%20from%20treatment%20initiation%20for%20clinical%20or%20microbiological%20TB%20recurrence.%20Unfavourable%20outcomes%20were%20matched%20~1%3A3%20to%20recurrence-free%20cure.%20Twenty-two%20published%20blood%20transcriptomic%20signatures%20were%20measured%20by%20microfluidic%20RT-qPCR%20and%20benchmarked%20against%20the%20WHO%20Target%20Product%20Profile%20%28TPP%29%20criteria.%5CnRESULTS%3A%20We%20matched%20263%20participants%20with%20recurrence-free%20cure%20to%2033%20with%20treatment%20failure%2C%2024%20who%20died%20%28TB%5C%2Funknown%20cause%29%2C%20and%209%20with%20recurrence.%20Signature%20scores%20generally%20declined%20from%20baseline%20to%20EoT.%20Multiple%20signatures%20predicted%20recurrence%20at%20baseline%20and%20M2%20%28AUC%20range%200.71-0.91%29%2C%20with%20waning%20performance%20at%20EoT%20%28AUC%20range%200.42-0.89%29.%20Against%20the%20WHO%20TPP%2C%202%5C%2F22%20signatures%20met%20minimum%20criteria%20at%20baseline%2C%2013%5C%2F22%20at%20M2%2C%20and%20none%20at%20EoT.%20Prediction%20of%20treatment%20failure%20was%20poor%20across%20timepoints%20%28AUC%20%26lt%3B0.70%29.%20In%20contrast%2C%20Thompson5%20and%20others%20at%20baseline%20predicted%20death%20during%20treatment%20or%20follow-up%20%28AUC%20%5Cu22650.80%29.%5CnCONCLUSION%3A%20Blood%20transcriptomic%20signatures%20tracked%20treatment%20response%20and%20predicted%20recurrence%20and%20death%2C%20meeting%20WHO%20TPP%20benchmarks%20at%20baseline%20and%20M2.%20These%20findings%20support%20prospective%2C%20biomarker-guided%20trials%20to%20individualise%20TB%20therapy-shortening%20regimens%20for%20early%20responders%20and%20intensifying%20care%20for%20high-risk%20patients.%5CnFUNDING%3A%20This%20work%20was%20supported%20by%20the%20U.S.%20National%20Institutes%20of%20Health%2C%20CRDF%20Global%2C%20and%20Departamento%20de%20Ci%5Cu00eancia%20e%20Tecnologia%20%28DECIT%29%20-%20Secretaria%20de%20Ci%5Cu00eancia%20e%20Tecnologia%20%28SCTIE%29%2C%20Minist%5Cu00e9rio%20da%20Sa%5Cu00fade%20%28MS%29%2C%20Brazil.%22%2C%22date%22%3A%222025-10-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1101%5C%2F2025.10.07.25337480%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241282706%22%2C%22PMCID%22%3A%22PMC12632667%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22R6J6NZ5K%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Vreeman%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVreeman%20RC%2C%20Yiannoutsos%20CT%2C%20Edmonds%20A%2C%20Leroy%20V%2C%20Fatti%20G%2C%20Kosalaraksa%20P%2C%20et%20al.%20Rates%20of%20adherence%2C%20adherence%20measurement%2C%20and%20support%20services%20for%20children%20and%20adolescents%20living%20with%20HIV%20followed%20in%20global%20sites%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29.%20BMC%20Pediatr.%202025%20Oct%202%3B25%281%29%3A706.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12887-025-05939-4%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12887-025-05939-4%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041039293%3B%20PubMed%20Central%20PMCID%3A%20PMC12492743.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rates%20of%20adherence%2C%20adherence%20measurement%2C%20and%20support%20services%20for%20children%20and%20adolescents%20living%20with%20HIV%20followed%20in%20global%20sites%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pope%22%2C%22lastName%22%3A%22Kosalaraksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winstone%22%2C%22lastName%22%3A%22Nyandiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safari%22%2C%22lastName%22%3A%22Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20L.%22%2C%22lastName%22%3A%22Scanlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxanne%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Supporting%20and%20improving%20antiretroviral%20therapy%20%28ART%29%20adherence%20and%20preventing%20the%20evolution%20of%20HIV%20drug%20resistance%20remain%20major%20challenges%20for%20children%20and%20adolescents%20living%20with%20HIV%20globally.%20In%20a%20large%20global%20HIV%20clinical%20data%20consortium%2C%20we%20sought%20to%20describe%20how%20global%20HIV%20care%20programs%20measure%20and%20support%20pediatric%20ART%20adherence%2C%20as%20well%20as%20patient-level%20measures%20of%20adherence.%5CnMETHODS%3A%20We%20prospectively%20collected%20site-level%20data%20between%20June%202014-March%202015%20using%20a%20site%20assessment%20survey%20and%20retrospectively%20examined%20patient-level%20data%20collected%20during%20routine%20clinical%20care%2C%20to%20provide%20a%20comprehensive%20assessment%20of%20pediatric%20ART%20adherence%20across%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20cohort%2C%20in%20six%20global%20regions.%20All%20regions%20capturing%20patient-level%20data%20on%20adherence%20by%20any%20measure%20for%20children%20living%20with%20HIV%20aged%20less%20than%2014%5Cu00a0years%20between%202000-2015%20were%20asked%20to%20contribute%20data.%20ART%20adherence%20was%20conceptualized%20as%20a%20binomial%20variable%20of%20%26quot%3Bgood%26quot%3B%20%28greater%20than%2090%25%29%20or%20%26quot%3Bpoor%26quot%3B%20%2890%25%20or%20less%29%20adherence%20per%20visit.%5CnRESULTS%3A%20Clinical%20staff%20from%20180%20pediatric%20sites%20in%2045%20countries%20completed%20the%20adherence%20survey.%20Clinician%20adherence%20assessment%20%28used%20at%2087%25%20of%20sites%29%20and%20pharmacy%20refills%20%2886%25%20of%20sites%29%20were%20the%20most%20common%20adherence%20measurement%20methods%20used%20globally.%20Counseling%20focused%20on%20adherence%20was%20the%20most%20commonly%20available%20support%20service%2C%20%2894%25%20of%20sites%29.%2028%2C664%20pediatric%20patients%20had%20at%20least%20one%20adherence%20measurement%2C%20to%20be%20included%20for%20adherence%20analyses.%20In%20East%20Africa%20and%20Southern%20Africa%2C%20higher%20baseline%20CD4%20counts%20were%20associated%20with%20a%20greater%20likelihood%20of%20viral%20suppression%3B%20however%2C%20in%20Central%20and%20South%20America%20and%20the%20Caribbean%20%28CCASAnet%29%20and%20Asia-Pacific%2C%20we%20did%20not%20find%20a%20consistent%20relationship%20between%20baseline%20CD4%20count%20and%20the%20likelihood%20of%20viral%20suppression.%20We%20found%20evidence%20that%20very%20young%20children%20%28%26lt%3B%5Cu20092%5Cu00a0years%20of%20age%29%2C%20older%20children%20%28%26gt%3B%5Cu200910%5Cu00a0years%20of%20age%29%2C%20and%20males%20were%20less%20likely%20to%20experience%20viral%20suppression%20in%20East%20Africa%20and%20Southern%20Africa.%5CnCONCLUSION%3A%20These%20findings%20indicate%20that%20the%20majority%20of%20global%20pediatric%20HIV%20care%20services%20routinely%20measure%20ART%20adherence%20for%20children%20living%20with%20HIV%3B%20however%2C%20few%20sites%20use%20objective%20or%20validated%20measures.%20Identifying%20subgroups%20of%20children%20and%20youth%20at%20highest%20risk%20for%20non-adherence%20allows%20care%20programs%20to%20target%20those%20most%20in%20need%20of%20adherence%20support%20or%20resistance%20monitoring.%22%2C%22date%22%3A%222025-10-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12887-025-05939-4%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241039293%22%2C%22PMCID%22%3A%22PMC12492743%22%2C%22ISSN%22%3A%221471-2431%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%2272IPUXGI%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Shepherd%20et%20al.%22%2C%22parsedDate%22%3A%222025-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BShepherd%20BE%2C%20Liang%20Z%2C%20Kim%20A%2C%20Cesar%20C%2C%20Veloso%20VG%2C%20Cortes%20CP%2C%20et%20al.%20Temporal%20trends%20in%20tuberculosis%20and%20time%20from%20enrolment%20in%20care%20to%20antiretroviral%20therapy%20initiation%3A%20A%20multicountry%20cohort%20study%20from%20Latin%20America.%20Int%20J%20Infect%20Dis.%202025%20Oct%3B159%3A107979.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2025.107979%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2025.107979%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040653148%3B%20PubMed%20Central%20PMCID%3A%20PMC12700299.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Temporal%20trends%20in%20tuberculosis%20and%20time%20from%20enrolment%20in%20care%20to%20antiretroviral%20therapy%20initiation%3A%20A%20multicountry%20cohort%20study%20from%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhuohui%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20T.%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karu%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serena%20P.%22%2C%22lastName%22%3A%22Koenig%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20HIV%20treatment%20guidelines%20have%20evolved%20to%20recommend%20rapid%20antiretroviral%20therapy%20%28ART%29%20initiation.%20Data%20on%20the%20impact%20of%20these%20changes%20in%20the%20Americas%20region%20are%20scarce.%5CnMETHODS%3A%20This%20study%20included%20data%20from%20CCASAnet%20sites%20in%20Brazil%2C%20Haiti%2C%20Honduras%2C%20Mexico%2C%20and%20Peru.%20ART-na%5Cu00efve%20adults%20who%20started%20ART%20from%202006%20to%202022%20were%20included.%20Trends%20in%20CD4%20count%2C%20tuberculosis%20%28TB%29%2C%20and%20treatment%20initiation%20were%20described%20using%20cumulative%20probability%20and%20logistic%20and%20Cox%20regression%20models.%5CnFINDINGS%3A%20Total%2029%2C881%20PLWH%20met%20inclusion%20criteria%3B%202179%20%287.3%25%29%20were%20diagnosed%20with%20prevalent%20TB%20and%20379%20%281.2%25%29%20with%20incident%20TB%20within%20six%20months%20after%20ART%20initiation.%20For%20individuals%20without%20TB%2C%20enrolment%20CD4%20count%20increased%20from%20160%20to%20320%20cells%5C%2Fmm3.%20Over%20the%20study%20period%2C%20TB%20prevalence%20declined%20from%20peak%20of%209.4%25%20to%205.4%25%2C%20and%20incident%20TB%20from%201.5%25%20to%200.8%25.%20Median%20time%20to%20ART%20initiation%20decreased%20from%20476%20to%201%20day%20for%20PLWH%20without%20TB%2C%20and%2098%20to%2016%20days%20for%20those%20with%20prevalent%20TB%3B%20time%20to%20TB%20treatment%20also%20decreased.%5CnCONCLUSIONS%3A%20Time%20to%20ART%20initiation%20has%20decreased%20in%20the%20CCASAnet%20consortium%2C%20with%20the%20majority%20of%20PLWH%20now%20starting%20ART%20within%20a%20week%20after%20enrolment.%20There%20has%20also%20been%20a%20decline%20in%20the%20prevalence%20and%20incidence%20of%20concurrent%20TB%20disease.%22%2C%22date%22%3A%222025-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2025.107979%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240653148%22%2C%22PMCID%22%3A%22PMC12700299%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22Y37P3KVP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pellegrino%20et%20al.%22%2C%22parsedDate%22%3A%222025-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPellegrino%20RA%2C%20Tu%20S%2C%20Ville-Benavides%20R%2C%20Jalil%20EM%2C%20Sudenga%20SL%2C%20Crabtree-Ram%26%23xED%3Brez%20B%2C%20et%20al.%20Incidence%20and%20outcomes%20of%20anal%20and%20cervical%20cancer%20among%20adults%20with%20HIV%20in%20Latin%20America%3A%20a%20retrospective%20cohort%20study.%20J%20Int%20AIDS%20Soc.%202025%20Oct%3B28%2810%29%3Ae70050.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70050%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.70050%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2041074705%3B%20PubMed%20Central%20PMCID%3A%20PMC12514557.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Incidence%20and%20outcomes%20of%20anal%20and%20cervical%20cancer%20among%20adults%20with%20HIV%20in%20Latin%20America%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachael%20A.%22%2C%22lastName%22%3A%22Pellegrino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengxin%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Ville-Benavides%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Staci%20L.%22%2C%22lastName%22%3A%22Sudenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevieve%22%2C%22lastName%22%3A%22Hilaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cynthia%22%2C%22lastName%22%3A%22Riviere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20Epidemiology%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Human%20papillomavirus%20%28HPV%29-associated%20cervical%20and%20anal%20cancers%20disproportionately%20affect%20people%20with%20HIV%20%28PWH%29.%20This%20study%20aimed%20to%20determine%20the%20incidence%20trends%20of%20and%20risk%20factors%20for%20these%20malignancies%20in%20PWH%20in%20Latin%20America.%5CnMETHODS%3A%20We%20included%20PWH%20from%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20who%20contributed%20person-time%20between%202000%20and%202019.%20We%20calculated%20crude%20and%20age-standardized%20incidence%20rates%2C%20examining%20trends%20over%20time%20with%20Poisson%20regression.%20Adjusted%20hazard%20ratios%20were%20calculated%20using%20Cox%20proportional%20hazard%20models%20with%20propensity%20score%20adjustment.%20We%20calculated%20the%20probability%20of%20survival%20after%20cancer%20diagnosis%20using%20Kaplan-Meier%20curves.%20To%20understand%20factors%20that%20influence%20our%20results%2C%20we%20surveyed%20all%20adult%20CCASAnet%20sites%20on%20current%20practices%20of%20cervical%20and%20anal%20cancer%20screening.%5CnRESULTS%3A%20Overall%2C%205739%20females%20with%20HIV%20%2843%2C417%20person-years%29%20were%20included%20in%20cervical%20cancer%20analyses.%20There%20were%2027%20incident%20cervical%20cancers%3A%20crude%20incidence%20rate%20of%2062.2%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2034.9-89.4%29%20per%20100%2C000%20person%20years.%20In%20the%20anal%20cancer%20analysis%2C%2012%2C489%20males%20who%20have%20sex%20with%20men%20%28MSM%29%2C%207324%20males%20other%20than%20MSM%20and%205739%20females%20were%20included%20for%20a%20total%20of%2025%2C552%20PWH%2C%20contributing%20157%2C166%20person-years.%20Anal%20cancer%20was%20diagnosed%20in%2056%20individuals%3A%20crude%20incidence%20rates%20of%2059.1%20%5B95%25%20CI%3A%2033.2-85.0%5D%2C%2020.7%20%5B95%25%20CI%3A%2011.6-29.7%5D%20and%2015.2%20%5B95%25%20CI%3A%208.6-21.9%5D%20per%20100%2C000%20person-years%20in%20MSM%2C%20females%20and%20males%20other%20than%20MSM%2C%20respectively.%20Age-standardized%20incidence%20rates%20did%20not%20significantly%20change%20over%20time.%20Anal%20cancer%20risk%20decreased%20significantly%20with%20higher%20time-updated%20CD4%20cell%20count.%20The%20predicted%20probability%20of%205-year%20survival%20after%20cancer%20diagnosis%20was%2072.6%25%20%2895%25%20CI%3A%2048.4-86.8%29%20for%20cervical%20cancer%20and%2058.5%25%20%2895%25%20CI%3A%2044.0-70.5%29%20for%20anal%20cancer.%5CnCONCLUSIONS%3A%20In%20one%20of%20the%20few%20reports%20outside%20the%20United%20States%20or%20Europe%2C%20we%20did%20not%20observe%20a%20decrease%20in%20age-standardized%20incidence%20rates%20for%20anal%20and%20cervical%20cancer%20between%202000%20and%202019.%20These%20data%20support%20continued%20efforts%20for%20cancer%20prevention%20through%20access%20to%20gender-neutral%20HPV%20vaccination%20and%20cancer%20screening.%22%2C%22date%22%3A%222025-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.70050%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2241074705%22%2C%22PMCID%22%3A%22PMC12514557%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A39%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22BN87T64G%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ferreira%20et%20al.%22%2C%22parsedDate%22%3A%222025-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BFerreira%20IBB%2C%20Menezes%20RC%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Rolla%20VC%2C%20Kritski%20AL%2C%20Cordeiro-Santos%20M%2C%20et%20al.%20Effects%20of%20missed%20anti-tuberculosis%20therapy%20doses%20on%20treatment%20outcome%3A%20a%20multi-center%20cohort%20study.%20Lancet%20Reg%20Health%20Am.%202025%20Aug%3B48%3A101162.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2025.101162%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2025.101162%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040657430%3B%20PubMed%20Central%20PMCID%3A%20PMC12246921.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20missed%20anti-tuberculosis%20therapy%20doses%20on%20treatment%20outcome%3A%20a%20multi-center%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabella%20B.%20B.%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%20C.%22%2C%22lastName%22%3A%22Menezes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cody%22%2C%22lastName%22%3A%22Staats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anete%22%2C%22lastName%22%3A%22Trajman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20remains%20a%20leading%20cause%20of%20infectious%20disease%20mortality%20globally.%20Although%20directly%20observed%20therapy%20%28DOT%29%20has%20been%20widely%20implemented%20to%20improve%20adherence%2C%20nonadherence%20continues%20to%20compromise%20treatment%20success%20rates%2C%20especially%20in%20real-world%20settings.%20Therefore%2C%20this%20study%20aims%20to%20assess%20the%20impact%20of%20missed%20doses%20on%20TB%20treatment%20outcomes.%5CnMETHODS%3A%20Prospective%20study%20that%20followed%20adults%20with%20drug-sensitive%20TB%20for%20two%20years%20after%20TB%20treatment%20initiation%20at%20five%20clinical%20centers%20of%20the%20RePORT-Brazil%20cohort%20between%20June%202015%20and%20June%202019.%20Participants%20not%20in%20DOT%20or%20followed%20for%20less%20than%2030%20days%20were%20excluded.%20Nonadherence%20was%20defined%20as%20the%20percentage%20of%20missed%20doses%20relative%20to%20the%20prescribed%20regimen%2C%20monitored%20daily%20through%20DOT.%20The%20primary%20composite%20outcome%20comprised%20treatment%20failure%2C%20disease%20recurrence%2C%20drug%20resistance%2C%20death%2C%20or%20loss%20to%20follow-up%20%28LTFU%29%20after%2030%20days%20of%20treatment.%20Associations%20were%20assessed%20with%20multivariable%20logistic%20regression.%5CnFINDINGS%3A%20Among%20the%20578%20participants%20analyzed%2C%20218%20%2837%5Cu00b77%25%29%20experienced%20unfavorable%20outcomes.%20Overall%2C%2023%25%20of%20participants%20missed%20more%20than%2010%25%20of%20prescribed%20doses%2C%20and%20this%20group%20had%20an%2081%5Cu00b72%25%20likelihood%20of%20experiencing%20unfavorable%20outcomes%2C%20compared%20to%20only%2021%5Cu00b76%25%20among%20those%20with%20complete%20adherence.%20A%20significant%20association%20was%20observed%20between%20the%20percentage%20of%20missed%20doses%20and%20unfavorable%20outcomes%20%28adjusted%20OR%3A%201%5Cu00b711%2C%2095%25%20CI%3A%201%5Cu00b707-1%5Cu00b714%2C%20p-value%20%26lt%3B%200%5Cu00b70001%29.%5CnINTERPRETATION%3A%20Even%20minor%20nonadherence%20in%20TB%20treatment%20was%20associated%20with%20an%20increased%20risk%20of%20unfavorable%20outcomes%2C%20highlighting%20the%20role%20of%20adherence%20in%20successful%20TB%20care.%5CnFUNDING%3A%20Funda%5Cu00e7%5Cu00e3o%20Oswaldo%20Cruz%2C%20Funda%5Cu00e7%5Cu00e3o%20Jos%5Cu00e9%20Silveira%2C%20Departamento%20de%20Ci%5Cu00eancia%20e%20Tecnologia%2C%20US%20National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%222025-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2025.101162%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240657430%22%2C%22PMCID%22%3A%22PMC12246921%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22WENBB2NH%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22de%20Waal%20et%20al.%22%2C%22parsedDate%22%3A%222025-07-18%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3Bde%20Waal%20R%2C%20Wools-Kaloustian%20K%2C%20Brazier%20E%2C%20Althoff%20KN%2C%20Jaquet%20A%2C%20Duda%20SN%2C%20et%20al.%20Global%20Trends%20in%20CD4%20Count%20Measurement%20and%20Distribution%20at%20First%20Antiretroviral%20Treatment%20Initiation.%20Clin%20Infect%20Dis.%202025%20Jul%2018%3B80%286%29%3A1332%26%23×2013%3B6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciae548%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciae548%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039501773%3B%20PubMed%20Central%20PMCID%3A%20PMC12264493.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20Trends%20in%20CD4%20Count%20Measurement%20and%20Distribution%20at%20First%20Antiretroviral%20Treatment%20Initiation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rene%5Cu00e9%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagalingeswaran%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodora%22%2C%22lastName%22%3A%22Savory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20K.%20U.%22%2C%22lastName%22%3A%22Pasayan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agness%22%2C%22lastName%22%3A%22Thawani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pelagie%22%2C%22lastName%22%3A%22Babakazo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maile%22%2C%22lastName%22%3A%22Karris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cordelia%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%20Yong%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noela%20C.%22%2C%22lastName%22%3A%22Owarwo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Niyongabo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Ezechi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathy%22%2C%22lastName%22%3A%22Petoumenos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20people%20with%20human%20immunodeficiency%20virus%20%28PWH%29%20start%20antiretroviral%20treatment%20%28ART%29%20regardless%20of%20CD4%20count%2C%20CD4%20measurement%20remains%20crucial%20for%20detecting%20advanced%20human%20immunodeficiency%20virus%20%28HIV%29%20disease%20and%20evaluating%20ART%20programs.%20We%20explored%20CD4%20measurement%20%28proportion%20of%20PWH%20with%20a%20CD4%20result%20available%29%20and%20prevalence%20of%20CD4%20%26lt%3B200%20cells%5C%2F%5Cu00b5L%20%28hereafter%20%26quot%3BCD4%20%26lt%3B200%26quot%3B%29%20at%20ART%20initiation%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20global%20collaboration.%5CnMETHODS%3A%20We%20included%20PWH%20at%20participating%20ART%20programs%20who%20first%20initiated%20ART%20at%20age%2015-80%20years%20during%202005-2019.%20We%20described%20proportions%20of%20PWH%20with%20a%20CD4%20result%20%28measured%20within%206%20months%20before%20to%202%20weeks%20after%20ART%20initiation%29%20and%2C%20among%20those%20with%20a%20CD4%20result%2C%20with%20CD4%20%26lt%3B200%2C%20by%20year%20of%20ART%20initiation%20and%20region.%5CnRESULTS%3A%20We%20included%201%20355%20104%20PWH%20from%2042%20countries%20in%207%20regions%3B%2063%25%20were%20female.%20The%20median%20%28interquartile%20range%29%20age%20at%20ART%20initiation%20was%2037%20%283144%29%20years%20in%20males%20and%2032%20%2826-39%29%20years%20in%20females.%20CD4%20measurement%20initially%20increased%2C%20or%20remained%20stable%20over%20time%20until%20around%202013%2C%20but%20then%20declined%20to%20low%20levels%20in%20some%20regions%20%28Southern%20Africa%2C%20except%20South%20Africa%3A%20from%2054%25%20to%2013%25%3B%20East%20Africa%3A%2085%25%20to%2031%25%3B%20Central%20Africa%3A%2072%25%20to%2020%25%3B%20West%20Africa%3A%2091%25%20to%2053%25%3B%20and%20Latin%20America%3A%2087%25%20to%2056%25%29.%20Prevalence%20of%20CD4%20%26lt%3B200%20declined%20over%20time%20in%20all%20regions%2C%20but%20plateaued%20after%202015%20at%20%5Cu226530%25.%5CnCONCLUSIONS%3A%20CD4%20measurement%20has%20declined%20sharply%20in%20recent%20years%2C%20especially%20in%20sub-Saharan%20Africa.%20Among%20those%20with%20a%20CD4%20measurement%2C%20the%20prevalence%20of%20CD4%20%26lt%3B200%20remains%20concerningly%20high.%20Scaling%20up%20CD4%20testing%20and%20securing%20adequate%20funding%20are%20urgent%20priorities.%22%2C%22date%22%3A%222025-07-18%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciae548%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239501773%22%2C%22PMCID%22%3A%22PMC12264493%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A29Z%22%7D%7D%2C%7B%22key%22%3A%228FTMSXRQ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Guerrero-Torres%20et%20al.%22%2C%22parsedDate%22%3A%222025-07-17%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGuerrero-Torres%20L%2C%20Barbosa-Ram%26%23xED%3Brez%20BM%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Alegre-D%26%23xED%3Baz%20J%2C%20Ram%26%23xED%3Brez%20R%2C%20Rosa-Parra%20A%2C%20et%20al.%20Improving%20estimators%20of%20HIV%20mortality%20and%20retention%20in%20care%20by%20linking%20clinical%20cohort%20data%20with%20national%20registries%20in%20Mexico.%20BMC%20Public%20Health.%202025%20Jul%2017%3B25%281%29%3A2489.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-025-23542-1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-025-23542-1%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040676585%3B%20PubMed%20Central%20PMCID%3A%20PMC12272977.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improving%20estimators%20of%20HIV%20mortality%20and%20retention%20in%20care%20by%20linking%20clinical%20cohort%20data%20with%20national%20registries%20in%20Mexico%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorena%22%2C%22lastName%22%3A%22Guerrero-Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bibiana%20Montserrat%22%2C%22lastName%22%3A%22Barbosa-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jes%5Cu00fas%22%2C%22lastName%22%3A%22Alegre-D%5Cu00edaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ra%5Cu00fal%22%2C%22lastName%22%3A%22Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Rosa-Parra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%20Caro%22%2C%22lastName%22%3A%22Vega%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Loss%20to%20follow-up%20%28LTFU%29%20bias%20mortality%20estimates%20in%20cohort%20studies.%20This%20study%20aimed%20to%20estimate%20the%20corrected%20incidence%20of%20LTFU%2C%20retention%20in%20care%2C%20and%20mortality%20rates%20in%20people%20with%20HIV%20%28PWH%29%20in%20an%20HIV%5C%2FAIDS%20Clinic%20in%20Mexico%20City%2C%20by%20linking%20clinic%20and%20national%20registry%20data%2C%20and%20to%20identify%20characteristics%20associated%20with%20LTFU.%5CnMETHODS%3A%20We%20linked%20adult%20PWH%20who%20met%20lost%20to%20follow-up%20criteria%20while%20enrolled%20at%20a%20Mexico%20City%20clinic%20with%20the%20national%20death%20registry%2C%20a%20national%20administrative%20HIV%20database%20and%20a%20clinical%20national%20registry%20in%20May%202019%20and%20January%202021.%20We%20defined%20lost%20to%20follow-up%20as%20absence%20of%20a%20documented%20clinical%20contact%20in%20the%20previous%20180%20days.%20We%20estimated%20corrected%20LTFU%2C%20retention%20in%20care%2C%20mortality%20rates%2C%20and%20survival%2C%20and%20identified%20characteristics%20associated%20to%20LTFU.%5CnRESULTS%3A%20Among%202%2C826%20PWH%20followed%20by%20a%20median%20of%205.9%20years%20%28IQR%3A%201.9-7.1%29%2C%20804%20%2828.4%25%29%20were%20lost%20and%20149%20%285.3%25%29%20died.%20After%20the%20second%20linkage%2C%20of%20the%20804%20lost%2C%20257%20%2832%25%29%20died%2C%20175%20%2821.8%25%29%20transferred%2C%2040%20%284.9%25%29%20were%20retained%20in%20care%2C%20and%20332%20%2841.3%25%29%20remained%20LTFU.%20Post%20second%20linkage%2C%20the%20corrected%20cumulative%20proportion%20of%20LTFU%20slightly%20decreased%20%28n%5Cu2009%3D%5Cu2009764%2C%2027%25%29%2C%20but%20deaths%20substantially%20increased%20%28n%5Cu2009%3D%5Cu2009459%2C%2016.2%25%29.%20A%20subset%20of%20PWH%20transferred%20to%20other%20centres%20%28n%5Cu2009%3D%5Cu2009184%2C%206.5%25%29.%20The%20unadjusted%20LTFU%20rate%20decreased%20from%204.0%20to%202.9%20per%20100%20person-years%20%28PY%29%2C%20while%20mortality%20increased%20from%200.7%20to%201.7%20per%20100%20PY.%20Younger%20age%20%28aHR%201.5%2C%2095%25CI%201.38-1.63%20per%2010-year%20change%29%2C%20and%20lower%20education%20%28aHR%201.05%2C%2095%25CI%201.01-1.08%20per%20year%29%20were%20associated%20to%20a%20higher%20risk%20of%20LTFU.%5CnCONCLUSION%3A%20Datasets%20linkages%20revealed%20mortality%20rates%20three%20times%20higher%20than%20the%20original%20estimates%2C%20highlighting%20the%20limitations%20of%20relying%20in%20single-source%20data.%20At%20the%20individual%20level%2C%20identifying%20predictors%20of%20LTFU%20can%20help%20target%20interventions%20to%20improve%20retention%20and%20may%20reduce%20mortality.%20However%2C%20at%20the%20system-level%2C%20our%20study%20demonstrates%20the%20feasibility%20and%20value%20of%20cross-institutional%20data%20linkage%20in%20fragmented%20health%20systems.%20Key%20lessons%20include%20the%20importance%20of%20long-term%2C%20privacy-preserving%20data-sharing%20collaboration%20between%20institutions%20to%20improve%20patient%20tracking%20across%20institutions%2C%20mortality%20surveillance%20and%20care%20continuity.%22%2C%22date%22%3A%222025-07-17%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-025-23542-1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240676585%22%2C%22PMCID%22%3A%22PMC12272977%22%2C%22ISSN%22%3A%221471-2458%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%2238STDGJ5%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Fonseca%20et%20al.%22%2C%22parsedDate%22%3A%222025-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BFonseca%20FF%2C%20Ranadive%20P%2C%20Shepherd%20BE%2C%20Ferreira%20FGF%2C%20Rodr%26%23xED%3Bguez%20MF%2C%20Machado%20DM%2C%20et%20al.%20Persistent%20sex%20disparities%20in%20access%20to%20dolutegravir-based%20antiretroviral%20therapy%20in%20Latin%20America%20and%20the%20Caribbean%3A%20results%20from%20a%20retrospective%20observational%20study%20using%20data%20from%202017%20to%202022.%20J%20Int%20AIDS%20Soc.%202025%20Jul%3B28%287%29%3Ae26470.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26470%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26470%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040635404%3B%20PubMed%20Central%20PMCID%3A%20PMC12241694.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Persistent%20sex%20disparities%20in%20access%20to%20dolutegravir-based%20antiretroviral%20therapy%20in%20Latin%20America%20and%20the%20Caribbean%3A%20results%20from%20a%20retrospective%20observational%20study%20using%20data%20from%202017%20to%202022%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%20F.%22%2C%22lastName%22%3A%22Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paridhi%22%2C%22lastName%22%3A%22Ranadive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flavia%20G.%20F.%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20F.%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Varela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Wagner%20Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CCASAnet%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Despite%20its%20reversal%20in%20July%202019%2C%20the%20World%20Health%20Organization%20warning%20issued%20in%20May%202018%20of%20potential%20teratogenicity%20associated%20with%20dolutegravir%20%28DTG%29%20may%20have%20produced%20persistent%20sex%20disparities%20in%20access%20to%20DTG.%20We%20compared%20DTG%20uptake%20of%20people%20with%20HIV%20%28PWH%29%20by%20sex%20in%20Latin%20America%20and%20the%20Caribbean%20%28LAC%29%20and%20its%20potential%20impact%20on%20virologic%20outcomes.%5CnMETHODS%3A%20We%20evaluated%20DTG%20initiation%20among%20antiretroviral%20therapy%20%28ART%29-na%5Cu00efve%20and%20-experienced%20cisgender%20PWH%20%5Cu226516%20years%20of%20age%20after%20DTG%20availability%20in%20Brazil%20%28February%5C%2F2017%29%2C%20Chile%20%28August%5C%2F2019%29%2C%20Haiti%20%28November%5C%2F2018%29%20and%20Honduras%20%28December%5C%2F2018%29.%20Time%20was%20divided%20into%20pre-%20%28before%20May%5C%2F2018%29%2C%20during-%20%28May%5C%2F2018-July%5C%2F2019%29%20and%20post-%20%28after%20July%5C%2F2019%29%20warning%20periods.%20We%20examined%20interactions%20of%20sex%2C%20age%20and%20calendar%20era%20with%20multivariable%20modified%20Poisson%20regression%20models%20and%20Cox%20proportional%20hazard%20models%20for%20the%20outcomes%20of%20DTG%20initiation%20among%20ART-na%5Cu00efve%20and%20ART-experienced%20PWH%2C%20respectively%2C%20and%20HIV%20RNA%20%26lt%3B50%20copies%5C%2Fml%20in%20the%20first%20year%20of%20therapy%20among%20ART-na%5Cu00efve%20PWH%2C%20adjusting%20for%20site%20and%20tuberculosis.%5CnRESULTS%3A%20Among%204622%20ART-na%5Cu00efve%20PWH%2C%203853%20%2883%25%29%20initiated%20DTG.%20ART-na%5Cu00efve%20females%20aged%2016-49%20years%20were%20less%20likely%20to%20initiate%20DTG%20compared%20to%20males%20of%20the%20same%20age%20both%20in%20the%20pre%5C%2Fduring-warning%20%28adjusted%20prevalence%20ratio%20%5BaPR%5D%3A%200.75%20%5B95%25%20confidence%20interval%20%2895%25%20CI%29%3A%200.71-0.80%5D%29%20and%20in%20the%20post-warning%20periods%20%28aPR%3A%200.97%20%5B95%25%20CI%3A%200.95-1.00%5D%29.%20Among%2016%2C154%20ART-experienced%20PWH%2C%209236%20%2857%25%29%20initiated%20DTG.%20ART-experienced%20females%2016-49%20years%20were%20less%20likely%20to%20initiate%20DTG%20compared%20to%20males%20of%20the%20same%20age%20in%20the%20pre%5C%2Fduring-warning%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%3A%200.69%20%5B95%25%20CI%3A%200.66-0.73%5D%29%20and%20post-warning%20periods%20%28aHR%3A%200.79%20%5B95%25%20CI%3A%200.70-0.90%5D%29.%20This%20sex%20difference%20was%20not%20observed%20among%20older%20ART-experienced%20females%20and%20males%20pre%5C%2Fduring-warning%20%28aHR%3A%201.06%20%5B95%25%20CI%3A%200.99-1.14%5D%29.%20Compared%20to%20starting%20ART%20without%20DTG%2C%20DTG-based%20ART%20use%20was%20associated%20with%20a%20higher%20likelihood%20of%20HIV%20RNA%20suppression%20in%20the%20first%20year%20%28aPR%20%3D%201.10%20%5B95%25%20CI%3A%201.04-1.16%5D%29.%20In%20the%20post-warning%20period%2C%20females%20aged%2016-49%20years%20had%20a%20likelihood%20of%20viral%20suppression%20similar%20to%20males%20of%20the%20same%20age%20%28aPR%3A%201.03%20%5B95%25%20CI%3A%200.96-1.10%5D%29%2C%20which%20did%20not%20change%20after%20adjusting%20for%20DTG%20use%20%28aPR%3A%201.03%20%5B95%25%20CI%3A%200.97-1.11%5D%29.%5CnCONCLUSIONS%3A%20Despite%20the%20updated%20guidelines%20recommending%20DTG%20for%20all%20PWH%2C%20there%20are%20persistent%20sex%20disparities%20in%20the%20access%20to%20DTG%20in%20LAC%2C%20especially%20among%20females%20within%20the%20reproductive%20age.%22%2C%22date%22%3A%222025-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26470%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240635404%22%2C%22PMCID%22%3A%22PMC12241694%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22BZZHTUIX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Machado%20et%20al.%22%2C%22parsedDate%22%3A%222025-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMachado%20DM%2C%20Duda%20SN%2C%20C%26%23xE9%3Blia%20de%20Menezes%20Succi%20R%2C%20Kim%20A%2C%20Ranadive%20P%2C%20Rouzier%20V%2C%20et%20al.%20HIV%20Care%20Continuum%20Outcomes%20Among%20Adolescents%20and%20Young%20Adults%20Living%20With%20HIV%20in%20Latin%20America%20and%20the%20Caribbean%3A%20Association%20With%20Depression%20and%20Substance%20Use.%20Open%20Forum%20Infect%20Dis.%202025%20Jul%3B12%287%29%3Aofaf353.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofaf353%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofaf353%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040657168%3B%20PubMed%20Central%20PMCID%3A%20PMC12247166.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20Care%20Continuum%20Outcomes%20Among%20Adolescents%20and%20Young%20Adults%20Living%20With%20HIV%20in%20Latin%20America%20and%20the%20Caribbean%3A%20Association%20With%20Depression%20and%20Substance%20Use%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%22%2C%22lastName%22%3A%22C%5Cu00e9lia%20de%20Menezes%20Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paridhi%22%2C%22lastName%22%3A%22Ranadive%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20T.%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Rodr%5Cu00edguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Wagner%20Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Adolescents%20and%20young%20adults%20with%20HIV%20%28AYAWH%29%20represent%20vulnerable%20populations%2C%20with%20increased%20risk%20of%20virologic%20failure%2C%20loss%20to%20follow-up%2C%20and%20death.%20Depression%20and%20substance%20use%20in%20AYAWH%20can%20lead%20to%20worse%20outcomes%2C%20yet%20this%20overlap%20is%20not%20well%20understood.%5CnMETHODS%3A%20This%20cross-sectional%20study%20included%20adolescents%20%2810-17%20years%29%20and%20young%20adults%20%2818-24%20years%29%20with%20HIV%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29.%20Participants%20were%20administered%20surveys%20to%20assess%20for%20depression%2C%20substance%20use%2C%20and%20antiretroviral%20therapy%20%28ART%29%20adherence.%20Risk%20factors%20for%20depression%3B%20alcohol%2C%20tobacco%2C%20and%20substance%20use%3B%20missing%20ART%20doses%3B%20viral%20suppression%3B%20and%201-year%20retention%20were%20assessed.%5CnRESULTS%3A%20Six%20hundred%20twenty-five%20AYAWH%20were%20included.%20Depression%20prevelance%20was%2016%25.%20Males%20%28adjusted%20odds%20ratio%20%5BaOR%5D%2C%200.26%3B%2095%25%20CI%2C%200.16-0.44%29%20and%20younger%20youth%20%2815-year-olds%20vs%2018-year-olds%3A%20aOR%2C%200.61%3B%2095%25%20CI%2C%200.40-0.95%29%20were%20less%20likely%20to%20have%20depression.%20Fifty-eight%20percent%20reported%20using%20alcohol%2C%2028%25%20reported%20tobacco%20use%2C%2017%25%20reported%20cannabis%20use%2C%20and%204%25%20reported%20cocaine%20use.%20Forty-one%20percent%20missed%201%20or%20more%20doses%20of%20ART%20in%20the%20past%20week.%20Forty%20percent%20had%20detectable%20viral%20loads%20at%20the%20time%20of%20survey%20completion.%20Those%20who%20acquired%20HIV%20perinatally%20were%20more%20likely%20to%20have%20an%20unsuppressed%20viral%20load%20%28aOR%2C%202.4%3B%2095%25%20CI%2C%201.24-4.62%3B%20P%20%3D%20.009%29.%20Only%2073%25%20of%20participants%20were%20retained%20in%20care%20following%20the%20survey%3B%20there%20was%20no%20statistical%20association%20between%20retention%20and%20age%2C%20sex%2C%20education%2C%20probable%20route%20of%20HIV%20acquisition%2C%20depression%2C%20and%20needing%20intervention%20for%20substance%20use.%5CnCONCLUSIONS%3A%20Substance%20use%20and%20depression%20were%20prevalent%20in%20AYAWH%2C%20as%20were%20missed%20doses%20of%20ART%20and%20detectable%20viral%20loads.%22%2C%22date%22%3A%222025-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofaf353%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240657168%22%2C%22PMCID%22%3A%22PMC12247166%22%2C%22ISSN%22%3A%222328-8957%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22X4UBT8EG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Fern%5Cu00e1ndez%20Villalobos%20et%20al.%22%2C%22parsedDate%22%3A%222025-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BFern%26%23xE1%3Bndez%20Villalobos%20NV%2C%20Helfenstein%20F%2C%20Khol%20V%2C%20Twizere%20C%2C%20Secco%20M%2C%20Castelnuovo%20B%2C%20et%20al.%20Scale%20of%20differentiated%20service%20delivery%20implementation%20in%20HIV%20care%20facilities%20in%20low-%20and%20middle-income%20countries%3A%20a%20global%20facility%20survey.%20J%20Int%20AIDS%20Soc.%202025%20Jul%3B28%20Suppl%203%28Suppl%203%29%3Ae26477.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26477%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26477%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040622380%3B%20PubMed%20Central%20PMCID%3A%20PMC12232477.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Scale%20of%20differentiated%20service%20delivery%20implementation%20in%20HIV%20care%20facilities%20in%20low-%20and%20middle-income%20countries%3A%20a%20global%20facility%20survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%20Ver%5Cu00f3nica%22%2C%22lastName%22%3A%22Fern%5Cu00e1ndez%20Villalobos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Helfenstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vohith%22%2C%22lastName%22%3A%22Khol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayara%22%2C%22lastName%22%3A%22Secco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%22%2C%22lastName%22%3A%22Huwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Tiendredbeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Siew%20Moy%22%2C%22lastName%22%3A%22Fong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%20Elias%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Idiovinio%22%2C%22lastName%22%3A%22Rafael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Djimon%20Marcel%22%2C%22lastName%22%3A%22Zannou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathy%22%2C%22lastName%22%3A%22Petoumenos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20Mahambou%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%20Bolton%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ounoo%20Elom%22%2C%22lastName%22%3A%22Takassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sasisopin%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%20Ajeh%22%2C%22lastName%22%3A%22Awoh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamim%20M.%22%2C%22lastName%22%3A%22Ali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%202016%2C%20the%20World%20Health%20Organization%20recommended%20differentiated%20service%20delivery%20%28DSD%29%20as%20a%20client-centred%20approach%20to%20simplify%20HIV%20care%20in%20frequency%20and%20intensity%2C%20thus%20reducing%20the%20clinic%20visit%20burden%20on%20individuals%20and%20HIV%20programmes.%20We%20describe%20the%20scale%20of%20DSD%20implementation%20among%20HIV%20facilities%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%20in%20Latin%20America%2C%20Africa%20and%20the%20Asia-Pacific%20before%20the%20COVID-19%20pandemic.%5CnMETHODS%3A%20We%20analysed%20facility-level%20survey%20data%20from%20HIV%20care%20facilities%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%20in%202019.%20We%20used%20descriptive%20statistics%20to%20summarise%20the%20availability%20of%20DSD%2C%20multi-month%20dispensing%20%28MMD%29%20and%20DSD%20for%20HIV%20treatment%20models.%20We%20explored%20factors%20associated%20with%20DSD%20implementation%20using%20multivariable%20models.%5CnRESULTS%3A%20We%20included%20175%20facilities%20in%20the%20Asia-Pacific%20%28n%20%3D%2030%29%2C%20Latin%20America%20%28n%20%3D%208%29%2C%20Central%20Africa%20%28n%20%3D%2021%29%2C%20East%20Africa%20%28n%20%3D%2074%29%2C%20Southern%20Africa%20%28n%20%3D%2028%29%20and%20West%20Africa%20%28n%20%3D%2014%29.%20Overall%2C%20133%20facilities%20%2876%25%29%20reported%20implementing%20DSD.%20Of%20these%2C%2091%25%20offered%20DSD%20for%20HIV%20treatment%2C%2061%25%20for%20HIV%20testing%20and%2059%25%20for%20antiretroviral%20therapy%20%28ART%29%20initiation.%20The%20most%20common%20duration%20of%20ART%20refills%20for%20clinically%20stable%20clients%20was%203MMD%2C%20%2870%25%29%2C%20followed%20by%20monthly%20%2814%25%29%20and%206MMD%20%2810%25%29.%20Facility-based%20individual%20models%20were%20the%20most%20frequently%20available%20DSD%20for%20the%20HIV%20treatment%20model%20%2882%25%29%2C%20followed%20by%20client-managed%20group%20models%20%2860%25%29.%20Out-of-facility%20individual%20models%20were%20available%20at%2048%25%20of%20facilities.%20Facility-based%20individual%20models%20were%20particularly%20common%20among%20facilities%20in%20East%20%2892%25%29%20and%20Southern%20Africa%20%2896%25%29.%20Facilities%20in%20medium%20and%20high%20HIV%20prevalence%20countries%2C%20and%20those%20with%203MMD%2C%20were%20more%20likely%20to%20implement%20DSD.%5CnCONCLUSIONS%3A%20In%202019%2C%20DSD%20was%20available%20in%20most%20HIV%20care%20facilities%20globally%20but%20was%20not%20evenly%20implemented%20across%20regions%20and%20HIV%20services.%20Most%20offered%20facility-based%20DSD%20for%20HIV%20treatment%20models%20and%203MMD%20for%20clinically%20stable%20clients.%20Efforts%20to%20expand%20DSD%20for%20HIV%20testing%20and%20ART%20initiation%20and%20to%20offer%20longer%20MMD%20can%20improve%20long-term%20retention%20in%20care%20of%20people%20living%20with%20HIV%20in%20LMICs%2C%20while%20further%20alleviating%20the%20operational%20burden%20on%20healthcare%20services.%20These%20findings%20from%20the%20pre-COVID-19%20era%20underline%20the%20need%20for%20strengthening%20DSD%20in%20HIV%20care%2C%20which%20remains%20at%20the%20centre%20of%20current%20efforts%20towards%20client-centred%20care.%22%2C%22date%22%3A%222025-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26477%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240622380%22%2C%22PMCID%22%3A%22PMC12232477%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22U9MPFR9U%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Laycock%20et%20al.%22%2C%22parsedDate%22%3A%222025-06-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLaycock%20K%2C%20Technau%20KG%2C%20Lelo%20P%2C%20Jantarabenjakul%20W%2C%20Yonaba%20C%2C%20Pinto%20J%2C%20et%20al.%20Tuberculosis%20Diagnosis%2C%20Treatment%2C%20and%20Prevention%20Services%20for%20Children%20Living%20with%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%3A%20A%20Multiregional%20Site%20Survey.%20J%20Pediatric%20Infect%20Dis%20Soc.%202025%20Jun%2016%3B14%286%29%3Apiaf050.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjpids%5C%2Fpiaf050%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjpids%5C%2Fpiaf050%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040425522%3B%20PubMed%20Central%20PMCID%3A%20PMC12257623.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tuberculosis%20Diagnosis%2C%20Treatment%2C%20and%20Prevention%20Services%20for%20Children%20Living%20with%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%3A%20A%20Multiregional%20Site%20Survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%22%2C%22lastName%22%3A%22Laycock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Watsamon%22%2C%22lastName%22%3A%22Jantarabenjakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Yonaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Menser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethel%22%2C%22lastName%22%3A%22Rambiki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%5Cu00e9lagie%22%2C%22lastName%22%3A%22Babakazo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Van%20Lam%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelson%22%2C%22lastName%22%3A%22Kalema%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Muula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dinh%20Qui%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joycelyn%22%2C%22lastName%22%3A%22Dame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20remains%20a%20leading%20cause%20of%20morbidity%20and%20mortality%20for%20children%20living%20with%20HIV%20%28CLHIV%29%2C%20with%20gaps%20in%20TB%20screening%2C%20diagnostics%2C%20management%2C%20and%20TB%20preventive%20therapy%20%28TPT%29.%20We%20investigated%20reported%20practices%20in%20these%20domains%20at%20sites%20caring%20for%20CLHIV%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%20within%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%5CnMETHODS%3A%20We%20implemented%20a%20site%20survey%20from%20September%202020%20to%20February%202021%2C%20querying%20pre-pandemic%20practices.%20This%20analysis%20included%20sites%20in%20LMICs%20providing%20care%20for%20CLHIV%20that%20diagnosed%20TB%20in%202019.%20We%20analyzed%20responses%20using%20descriptive%20statistics%20and%20assessed%20regional%20differences%20using%20Fisher%26%23039%3Bs%20exact%20or%20chi-square%20tests.%5CnRESULTS%3A%20Of%20238%20IeDEA%20sites%2C%20227%20%2895%25%29%20responded%20and%20135%20met%20the%20inclusion%20criteria.%20Most%20%2890%25%29%20reported%20screening%20for%20TB%20at%20HIV%20care%20enrollment.%20Access%20to%20diagnostics%20varied%20significantly%20by%20region%2C%20including%20nucleic%20acid%20amplification%20testing%20%28NAAT%2C%20range%2067-100%25%29%2C%20mycobacterial%20culture%20%28range%2043%25-83%25%29%2C%20and%20drug%20susceptibility%20testing%20%28range%2030%25-82%25%29%20%28P%5Cu2005%26lt%3B%5Cu2005.001%29.%20On-site%20TB%20treatment%20was%20high%20%2890%25%29.%20Reported%20stock-outs%20occurred%20for%20isoniazid%20%2823%5C%2F116%2C%2020%25%29%20and%20other%20TB%20medications%20%2811%5C%2F114%2C%209.6%25%2C%20range%200%25-33%25%2C%20P%5Cu2005%3D%5Cu2005.008%29.%20TPT%20provision%20ranged%2050%25-100%25%20%28P%5Cu2005%26lt%3B%5Cu2005.001%29.%20Six%20months%20of%20isoniazid%20was%20the%20most%20common%20TPT%20regimen%20for%20children%20%2888%25%29.%20Shorter%20TPT%20regimens%20were%20uncommon%20%280.9%25-2.8%25%29%2C%20as%20were%20regimens%20for%20multidrug-resistant%20TB%20exposure%20%284.6%25%29.%5CnCONCLUSIONS%3A%20Overall%20reported%20availability%20of%20NAAT%20and%20integrated%20TB%5C%2FHIV%20treatment%20for%20CLHIV%20cared%20for%20at%20these%20IeDEA%20sites%20in%20LMICs%20is%20encouraging%20but%20varies%20by%20context.%20Heterogeneous%20implementation%20gaps%20remain-particularly%20for%20drug%20susceptibility%20testing%2C%20TPT%20delivery%2C%20and%20TPT%20regimens-which%20may%20impede%20TB%20prevention%2C%20management%2C%20and%20successful%20outcomes%20for%20CLHIV%2C%20warranting%20continued%20close%20attention%20over%20time%20and%20as%20global%20TB%20care%20guidelines%20and%20services%20evolve.%22%2C%22date%22%3A%222025-06-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fjpids%5C%2Fpiaf050%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240425522%22%2C%22PMCID%22%3A%22PMC12257623%22%2C%22ISSN%22%3A%222048-7207%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22QTSBRQ4G%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castillo-Rozas%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastillo-Rozas%20G%2C%20Fonseca%20FF%2C%20Castilho%20J%2C%20Rebeiro%20PF%2C%20Machado%20DM%2C%20Luque%20MT%2C%20et%20al.%20ART%20to%20prevent%20vertical%20transmission%20in%20Latin%20America%3A%20where%20are%20we%20in%20the%20%26%23x201C%3BTreat-All%26%23x201D%3B%20era%3F%20J%20Int%20AIDS%20Soc.%202025%20May%3B28%285%29%3Ae26411.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26411%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26411%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040292653%3B%20PubMed%20Central%20PMCID%3A%20PMC12035647.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ART%20to%20prevent%20vertical%20transmission%20in%20Latin%20America%3A%20where%20are%20we%20in%20the%20%5C%22Treat-All%5C%22%20era%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Castillo-Rozas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%20F.%22%2C%22lastName%22%3A%22Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Antiretroviral%20therapy%20%28ART%29%20during%20pregnancy%20and%20at%20delivery%20has%20nearly%20eliminated%20vertical%20transmission%20%28VT%29%20in%20some%20settings%20but%20previously%20reported%20VT%20prevalence%20has%20been%20as%20high%20as%2015%25%20in%20Latin%20America%20and%20the%20Caribbean%20%28LAC%29.%20We%20evaluated%20VT%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20to%20further%20study%20the%20benefit%20of%20ART%20on%20VT%20in%20our%20region.%5CnMETHODS%3A%20We%20retrospectively%20collected%20data%20on%20cis-gender%20women%20%5Cu226515%20years%20of%20age%20enrolled%20in%20HIV%20clinics%20in%20Brazil%2C%20Chile%2C%20Honduras%20and%20Peru%20from%202003%20to%202018%20with%20%5Cu22651%20pregnancy%20resulting%20in%20a%20live%20birth%20after%20clinic%20entry%20to%20examine%20the%20association%20of%20ART%20use%20at%20the%20time%20of%20delivery%20and%20VT.%20We%20used%20propensity-score-matched%20logistic%20regression%20to%20examine%20the%20odds%20of%20VT%20by%20ART%20use.%20Matching%20weights%20incorporated%20site%2C%20HIV%20RNA%2C%20CD4%20cell%20count%2C%20maternal%20age%2C%20year%20and%20HIV%20diagnosis%20before%20or%20during%20pregnancy.%20We%20also%20examined%20the%20proportion%20of%20women%20who%20received%20ART%20during%20pregnancy%20before%20and%20after%20the%20treat-all%20era%2C%20as%20defined%20within%20each%20country.%5CnRESULTS%3A%20A%20total%20of%20623%20pregnant%20women%20with%20HIV%20contributed%20727%20live%20births.%20Of%20all%20births%2C%20613%20%2884.3%25%29%20infants%20had%20known%20HIV%20status%20and%20there%20were%2022%20%283.6%25%29%20VT%20events.%20Four%20of%20the%2022%20%2818%25%29%20were%20born%20to%20women%20on%20ART%20at%20delivery%2C%20compared%20to%20403%20of%20591%20%2868%25%29%20infants%20negative%20for%20HIV.%20In%20the%20propensity-score-matched%20model%2C%20ART%20use%20at%20delivery%20was%20associated%20with%2085%25%20decreased%20odds%20of%20VT%20%28odds%20ratio%20%3D%200.15%2C%2095%25%20confidence%20interval%200.04-0.58%29.%20In%20the%20pre-treat-all%20era%2C%2037%25%20%28181%5C%2F485%29%20of%20women%20received%20ART%20within%2030%20days%20of%20pregnancy%20diagnosis%2C%20compared%20to%2059%25%20%2875%5C%2F128%29%20during%20the%20treat-all%20era%20%28p%26lt%3B0.001%29.%20In%20the%20pre-treat-all%20era%2C%204.3%25%20%2821%5C%2F485%29%20of%20infants%20were%20born%20HIV%20positive%2C%20compared%20to%200.8%25%20%281%5C%2F128%29%20in%20the%20treat-all%20era%20%28p%20%3D%200.055%29.%5CnCONCLUSIONS%3A%20We%20found%20a%20low%20prevalence%20of%20VT%20in%20our%20cohort%2C%20especially%20in%20the%20treat-all%20era.%20ART%20use%20at%20delivery%20was%20strongly%20associated%20with%20a%20lower%20odd%20of%20VT.%20Despite%20improvements%2C%20access%20to%20ART%20during%20pregnancy%20remained%20far%20from%20universal.%20Therefore%2C%20new%20strategies%20to%20ensure%20its%20effective%20implementation%20in%20LAC%20are%20still%20warranted.%22%2C%22date%22%3A%222025-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26411%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240292653%22%2C%22PMCID%22%3A%22PMC12035647%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22NQHAV8HB%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pen%5Cu00e3%20Avila%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPen%26%23xE3%3B%20Avila%20J%2C%20Simmons%20J%2C%20Figueiredo%20MC%2C%20Turner%20M%2C%20Cordeiro-Santos%20M%2C%20Rolla%20VC%2C%20et%20al.%20Single-cell%20immune%20profiling%20at%20time%20of%20M.%20tuberculosis%20exposure%20reveals%20antigen-reactive%20programs%20that%20predict%20progression%20to%20active%20disease.%20medRxiv.%202025%20Apr%2030%3B2025.04.29.25326433.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.04.29.25326433%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.04.29.25326433%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040343021%3B%20PubMed%20Central%20PMCID%3A%20PMC12060959.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Single-cell%20immune%20profiling%20at%20time%20of%20M.%20tuberculosis%20exposure%20reveals%20antigen-reactive%20programs%20that%20predict%20progression%20to%20active%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Pen%5Cu00e3%20Avila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joshua%22%2C%22lastName%22%3A%22Simmons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%20L.%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rama%22%2C%22lastName%22%3A%22Gangula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cynthia%22%2C%22lastName%22%3A%22Nochowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramesh%22%2C%22lastName%22%3A%22Ram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Bailin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Mallal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvana%22%2C%22lastName%22%3A%22Gaudieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%20Barreto%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helder%20I.%22%2C%22lastName%22%3A%22Nakaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%20A.%22%2C%22lastName%22%3A%22Kalams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22Early%20delineation%20of%20host%20immune%20responses%20at%20the%20moment%20of%20Mycobacterium%20tuberculosis%20%28Mtb%29%20exposure%20and%20infection%20is%20critical%20to%20identify%20individuals%20at%20risk%20of%20progressing%20to%20active%20tuberculosis%20%28TB%29.%20We%20performed%20single-cell%20transcriptional%20profiling%20of%20over%20500%2C000%20peripheral%20blood%20mononuclear%20cells%20from%2057%20HIV-negative%20close%20contacts%20of%20TB%20cases%20in%20Brazil%2C%20including%2025%20individuals%20who%20developed%20active%20disease%20within%20two%20years%20%28progressors%29%20and%2032%20matched%20controls%20who%20remained%20disease-free%20%28non-progressors%29.%20Cells%20were%20stimulated%20separately%20with%20the%20MTB300%20peptide%20pool%20or%20irradiated%20Mtb%20%28gRV%29%2C%20enabling%20resolution%20of%20antigen-reactive%20states%20across%20adaptive%20%28CD4%5Cu207a%20T-cells%20expressing%20abundant%20cytokines%20including%20IFNG%2C%20TNF%2C%20and%20IL17F%29%20and%20trained-innate%20lineages%2C%20such%20as%20NK%20cells%20%28producing%20GM-CSF%2C%20IFNG%2C%20CCL3%2C%20CCL4%29%20and%20monocytes%20%28GM-CSF%2C%20IL12B%2C%20IL36G%29.%20Progressors%20exhibited%20early%20hyper-metabolic%20CD4%5Cu207a%20T-cell%20programs%20and%20proliferative%20NK%20cell%20signatures%2C%20whereas%20non-progressors%20preferentially%20upregulated%20complement%20activation%20and%20CCL3%5C%2F4-driven%20chemokine%20signaling%20in%20monocytes.%20Notably%2C%20among%20progressors%2C%20gene%20expression%20profiles%20within%20antigen-reactive%20CD4%5Cu207a%20T-cells%20and%20monocytes%20predicted%20the%20timing%20of%20progression%20to%20active%20TB.%20Together%2C%20these%20findings%20reveal%20high%20frequencies%20and%20functional%20diversity%20of%20antigen-reactive%20cells%20in%20Mtb-exposed%20individuals%20and%20nominate%20tractable%20immune%20correlates%20for%20the%20rational%20design%20of%20next-generation%20TB%20vaccines.%22%2C%22date%22%3A%222025-04-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1101%5C%2F2025.04.29.25326433%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240343021%22%2C%22PMCID%22%3A%22PMC12060959%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A35Z%22%7D%7D%2C%7B%22key%22%3A%224W3J4ARQ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Dill-McFarland%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BDill-McFarland%20KA%2C%20Andrade%20BB%2C%20Figueiredo%20MC%2C%20Andrade%20AMS%2C%20Avenda%26%23xF1%3Bo-Rangel%20F%2C%20Cordeiro-Santos%20M%2C%20et%20al.%20Genome-wide%20association%20study%20in%20Brazil%20identifies%20genetic%20susceptibility%20to%20tuberculosis%20with%20single-cell%20gene%20expression%20effects.%20medRxiv.%202025%20Apr%207%3B2025.03.13.25323932.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.03.13.25323932%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2025.03.13.25323932%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040162286%3B%20PubMed%20Central%20PMCID%3A%20PMC11952600.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genome-wide%20association%20study%20in%20Brazil%20identifies%20genetic%20susceptibility%20to%20tuberculosis%20with%20single-cell%20gene%20expression%20effects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberly%20A.%22%2C%22lastName%22%3A%22Dill-McFarland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francys%22%2C%22lastName%22%3A%22Avenda%5Cu00f1o-Rangel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20M.%22%2C%22lastName%22%3A%22Cubillos-Angulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%20A.%22%2C%22lastName%22%3A%22Kalams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josh%20D.%22%2C%22lastName%22%3A%22Simmons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jared%20M.%22%2C%22lastName%22%3A%22Oakes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20Pe%5Cu00f1a%22%2C%22lastName%22%3A%22Avila%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helder%20I.%22%2C%22lastName%22%3A%22Nakaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rama%20D.%22%2C%22lastName%22%3A%22Gangula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20A.%22%2C%22lastName%22%3A%22Mallal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20R.%22%2C%22lastName%22%3A%22Hawn%22%7D%5D%2C%22abstractNote%22%3A%22Although%20genetic%20factors%20contribute%20to%20tuberculosis%20%28TB%29%20risk%2C%20no%20cross-population%20causal%20variants%20have%20been%20identified%20by%20genome-wide%20association%20studies%20%28GWAS%29.%20Here%2C%20we%20utilized%20low-pass%20whole%20genome%20sequencing%20%28lpWGS%29%20with%20imputation%20plus%20detailed%20epidemiologic%20risk%20factors%20and%20single-cell%20expression%20quantitative%20loci%20%28sceQTL%29%20to%20address%20prior%20GWAS%20limitations.%20Using%20947%20pulmonary%20tuberculosis%20%28PTB%29%20cases%20and%201807%20close%20contact%20controls%20in%20the%20Regional%20Prospective%20Observational%20Research%20in%20TB%20%28RePORT%29%20study%20in%20Brazil%2C%20we%20estimated%20PTB%20heritability%20to%20be%2047.7%25.%20We%20identified%2019%20SNPs%20associated%20with%20PTB%20%28P%26lt%3B5E-8%29%20after%20adjustment%20for%20major%20risk%20factors%20%28HIV%2C%20diabetes%2C%20smoking%29.%20Seven%20of%20these%20SNPs%20were%20associated%20with%20peripheral%20blood%20cell-specific%20sceQTLs%20in%20controls.%20Specifically%2C%20SNPs%20cis%20to%20transcription%20factors%20ZNF717%20and%20MAML3%20were%20associated%20with%20PTB%20disease%20and%20gene%20expression%20in%20monocytes%2C%20T%20cells%2C%20or%20B%20cells.%20Overall%2C%20this%20study%20utilized%20lpWGS%2C%20in-depth%20epidemiology%2C%20and%20single-cell%20analyses%20to%20detect%20population-specific%20genetic%20risk%20factors%20for%20PTB%20in%20Brazil.%5CnSUMMARY%3A%20Robust%20correction%20for%20tuberculosis%20risk%20factors%20in%20GWAS%20in%20combination%20with%20paired%20single-cell%20transcriptomics%20reveals%20novel%20genetic%20risk%20of%20pulmonary%20tuberculosis%20with%20measurable%20consequences%20for%20baseline%20gene%20expression%20in%20multiple%20cell%20types.%22%2C%22date%22%3A%222025-04-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1101%5C%2F2025.03.13.25323932%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240162286%22%2C%22PMCID%22%3A%22PMC11952600%22%2C%22ISSN%22%3A%22%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A38%3A35Z%22%7D%7D%2C%7B%22key%22%3A%2282MDU9LE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Patten%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPatten%20G%2C%20Malateste%20K%2C%20Bolton%20Moore%20C%2C%20Sipambo%20N%2C%20Mokone%20L%2C%20Anderegg%20N%2C%20et%20al.%20Global%20Trends%20in%20CD4%20Measurement%20and%20Immunosuppression%20at%20ART%20Initiation%20Among%20Children%20With%20HIV.%20Pediatr%20Infect%20Dis%20J.%202025%20Apr%204%3B44%289%29%3A873%26%23×2013%3B5.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000004819%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000004819%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040233289%3B%20PubMed%20Central%20PMCID%3A%20PMC12314732.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20Trends%20in%20CD4%20Measurement%20and%20Immunosuppression%20at%20ART%20Initiation%20Among%20Children%20With%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%22%2C%22lastName%22%3A%22Bolton%20Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nosisa%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Limpho%22%2C%22lastName%22%3A%22Mokone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanina%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denna%22%2C%22lastName%22%3A%22Michael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dewi%22%2C%22lastName%22%3A%22Kumara%20Wati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Revathy%22%2C%22lastName%22%3A%22Nallusamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aarti%22%2C%22lastName%22%3A%22Kinikar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Du%20Tuan%22%2C%22lastName%22%3A%22Quy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Vanes%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nel%20Jason%22%2C%22lastName%22%3A%22Haw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20collaboration%22%7D%5D%2C%22abstractNote%22%3A%22Eligibility%20for%20antiretroviral%20therapy%20is%20no%20longer%20based%20on%20immune%20criteria.%20In%20a%20global%20cohort%20of%2097%2C453%20children%2C%20between%202005%20and%202021%2C%20we%20observed%20large%20declines%20in%20CD4%20measurement%2C%20from%2051%25%20to%2012%25%20among%20%26lt%3B5%20seconds%2C%20and%20from%2074%25%20to%2020%25%20among%20those%205-14%20years%20of%20age.%20Lack%20of%20CD4%20testing%20may%20negatively%20affect%20clinical%20care%20and%20surveillance%20of%20severe%20immune%20suppression.%22%2C%22date%22%3A%222025-04-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FINF.0000000000004819%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240233289%22%2C%22PMCID%22%3A%22PMC12314732%22%2C%22ISSN%22%3A%221532-0987%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22EV4W8MDV%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Embleton%20et%20al.%22%2C%22parsedDate%22%3A%222025-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEmbleton%20L%2C%20Sudjaritruk%20T%2C%20Machado%20DM%2C%20Chihota%20B%2C%20Musabyimana%20F%2C%20Jesson%20J%2C%20et%20al.%20Characterizing%20adolescent%20and%20youth-friendly%20HIV%20services%3A%20a%20cross-sectional%20assessment%20across%2016%20global%20sites.%20J%20Int%20AIDS%20Soc.%202025%20Apr%3B28%284%29%3Ae26437.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26437%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26437%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040181514%3B%20PubMed%20Central%20PMCID%3A%20PMC11968415.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Characterizing%20adolescent%20and%20youth-friendly%20HIV%20services%3A%20a%20cross-sectional%20assessment%20across%2016%20global%20sites%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lonnie%22%2C%22lastName%22%3A%22Embleton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Belinda%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Musabyimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Apondi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thanyawee%22%2C%22lastName%22%3A%22Puthanakit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%20Ellen%22%2C%22lastName%22%3A%22van%20Dongen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%22%2C%22lastName%22%3A%22Kwena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Perreras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%22%2C%22lastName%22%3A%22Lyamuya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Batya%22%2C%22lastName%22%3A%22Elul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxanne%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Adolescent%20and%20youth-friendly%20health%20services%20%28AYFHS%29%20have%20been%20promoted%20as%20a%20best%20practice%20for%20adolescents%20and%20young%20people%20living%20with%20HIV%20%28AYLH%29.%20However%2C%20thorough%20descriptions%20of%20AYFHS%20for%20AYLH%20remain%20scarce.%20We%20sought%20to%20characterize%20adolescent-friendly%20HIV%20services%20in%20a%20global%20paediatric%20research%20consortium.%5CnMETHODS%3A%20Cross-sectional%20data%20were%20collected%20from%2016%20global%20sites%20in%20the%20Adolescent%20and%20Young%20Adult%20Network%20of%20IeDEA%20%28AYANI%29%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%20between%20August%202020%20and%20October%202022%20using%20a%20standardized%20site%20assessment%20tool%20that%20collected%20data%20on%20clinic%2C%20patient%20and%20provider%20characteristics%2C%20differentiated%20care%2C%20and%20transition%20to%20adult%20services%20processes.%20Descriptive%20analyses%20characterized%20the%20health%20services%20available%20across%20the%20participating%20sites%2C%20using%20frequencies%20and%20proportions%20for%20categorical%20variables%20and%20medians%20and%20interquartile%20range%20for%20continuous%20variables.%20Data%20were%20analysed%20using%20RStudio.%5CnRESULTS%3A%20Overall%2C%2013%20of%2016%20sites%20%2881%25%29%20reported%20having%20dedicated%20adolescent%20services%2C%20which%20most%20often%20consisted%20of%20dedicated%20clinic%20days%20%2862%25%2C%20n%20%3D%208%5C%2F13%29%2C%20primarily%20offered%20on%20weekdays.%20Across%20all%20sites%2C%20nurses%20and%20counsellors%20delivered%20services%20to%20adolescents.%20Over%20half%20of%20all%20clinics%20%2869%25%2C%20n%20%3D%2011%5C%2F16%29%20reported%20offering%20health%20education%20to%20adolescents%20to%20facilitate%20adolescent%20health%20literacy.%20Peer%20educators%20and%20navigators%20were%20involved%20in%20delivering%20services%20at%2062%25%20of%20sites%2C%20primarily%20in%20those%20with%20dedicated%20adolescent%20services%20%2869%25%2C%20n%20%3D%209%5C%2F13%29.%20There%20was%20limited%20integration%20of%20sexual%20and%20reproductive%20health%20services%20into%20HIV%20clinics%20for%20adolescents.%20With%2063%25%20of%20clinics%20conducting%20pregnancy%20screening%2C%2050%25%20providing%20family%20planning%20methods%20and%2038%25%20providing%20cervical%20cancer%20screening.%20Under%20half%20of%20all%20HIV%20clinics%20screened%20for%20physical%20abuse%20or%20violence%20%2844%25%2C%20n%20%3D%207%5C%2F16%29%20and%20sexual%20abuse%20or%20rape%20%2838%25%2C%20n%20%3D%206%5C%2F16%29.%20A%20low%20proportion%20of%20clinics%20screened%20for%20risk%20factors%20related%20to%20young%20key%20populations%2C%20including%20drug%20use%20%2856%25%2C%20n%20%3D%209%5C%2F16%29%2C%20homelessness%20%2838%25%2C%20n%20%3D%206%5C%2F16%29%20young%20men%20having%20sex%20with%20men%20%2831%25%2C%20n%20%3D%205%5C%2F16%29%20and%20transactional%20sex%20%2831%25%2C%20n%20%3D%205%5C%2F16%29.%20Mental%20health%20screening%20for%20concerns%20was%20variable.%5CnCONCLUSIONS%3A%20Findings%20suggest%20gaps%20in%20AYFHS%20for%20AYLH%20across%20the%20HIV%20clinics%20included%20in%20this%20analysis.%20There%20is%20a%20vital%20need%20to%20design%20health%20services%20for%20AYLH%20that%20are%20accessible%2C%20equitable%2C%20and%20effective%20and%20meet%20the%20global%20standards%20for%20delivering%20high-quality%20healthcare%20to%20adolescents.%22%2C%22date%22%3A%222025-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26437%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240181514%22%2C%22PMCID%22%3A%22PMC11968415%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A40Z%22%7D%7D%2C%7B%22key%22%3A%225WP8YNAC%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Belaunzar%5Cu00e1n-Zamudio%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBelaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Rebeiro%20PF%2C%20Caro-Vega%20Y%2C%20Castilho%20J%2C%20Crabtree-Ram%26%23xED%3Brez%20BE%2C%20Cesar%20C%2C%20et%20al.%20Transitions%20through%20the%20HIV%20continuum%20of%20care%20in%20people%20enrolling%20in%20care%20with%20advanced%20HIV%20disease%20in%20Latin%20America.%20IJID%20Reg.%202025%20Mar%3B14%3A100550.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijregi.2024.100550%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijregi.2024.100550%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039877417%3B%20PubMed%20Central%20PMCID%3A%20PMC11772978.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transitions%20through%20the%20HIV%20continuum%20of%20care%20in%20people%20enrolling%20in%20care%20with%20advanced%20HIV%20disease%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mej%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilherme%22%2C%22lastName%22%3A%22Calvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Advanced%20HIV%20disease%20%28AHD%29%20at%20HIV%20care%20enrollment%20is%20common%20in%20Latin%20America%20and%20may%20bias%20cross-sectional%20care%20continuum%20estimates.%20We%20therefore%20explored%20the%20impact%20of%20AHD%20on%20HIV%20care%20continuum%20outcomes%20using%20a%20longitudinal%20approach.%5CnMETHODS%3A%20We%20analyzed%20trajectories%20of%2026%2C174%20adult%20people%20with%20HIV%20enrolled%20at%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20sites%20%282003-2019%29%20using%20multi-state%20Cox%20regression%20across%20five%20stages%3A%20%28i%29%20enrolled%20without%20antiretroviral%20therapy%20%28no-ART%29%3B%20%28ii%29%20on%20ART%20without%20viral%20suppression%20%28viral%20load%20%5Cu2265200%20copies%5C%2Fm%3B%20ART%20%2B%20non-VS%29%3B%20%28iii%29%20on%20ART%20with%20viral%20suppression%20%28viral%20load%20%26lt%3B200%20copies%5C%2Fml%3B%20ART%20%2B%20VS%29%3B%20%28iv%29%20lost%20to%20follow-up%3B%20%28v%29%20death.%20We%20defined%20AHD%20as%20clusters%20of%20differentiation%204%2B%20count%20%26lt%3B200%20cells%5C%2F%5Cu00b5l%20and%5C%2For%20an%20AIDS-defining%20illness%20at%20enrollment.%5CnRESULTS%3A%20People%20with%20HIV%20with%20AHD%20had%20a%20shorter%20time%20with%20no-ART%2C%20a%20similar%20time%20ART%20%2B%20non-VS%2C%20but%20less%20time%20ART%20%2B%20VS%20before%202013%20than%20non-AHD.%20After%202013%2C%20time%20with%20no-ART%20decreased%20but%20the%205-year%20probability%20of%20transitioning%20from%20no-ART%20to%20ART%20%2B%20VS%20decreased%20in%20both%20groups.%20The%20time%20spent%20virally%20suppressed%20while%20in%20care%20was%20low%2C%20overall.%20Risk%20of%20loss%20to%20follow-up%20and%20death%20was%20persistently%20worse%20among%20adults%20with%20AHD.%5CnCONCLUSIONS%3A%20Using%20a%20longitudinal%20approach%20to%20assess%20the%20HIV%20continuum%20of%20care%20provided%20insight%20into%20limitations%20in%20HIV%20care%20provision%20in%20our%20region%20previously%20underexplained%20by%20cross-sectional%20assessments.%22%2C%22date%22%3A%222025-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijregi.2024.100550%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239877417%22%2C%22PMCID%22%3A%22PMC11772978%22%2C%22ISSN%22%3A%222772-7076%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A40Z%22%7D%7D%2C%7B%22key%22%3A%222J5B4R6L%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRoss%20JL%2C%20Rupasinghe%20D%2C%20Chanyachukul%20T%2C%20Crabtree%20Ram%26%23xED%3Brez%20B%2C%20Murenzi%20G%2C%20Kwobah%20E%2C%20et%20al.%20Comorbidities%20and%20HIV-related%20factors%20associated%20with%20mental%20health%20symptoms%20and%20unhealthy%20substance%20use%20among%20older%20adults%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study.%20J%20Int%20AIDS%20Soc.%202025%20Mar%3B28%283%29%3Ae26434.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26434%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26434%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2040045453%3B%20PubMed%20Central%20PMCID%3A%20PMC11882396.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comorbidities%20and%20HIV-related%20factors%20associated%20with%20mental%20health%20symptoms%20and%20unhealthy%20substance%20use%20among%20older%20adults%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%20L.%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thida%22%2C%22lastName%22%3A%22Chanyachukul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree%20Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fiona%22%2C%22lastName%22%3A%22Mureithi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Marbaniang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dung%22%2C%22lastName%22%3A%22Thi%20Hoai%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22L%5Cu00f3pez-I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smita%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Sentinel%20Research%20Network%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20People%20with%20HIV%20%28PWH%29%20are%20vulnerable%20to%20mental%20health%20and%20substance%20use%20disorders%20%28MSDs%29%2C%20but%20the%20extent%20to%20which%20these%20are%20associated%20with%20other%20non-communicable%20diseases%20in%20ageing%20PWH%20populations%20remains%20poorly%20documented.%20We%20assessed%20comorbidities%20associated%20with%20symptoms%20of%20MSD%20among%20PWH%20%5Cu226540%20years%20in%20the%20Sentinel%20Research%20Network%20%28SRN%29%20of%20the%20International%20epidemiology%20Database%20to%20Evaluate%20AIDS%20%28IeDEA%29.%5CnMETHODS%3A%20Baseline%20data%20collected%20between%20June%202020%20and%20September%202022%2C%20from%2010%20HIV%20clinics%20in%20Asia%2C%20Latin%20America%20and%20Africa%20contributing%20to%20the%20SRN%2C%20were%20analysed.%20Symptoms%20of%20MSDs%20and%20comorbidities%20were%20assessed%20using%20standardized%20questionnaires%2C%20anthropometric%20and%20laboratory%20tests%2C%20including%20weight%2C%20height%2C%20blood%20pressure%2C%20glucose%2C%20lipids%2C%20chronic%20viral%20hepatitis%20and%20liver%20transient%20elastography.%20HIV%20viral%20load%2C%20CD4%20count%20and%20additional%20routine%20clinical%20data%20were%20accessed%20from%20participant%20interview%20or%20medical%20records.%20HIV%20and%20non-HIV%20clinical%20associations%20of%20mental%20illness%20symptoms%20and%20unhealthy%20substance%20use%20were%20analysed%20using%20logistic%20regression.%20Mental%20illness%20symptoms%20were%20defined%20as%20moderate-to-severe%20depressive%20symptoms%20%28PHQ-9%20score%20%26gt%3B9%29%2C%20moderate-to-severe%20anxiety%20symptoms%20%28GAD-7%20%26gt%3B9%29%20or%20probable%20post-traumatic%20stress%20disorder%20%28PCL-5%20%26gt%3B32%29.%20Unhealthy%20substance%20use%20was%20defined%20as%20ASSIST%20score%20%26gt%3B3%2C%20or%20AUDIT%20%5Cu22657%20for%20women%20%28%5Cu22658%20for%20men%29.%5CnRESULTS%3A%20Of%202614%20participants%20assessed%20at%20baseline%20study%20visits%2C%2057%25%20were%20female%2C%20median%20age%20was%2050%20years%2C%20median%20CD4%20was%20548%20cells%5C%2Fmm3%20and%2086%25%20had%20HIV%20viral%20load%20%26lt%3B1000%20copies%5C%2Fml.%20Overall%2C%2019%25%20had%20mental%20illness%20symptoms%2C%2015%25%20unhealthy%20substance%20use%2C%2049%25%20BMI%20%26gt%3B25%20kg%5C%2Fm2%2C%2038%25%20hypertension%2C%2015%25%20type%202%20diabetes%2C%2035%25%20dyslipidaemia%2C%2034%25%20liver%20disease%20and%2023%25%20history%20of%20tuberculosis.%20BMI%20%26gt%3B25%20and%20dyslipidaemia%20were%20found%20in%2054%25%20and%2040%25%20of%20those%20with%20mental%20illness%20symptoms%20compared%20to%2049%25%20and%2034%25%20of%20those%20without.%20Mental%20illness%20symptoms%20were%20not%20significantly%20associated%20with%20the%20clinical%20factors%20assessed.%20Unhealthy%20substance%20use%20was%20more%20likely%20among%20those%20with%20dyslipidaemia%20%28OR%201.55%2C%20CI%201.16-2.09%2C%20p%20%3D%200.003%29%2C%20and%20less%20likely%20in%20those%20with%20BMI%20%26gt%3B25%20%28OR%200.48%2C%20CI%200.30-0.77%2C%20p%20%3D%200.009%29.%5CnCONCLUSIONS%3A%20Improved%20integration%20of%20MSD%20and%20comorbidity%20services%20in%20HIV%20clinical%20settings%2C%20and%20further%20research%20on%20the%20association%20between%20MSD%20and%20comorbidities%2C%20and%20care%20integration%20among%20older%20PWH%20in%20low-middle-income%20countries%2C%20are%20required.%22%2C%22date%22%3A%222025-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26434%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2240045453%22%2C%22PMCID%22%3A%22PMC11882396%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22VFPVR2N2%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Amorim%20G%2C%20Figueiredo%20MC%2C%20Staats%20C%2C%20Kritski%20AL%2C%20Cordeiro-Santos%20M%2C%20et%20al.%20Effect%20of%20Smoking%20on%20Longitudinal%20Interferon%20%26%23x3B3%3B%20Release%20Assay%20Results%20Among%20Close%20Contacts%20of%20People%20with%20Pulmonary%20Tuberculosis.%20J%20Infect%20Dis.%202025%20Feb%204%3B231%281%29%3A103%26%23×2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae285%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae285%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038820119%3B%20PubMed%20Central%20PMCID%3A%20PMC11793032.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Smoking%20on%20Longitudinal%20Interferon%20%5Cu03b3%20Release%20Assay%20Results%20Among%20Close%20Contacts%20of%20People%20with%20Pulmonary%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cody%22%2C%22lastName%22%3A%22Staats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22Diagnosis%20of%20Mycobacterium%20tuberculosis%20infection%20in%20close%20contacts%20is%20critical%20for%20tuberculosis%20control.%20Smoking%20is%20a%20risk%20factor%20for%20M.%20tuberculosis%20infection%20and%20tuberculosis%20disease%20but%20its%20effect%20on%20longitudinal%20interferon%20%5Cu03b3%20release%20assay%20%28IGRA%29%20results%20remains%20unknown.%20We%20conducted%20a%20multisite%20prospective%20study%20in%20Brazil%20between%202015%20and%202019%2C%20among%20close%20contacts%20of%20adults%20with%20culture-confirmed%20pulmonary%20tuberculosis.%20IGRA%20was%20performed%20at%20baseline%2C%20at%20month%206%20if%20results%20were%20negative%20at%20baseline%2C%20and%20at%20months%2024-30%20after%20enrollment.%20IGRA%20results%20were%20categorized%20as%20IGRA%20positive%20%28maintained%20from%20baseline%20to%20the%20last%20visit%29%2C%20IGRA%20conversion%20%28from%20negative%20to%20positive%20at%20any%20time%29%2C%20IGRA%20reversion%20%28from%20positive%20to%20negative%20at%20any%20time%29%2C%20and%20IGRA%20negative%20%28maintained%20from%20baseline%20to%20the%20last%20visit%29.%20Associations%20between%20IGRA%20results%20and%20smoking%20status%20at%20baseline%20%28current%5C%2Fformer%20vs%20never%29%20in%20contacts%20were%20evaluated%20using%20propensity%20score-adjusted%20logistic%20regression%20models.%20Estimated%20propensity%20score%20was%20used%20as%20a%20covariate%20in%20models%2C%20which%20regressed%20the%20outcome%20%28IGRA%20positive%2C%20IGRA%20conversion%2C%20IGRA%20reversion%29%20on%20smoking%20status.%20Of%20430%20close%20contacts%2C%2089%20%2821%25%29%20were%20IGRA%20positive%2C%2030%20%287%25%29%20were%20converters%2C%2030%20%287%25%29%20were%20reverters%20and%2022%20were%20indeterminate.%20Smoking%20frequency%20was%2026%20%2829%25%29%20among%20IGRA-positive%20contacts%2C%207%20%2823%25%29%20in%20converters%2C%20and%203%20%2810%25%29%20in%20reverters.%20Smoking%20in%20contacts%20was%20associated%20with%20lower%20odds%20of%20IGRA%20reversion%20%28adjusted%20odds%20ratio%2C%200.16%20%5B95%25%20confidence%20interval%2C%20.03-.70%5D%29.%20We%20did%20not%20detect%20associations%20between%20smoking%20and%20IGRA%20positive%20or%20IGRA%20conversion.%20Our%20findings%20highlight%20the%20importance%20of%20smoking%20on%20longitudinal%20IGRA%20results.%20This%20has%20implications%20for%20clinical%20care%20and%20clinical%20trials%20in%20which%20IGRA%20status%20is%20monitored%20or%20used%20as%20an%20outcome.%22%2C%22date%22%3A%222025-02-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiae285%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238820119%22%2C%22PMCID%22%3A%22PMC11793032%22%2C%22ISSN%22%3A%221537-6613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A39Z%22%7D%7D%2C%7B%22key%22%3A%223Y6B28C6%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Amorim%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAmorim%20G%2C%20Jaworski%20J%2C%20Yang%20J%2C%20Cordeiro-Santos%20M%2C%20Kritski%20AL%2C%20Figueiredo%20MC%2C%20et%20al.%20Pharmacogenetics%20of%20tuberculosis%20treatment%20toxicity%20and%20effectiveness%20in%20a%20large%20Brazilian%20cohort.%20Pharmacogenet%20Genomics.%202025%20Feb%201%3B35%282%29%3A55%26%23×2013%3B64.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFPC.0000000000000552%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FFPC.0000000000000552%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039470346%3B%20PubMed%20Central%20PMCID%3A%20PMC11695165.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacogenetics%20of%20tuberculosis%20treatment%20toxicity%20and%20effectiveness%20in%20a%20large%20Brazilian%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%22%2C%22lastName%22%3A%22Jaworski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Digna%20R.%22%2C%22lastName%22%3A%22Velez%20Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adalberto%20R.%22%2C%22lastName%22%3A%22Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Genetic%20polymorphisms%20have%20been%20associated%20with%20risk%20of%20antituberculosis%20treatment%20toxicity.%20We%20characterized%20associations%20with%20adverse%20events%20and%20treatment%20failure%5C%2Frecurrence%20among%20adults%20treated%20for%20tuberculosis%20in%20Brazil.%5CnMETHODS%3A%20Participants%20were%20followed%20in%20Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil.%20We%20included%20persons%20with%20culture-confirmed%20drug-susceptible%20pulmonary%20tuberculosis%20who%20started%20treatment%20between%202015%20and%202019%2C%20and%20who%20were%20eligible%20for%20pharmacogenetics.%20Treatment%20included%202%5Cu2005months%20of%20isoniazid%2C%20rifampin%20or%20rifabutin%2C%20pyrazinamide%2C%20and%20ethambutol%2C%20then%204%5Cu2005months%20of%20isoniazid%20and%20rifampin%20or%20rifabutin%2C%20with%2024-month%20follow-up.%20Analyses%20included%2043%20polymorphisms%20in%2020%20genes%20related%20to%20antituberculosis%20drug%20hepatotoxicity%20or%20pharmacokinetics.%20Whole%20exome%20sequencing%20was%20done%20in%20a%20case-control%20toxicity%20subset.%5CnRESULTS%3A%20Among%20903%20participants%20in%20multivariable%20genetic%20association%20analyses%2C%20NAT2%20slow%20acetylator%20status%20was%20associated%20with%20increased%20risk%20of%20treatment-related%20grade%202%20or%20greater%20adverse%20events%2C%20including%20hepatotoxicity.%20Treatment%20failure%5C%2Frecurrence%20was%20more%20likely%20among%20NAT2%20rapid%20acetylators%2C%20but%20not%20statistically%20significant%20at%20the%205%25%20level.%20A%20GSTM1%20polymorphism%20%28rs412543%29%20was%20associated%20with%20increased%20risk%20of%20treatment-related%20adverse%20events%2C%20including%20hepatotoxicity.%20SLCO1B1%20polymorphisms%20were%20associated%20with%20increased%20risk%20of%20treatment-related%20hepatoxicity%20and%20treatment%20failure%5C%2Frecurrence.%20Polymorphisms%20in%20NR1%5C%2F2%20were%20associated%20with%20decreased%20risk%20of%20adverse%20events%20and%20increased%20risk%20of%20failure%5C%2Frecurrence.%20In%20whole%20exome%20sequencing%2C%20hepatotoxicity%20was%20associated%20with%20a%20polymorphism%20in%20VTI1A%20%2C%20and%20the%20genes%20METTL17%20and%20PRSS57%20%2C%20but%20none%20achieved%20genome-wide%20significance.%5CnCONCLUSION%3A%20In%20a%20clinical%20cohort%20representing%20three%20regions%20of%20Brazil%2C%20NAT2%20acetylator%20status%20was%20associated%20with%20risk%20for%20treatment-related%20adverse%20events.%20Additional%20significant%20polymorphisms%20merit%20investigation%20in%20larger%20study%20populations%2C%20particularly%20regarding%20risk%20of%20treatment%20failure%5C%2Frecurrence.%22%2C%22date%22%3A%222025-02-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FFPC.0000000000000552%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239470346%22%2C%22PMCID%22%3A%22PMC11695165%22%2C%22ISSN%22%3A%221744-6880%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22QENUDXIK%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Mej%5Cu00eda-Castrej%5Cu00f3n%20et%20al.%22%2C%22parsedDate%22%3A%222025-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMej%26%23xED%3Ba-Castrej%26%23xF3%3Bn%20J%2C%20Caro-Vega%20Y%2C%20Sierra-Madero%20JG%2C%20L%26%23xF3%3Bpez-I%26%23xF1%3Biguez%20A%2C%20Crabtree-Ram%26%23xED%3Brez%20BE.%20The%20Trend%20in%20Suicide%20Risk%20Among%20People%20with%20HIV%20Before%2C%20During%2C%20and%20After%20the%20COVID-19%20Pandemic%20Lockdown.%20AIDS%20Behav.%202025%20Feb%3B29%282%29%3A664%26%23×2013%3B72.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-024-04548-z%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-024-04548-z%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039643783%3B%20PubMed%20Central%20PMCID%3A%20PMC11814011.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Trend%20in%20Suicide%20Risk%20Among%20People%20with%20HIV%20Before%2C%20During%2C%20and%20After%20the%20COVID-19%20Pandemic%20Lockdown%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Mej%5Cu00eda-Castrej%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22L%5Cu00f3pez-I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%5D%2C%22abstractNote%22%3A%22Suicide%20Risk%20%28SR%29%20and%20the%20COVID-19%20pandemic%20affected%20People%20with%20HIV%20%28PWH%29%20disproportionately%20in%20comparison%20with%20the%20general%20population%2C%20but%20little%20information%20on%20SR%20during%20and%20after%20the%20COVID-19%20lockdown%20on%20the%20Latino%20PWH%20has%20been%20described%2C%20therefore%2C%20this%20study%20aimed%20to%20describe%20SR%20in%20PWH%20attended%20the%20HIV%20clinic%20before%20%282018-2019%29%2C%20during%20%282020%29%2C%20and%20after%20%282021-2022%29%20the%20COVID-19%20lockdown%2C%20the%20trend%20of%20SR%2C%20and%20the%20factors%20associated.%20Three%20standardized%20questions%20from%20the%20%26quot%3BColumbia-Suicide%20Severity%20Rating%20Scale%26quot%3B%20%28C-SSRS%29%20were%20routinely%20applied%20as%20screening%20for%20suicide%20risk%20to%20all%20PWH%20attending%20their%20clinical%20visits%20during%202018-2022.%20We%20estimated%20suicidality%20risk%20and%20rate.%20We%20compared%20sociodemographic%20characteristics%20in%20those%20with%20and%20without%20SR.%20We%20evaluated%20the%20potential%20association%20of%20SR%20with%20the%20calendar%20year%20before%2C%20during%2C%20and%20after%20the%20COVID-19%20lockdown%20using%20a%20mixed-effects%20logistic%20regression.%20A%20total%20of%202330%20patients%20were%20seen%20during%20the%20study%20period%3B%202157%20%2893%25%29%20were%20evaluated%20for%20suicidality%20at%20least%20once%2C%20of%20those%2C%2075%20%283.5%25%29%20had%20SR.%20Those%20with%20SR%20compared%20with%20non-SR%20were%20more%20frequently%20women%20%2820%25%20vs%2010%25%29%20and%20with%20a%20heterosexual%20HIV%20transmission%20route%20%2829%25%20vs%2023%25%29.%20SR%20rates%20per%201000%20patients-day%20among%20those%20evaluated%20were%200.03%20in%202018%2C%200.25%20in%202019%2C%203.16%20in%202020%2C%207.0%20in%202021%20and%2011.98%20in%202022.%20Throughout%20the%20model%2C%20independently%20of%20covariables%2C%20a%20significant%20increase%20in%20the%20OR%20of%20SR%20was%20observed%20in%20these%20years%20compared%20to%202018%3A%201.07%20in%202019%3B%202.74%20in%202021%3B%20and%204.82%20in%202022%2C%20except%20in%202020%2C%20OR%5Cu2009%3D%5Cu20090.18.%22%2C%22date%22%3A%222025-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-024-04548-z%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239643783%22%2C%22PMCID%22%3A%22PMC11814011%22%2C%22ISSN%22%3A%221573-3254%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22QSX5H87Q%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ford%20et%20al.%22%2C%22parsedDate%22%3A%222025-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BFord%20N%2C%20Kassanjee%20R%2C%20Stelzle%20D%2C%20Jarvis%20JN%2C%20Sued%20O%2C%20Perrin%20G%2C%20et%20al.%20Global%20prevalence%20of%20advanced%20HIV%20disease%20in%20healthcare%20settings%3A%20a%20rapid%20review.%20J%20Int%20AIDS%20Soc.%202025%20Feb%3B28%282%29%3Ae26415.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26415%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26415%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039915008%3B%20PubMed%20Central%20PMCID%3A%20PMC11802239.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20prevalence%20of%20advanced%20HIV%20disease%20in%20healthcare%20settings%3A%20a%20rapid%20review%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominik%22%2C%22lastName%22%3A%22Stelzle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20N.%22%2C%22lastName%22%3A%22Jarvis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Sued%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meg%22%2C%22lastName%22%3A%22Doherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%22%2C%22lastName%22%3A%22Rangaraj%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Recent%20studies%20have%20indicated%20a%20high%20enduring%20burden%20of%20advanced%20HIV%20disease%2C%20but%20estimates%20across%20regions%20and%20settings%20are%20lacking.%20The%20aim%20of%20this%20study%20was%20to%20estimate%20the%20prevalence%20of%20advanced%20HIV%20disease%20since%202015%20among%20those%20people%20with%20CD4%20measured%20in%20healthcare%20settings%2C%20disaggregated%20by%20age%20group%2C%20level%20of%20healthcare%20and%20region.%5CnMETHODS%3A%20We%20searched%20MedLine%20via%20Pubmed%20and%20Hinari%20for%20studies%20that%20reported%20the%20proportion%20of%20individuals%20with%20advanced%20HIV%20disease%20%28defined%20as%20CD4%20cell%20count%20%26lt%3B200%20cells%5C%2Fmm3%29%20in%20healthcare%20settings%20since%202015%3B%20this%20search%20was%20complemented%20by%20conference%20abstracts%20and%20data%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20Consortium%20%28IeDEA%29.%20We%20estimated%20pooled%20prevalence%20of%20advanced%20HIV%20disease%20using%20random-effects%20models%20and%20performed%20subgroup%20and%20sensitivity%20analyses%20to%20explore%20heterogeneity.%5CnRESULTS%3A%20We%20obtained%20data%20from%20117%20cohorts%2C%20representing%201%2C814%2C362%20individuals%20from%2052%20countries%20across%20all%20six%20World%20Health%20Organization%20regions.%20The%20majority%20of%20studies%20%28n%20%3D%2083%29%20were%20conducted%20among%20adults%20and%20recorded%20CD4%20cell%20count%20among%20treatment%20na%5Cu00efve%20individuals%20at%20antiretroviral%20therapy%20start%20%28n%20%3D%2086%29.%20Studies%20included%20data%20reported%20up%20to%202023.%20The%20proportion%20of%20individuals%20with%20advanced%20HIV%20disease%20was%20higher%20in%20inpatient%20settings%20%2844.3%25%2C%2095%25%20CI%2039.1-49.6%25%29%20compared%20to%20outpatient%20settings%20%2833.5%25%2C%2095%25%20CI%2031.5-35.4%25%29.%20Prevalence%20was%20similar%20across%20age%20groups%2C%20time%20since%20HIV%20diagnosis%20and%20treatment%20status%2C%20and%20highest%20in%20West%20and%20Central%20Africa%2C%20South-East%20Asia%20and%20the%20Eastern%20Mediterranean%20region.%5CnDISCUSSION%3A%20This%20review%20finds%20that%20at%20least%20a%20third%20of%20people%20presenting%20to%20healthcare%20settings%20have%20advanced%20HIV%20disease%2C%20with%20no%20evidence%20that%20this%20has%20changed%20in%20recent%20years.%20Screening%20for%20advanced%20HIV%20remains%20important%20to%20be%20able%20to%20direct%20appropriate%20preventive%2C%20diagnostic%20and%20therapeutic%20interventions%20to%20prevent%20progression%20to%20severe%20illness%20and%20death.%5CnCONCLUSIONS%3A%20This%20review%20summarizes%20recent%20evidence%20of%20the%20continued%20high%20proportion%20of%20individuals%20who%20%28re%29present%20to%20care%20with%20advanced%20HIV%20disease.%20These%20findings%20underscore%20the%20urgent%20need%20to%20reinforce%20programme%20capacity%20to%20diagnose%2C%20prevent%20and%20treat%20advanced%20HIV%20disease%20as%20an%20essential%20pillar%20of%20the%20global%20AIDS%20response.%22%2C%22date%22%3A%222025-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26415%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239915008%22%2C%22PMCID%22%3A%22PMC11802239%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A37%3A28Z%22%7D%7D%2C%7B%22key%22%3A%2279VW6SSF%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Kuniholm%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKuniholm%20MH%2C%20Murenzi%20G%2C%20Shumbusho%20F%2C%20Brazier%20E%2C%20Plaisy%20MK%2C%20Mensah%20E%2C%20et%20al.%20Association%20of%20cardiovascular%20disease%20risk%20with%20liver%20steatosis%20and%20fibrosis%20in%20people%20with%20HIV%20in%20low-%20and%20middle-income%20countries.%20AIDS.%202025%20Jan%201%3B39%281%29%3A11%26%23×2013%3B21.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004012%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004012%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039264586%3B%20PubMed%20Central%20PMCID%3A%20PMC11624086.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20cardiovascular%20disease%20risk%20with%20liver%20steatosis%20and%20fibrosis%20in%20people%20with%20HIV%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20K.%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlotta%22%2C%22lastName%22%3A%22Riebensahm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Belinda%20V.%22%2C%22lastName%22%3A%22Chihota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niharika%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20S.%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thida%22%2C%22lastName%22%3A%22Chanyachukul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohidas%22%2C%22lastName%22%3A%22Borse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dung%20T.%20H.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez-Iniguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20understand%20the%20relationship%20between%20cardiovascular%20disease%20%28CVD%29%20risk%20and%20liver%20steatosis%20and%20fibrosis%20among%20people%20with%20HIV%20%28PLWH%29%20at%20least%2040%5Cu200ayears%20of%20age%20on%20antiretroviral%20therapy%20%28ART%29%20in%20low%20and%20middle-income%20countries%20%28LMIC%29.%5CnDESIGN%3A%20We%20used%20cross-sectional%20behavioral%20and%20clinical%20data%20collected%20during%20study%20enrollment%20visits%20in%202020-2022%20for%20the%20Sentinel%20Research%20Network%20of%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28SRN%20of%20IeDEA%29.%5CnMETHODS%3A%20Ten-year%20CVD%20risk%20was%20calculated%20using%202019%20WHO%20nonlaboratory%20and%20laboratory%20models.%20Transient%20elastography%20was%20used%20to%20assess%20liver%20disease.%20Presence%20of%20steatosis%20and%20significant%20fibrosis%20were%20defined%20by%20controlled%20attenuation%20parameter%20%28CAP%29%20at%20least%20248%5Cu200adB%5C%2Fm%20and%20liver%20stiffness%20measurement%20%28LSM%29%20at%20least%207.1%5Cu200akPa%2C%20respectively.%20Participants%20with%20viral%20hepatitis%2C%20hazardous%20alcohol%20consumption%2C%20and%20unsuppressed%20HIV%20viral%20load%20were%20excluded%20from%20the%20analysis.%20Logistic%20regression%20was%20used%20to%20estimate%20odds%20ratios%2C%20adjusting%20for%20study%20site%2C%20CD4%20%2B%20%5Cu200aT%20cell%20count%2C%20stavudine%20and%20didanosine%20exposure%2C%20and%20in%20models%20stratified%20by%20sex%20and%20geographic%20region.%5CnRESULTS%3A%20There%20were%201750%20participants%20from%20nine%20LMIC.%20Median%20CVD%20risk%20was%203%25%20for%20both%20nonlaboratory%20and%20laboratory-based%20models.%20Adjusted%20odds%20ratios%20%28ORs%29%20for%20steatosis%20and%20significant%20fibrosis%20associated%20with%20laboratory%20CVD%20risk%20%28%5Cu226510%20vs.%20%26lt%3B5%25%29%20were%20OR%5Cu200a%3D%5Cu200a1.83%20%5B95%25%20confidence%20interval%20%2895%25%20CI%29%5Cu200a%3D%5Cu200a1.21-2.76%3B%20P%20%5Cu200a%3D%5Cu200a0.004%5D%20and%20OR%5Cu200a%3D%5Cu200a1.62%20%2895%25%20CI%5Cu200a%3D%5Cu200a0.85-3.07%3B%20P%20%5Cu200a%3D%5Cu200a0.14%29%2C%20respectively.%20Associations%20of%20CVD%20risk%20with%20steatosis%20were%20stronger%20in%20men%20and%20among%20participants%20at%20study%20sites%20outside%20Africa.%5CnCONCLUSION%3A%20Higher%20CVD%20risk%20was%20associated%20with%20steatosis%20but%20not%20with%20significant%20fibrosis%20in%20PWH%20in%20our%20LMIC%20cohort.%22%2C%22date%22%3A%222025-01-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000004012%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239264586%22%2C%22PMCID%22%3A%22PMC11624086%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A36%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22PSEZXA9F%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Villalva-Serra%20et%20al.%22%2C%22parsedDate%22%3A%222025-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVillalva-Serra%20K%2C%20Barreto-Duarte%20B%2C%20Rodrigues%20MM%2C%20Queiroz%20ATL%2C%20Martinez%20L%2C%20Croda%20J%2C%20et%20al.%20Impact%20of%20strategic%20public%20health%20interventions%20to%20reduce%20tuberculosis%20incidence%20in%20Brazil%3A%20a%20Bayesian%20structural%20time-series%20scenario%20analysis.%20Lancet%20Reg%20Health%20Am.%202025%20Jan%3B41%3A100963.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100963%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100963%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039759249%3B%20PubMed%20Central%20PMCID%3A%20PMC11697790.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20strategic%20public%20health%20interventions%20to%20reduce%20tuberculosis%20incidence%20in%20Brazil%3A%20a%20Bayesian%20structural%20time-series%20scenario%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klauss%22%2C%22lastName%22%3A%22Villalva-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julio%22%2C%22lastName%22%3A%22Croda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20government%20efforts%2C%20tuberculosis%20%28TB%29%20remains%20a%20major%20public%20health%20threat%20in%20Brazil.%20In%202023%2C%20TB%20incidence%20was%2039.8%20cases%20per%20100%2C000%20population%2C%20far%20above%20the%20WHO%26%23039%3Bs%20target%20of%206.7%20cases%20per%20100%2C000.%20Using%20national-level%20datasets%2C%20we%20investigated%20and%20forecasted%20the%20potential%20impact%20of%20proposed%20public%20health%20interventions%20aimed%20at%20reducing%20TB%20incidence%20in%20Brazil.%5CnMETHODS%3A%20Monthly%20TB%20surveillance%20data%20%28January%202018-December%202023%29%20were%20collected%20from%20Brazilian%20national%20reporting%20systems%3A%20SINAN-TB%20%28TB%20cases%29%2C%20SITE-TB%20%28TB%20drug%20resistance%29%2C%20and%20IL-TB%20%28preventive%20therapy%29.%20These%20data%20were%20used%20to%20create%20a%20multivariable%20Bayesian%20Structural%20Time-Series%20%28BSTS%29%20model%2C%20with%205000%20Monte-Carlo%20simulations%2C%20which%20identified%20key%20predictors%20of%20TB%20incidence%20and%20forecasted%20these%20rates%20from%202024%20to%202030%20under%20various%20scenarios.%5CnFINDINGS%3A%20Vulnerabilities%20including%20incarceration%2C%20TB-HIV%20coinfection%20and%20TB-diabetes%20mellitus%2C%20as%20well%20as%20coverages%20of%20directly%20observed%20therapy%20%28DOT%29%2C%20contact%20investigation%20and%20preventive%20treatment%20%28TPT%29%20completion%20rates%2C%20were%20identified%20as%20key%20predictors%20of%20TB%20incidence.%20Under%20current%20trends%2C%20we%20forecasted%20TB%20incidence%20in%20Brazil%20to%20be%2042.1%20%5B34.1-49.8%5D%20per%20100%2C000%20person-years%20by%202030%20%28mean%20%5B95%25%20prediction%20intervals%5D%29.%20A%20scenario%20considering%20decreases%20in%20TB%20cases%20among%20vulnerable%20populations%20resulted%20in%20an%20absolute%20reduction%20of%5Cu00a0-10.6%20%5B-9.4%20to%5Cu00a0-12.0%5D%20in%20projected%20TB%20incidence.%20Additional%20reductions%20were%20seen%20with%20increased%20coverage%20of%20DOT%2C%20TPT%20adherence%2C%20and%20contact%20investigation%20rates%20%28-14.4%20%5B-13%20to%5Cu00a0-16.2%5D%29%2C%20and%20by%20combining%20these%20with%20efforts%20to%20reduce%20TB%20cases%20among%20vulnerable%20populations%20%28-23.6%20%5B-26.3%20to%5Cu00a0-41.4%5D%29%2C%20potentially%20lowering%20incidence%20to%2018.5%20%5B7.8-28.4%5D%20per%20100%2C000%2C%20though%20still%20above%20WHO%20targets.%5CnINTERPRETATION%3A%20Our%20findings%20demonstrate%20that%20interventions%20focused%20on%20enhancing%20health%20policies%20focused%20on%20decreasing%20TB%20cases%20among%20vulnerable%20populations%2C%20such%20as%20individuals%20with%20TB-HIV%20coinfection%2C%20incarcerated%20populations%2C%20and%20those%20with%20TB-diabetes%20comorbidity%2C%20along%20with%20improvements%20in%20health%20management%20indicators%20such%20as%20DOT%20implementation%2C%20contact%20investigation%20coverage%2C%20and%20TPT%20completion%20rates%2C%20are%20effective%20in%20reducing%20TB%20incidence%20nationwide.%5CnFUNDING%3A%20Oswaldo%20Cruz%20Foundation.%22%2C%22date%22%3A%222025-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2024.100963%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239759249%22%2C%22PMCID%22%3A%22PMC11697790%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A47Z%22%7D%7D%5D%7D
1.
Plaisy MK, Mondoka C, Moreira R, Samala N, Borse R, Kuniholm MH, et al. Diagnostic value of serological scores for the detection of liver steatosis in people living with HIV in low- and middle-income countries. AIDS. 2025 Dec 30. http://doi.org/10.1097/QAD.0000000000004434 PubMed PMID: 41467701.
1.
Sobral L, Arriaga MB, Souza AB, Barreto-Duarte B, Garcia-Rosa BS, Fernandes CD, et al. Mycobacterium tuberculosis transmission among child and adolescent contacts of people with pulmonary tuberculosis in Brazil: a multi-center prospective cohort study. BMC Infect Dis. 2025 Dec 22;25(1):1789. http://doi.org/10.1186/s12879-025-12268-5 PubMed PMID: 41430120; PubMed Central PMCID: PMC12750610.
1.
Pan Z, Brazier E, Duda SN, Ross J, Templeton DJ, Pujari S, et al. Limited user fees for adult HIV diagnosis and routine laboratory monitoring in the global IeDEA consortium: analysis in 42 countries. medRxiv. 2025 Dec 7;2025.12.05.25341715. http://doi.org/10.64898/2025.12.05.25341715 PubMed PMID: 41404269; PubMed Central PMCID: PMC12704637.
1.
Amorim G, Slone J, Semeere A, Diero L, Otero L, Crabtree-Ramirez B, et al. Data validation in multinational observational studies with error-prone data: applying an optimal validation sampling strategy in a study of Kaposi sarcoma and HIV. Am J Epidemiol. 2025 Nov 25;kwaf264. http://doi.org/10.1093/aje/kwaf264 PubMed PMID: 41288120.
1.
Liang ZJ, Li Z, Jackson NJ, Caro-Vega Y, Moreira RI, Paredes F, et al. Generating Synthetic Multi-national Longitudinal Cohorts for Clinically Grounded HIV Research. medRxiv. 2025 Nov 17;2025.11.14.25340245. http://doi.org/10.1101/2025.11.14.25340245 PubMed PMID: 41332815; PubMed Central PMCID: PMC12668065.
1.
Arabadjis SD, Davenport F, Vecedo Cabrera AM, Shahn Z, Brazier E, Maroko A, et al. Modeling the Burden of Extreme Weather Events in a Large Network of International HIV Care Cohorts. Geohealth. 2025 Nov;9(11):e2025GH001514. http://doi.org/10.1029/2025GH001514 PubMed PMID: 41195258; PubMed Central PMCID: PMC12583239.
1.
He J, Brewer E, Novotney A, Carter A, Paul H, Walters MK, et al. HIV-related mortality time trends among children and young adolescents on antiretroviral therapy by age, treatment duration, and region: a systematic review and meta-regression analysis. Lancet HIV. 2025 Nov;12(11):e774–88. http://doi.org/10.1016/S2352-3018(25)00168-7 PubMed PMID: 40912259; PubMed Central PMCID: PMC12774562.
1.
Mendelsohn SC, Andrade BB, Araújo-Pereira M, Amorim GC, Erasmus M, Andrade AM, et al. Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in Brazil. medRxiv. 2025 Oct 8;2025.10.07.25337480. http://doi.org/10.1101/2025.10.07.25337480 PubMed PMID: 41282706; PubMed Central PMCID: PMC12632667.
1.
Vreeman RC, Yiannoutsos CT, Edmonds A, Leroy V, Fatti G, Kosalaraksa P, et al. Rates of adherence, adherence measurement, and support services for children and adolescents living with HIV followed in global sites of the International Epidemiology Databases to Evaluate AIDS (IeDEA). BMC Pediatr. 2025 Oct 2;25(1):706. http://doi.org/10.1186/s12887-025-05939-4 PubMed PMID: 41039293; PubMed Central PMCID: PMC12492743.
1.
Shepherd BE, Liang Z, Kim A, Cesar C, Veloso VG, Cortes CP, et al. Temporal trends in tuberculosis and time from enrolment in care to antiretroviral therapy initiation: A multicountry cohort study from Latin America. Int J Infect Dis. 2025 Oct;159:107979. http://doi.org/10.1016/j.ijid.2025.107979 PubMed PMID: 40653148; PubMed Central PMCID: PMC12700299.
1.
Pellegrino RA, Tu S, Ville-Benavides R, Jalil EM, Sudenga SL, Crabtree-Ramírez B, et al. Incidence and outcomes of anal and cervical cancer among adults with HIV in Latin America: a retrospective cohort study. J Int AIDS Soc. 2025 Oct;28(10):e70050. http://doi.org/10.1002/jia2.70050 PubMed PMID: 41074705; PubMed Central PMCID: PMC12514557.
1.
Ferreira IBB, Menezes RC, Araújo-Pereira M, Rolla VC, Kritski AL, Cordeiro-Santos M, et al. Effects of missed anti-tuberculosis therapy doses on treatment outcome: a multi-center cohort study. Lancet Reg Health Am. 2025 Aug;48:101162. http://doi.org/10.1016/j.lana.2025.101162 PubMed PMID: 40657430; PubMed Central PMCID: PMC12246921.
1.
de Waal R, Wools-Kaloustian K, Brazier E, Althoff KN, Jaquet A, Duda SN, et al. Global Trends in CD4 Count Measurement and Distribution at First Antiretroviral Treatment Initiation. Clin Infect Dis. 2025 Jul 18;80(6):1332–6. http://doi.org/10.1093/cid/ciae548 PubMed PMID: 39501773; PubMed Central PMCID: PMC12264493.
1.
Guerrero-Torres L, Barbosa-Ramírez BM, Belaunzarán-Zamudio PF, Alegre-Díaz J, Ramírez R, Rosa-Parra A, et al. Improving estimators of HIV mortality and retention in care by linking clinical cohort data with national registries in Mexico. BMC Public Health. 2025 Jul 17;25(1):2489. http://doi.org/10.1186/s12889-025-23542-1 PubMed PMID: 40676585; PubMed Central PMCID: PMC12272977.
1.
Fonseca FF, Ranadive P, Shepherd BE, Ferreira FGF, Rodríguez MF, Machado DM, et al. Persistent sex disparities in access to dolutegravir-based antiretroviral therapy in Latin America and the Caribbean: results from a retrospective observational study using data from 2017 to 2022. J Int AIDS Soc. 2025 Jul;28(7):e26470. http://doi.org/10.1002/jia2.26470 PubMed PMID: 40635404; PubMed Central PMCID: PMC12241694.
1.
Machado DM, Duda SN, Célia de Menezes Succi R, Kim A, Ranadive P, Rouzier V, et al. HIV Care Continuum Outcomes Among Adolescents and Young Adults Living With HIV in Latin America and the Caribbean: Association With Depression and Substance Use. Open Forum Infect Dis. 2025 Jul;12(7):ofaf353. http://doi.org/10.1093/ofid/ofaf353 PubMed PMID: 40657168; PubMed Central PMCID: PMC12247166.
1.
Fernández Villalobos NV, Helfenstein F, Khol V, Twizere C, Secco M, Castelnuovo B, et al. Scale of differentiated service delivery implementation in HIV care facilities in low- and middle-income countries: a global facility survey. J Int AIDS Soc. 2025 Jul;28 Suppl 3(Suppl 3):e26477. http://doi.org/10.1002/jia2.26477 PubMed PMID: 40622380; PubMed Central PMCID: PMC12232477.
1.
Laycock K, Technau KG, Lelo P, Jantarabenjakul W, Yonaba C, Pinto J, et al. Tuberculosis Diagnosis, Treatment, and Prevention Services for Children Living with HIV in Low- and Middle-Income Countries: A Multiregional Site Survey. J Pediatric Infect Dis Soc. 2025 Jun 16;14(6):piaf050. http://doi.org/10.1093/jpids/piaf050 PubMed PMID: 40425522; PubMed Central PMCID: PMC12257623.
1.
Castillo-Rozas G, Fonseca FF, Castilho J, Rebeiro PF, Machado DM, Luque MT, et al. ART to prevent vertical transmission in Latin America: where are we in the “Treat-All” era? J Int AIDS Soc. 2025 May;28(5):e26411. http://doi.org/10.1002/jia2.26411 PubMed PMID: 40292653; PubMed Central PMCID: PMC12035647.
1.
Penã Avila J, Simmons J, Figueiredo MC, Turner M, Cordeiro-Santos M, Rolla VC, et al. Single-cell immune profiling at time of M. tuberculosis exposure reveals antigen-reactive programs that predict progression to active disease. medRxiv. 2025 Apr 30;2025.04.29.25326433. http://doi.org/10.1101/2025.04.29.25326433 PubMed PMID: 40343021; PubMed Central PMCID: PMC12060959.
1.
Dill-McFarland KA, Andrade BB, Figueiredo MC, Andrade AMS, Avendaño-Rangel F, Cordeiro-Santos M, et al. Genome-wide association study in Brazil identifies genetic susceptibility to tuberculosis with single-cell gene expression effects. medRxiv. 2025 Apr 7;2025.03.13.25323932. http://doi.org/10.1101/2025.03.13.25323932 PubMed PMID: 40162286; PubMed Central PMCID: PMC11952600.
1.
Patten G, Malateste K, Bolton Moore C, Sipambo N, Mokone L, Anderegg N, et al. Global Trends in CD4 Measurement and Immunosuppression at ART Initiation Among Children With HIV. Pediatr Infect Dis J. 2025 Apr 4;44(9):873–5. http://doi.org/10.1097/INF.0000000000004819 PubMed PMID: 40233289; PubMed Central PMCID: PMC12314732.
1.
Embleton L, Sudjaritruk T, Machado DM, Chihota B, Musabyimana F, Jesson J, et al. Characterizing adolescent and youth-friendly HIV services: a cross-sectional assessment across 16 global sites. J Int AIDS Soc. 2025 Apr;28(4):e26437. http://doi.org/10.1002/jia2.26437 PubMed PMID: 40181514; PubMed Central PMCID: PMC11968415.
1.
Belaunzarán-Zamudio PF, Rebeiro PF, Caro-Vega Y, Castilho J, Crabtree-Ramírez BE, Cesar C, et al. Transitions through the HIV continuum of care in people enrolling in care with advanced HIV disease in Latin America. IJID Reg. 2025 Mar;14:100550. http://doi.org/10.1016/j.ijregi.2024.100550 PubMed PMID: 39877417; PubMed Central PMCID: PMC11772978.
1.
Ross JL, Rupasinghe D, Chanyachukul T, Crabtree Ramírez B, Murenzi G, Kwobah E, et al. Comorbidities and HIV-related factors associated with mental health symptoms and unhealthy substance use among older adults living with HIV in low- and middle-income countries: a cross-sectional study. J Int AIDS Soc. 2025 Mar;28(3):e26434. http://doi.org/10.1002/jia2.26434 PubMed PMID: 40045453; PubMed Central PMCID: PMC11882396.
1.
Arriaga MB, Amorim G, Figueiredo MC, Staats C, Kritski AL, Cordeiro-Santos M, et al. Effect of Smoking on Longitudinal Interferon γ Release Assay Results Among Close Contacts of People with Pulmonary Tuberculosis. J Infect Dis. 2025 Feb 4;231(1):103–8. http://doi.org/10.1093/infdis/jiae285 PubMed PMID: 38820119; PubMed Central PMCID: PMC11793032.
1.
Amorim G, Jaworski J, Yang J, Cordeiro-Santos M, Kritski AL, Figueiredo MC, et al. Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. Pharmacogenet Genomics. 2025 Feb 1;35(2):55–64. http://doi.org/10.1097/FPC.0000000000000552 PubMed PMID: 39470346; PubMed Central PMCID: PMC11695165.
1.
Mejía-Castrejón J, Caro-Vega Y, Sierra-Madero JG, López-Iñiguez A, Crabtree-Ramírez BE. The Trend in Suicide Risk Among People with HIV Before, During, and After the COVID-19 Pandemic Lockdown. AIDS Behav. 2025 Feb;29(2):664–72. http://doi.org/10.1007/s10461-024-04548-z PubMed PMID: 39643783; PubMed Central PMCID: PMC11814011.
1.
Ford N, Kassanjee R, Stelzle D, Jarvis JN, Sued O, Perrin G, et al. Global prevalence of advanced HIV disease in healthcare settings: a rapid review. J Int AIDS Soc. 2025 Feb;28(2):e26415. http://doi.org/10.1002/jia2.26415 PubMed PMID: 39915008; PubMed Central PMCID: PMC11802239.
1.
Kuniholm MH, Murenzi G, Shumbusho F, Brazier E, Plaisy MK, Mensah E, et al. Association of cardiovascular disease risk with liver steatosis and fibrosis in people with HIV in low- and middle-income countries. AIDS. 2025 Jan 1;39(1):11–21. http://doi.org/10.1097/QAD.0000000000004012 PubMed PMID: 39264586; PubMed Central PMCID: PMC11624086.
1.
Villalva-Serra K, Barreto-Duarte B, Rodrigues MM, Queiroz ATL, Martinez L, Croda J, et al. Impact of strategic public health interventions to reduce tuberculosis incidence in Brazil: a Bayesian structural time-series scenario analysis. Lancet Reg Health Am. 2025 Jan;41:100963. http://doi.org/10.1016/j.lana.2024.100963 PubMed PMID: 39759249; PubMed Central PMCID: PMC11697790.
2024
76770
IP6F4TRX
2024
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%226TDAINR2%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ridolfi%20et%20al.%22%2C%22parsedDate%22%3A%222024-12-16%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRidolfi%20F%2C%20Amorim%20G%2C%20Haas%20DW%2C%20Arriaga%20M%2C%20Staats%20C%2C%20Cordeiro-Santos%20M%2C%20et%20al.%20Pharmacogenomic%20associations%20with%20HIV-1%20virologic%20suppression%20in%20TB%5C%2FHIV%20patients.%20Res%20Sq.%202024%20Dec%2016%3Brs.3.rs-5418156.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-5418156%5C%2Fv1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-5418156%5C%2Fv1%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039764089%3B%20PubMed%20Central%20PMCID%3A%20PMC11702782.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pharmacogenomic%20associations%20with%20HIV-1%20virologic%20suppression%20in%20TB%5C%2FHIV%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cody%22%2C%22lastName%22%3A%22Staats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20Brazil%20consortium%20%28RePORT-Brazil%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Human%20genetic%20variants%20can%20affect%20TB%20and%20HIV%20drug%20metabolism%2C%20which%20may%20lead%20to%20toxicity%20or%20treatment%20failure.%20We%20evaluated%20associations%20between%20genetic%20variants%20of%20antiretroviral%20therapy%20%28ART%29%20and%20HIV-1%20outcomes%20among%20TB%5C%2FHIV%20patients.%5CnMETHODS%3A%20We%20included%20RePORT-Brazil%20participants%20with%20TB%5C%2FHIV%20who%20initiated%20standard%20TB%20treatment%20%5B2%20months%20of%20isoniazid%5C%2Frifampicin%20%28or%20rifabutin%29%5C%2Fpyrazinamide%5C%2Fethambutol%2C%20then%204%20months%20or%20more%20of%20isoniazid%5C%2Frifampicin%20%28or%20rifabutin%29%5D%2C%20and%20ART.%20The%20endpoint%20was%20HIV-1%20virologic%20suppression%20%28defined%20as%20%26lt%3B1%2C000%20HIV-1%20RNA%20copies%5C%2FmL%2C%20for%20primary%20analysis%2C%20and%20%26lt%3B50%20HIV-1%20RNA%20copies%5C%2FmL%2C%20for%20secondary%20analysis%29%20after%20at%20least%202%20weeks%20of%20ART.%20We%20compared%20non-nucleoside%20reverse%20transcriptase%20inhibitor%20%28NNRTI%29-based%20and%20integrase%20strand%20transfer%20inhibitor%20%28INSTI%29-based%20ART%20regimens.%20We%20genotyped%20CYP2B6%20%28rs3745274%2C%20rs28399499%2C%20rs4803419%3B%20affects%20efavirenz%20metabolism%29%20and%20UGT1A1%20%28rs887829%3B%20affects%20dolutegravir%20and%20raltegravir%20metabolism%29%3B%20all%20have%20defined%20normal%2C%20intermediate%2C%20and%20slow%20genotypes.%20Genotyping%20was%20performed%20by%20MassARRAY%20iPLEX%20Gold.%20We%20compared%20outcome%20proportions%20%28Fisher%26%23039%3Bs%20test%29%20and%20time-to-virologic%20suppression%20%28survival%20analysis%2C%20Wilcoxon-Gehan%20test%29.%5CnRESULTS%3A%20Among%20194%20TB%5C%2FHIV%20participants%20included%2C%20efavirenz%20was%20the%20most%20frequent%20NNRTI%20%28%5Bn%3D76%5D%2C%20one%20participant%20received%20etravirine%29%2C%20and%20raltegravir%20was%20the%20most%20frequent%20INSTI%20%28n%3D88%29.%20The%20overall%20virologic%20suppression%20was%20suboptimal%2C%20with%2032%25%20%28n%3D62%29%20of%20participants%20not%20achieving%20HIV-1%20virologic%20suppression.%20Among%20them%2C%2036%25%20%28n%3D28%29%20used%20efavirenz-based%20ART%20and%20were%20more%20likely%20to%20be%20CYP2B6%20normal%20metabolizers%20%28n%3D8%2C%2044%25%29%3B%20and%2030%25%20%28n%3D30%29%20used%20INSTI-based%20ART%20and%20the%20UGT1A1%20normal%20genotype%20was%20also%20the%20most%20common%20%28n%3D13%2C%2050%25%29.%20The%20median%20time%20to%20virologic%20suppression%20for%20efavirenz-based%20ART%20was%20184%20days%20%2895%25%20Confidence%20Interval%20%28CI%29160-207%29%2C%20and%20for%20INSTI-based%20ART%2C%20188%20days%20%2895%25%20CI%20144-231%29%20%28p%3D0.84%29.%20No%20significant%20associations%20were%20found%20comparing%20the%20proportions%20and%20time%20to%20virologic%20suppression%20among%20CYP2B6%20and%20UGT1A1genotypes.%5CnCONCLUSIONS%3A%20In%20this%20observational%20cohort%20of%20patients%20treated%20for%20TB%5C%2FHIV%2C%20the%20proportion%20of%20participants%20achieving%20virologic%20suppression%20was%20low%2C%20and%20genetic%20variants%20affecting%20ART%20metabolism%20were%20not%20significantly%20associated%20with%20the%20likelihood%20of%20virologic%20suppression.%22%2C%22date%22%3A%222024-12-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-5418156%5C%2Fv1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239764089%22%2C%22PMCID%22%3A%22PMC11702782%22%2C%22ISSN%22%3A%222693-5015%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A45Z%22%7D%7D%2C%7B%22key%22%3A%2237U3NP7H%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Zaniewski%20et%20al.%22%2C%22parsedDate%22%3A%222024-12-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZaniewski%20E%2C%20Skrivankova%20VW%2C%20Brazier%20E%2C%20Avihingsanon%20A%2C%20Wagner%20Cardoso%20S%2C%20Cesar%20C%2C%20et%20al.%20Transition%20to%20dolutegravir-based%20ART%20in%2035%20low-%20and%20middle-income%20countries%3A%20a%20global%20survey%20of%20HIV%20care%20clinics.%20AIDS.%202024%20Dec%201%3B38%2815%29%3A2073%26%23×2013%3B85.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004007%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000004007%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039236112%3B%20PubMed%20Central%20PMCID%3A%20PMC11562491.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transition%20to%20dolutegravir-based%20ART%20in%2035%20low-%20and%20middle-income%20countries%3A%20a%20global%20survey%20of%20HIV%20care%20clinics%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronika%20Whitesell%22%2C%22lastName%22%3A%22Skrivankova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Wagner%20Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%20A.%22%2C%22lastName%22%3A%22Ditangco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20Vanes%22%2C%22lastName%22%3A%22Ebasone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20George%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacqueline%20Madalitso%22%2C%22lastName%22%3A%22Huwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Lelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugene%20Kouassi%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20Kla%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Muleebwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Mundhe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%20R.%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20Mahambou%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20M.%22%2C%22lastName%22%3A%22Obatsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Odhiambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hans%20Walter%22%2C%22lastName%22%3A%22Prozesky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Supattra%22%2C%22lastName%22%3A%22Rungmaitree%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%20Semwendero%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moussa%22%2C%22lastName%22%3A%22Seydi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nosisa%22%2C%22lastName%22%3A%22Sipambo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Tiendrebeogo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20studied%20the%20transition%20to%20dolutegravir-containing%20antiretroviral%20therapy%20%28ART%29%20at%20HIV%20treatment%20clinics%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29.%5CnDESIGN%3A%20Site-level%20survey%20conducted%20in%202020-2021%20among%20HIV%20clinics%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29.%5CnMETHODS%3A%20We%20assessed%20the%20status%20of%20dolutegravir%20rollout%20and%20viral%20load%20and%20drug%20resistance%20testing%20practices%20for%20persons%20on%20ART%20switching%20to%20dolutegravir-based%20regimens.%20We%20used%20generalized%20estimating%20equations%20to%20assess%20associations%20between%20clinic%20rollout%20of%20both%20first-%20and%20second-line%20dolutegravir-based%20ART%20regimens%20%28dual%20rollout%29%20and%20site-level%20factors.%5CnRESULTS%3A%20Of%20179%20surveyed%20clinics%2C%20175%20%2898%25%29%20participated%3B%20137%20%2878%25%29%20from%20Africa%2C%2030%20%2817%25%29%20from%20the%20Asia-Pacific%2C%20and%208%20%285%25%29%20from%20Latin%20America.%20Most%20clinics%20%2880%25%29%20were%20in%20low-%20or%20lower-middle-income%20countries%2C%20and%20there%20were%20a%20mix%20of%20primary-%2C%20secondary-%20and%20tertiary-level%20clinics.%20Ninety%20percent%20reported%20rollout%20of%20first-line%20dolutegravir%2C%2059%25%20of%20second-line%2C%2094%25%20of%20first-%20or%20second-line%20and%2055%25%20of%20dual%20rollout.%20The%20adjusted%20odds%20of%20dual%20rollout%20were%20higher%20among%20tertiary-level%20%5Badjusted%20odds%20ratio%20%28aOR%29%204.00%3B%2095%25%20confidence%20interval%20%28CI%29%201.39-11.47%5D%20and%20secondary-level%20clinics%20%28aOR%203.66%3B%2095%25%20CI%202.19-6.11%29%20than%20in%20primary-level%20clinics.%20Over%20half%20%2859%25%29%20of%20clinics%20that%20introduced%20first-%20or%20second-line%20dolutegravir-based%20ART%20required%20recent%20viral%20load%20testing%20before%20switching%20to%20dolutegravir%2C%20and%2015%25%20performed%20genotypic%20resistance%20testing%20at%20switch.%5CnCONCLUSIONS%3A%20Dolutegravir-based%20ART%20was%20rolled%20out%20at%20nearly%20all%20IeDEA%20clinics%20in%20LMICs%2C%20yet%20many%20switched%20persons%20to%20dolutegravir%20without%20recent%20viral%20load%20testing%20and%20drug%20resistance%20testing%20was%20rarely%20performed.%20Without%20such%20testing%2C%20drug%20resistance%20among%20persons%20switching%20to%20dolutegravir%20may%20go%20undetected.%22%2C%22date%22%3A%222024-12-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000004007%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239236112%22%2C%22PMCID%22%3A%22PMC11562491%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22SQI24IPD%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Espejo-Ortiz%20et%20al.%22%2C%22parsedDate%22%3A%222024-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEspejo-Ortiz%20CE%2C%20Sierra-Barajas%20N%2C%20Silva-Casarrubias%20A%2C%20Guerrero-Torres%20L%2C%20Caro-Vega%20Y%2C%20Serrano-Pinto%20YG%2C%20et%20al.%20A%20cascade%20of%20care%20for%20diabetes%20in%20people%20living%20with%20HIV%20in%20a%20tertiary%20care%20center%20in%20Mexico%20City.%20HIV%20Res%20Clin%20Pract.%202024%20Dec%3B25%281%29%3A2411481.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F25787489.2024.2411481%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F25787489.2024.2411481%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039377112%3B%20PubMed%20Central%20PMCID%3A%20PMC11805464.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20cascade%20of%20care%20for%20diabetes%20in%20people%20living%20with%20HIV%20in%20a%20tertiary%20care%20center%20in%20Mexico%20City%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristian%20E.%22%2C%22lastName%22%3A%22Espejo-Ortiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Sierra-Barajas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelina%22%2C%22lastName%22%3A%22Silva-Casarrubias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorena%22%2C%22lastName%22%3A%22Guerrero-Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yamile%20G.%22%2C%22lastName%22%3A%22Serrano-Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez-I%5Cu00f1iguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Diabetes%20affects%204.5%25%20of%20people%20living%20with%20HIV%20in%20Mexico.%20This%20study%20aims%20to%20describe%20the%20diabetes%20cascade%20of%20care%20%28DMC%29%20in%20people%20with%20HIV%20in%20a%20tertiary%20center%20in%20Mexico%20City.%5CnMETHODS%3A%20We%20conducted%20a%20single-center%20review%20of%20people%20with%20HIV%20aged%20over%2018%2C%20using%20medical%20records%20of%20active%20people%20enrolled%20at%20the%20Instituto%20Nacional%20de%20Ciencias%20M%5Cu00e9dicas%20y%20Nutrici%5Cu00f3n%20Salvador%20Zubir%5Cu00e1n%20%28INCMNSZ%29%20HIV%20Clinic%20%28HIVC%29.%20Our%20analysis%20focused%20on%20their%20last%20visit%20to%20describe%20the%20DMC%2C%20aiming%20to%20identify%20gaps%20in%20control%20goals.%20We%20included%20people%20who%20had%20a%20consultation%20within%20the%2012%5Cu2009months%20preceding%20May%202020.%5CnRESULTS%3A%20Out%20of%20the%202072%20active%20people%2C%20medical%20records%20were%20available%20for%202050%20%2898.9%25%29.%20Among%20these%2C%20326%20people%20%2815.9%25%29%20had%20fasting%20glucose%20%28FG%29%20abnormalities%2C%20of%20which%20133%20%2840.7%25%29%20had%20diabetes.%20The%20prevalence%20of%20diabetes%20among%20people%20with%20HIV%20was%20of%206.4%25%20%28133%5C%2F2050%29.%20Regarding%20the%20DMC%2C%20the%20following%20proportions%20of%20people%20achieved%20control%20goals%3A%20133%5C%2F133%20%28100%25%29%20received%20medical%20care%20in%20the%20last%2012%5Cu2009months%2C%20123%5C%2F123%20%28100%25%29%20had%20blood%20pressure%20%28BP%29%20%26lt%3B140%5C%2F90%5Cu2009mmHg%2C%2073%5C%2F132%20%2855.3%25%29%20had%20LDL%20cholesterol%20%28c-LDL%29%20%26lt%3B100%5Cu2009mg%5C%2Fdl%2C%2063%5C%2F132%20%2847.7%25%29%20had%20FG%20%26lt%3B130%5Cu2009mg%5C%2Fdl%2C%2050%5C%2F116%20%2843.1%25%29%20had%20glycosylated%20hemoglobin%20%28HbA1c%29%20%26lt%3B7%25.%20ABC%20goals%20%28HbA1c%20%26lt%3B7%25%2C%20c-LDL%20%26lt%3B100%5Cu2009mg%5C%2Fdl%2C%20BP%20%26lt%3B140%5C%2F90%5Cu2009mmHg%29%20were%20met%20in%2028%5C%2F109%20%2825.6%25%29%20people.%20126%5C%2F133%20%2894%25%29%20people%20with%20HIV%20achieved%20HIV-viral%20load%20%26lt%3B50%20copies%5C%2FmL.%5CnCONCLUSIONS%3A%20Despite%20the%20high%20rate%20of%20viral%20suppression%20among%20people%20with%20HIV%20and%20diabetes%2C%20significant%20challenges%20remain%20in%20achieving%20comprehensive%20diabetes%20control.%20These%20findings%20highlight%20the%20need%20for%20targeted%20interventions%20to%20improve%20metabolic%20outcomes%20and%20the%20overall%20management%20of%20diabetes%20in%20people%20with%20HIV.%22%2C%22date%22%3A%222024-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F25787489.2024.2411481%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239377112%22%2C%22PMCID%22%3A%22PMC11805464%22%2C%22ISSN%22%3A%222578-7470%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22I5GHB942%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castilho%20et%20al.%22%2C%22parsedDate%22%3A%222024-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastilho%20JL%2C%20Fonseca%20FF%2C%20Kim%20A%2C%20Jalil%20E%2C%20Tu%20S%2C%20Beber%20AMB%2C%20et%20al.%20Prenatal%20syphilis%20and%20adverse%20pregnancy%20outcomes%20in%20women%20with%20HIV%20receiving%20ART%20in%20Brazil%3A%20a%20population-based%20study.%20Lancet%20Reg%20Health%20Am.%202024%20Nov%3B39%3A100894.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100894%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100894%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039839683%3B%20PubMed%20Central%20PMCID%3A%20PMC11747186.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prenatal%20syphilis%20and%20adverse%20pregnancy%20outcomes%20in%20women%20with%20HIV%20receiving%20ART%20in%20Brazil%3A%20a%20population-based%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%20F.%22%2C%22lastName%22%3A%22Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengxin%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9a%20M.%20B.%22%2C%22lastName%22%3A%22Beber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adele%20S.%22%2C%22lastName%22%3A%22Benzaken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e9lica%20E.%20B.%22%2C%22lastName%22%3A%22Miranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22National%20Cohort%20Study%20of%20Dolutegravir%20and%20Pregnancy%20Outcomes%20in%20Brazil%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20We%20aimed%20to%20examine%20factors%20associated%20with%20prenatal%20syphilis%2C%20including%20prenatal%20care%2C%20and%20pregnancy%20outcomes%20of%20pregnant%20women%20with%20HIV%20in%20Brazil.%5CnMETHODS%3A%20Retrospective%20data%20were%20gathered%20from%20a%20national%20cohort%20of%20Brazilian%20women%20with%20HIV%20on%20antiretroviral%20therapy%20who%20became%20pregnant%20between%20January%202015%20and%20May%202018.%20Prenatal%20syphilis%20was%20defined%20by%20clinical%20diagnoses%20with%20treatment%20or%20any%20positive%20syphilis%20laboratory%20result%20between%2030%20days%20before%20conception%20and%20pregnancy%20conclusion.%20Multivariable%20logistic%20regression%20models%20examined%20factors%20associated%20with%20prenatal%20syphilis%20risk%20and%20adverse%20pregnancy%20outcomes%20%28including%20stillbirth%2C%20abortion%2C%20preterm%20delivery%2C%20small%20for%20gestational%20age%2C%20and%20congenital%20abnormalities%29.%20Receipt%20of%20recommended%20prenatal%20syphilis%20screening%20and%20adequacy%20of%20prenatal%20care%20were%20also%20evaluated.%5CnFINDINGS%3A%20Among%202169%20women%2C%20166%20%287.77%25%20%5B95%25%20CI%3A%206.5-8.8%25%5D%29%20had%20prenatal%20syphilis%2C%20of%20whom%20151%20%2891%25%29%20had%20documented%20treatment.%20Prevalence%20of%20prenatal%20syphilis%20was%20higher%20among%20women%20of%20Black%5C%2FPardo%5C%2FIndigenous%20race%20%2813.7%5C%2F7.7%5C%2F8.3%25%20vs.%205.8%25%20in%20White%20women%29%2C%20those%20of%20younger%20age%20%28median%20age%2025.9%20years%20vs.%2027.6%20in%20total%20cohort%29%20and%20those%20with%20crack%5C%2Fcocaine%20use%20during%5C%2Fbefore%20pregnancy%20%2820%25%29.%20Of%201042%5C%2F2169%20women%20with%20prenatal%20care%20and%20screening%20data%2C%20475%20%2846%25%29%20received%20inadequate%20prenatal%20care%20and%20only%20301%20%2829%25%29%20received%20the%20recommended%20antenatal%20syphilis%20screening.%20Prenatal%20syphilis%20was%20not%20associated%20with%20adverse%20pregnancy%20outcomes%20%28aOR%200.91%20%5B0.64-1.30%5D%29.%5CnINTERPRETATION%3A%20Prenatal%20syphilis%20was%20prevalent%20in%20this%20cohort%20of%20pregnant%20women%20with%20HIV.%20Prenatal%20syphilis%20was%20not%20associated%20with%20adverse%20pregnancy%20outcomes.%20Attention%20to%20syphilis%20prevention%20and%20treatment%20is%20especially%20needed%20in%20marginalised%20women.%5CnFUNDING%3A%20Brazilian%20Ministry%20of%20Health%20and%20United%20States%26%23039%3B%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%222024-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2024.100894%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239839683%22%2C%22PMCID%22%3A%22PMC11747186%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22W98RI22I%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Barreto-Duarte%20et%20al.%22%2C%22parsedDate%22%3A%222024-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBarreto-Duarte%20B%2C%20Villalva-Serra%20K%2C%20Campos%20VMS%2C%20Cordeiro-Santos%20M%2C%20Kritski%20AL%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20et%20al.%20Nationwide%20economic%20analysis%20of%20pulmonary%20tuberculosis%20in%20the%20Brazilian%20healthcare%20system%20over%20seven%20years%20%282015-2022%29%3A%20a%20population-based%20study.%20Lancet%20Reg%20Health%20Am.%202024%20Nov%3B39%3A100905.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100905%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2024.100905%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039839682%3B%20PubMed%20Central%20PMCID%3A%20PMC11747192.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nationwide%20economic%20analysis%20of%20pulmonary%20tuberculosis%20in%20the%20Brazilian%20healthcare%20system%20over%20seven%20years%20%282015-2022%29%3A%20a%20population-based%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klauss%22%2C%22lastName%22%3A%22Villalva-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%20S.%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20remains%20a%20global%20challenge%20and%20disproportionately%20affecting%20vulnerable%20populations.%20This%20study%20analyses%20the%20economic%20burden%20of%20pulmonary%20TB%20in%20Brazil%2C%20focusing%20on%20direct%20healthcare%20costs.%20It%20also%20evaluates%20the%20cost-effectiveness%20of%20the%20Directly%20Observed%20Treatment%20%28DOT%29%20strategy%20and%20the%20economic%20effort%20required%20to%20achieve%20a%2090%25%20probability%20of%20cure.%5CnMETHODS%3A%20A%20nationwide%20retrospective%20study%20utilized%20data%20from%20the%20Brazilian%20Information%20System%20for%20Notifiable%20Diseases%20%28SINAN%29%20between%202015%20and%202022.%20The%20cost%20per%20pulmonary%20TB%20case%20was%20estimated%2C%20encompassing%20expenses%20related%20to%20healthcare%20professionals%2C%20medication%2C%20laboratory%20exams%2C%20and%20the%20duration%20of%20treatment%20reported%20in%20SINAN.%20The%20population%20was%20stratified%20based%20on%20the%20presence%20of%20social%20vulnerabilities%20or%20a%20history%20of%20previous%20anti-TB%20treatment.%20Number%20Needed%20to%20Treat%20%28NNT%29%20analyses%20assessed%20the%20effectiveness%20of%20DOT%20implementation.%20Additionally%2C%20the%20study%20calculated%20the%20cost%20needed%20to%20achieve%20a%2090%25%20probability%20of%20cure%20through%20binomial%20regression%20models.%5CnFINDINGS%3A%20The%20total%20direct%20cost%20for%20pulmonary%20TB%20in%20Brazil%20during%20the%20seven%20years%20exceeded%20%241.3%20billion%2C%20with%20retreatment%20cases%20accounting%20for%20%2423.5%20million.%20The%20lowest%20NNT%20of%20DOT%20were%20homeless%20%283.0%29%2C%20people%20who%20use%20drugs%20%283.72%29%2C%20and%20retreatment%20%284.56%29%20subpopulations.%20These%20groups%20also%20presented%20the%20highest%20cost%20to%20achieve%20a%2090%25%20probability%20of%20cure.%5CnINTERPRETATION%3A%20This%20study%20highlights%20the%20economic%20impact%20of%20pulmonary%20TB%20on%20the%20Brazilian%20healthcare%20system.%20It%20underscores%20the%20effectiveness%20of%20DOT%20across%20various%20patient%20groups%2C%20regardless%20of%20their%20vulnerabilities%20or%20previous%20anti-TB%20treatment%20history.%20NNT%20analyses%20highlighted%20retreatment%2C%20homeless%2C%20and%20people%20who%20use%20drugs%20subpopulations%20as%20the%20most%20effective%20for%20DOT%20implementation.%5CnFUNDING%3A%20Intramural%20Research%20Program-Oswaldo%20Cruz%20Foundation.%22%2C%22date%22%3A%222024-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2024.100905%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239839682%22%2C%22PMCID%22%3A%22PMC11747192%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A47Z%22%7D%7D%2C%7B%22key%22%3A%226LFLLLJ7%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222024-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BParcesepe%20AM%2C%20Stockton%20M%2C%20Bernard%20C%2C%20Kanguya%20T%2C%20Kwobah%20EK%2C%20Lopez%20A%2C%20et%20al.%20Prevalence%20and%20co-occurrence%20of%20symptoms%20of%20mental%20and%20substance%20use%20disorders%20among%20people%20with%20HIV%20age%2040%20and%20older%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study.%20J%20Int%20AIDS%20Soc.%202024%20Oct%3B27%2810%29%3Ae26359.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26359%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26359%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039375051%3B%20PubMed%20Central%20PMCID%3A%20PMC11458263.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20and%20co-occurrence%20of%20symptoms%20of%20mental%20and%20substance%20use%20disorders%20among%20people%20with%20HIV%20age%2040%20and%20older%20in%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tukiya%22%2C%22lastName%22%3A%22Kanguya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%20Kamaru%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Musabyimana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Smita%22%2C%22lastName%22%3A%22Nimkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22IeDEA%22%2C%22lastName%22%3A%22Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Due%20to%20the%20increased%20effectiveness%20of%20and%20access%20to%20antiretroviral%20therapy%20%28ART%29%2C%20people%20with%20HIV%20%28PWH%29%20are%20living%20longer.%20As%20a%20result%2C%20the%20population%20of%20older%20PWH%20has%20increased.%20Mental%20and%20substance%20use%20disorders%20%28MSDs%29%20are%20common%20and%20frequently%20co-occurring%20among%20PWH%20and%20are%20associated%20with%20poor%20HIV%20care%20outcomes.%20Research%20into%20the%20prevalence%20and%20co-occurrence%20of%20MSDs%20among%20ageing%20PWH%20remains%20limited%2C%20particularly%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29.%5CnMETHODS%3A%20We%20analysed%20data%20collected%20between%202020%20and%202022%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Sentinel%20Research%20Network%20cohort%20of%20PWH%20aged%2040%20years%20or%20older%20on%20ART%20at%2011%20HIV%20clinics%20in%20Brazil%2C%20C%5Cu00f4te%20d%26%23039%3BIvoire%2C%20India%2C%20Kenya%2C%20Mexico%2C%20Uganda%2C%20Rwanda%2C%20Togo%2C%20Vietnam%2C%20Zambia%20and%20Zimbabwe.%20We%20estimated%20the%20prevalence%20and%20co-occurrence%20of%20unhealthy%20alcohol%20use%20%28AUDIT-C%20%5Cu22653%20for%20women%2C%20%5Cu22654%20for%20men%29%2C%20unhealthy%20drug%20use%20%28ASSIST%20%26gt%3B3%20for%20cannabis%2C%20cocaine%2C%20amphetamines%2C%20inhalants%2C%20sedatives%2C%20hallucinogens%20and%5C%2For%20opioids%29%2C%20and%20moderate%20to%20severe%20symptoms%20of%20depression%20%28PHQ-9%20%5Cu226510%29%2C%20anxiety%20%28GAD-7%20%5Cu226510%29%20and%20post-traumatic%20stress%20disorder%20%28PTSD%29%20%28PCL-5%20%5Cu226533%29.%20Psychiatric%20multimorbidity%20was%20defined%20as%20having%20symptoms%20of%20two%20or%20more%20disorders%20assessed.%20Log%20binomial%20models%20assessed%20the%20association%20between%20socio-demographic%20and%20HIV%20care%20characteristics%20and%20symptoms%20of%20anxiety%2C%20depression%2C%20PTSD%20or%20unhealthy%20substance%20use.%5CnRESULTS%3A%20Of%202821%20participants%2C%20the%20prevalence%20of%20unhealthy%20alcohol%20and%20drug%20use%20was%2021%25%20and%205%25%2C%20respectively.%20The%20prevalence%20of%20moderate%20to%20severe%20symptoms%20of%20depression%2C%20anxiety%20and%20PTSD%20was%2014%25%2C%209%25%20and%206%25%2C%20respectively.%20Overall%2C%20the%20prevalence%20of%20psychiatric%20multimorbidity%20was%2011%25.%20Among%20those%20with%20symptoms%20of%20at%20least%20one%20mental%20health%20or%20substance%20use%20outcome%20assessed%20%28n%20%3D%201036%29%2C%20the%20prevalence%20of%20psychiatric%20multimorbidity%20was%2031%25.%20In%20binomial%20models%2C%20the%20prevalence%20of%20symptoms%20of%20depression%20and%20anxiety%20was%20higher%2C%20while%20the%20prevalence%20of%20unhealthy%20alcohol%20and%20drug%20use%20was%20lower%20among%20women%20than%20men.%5CnCONCLUSIONS%3A%20Unhealthy%20alcohol%20use%20and%20symptoms%20of%20depression%20were%20most%20commonly%20reported%2C%20among%20this%20cohort%20of%20PWH%20aged%2040%20or%20older%20across%2011%20LMICs.%20Integration%20of%20MSD%20screening%20and%20treatment%20into%20HIV%20care%20should%20be%20prioritized.%20The%20effectiveness%20and%20implementation%20of%20transdiagnostic%20or%20multi-focus%20mental%20health%20treatment%20approaches%20in%20HIV%20care%20settings%20should%20be%20examined.%22%2C%22date%22%3A%222024-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26359%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239375051%22%2C%22PMCID%22%3A%22PMC11458263%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22HTNV8N6N%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Egger%20et%20al.%22%2C%22parsedDate%22%3A%222024-08-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEgger%20M%2C%20Sauermann%20M%2C%20Loosli%20T%2C%20Hossmann%20S%2C%20Riedo%20S%2C%20Beerenwinkel%20N%2C%20et%20al.%20HIV-1%20subtype-specific%20drug%20resistance%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20protocol%20for%20a%20multicentre%20study%20%28DTG%20RESIST%29.%20BMJ%20Open.%202024%20Aug%2021%3B14%288%29%3Ae085819.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085819%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2024-085819%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039174068%3B%20PubMed%20Central%20PMCID%3A%20PMC11340720.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-1%20subtype-specific%20drug%20resistance%20on%20dolutegravir-based%20antiretroviral%20therapy%3A%20protocol%20for%20a%20multicentre%20study%20%28DTG%20RESIST%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mamatha%22%2C%22lastName%22%3A%22Sauermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Loosli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Selma%22%2C%22lastName%22%3A%22Riedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niko%22%2C%22lastName%22%3A%22Beerenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Giandhari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20D.%22%2C%22lastName%22%3A%22Kouyos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lessells%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20HIV%20drug%20resistance%20poses%20a%20challenge%20to%20the%20United%20Nation%26%23039%3Bs%20goal%20of%20ending%20the%20HIV%5C%2FAIDS%20epidemic.%20The%20integrase%20strand%20transfer%20inhibitor%20%28InSTI%29%20dolutegravir%2C%20which%20has%20a%20higher%20resistance%20barrier%2C%20was%20endorsed%20by%20the%20WHO%20in%202019%20for%20first-line%2C%20second-line%20and%20third-line%20antiretroviral%20therapy%20%28ART%29.%20This%20multiplicity%20of%20roles%20of%20dolutegravir%20in%20ART%20may%20facilitate%20the%20emergence%20of%20dolutegravir%20resistance.%5CnMETHODS%20AND%20ANALYSIS%3A%20Nested%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%2C%20DTG%20RESIST%20is%20a%20multicentre%20study%20of%20adults%20and%20adolescents%20living%20with%20HIV%20in%20sub-Saharan%20Africa%2C%20Asia%2C%20and%20South%20and%20Central%20America%20who%20experienced%20virological%20failure%20on%20dolutegravir-based%20ART.%20At%20the%20time%20of%20virological%20failure%2C%20whole%20blood%20will%20be%20collected%20and%20processed%20to%20prepare%20plasma%20or%20dried%20blood%20spots.%20Laboratories%20in%20Durban%2C%20Mexico%20City%20and%20Bangkok%20will%20perform%20genotyping.%20Analyses%20will%20focus%20on%20%281%29%20individuals%20who%20experienced%20virological%20failure%20on%20dolutegravir%20and%20%282%29%20those%20who%20started%20or%20switched%20to%20such%20a%20regimen%20and%20were%20at%20risk%20of%20virological%20failure.%20For%20population%20%281%29%2C%20the%20outcome%20will%20be%20any%20InSTI%20drug%20resistance%20mutations%2C%20and%20for%20population%20%282%29%20virological%20failure%20is%20defined%20as%20a%20viral%20load%20%26gt%3B1000%20copies%5C%2FmL.%20Phenotypic%20testing%20will%20focus%20on%20non-B%20subtype%20viruses%20with%20major%20InSTI%20resistance%20mutations.%20Bayesian%20evolutionary%20models%20will%20explore%20and%20predict%20treatment%20failure%20genotypes.%20The%20study%20will%20have%20intermediate%20statistical%20power%20to%20detect%20differences%20in%20resistance%20mutation%20prevalence%20between%20major%20HIV-1%20subtypes%3B%20ample%20power%20to%20identify%20risk%20factors%20for%20virological%20failure%20and%20limited%20power%20for%20analysing%20factors%20associated%20with%20individual%20InSTI%20drug%20resistance%20mutations.%5CnETHICS%20AND%20DISSEMINATION%3A%20The%20research%20protocol%20was%20approved%20by%20the%20Biomedical%20Research%20Ethics%20Committee%20at%20the%20University%20of%20KwaZulu-Natal%2C%20South%20Africa%20and%20the%20Ethics%20Committee%20of%20the%20Canton%20of%20Bern%2C%20Switzerland.%20All%20sites%20participate%20in%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20and%20have%20obtained%20ethics%20approval%20from%20their%20local%20ethics%20committee%20to%20collect%20additional%20data.%5CnTRIAL%20REGISTRATION%20NUMBER%3A%20NCT06285110.%22%2C%22date%22%3A%222024-08-21%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2024-085819%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239174068%22%2C%22PMCID%22%3A%22PMC11340720%22%2C%22ISSN%22%3A%222044-6055%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22HZ43IW77%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Barreto-Duarte%20et%20al.%22%2C%22parsedDate%22%3A%222024-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBarreto-Duarte%20B%2C%20Villalva-Serra%20K%2C%20Miguez-Pinto%20JP%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Campos%20VMS%2C%20Rosier%20G%2C%20et%20al.%20Retreatment%20and%20Anti-tuberculosis%20Therapy%20Outcomes%20in%20Brazil%20Between%202015%20and%202022%3A%20A%20Nationwide%20Study.%20Open%20Forum%20Infect%20Dis.%202024%20Aug%3B11%288%29%3Aofae416.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae416%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofae416%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039100532%3B%20PubMed%20Central%20PMCID%3A%20PMC11297487.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Retreatment%20and%20Anti-tuberculosis%20Therapy%20Outcomes%20in%20Brazil%20Between%202015%20and%202022%3A%20A%20Nationwide%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klauss%22%2C%22lastName%22%3A%22Villalva-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e3o%20P.%22%2C%22lastName%22%3A%22Miguez-Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%20S.%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Rosier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Adherence%20to%20anti-tuberculosis%20treatment%20%28ATT%29%20in%20Brazil%20remains%20a%20challenge%20in%20achieving%20the%20goals%20set%20by%20the%20World%20Health%20Organization%20%28WHO%29.%20Patients%20who%20are%20lost%20to%20follow-up%20during%20treatment%20pose%20a%20significant%20public%20health%20problem.%20This%20study%20aimed%20to%20investigate%20the%20factors%20associated%20with%20unfavorable%20ATT%20outcomes%20among%20those%20undergoing%20retreatment%20in%20Brazil.%5CnMETHODS%3A%20We%20conducted%20an%20observational%20study%20of%20patients%20aged%20%5Cu226518%20years%20with%20tuberculosis%20%28TB%29%20reported%20to%20the%20Brazilian%20National%20Notifiable%20Disease%20Information%20System%20between%202015%20and%202022.%20Clinical%20and%20epidemiologic%20variables%20were%20compared%20between%20the%20study%20groups%20%28new%20cases%20and%20retreatment%29.%20Regression%20models%20identified%20variables%20associated%20with%20unfavorable%20outcomes.%5CnRESULTS%3A%20Among%20743%20823%20reported%20TB%20cases%20in%20the%20study%20period%2C%20555%20632%20cases%20were%20eligible%2C%20consisting%20of%20462%20061%20new%20cases%20and%2093%20571%20undergoing%20retreatments%20%2844%20642%20recurrent%20and%2048%20929%20retreatments%20after%20loss%20to%20follow-up%20%5BRLTFU%5D%29.%20RLTFU%20%28odds%20ratio%20%5BOR%5D%2C%203.96%20%5B95%25%20confidence%20interval%20%7BCI%7D%2C%203.83-4.1%5D%29%20was%20a%20significant%20risk%20factor%20for%20any%20type%20of%20unfavorable%20ATT.%20Furthermore%2C%20RLTFU%20%28OR%2C%204.93%20%5B95%25%20CI%2C%204.76-5.11%5D%29%20was%20the%20main%20risk%20factor%20for%20subsequent%20LTFU.%20For%20death%2C%20aside%20from%20advanced%20age%2C%20living%20with%20HIV%20%28OR%2C%206.28%20%5B95%25%20CI%2C%206.03-6.54%5D%29%20was%20the%20top%20risk%20factor.%5CnCONCLUSIONS%3A%20Retreatment%20is%20a%20substantial%20risk%20factor%20for%20unfavorable%20ATT%20outcomes%2C%20especially%20after%20LTFU.%20The%20rates%20of%20treatment%20success%20in%20RLTFU%20are%20distant%20from%20the%20WHO%20End%20TB%20Strategy%20targets%20throughout%20Brazil.%20These%20findings%20underscore%20the%20need%20for%20targeted%20interventions%20to%20improve%20treatment%20adherence%20and%20outcomes%20in%20persons%20who%20experience%20RLTFU.%22%2C%22date%22%3A%222024-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofae416%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239100532%22%2C%22PMCID%22%3A%22PMC11297487%22%2C%22ISSN%22%3A%222328-8957%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22W36H3ZKL%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Gorsline%20et%20al.%22%2C%22parsedDate%22%3A%222024-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGorsline%20CA%2C%20Lotspeich%20SC%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Mejia%20F%2C%20Cortes%20CP%2C%20Crabtree-Ram%26%23xED%3Brez%20B%2C%20et%20al.%20The%20impact%20of%20earthquakes%20in%20Latin%20America%20on%20the%20continuity%20of%20HIV%20care%3A%20A%20retrospective%20observational%20cohort%20study.%20Public%20Health%20Pract%20%28Oxf%29.%202024%20Jun%3B7%3A100479.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.puhip.2024.100479%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.puhip.2024.100479%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038405231%3B%20PubMed%20Central%20PMCID%3A%20PMC10883833.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20impact%20of%20earthquakes%20in%20Latin%20America%20on%20the%20continuity%20of%20HIV%20care%3A%20A%20retrospective%20observational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chelsea%20A.%22%2C%22lastName%22%3A%22Gorsline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damocles%20Patrice%22%2C%22lastName%22%3A%22Severe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20As%20earthquakes%20occur%20frequently%20in%20Latin%20America%20and%20can%20cause%20significant%20disruptions%20in%20HIV%20care%2C%20we%20sought%20to%20analyze%20patterns%20of%20HIV%20care%20for%20adults%20at%20Latin%20American%20clinical%20sites%20experiencing%20a%20significant%20earthquake%20within%20the%20past%20two%20decades.%5CnSTUDY%20DESIGN%3A%20Retrospective%20clinical%20cohort%20study.%5CnMETHODS%3A%20Adults%20receiving%20HIV%20care%20at%20sites%20experiencing%20at%20least%20a%20%26quot%3Bmoderate%20intensity%26quot%3B%20%28Modified%20Mercalli%20scale%29%20earthquake%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20contributed%20data%20from%202003%20to%202017.%20Interrupted%20Time%20Series%20models%20were%20fit%20with%20discontinuities%20at%20site-specific%20earthquake%20dates%20%28Sept.%2016%2C%202015%20in%20Chile%3B%20Apr.%2018%2C%202014%20and%20Sept.%2019%2C%202017%20in%20Mexico%3B%20and%20Aug.%2015%2C%202007%20in%20Peru%29%20to%20assess%20clinical%20visit%2C%20CD4%20measure%2C%20viral%20load%20lab%2C%20and%20ART%20initiation%20rates%203-%20and%206-months%20after%20versus%20before%20earthquakes.%5CnRESULTS%3A%20Comparing%20post-to%20pre-earthquake%20periods%2C%20there%20was%20a%20sharp%20drop%20in%20median%20visit%20%28incidence%20rate%20ratio%20%5BIRR%5D%5Cu00a0%3D%5Cu00a00.79%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%200.68-0.91%29%20and%20viral%20load%20lab%20%28IRR%5Cu00a0%3D%5Cu00a00.78%2C%2095%25%20CI%3A%200.62-0.99%29%20rates%20per%20week%2C%20using%20a%203-month%20window.%20CD4%20measurement%20rates%20also%20decreased%20%28IRR%5Cu00a0%3D%5Cu00a00.43%3B%2095%25%20CI%3A%200.37-0.51%29%2C%20though%20only%20using%20a%206-month%20window.%5CnCONCLUSIONS%3A%20Given%20that%20earthquakes%20occur%20frequently%20in%20Latin%20America%2C%20disaster%20preparedness%20plans%20must%20be%20more%20broadly%20implemented%20to%20avoid%20disruptions%20in%20HIV%20care%20and%20attendant%20poor%20outcomes.%22%2C%22date%22%3A%222024-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.puhip.2024.100479%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238405231%22%2C%22PMCID%22%3A%22PMC10883833%22%2C%22ISSN%22%3A%222666-5352%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22MYVPXCK6%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Lotspeich%20et%20al.%22%2C%22parsedDate%22%3A%222024-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLotspeich%20SC%2C%20Amorim%20GGC%2C%20Shaw%20PA%2C%20Tao%20R%2C%20Shepherd%20BE.%20Optimal%20multiwave%20validation%20of%20secondary%20use%20data%20with%20outcome%20and%20exposure%20misclassification.%20Can%20J%20Stat.%202024%20Jun%3B52%282%29%3A532%26%23×2013%3B54.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcjs.11772%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcjs.11772%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039629097%3B%20PubMed%20Central%20PMCID%3A%20PMC11610482.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Optimal%20multiwave%20validation%20of%20secondary%20use%20data%20with%20outcome%20and%20exposure%20misclassification%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20G.%20C.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22Observational%20databases%20provide%20unprecedented%20opportunities%20for%20secondary%20use%20in%20biomedical%20research.%20However%2C%20these%20data%20can%20be%20error-prone%20and%20must%20be%20validated%20before%20use.%20It%20is%20usually%20unrealistic%20to%20validate%20the%20whole%20database%20because%20of%20resource%20constraints.%20A%20cost-effective%20alternative%20is%20a%20two-phase%20design%20that%20validates%20a%20subset%20of%20records%20enriched%20for%20information%20about%20a%20particular%20research%20question.%20We%20consider%20odds%20ratio%20estimation%20under%20differential%20outcome%20and%20exposure%20misclassification%20and%20propose%20optimal%20designs%20that%20minimize%20the%20variance%20of%20the%20maximum%20likelihood%20estimator.%20Our%20adaptive%20grid%20search%20algorithm%20can%20locate%20the%20optimal%20design%20in%20a%20computationally%20feasible%20manner.%20Because%20the%20optimal%20design%20relies%20on%20unknown%20parameters%2C%20we%20introduce%20a%20multiwave%20strategy%20to%20approximate%20the%20optimal%20design.%20We%20demonstrate%20the%20proposed%20design%26%23039%3Bs%20efficiency%20gains%20through%20simulations%20and%20two%20large%20observational%20studies.%22%2C%22date%22%3A%222024-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fcjs.11772%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239629097%22%2C%22PMCID%22%3A%22PMC11610482%22%2C%22ISSN%22%3A%220319-5724%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A40Z%22%7D%7D%2C%7B%22key%22%3A%223EJETF6G%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-23%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRodrigues%20MMS%2C%20Barreto-Duarte%20B%2C%20Vinhaes%20CL%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Fukutani%20ER%2C%20Bergamaschi%20KB%2C%20et%20al.%20Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-up%20during%20tuberculosis%20treatment.%20BMC%20Public%20Health.%202024%20May%2023%3B24%281%29%3A1385.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-024-18815-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-024-18815-0%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038783264%3B%20PubMed%20Central%20PMCID%3A%20PMC11112756.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-up%20during%20tuberculosis%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keityane%20Bone%22%2C%22lastName%22%3A%22Bergamaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Identifying%20patients%20at%20increased%20risk%20of%20loss%20to%20follow-up%20%28LTFU%29%20is%20key%20to%20developing%20strategies%20to%20optimize%20the%20clinical%20management%20of%20tuberculosis%20%28TB%29.%20The%20use%20of%20national%20registry%20data%20in%20prediction%20models%20may%20be%20a%20useful%20tool%20to%20inform%20healthcare%20workers%20about%20risk%20of%20LTFU.%20Here%20we%20developed%20a%20score%20to%20predict%20the%20risk%20of%20LTFU%20during%20anti-TB%20treatment%20%28ATT%29%20in%20a%20nationwide%20cohort%20of%20cases%20using%20clinical%20data%20reported%20to%20the%20Brazilian%20Notifiable%20Disease%20Information%20System%20%28SINAN%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20study%20of%20all%20TB%20cases%20reported%20to%20SINAN%20between%202015%20and%202022%3B%20excluding%20children%20%28%26lt%3B%5Cu200918%20years-old%29%2C%20vulnerable%20groups%20or%20drug-resistant%20TB.%20For%20the%20score%2C%20data%20before%20treatment%20initiation%20were%20used.%20We%20trained%20and%20internally%20validated%20three%20different%20prediction%20scoring%20systems%2C%20based%20on%20Logistic%20Regression%2C%20Random%20Forest%2C%20and%20Light%20Gradient%20Boosting.%20Before%20applying%20our%20models%20we%20splitted%20our%20data%20into%20training%20%28~%5Cu200980%25%20data%29%20and%20test%20%28~%5Cu200920%25%29%20sets%2C%20and%20then%20compared%20the%20model%20metrics%20using%20the%20test%20data%20set.%5CnRESULTS%3A%20Of%20the%20243%2C726%20cases%20included%2C%2041%2C373%20experienced%20LTFU%20whereas%20202%2C353%20were%20successfully%20treated.%20The%20groups%20were%20different%20with%20regards%20to%20several%20clinical%20and%20sociodemographic%20characteristics.%20The%20directly%20observed%20treatment%20%28DOT%29%20was%20unbalanced%20between%20the%20groups%20with%20lower%20prevalence%20in%20those%20who%20were%20LTFU.%20Three%20models%20were%20developed%20to%20predict%20LTFU%20using%208%20features%20%28prior%20TB%2C%20drug%20use%2C%20age%2C%20sex%2C%20HIV%20infection%20and%20schooling%20level%29%20with%20different%20score%20composition%20approaches.%20Those%20prediction%20scoring%20systems%20exhibited%20an%20area%20under%20the%20curve%20%28AUC%29%20ranging%20between%200.71%20and%200.72.%20The%20Light%20Gradient%20Boosting%20technique%20resulted%20in%20the%20best%20prediction%20performance%2C%20weighting%20specificity%20and%20sensitivity.%20A%20user-friendly%20web%20calculator%20app%20was%20developed%20%28%20https%3A%5C%2F%5C%2Ftbprediction.herokuapp.com%5C%2F%20%29%20to%20facilitate%20implementation.%5CnCONCLUSIONS%3A%20Our%20nationwide%20risk%20score%20predicts%20the%20risk%20of%20LTFU%20during%20ATT%20in%20Brazilian%20adults%20prior%20to%20treatment%20commencement%20utilizing%20schooling%20level%2C%20sex%2C%20age%2C%20prior%20TB%20status%2C%20and%20substance%20use%20%28drug%2C%20alcohol%2C%20and%5C%2For%20tobacco%29.%20This%20is%20a%20potential%20tool%20to%20assist%20in%20decision-making%20strategies%20to%20guide%20resource%20allocation%2C%20DOT%20indications%2C%20and%20improve%20TB%20treatment%20adherence.%22%2C%22date%22%3A%222024-05-23%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-024-18815-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238783264%22%2C%22PMCID%22%3A%22PMC11112756%22%2C%22ISSN%22%3A%221471-2458%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22PAW4IQ36%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Kebede%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKebede%20S%2C%20Brazier%20E%2C%20Freeman%20AM%2C%20Muwonge%20TR%2C%20Choi%20JY%2C%20de%20Waal%20R%2C%20et%20al.%20Preexposure%20prophylaxis%20availability%20among%20health%20facilities%20participating%20in%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20AIDS.%202024%20Apr%201%3B38%285%29%3A751%26%23×2013%3B6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003824%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003824%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038133656%3B%20PubMed%20Central%20PMCID%3A%20PMC10939841.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preexposure%20prophylaxis%20availability%20among%20health%20facilities%20participating%20in%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Kebede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%20M.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Muwonge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%20Yong%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renee%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20Kristoffer%20U.%22%2C%22lastName%22%3A%22Pasayan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alisho%22%2C%22lastName%22%3A%22Shongo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Low%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20recognized%20as%20a%20key%20HIV%20prevention%20strategy%2C%20preexposure%20prophylaxis%20%28PrEP%29%20availability%20and%20accessibility%20are%20not%20well%20documented%20globally.%20We%20aimed%20to%20describe%20PrEP%20drug%20registration%20status%20and%20the%20availability%20of%20PrEP%20services%20across%20HIV%20care%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium.%5CnMETHODS%3A%20We%20used%20country-level%20PrEP%20drug%20registration%20status%20from%20the%20AIDS%20Vaccine%20Advocacy%20Coalition%20and%20data%20from%20IeDEA%20surveys%20conducted%20in%202014%2C%202017%20and%202020%20among%20participating%20HIV%20clinics%20in%20seven%20global%20regions.%20We%20used%20descriptive%20statistics%20to%20assess%20PrEP%20availability%20across%20IeDEA%20sites%20serving%20adult%20patients%20in%202020%20and%20examined%20trends%20in%20PrEP%20availability%20among%20sites%20that%20responded%20to%20all%20three%20surveys.%5CnRESULTS%3A%20Of%20199%20sites%20that%20completed%20the%202020%20survey%2C%20PrEP%20was%20available%20in%20161%20%2881%25%29.%20PrEP%20availability%20was%20highest%20at%20sites%20in%20North%20America%20%2829%5C%2F30%3B%2097%25%29%20and%20East%20Africa%20%2870%5C%2F74%3B%2095%25%29%20and%20lowest%20at%20sites%20in%20Central%20%2810%5C%2F20%3B%2050%25%29%20and%20West%20Africa%20%281%5C%2F6%3B%2017%25%29.%20PrEP%20availability%20was%20higher%20among%20sites%20in%20countries%20where%20PrEP%20was%20officially%20registered%20%28146%5C%2F161%3B%2091%25%29%20than%20where%20it%20was%20not%20%2814%5C%2F32%3B%2044%25%29.%20Availability%20was%20higher%20at%20health%20centers%20%28109%5C%2F120%3B%2090%25%29%20and%20district%20hospitals%20%2814%5C%2F16%3B%2088%25%29%20compared%20to%20regional%5C%2Fteaching%20hospitals%20%2836%5C%2F63%29.%20Among%20the%2094%20sites%20that%20responded%20to%20all%20three%20surveys%2C%20PrEP%20availability%20increased%20from%2047%25%20in%202014%20to%2060%25%20in%202017%20and%2076%25%20in%202020.%5CnCONCLUSION%3A%20PrEP%20availability%20has%20substantially%20increased%20since%202014%20and%20is%20now%20available%20at%20most%20IeDEA%20sites.%20However%2C%20PrEP%20service%20provision%20varies%20markedly%20across%20global%20regions.%22%2C%22date%22%3A%222024-04-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003824%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238133656%22%2C%22PMCID%22%3A%22PMC10939841%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A50Z%22%7D%7D%2C%7B%22key%22%3A%229NFSBW97%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Plaisy%20et%20al.%22%2C%22parsedDate%22%3A%222024-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPlaisy%20MK%2C%20Minga%20AK%2C%20Wandeler%20G%2C%20Murenzi%20G%2C%20Samala%20N%2C%20Ross%20J%2C%20et%20al.%20Metabolic%20causes%20of%20liver%20disease%20among%20adults%20living%20with%20HIV%20from%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study.%20J%20Int%20AIDS%20Soc.%202024%20Apr%3B27%284%29%3Ae26238.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26238%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26238%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038566493%3B%20PubMed%20Central%20PMCID%3A%20PMC10988113.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metabolic%20causes%20of%20liver%20disease%20among%20adults%20living%20with%20HIV%20from%20low-%20and%20middle-income%20countries%3A%20a%20cross-sectional%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Kerbie%22%2C%22lastName%22%3A%22Plaisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20K.%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niharika%22%2C%22lastName%22%3A%22Samala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alvaro%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ephrem%22%2C%22lastName%22%3A%22Mensah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ren%5Cu00e9e%22%2C%22lastName%22%3A%22de%20Waal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20H.%22%2C%22lastName%22%3A%22Kuniholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonali%22%2C%22lastName%22%3A%22Salvi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Attia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ardele%22%2C%22lastName%22%3A%22Mandiriri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Shumbusho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Goodrich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Alarcon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Perrazo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Sentinel%20Research%20Network%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Liver%20disease%20is%20a%20leading%20cause%20of%20morbidity%20and%20mortality%20among%20persons%20living%20with%20HIV%20%28PLHIV%29.%20While%20chronic%20viral%20hepatitis%20has%20been%20extensively%20studied%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%2C%20there%20is%20limited%20information%20about%20the%20burden%20of%20metabolic%20disorders%20on%20liver%20disease%20in%20PLHIV.%5CnMETHODS%3A%20We%20conducted%20a%20cross-sectional%20analysis%20of%20baseline%20data%20collected%20between%20October%202020%20and%20July%202022%20from%20the%20IeDEA-Sentinel%20Research%20Network%2C%20a%20prospective%20cohort%20enrolling%20PLHIV%20%5Cu226540%20years%20on%20antiretroviral%20treatment%20%28ART%29%20for%20%5Cu22656%20months%20from%20eight%20clinics%20in%20Asia%2C%20Americas%2C%20and%20central%2C%20East%2C%20southern%20and%20West%20Africa.%20Clinical%20assessments%2C%20laboratory%20testing%20on%20fasting%20blood%20samples%20and%20liver%20stiffness%20measurement%20%28LSM%29%5C%2Fcontrolled%20attenuation%20parameter%20%28CAP%29%20by%20vibration-controlled%20transient%20elastography%20were%20performed.%20Multivariable%20logistic%20regression%20models%20assessed%20factors%20associated%20with%20liver%20fibrosis%20%28LSM%20%5Cu22657.1%20kPa%29%20and%20steatosis%20%28CAP%20%5Cu2265248%20dB%5C%2Fm%29.%20Population%20attributable%20fraction%20%28PAF%29%20of%20each%20variable%20associated%20with%20significant%20liver%20fibrosis%20was%20estimated%20using%20Levin%26%23039%3Bs%20formula.%5CnRESULTS%3A%20Overall%2C%202120%20PLHIV%20%2856%25%20female%2C%20median%20age%2050%20%5Binterquartile%20range%3A%2045-56%5D%20years%29%20were%20included.%20The%20prevalence%20of%20obesity%20was%2019%25%2C%2012%25%20had%20type%202%20diabetes%20mellitus%20%28T2DM%29%2C%2029%25%20had%20hypertension%20and%2053%25%20had%20dyslipidaemia.%20The%20overall%20prevalence%20of%20liver%20fibrosis%20and%20steatosis%20was%207.6%25%20%2895%25%20confidence%20interval%20%5BCI%5D%206.1-8.4%29%20and%2028.4%25%20%2895%25%20CI%2026.5-30.7%29%2C%20respectively%2C%20with%20regional%20variability.%20Male%20sex%20at%20birth%20%28odds%20ratio%20%5BOR%5D%201.62%2C%20CI%201.10-2.40%29%2C%20overweight%5C%2Fobesity%20%28OR%20%3D%202.50%2C%2095%25%20CI%201.69-3.75%29%2C%20T2DM%20%28OR%202.26%2C%2095%25%20CI%201.46-3.47%29%20and%20prolonged%20exposure%20to%20didanosine%20%28OR%203.13%2C%2095%25%20CI%201.46-6.49%29%20were%20associated%20with%20liver%20fibrosis.%20Overweight%5C%2Fobesity%20and%20T2DM%20accounted%20for%2042%25%20and%2011%25%20of%20the%20PAF%20for%20liver%20fibrosis%2C%20while%20HBsAg%20and%20anti-HCV%20accounted%20for%203%25%20and%201%25%2C%20respectively.%20Factors%20associated%20with%20steatosis%20included%20overweight%5C%2Fobesity%20%28OR%204.25%2C%2095%25%20CI%203.29-5.51%29%2C%20T2DM%20%28OR%202.06%2C%2095%25%20CI%201.47-2.88%29%2C%20prolonged%20exposure%20to%20stavudine%20%28OR%201.69%2C%2095%25%20CI%201.27-2.26%29%20and%20dyslipidaemia%20%28OR%201.68%2C%2095%25%20CI%201.31-2.16%29.%5CnCONCLUSIONS%3A%20Metabolic%20disorders%20were%20significant%20risk%20factors%20for%20liver%20disease%20among%20PLHIV%20in%20LMICs.%20Early%20recognition%20of%20metabolic%20disorders%20risk%20factors%20might%20be%20helpful%20to%20guide%20clinical%20and%20lifestyle%20interventions.%20Further%20prospective%20studies%20are%20needed%20to%20determine%20the%20causative%20natures%20of%20these%20findings.%22%2C%22date%22%3A%222024-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26238%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238566493%22%2C%22PMCID%22%3A%22PMC10988113%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%224U4K3X2W%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Baker%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-27%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBaker%20PJ%2C%20Bohrer%20AC%2C%20Castro%20E%2C%20Amaral%20EP%2C%20Snow-Smith%20M%2C%20Torres-Ju%26%23xE1%3Brez%20F%2C%20et%20al.%20The%20inflammatory%20microenvironment%20of%20the%20lung%20at%20the%20time%20of%20infection%20governs%20innate%20control%20of%20SARS-CoV-2%20replication.%20bioRxiv.%202024%20Mar%2027%3B2024.03.27.586885.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.03.27.586885%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2024.03.27.586885%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038585846%3B%20PubMed%20Central%20PMCID%3A%20PMC10996686.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20inflammatory%20microenvironment%20of%20the%20lung%20at%20the%20time%20of%20infection%20governs%20innate%20control%20of%20SARS-CoV-2%20replication%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20J.%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20C.%22%2C%22lastName%22%3A%22Bohrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ehydel%22%2C%22lastName%22%3A%22Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20P.%22%2C%22lastName%22%3A%22Amaral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryonne%22%2C%22lastName%22%3A%22Snow-Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flor%22%2C%22lastName%22%3A%22Torres-Ju%5Cu00e1rez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sydnee%20T.%22%2C%22lastName%22%3A%22Gould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandra%20M.%22%2C%22lastName%22%3A%22Jordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaspal%20S.%22%2C%22lastName%22%3A%22Khillan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kyoungin%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%20L.%22%2C%22lastName%22%3A%22Barber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reed%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kerry%20L.%22%2C%22lastName%22%3A%22Hilligan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%20D.%22%2C%22lastName%22%3A%22Mayer-Barber%22%7D%5D%2C%22abstractNote%22%3A%22SARS-CoV-2%20infection%20leads%20to%20vastly%20divergent%20clinical%20outcomes%20ranging%20from%20asymptomatic%20infection%20to%20fatal%20disease.%20Co-morbidities%2C%20sex%2C%20age%2C%20host%20genetics%20and%20vaccine%20status%20are%20known%20to%20affect%20disease%20severity.%20Yet%2C%20how%20the%20inflammatory%20milieu%20of%20the%20lung%20at%20the%20time%20of%20SARS-CoV-2%20exposure%20impacts%20the%20control%20of%20viral%20replication%20remains%20poorly%20understood.%20We%20demonstrate%20here%20that%20immune%20events%20in%20the%20mouse%20lung%20closely%20preceding%20SARS-CoV-2%20infection%20significantly%20impact%20viral%20control%20and%20we%20identify%20key%20innate%20immune%20pathways%20required%20to%20limit%20viral%20replication.%20A%20diverse%20set%20of%20pulmonary%20inflammatory%20stimuli%2C%20including%20resolved%20antecedent%20respiratory%20infections%20with%20S.%20aureus%20or%20influenza%2C%20ongoing%20pulmonary%20M.%20tuberculosis%20infection%2C%20ovalbumin%5C%2Falum-induced%20asthma%20or%20airway%20administration%20of%20defined%20TLR%20ligands%20and%20recombinant%20cytokines%2C%20all%20establish%20an%20antiviral%20state%20in%20the%20lung%20that%20restricts%20SARS-CoV-2%20replication%20upon%20infection.%20In%20addition%20to%20antiviral%20type%20I%20interferons%2C%20the%20broadly%20inducible%20inflammatory%20cytokines%20TNF%5Cu03b1%20and%20IL-1%20precondition%20the%20lung%20for%20enhanced%20viral%20control.%20Collectively%2C%20our%20work%20shows%20that%20SARS-CoV-2%20may%20benefit%20from%20an%20immunologically%20quiescent%20lung%20microenvironment%20and%20suggests%20that%20heterogeneity%20in%20pulmonary%20inflammation%20that%20precedes%20or%20accompanies%20SARS-CoV-2%20exposure%20may%20be%20a%20significant%20factor%20contributing%20to%20the%20population-wide%20variability%20in%20COVID-19%20disease%20outcomes.%22%2C%22date%22%3A%222024-03-27%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1101%5C%2F2024.03.27.586885%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238585846%22%2C%22PMCID%22%3A%22PMC10996686%22%2C%22ISSN%22%3A%222692-8205%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22R4HRHDDT%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Vinhaes%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-15%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVinhaes%20CL%2C%20Fukutani%20ER%2C%20Santana%20GC%2C%20Arriaga%20MB%2C%20Barreto-Duarte%20B%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20et%20al.%20An%20integrative%20multi-omics%20approach%20to%20characterize%20interactions%20between%20tuberculosis%20and%20diabetes%20mellitus.%20iScience.%202024%20Mar%2015%3B27%283%29%3A109135.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2024.109135%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2024.109135%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038380250%3B%20PubMed%20Central%20PMCID%3A%20PMC10877940.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22An%20integrative%20multi-omics%20approach%20to%20characterize%20interactions%20between%20tuberculosis%20and%20diabetes%20mellitus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%20C.%22%2C%22lastName%22%3A%22Santana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateus%22%2C%22lastName%22%3A%22Maggitti-Bezerril%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ginger%20L.%22%2C%22lastName%22%3A%22Milne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis-diabetes%20mellitus%20%28TB-DM%29%20is%20linked%20to%20a%20distinct%20inflammatory%20profile%2C%20which%20can%20be%20assessed%20using%20multi-omics%20analyses.%20Here%2C%20a%20machine%20learning%20algorithm%20was%20applied%20to%20multi-platform%20data%2C%20including%20cytokines%20and%20gene%20expression%20in%20peripheral%20blood%20and%20eicosanoids%20in%20urine%2C%20in%20a%20Brazilian%20multi-center%20TB%20cohort.%20There%20were%20four%20clinical%20groups%3A%20TB-DM%28n%5Cu00a0%3D%2024%29%2C%20TB%20only%28n%5Cu00a0%3D%2028%29%2C%20DM%28HbA1c%20%5Cu2265%206.5%25%29%20only%28n%5Cu00a0%3D%2011%29%2C%20and%20a%20control%20group%20of%20close%20TB%20contacts%20who%20did%20not%20have%20TB%20or%20DM%28n%5Cu00a0%3D%2013%29.%20After%5Cu00a0cross-validation%2C%20baseline%20expression%20or%20abundance%20of%20MMP-28%2C%20LTE-4%2C%2011-dTxB2%2C%20PGDM%2C%20FBXO6%2C%20SECTM1%2C%20and%20LINCO2009%20differentiated%20the%20four%20patient%20groups.%20A%20distinct%20multi-omic-derived%2C%20dimensionally%20reduced%2C%20signature%20was%20associated%20with%20TB%2C%20regardless%20of%20glycemic%20status.%20SECTM1%20and%20FBXO6%20mRNA%20levels%20were%20positively%20correlated%20with%20sputum%20acid-fast%20bacilli%20grade%20in%20TB-DM.%20Values%20of%20the%20biomarkers%20decreased%20during%20the%20course%20of%20anti-TB%20therapy.%20Our%20study%20identified%20several%20markers%20associated%20with%20the%20pathophysiology%20of%20TB-DM%20that%20could%20be%20evaluated%20in%20future%20mechanistic%20investigations.%22%2C%22date%22%3A%222024-03-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.isci.2024.109135%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238380250%22%2C%22PMCID%22%3A%22PMC10877940%22%2C%22ISSN%22%3A%222589-0042%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%2292SUSR59%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ridolfi%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-14%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRidolfi%20F%2C%20Amorim%20G%2C%20Peetluk%20LS%2C%20Haas%20DW%2C%20Staats%20C%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20et%20al.%20Prediction%20Models%20for%20Adverse%20Drug%20Reactions%20During%20Tuberculosis%20Treatment%20in%20Brazil.%20J%20Infect%20Dis.%202024%20Mar%2014%3B229%283%29%3A813%26%23×2013%3B23.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae025%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiae025%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038262629%3B%20PubMed%20Central%20PMCID%3A%20PMC10938211.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prediction%20Models%20for%20Adverse%20Drug%20Reactions%20During%20Tuberculosis%20Treatment%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cody%22%2C%22lastName%22%3A%22Staats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29%5Cu2013Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20treatment-related%20adverse%20drug%20reactions%20%28TB-ADRs%29%20can%20negatively%20affect%20adherence%20and%20treatment%20success%20rates.%5CnMETHODS%3A%20We%20developed%20prediction%20models%20for%20TB-ADRs%2C%20considering%20participants%20with%20drug-susceptible%20pulmonary%20TB%20who%20initiated%20standard%20TB%20therapy.%20TB-ADRs%20were%20determined%20by%20the%20physician%20attending%20the%20participant%2C%20assessing%20causality%20to%20TB%20drugs%2C%20the%20affected%20organ%20system%2C%20and%20grade.%20Potential%20baseline%20predictors%20of%20TB-ADR%20included%20concomitant%20medication%20%28CM%29%20use%2C%20human%20immunodeficiency%20virus%20%28HIV%29%20status%2C%20glycated%20hemoglobin%20%28HbA1c%29%2C%20age%2C%20body%20mass%20index%20%28BMI%29%2C%20sex%2C%20substance%20use%2C%20and%20TB%20drug%20metabolism%20variables%20%28NAT2%20acetylator%20profiles%29.%20The%20models%20were%20developed%20through%20bootstrapped%20backward%20selection.%20Cox%20regression%20was%20used%20to%20evaluate%20TB-ADR%20risk.%5CnRESULTS%3A%20There%20were%20156%20TB-ADRs%20among%20102%20of%20the%20945%20%2811%25%29%20participants%20included.%20Most%20TB-ADRs%20were%20hepatic%20%28n%20%3D%2082%20%5B53%25%5D%29%2C%20of%20moderate%20severity%20%28grade%202%3B%20n%20%3D%20121%20%5B78%25%5D%29%2C%20and%20occurred%20in%20NAT2%20slow%20acetylators%20%28n%20%3D%2062%20%5B61%25%5D%29.%20The%20main%20prediction%20model%20included%20CM%20use%2C%20HbA1c%2C%20alcohol%20use%2C%20HIV%20seropositivity%2C%20BMI%2C%20and%20age%2C%20with%20robust%20performance%20%28c-statistic%20%3D%200.79%20%5B95%25%20confidence%20interval%20%7BCI%7D%2C%20.74-.83%29%20and%20fit%20%28optimism-corrected%20slope%20and%20intercept%20of%20-0.09%20and%200.94%2C%20respectively%29.%20An%20alternative%20model%20replacing%20BMI%20with%20NAT2%20had%20similar%20performance.%20HIV%20seropositivity%20%28hazard%20ratio%20%5BHR%5D%2C%202.68%20%5B95%25%20CI%2C%201.75-4.09%5D%29%20and%20CM%20use%20%28HR%2C%205.26%20%5B95%25%20CI%2C%202.63-10.52%5D%29%20increased%20TB-ADR%20risk.%5CnCONCLUSIONS%3A%20The%20models%2C%20with%20clinical%20variables%20and%20with%20NAT2%2C%20were%20highly%20predictive%20of%20TB-ADRs.%22%2C%22date%22%3A%222024-03-14%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiae025%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238262629%22%2C%22PMCID%22%3A%22PMC10938211%22%2C%22ISSN%22%3A%221537-6613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22EZTXCMSE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Tymejczyk%20O%2C%20Wools-Kaloustian%20K%2C%20Jiamsakul%20A%2C%20Torres%20MTL%2C%20Lee%20JS%2C%20et%20al.%20Long-term%20HIV%20care%20outcomes%20under%20universal%20HIV%20treatment%20guidelines%3A%20A%20retrospective%20cohort%20study%20in%2025%20countries.%20PLoS%20Med.%202024%20Mar%3B21%283%29%3Ae1004367.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004367%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004367%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038498589%3B%20PubMed%20Central%20PMCID%3A%20PMC10962811.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20HIV%20care%20outcomes%20under%20universal%20HIV%20treatment%20guidelines%3A%20A%20retrospective%20cohort%20study%20in%2025%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Tymejczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%20Luque%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Abuogi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vohith%22%2C%22lastName%22%3A%22Khol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mej%5Cu00eda%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20G.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20national%20adoption%20of%20universal%20HIV%20treatment%20guidelines%20has%20led%20to%20improved%2C%20timely%20uptake%20of%20antiretroviral%20therapy%20%28ART%29%2C%20longer-term%20care%20outcomes%20are%20understudied.%20There%20is%20little%20data%20from%20real-world%20service%20delivery%20settings%20on%20patient%20attrition%2C%20viral%20load%20%28VL%29%20monitoring%2C%20and%20viral%20suppression%20%28VS%29%20at%2024%20and%2036%20months%20after%20HIV%20treatment%20initiation.%5CnMETHODS%20AND%20FINDINGS%3A%20For%20this%20retrospective%20cohort%20analysis%2C%20we%20used%20observational%20data%20from%2025%20countries%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%26%23039%3Bs%20Asia-Pacific%2C%20Central%20Africa%2C%20East%20Africa%2C%20Central%5C%2FSouth%20America%2C%20and%20North%20America%20regions%20for%20patients%20who%20were%20ART%20na%5Cu00efve%20and%20aged%20%5Cu226515%20years%20at%20care%20enrollment%20between%2024%20months%20before%20and%2012%20months%20after%20national%20adoption%20of%20universal%20treatment%20guidelines%2C%20occurring%202012%20to%202018.%20We%20estimated%20crude%20cumulative%20incidence%20of%20loss-to-clinic%20%28CI-LTC%29%20at%2012%2C%2024%2C%20and%2036%20months%20after%20enrollment%20among%20patients%20enrolling%20in%20care%20before%20and%20after%20guideline%20adoption%20using%20competing%20risks%20regression.%20Guideline%20change-associated%20hazard%20ratios%20of%20LTC%20at%20each%20time%20point%20after%20enrollment%20were%20estimated%20via%20cause-specific%20Cox%20proportional%20hazards%20regression%20models.%20Modified%20Poisson%20regression%20was%20used%20to%20estimate%20relative%20risks%20of%20retention%2C%20VL%20monitoring%2C%20and%20VS%20at%2012%2C%2024%2C%20and%2036%20months%20after%20ART%20initiation.%20There%20were%2066%2C963%20patients%20enrolling%20in%20HIV%20care%20at%20109%20clinics%20with%20%5Cu226512%20months%20of%20follow-up%20time%20after%20enrollment%20%2846%2C484%20%5B69.4%25%5D%20enrolling%20before%20guideline%20adoption%20and%2020%2C479%20%5B30.6%25%5D%20enrolling%20afterwards%29.%20More%20than%20half%20%2854.9%25%29%20were%20females%2C%20and%20median%20age%20was%2034%20years%20%28interquartile%20range%20%5BIQR%5D%3A%2027%20to%2043%29.%20Mean%20follow-up%20time%20was%2051%20months%20%28standard%20deviation%3A%2017%20months%3B%20range%3A%2012%2C%20110%20months%29.%20Among%20patients%20enrolling%20before%20guideline%20adoption%2C%20crude%20CI-LTC%20was%2023.8%25%20%2895%25%20confidence%20interval%20%5B95%25%20CI%5D%2023.4%2C%2024.2%29%20at%2012%20months%2C%2031.0%25%20%2895%25%20CI%20%5B30.6%2C%2031.5%5D%29%20at%2024%20months%2C%20and%2037.2%25%20%2895%25%20%5BCI%2036.8%2C%2037.7%5D%29%20at%2036%20months%20after%20enrollment.%20Adjusting%20for%20sex%2C%20age%20group%2C%20enrollment%20CD4%2C%20clinic%20location%20and%20type%2C%20and%20country%20income%20level%2C%20enrolling%20in%20care%20and%20initiating%20ART%20after%20guideline%20adoption%20was%20associated%20with%20increased%20hazard%20of%20LTC%20at%2012%20months%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%201.25%20%5B95%25%20CI%201.08%2C%201.44%5D%3B%20p%20%3D%200.003%29%3B%2024%20months%20%28aHR%201.38%20%5B95%25%20CI%201.19%2C%201.59%5D%3B%20p%20%26lt%3B%20.001%29%3B%20and%2036%20months%20%28aHR%201.34%20%5B95%25%20CI%201.18%2C%201.53%5D%2C%20p%20%26lt%3B%20.001%29%20compared%20with%20enrollment%20before%20guideline%20adoption%2C%20with%20no%20before-after%20differences%20among%20patients%20with%20no%20record%20of%20ART%20initiation%20by%20end%20of%20follow-up.%20Among%20patients%20retained%20after%20ART%20initiation%2C%20VL%20monitoring%20was%20low%2C%20with%20marginal%20improvements%20associated%20with%20guideline%20adoption%20only%20at%2012%20months%20after%20ART%20initiation.%20Among%20those%20with%20VL%20monitoring%2C%20VS%20was%20high%20at%20each%20time%20point%20among%20patients%20enrolling%20before%20guideline%20adoption%20%2886.0%25%20to%2088.8%25%29%20and%20afterwards%20%2886.2%25%20to%2090.3%25%29%2C%20with%20no%20substantive%20difference%20associated%20with%20guideline%20adoption.%20Study%20limitations%20include%20lags%20in%20and%20potential%20underascertainment%20of%20care%20outcomes%20in%20real-world%20service%20delivery%20data%20and%20potential%20lack%20of%20generalizability%20beyond%20IeDEA%20sites%20and%20regions%20included%20in%20this%20analysis.%5CnCONCLUSIONS%3A%20In%20this%20study%2C%20adoption%20of%20universal%20HIV%20treatment%20guidelines%20was%20associated%20with%20lower%20retention%20after%20ART%20initiation%20out%20to%2036%20months%20of%20follow-up%2C%20with%20little%20change%20in%20VL%20monitoring%20or%20VS%20among%20retained%20patients.%20Monitoring%20long-term%20HIV%20care%20outcomes%20remains%20critical%20to%20identify%20and%20address%20causes%20of%20attrition%20and%20gaps%20in%20HIV%20care%20quality.%22%2C%22date%22%3A%222024-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004367%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238498589%22%2C%22PMCID%22%3A%22PMC10962811%22%2C%22ISSN%22%3A%221549-1676%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%227MBP3TFQ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castillo-Rozas%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastillo-Rozas%20G%2C%20Tu%20S%2C%20Luz%20PM%2C%20Mejia%20F%2C%20Sierra-Madero%20J%2C%20Rouzier%20V%2C%20et%20al.%20Clinical%20outcomes%20and%20risk%20factors%20for%20immune%20recovery%20and%20all-cause%20mortality%20in%20Latin%20Americans%20living%20with%20HIV%20with%20virological%20success%3A%20a%20retrospective%20cohort%20study.%20J%20Int%20AIDS%20Soc.%202024%20Mar%3B27%283%29%3Ae26214.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26214%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26214%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038494667%3B%20PubMed%20Central%20PMCID%3A%20PMC10945036.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20outcomes%20and%20risk%20factors%20for%20immune%20recovery%20and%20all-cause%20mortality%20in%20Latin%20Americans%20living%20with%20HIV%20with%20virological%20success%3A%20a%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Castillo-Rozas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengxin%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20Mendes%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Immune%20reconstitution%20following%20antiretroviral%20therapy%20%28ART%29%20initiation%20is%20crucial%20to%20prevent%20AIDS%20and%20non-AIDS-related%20comorbidities.%20Patients%20with%20suppressed%20viraemia%20who%20fail%20to%20restore%20cellular%20immunity%20are%20exposed%20to%20an%20increased%20risk%20of%20morbidity%20and%20mortality%20during%20long-term%20follow-up%2C%20although%20the%20underlying%20mechanisms%20remain%20poorly%20understood.%20We%20aim%20to%20describe%20clinical%20outcomes%20and%20factors%20associated%20with%20the%20worse%20immune%20recovery%20and%20all-cause%20mortality%20in%20people%20living%20with%20HIV%20%28PLWH%29%20from%20Latin%20America%20following%20ART%20initiation.%5CnMETHODS%3A%20Retrospective%20cohort%20study%20using%20the%20CCASAnet%20database%3A%20PLWH%20%5Cu226518%20years%20of%20age%20at%20ART%20initiation%20using%20a%20three%20drug-based%20combination%20therapy%20and%20with%20medical%20follow-up%20for%20%5Cu226524%20months%20after%20ART%20initiation%20and%20undetectable%20viral%20load%20were%20included.%20Patients%20were%20divided%20into%20four%20immune%20recovery%20groups%20based%20on%20rounded%20quartiles%20of%20increase%20in%20CD4%20T-cell%20count%20at%202%20years%20of%20treatment%20%28%26lt%3B150%2C%20%5B150%2C%20250%29%2C%20%5B250%2C%20350%5D%20and%20%26gt%3B350%20cells%5C%2Fmm3%20%29.%20Primary%20outcomes%20included%20all-cause%20mortality%2C%20AIDS-defining%20events%20and%20non-communicable%20diseases%20that%20occurred%20%26gt%3B2%20years%20after%20ART%20initiation.%20Factors%20associated%20with%20an%20increase%20in%20CD4%20T-cell%20count%20at%202%20years%20of%20treatment%20were%20evaluated%20using%20a%20cumulative%20probability%20model%20with%20a%20logit%20link.%5CnRESULTS%3A%20In%20our%20cohort%20of%204496%20Latin%20American%20PLWH%2C%20we%20found%20that%20patients%20with%20the%20lowest%20CD4%20increase%20%28%26lt%3B150%29%20had%20the%20lowest%20survival%20probability%20at%2010%20years%20of%20follow-up.%20Lower%20increase%20in%20CD4%20count%20following%20therapy%20initiation%20%28and%20remarkably%20not%20a%20lower%20baseline%20CD4%20T-cell%20count%29%20and%20older%20age%20were%20risk%20factors%20for%20all-cause%20mortality.%20We%20also%20found%20that%20older%20age%2C%20male%20sex%20and%20higher%20baseline%20CD4%20T-cell%20count%20were%20associated%20with%20lower%20CD4%20count%20increase%20following%20therapy%20initiation.%5CnCONCLUSIONS%3A%20Our%20study%20shows%20that%20PLWH%20with%20lower%20increases%20in%20CD4%20count%20have%20lower%20survival%20probabilities.%20CD4%20increase%20during%20follow-up%20might%20be%20a%20better%20predictor%20of%20mortality%20in%20undetectable%20PLWH%20than%20baseline%20CD4%20count.%20Therefore%2C%20it%20should%20be%20included%20as%20a%20routine%20clinical%20variable%20to%20assess%20immune%20recovery%20and%20overall%20survival.%22%2C%22date%22%3A%222024-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26214%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238494667%22%2C%22PMCID%22%3A%22PMC10945036%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22CRI3IEHD%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Davidovi%5Cu0107%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BDavidovi%26%23×107%3B%20M%2C%20Asangbeh%20SL%2C%20Taghavi%20K%2C%20Dhokotera%20T%2C%20Jaquet%20A%2C%20Musick%20B%2C%20et%20al.%20Facility-Based%20Indicators%20to%20Manage%20and%20Scale%20Up%20Cervical%20Cancer%20Prevention%20and%20Care%20Services%20for%20Women%20Living%20With%20HIV%20in%20Sub-Saharan%20Africa%3A%20a%20Three-Round%20Online%20Delphi%20Consensus%20Method.%20J%20Acquir%20Immune%20Defic%20Syndr.%202024%20Feb%201%3B95%282%29%3A170%26%23×2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003343%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003343%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038211958%3B%20PubMed%20Central%20PMCID%3A%20PMC10794028.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Facility-Based%20Indicators%20to%20Manage%20and%20Scale%20Up%20Cervical%20Cancer%20Prevention%20and%20Care%20Services%20for%20Women%20Living%20With%20HIV%20in%20Sub-Saharan%20Africa%3A%20a%20Three-Round%20Online%20Delphi%20Consensus%20Method%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu0161a%22%2C%22lastName%22%3A%22Davidovi%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serra%20Lem%22%2C%22lastName%22%3A%22Asangbeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katayoun%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tafadzwa%22%2C%22lastName%22%3A%22Dhokotera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cari%22%2C%22lastName%22%3A%22Van%20Schalkwyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Schwappach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Orang%27o%20Elkanah%22%2C%22lastName%22%3A%22Omenge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20Pierre%22%2C%22lastName%22%3A%22Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%22%2C%22lastName%22%3A%22von%20Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Bohlius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Of%20women%20with%20cervical%20cancer%20%28CC%29%20and%20HIV%2C%2085%25%20live%20in%20sub-Saharan%20Africa%2C%20where%2021%25%20of%20all%20CC%20cases%20are%20attributable%20to%20HIV%20infection.%20We%20aimed%20to%20generate%20internationally%20acceptable%20facility-based%20indicators%20to%20monitor%20and%20guide%20scale%20up%20of%20CC%20prevention%20and%20care%20services%20offered%20on-site%20or%20off-site%20by%20HIV%20clinics.%5CnMETHODS%3A%20We%20reviewed%20the%20literature%20and%20extracted%20relevant%20indicators%2C%20grouping%20them%20into%20domains%20along%20the%20CC%20control%20continuum.%20From%20February%202021%20to%20March%202022%2C%20we%20conducted%20a%20three-round%2C%20online%20Delphi%20process%20to%20reach%20consensus%20on%20indicators.%20We%20invited%20106%20experts%20to%20participate.%20Through%20an%20anonymous%2C%20iterative%20process%2C%20participants%20adapted%20the%20indicators%20to%20their%20context%20%28round%201%29%2C%20then%20rated%20them%20for%205%20criteria%20on%20a%205-point%20Likert-type%20scale%20%28rounds%202%20and%203%29%20and%20then%20ranked%20their%20importance%20%28round%203%29.%5CnRESULTS%3A%20We%20reviewed%2039%20policies%20from%2021%20African%20countries%20and%207%20from%20international%20organizations%3B%2072%20experts%20from%2015%20sub-Saharan%20Africa%20countries%20or%20international%20organizations%20participated%20in%20our%20Delphi%20process.%20Response%20rates%20were%2034%25%20in%20round%201%2C%2040%25%20in%20round%202%2C%20and%2044%25%20in%20round%203.%20Experts%20reached%20consensus%20for%2017%20indicators%20in%20the%20following%20domains%3A%20primary%20prevention%20%28human%20papillomavirus%20prevention%2C%20n%20%3D%202%29%2C%20secondary%20prevention%20%28screening%2C%20triage%2C%20treatment%20of%20precancerous%20lesions%2C%20n%20%3D%2011%29%2C%20tertiary%20prevention%20%28CC%20diagnosis%20and%20care%2C%20n%20%3D%202%29%2C%20and%20long-term%20impact%20of%20the%20program%20and%20linkage%20to%20HIV%20service%20%28n%20%3D%202%29.%5CnCONCLUSION%3A%20We%20recommend%20that%20HIV%20clinics%20that%20offer%20CC%20control%20services%20in%20sub-Saharan%20Africa%20implement%20the%2017%20indicators%20stepwise%20and%20adapt%20them%20to%20context%20to%20improve%20monitoring%20along%20the%20CC%20control%20cascade.%22%2C%22date%22%3A%222024-02-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003343%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238211958%22%2C%22PMCID%22%3A%22PMC10794028%22%2C%22ISSN%22%3A%221944-7884%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22ZHEDW7E3%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Lancaster%20et%20al.%22%2C%22parsedDate%22%3A%222024-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLancaster%20KE%2C%20Stockton%20M%2C%20Remch%20M%2C%20Wester%20CW%2C%20Nash%20D%2C%20Brazier%20E%2C%20et%20al.%20Availability%20of%20substance%20use%20screening%20and%20treatment%20within%20HIV%20clinical%20sites%20across%20seven%20geographic%20regions%20within%20the%20IeDEA%20consortium.%20Int%20J%20Drug%20Policy.%202024%20Feb%3B124%3A104309.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2023.104309%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.drugpo.2023.104309%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038228025%3B%20PubMed%20Central%20PMCID%3A%20PMC10939808.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20of%20substance%20use%20screening%20and%20treatment%20within%20HIV%20clinical%20sites%20across%20seven%20geographic%20regions%20within%20the%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20E.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Molly%22%2C%22lastName%22%3A%22Remch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Finlayson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Breanna%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%20Kamaru%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%20Lewis%22%2C%22lastName%22%3A%22Kulzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tuti%22%2C%22lastName%22%3A%22Merati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judiacel%22%2C%22lastName%22%3A%22Tine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Per%20von%22%2C%22lastName%22%3A%22Groote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Jennifer%22%2C%22lastName%22%3A%22Edelman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Overwhelming%20evidence%20highlights%20the%20negative%20impact%20of%20substance%20use%20on%20HIV%20care%20and%20treatment%20outcomes.%20Yet%2C%20the%20extent%20to%20which%20alcohol%20use%20disorder%20%28AUD%29%20and%20other%20substance%20use%20disorders%20%28SUD%29%20services%20have%20been%20integrated%20within%20HIV%20clinical%20settings%20is%20limited.%20We%20describe%20AUD%5C%2FSUD%20screening%20and%20treatment%20availability%20in%20HIV%20clinical%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%5CnMETHODS%3A%20In%202020%2C%20223%20IeDEA%20HIV%20clinical%20sites%20from%2041%20countries%20across%20seven%20geographic%20regions%20completed%20a%20survey%20on%20capacity%20and%20practices%20related%20to%20management%20of%20AUD%5C%2F%20SUD.%20Sites%20provided%20information%20on%20AUD%20and%20other%20SUD%20screening%20and%20treatment%20practices.%5CnRESULTS%3A%20Sites%20were%20from%20low-income%20countries%20%2823%25%29%2C%20lower-middle-income%20countries%20%2838%25%29%2C%20upper-middle%20income%20countries%20%2817%25%29%20and%20high-income%20counties%20%2823%25%29.%20AUD%20and%20SUD%20screening%20using%20validated%20instruments%20were%20reported%20at%2032%25%20%28n%3D71%20located%20in%2012%20countries%29%20and%2012%25%20%28n%3D27%20located%20in%206%20countries%29%20of%20the%20223%20sites%20from%2041%20countries%2C%20respectively.%20The%20North%20American%20region%20had%20the%20highest%20proportion%20of%20clinics%20that%20reported%20AUD%20screening%20%2876%25%29%2C%20followed%20by%20East%20Africa%20%2846%25%29%3B%20none%20of%20the%20sites%20in%20West%20or%20Central%20Africa%20reported%20AUD%20screening.%2031%25%20%28n%3D69%29%20reported%20both%20AUD%20screening%20and%20counseling%2C%20brief%20intervention%2C%20psychotherapy%2C%20or%20Screening%2C%20Brief%20Intervention%2C%20and%20Referral%20to%20Treatment%3B%208%25%20%28n%3D18%29%20reported%20AUD%20screening%20and%20detox%20hospitalization%3B%20and%2010%25%20%28n%3D24%29%20reported%20both%20AUD%20screening%20and%20medication.%20While%20the%20proportion%20of%20clinics%20providing%20treatment%20for%20SUD%20was%20lower%20than%20those%20treating%20AUD%2C%20the%20prevalence%20estimates%20of%20treatment%20availability%20were%20similar.%5CnCONCLUSIONS%3A%20Availability%20of%20screening%20and%20treatment%20for%20AUD%5C%2FSUD%20in%20HIV%20care%20settings%20is%20limited%2C%20leaving%20a%20substantial%20gap%20for%20integration%20into%20ongoing%20HIV%20care.%20A%20critical%20understanding%20is%20needed%20of%20the%20multilevel%20implementation%20factors%20or%20feasible%20implementation%20strategies%20for%20integrating%20screening%20and%20treatment%20of%20AUD%5C%2FSUD%20into%20HIV%20care%20settings%2C%20particularly%20for%20resource-constrained%20regions.%22%2C%22date%22%3A%222024-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.drugpo.2023.104309%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238228025%22%2C%22PMCID%22%3A%22PMC10939808%22%2C%22ISSN%22%3A%221873-4758%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22HEJ86T42%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rocha%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRocha%20EF%2C%20Vinhaes%20CL%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Mota%20TF%2C%20Gupte%20AN%2C%20Kumar%20NP%2C%20et%20al.%20The%20sound%20of%20silent%20RNA%20in%20tuberculosis%20and%20the%20lncRNA%20role%20on%20infection.%20iScience.%202024%20Jan%2019%3B27%281%29%3A108662.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.108662%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.108662%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038205253%3B%20PubMed%20Central%20PMCID%3A%20PMC10777062.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20sound%20of%20silent%20RNA%20in%20tuberculosis%20and%20the%20lncRNA%20role%20on%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20Fukutani%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20Leal%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiago%20Feitosa%22%2C%22lastName%22%3A%22Mota%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akshay%20N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathella%20Pavan%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Belen%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subash%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Gaikwad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Karyakarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vidya%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vandana%22%2C%22lastName%22%3A%22Kulkarni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mandar%22%2C%22lastName%22%3A%22Paradkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Viswanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardy%22%2C%22lastName%22%3A%22Kornfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amita%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20Bezerril%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20Trancoso%20Lopo%20de%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20India%20Consortia%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20one%20of%20the%20leading%20causes%20of%20death%20worldwide%2C%20and%20Diabetes%20Mellitus%20is%20one%20of%20the%20major%20comorbidities%20%28TB%5C%2FDM%29%20associated%20with%20the%20disease.%20A%20total%20of%20103%20differentially%20expressed%20ncRNAs%20have%20been%20identified%20in%20the%20TB%20and%20TB%5C%2FDM%20comparisons.%20A%20machine%20learning%20algorithm%20was%20employed%20to%20identify%20the%20most%20informative%20lncRNAs%3A%20ADM-DT%2C%20LINC02009%2C%20LINC02471%2C%20SOX2-OT%2C%20and%20GK-AS1.%20These%20lncRNAs%20presented%20substantial%20accuracy%20in%20classifying%20TB%20from%20HC%20%28AUCs%20%26gt%3B0.85%29%20and%20TB%5C%2FDM%20from%20HC%20%28AUCs%20%26gt%3B0.90%29%20in%20the%20other%20three%20countries.%20Genes%20with%20significant%20correlations%20with%20the%20five%20lncRNAs%20enriched%20common%20pathways%20in%20Brazil%20and%20India%20for%20both%20TB%20and%20TB%5C%2FDM.%20This%20suggests%20that%20lncRNAs%20play%20an%20important%20role%20in%20the%20regulation%20of%20genes%20related%20to%20the%20TB%20immune%20response.%22%2C%22date%22%3A%222024-01-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.isci.2023.108662%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238205253%22%2C%22PMCID%22%3A%22PMC10777062%22%2C%22ISSN%22%3A%222589-0042%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22VMDJ88LW%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Enane%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEnane%20LA%2C%20Duda%20SN%2C%20Chanyachukul%20T%2C%20Bolton-Moore%20C%2C%20Navuluri%20N%2C%20Messou%20E%2C%20et%20al.%20The%20Tuberculosis%20Sentinel%20Research%20Network%20%28TB-SRN%29%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%3A%20protocol%20for%20a%20prospective%20cohort%20study%20in%20Africa%2C%20Southeast%20Asia%20and%20Latin%20America.%20BMJ%20Open.%202024%20Jan%209%3B14%281%29%3Ae079138.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2023-079138%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2023-079138%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038195167%3B%20PubMed%20Central%20PMCID%3A%20PMC10806577.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Tuberculosis%20Sentinel%20Research%20Network%20%28TB-SRN%29%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%3A%20protocol%20for%20a%20prospective%20cohort%20study%20in%20Africa%2C%20Southeast%20Asia%20and%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thida%22%2C%22lastName%22%3A%22Chanyachukul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neelima%22%2C%22lastName%22%3A%22Navuluri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nana%22%2C%22lastName%22%3A%22Mbonze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22LaQuita%20R.%22%2C%22lastName%22%3A%22McDade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20Cruvinel%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denise%22%2C%22lastName%22%3A%22Evans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Akpata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Zotova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Flore%22%2C%22lastName%22%3A%22Pierre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanushi%22%2C%22lastName%22%3A%22Rupasinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22de%20Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martine%22%2C%22lastName%22%3A%22Tabala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Huebner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Tuberculosis%20%28TB%29%20is%20a%20leading%20infectious%20cause%20of%20death%20globally.%20It%20is%20the%20most%20common%20opportunistic%20infection%20in%20people%20living%20with%20HIV%2C%20and%20the%20most%20common%20cause%20of%20their%20morbidity%20and%20mortality.%20Following%20TB%20treatment%2C%20surviving%20individuals%20may%20be%20at%20risk%20for%20post-TB%20lung%20disease.%20The%20TB%20Sentinel%20Research%20Network%20%28TB-SRN%29%20provides%20a%20platform%20for%20coordinated%20observational%20TB%20research%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%5CnMETHODS%20AND%20ANALYSIS%3A%20This%20prospective%2C%20observational%20cohort%20study%20will%20assess%20treatment%20and%20post-treatment%20outcomes%20of%20pulmonary%20TB%20%28microbiologically%20confirmed%20or%20clinically%20diagnosed%29%20among%202600%20people%20aged%20%5Cu226515%20years%2C%20with%20and%20without%20HIV%20coinfection%2C%20consecutively%20enrolled%20at%2016%20sites%20in%2011%20countries%2C%20across%206%20of%20IeDEA%26%23039%3Bs%20global%20regions.%20Data%20regarding%20clinical%20and%20sociodemographic%20factors%2C%20mental%20health%2C%20health-related%20quality%20of%20life%2C%20pulmonary%20function%2C%20and%20laboratory%20and%20radiographic%20findings%20will%20be%20collected%20using%20standardised%20questionnaires%20and%20data%20collection%20tools%2C%20beginning%20from%20the%20initiation%20of%20TB%20treatment%20and%20through%2012%20months%20after%20the%20end%20of%20treatment.%20Data%20will%20be%20aggregated%20for%20proposed%20analyses.%5CnETHICS%20AND%20DISSEMINATION%3A%20Ethics%20approval%20was%20obtained%20at%20all%20implementing%20study%20sites%2C%20including%20the%20Vanderbilt%20University%20Medical%20Center%20Human%20Research%20Protections%20Programme.%20Participants%20will%20provide%20informed%20consent%3B%20for%20minors%2C%20this%20includes%20both%20adolescent%20assent%20and%20the%20consent%20of%20their%20parent%20or%20primary%20caregiver.%20Protections%20for%20vulnerable%20groups%20are%20included%2C%20in%20alignment%20with%20local%20standards%20and%20considerations%20at%20sites.%20Procedures%20for%20requesting%20use%20and%20analysis%20of%20TB-SRN%20data%20are%20publicly%20available.%20Findings%20from%20TB-SRN%20analyses%20will%20be%20shared%20with%20national%20TB%20programmes%20to%20inform%20TB%20programming%20and%20policy%2C%20and%20disseminated%20at%20regional%20and%20global%20conferences%20and%20other%20venues.%22%2C%22date%22%3A%222024-01-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2023-079138%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238195167%22%2C%22PMCID%22%3A%22PMC10806577%22%2C%22ISSN%22%3A%222044-6055%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A33%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22CYQ72Q6V%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Garcia%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGarcia%20LS%2C%20Costa%20AG%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Spener-Gomes%20R%2C%20Aguiar%20AF%2C%20Souza%20AB%2C%20et%20al.%20The%20Xpert%26%23xAE%3B%20MTB%5C%2FRIF%20cycle%20threshold%20value%20predicts%20M.%20tuberculosis%20transmission%20to%20close%20contacts%20in%20a%20Brazilian%20prospective%20multicenter%20cohort.%20Clin%20Infect%20Dis.%202024%20Jan%203%3Bciad794.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad794%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad794%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038170196%3B%20PubMed%20Central%20PMCID%3A%20PMC12609578.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20cycle%20threshold%20value%20predicts%20M.%20tuberculosis%20transmission%20to%20close%20contacts%20in%20a%20Brazilian%20prospective%20multicenter%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leandro%20S.%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allyson%20G.%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20Fran%5Cu00e7a%22%2C%22lastName%22%3A%22Aguiar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%20O.%20A.%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaquelane%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saulo%20R.%20N.%22%2C%22lastName%22%3A%22Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Cristina%22%2C%22lastName%22%3A%22Louren%5Cu00e7o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20rapid%20molecular%20test%20provides%20a%20quantitative%20measure%20of%20Mycobacterium%20tuberculosis%20%28Mtb%29%20DNA%20in%20the%20form%20of%20cycle%20threshold%20%28Ct%29%20values.%20This%20information%20can%20be%20translated%20into%20mycobacterial%20load%20and%20used%20as%20a%20potential%20risk%20measure%20of%20bacterial%20spread%20for%20tuberculosis%20cases%2C%20which%20can%20impact%20infection%20control.%20However%2C%20the%20role%20of%20Ct%20values%20in%20assessing%20Mtb%20transmission%20to%20close%20contacts%20has%20not%20yet%20been%20demonstrated.%5CnMETHODS%3A%20A%20prospective%20study%20was%20performed%20to%20investigate%20the%20association%20between%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20Ct%20values%20and%20Mtb%20transmission%20to%20close%20contacts%20of%20patients%20with%20culture-confirmed%20pulmonary%20TB%20in%20a%20multi-center%20Brazilian%20cohort.%20We%20evaluated%20clinical%20and%20laboratory%20data%2C%20such%20as%20age%2C%20sex%2C%20race%2C%20smoking%20habits%2C%20drug%20use%2C%20alcohol%20use%2C%20chest%20radiograph%2C%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20results%20among%20pulmonary%20tuberculosis%20cases%2C%20and%20QuantiFERON%28QFT%29-Plus%20results%20at%20baseline%20and%20after%20six%20months%20for%20close%20contacts%20who%20had%20a%20negative%20result%20at%20baseline.%5CnRESULTS%3A%20A%20total%20of%201%2C055%20close%20contacts%20of%20382%20pulmonary%20tuberculosis%20cases%20were%20included%20in%20the%20study.%20The%20median%20Ct%20values%20from%20pulmonary%20tuberculosis%20cases%20of%20QFT-Plus%20positive%20%28at%20baseline%20or%20six%20months%29%20close%20contacts%20were%20lower%20compared%20with%20those%20who%20were%20QFT-Plus%20negative.%20An%20adjusted%20logistic%20regression%20demonstrated%20that%20reduced%20Ct%20values%20from%20the%20index%20cases%20were%20independently%20associated%20with%20QFT-Plus%20conversion%20from%20negative%20to%20positive%20%28OR%3A%201.61%2C%2095%25%20CI%3A%201.12-2.32%29%20after%20adjusting%20for%20clinical%20characteristics.%5CnCONCLUSION%3A%20Close%20contacts%20of%20pulmonary%20TB%20index%20cases%20exhibiting%20low%20Xpert%20MTB%5C%2FRIF%20Ct%20values%20displayed%20higher%20rates%20of%20TB%20infection%2C%20reflecting%20Mtb%20transmission.%22%2C%22date%22%3A%222024-01-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad794%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238170196%22%2C%22PMCID%22%3A%22PMC12609578%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22Y6F2LN8M%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ara%5Cu00fajo-Pereira%20et%20al.%22%2C%22parsedDate%22%3A%222024-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAra%26%23xFA%3Bjo-Pereira%20M%2C%20Arriaga%20MB%2C%20Carvalho%20ACC%2C%20Spener-Gomes%20R%2C%20Schmaltz%20CAS%2C%20Nogueira%20BMF%2C%20et%20al.%20Isoniazid%20Monoresistance%20and%20Antituberculosis%20Treatment%20Outcome%20in%20Persons%20With%20Pulmonary%20Tuberculosis%20in%20Brazil.%20Open%20Forum%20Infect%20Dis.%202024%20Jan%3B11%281%29%3Aofad691.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofad691%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofad691%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038221983%3B%20PubMed%20Central%20PMCID%3A%20PMC10785213.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Isoniazid%20Monoresistance%20and%20Antituberculosis%20Treatment%20Outcome%20in%20Persons%20With%20Pulmonary%20Tuberculosis%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Cristina%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%20A.%20S.%22%2C%22lastName%22%3A%22Schmaltz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20for%20Tuberculosis%20%28RePORT%29-Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20high%20burden%20of%20drug-resistant%20tuberculosis%20%28TB%29%20is%20a%20problem%20to%20achieve%20the%20goals%20of%20the%20End%20TB%20Strategy%20by%202035.%20Whether%20isoniazid%20monoresistance%20%28Hr%29%20affects%20anti-TB%20treatment%20%28ATT%29%20outcomes%20remains%20unknown%20in%20high-burden%20countries.%5CnMETHODS%3A%20We%20evaluated%20determinants%20of%20ATT%20outcome%20among%20pulmonary%20TB%20cases%20reported%20to%20the%20National%20Notifiable%20Disease%20Information%20System%20%28SINAN%29%20between%20June%202015%20and%20June%202019%2C%20according%20to%20drug%20sensitivity%20testing%20%28DST%29%20results.%20Binomial%20logistic%20regression%20models%20were%20employed%20to%20evaluate%20whether%20Hr%20was%20associated%20with%20an%20unfavorable%20ATT%20outcome%3A%20death%20or%20failure%2C%20compared%20to%20cure%20or%20treatment%20completion.%5CnRESULTS%3A%20Among%2060%20804%20TB%20cases%20reported%20in%20SINAN%2C%2021%20197%20%2834.9%25%29%20were%20included%20in%20the%20study.%20In%20this%20database%2C%20the%20frequency%20of%20unfavorable%20outcomes%20was%20significantly%20higher%20in%20those%20with%20Hr%20in%20contrast%20to%20isoniazid-sensitive%20persons%20with%20pulmonary%20TB%20%289.1%25%20vs%203.05%25%3B%20P%20%26lt%3B%20.001%29.%20Using%20a%20binomial%20logistic%20regression%20model%2C%20Hr%20was%20independently%20associated%20with%20unfavorable%20outcomes%20%28odds%20ratio%2C%203.34%20%5B95%25%20confidence%20interval%2C%202.06-5.40%5D%3B%20P%20%26lt%3B%20.001%29.%5CnCONCLUSIONS%3A%20Hr%20detected%20prior%20to%20ATT%20was%20predictive%20of%20unfavorable%20outcomes%20at%20the%20national%20level%20in%20Brazil.%20Our%20data%20reinforce%20the%20need%20for%20high-TB-burden%20countries%20to%20prioritize%20DST%20to%20detect%20Hr.%20Effective%20treatment%20regimens%20for%20Hr-TB%20are%20needed%20to%20improve%20outcomes.%22%2C%22date%22%3A%222024-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofad691%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238221983%22%2C%22PMCID%22%3A%22PMC10785213%22%2C%22ISSN%22%3A%222328-8957%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22FV5NWFPM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Cumming%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCumming%20BM%2C%20Addicott%20KW%2C%20Maruri%20F%2C%20Pillay%20V%2C%20Asmal%20R%2C%20Moodley%20S%2C%20et%20al.%20Longitudinal%20mitochondrial%20bioenergetic%20signatures%20of%20blood%20monocytes%20and%20lymphocytes%20improve%20during%20treatment%20of%20drug-susceptible%20pulmonary%20tuberculosis%20patients%20Monocyte%5C%2Flymphocyte%20bioenergetic%20signatures%20post-TB%20treatment.%20Front%20Immunol.%202024%3B15%3A1465448.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1465448%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1465448%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039606220%3B%20PubMed%20Central%20PMCID%3A%20PMC11599235.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Longitudinal%20mitochondrial%20bioenergetic%20signatures%20of%20blood%20monocytes%20and%20lymphocytes%20improve%20during%20treatment%20of%20drug-susceptible%20pulmonary%20tuberculosis%20patients%20Monocyte%5C%2Flymphocyte%20bioenergetic%20signatures%20post-TB%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bridgette%20M.%22%2C%22lastName%22%3A%22Cumming%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelvin%20W.%22%2C%22lastName%22%3A%22Addicott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Pillay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rukaya%22%2C%22lastName%22%3A%22Asmal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sashen%22%2C%22lastName%22%3A%22Moodley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Durate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matilda%22%2C%22lastName%22%3A%22Mazibuko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zoey%22%2C%22lastName%22%3A%22Mhlane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikiwe%22%2C%22lastName%22%3A%22Mbatha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khadija%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Senamile%22%2C%22lastName%22%3A%22Makhari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farina%22%2C%22lastName%22%3A%22Karim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20S.%22%2C%22lastName%22%3A%22Pym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahomed%20Yunus%20S.%22%2C%22lastName%22%3A%22Moosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuri%20F.%22%2C%22lastName%22%3A%22van%20der%20Heijden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20S.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alasdair%22%2C%22lastName%22%3A%22Leslie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrie%20J.%20C.%22%2C%22lastName%22%3A%22Steyn%22%7D%5D%2C%22abstractNote%22%3A%22The%20impact%20of%20human%20pulmonary%20tuberculosis%20%28TB%29%20on%20the%20bioenergetic%20metabolism%20of%20circulating%20immune%20cells%20remains%20elusive%2C%20as%20does%20the%20resolution%20of%20these%20effects%20with%20TB%20treatment.%20In%20this%20study%2C%20the%20rates%20of%20oxidative%20phosphorylation%20%28OXPHOS%29%20and%20glycolysis%20in%20circulating%20lymphocytes%20and%20monocytes%20of%20patients%20with%20drug-susceptible%20TB%20at%20diagnosis%2C%202%20months%2C%20and%206%20months%20during%20treatment%2C%20and%2012%20months%20after%20diagnosis%20were%20investigated%20using%20extracellular%20flux%20analysis.%20At%20diagnosis%2C%20the%20bioenergetic%20parameters%20of%20both%20blood%20lymphocytes%20and%20monocytes%20of%20TB%20patients%20were%20severely%20impaired%20in%20comparison%20to%20non-TB%20and%20non-HIV-infected%20controls.%20However%2C%20most%20bioenergetic%20parameters%20were%20not%20affected%20by%20HIV%20status%20or%20glycemic%20index.%20Treatment%20of%20TB%20patients%20restored%20the%20%25%20spare%20respiratory%20capacity%20%28%25SRC%29%20of%20the%20circulating%20lymphocytes%20to%20that%20observed%20in%20non-TB%20and%20non-HIV%20infected%20controls%20by%2012%20months.%20Treatment%20also%20improved%20the%20maximal%20respiration%20of%20circulating%20lymphocytes%20and%20the%20%25SRC%20of%20circulating%20monocytes%20of%20the%20TB%20patients.%20Notably%2C%20the%20differential%20correlation%20of%20the%20clinical%20and%20bioenergetic%20parameters%20of%20the%20monocytes%20and%20lymphocytes%20from%20the%20controls%20and%20TB%20patients%20at%20baseline%20and%20month%2012%20was%20consistent%20with%20improved%20metabolic%20health%20and%20resolution%20of%20inflammation%20following%20successful%20TB%20treatment.%20Network%20analysis%20of%20the%20bioenergetic%20parameters%20of%20circulating%20immune%20cells%20with%20serum%20cytokine%20levels%20indicated%20a%20highly%20coordinated%20immune%20response%20at%20month%206.%20These%20findings%20underscore%20the%20importance%20of%20metabolic%20health%20in%20combating%20TB%2C%20supporting%20the%20need%20for%20further%20investigation%20of%20the%20bioenergetic%20immunometabolism%20associated%20with%20TB%20infection%20for%20novel%20therapeutic%20approaches%20aimed%20at%20bolstering%20cellular%20energetics%20to%20enhance%20immune%20responses%20and%20expedite%20recovery%20in%20TB%20patients.%22%2C%22date%22%3A%222024%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2024.1465448%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239606220%22%2C%22PMCID%22%3A%22PMC11599235%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A35%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22QKIF9EQM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Tian%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTian%20Y%2C%20Li%20C%2C%20Tu%20S%2C%20James%20NT%2C%20Harrell%20FE%2C%20Shepherd%20BE.%20Addressing%20Multiple%20Detection%20Limits%20with%20Semiparametric%20Cumulative%20Probability%20Models.%20J%20Am%20Stat%20Assoc.%202024%3B119%28546%29%3A864%26%23×2013%3B74.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F01621459.2024.2315667%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F01621459.2024.2315667%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2039463921%3B%20PubMed%20Central%20PMCID%3A%20PMC11500994.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Addressing%20Multiple%20Detection%20Limits%20with%20Semiparametric%20Cumulative%20Probability%20Models%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuqi%22%2C%22lastName%22%3A%22Tian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shengxin%22%2C%22lastName%22%3A%22Tu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%20T.%22%2C%22lastName%22%3A%22James%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20E.%22%2C%22lastName%22%3A%22Harrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22Detection%20limits%20%28DLs%29%2C%20where%20a%20variable%20cannot%20be%20measured%20outside%20of%20a%20certain%20range%2C%20are%20common%20in%20research.%20DLs%20may%20vary%20across%20study%20sites%20or%20over%20time.%20Most%20approaches%20to%20handling%20DLs%20in%20response%20variables%20implicitly%20make%20strong%20parametric%20assumptions%20on%20the%20distribution%20of%20data%20outside%20DLs.%20We%20propose%20a%20new%20approach%20to%20deal%20with%20multiple%20DLs%20based%20on%20a%20widely%20used%20ordinal%20regression%20model%2C%20the%20cumulative%20probability%20model%20%28CPM%29.%20The%20CPM%20is%20a%20rank-based%2C%20semiparametric%20linear%20transformation%20model%20that%20can%20handle%20mixed%20distributions%20of%20continuous%20and%20discrete%20outcome%20variables.%20These%20features%20are%20key%20for%20analyzing%20data%20with%20DLs%20because%20while%20observations%20inside%20DLs%20are%20continuous%2C%20those%20outside%20DLs%20are%20censored%20and%20generally%20put%20into%20discrete%20categories.%20With%20a%20single%20lower%20DL%2C%20CPMs%20assign%20values%20below%20the%20DL%20as%20having%20the%20lowest%20rank.%20With%20multiple%20DLs%2C%20the%20CPM%20likelihood%20can%20be%20modified%20to%20appropriately%20distribute%20probability%20mass.%20We%20demonstrate%20the%20use%20of%20CPMs%20with%20DLs%20via%20simulations%20and%20a%20data%20example.%20This%20work%20is%20motivated%20by%20a%20study%20investigating%20factors%20associated%20with%20HIV%20viral%20load%206%20months%20after%20starting%20antiretroviral%20therapy%20in%20Latin%20America%3B%2056%25%20of%20observations%20are%20below%20lower%20DLs%20that%20vary%20across%20study%20sites%20and%20over%20time.%22%2C%22date%22%3A%222024%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F01621459.2024.2315667%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2239463921%22%2C%22PMCID%22%3A%22PMC11500994%22%2C%22ISSN%22%3A%220162-1459%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22NKRSICR9%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Passos%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPassos%20BBS%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Vinhaes%20CL%2C%20Amaral%20EP%2C%20Andrade%20BB.%20The%20role%20of%20ESAT-6%20in%20tuberculosis%20immunopathology.%20Front%20Immunol.%202024%3B15%3A1383098.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1383098%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1383098%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038633252%3B%20PubMed%20Central%20PMCID%3A%20PMC11021698.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20role%20of%20ESAT-6%20in%20tuberculosis%20immunopathology%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%20B.%20S.%22%2C%22lastName%22%3A%22Passos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20P.%22%2C%22lastName%22%3A%22Amaral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20major%20global%20efforts%20to%20eliminate%20tuberculosis%2C%20which%20is%20caused%20by%20Mycobacterium%20tuberculosis%20%28Mtb%29%2C%20this%20disease%20remains%20as%20a%20major%20plague%20of%20humanity.%20Several%20factors%20associated%20with%20the%20host%20and%20Mtb%20interaction%20favor%20the%20infection%20establishment%20and%5C%2For%20determine%20disease%20progression.%20The%20Early%20Secreted%20Antigenic%20Target%206%20kDa%20%28ESAT-6%29%20is%20one%20of%20the%20most%20important%20and%20well-studied%20mycobacterial%20virulence%20factors.%20This%20molecule%20has%20been%20described%20to%20play%20an%20important%20role%20in%20the%20development%20of%20tuberculosis-associated%20pathology%20by%20subverting%20crucial%20components%20of%20the%20host%20immune%20responses.%20This%20review%20highlights%20the%20main%20effector%20mechanisms%20by%20which%20ESAT-6%20modulates%20the%20immune%20system%2C%20directly%20impacting%20cell%20fate%20and%20disease%20progression.%22%2C%22date%22%3A%222024%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2024.1383098%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238633252%22%2C%22PMCID%22%3A%22PMC11021698%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A34%3A39Z%22%7D%7D%5D%7D
1.
Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, et al. Pharmacogenomic associations with HIV-1 virologic suppression in TB/HIV patients. Res Sq. 2024 Dec 16;rs.3.rs-5418156. http://doi.org/10.21203/rs.3.rs-5418156/v1 PubMed PMID: 39764089; PubMed Central PMCID: PMC11702782.
1.
Zaniewski E, Skrivankova VW, Brazier E, Avihingsanon A, Wagner Cardoso S, Cesar C, et al. Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS. 2024 Dec 1;38(15):2073–85. http://doi.org/10.1097/QAD.0000000000004007 PubMed PMID: 39236112; PubMed Central PMCID: PMC11562491.
1.
Espejo-Ortiz CE, Sierra-Barajas N, Silva-Casarrubias A, Guerrero-Torres L, Caro-Vega Y, Serrano-Pinto YG, et al. A cascade of care for diabetes in people living with HIV in a tertiary care center in Mexico City. HIV Res Clin Pract. 2024 Dec;25(1):2411481. http://doi.org/10.1080/25787489.2024.2411481 PubMed PMID: 39377112; PubMed Central PMCID: PMC11805464.
1.
Castilho JL, Fonseca FF, Kim A, Jalil E, Tu S, Beber AMB, et al. Prenatal syphilis and adverse pregnancy outcomes in women with HIV receiving ART in Brazil: a population-based study. Lancet Reg Health Am. 2024 Nov;39:100894. http://doi.org/10.1016/j.lana.2024.100894 PubMed PMID: 39839683; PubMed Central PMCID: PMC11747186.
1.
Barreto-Duarte B, Villalva-Serra K, Campos VMS, Cordeiro-Santos M, Kritski AL, Araújo-Pereira M, et al. Nationwide economic analysis of pulmonary tuberculosis in the Brazilian healthcare system over seven years (2015-2022): a population-based study. Lancet Reg Health Am. 2024 Nov;39:100905. http://doi.org/10.1016/j.lana.2024.100905 PubMed PMID: 39839682; PubMed Central PMCID: PMC11747192.
1.
Parcesepe AM, Stockton M, Bernard C, Kanguya T, Kwobah EK, Lopez A, et al. Prevalence and co-occurrence of symptoms of mental and substance use disorders among people with HIV age 40 and older in low- and middle-income countries: a cross-sectional study. J Int AIDS Soc. 2024 Oct;27(10):e26359. http://doi.org/10.1002/jia2.26359 PubMed PMID: 39375051; PubMed Central PMCID: PMC11458263.
1.
Egger M, Sauermann M, Loosli T, Hossmann S, Riedo S, Beerenwinkel N, et al. HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST). BMJ Open. 2024 Aug 21;14(8):e085819. http://doi.org/10.1136/bmjopen-2024-085819 PubMed PMID: 39174068; PubMed Central PMCID: PMC11340720.
1.
Barreto-Duarte B, Villalva-Serra K, Miguez-Pinto JP, Araújo-Pereira M, Campos VMS, Rosier G, et al. Retreatment and Anti-tuberculosis Therapy Outcomes in Brazil Between 2015 and 2022: A Nationwide Study. Open Forum Infect Dis. 2024 Aug;11(8):ofae416. http://doi.org/10.1093/ofid/ofae416 PubMed PMID: 39100532; PubMed Central PMCID: PMC11297487.
1.
Gorsline CA, Lotspeich SC, Belaunzarán-Zamudio PF, Mejia F, Cortes CP, Crabtree-Ramírez B, et al. The impact of earthquakes in Latin America on the continuity of HIV care: A retrospective observational cohort study. Public Health Pract (Oxf). 2024 Jun;7:100479. http://doi.org/10.1016/j.puhip.2024.100479 PubMed PMID: 38405231; PubMed Central PMCID: PMC10883833.
1.
Lotspeich SC, Amorim GGC, Shaw PA, Tao R, Shepherd BE. Optimal multiwave validation of secondary use data with outcome and exposure misclassification. Can J Stat. 2024 Jun;52(2):532–54. http://doi.org/10.1002/cjs.11772 PubMed PMID: 39629097; PubMed Central PMCID: PMC11610482.
1.
Rodrigues MMS, Barreto-Duarte B, Vinhaes CL, Araújo-Pereira M, Fukutani ER, Bergamaschi KB, et al. Machine learning algorithms using national registry data to predict loss to follow-up during tuberculosis treatment. BMC Public Health. 2024 May 23;24(1):1385. http://doi.org/10.1186/s12889-024-18815-0 PubMed PMID: 38783264; PubMed Central PMCID: PMC11112756.
1.
Kebede S, Brazier E, Freeman AM, Muwonge TR, Choi JY, de Waal R, et al. Preexposure prophylaxis availability among health facilities participating in the global International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. AIDS. 2024 Apr 1;38(5):751–6. http://doi.org/10.1097/QAD.0000000000003824 PubMed PMID: 38133656; PubMed Central PMCID: PMC10939841.
1.
Plaisy MK, Minga AK, Wandeler G, Murenzi G, Samala N, Ross J, et al. Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study. J Int AIDS Soc. 2024 Apr;27(4):e26238. http://doi.org/10.1002/jia2.26238 PubMed PMID: 38566493; PubMed Central PMCID: PMC10988113.
1.
Baker PJ, Bohrer AC, Castro E, Amaral EP, Snow-Smith M, Torres-Juárez F, et al. The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication. bioRxiv. 2024 Mar 27;2024.03.27.586885. http://doi.org/10.1101/2024.03.27.586885 PubMed PMID: 38585846; PubMed Central PMCID: PMC10996686.
1.
Vinhaes CL, Fukutani ER, Santana GC, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, et al. An integrative multi-omics approach to characterize interactions between tuberculosis and diabetes mellitus. iScience. 2024 Mar 15;27(3):109135. http://doi.org/10.1016/j.isci.2024.109135 PubMed PMID: 38380250; PubMed Central PMCID: PMC10877940.
1.
Ridolfi F, Amorim G, Peetluk LS, Haas DW, Staats C, Araújo-Pereira M, et al. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil. J Infect Dis. 2024 Mar 14;229(3):813–23. http://doi.org/10.1093/infdis/jiae025 PubMed PMID: 38262629; PubMed Central PMCID: PMC10938211.
1.
Brazier E, Tymejczyk O, Wools-Kaloustian K, Jiamsakul A, Torres MTL, Lee JS, et al. Long-term HIV care outcomes under universal HIV treatment guidelines: A retrospective cohort study in 25 countries. PLoS Med. 2024 Mar;21(3):e1004367. http://doi.org/10.1371/journal.pmed.1004367 PubMed PMID: 38498589; PubMed Central PMCID: PMC10962811.
1.
Castillo-Rozas G, Tu S, Luz PM, Mejia F, Sierra-Madero J, Rouzier V, et al. Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study. J Int AIDS Soc. 2024 Mar;27(3):e26214. http://doi.org/10.1002/jia2.26214 PubMed PMID: 38494667; PubMed Central PMCID: PMC10945036.
1.
Davidović M, Asangbeh SL, Taghavi K, Dhokotera T, Jaquet A, Musick B, et al. Facility-Based Indicators to Manage and Scale Up Cervical Cancer Prevention and Care Services for Women Living With HIV in Sub-Saharan Africa: a Three-Round Online Delphi Consensus Method. J Acquir Immune Defic Syndr. 2024 Feb 1;95(2):170–8. http://doi.org/10.1097/QAI.0000000000003343 PubMed PMID: 38211958; PubMed Central PMCID: PMC10794028.
1.
Lancaster KE, Stockton M, Remch M, Wester CW, Nash D, Brazier E, et al. Availability of substance use screening and treatment within HIV clinical sites across seven geographic regions within the IeDEA consortium. Int J Drug Policy. 2024 Feb;124:104309. http://doi.org/10.1016/j.drugpo.2023.104309 PubMed PMID: 38228025; PubMed Central PMCID: PMC10939808.
1.
Rocha EF, Vinhaes CL, Araújo-Pereira M, Mota TF, Gupte AN, Kumar NP, et al. The sound of silent RNA in tuberculosis and the lncRNA role on infection. iScience. 2024 Jan 19;27(1):108662. http://doi.org/10.1016/j.isci.2023.108662 PubMed PMID: 38205253; PubMed Central PMCID: PMC10777062.
1.
Enane LA, Duda SN, Chanyachukul T, Bolton-Moore C, Navuluri N, Messou E, et al. The Tuberculosis Sentinel Research Network (TB-SRN) of the International epidemiology Databases to Evaluate AIDS (IeDEA): protocol for a prospective cohort study in Africa, Southeast Asia and Latin America. BMJ Open. 2024 Jan 9;14(1):e079138. http://doi.org/10.1136/bmjopen-2023-079138 PubMed PMID: 38195167; PubMed Central PMCID: PMC10806577.
1.
Garcia LS, Costa AG, Araújo-Pereira M, Spener-Gomes R, Aguiar AF, Souza AB, et al. The Xpert® MTB/RIF cycle threshold value predicts M. tuberculosis transmission to close contacts in a Brazilian prospective multicenter cohort. Clin Infect Dis. 2024 Jan 3;ciad794. http://doi.org/10.1093/cid/ciad794 PubMed PMID: 38170196; PubMed Central PMCID: PMC12609578.
1.
Araújo-Pereira M, Arriaga MB, Carvalho ACC, Spener-Gomes R, Schmaltz CAS, Nogueira BMF, et al. Isoniazid Monoresistance and Antituberculosis Treatment Outcome in Persons With Pulmonary Tuberculosis in Brazil. Open Forum Infect Dis. 2024 Jan;11(1):ofad691. http://doi.org/10.1093/ofid/ofad691 PubMed PMID: 38221983; PubMed Central PMCID: PMC10785213.
1.
Cumming BM, Addicott KW, Maruri F, Pillay V, Asmal R, Moodley S, et al. Longitudinal mitochondrial bioenergetic signatures of blood monocytes and lymphocytes improve during treatment of drug-susceptible pulmonary tuberculosis patients Monocyte/lymphocyte bioenergetic signatures post-TB treatment. Front Immunol. 2024;15:1465448. http://doi.org/10.3389/fimmu.2024.1465448 PubMed PMID: 39606220; PubMed Central PMCID: PMC11599235.
1.
Tian Y, Li C, Tu S, James NT, Harrell FE, Shepherd BE. Addressing Multiple Detection Limits with Semiparametric Cumulative Probability Models. J Am Stat Assoc. 2024;119(546):864–74. http://doi.org/10.1080/01621459.2024.2315667 PubMed PMID: 39463921; PubMed Central PMCID: PMC11500994.
1.
Passos BBS, Araújo-Pereira M, Vinhaes CL, Amaral EP, Andrade BB. The role of ESAT-6 in tuberculosis immunopathology. Front Immunol. 2024;15:1383098. http://doi.org/10.3389/fimmu.2024.1383098 PubMed PMID: 38633252; PubMed Central PMCID: PMC11021698.
2023
76770
IP6F4TRX
2023
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%222XA9XSDG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRodrigues%20MMS%2C%20Barreto-Duarte%20B%2C%20Vinhaes%20CL%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Fukutani%20ER%2C%20Bergamaschi%20KB%2C%20et%20al.%20Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-%20up%20during%20tuberculosis%20treatment.%20Res%20Sq.%202023%20Dec%2011%3Brs.3.rs-3706875.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038168296%3B%20PubMed%20Central%20PMCID%3A%20PMC10760311.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Machine%20learning%20algorithms%20using%20national%20registry%20data%20to%20predict%20loss%20to%20follow-%20up%20during%20tuberculosis%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keityane%20Bone%22%2C%22lastName%22%3A%22Bergamaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Identifying%20patients%20at%20increased%20risk%20of%20loss%20to%20follow-up%20%28LTFU%29%20is%20key%20to%20developing%20strategies%20to%20optimize%20the%20clinical%20management%20of%20tuberculosis%20%28TB%29.%20The%20use%20of%20national%20registry%20data%20in%20prediction%20models%20may%20be%20a%20useful%20tool%20to%20inform%20healthcare%20workers%20about%20risk%20of%20LTFU.%20Here%20we%20developed%20a%20score%20to%20predict%20the%20risk%20of%20LTFU%20during%20anti-TB%20treatment%20%28ATT%29%20in%20a%20nationwide%20cohort%20of%20cases%20using%20clinical%20data%20reported%20to%20the%20Brazilian%20Notifiable%20Disease%20Information%20System%20%28SINAN%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20study%20of%20all%20TB%20cases%20reported%20to%20SINAN%20between%202015-2022%3B%20excluding%20children%20%28%26lt%3B18%20years-old%29%2C%20vulnerable%20groups%20or%20drug-resistant%20TB.%20For%20the%20score%2C%20data%20before%20treatment%20initiation%20were%20used.%20We%20trained%20and%20internally%20validated%20three%20different%20prediction%20scoring%20systems%2C%20based%20on%20Logistic%20Regression%2C%20Random%20Forest%2C%20and%20Light%20Gradient%20Boosting.%20Before%20applying%20our%20models%20we%20split%20our%20data%20into%20train%20%28~80%25%20data%29%20and%20test%20%28~20%25%29%2C%20and%20then%20we%20compare%20model%20metrics%20using%20a%20test%20data%20set.%5CnRESULTS%3A%20Of%20the%20243%2C726%20cases%20included%2C%2041%2C373%20experienced%20LTFU%20whereas%20202%2C353%20were%20successfully%20treated%20and%20cured.%20The%20groups%20were%20different%20with%20regards%20to%20several%20clinical%20and%20sociodemographic%20characteristics.%20The%20directly%20observed%20treatment%20%28DOT%29%20was%20unbalanced%20between%20the%20groups%20with%20lower%20prevalence%20in%20those%20who%20were%20LTFU.%20Three%20models%20were%20developed%20to%20predict%20LTFU%20using%208%20features%20%28prior%20TB%2C%20drug%20use%2C%20age%2C%20sex%2C%20HIV%20infection%20and%20schooling%20level%29%20with%20different%20score%20composition%20approaches.%20Those%20prediction%20scoring%20system%20exhibited%20an%20area%20under%20the%20curve%20%28AUC%29%20ranging%20between%200.71%20and%200.72.%20The%20Light%20Gradient%20Boosting%20technique%20resulted%20in%20the%20best%20prediction%20performance%2C%20weighting%20specificity%2C%20and%20sensibility.%20A%20user-friendly%20web%20calculator%20app%20was%20created%20%28https%3A%5C%2F%5C%2Ftbprediction.herokuapp.com%5C%2F%29%20to%20facilitate%20implementation.%5CnCONCLUSIONS%3A%20Our%20nationwide%20risk%20score%20predicts%20the%20risk%20of%20LTFU%20during%20ATT%20in%20Brazilian%20adults%20prior%20to%20treatment%20commencement.%20This%20is%20a%20potential%20tool%20to%20assist%20in%20decision-making%20strategies%20to%20guide%20resource%20allocation%2C%20DOT%20indications%2C%20and%20improve%20TB%20treatment%20adherence.%22%2C%22date%22%3A%222023-12-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.21203%5C%2Frs.3.rs-3706875%5C%2Fv1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238168296%22%2C%22PMCID%22%3A%22PMC10760311%22%2C%22ISSN%22%3A%222693-5015%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22UTETTLAX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Grinsztejn%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGrinsztejn%20E%2C%20Cardoso%20SW%2C%20Velasque%20L%2C%20Hoagland%20B%2C%20Dos%20Santos%20DG%2C%20Coutinho%20C%2C%20et%20al.%20Impact%20of%20Latent%20M.%20tuberculosis%20Infection%20Treatment%20on%20Time%20to%20CD4%5C%2FCD8%20Recovery%20in%20Acute%2C%20Recent%2C%20and%20Chronic%20HIV%20Infection.%20J%20Acquir%20Immune%20Defic%20Syndr.%202023%20Dec%201%3B94%284%29%3A355%26%23×2013%3B63.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003284%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000003284%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037595204%3B%20PubMed%20Central%20PMCID%3A%20PMC10609716.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Latent%20M.%20tuberculosis%20Infection%20Treatment%20on%20Time%20to%20CD4%5C%2FCD8%20Recovery%20in%20Acute%2C%20Recent%2C%20and%20Chronic%20HIV%20Infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduarda%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciane%22%2C%22lastName%22%3A%22Velasque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Hoagland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desiree%20Gomes%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%22%2C%22lastName%22%3A%22Coutinho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%20da%20Costa%22%2C%22lastName%22%3A%22Cruz%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandro%20Coutinho%22%2C%22lastName%22%3A%22Nazer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Cristina%20Garcia%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%20people%20living%20with%20HIV%2C%20active%20and%20latent%20tuberculosis%20%28TB%29%20coinfections%20are%20associated%20with%20immune%20activation%20that%20correlate%20with%20HIV%20progression%20and%20mortality.%20We%20investigated%20the%20effect%20of%20initiating%20antiretroviral%20therapy%20%28ART%29%20during%20acute%20%28AHI%29%2C%20recent%20%28RHI%29%2C%20or%20chronic%20HIV%20infection%20%28CHI%29%20on%20CD4%5C%2FCD8%20ratio%20normalization%20and%20associated%20factors%2C%20the%20impact%20of%20latent%20TB%20infection%20treatment%2C%20and%20prior%5C%2Fconcomitant%20TB%20diagnosis%20at%20the%20time%20of%20ART%20initiation.%5CnMETHODS%3A%20We%20included%20sex%20with%20men%20and%20transgender%20women%20individuals%20initiating%20ART%20with%20AHI%2C%20RHI%20and%20CHI%20between%202013%20and%202019%2C%20from%20a%20prospective%20cohort%20in%20Brazil.%20We%20compared%20time%20from%20ART%20initiation%20to%20the%20first%20normal%20CD4%5C%2FCD8%20ratio%20%28CD4%5C%2FCD8%20%5Cu22651%29%20using%20Kaplan-Meier%20curves%20and%20multivariable%20Cox%20proportional%20hazards%20models.%20Sociodemographic%20and%20clinical%20variables%20were%20explored.%20Variables%20with%20P%20-values%20%26lt%3B0.20%20in%20univariable%20analyses%20were%20included%20in%20multivariable%20analyses.%5CnRESULTS%3A%20Five%20hundred%20fifty%20participants%20were%20included%2C%2011.8%25%20classified%20as%20AHI%20and%206.4%25%20as%20RHI%2C%2046.7%25%20with%20CHI-CD4%20cell%20counts%20%5Cu2265350%20cells%5C%2Fmm%203%20and%2035.1%25%20with%20CHI-CD4%20cell%20counts%20%26lt%3B350%20cells%5C%2Fmm%203%20.%20Time%20to%20normalization%20was%20shortest%20among%20AHI%20patients%2C%20followed%20by%20RHI%20and%20CHI%20individuals%20with%20higher%20baseline%20CD4.%20In%20the%20multivariable%20model%2C%20AHI%20was%20associated%20with%20a%20six-fold%20increased%20likelihood%20of%20achieving%20a%20CD4%5C%2FCD8%20ratio%20%5Cu22651%20%28hazard%20ratio%20%5BHR%5D%3A%206.03%3B%2095%25%20confidence%20interval%20%5BCI%5D%3A%203.70%20to%209.82%3B%20P%20%26lt%3B%200.001%29%2C%20RHI%20with%20HR%3A%204.47%20%2895%25%20CI%3A%202.57%20to%207.76%3B%20P%20%26lt%3B%200.001%29%2C%20and%20CHI%20CD4%20%5Cu2265350%20cells%5C%2Fmm%203%20with%20HR%3A%201.87%20%2895%25%20CI%3A%201.24%20to%202.84%3B%20P%20%3D%200.003%29.%20Latent%20TB%20infection%20treatment%20was%20significantly%20associated%20with%20a%20higher%20likelihood%20of%20the%20outcome%20%28HR%3A%201.79%3B%2095%25%20CI%3A%201.22%20to%202.62%3B%20P%20%3D%200.003%29.%20Previous%20history%20or%20concomitant%20active%20TB%20at%20ART%20initiation%20was%20associated%20with%20a%20lower%20likelihood%20of%20the%20outcome%20%28HR%3A%200.41%3B%2095%25%20CI%3A%200.16%20to%201.02%3B%20P%20%3D%200.054%29.%5CnCONCLUSIONS%3A%20Initiating%20ART%20early%20during%20AHI%20may%20offer%20an%20opportunity%20to%20mitigate%20immune%20damage.%20Efforts%20to%20implement%20HIV%20diagnosis%20and%20ART%20initiation%20during%20AHI%20are%20critical%20to%20amplify%20ART%20benefits.%22%2C%22date%22%3A%222023-12-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000003284%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237595204%22%2C%22PMCID%22%3A%22PMC10609716%22%2C%22ISSN%22%3A%221944-7884%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A30%3A51Z%22%7D%7D%2C%7B%22key%22%3A%228QH62IHY%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Eden%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEden%20SK%2C%20Li%20C%2C%20Shepherd%20BE.%20Spearman-like%20correlation%20measure%20adjusting%20for%20covariates%20in%20bivariate%20survival%20data.%20Biom%20J.%202023%20Dec%3B65%288%29%3Ae2200137.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202200137%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202200137%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037753794%3B%20PubMed%20Central%20PMCID%3A%20PMC10897866.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Spearman-like%20correlation%20measure%20adjusting%20for%20covariates%20in%20bivariate%20survival%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svetlana%20K.%22%2C%22lastName%22%3A%22Eden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22We%20propose%20an%20extension%20of%20Spearman%26%23039%3Bs%20correlation%20for%20censored%20continuous%20and%20discrete%20data%20that%20permits%20covariate%20adjustment.%20Previously%20proposed%20nonparametric%20and%20semiparametric%20Spearman%26%23039%3Bs%20correlation%20estimators%20require%20either%20nonparametric%20estimation%20of%20the%20bivariate%20survival%20surface%20or%20parametric%20assumptions%20about%20the%20dependence%20structure.%20In%20practice%2C%20nonparametric%20estimation%20of%20the%20bivariate%20survival%20surface%20is%20difficult%2C%20and%20parametric%20assumptions%20about%20the%20correlation%20structure%20may%20not%20be%20satisfied.%20Therefore%2C%20we%20propose%20a%20method%20that%20requires%20neither%20and%20uses%20only%20the%20marginal%20survival%20distributions.%20Our%20method%20estimates%20the%20correlation%20of%20probability-scale%20residuals%2C%20which%20has%20been%20shown%20to%20equal%20Spearman%26%23039%3Bs%20correlation%20when%20there%20is%20no%20censoring.%20Because%20this%20method%20relies%20only%20on%20marginal%20distributions%2C%20it%20tends%20to%20be%20less%20variable%20than%20the%20previously%20suggested%20nonparametric%20estimators%2C%20and%20the%20confidence%20intervals%20are%20easily%20constructed.%20Although%20under%20censoring%2C%20it%20is%20biased%20for%20Spearman%26%23039%3Bs%20correlation%20as%20our%20simulations%20show%2C%20it%20performs%20well%20under%20moderate%20censoring%2C%20with%20a%20smaller%20mean%20squared%20error%20than%20nonparametric%20approaches.%20We%20also%20extend%20it%20to%20partial%20%28adjusted%29%2C%20conditional%2C%20and%20partial-conditional%20correlation%2C%20which%20makes%20it%20particularly%20relevant%20for%20practical%20applications.%20We%20apply%20our%20method%20to%20estimate%20the%20correlation%20between%20time%20to%20viral%20failure%20and%20time%20to%20regimen%20change%20in%20a%20multisite%20cohort%20of%20persons%20living%20with%20HIV%20in%20Latin%5Cu00a0America.%22%2C%22date%22%3A%222023-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fbimj.202200137%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237753794%22%2C%22PMCID%22%3A%22PMC10897866%22%2C%22ISSN%22%3A%221521-4036%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22DFJYAPTI%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Meireles%20et%20al.%22%2C%22parsedDate%22%3A%222023-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMeireles%20G%2C%20Nobre%20AA%2C%20Cardoso%20SW%2C%20Velasque%20L%2C%20Veloso%20VG%2C%20Grinsztejn%20B%2C%20et%20al.%20Real-world%20effectiveness%20of%20WHO%20recommended%20first-line%20antiretroviral%20therapies%3A%20a%20cohort%20study%20from%20a%20middle-income%20country.%20AIDS%20Care.%202023%20Dec%3B35%2812%29%3A1891%26%23×2013%3B903.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2190954%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F09540121.2023.2190954%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037001113%3B%20PubMed%20Central%20PMCID%3A%20PMC10935654.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-world%20effectiveness%20of%20WHO%20recommended%20first-line%20antiretroviral%20therapies%3A%20a%20cohort%20study%20from%20a%20middle-income%20country%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glaucia%22%2C%22lastName%22%3A%22Meireles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%20A.%22%2C%22lastName%22%3A%22Nobre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciane%22%2C%22lastName%22%3A%22Velasque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22We%20estimate%20the%20effectiveness%20of%20antiretroviral%20therapy%20%28ART%29%20among%20individuals%20receiving%20HIV%20care%20in%20Rio%20de%20Janeiro%2C%20Brazil.%20Adults%20%2818y%2B%29%20initiating%20ART%20between%20Jan%5C%2F2008%20and%20Dec%5C%2F2018%20%28follow-up%20through%20Dec%5C%2F2020%29%20were%20included.%20First-line%20ART%20%28two%20nucleoside%20reverse%20transcriptase%20inhibitors%20plus%20one%20antiretroviral%20from%20another%20class%29%20was%20categorized%20into%20four%20categories%3A%20non-nucleoside%20reverse%20transcriptase%20inhibitor%5C%2FNNRTI-based%2C%20protease%20inhibitor%5C%2FPI-based%2C%20integrase%20strand%20transfer%20inhibitor%5C%2FINSTI-based%2C%20and%20single-tablet%20regimen%20%28STR%2C%20Tenofovir%20300mg%5Cu2009%2B%5Cu2009Lamivudine%20300mg%5Cu2009%2B%5Cu2009Efavirenz%20600mg%29.%20Effectiveness%20%28viral%20load%20%5Cu226450%20copies%5C%2F%5Cu00b5L%29%20was%20evaluated%20at%206%283-9%29%20and%2012%289-15%29%20months%20from%20ART%20initiation.%20Bayesian%20logistic%20regression%20models%20were%20used%20to%20quantify%20the%20association%20between%20exposure%20and%20outcomes%20while%20accounting%20for%20missing%20data.%20Overall%2C%201863%2857%25%29%2C%20652%2819.9%25%29%2C%20412%2812.6%25%29%2C%20and%20342%2810.5%25%29%20individuals%20used%2C%20respectively%2C%20NNRTI-based%2C%20PI-based%2C%20INSTI-based%20regimens%2C%20and%20STR.%20Compared%20to%20NNRTIs%2C%20the%20odds%20of%20viral%20suppression%20with%20INSTI-based%20regimens%20was%2076%25%20higher%20%28adjusted%20OR%3A1.76%2C%2095%25CI%3A1.23-2.51%29%20at%20six%20months%20but%20no%20higher%20at%2012%20months.%20Older%20age%2C%20higher%20education%2C%20CD4%20count%20%5Cu2265500%20cells%5C%2Fmm3%20and%20viral%20load%20%26lt%3B100%2C000%20copies%5C%2F%5Cu00b5L%20at%20ART%20initiation%20increased%20the%20odds%20of%20viral%20suppression.%20Viral%20suppression%20at%20six%20months%20was%20the%20strongest%20predictor%20of%20viral%20suppression%20at%2012%20months.%20These%20results%20highlight%20population%20groups%20that%20could%20benefit%20from%20close%20monitoring%20during%20the%20first%20year%20of%20ART.%22%2C%22date%22%3A%222023-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F09540121.2023.2190954%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237001113%22%2C%22PMCID%22%3A%22PMC10935654%22%2C%22ISSN%22%3A%221360-0451%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A29Z%22%7D%7D%2C%7B%22key%22%3A%2269BDRMP6%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGlobal%20variations%20in%20pubertal%20growth%20spurts%20in%20adolescents%20living%20with%20perinatal%20HIV.%20AIDS.%202023%20Aug%201%3B37%2810%29%3A1603%26%23×2013%3B15.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003602%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003602%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037204259%3B%20PubMed%20Central%20PMCID%3A%20PMC10355801.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20variations%20in%20pubertal%20growth%20spurts%20in%20adolescents%20living%20with%20perinatal%20HIV%22%2C%22creators%22%3A%5B%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20describe%20pubertal%20growth%20spurts%20among%20adolescents%20living%20with%20perinatally%20acquired%20HIV%20%28ALWPHIV%29%20on%20antiretroviral%20therapy%20%28ART%29.%5CnDESIGN%3A%20Observational%20data%20collected%20from%201994%20to%202015%20in%20the%20CIPHER%20global%20cohort%20collaboration.%5CnMETHODS%3A%20ALWPHIV%20who%20initiated%20ART%20age%20less%20than%2010%5Cu200ayears%20with%20at%20least%20four%20height%20measurements%20age%20at%20least%208%20years%20were%20included.%20Super%20Imposition%20by%20Translation%20And%20Rotation%20%28SITAR%29%20models%2C%20with%20parameters%20representing%20timing%20and%20intensity%20of%20the%20growth%20spurt%2C%20were%20used%20to%20describe%20growth%2C%20separately%20by%20sex.%20Associations%20between%20region%2C%20ART%20regimen%2C%20age%2C%20height-for-age%20%28HAZ%29%2C%20and%20BMI-for-age%20z%20-scores%20%28BMIz%29%20at%20ART%20initiation%20%28baseline%29%20and%20age%2010%5Cu200ayears%2C%20and%20SITAR%20parameters%20were%20explored.%5CnRESULTS%3A%20Four%20thousand%20seven%20hundred%20and%20twenty-three%20ALWPHIV%20were%20included%3A%2051%25%20from%20East%20and%20Southern%20Africa%20%28excluding%20Botswana%20and%20South%20Africa%29%2C%2017%25%20Botswana%20and%20South%20Africa%2C%206%25%20West%20and%20Central%20Africa%2C%2011%25%20Europe%20and%20North%20America%2C%2011%25%20Asia-Pacific%2C%20and%204%25%20Central%2C%20South%20America%2C%20and%20Caribbean.%20Growth%20spurts%20were%20later%20and%20least%20intense%20in%20sub-Saharan%20regions.%20In%20females%2C%20older%20baseline%20age%20and%20lower%20BMIz%20at%20baseline%20were%20associated%20with%20later%20and%20more%20intense%20growth%20spurts%3B%20lower%20HAZ%20was%20associated%20with%20later%20growth%20spurts.%20In%20males%2C%20older%20baseline%20age%20and%20lower%20HAZ%20were%20associated%20with%20later%20and%20less%20intense%20growth%20spurts%3B%20however%2C%20associations%20between%20baseline%20HAZ%20and%20timing%20varied%20by%20age.%20Lower%20HAZ%20and%20BMIz%20at%2010%5Cu200ayears%20were%20associated%20with%20later%20and%20less%20intense%20growth%20spurts%20in%20both%20sexes.%5CnCONCLUSION%3A%20ALWPHIV%20who%20started%20ART%20at%20older%20ages%20or%20already%20stunted%20were%20more%20likely%20to%20have%20delayed%20pubertal%20growth%20spurts.%20Longer-term%20follow-up%20is%20important%20to%20understand%20the%20impact%20of%20delayed%20growth.%22%2C%22date%22%3A%222023-08-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003602%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237204259%22%2C%22PMCID%22%3A%22PMC10355801%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22D74JE486%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BParcesepe%20AM%2C%20Stockton%20M%2C%20Remch%20M%2C%20Wester%20CW%2C%20Bernard%20C%2C%20Ross%20J%2C%20et%20al.%20Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020.%20J%20Int%20AIDS%20Soc.%202023%20Aug%3B26%288%29%3Ae26147.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26147%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037535703%3B%20PubMed%20Central%20PMCID%3A%20PMC10399924.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Availability%20of%20screening%20and%20treatment%20for%20common%20mental%20disorders%20in%20HIV%20clinic%20settings%3A%20data%20from%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%2C%202016-2017%20and%202020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Stockton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Molly%22%2C%22lastName%22%3A%22Remch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Kwobah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junko%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Nsonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Common%20mental%20disorders%20%28CMDs%29%20are%20highly%20prevalent%20among%20people%20with%20HIV.%20Integrating%20mental%20healthcare%20into%20HIV%20care%20may%20improve%20mental%20health%20and%20HIV%20treatment%20outcomes.%20We%20describe%20the%20reported%20availability%20of%20screening%20and%20treatment%20for%20depression%2C%20anxiety%20and%20post-traumatic%20stress%20disorder%20%28PTSD%29%20at%20global%20HIV%20treatment%20centres%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%20in%202020%20and%20changes%20in%20availability%20at%20sites%20in%20low-%20or%20middle-income%20countries%20%28LMICs%29%20between%202016%5C%2F2017%20and%202020.%5CnMETHODS%3A%20In%202020%2C%20238%20sites%20contributing%20individual-level%20data%20to%20the%20IeDEA%20Consortium%20and%20in%202016%5C%2F2017%20a%20stratified%20random%20sample%20of%20IeDEA%20sites%20in%20LMICs%20were%20eligible%20to%20participate%20in%20site%20surveys%20on%20the%20availability%20of%20screening%20and%20treatment%20for%20CMDs.%20We%20assessed%20trends%20over%20time%20for%2068%20sites%20across%2027%20LMICs%20that%20participated%20in%20both%20surveys.%5CnRESULTS%3A%20Among%20the%20238%20sites%20eligible%20to%20participate%20in%20the%202020%20site%20survey%2C%20227%20%2895%25%29%20participated%2C%20and%20mental%20health%20screening%20and%20treatment%20data%20were%20available%20for%20223%20%2898%25%29%20sites%20across%2041%20countries.%20A%20total%20of%2095%20sites%20across%2029%20LMICs%20completed%20the%202016%5C%2F2017%20survey.%20In%202020%2C%2068%25%20of%20sites%20were%20in%20urban%20settings%2C%20and%2077%25%20were%20in%20LMICs.%20Overall%2C%2050%25%2C%2014%25%20and%2012%25%20of%20sites%20reported%20screening%20with%20a%20validated%20instrument%20for%20depression%2C%20anxiety%20and%20PTSD%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20counselling%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2046%25%2C%2013%25%20and%2011%25%20of%20sites%2C%20respectively.%20Screening%20plus%20treatment%20in%20the%20form%20of%20medication%20was%20available%20for%20depression%2C%20anxiety%20and%20PTSD%20at%2036%25%2C%2011%25%20and%208%25%20of%20sites%2C%20respectively.%20Among%20sites%20that%20participated%20in%20both%20surveys%2C%20screening%20for%20depression%20was%20more%20commonly%20available%20in%202020%20than%202016%5C%2F2017%20%2875%25%20vs.%2059%25%2C%20respectively%2C%20p%20%3D%200.048%29.%5CnCONCLUSIONS%3A%20Reported%20availability%20of%20screening%20for%20depression%20increased%20among%20this%20group%20of%20IeDEA%20sites%20in%20LMICs%20between%202016%5C%2F2017%20and%202020.%20However%2C%20substantial%20gaps%20persist%20in%20the%20availability%20of%20mental%20healthcare%20at%20HIV%20treatment%20sites%20across%20global%20settings%2C%20particularly%20in%20resource-constrained%20settings.%20Implementation%20of%20sustainable%20strategies%20to%20integrate%20mental%20health%20services%20into%20HIV%20care%20is%20needed.%22%2C%22date%22%3A%222023-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26147%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237535703%22%2C%22PMCID%22%3A%22PMC10399924%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22UT9HBN72%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Bocage%20et%20al.%22%2C%22parsedDate%22%3A%222023-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBocage%20AE%2C%20Coelho%20LE%2C%20Lake%20JE%2C%20Clark%20JL%2C%20Torres%20TS%2C%20Jalil%20EM%2C%20et%20al.%20The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender.%20AIDS%20Behav.%202023%20Aug%3B27%288%29%3A2629%26%23×2013%3B41.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-023-03988-3%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036715887%3B%20PubMed%20Central%20PMCID%3A%20PMC9885404.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Impact%20of%20COVID-19%20on%20HIV%20Care%20in%20Rio%20de%20Janeiro%2C%20Brazil%202019-2021%3A%20Disparities%20by%20Age%20and%20Gender%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20E.%22%2C%22lastName%22%3A%22Bocage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordan%20E.%22%2C%22lastName%22%3A%22Lake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesse%20L.%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thiago%20S.%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Em%5Cu00edlia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronaldo%20I.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22We%20evaluated%20COVID-19%26%23039%3Bs%20impact%20on%20HIV%20care%20indicators%20among%20INI%5C%2FFIOCRUZ%26%23039%3Bs%20HIV%20Clinical%20Cohort%20in%20Rio%20de%20Janeiro%2C%20Brazil%3A%20%281%29%20Adequate%20care%20visits%3A%20two%20visits%5Cu2009%5Cu2265%5Cu200990%5Cu00a0days%20apart%3B%20%282%29%20Adequate%20viral%20load%20monitoring%3A%5Cu2009%5Cu2265%5Cu20092%20viral%20load%20results%5Cu2009%5Cu2265%5Cu200990%5Cu00a0days%20apart%3B%20%283%29%20Consistent%20viral%20suppression%3A%20all%20viral%20loads%5Cu2009%26lt%3B%5Cu200940%20copies%5C%2FmL%3B%20and%20%284%29%20ART%20medication%20possession%20ratio%20%28MPR%29%5Cu2009%5Cu2265%5Cu200995%25.%20Chi-square%20tests%20compared%20the%20fraction%20of%20participants%20meeting%20each%20indicator%20per%20period%3A%20pre-pandemic%20%283%5C%2F1%5C%2F2019-2%5C%2F29%5C%2F2020%29%20and%20post-pandemic%20%283%5C%2F1%5C%2F2020-2%5C%2F28%5C%2F2021%29.%20Logistic%20regression%20models%20were%20used%20to%20assess%20disparities%20in%20adequate%20care%20visits.%20Among%20906%20participants%2C%20care%20visits%20and%20viral%20load%20monitoring%20decreased%20pre-pandemic%20to%20post-pandemic%3A%2077.0-55.1%25%20and%2036.6-11.6%25%20%28both%20p%5Cu2009%26lt%3B%5Cu20090.001%29%2C%20respectively.%20The%20optimal%20MPR%20rate%20improved%20from%2025.5%20to%2040.0%25%20%28p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Post-pandemic%20period%20%28aOR%200.33%2C%20CI%200.28-0.40%29%2C%20transgender%20women%20%28aOR%200.34%2C%20CI%200.22-0.53%29%2C%20and%20those%20aged%2018-24%5Cu00a0years%20%28aOR%200.67%2C%20CI%200.45-0.97%29%20had%20lower%20odds%20of%20adequate%20care%20visits.%20COVID-19%20disrupted%20care%20access%20disproportionately%20for%20transgender%20women%20and%20younger%20participants.%22%2C%22date%22%3A%222023-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-023-03988-3%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236715887%22%2C%22PMCID%22%3A%22PMC9885404%22%2C%22ISSN%22%3A%221573-3254%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A30%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22XYQ4UJJS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Person%20et%20al.%22%2C%22parsedDate%22%3A%222023-06-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPerson%20AK%2C%20Crabtree-Ramirez%20B%2C%20Kim%20A%2C%20Veloso%20V%2C%20Maruri%20F%2C%20Wandeler%20G%2C%20et%20al.%20Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View.%20Clin%20Infect%20Dis.%202023%20Jun%2016%3B76%2812%29%3A2116%26%23×2013%3B25.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciad076%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036821489.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cryptococcal%20Meningitis%20and%20Clinical%20Outcomes%20in%20Persons%20With%20Human%20Immunodeficiency%20Virus%3A%20A%20Global%20View%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Wandeler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22John%20Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darma%22%2C%22lastName%22%3A%22Imran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kinh%22%2C%22lastName%22%3A%22Van%20Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Nalitya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winnie%22%2C%22lastName%22%3A%22Muyindike%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cryptococcal%20meningitis%20%28CM%29%20is%20a%20major%20cause%20of%20morbidity%20and%20mortality%20in%20persons%20with%20human%20immunodeficiency%20virus%20%28HIV%3B%20PWH%29.%20Little%20is%20known%20about%20CM%20outcomes%20and%20availability%20of%20diagnostic%20and%20treatment%20modalities%20globally.%5CnMETHODS%3A%20In%20this%20retrospective%20cohort%20study%2C%20we%20investigated%20CM%20incidence%20and%20all-cause%20mortality%20in%20PWH%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20cohort%20from%201996%20to%202017.%20We%20estimated%20incidence%20using%20quasi-Poisson%20models%20adjusted%20for%20sex%2C%20age%2C%20calendar%20year%2C%20CD4%20cell%20count%20%28CD4%29%2C%20and%20antiretroviral%20therapy%20%28ART%29%20status.%20Mortality%20after%20CM%20diagnosis%20was%20examined%20using%20multivariable%20Cox%20models.%20A%20site%20survey%20from%202017%20assessed%20availability%20of%20CM%20diagnostic%20and%20treatment%20modalities.%5CnRESULTS%3A%20Among%20518%20852%20PWH%2C%20there%20were%203857%20cases%20of%20CM%20with%20an%20estimated%20incidence%20of%201.54%20per%201000%20person-years.%20Mortality%20over%20a%20median%20of%202.6%20years%20of%20post-CM%20diagnosis%20follow-up%20was%2031.6%25%2C%20with%2029%25%20lost%20to%20follow-up.%20In%20total%2C%202478%20%2864%25%29%20were%20diagnosed%20with%20CM%20after%20ART%20start%20with%20a%20median%20of%20253%20days%20from%20ART%20start%20to%20CM%20diagnosis.%20Older%20age%20%28hazard%20%5BHR%5D%2C%201.31%20for%2050%20vs%2035%20years%29%2C%20lower%20CD4%20%28HR%2C%201.15%20for%20200%20vs%20350%20cells%5C%2Fmm3%29%2C%20and%20earlier%20year%20of%20CM%20diagnosis%20%28HR%2C%200.51%20for%202015%20vs%202000%29%20were%20associated%20with%20higher%20mortality.%20Of%2089%20sites%2C%2034%25%20reported%20access%20to%20amphotericin%20B%3B%2012%25%20had%20access%20to%20flucytosine.%5CnCONCLUSIONS%3A%20Mortality%20after%20CM%20diagnosis%20was%20high.%20A%20substantial%20portion%20of%20CM%20cases%20occurred%20after%20ART%20start%2C%20though%20incidence%20and%20mortality%20may%20be%20higher%20than%20reported%20due%20to%20ascertainment%20bias.%20Many%20sites%20lacked%20access%20to%20recommended%20CM%20treatment.%22%2C%22date%22%3A%222023-06-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciad076%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236821489%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A23%3A37Z%22%7D%7D%2C%7B%22key%22%3A%227PCTVUZA%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ara%5Cu00fajo-Pereira%20et%20al.%22%2C%22parsedDate%22%3A%222023-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAra%26%23xFA%3Bjo-Pereira%20M%2C%20Nogueira%20BMF%2C%20Spener-Gomes%20R%2C%20Carvalho%20ACC%2C%20Sant%26%23×2019%3BAnna%20FM%2C%20Figueiredo%20MC%2C%20et%20al.%20Anemia%20and%20anti-tuberculosis%20treatment%20outcome%20in%20persons%20with%20pulmonary%20tuberculosis%3A%20A%20multi-center%20prospective%20cohort%20study.%20J%20Infect%20Public%20Health.%202023%20Jun%3B16%286%29%3A974%26%23×2013%3B80.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jiph.2023.04.009%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jiph.2023.04.009%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037121049%3B%20PubMed%20Central%20PMCID%3A%20PMC10194045.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anemia%20and%20anti-tuberculosis%20treatment%20outcome%20in%20persons%20with%20pulmonary%20tuberculosis%3A%20A%20multi-center%20prospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20C.%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fl%5Cu00e1via%20Marinho%22%2C%22lastName%22%3A%22Sant%27Anna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20remains%20a%20major%20plague%20of%20humanity.%20People%20with%20TB%20%28PWTB%29%20are%20commonly%20anemic.%20Here%2C%20we%20assessed%20whether%20the%20severity%20of%20anemia%20in%20PWTB%20prior%20to%20anti-TB%20treatment%20%28ATT%29%20was%20a%20risk%20factor%20for%20an%20unfavorable%20outcome.%5CnMETHODS%3A%20Patients%20%5Cu2265%5Cu00a018%20years%20old%20with%20culture-confirmed%20drug-susceptible%20pulmonary%20TB%20enrolled%20between%202015%20and%202019%20in%20a%20multi-center%20Brazilian%20cohort%20were%20followed%20for%20up%20to%2024%20months%20and%20classified%20according%20to%20anemia%20severity%20%28mild%2C%20moderate%2C%20and%20severe%29%2C%20based%20on%20hemoglobin%20levels.%20A%20multinomial%20logistic%20regression%20model%20was%20employed%20to%20assess%20whether%20anemia%20was%20associated%20with%20unfavorable%20outcome%20%28death%2C%20failure%2C%20loss%20to%20follow-up%2C%20regimen%20modification%20or%20relapse%29%2C%20compared%20to%20treatment%20success%20%28cure%20or%20treatment%20completion%29.%5CnRESULTS%3A%20Among%20786%20participants%20who%20met%20inclusion%20criteria%2C%20441%20%2856%20%25%29%20were%20anemic%20at%20baseline.%20Patients%20with%20moderate%5C%2Fsevere%20anemia%20were%20more%20HIV-seropositive%2C%20as%20well%20as%20more%20symptomatic%20and%20had%20higher%20frequencies%20of%20unfavorable%20outcomes%20compared%20to%20the%20other%20groups.%20Moderate%5C%2Fsevere%20anemia%20%28adjusted%20OR%20%5BaOR%5D%3A%207.80%2C%2095%20%25CI%3A1.34-45.4%2C%20p%5Cu00a0%3D%5Cu00a00.022%29%20was%20associated%20with%20death%20independent%20of%20sex%2C%20age%2C%20BMI%2C%20HIV%20and%20glycemic%20status.%5CnCONCLUSION%3A%20Moderate%5C%2Fsevere%20anemia%20prior%20to%20ATT%20was%20a%20significant%20risk%20factor%20for%20death.%20Such%20patients%20should%20be%20closely%20monitored%20given%20the%20high%20risk%20of%20unfavorable%20ATT%20outcomes.%22%2C%22date%22%3A%222023-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jiph.2023.04.009%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237121049%22%2C%22PMCID%22%3A%22PMC10194045%22%2C%22ISSN%22%3A%221876-035X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22SYUGHCPC%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Queiroz%20et%20al.%22%2C%22parsedDate%22%3A%222023-05-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BQueiroz%20ATL%2C%20Vinhaes%20CL%2C%20Fukutani%20ER%2C%20Gupte%20AN%2C%20Kumar%20NP%2C%20Fukutani%20KF%2C%20et%20al.%20A%20multi-center%2C%20prospective%20cohort%20study%20of%20whole%20blood%20gene%20expression%20in%20the%20tuberculosis-diabetes%20interaction.%20Sci%20Rep.%202023%20May%2012%3B13%281%29%3A7769.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-34847-9%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-023-34847-9%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037173394%3B%20PubMed%20Central%20PMCID%3A%20PMC10180618.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20multi-center%2C%20prospective%20cohort%20study%20of%20whole%20blood%20gene%20expression%20in%20the%20tuberculosis-diabetes%20interaction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20R.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akshay%20N.%22%2C%22lastName%22%3A%22Gupte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathella%20Pavan%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subash%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Gaikwad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Karyakarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vidya%22%2C%22lastName%22%3A%22Mave%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mandar%22%2C%22lastName%22%3A%22Paradhkar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Viswanathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amita%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hardy%22%2C%22lastName%22%3A%22Kornfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20India%20Consortia%22%7D%5D%2C%22abstractNote%22%3A%22Diabetes%20mellitus%20%28DM%29%20increases%20tuberculosis%20%28TB%29%20severity.%20We%20compared%20blood%20gene%20expression%20in%20adults%20with%20pulmonary%20TB%2C%20with%20or%20without%20diabetes%20mellitus%20%28DM%29%20from%20sites%20in%20Brazil%20and%20India.%20RNA%20sequencing%20%28RNAseq%29%20performed%20at%20baseline%20and%20during%20TB%20treatment.%20Publicly%20available%20baseline%20RNAseq%20data%20from%20South%20Africa%20and%20Romania%20reported%20by%20the%20TANDEM%20Consortium%20were%20also%20analyzed.%20Across%20the%20sites%2C%20differentially%20expressed%20genes%20varied%20for%20each%20condition%20%28DM%2C%20TB%2C%20and%20TBDM%29%20and%20no%20pattern%20classified%20any%20one%20group%20across%20all%20sites.%20A%20concise%20signature%20of%20TB%20disease%20was%20identified%20but%20this%20was%20expressed%20equally%20in%20TB%20and%20TBDM.%20Pathway%20enrichment%20analysis%20failed%20to%20distinguish%20TB%20from%20TBDM%2C%20although%20there%20was%20a%20trend%20for%20greater%20neutrophil%20and%20innate%20immune%20pathway%20activation%20in%20TBDM%20participants.%20Pathways%20associated%20with%20insulin%20resistance%2C%20metabolic%20dysfunction%2C%20diabetic%20complications%2C%20and%20chromosomal%20instability%20were%20positively%20correlated%20with%20glycohemoglobin.%20The%20immune%20response%20to%20pulmonary%20TB%20as%20reflected%20by%20whole%20blood%20gene%20expression%20is%20substantially%20similar%20with%20or%20without%20comorbid%20DM.%20Gene%20expression%20pathways%20associated%20with%20the%20microvascular%20and%20macrovascular%20complications%20of%20DM%20are%20upregulated%20during%20TB%2C%20supporting%20a%20syndemic%20interaction%20between%20these%20coprevalent%20diseases.%22%2C%22date%22%3A%222023-05-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-023-34847-9%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237173394%22%2C%22PMCID%22%3A%22PMC10180618%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A30%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22WHS786YM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Vreeman%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-13%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVreeman%20RC%2C%20Yiannoutsos%20CT%2C%20Yusoff%20NKN%2C%20Wester%20CW%2C%20Edmonds%20A%2C%20Ofner%20S%2C%20et%20al.%20Global%20HIV%20prevention%2C%20care%20and%20treatment%20services%20for%20children%3A%20a%20cross-sectional%20survey%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20BMJ%20Open.%202023%20Mar%2013%3B13%283%29%3Ae069399.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-069399%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2022-069399%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036914183%3B%20PubMed%20Central%20PMCID%3A%20PMC10016275.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20HIV%20prevention%2C%20care%20and%20treatment%20services%20for%20children%3A%20a%20cross-sectional%20survey%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20C.%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nik%20Khairulddin%20Nik%22%2C%22lastName%22%3A%22Yusoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susan%22%2C%22lastName%22%3A%22Ofner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pagakrong%22%2C%22lastName%22%3A%22Lumbiganon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20C%5Cu00e9lia%22%2C%22lastName%22%3A%22de%20Menezes%20Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%22%2C%22lastName%22%3A%22Bolton-Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ounoo%20Elom%22%2C%22lastName%22%3A%22Takassi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Scanlon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxanne%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20assess%20access%20children%20with%20HIV%20have%20to%20comprehensive%20HIV%20care%20services%2C%20to%20longitudinally%20evaluate%20the%20implementation%20and%20scale-up%20of%20services%2C%20and%20to%20use%20site%20services%20and%20clinical%20cohort%20data%20to%20explore%20whether%20access%20to%20these%20services%20influences%20retention%20in%20care.%5CnMETHODS%3A%20A%20cross-sectional%20standardised%20survey%20was%20completed%20in%202014-2015%20by%20sites%20providing%20paediatric%20HIV%20care%20across%20regions%20of%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20We%20developed%20a%20comprehensiveness%20score%20based%20on%20the%20WHO%26%23039%3Bs%20nine%20categories%20of%20essential%20services%20to%20categorise%20sites%20as%20%26%23039%3Blow%26%23039%3B%20%280-5%29%2C%20%26%23039%3Bmedium%26%23039%3B%2C%20%286-7%29%20or%20%26%23039%3Bhigh%26%23039%3B%20%288-9%29.%20When%20available%2C%20comprehensiveness%20scores%20were%20compared%20with%20scores%20from%20a%202009%20survey.%20We%20used%20patient-level%20data%20with%20site%20services%20to%20investigate%20the%20relationship%20between%20the%20comprehensiveness%20of%20services%20and%20retention.%5CnRESULTS%3A%20Survey%20data%20from%20174%20IeDEA%20sites%20in%2032%20countries%20were%20analysed.%20Of%20the%20WHO%20essential%20services%2C%20sites%20were%20most%20likely%20to%20offer%20antiretroviral%20therapy%20%28ART%29%20provision%20and%20counselling%20%28n%3D173%3B%2099%25%29%2C%20co-trimoxazole%20prophylaxis%20%28168%3B%2097%25%29%2C%20prevention%20of%20perinatal%20transmission%20services%20%28167%3B%2096%25%29%2C%20outreach%20for%20patient%20engagement%20and%20follow-up%20%28166%3B%2095%25%29%2C%20CD4%20cell%20count%20testing%20%28126%3B%2088%25%29%2C%20tuberculosis%20screening%20%28151%3B%2087%25%29%20and%20select%20immunisation%20services%20%28126%3B%2072%25%29.%20Sites%20were%20less%20likely%20to%20offer%20nutrition%5C%2Ffood%20support%20%2897%3B%2056%25%29%2C%20viral%20load%20testing%20%2899%3B%2069%25%29%20and%20HIV%20counselling%20and%20testing%20%2869%3B%2040%25%29.%2010%25%20of%20sites%20rated%20%26%23039%3Blow%26%23039%3B%2C%2059%25%20%26%23039%3Bmedium%26%23039%3B%20and%2031%25%20%26%23039%3Bhigh%26%23039%3B%20in%20the%20comprehensiveness%20score.%20The%20mean%20comprehensiveness%20of%20services%20score%20increased%20significantly%20from%205.6%20in%202009%20to%207.3%20in%202014%20%28p%26lt%3B0.001%3B%20n%3D30%29.%20Patient-level%20analysis%20of%20lost%20to%20follow-up%20after%20ART%20initiation%20estimated%20the%20hazard%20was%20highest%20in%20sites%20rated%20%26%23039%3Blow%26%23039%3B%20and%20lowest%20in%20sites%20rated%20%26%23039%3Bhigh%26%23039%3B.%5CnCONCLUSION%3A%20This%20global%20assessment%20suggests%20the%20potential%20care%20impact%20of%20scaling-up%20and%20sustaining%20comprehensive%20paediatric%20HIV%20services.%20Meeting%20recommendations%20for%20comprehensive%20HIV%20services%20should%20remain%20a%20global%20priority.%22%2C%22date%22%3A%222023-03-13%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2022-069399%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236914183%22%2C%22PMCID%22%3A%22PMC10016275%22%2C%22ISSN%22%3A%222044-6055%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A24%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22FTJEJ9SX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ridolfi%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-08%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRidolfi%20F%2C%20Peetluk%20L%2C%20Amorim%20G%2C%20Turner%20M%2C%20Figueiredo%20M%2C%20Cordeiro-Santos%20M%2C%20et%20al.%20Tuberculosis%20Treatment%20Outcomes%20in%20Brazil%3A%20Different%20Predictors%20for%20Each%20Type%20of%20Unsuccessful%20Outcome.%20Clin%20Infect%20Dis.%202023%20Feb%208%3B76%283%29%3Ae930%26%23×2013%3B7.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac541%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac541%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035788646%3B%20PubMed%20Central%20PMCID%3A%20PMC10169436.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tuberculosis%20Treatment%20Outcomes%20in%20Brazil%3A%20Different%20Predictors%20for%20Each%20Type%20of%20Unsuccessful%20Outcome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29%5Cu2013Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Successful%20tuberculosis%20%28TB%29%20treatment%20is%20necessary%20for%20disease%20control.%20The%20World%20Health%20Organization%20%28WHO%29%20has%20a%20target%20TB%20treatment%20success%20rate%20of%20%5Cu226590%25.%20We%20assessed%20whether%20the%20different%20types%20of%20unfavorable%20TB%20treatment%20outcome%20had%20different%20predictors.%5CnMETHODS%3A%20Using%20data%20from%20Regional%20Prospective%20Observational%20Research%20for%20Tuberculosis-Brazil%2C%20we%20evaluated%20biological%20and%20behavioral%20factors%20associated%20with%20each%20component%20of%20unsuccessful%20TB%20outcomes%2C%20recently%20updated%20by%20WHO%20%28death%2C%20loss%20to%20follow-up%20%5BLTFU%5D%2C%20and%20treatment%20failure%29.%20We%20included%20culture-confirmed%2C%20drug-susceptible%2C%20pulmonary%20TB%20participants%20receiving%20standard%20treatment%20in%202015-2019.%20Multinomial%20logistic%20regression%20models%20with%20inverse%20probability%20weighting%20were%20used%20to%20evaluate%20the%20distinct%20determinants%20of%20each%20unsuccessful%20outcome.%5CnRESULTS%3A%20Of%20915%20participants%20included%2C%20727%20%2879%25%29%20were%20successfully%20treated%2C%20118%20%2813%25%29%20were%20LTFU%2C%2044%20%285%25%29%20had%20treatment%20failure%2C%20and%2026%20%283%25%29%20died.%20LTFU%20was%20associated%20with%20current%20drug-use%20%28adjusted%20odds%20ratio%20%5BaOR%5D%20%3D%205.3%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%203.0-9.4%29%2C%20current%20tobacco%20use%20%28aOR%20%3D%202.9%3B%2095%25%20CI%2C%201.7-4.9%29%2C%20and%20being%20a%20person%20with%20HIV%20%28PWH%29%20%28aOR%20%3D%202.0%3B%2095%25%20CI%2C%201.1-3.5%29.%20Treatment%20failure%20was%20associated%20with%20PWH%20%28aOR%20%3D%202.7%3B%2095%25%20CI%2C%201.2-6.2%29%20and%20having%20diabetes%20%28aOR%20%3D%202.2%3B%2095%25%20CI%2C%201.1-4.4%29.%20Death%20was%20associated%20with%20anemia%20%28aOR%20%3D%205.3%3B%2095%25%20CI%2C%201.4-19.7%29%2C%20diabetes%20%28aOR%20%3D%203.1%3B%2095%25%20CI%2C%201.4-6.7%29%2C%20and%20PWH%20%28aOR%20%3D%203.9%3B%2095%25%20CI%2C%201.3-11.4%29.%20Direct%20observed%20therapy%20was%20protective%20for%20treatment%20failure%20%28aOR%20%3D%200.5%3B%2095%25%20CI%2C%20.3-.9%29%20and%20death%20%28aOR%20%3D%200.5%3B%2095%25%20CI%2C%20.2-1.0%29.%5CnCONCLUSIONS%3A%20The%20treatment%20success%20rate%20was%20below%20the%20WHO%20target.%20Behavioral%20factors%20were%20most%20associated%20with%20LTFU%2C%20whereas%20clinical%20comorbidities%20were%20correlated%20with%20treatment%20failure%20and%20death.%20Because%20determinants%20of%20unsuccessful%20outcomes%20are%20distinct%2C%20different%20intervention%20strategies%20may%20be%20needed%20to%20improve%20TB%20outcomes.%22%2C%22date%22%3A%222023-02-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac541%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235788646%22%2C%22PMCID%22%3A%22PMC10169436%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A30%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22LWXZDILG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ross%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRoss%20J%2C%20Brazier%20E%2C%20Fatti%20G%2C%20Jaquet%20A%2C%20Tanon%20A%2C%20Haas%20AD%2C%20et%20al.%20Same-Day%20Antiretroviral%20Therapy%20Initiation%20as%20a%20Predictor%20of%20Loss%20to%20Follow-up%20and%20Viral%20Suppression%20Among%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20Sub-Saharan%20Africa.%20Clin%20Infect%20Dis.%202023%20Jan%206%3B76%281%29%3A39%26%23×2013%3B47.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac759%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac759%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036097726%3B%20PubMed%20Central%20PMCID%3A%20PMC10202422.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Same-Day%20Antiretroviral%20Therapy%20Initiation%20as%20a%20Predictor%20of%20Loss%20to%20Follow-up%20and%20Viral%20Suppression%20Among%20People%20With%20Human%20Immunodeficiency%20Virus%20in%20Sub-Saharan%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Fatti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aristophane%22%2C%22lastName%22%3A%22Tanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20D.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20M.%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Treat-All%20guidelines%20recommend%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20for%20all%20people%20with%20HIV%20%28PWH%29%20on%20the%20day%20of%20diagnosis%20when%20possible%2C%20yet%20uncertainty%20exists%20about%20the%20impact%20of%20same-day%20ART%20initiation%20on%20subsequent%20care%20engagement.%20We%20examined%20the%20association%20of%20same-day%20ART%20initiation%20with%20loss%20to%20follow-up%20and%20viral%20suppression%20among%20patients%20in%2011%20sub-Saharan%20African%20countries.%5CnMETHODS%3A%20We%20included%20ART-naive%20adult%20PWH%20from%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20who%20enrolled%20in%20care%20after%20Treat-All%20implementation%20and%20prior%20to%20January%202019.%20We%20used%20multivariable%20Cox%20regression%20to%20estimate%20the%20association%20between%20same-day%20ART%20initiation%20and%20loss%20to%20follow-up%20and%20Poisson%20regression%20to%20estimate%20the%20association%20between%20same-day%20ART%20initiation%20and%206-month%20viral%20suppression.%5CnRESULTS%3A%20Among%2029%20017%20patients%20from%2063%20sites%2C%2018%20584%20%2864.0%25%29%20initiated%20ART%20on%20the%20day%20of%20enrollment.%20Same-day%20ART%20initiation%20was%20less%20likely%20among%20those%20with%20advanced%20HIV%20disease%20versus%20early-stage%20disease.%20Loss%20to%20follow-up%20was%20significantly%20lower%20among%20those%20initiating%20ART%20%5Cu22651%20day%20of%20enrollment%2C%20compared%20with%20same-day%20ART%20initiators%20%2820.6%25%20vs%2027.7%25%3B%20adjusted%20hazard%20ratio%3A%20.66%3B%2095%25%20CI%20.57-.76%29.%20No%20difference%20in%20viral%20suppression%20was%20observed%20by%20time%20to%20ART%20initiation%20%28adjusted%20rate%20ratio%3A%201.00%3B%2095%25%20CI%3A%20.98-1.02%29.%5CnCONCLUSIONS%3A%20Patients%20initiating%20ART%20on%20the%20day%20of%20enrollment%20were%20more%20frequently%20lost%20to%20follow-up%20than%20those%20initiating%20later%20but%20were%20equally%20likely%20to%20be%20virally%20suppressed.%20Our%20findings%20support%20recent%20World%20Health%20Organization%20recommendations%20for%20providing%20tailored%20counseling%20and%20support%20to%20patients%20who%20accept%20an%20offer%20of%20same-day%20ART.%22%2C%22date%22%3A%222023-01-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac759%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236097726%22%2C%22PMCID%22%3A%22PMC10202422%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%2227LEDMJE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Humphrey%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHumphrey%20J%2C%20Nagel%20E%2C%20Carlucci%20JG%2C%20Edmonds%20A%2C%20Kinikar%20A%2C%20Anderson%20K%2C%20et%20al.%20Integration%20of%20HIV%20care%20into%20maternal%20and%20child%20health%20services%20in%20the%20global%20IeDEA%20consortium.%20Front%20Glob%20Womens%20Health.%202023%3B4%3A1066297.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffgwh.2023.1066297%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffgwh.2023.1066297%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2037139173%3B%20PubMed%20Central%20PMCID%3A%20PMC10150067.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Integration%20of%20HIV%20care%20into%20maternal%20and%20child%20health%20services%20in%20the%20global%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Nagel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aarti%22%2C%22lastName%22%3A%22Kinikar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dwight%20E.%22%2C%22lastName%22%3A%22Yin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%22%2C%22lastName%22%3A%22Tulio%20Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madeleine%22%2C%22lastName%22%3A%22Amorissani-Folquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Safari%22%2C%22lastName%22%3A%22Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tulathip%22%2C%22lastName%22%3A%22Suwanlerk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Athanase%22%2C%22lastName%22%3A%22Munyaneza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rena%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Abuogi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%5D%2C%22abstractNote%22%3A%22The%20WHO%20recommends%20the%20integration%20of%20routine%20HIV%20services%20within%20maternal%20and%20child%20health%20%28MCH%29%20services%20to%20reduce%20the%20fragmentation%20of%20and%20to%20promote%20retention%20in%20care%20for%20pregnant%20and%20postpartum%20women%20living%20with%20HIV%20%28WWH%29%20and%20their%20infants%20and%20children%20exposed%20to%20HIV%20%28ICEH%29.%20During%202020-2021%2C%20we%20surveyed%20202%20HIV%20treatment%20sites%20across%2040%20low-%20and%20middle-income%20countries%20within%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20We%20determined%20the%20proportion%20of%20sites%20providing%20HIV%20services%20integrated%20within%20MCH%20clinics%2C%20defined%20as%20full%20%5BHIV%20care%20and%20antiretroviral%20treatment%20%28ART%29%20initiation%20in%20MCH%20clinic%5D%2C%20partial%20%28HIV%20care%20or%20ART%20initiation%20in%20MCH%20clinic%29%2C%20or%20no%20integration.%20Among%20sites%20serving%20pregnant%20WWH%2C%2054%25%20were%20fully%20and%2021%25%20partially%20integrated%2C%20with%20the%20highest%20proportions%20of%20fully%20integrated%20sites%20in%20Southern%20Africa%20%2880%25%29%20and%20East%20Africa%20%2876%25%29%20compared%20to%2014%25-40%25%20in%20other%20regions%20%28i.e.%2C%20Asia-Pacific%3B%20the%20Caribbean%2C%20Central%20and%20South%20America%20Network%20for%20HIV%20Epidemiology%3B%20Central%20Africa%3B%20West%20Africa%29.%20Among%20sites%20serving%20postpartum%20WWH%2C%2051%25%20were%20fully%20and%2010%25%20partially%20integrated%2C%20with%20a%20similar%20regional%20integration%20pattern%20to%20sites%20serving%20pregnant%20WWH.%20Among%20sites%20serving%20ICEH%2C%2056%25%20were%20fully%20and%209%25%20were%20partially%20integrated%2C%20with%20the%20highest%20proportions%20of%20fully%20integrated%20sites%20in%20East%20Africa%20%2876%25%29%2C%20West%20Africa%20%2858%25%29%20and%20Southern%20Africa%20%2854%25%29%20compared%20to%20%5Cu226433%25%20in%20the%20other%20regions.%20Integration%20was%20heterogenous%20across%20IeDEA%20regions%20and%20most%20prevalent%20in%20East%20and%20Southern%20Africa.%20More%20research%20is%20needed%20to%20understand%20this%20heterogeneity%20and%20the%20impacts%20of%20integration%20on%20MCH%20outcomes%20globally.%22%2C%22date%22%3A%222023%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffgwh.2023.1066297%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2237139173%22%2C%22PMCID%22%3A%22PMC10150067%22%2C%22ISSN%22%3A%222673-5059%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22XZG7SRLL%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Lotspeich%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLotspeich%20SC%2C%20Shepherd%20BE%2C%20Kariuki%20MA%2C%20Wools-Kaloustian%20K%2C%20McGowan%20CC%2C%20Musick%20B%2C%20et%20al.%20Lessons%20learned%20from%20over%20a%20decade%20of%20data%20audits%20in%20international%20observational%20HIV%20cohorts%20in%20Latin%20America%20and%20East%20Africa.%20J%20Clin%20Transl%20Sci.%202023%3B7%281%29%3Ae245.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2Fcts.2023.659%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2Fcts.2023.659%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038033704%3B%20PubMed%20Central%20PMCID%3A%20PMC10685260.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lessons%20learned%20from%20over%20a%20decade%20of%20data%20audits%20in%20international%20observational%20HIV%20cohorts%20in%20Latin%20America%20and%20East%20Africa%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%20Achieng%22%2C%22lastName%22%3A%22Kariuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree%20Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denna%20M.%22%2C%22lastName%22%3A%22Mkwashapi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Ssemakadde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antony%22%2C%22lastName%22%3A%22Ngeresa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fl%5Cu00e1via%20Faleiro%22%2C%22lastName%22%3A%22Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Lwali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adias%22%2C%22lastName%22%3A%22Marcelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larissa%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cort%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Routine%20patient%20care%20data%20are%20increasingly%20used%20for%20biomedical%20research%2C%20but%20such%20%26quot%3Bsecondary%20use%26quot%3B%20data%20have%20known%20limitations%2C%20including%20their%20quality.%20When%20leveraging%20routine%20care%20data%20for%20observational%20research%2C%20developing%20audit%20protocols%20that%20can%20maximize%20informational%20return%20and%20minimize%20costs%20is%20paramount.%5CnMETHODS%3A%20For%20more%20than%20a%20decade%2C%20the%20Latin%20America%20and%20East%20Africa%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20have%20been%20auditing%20the%20observational%20data%20drawn%20from%20participating%20human%20immunodeficiency%20virus%20clinics.%20Since%20our%20earliest%20audits%2C%20where%20external%20auditors%20used%20paper%20forms%20to%20record%20audit%20findings%20from%20paper%20medical%20records%2C%20we%20have%20streamlined%20our%20protocols%20to%20obtain%20more%20efficient%20and%20informative%20audits%20that%20keep%20up%20with%20advancing%20technology%20while%20reducing%20travel%20obligations%20and%20associated%20costs.%5CnRESULTS%3A%20We%20present%20five%20key%20lessons%20learned%20from%20conducting%20data%20audits%20of%20secondary-use%20data%20from%20resource-limited%20settings%20for%20more%20than%2010%20years%20and%20share%20eight%20recommendations%20for%20other%20consortia%20looking%20to%20implement%20data%20quality%20initiatives.%5CnCONCLUSION%3A%20After%20completing%20multiple%20audit%20cycles%20in%20both%20the%20Latin%20America%20and%20East%20Africa%20regions%20of%20the%20IeDEA%20consortium%2C%20we%20have%20established%20a%20rich%20reference%20for%20data%20quality%20in%20our%20cohorts%2C%20as%20well%20as%20large%2C%20audited%20analytical%20datasets%20that%20can%20be%20used%20to%20answer%20important%20clinical%20questions%20with%20confidence.%20By%20sharing%20our%20audit%20processes%20and%20how%20they%20have%20been%20adapted%20over%20time%2C%20we%20hope%20that%20others%20can%20develop%20protocols%20informed%20by%20our%20lessons%20learned%20from%20more%20than%20a%20decade%20of%20experience%20in%20these%20large%2C%20diverse%20cohorts.%22%2C%22date%22%3A%222023%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1017%5C%2Fcts.2023.659%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238033704%22%2C%22PMCID%22%3A%22PMC10685260%22%2C%22ISSN%22%3A%222059-8661%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A31%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22U5B5H63J%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Andrade%20VMB%2C%20Queiroz%20ATL%2C%20Fernandes%20CD%2C%20Sales%20C%2C%20et%20al.%20Influence%20of%20dietary%20pattern%20on%20anti-tuberculosis%20treatment%20outcomes%20in%20persons%20with%20dysglycemia%3A%20a%20Peruvian%20prospective%20cohort%20study.%20Front%20Nutr.%202023%3B10%3A1254983.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffnut.2023.1254983%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffnut.2023.1254983%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2038164414%3B%20PubMed%20Central%20PMCID%3A%20PMC10757910.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20dietary%20pattern%20on%20anti-tuberculosis%20treatment%20outcomes%20in%20persons%20with%20dysglycemia%3A%20a%20Peruvian%20prospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catarina%20D.%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caio%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Gonzalo%22%2C%22lastName%22%3A%22Aliaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rupak%22%2C%22lastName%22%3A%22Shivakoti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonid%22%2C%22lastName%22%3A%22Lecca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20I.%22%2C%22lastName%22%3A%22Calderon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dietary%20patterns%20%28DPs%29%20are%20associated%20with%20overall%20nutritional%20status%20and%20may%20alter%20the%20clinical%20prognosis%20of%20tuberculosis.%20This%20interaction%20can%20be%20further%20intricated%20by%20dysglycemia%20%28i.e.%2C%20diabetes%20or%20prediabetes%29.%20Here%2C%20we%20identified%20DPs%20that%20are%20more%20common%20with%20tuberculosis-dysglycemia%20and%20depicted%20their%20association%20with%20tuberculosis%20treatment%20outcomes.%5CnMETHODS%3A%20A%20prospective%20cohort%20study%20of%20persons%20with%20tuberculosis%20and%20their%20contacts%20was%20conducted%20in%20Peru.%20A%20food%20frequency%20questionnaire%20and%20a%20multidimensional%20systems%20biology-based%20analytical%20approach%20were%20employed%20to%20identify%20DPs%20associated%20with%20these%20clinical%20groups.%20Potential%20independent%20associations%20between%20clinical%20features%20and%20DPs%20were%20analyzed.%5CnRESULTS%3A%20Three%20major%20DPs%20were%20identified.%20TB-dysglycemia%20cases%20more%20often%20had%20a%20high%20intake%20of%20carbohydrates%20%28DP1%29.%20Furthermore%2C%20DP1%20was%20found%20to%20be%20associated%20with%20an%20increased%20risk%20of%20unfavorable%20TB%20outcomes%20independent%20of%20other%20factors%2C%20including%20dysglycemia.%5CnCONCLUSION%3A%20Our%20findings%20suggest%20that%20the%20evaluation%20of%20nutritional%20status%20through%20DPs%20in%20comorbidities%20such%20as%20dysglycemia%20is%20a%20fundamental%20action%20to%20predict%20TB%20treatment%20outcomes.%20The%20mechanisms%20underlying%20the%20association%20between%20high%20intake%20of%20carbohydrates%2C%20dysglycemia%2C%20and%20unfavorable%20tuberculosis%20treatment%20outcomes%20warrant%20further%20investigation.%22%2C%22date%22%3A%222023%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffnut.2023.1254983%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2238164414%22%2C%22PMCID%22%3A%22PMC10757910%22%2C%22ISSN%22%3A%222296-861X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222026-03-06T19%3A32%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22AXCAVDNM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222023%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Maruri%20F%2C%20Wester%20CW%2C%20Musick%20B%2C%20Freeman%20A%2C%20Parcesepe%20A%2C%20et%20al.%20Design%20and%20implementation%20of%20a%20global%20site%20assessment%20survey%20among%20HIV%20clinics%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium.%20PLoS%20One.%202023%3B18%283%29%3Ae0268167.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0268167%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0268167%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036917598%3B%20PubMed%20Central%20PMCID%3A%20PMC10013879.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Design%20and%20implementation%20of%20a%20global%20site%20assessment%20survey%20among%20HIV%20clinics%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefanie%22%2C%22lastName%22%3A%22Hossmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedikt%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%22%2C%22lastName%22%3A%22Kimmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%20E.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20E.%22%2C%22lastName%22%3A%22Golub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Timely%20descriptions%20of%20HIV%20service%20characteristics%20and%20their%20evolution%20over%20time%20across%20diverse%20settings%20are%20important%20for%20monitoring%20the%20scale-up%20of%20evidence-based%20program%20strategies%2C%20understanding%20the%20implementation%20landscape%2C%20and%20examining%20service%20delivery%20factors%20that%20influence%20HIV%20care%20outcomes.%5CnMETHODS%3A%20The%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20undertakes%20periodic%20cross-sectional%20surveys%20on%20service%20availability%20and%20care%20at%20participating%20HIV%20treatment%20sites%20to%20characterize%20trends%20and%20inform%20the%20scientific%20agenda%20for%20HIV%20care%20and%20implementation%20science%20communities.%20IeDEA%26%23039%3Bs%202020%20general%20site%20assessment%20survey%20was%20developed%20through%20a%20consultative%2C%2018-month%20process%20that%20engaged%20diverse%20researchers%20in%20identifying%20content%20from%20previous%20surveys%20that%20should%20be%20retained%20for%20longitudinal%20analyses%20and%20in%20developing%20expanded%20and%20new%20content%20to%20address%20gaps%20in%20the%20literature.%20An%20iterative%20review%20process%20was%20undertaken%20to%20standardize%20the%20format%20of%20new%20survey%20questions%20and%20align%20them%20with%20best%20practices%20in%20survey%20design%20and%20measurement%20and%20lessons%20learned%20through%20prior%20IeDEA%20site%20assessment%20surveys.%5CnRESULTS%3A%20The%20survey%20questionnaire%20developed%20through%20this%20process%20included%20eight%20content%20domains%20covered%20in%20prior%20surveys%20%28patient%20population%2C%20staffing%20and%20community%20linkages%2C%20HIV%20testing%20and%20diagnosis%2C%20new%20patient%20care%2C%20treatment%20monitoring%20and%20retention%2C%20routine%20HIV%20care%20and%20screening%2C%20pharmacy%2C%20record-keeping%20and%20patient%20tracing%29%2C%20along%20with%20expanded%20content%20related%20to%20antiretroviral%20therapy%20%28differentiated%20service%20delivery%20and%20roll-out%20of%20dolutegravir-based%20regimens%29%3B%20mental%20health%20and%20substance%20use%20disorders%3B%20care%20for%20pregnant%5C%2Fpostpartum%20women%20and%20HIV-exposed%20infants%3B%20tuberculosis%20preventive%20therapy%3B%20and%20pediatric%5C%2Fadolescent%20tuberculosis%20care%3B%20and%20new%20content%20related%20to%20Kaposi%26%23039%3Bs%20sarcoma%20diagnostics%2C%20the%20impact%20of%20COVID-19%20on%20service%20delivery%2C%20and%20structural%20barriers%20to%20HIV%20care.%20The%20survey%20was%20distributed%20to%20238%20HIV%20treatment%20sites%20in%20late%202020%2C%20with%20a%2095%25%20response%20rate.%5CnCONCLUSION%3A%20IeDEA%26%23039%3Bs%20approach%20for%20site%20survey%20development%20has%20broad%20relevance%20for%20HIV%20research%20networks%20and%20other%20priority%20health%20conditions.%22%2C%22date%22%3A%222023%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0268167%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236917598%22%2C%22PMCID%22%3A%22PMC10013879%22%2C%22ISSN%22%3A%221932-6203%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A23%3A54Z%22%7D%7D%5D%7D
1.
Rodrigues MMS, Barreto-Duarte B, Vinhaes CL, Araújo-Pereira M, Fukutani ER, Bergamaschi KB, et al. Machine learning algorithms using national registry data to predict loss to follow- up during tuberculosis treatment. Res Sq. 2023 Dec 11;rs.3.rs-3706875. http://doi.org/10.21203/rs.3.rs-3706875/v1 PubMed PMID: 38168296; PubMed Central PMCID: PMC10760311.
1.
Grinsztejn E, Cardoso SW, Velasque L, Hoagland B, Dos Santos DG, Coutinho C, et al. Impact of Latent M. tuberculosis Infection Treatment on Time to CD4/CD8 Recovery in Acute, Recent, and Chronic HIV Infection. J Acquir Immune Defic Syndr. 2023 Dec 1;94(4):355–63. http://doi.org/10.1097/QAI.0000000000003284 PubMed PMID: 37595204; PubMed Central PMCID: PMC10609716.
1.
Eden SK, Li C, Shepherd BE. Spearman-like correlation measure adjusting for covariates in bivariate survival data. Biom J. 2023 Dec;65(8):e2200137. http://doi.org/10.1002/bimj.202200137 PubMed PMID: 37753794; PubMed Central PMCID: PMC10897866.
1.
Meireles G, Nobre AA, Cardoso SW, Velasque L, Veloso VG, Grinsztejn B, et al. Real-world effectiveness of WHO recommended first-line antiretroviral therapies: a cohort study from a middle-income country. AIDS Care. 2023 Dec;35(12):1891–903. http://doi.org/10.1080/09540121.2023.2190954 PubMed PMID: 37001113; PubMed Central PMCID: PMC10935654.
1.
Global variations in pubertal growth spurts in adolescents living with perinatal HIV. AIDS. 2023 Aug 1;37(10):1603–15. http://doi.org/10.1097/QAD.0000000000003602 PubMed PMID: 37204259; PubMed Central PMCID: PMC10355801.
1.
Parcesepe AM, Stockton M, Remch M, Wester CW, Bernard C, Ross J, et al. Availability of screening and treatment for common mental disorders in HIV clinic settings: data from the global International epidemiology Databases to Evaluate AIDS (IeDEA) Consortium, 2016-2017 and 2020. J Int AIDS Soc. 2023 Aug;26(8):e26147. http://doi.org/10.1002/jia2.26147 PubMed PMID: 37535703; PubMed Central PMCID: PMC10399924.
1.
Bocage AE, Coelho LE, Lake JE, Clark JL, Torres TS, Jalil EM, et al. The Impact of COVID-19 on HIV Care in Rio de Janeiro, Brazil 2019-2021: Disparities by Age and Gender. AIDS Behav. 2023 Aug;27(8):2629–41. http://doi.org/10.1007/s10461-023-03988-3 PubMed PMID: 36715887; PubMed Central PMCID: PMC9885404.
1.
Person AK, Crabtree-Ramirez B, Kim A, Veloso V, Maruri F, Wandeler G, et al. Cryptococcal Meningitis and Clinical Outcomes in Persons With Human Immunodeficiency Virus: A Global View. Clin Infect Dis. 2023 Jun 16;76(12):2116–25. http://doi.org/10.1093/cid/ciad076 PubMed PMID: 36821489.
1.
Araújo-Pereira M, Nogueira BMF, Spener-Gomes R, Carvalho ACC, Sant’Anna FM, Figueiredo MC, et al. Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study. J Infect Public Health. 2023 Jun;16(6):974–80. http://doi.org/10.1016/j.jiph.2023.04.009 PubMed PMID: 37121049; PubMed Central PMCID: PMC10194045.
1.
Queiroz ATL, Vinhaes CL, Fukutani ER, Gupte AN, Kumar NP, Fukutani KF, et al. A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction. Sci Rep. 2023 May 12;13(1):7769. http://doi.org/10.1038/s41598-023-34847-9 PubMed PMID: 37173394; PubMed Central PMCID: PMC10180618.
1.
Vreeman RC, Yiannoutsos CT, Yusoff NKN, Wester CW, Edmonds A, Ofner S, et al. Global HIV prevention, care and treatment services for children: a cross-sectional survey from the International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium. BMJ Open. 2023 Mar 13;13(3):e069399. http://doi.org/10.1136/bmjopen-2022-069399 PubMed PMID: 36914183; PubMed Central PMCID: PMC10016275.
1.
Ridolfi F, Peetluk L, Amorim G, Turner M, Figueiredo M, Cordeiro-Santos M, et al. Tuberculosis Treatment Outcomes in Brazil: Different Predictors for Each Type of Unsuccessful Outcome. Clin Infect Dis. 2023 Feb 8;76(3):e930–7. http://doi.org/10.1093/cid/ciac541 PubMed PMID: 35788646; PubMed Central PMCID: PMC10169436.
1.
Ross J, Brazier E, Fatti G, Jaquet A, Tanon A, Haas AD, et al. Same-Day Antiretroviral Therapy Initiation as a Predictor of Loss to Follow-up and Viral Suppression Among People With Human Immunodeficiency Virus in Sub-Saharan Africa. Clin Infect Dis. 2023 Jan 6;76(1):39–47. http://doi.org/10.1093/cid/ciac759 PubMed PMID: 36097726; PubMed Central PMCID: PMC10202422.
1.
Humphrey J, Nagel E, Carlucci JG, Edmonds A, Kinikar A, Anderson K, et al. Integration of HIV care into maternal and child health services in the global IeDEA consortium. Front Glob Womens Health. 2023;4:1066297. http://doi.org/10.3389/fgwh.2023.1066297 PubMed PMID: 37139173; PubMed Central PMCID: PMC10150067.
1.
Lotspeich SC, Shepherd BE, Kariuki MA, Wools-Kaloustian K, McGowan CC, Musick B, et al. Lessons learned from over a decade of data audits in international observational HIV cohorts in Latin America and East Africa. J Clin Transl Sci. 2023;7(1):e245. http://doi.org/10.1017/cts.2023.659 PubMed PMID: 38033704; PubMed Central PMCID: PMC10685260.
1.
Arriaga MB, Araújo-Pereira M, Andrade VMB, Queiroz ATL, Fernandes CD, Sales C, et al. Influence of dietary pattern on anti-tuberculosis treatment outcomes in persons with dysglycemia: a Peruvian prospective cohort study. Front Nutr. 2023;10:1254983. http://doi.org/10.3389/fnut.2023.1254983 PubMed PMID: 38164414; PubMed Central PMCID: PMC10757910.
1.
Brazier E, Maruri F, Wester CW, Musick B, Freeman A, Parcesepe A, et al. Design and implementation of a global site assessment survey among HIV clinics participating in the International epidemiology Databases to Evaluate AIDS (IeDEA) research consortium. PLoS One. 2023;18(3):e0268167. http://doi.org/10.1371/journal.pone.0268167 PubMed PMID: 36917598; PubMed Central PMCID: PMC10013879.
2022
76770
IP6F4TRX
2022
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22FD5QZYVM%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Lotspeich%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLotspeich%20SC%2C%20Shepherd%20BE%2C%20Amorim%20GGC%2C%20Shaw%20PA%2C%20Tao%20R.%20Efficient%20odds%20ratio%20estimation%20under%20two-phase%20sampling%20using%20error-prone%20data%20from%20a%20multi-national%20HIV%20research%20cohort.%20Biometrics.%202022%20Dec%3B78%284%29%3A1674%26%23×2013%3B85.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbiom.13512%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbiom.13512%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034213008%3B%20PubMed%20Central%20PMCID%3A%20PMC8720323.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficient%20odds%20ratio%20estimation%20under%20two-phase%20sampling%20using%20error-prone%20data%20from%20a%20multi-national%20HIV%20research%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20G.%20C.%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%5D%2C%22abstractNote%22%3A%22Persons%20living%20with%20HIV%20engage%20in%20routine%20clinical%20care%2C%20generating%20large%20amounts%20of%20data%20in%20observational%20HIV%20cohorts.%20These%20data%20are%20often%20error-prone%2C%20and%20directly%20using%20them%20in%20biomedical%20research%20could%20bias%20estimation%20and%20give%20misleading%20results.%20A%20cost-effective%20solution%20is%20the%20two-phase%20design%2C%20under%20which%20the%20error-prone%20variables%20are%20observed%20for%20all%20patients%20during%20Phase%20I%2C%20and%20that%20information%20is%20used%20to%20select%20patients%20for%20data%20auditing%20during%20Phase%20II.%20For%20example%2C%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20selected%20a%20random%20sample%20from%20each%20site%20for%20data%20auditing.%20Herein%2C%20we%20consider%20efficient%20odds%20ratio%20estimation%20with%20partially%20audited%2C%20error-prone%20data.%20We%20propose%20a%20semiparametric%20approach%20that%20uses%20all%20information%20from%20both%20phases%20and%20accommodates%20a%20number%20of%20error%20mechanisms.%20We%20allow%20both%20the%20outcome%20and%20covariates%20to%20be%20error-prone%20and%20these%20errors%20to%20be%20correlated%2C%20and%20selection%20of%20the%20Phase%20II%20sample%20can%20depend%20on%20Phase%20I%20data%20in%20an%20arbitrary%20manner.%20We%20devise%20a%20computationally%20efficient%2C%20numerically%20stable%20EM%20algorithm%20to%20obtain%20estimators%20that%20are%20consistent%2C%20asymptotically%20normal%2C%20and%20asymptotically%20efficient.%20We%20demonstrate%20the%20advantages%20of%20the%20proposed%20methods%20over%20existing%20ones%20through%20extensive%20simulations.%20Finally%2C%20we%20provide%20applications%20to%20the%20CCASAnet%5Cu00a0cohort.%22%2C%22date%22%3A%222022-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fbiom.13512%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234213008%22%2C%22PMCID%22%3A%22PMC8720323%22%2C%22ISSN%22%3A%221541-0420%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A17%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22Y7R5MCJS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Ajeh%20R%2C%20Maruri%20F%2C%20Musick%20B%2C%20Freeman%20A%2C%20Wester%20CW%2C%20et%20al.%20Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium.%20J%20Int%20AIDS%20Soc.%202022%20Dec%3B25%2812%29%3Ae26036.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.26036%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036504431%3B%20PubMed%20Central%20PMCID%3A%20PMC9742047.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Service%20delivery%20challenges%20in%20HIV%20care%20during%20the%20first%20year%20of%20the%20COVID-19%20pandemic%3A%20results%20from%20a%20site%20assessment%20survey%20across%20the%20global%20IeDEA%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogers%22%2C%22lastName%22%3A%22Ajeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Man-Po%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinei%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree%20Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelline%22%2C%22lastName%22%3A%22d%27Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christella%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Tanser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Interruptions%20in%20treatment%20pose%20risks%20for%20people%20with%20HIV%20%28PWH%29%20and%20threaten%20progress%20in%20ending%20the%20HIV%20epidemic%3B%20however%2C%20the%20COVID-19%20pandemic%26%23039%3Bs%20impact%20on%20HIV%20service%20delivery%20across%20diverse%20settings%20is%20not%20broadly%20documented.%5CnMETHODS%3A%20From%20September%202020%20to%20March%202021%2C%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20research%20consortium%20surveyed%20238%20HIV%20care%20sites%20across%20seven%20geographic%20regions%20to%20document%20constraints%20in%20HIV%20service%20delivery%20during%20the%20first%20year%20of%20the%20pandemic%20and%20strategies%20for%20ensuring%20care%20continuity%20for%20PWH.%20Descriptive%20statistics%20were%20stratified%20by%20national%20HIV%20prevalence%20%28%26lt%3B1%25%2C%201-4.9%25%20and%20%5Cu22655%25%29%20and%20country%20income%20levels.%5CnRESULTS%3A%20Questions%20about%20pandemic-related%20consequences%20for%20HIV%20care%20were%20completed%20by%20225%20%2895%25%29%20sites%20in%2042%20countries%20with%20low%20%28n%20%3D%2082%29%2C%20medium%20%28n%20%3D%2086%29%20and%20high%20%28n%20%3D%2057%29%20HIV%20prevalence%2C%20including%20low-%20%28n%20%3D%2057%29%2C%20lower-middle%20%28n%20%3D%2079%29%2C%20upper-middle%20%28n%20%3D%2039%29%20and%20high-%20%28n%20%3D%2050%29%20income%20countries.%20Most%20sites%20reported%20being%20subject%20to%20pandemic-related%20restrictions%20on%20travel%2C%20service%20provision%20or%20other%20operations%20%2875%25%29%2C%20and%20experiencing%20negative%20impacts%20%2876%25%29%20on%20clinic%20operations%2C%20including%20decreased%20hours%5C%2Fdays%2C%20reduced%20provider%20availability%2C%20clinic%20reconfiguration%20for%20COVID-19%20services%2C%20record-keeping%20interruptions%20and%20suspension%20of%20partner%20support.%20Almost%20all%20sites%20in%20low-prevalence%20and%20high-income%20countries%20reported%20increased%20use%20of%20telemedicine%20%2885%25%20and%20100%25%2C%20respectively%29%2C%20compared%20with%20less%20than%20half%20of%20sites%20in%20high-prevalence%20and%20lower-income%20settings.%20Few%20sites%20in%20high-prevalence%20settings%20%282%25%29%20reported%20suspending%20antiretroviral%20therapy%20%28ART%29%20clinic%20services%2C%20and%20many%20reported%20adopting%20mitigation%20strategies%20to%20support%20adherence%2C%20including%20multi-month%20dispensing%20of%20ART%20%2895%25%29%20and%20designating%20community%20ART%20pick-up%20points%20%2844%25%29.%20While%20few%20sites%20%285%25%29%20reported%20stockouts%20of%20first-line%20ART%20regimens%2C%2010-11%25%20reported%20stockouts%20of%20second-%20and%20third-line%20regimens%2C%20respectively%2C%20primarily%20in%20high-prevalence%20and%20lower-income%20settings.%20Interruptions%20in%20HIV%20viral%20load%20%28VL%29%20testing%20included%20suspension%20of%20testing%20%2822%25%29%2C%20longer%20turnaround%20times%20%2841%25%29%20and%20supply%5C%2Freagent%20stockouts%20%2822%25%29%2C%20but%20did%20not%20differ%20across%20settings.%5CnCONCLUSIONS%3A%20While%20many%20sites%20in%20high%20HIV%20prevalence%20settings%20and%20lower-income%20countries%20reported%20introducing%20or%20expanding%20measures%20to%20support%20treatment%20adherence%20and%20continuity%20of%20care%2C%20the%20COVID-19%20pandemic%20resulted%20in%20disruptions%20to%20VL%20testing%20and%20ART%20supply%20chains%20that%20may%20negatively%20affect%20the%20quality%20of%20HIV%20care%20in%20these%20settings.%22%2C%22date%22%3A%222022-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.26036%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236504431%22%2C%22PMCID%22%3A%22PMC9742047%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A22%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22L7N5GCQJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Girardi%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGirardi%20E%2C%20Caro-Vega%20Y%2C%20Cozzi-Lepri%20A%2C%20Musaazi%20J%2C%20Carriquiry%20G%2C%20Castelnuovo%20B%2C%20et%20al.%20The%20contribution%20of%20late%20HIV%20diagnosis%20on%20the%20occurrence%20of%20HIV-associated%20tuberculosis.%20AIDS.%202022%20Nov%2015%3B36%2814%29%3A2005%26%23×2013%3B13.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003321%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000003321%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035848588.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20contribution%20of%20late%20HIV%20diagnosis%20on%20the%20occurrence%20of%20HIV-associated%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Girardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Cozzi-Lepri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Musaazi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Gori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yukari%20C.%22%2C%22lastName%22%3A%22Manabe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22D%27arminio%20Monforte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Mussini%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20describe%20the%20timing%20of%20tuberculosis%20%28TB%29%20presentation%20in%20relation%20to%20diagnosis%20of%20HIV%20infection%20and%20antiretroviral%20therapy%20%28ART%29%20initiation%20and%20to%20evaluate%20whether%20the%20established%20impact%20from%20late%20presentation%20to%20care%20and%20late%20initiation%20of%20ART%20on%20the%20risk%20of%20TB%20is%20retained%20beyond%20the%20observation%20period%20of%20clinical%20trials.%5CnDESIGN%3A%20We%20used%20marginal%20structural%20models%20to%20emulate%20a%20clinical%20trial%20with%20up%20to%205%5Cu200ayears%20of%20follow-up%20to%20evaluate%20the%20impact%20of%20late%20initiation%20on%20TB%20risk.%5CnMETHODS%3A%20People%20with%20HIV%20%28PWH%29%20were%20enrolled%20from%202007%20to%202016%20in%20observational%20cohorts%20from%20Uganda%2C%20Peru%2C%20Mexico%20and%20Italy.%20The%20risk%20of%20TB%20was%20compared%20in%20LP%20%28accessing%20care%20with%20CD4%20%2B%20cell%20count%20%5Cu2264350%5Cu200acells%5C%2F%5Cu03bcl%29%20vs.%20nonlate%20presentation%20using%20survival%20curves%20and%20a%20weighted%20Cox%20regression.%20We%20emulated%20two%20strategies%3A%20initiating%20ART%20with%20CD4%20%2B%20cell%20count%20less%20than%20350%5Cu200acells%5C%2F%5Cu03bcl%20vs.%20CD4%20%2B%20cell%20count%20at%20least%20350%5Cu200acells%5C%2F%5Cu03bcl%20%28late%20initiation%29.%20We%20estimated%20TB%20attributable%20risk%20and%20population%20attributable%20fraction%20up%20to%205%5Cu200ayears%20from%20the%20emulated%20date%20of%20randomization.%5CnRESULTS%3A%20Twenty%20thousand%20one%20hundred%20and%20twelve%20patients%20and%201936%20TB%20cases%20were%20recorded.%20Over%2050%25%20of%20TB%20cases%20were%20diagnosed%20at%20presentation%20for%20HIV%20care.%20More%20than%2050%25%20of%20the%20incident%20cases%20of%20TB%20after%20ART%20initiation%20were%20attributable%20to%20late%20presentation%3B%20nearly%2070%25%20of%20TB%20cases%20during%20the%20first%20year%20of%20follow-up%20could%20be%20attributed%20to%20late%20presentation%20and%20more%20than%2050%25%2C%205%20years%20after%20first%20attending%20HIV%20care.%5CnCONCLUSION%3A%20Late%20presentation%20accounted%20for%20a%20large%20share%20of%20TB%20cases.%20Delaying%20ART%20initiation%20was%20detrimental%20for%20incident%20TB%20rates%2C%20and%20the%20impact%20of%20late%20presentation%20persisted%20up%20to%205%5Cu200ayears%20from%20HIV%20care%20entry.%22%2C%22date%22%3A%222022-11-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000003321%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235848588%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A23%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22S266LR8R%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Sobral%20et%20al.%22%2C%22parsedDate%22%3A%222022-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSobral%20L%2C%20Arriaga%20MB%2C%20Souza%20AB%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Sales%20C%2C%20et%20al.%20Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study.%20Lancet%20Reg%20Health%20Am.%202022%20Nov%3B15%3A100358.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2022.100358%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036438860%3B%20PubMed%20Central%20PMCID%3A%20PMC9696515.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20losses%20in%20the%20tuberculosis%20infection%20cascade%20of%20care%20among%20children%20and%20adolescent%20contacts%20of%20pulmonary%20tuberculosis%20cases%3A%20A%20Brazilian%20multi-centre%20longitudinal%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciana%22%2C%22lastName%22%3A%22Sobral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caio%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Cristina%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Approximately%2010%25%20of%20the%20global%20tuberculosis%20%28TB%29%20burden%20is%20in%20children.%20Identification%2C%20diagnosis%2C%20and%20early%20treatment%20of%20Mycobacterium%20tuberculosis%20infection%20%28TBI%29%20is%20critical%20to%20prevent%20progression%20to%20TB%20in%20children.%20The%20risk%20of%20TB%2C%20including%20severe%20disease%2C%20is%20highest%20in%20children%20%26lt%3B5%20years%20old.%20We%20evaluated%20the%20cascade%20of%20TBI%20care%20among%20child%20and%20adolescent%20TB%20contacts%20to%20identify%20factors%20associated%20with%20losses%20in%20the%20cascade.%5CnMETHODS%3A%20Close%20contacts%20%5Cu2264%2018%20years%20old%20of%20pulmonary%20TB%20patients%20enrolled%20between%202015%20and%202019%20in%20a%20multi-centre%20Brazilian%20cohort%20were%20followed%20for%20up%20to%2024%20months%20and%20classified%20according%20to%20age%20groups%3A%20%26lt%3B5%20years%2C%205-9%20years%2C%2010-14%20years%20and%2015-18%20years.%20Data%20on%20clinical%20investigation%2C%20radiographic%20examination%2C%20IGRA%20testing%20at%20baseline%20and%206%20months%2C%20initiation%20and%20completion%20of%20TB%20preventive%20treatment%20%28TPT%29%20were%20collected.%20Multivariable%20regression%20analyses%20identified%20factors%20associated%20with%20TBI%20and%20losses%20in%20the%20cascade%20of%20care%20in%20children%20and%20adolescents.%5CnFINDINGS%3A%20Among%201795%20TB%20contacts%20initially%20identified%2C%20530%20%2829%5Cu00b75%25%29%20were%20%5Cu226418%20years%20old.%20Losses%20for%20all%20steps%20in%20the%20cascade%20were%20especially%20high%20in%20children%20%26lt%3B5%20years%20old%20%2888%25%29%20because%20at%20this%20age%20all%20contacts%20are%20recommended%20to%20initiate%20TPT.%20As%20a%20proportion%20of%20all%20children%2C%20completion%20of%20TPT%20was%20low%20%28between%2010%25%20and%2013%25%29%20in%20all%20age-groups.%20Furthermore%2C%20multivariable%20regression%20revealed%20that%20younger%20age%20of%20contacts%20and%20TB%20index%20cases%20who%20were%20female%2C%20had%20pulmonary%20cavities%2C%20and%20persistent%20cough%20were%20independently%20associated%20with%20losses%20in%20the%20cascade%20of%20care%20among%20persons%20%5Cu226418%20years%20old.%5CnINTERPRETATION%3A%20Losses%20in%20the%20TBI%20cascade%20were%20the%20highest%20among%20children%20%26lt%3B5%20years%2C%20which%20was%20the%20group%20at%20highest%20risk%20for%20TB%20among%20the%20four%20age%20groups.%20The%20findings%20highlight%20the%20need%20to%20improve%20screening%2C%20initiation%2C%20and%20completion%20of%20TPT%20of%20young%20children%20who%20are%20close%20contacts%20of%20people%20with%20TB%20in%20Brazil.%5CnFUNDING%3A%20National%20Institutes%20of%20Allergy%20and%20Infectious%20Diseases.%22%2C%22date%22%3A%222022-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2022.100358%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236438860%22%2C%22PMCID%22%3A%22PMC9696515%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A22%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22IYFS3M3U%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Wada%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BWada%20PY%2C%20Kim%20A%2C%20Jayathilake%20K%2C%20Duda%20SN%2C%20Abo%20Y%2C%20Althoff%20KN%2C%20et%20al.%20Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016.%20AIDS%20Patient%20Care%20STDS.%202022%20Sep%3B36%289%29%3A343%26%23×2013%3B55.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1089%5C%2Fapc.2022.0042%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036037010%3B%20PubMed%20Central%20PMCID%3A%20PMC9514598.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Site-Level%20Comprehensiveness%20of%20Care%20Is%20Associated%20with%20Individual%20Clinical%20Retention%20Among%20Adults%20Living%20with%20HIV%20in%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%2C%20a%20Global%20HIV%20Cohort%20Collaboration%2C%202000-2016%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20Y.%22%2C%22lastName%22%3A%22Wada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karu%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yao%22%2C%22lastName%22%3A%22Abo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steve%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%20Jiun%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22Retention%20in%20care%20%28RIC%29%20reduces%20HIV%20transmission%20and%20associated%20morbidity%20and%20mortality.%20We%20examined%20whether%20delivery%20of%20comprehensive%20services%20influenced%20individual%20RIC%20within%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20network.%20We%20collected%20site%20data%20through%20IeDEA%20assessments%201.0%20%282000-2009%29%20and%202.0%20%282010-2016%29.%20Each%20site%20received%20a%20comprehensiveness%20score%20for%20service%20availability%20%281%5Cu2009%3D%5Cu2009present%2C%200%5Cu2009%3D%5Cu2009absent%29%2C%20with%20tallies%20ranging%20from%200%20to%207.%20We%20obtained%20individual-level%20cohort%20data%20for%20adults%20with%20at%20least%20one%20visit%20from%202000%20to%202016%20at%20sites%20responding%20to%20either%20assessment.%20Person-time%20was%20recorded%20annually%2C%20with%20RIC%20defined%20as%20completing%20two%20visits%20at%20least%2090%20days%20apart%20in%20each%20calendar%20year.%20Multivariable%20modified%20Poisson%20regression%20clustered%20by%20site%20yielded%20risk%20ratios%20and%20predicted%20probabilities%20for%20individual%20RIC%20by%20comprehensiveness.%20Among%20347%2C060%20individuals%20in%20care%20at%20122%20sites%20with%201%2C619%2C558%20person-years%20of%20follow-up%2C%2069.8%25%20of%20person-time%20was%20retained%20in%20care%2C%20varying%20by%20region%20from%2053.8%25%20%28Asia-Pacific%29%20to%2082.7%25%20%28East%20Africa%29%3B%20RIC%20improved%20by%20about%202%25%20per%20year%20from%202000%20to%202016%20%28p%5Cu2009%3D%5Cu20090.012%29.%20Every%20site%20provided%20CD4%2B%20count%20testing%2C%20and%20%26gt%3B90%25%20of%20individuals%20received%20care%20at%20sites%20that%20provided%20combination%20antiretroviral%20therapy%20adherence%20measures%2C%20prevention%20of%20mother-to-child%20transmission%2C%20tuberculosis%20screening%2C%20HIV-related%20prevention%2C%20and%20community%20tracing%20services.%20In%20adjusted%20models%2C%20individuals%20at%20sites%20with%20more%20comprehensive%20services%20had%20higher%20probabilities%20of%20RIC%20%280.71%2C%200.74%2C%20and%200.83%20for%20scores%205%2C%206%2C%20and%207%2C%20respectively%3B%20p%5Cu2009%3D%5Cu20090.019%29.%20Within%20IeDEA%2C%20greater%20site-level%20comprehensiveness%20of%20services%20was%20associated%20with%20improved%20individual%20RIC.%20Much%20work%20remains%20in%20exploring%20this%20relationship%2C%20which%20may%20inform%20HIV%20clinical%20practice%20and%20health%20systems%20planning.%22%2C%22date%22%3A%222022-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1089%5C%2Fapc.2022.0042%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236037010%22%2C%22PMCID%22%3A%22PMC9514598%22%2C%22ISSN%22%3A%221557-7449%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22BKWMNSHS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22N%5Cu00fa%5Cu00f1ez%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BN%26%23xFA%3B%26%23xF1%3Bez%20I%2C%20Crabtree-Ramirez%20B%2C%20Shepherd%20BE%2C%20Sterling%20TR%2C%20Cahn%20P%2C%20Veloso%20VG%2C%20et%20al.%20Late-onset%20opportunistic%20infections%20while%20receiving%20anti-retroviral%20therapy%20in%20Latin%20America%3A%20burden%20and%20risk%20factors.%20Int%20J%20Infect%20Dis.%202022%20Sep%3B122%3A469%26%23×2013%3B75.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.06.041%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.06.041%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035768025%3B%20PubMed%20Central%20PMCID%3A%20PMC9851270.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Late-onset%20opportunistic%20infections%20while%20receiving%20anti-retroviral%20therapy%20in%20Latin%20America%3A%20burden%20and%20risk%20factors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isaac%22%2C%22lastName%22%3A%22N%5Cu00fa%5Cu00f1ez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20The%20aim%20of%20this%20study%20was%20to%20describe%20the%20incidence%2C%20clinical%20characteristics%2C%20and%20risk%20factors%20of%20late-onset%20opportunistic%20infections%20%28LOI%29%20in%20people%20who%20live%20with%20HIV%20%28PWLHA%29%20within%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20including%20treatment-naive%20PWLHA%20enrolled%20at%20seven%20sites%20%28Argentina%2C%20Brazil%2C%20Chile%2C%20Peru%2C%20Mexico%2C%20and%20two%20sites%20in%20Honduras%29.%20Follow-up%20began%20at%206%20months%20after%20treatment%20started.%20Outcomes%20were%20LOI%2C%20loss%20to%20follow-up%2C%20and%20death.%20We%20used%20a%20Cox%20proportional%20hazards%20model%20and%20a%20competing%20risks%20model%20to%20evaluate%20risk%20factors.%5CnRESULTS%3A%20A%20total%20of%2010%2C583%20patients%20were%20included.%20Median%20follow%20up%20was%20at%205.4%20years.%20LOI%20occurred%20in%20895%20%288.4%25%29%20patients.%20Median%20time%20to%20opportunistic%20infection%20was%202.1%20years.%20The%20most%20common%20infections%20were%20tuberculosis%20%2839%25%29%2C%20esophageal%20candidiasis%20%2810%25%29%2C%20and%20Pneumocystis%20jirovecii%20%28P.%20jirovecii%29%20pneumonia%20%2810%25%29.%20Death%20occurred%20in%20576%20%285.4%25%29%20patients%2C%20and%203021%20%2828.5%25%29%20patients%20were%20lost%20to%20follow-up.%20A%20protease%20inhibitor-based%20regimen%20%28hazard%20ratio%201.25%29%2C%20AIDS-defining%20events%20during%20the%20first%206%20months%20of%20antiretroviral-treatment%20%28hazard%20ratio%202.12%29%2C%20starting%20antiretroviral-treatment%20in%20earlier%20years%20%28hazard%20ratio%201.52%20for%202005%20vs%202010%29%2C%20and%20treatment%20switch%20%28hazard%20ratio%201.31%29%20were%20associated%20with%20a%20higher%20risk%20of%20LOI.%5CnCONCLUSION%3A%20LOI%20occurred%20in%20nearly%20one%20in%2010%20patients.%20People%20with%20risk%20factors%20could%20benefit%20from%20closer%20follow-up.%22%2C%22date%22%3A%222022-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.06.041%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235768025%22%2C%22PMCID%22%3A%22PMC9851270%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A20%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22FFW5IAYE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Wada%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BWada%20PY%2C%20Costa%20AG%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Souza%20AB%2C%20Rocha%20MS%2C%20et%20al.%20Possible%20sex%20difference%20in%20latent%20tuberculosis%20infection%20risk%20among%20close%20tuberculosis%20contacts.%20Int%20J%20Infect%20Dis.%202022%20Sep%3B122%3A685%26%23×2013%3B92.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.07.031%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2022.07.031%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035843494%3B%20PubMed%20Central%20PMCID%3A%20PMC10041676.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Possible%20sex%20difference%20in%20latent%20tuberculosis%20infection%20risk%20among%20close%20tuberculosis%20contacts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20Y.%22%2C%22lastName%22%3A%22Wada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allyson%20G.%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29%20Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20More%20men%20than%20women%20develop%20and%20die%20of%20tuberculosis%20%28TB%29.%20Fewer%20data%20exist%20on%20sex%20differences%20in%20latent%20TB%20infection%20%28LTBI%29.%20We%20assessed%20for%20potential%20sex%20differences%20in%20LTBI%20acquisition%20among%20close%20TB%20contacts.%5CnMETHODS%3A%20Regional%20Prospective%20Observational%20Research%20for%20TB-Brazil%20is%20an%20observational%20multi-center%20cohort%20of%20individuals%20with%20culture-confirmed%20pulmonary%20TB%20and%20their%20close%20contacts.%20Participants%20were%20enrolled%20from%20five%20sites%20in%20Brazil%20from%20June%202015%20-%20June%202019.%20Close%20contacts%20were%20followed%20for%2024%20months%20after%20enrollment%2C%20with%20LTBI%20defined%20as%20a%20positive%20interferon-%5Cu03b3%20release%20assay%20%28IGRA%3B%20QuantiFERON%203rd%20or%204th%20generation%29%20at%20baseline%20or%206%20months.%20We%20performed%20univariate%2C%20bivariate%2C%20and%20multivariable%20logistic%20regression%20and%20propensity-score%20weighted%20models%20to%20assess%20odds%20ratios%20%28OR%29%20and%2095%25%20confidence%20intervals%20%28CI%29%20for%20LTBI%20acquisition%20by%20birth%20sex%20among%20close%20contacts.%5CnRESULTS%3A%20Of%201093%2C%20504%20%2846%25%29%20female%20close%20contacts%20were%20IGRA%20positive%20compared%20to%20295%20of%20745%20%2840%25%29%20men.%20The%20unadjusted%20OR%20for%20IGRA%20positivity%20among%20women%20vs%20men%20was%201.31%20%2895%25%20CI%3A%201.08-1.58%29.%20Bivariate%20adjustments%20yielded%20ORs%20in%20women%20vs%20men%20ranging%20from%201.19%20to%201.33%20%28P-value%20range%3A%20%26lt%3B0.01-0.07%29.%20Multivariable%20regression%20and%20weighted%20models%20yielded%20similar%20ORs%20in%20women%20vs%20men%2C%20of%201.14%20%2895%25%20CI%3A%200.92-1.41%29%20and%201.15%20%2895%25%20CI%3A%200.94-1.40%29%2C%20respectively.%5CnCONCLUSION%3A%20The%20point%20estimate%20for%20LTBI%20among%20close%20TB%20contacts%20in%20Brazil%20was%20higher%20in%20women%2C%20though%20less%20pronounced%20in%20multivariable%20models.%20If%20the%20sex%20difference%20in%20LTBI%20is%20confirmed%20in%20additional%20settings%2C%20studies%20of%20possible%20underlying%20differences%20in%20socio-behavioral%20factors%20or%20TB%20pathogenesis%20are%20warranted.%22%2C%22date%22%3A%222022-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2022.07.031%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235843494%22%2C%22PMCID%22%3A%22PMC10041676%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A21%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22R2CLKZMG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Edmonds%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEdmonds%20A%2C%20Brazier%20E%2C%20Musick%20BS%2C%20Yotebieng%20M%2C%20Humphrey%20J%2C%20Abuogi%20LL%2C%20et%20al.%20Clinical%20and%20programmatic%20outcomes%20of%20HIV-exposed%20infants%20enrolled%20in%20care%20at%20geographically%20diverse%20clinics%2C%201997-2021%3A%20A%20cohort%20study.%20PLoS%20Med.%202022%20Sep%3B19%289%29%3Ae1004089.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004089%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1004089%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036107857%3B%20PubMed%20Central%20PMCID%3A%20PMC9477260.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20programmatic%20outcomes%20of%20HIV-exposed%20infants%20enrolled%20in%20care%20at%20geographically%20diverse%20clinics%2C%201997-2021%3A%20A%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%20L.%22%2C%22lastName%22%3A%22Abuogi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adebola%22%2C%22lastName%22%3A%22Adedimeji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Keiser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malango%22%2C%22lastName%22%3A%22Msukwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelle%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Although%201%5Cu00b73%20million%20women%20with%20HIV%20give%20birth%20annually%2C%20care%20and%20outcomes%20for%20HIV-exposed%20infants%20remain%20incompletely%20understood.%20We%20analyzed%20programmatic%20and%20health%20indicators%20in%20a%20large%2C%20multidecade%20global%20dataset%20of%20linked%20mother-infant%20records%20from%20clinics%20and%20programs%20associated%20with%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%5CnMETHODS%20AND%20FINDINGS%3A%20HIV-exposed%20infants%20were%20eligible%20for%20this%20retrospective%20cohort%20analysis%20if%20enrolled%20at%20%26lt%3B18%20months%20at%20198%20clinics%20in%2010%20countries%20across%205%20IeDEA%20regions%3A%20East%20Africa%20%28EA%29%2C%20Central%20Africa%20%28CA%29%2C%20West%20Africa%20%28WA%29%2C%20Southern%20Africa%20%28SA%29%2C%20and%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20%28CCASAnet%29.%20We%20estimated%20cumulative%20incidences%20of%20DNA%20PCR%20testing%2C%20loss%20to%20follow-up%20%28LTFU%29%2C%20HIV%20diagnosis%2C%20and%20death%20through%2024%20months%20of%20age%20using%20proportional%20subdistribution%20hazard%20models%20accounting%20for%20competing%20risks.%20Competing%20risks%20were%20transfer%2C%20care%20withdrawal%2C%20and%20confirmation%20of%20negative%20HIV%20status%2C%20along%20with%20LTFU%20and%20death%2C%20when%20not%20the%20outcome%20of%20interest.%20In%20CA%20and%20EA%2C%20we%20quantified%20associations%20between%20maternal%5C%2Finfant%20characteristics%20and%20each%20outcome.%20A%20total%20of%2082%2C067%20infants%20%2847%2C300%20EA%2C%2010%2C699%20CA%2C%206%2C503%20WA%2C%2015%2C770%20SA%2C%201%2C795%20CCASAnet%29%20born%20from%201997%20to%202021%20were%20included.%20Maternal%20antiretroviral%20therapy%20%28ART%29%20use%20during%20pregnancy%20ranged%20from%2065%5Cu00b76%25%20%28CCASAnet%29%20to%2089%5Cu00b75%25%20%28EA%29%2C%20with%20improvements%20in%20all%20regions%20over%20time.%20Twenty-four-month%20cumulative%20incidences%20varied%20widely%20across%20regions%2C%20ranging%20from%2012%5Cu00b73%25%20%2895%25%20confidence%20limit%20%5BCL%5D%2C%2011%5Cu00b72%25%2C13%5Cu00b75%25%29%20in%20WA%20to%2094%5Cu00b78%25%20%2895%25%20CL%2C%2094%5Cu00b76%25%2C95%5Cu00b71%25%29%20in%20EA%20for%20DNA%20PCR%20testing%3B%2056%5Cu00b72%25%20%2895%25%20CL%2C%2055%5Cu00b72%25%2C57%5Cu00b71%25%29%20in%20EA%20to%2098%5Cu00b75%25%20%2895%25%20CL%2C%2098%5Cu00b73%25%2C98%5Cu00b77%25%29%20in%20WA%20for%20LTFU%3B%201%5Cu00b79%25%20%2895%25%20CL%2C%201%5Cu00b76%25%2C2%5Cu00b73%25%29%20in%20WA%20to%2010%5Cu00b73%25%20%2895%25%20CL%2C%209%5Cu00b77%25%2C10%5Cu00b79%25%29%20in%20EA%20for%20HIV%20diagnosis%3B%20and%200%5Cu00b75%25%20%2895%25%20CL%2C%200%5Cu00b72%25%2C1%5Cu00b70%25%29%20in%20CCASAnet%20to%204%5Cu00b77%25%20%2895%25%20CL%2C%204%5Cu00b74%25%2C5%5Cu00b70%25%29%20in%20EA%20for%20death.%20Although%20infant%20retention%20did%20not%20improve%2C%20HIV%20diagnosis%20and%20death%20decreased%20over%20time%2C%20and%20in%20EA%2C%20the%20cumulative%20incidence%20of%20HIV%20diagnosis%20decreased%20substantially%2C%20declining%20to%202%5Cu00b79%25%20%2895%25%20CL%2C%201%5Cu00b75%25%2C5%5Cu00b74%25%29%20in%202020.%20Maternal%20ART%20was%20associated%20with%20decreased%20infant%20mortality%20%28subdistribution%20hazard%20ratio%20%5BsdHR%5D%2C%200%5Cu00b765%3B%2095%25%20CL%2C%200%5Cu00b747%2C0%5Cu00b791%20in%20EA%2C%20and%20sdHR%2C%200%5Cu00b751%3B%2095%25%20CL%2C%200%5Cu00b736%2C0%5Cu00b774%20in%20CA%29%20and%20HIV%20diagnosis%20%28sdHR%2C%200%5Cu00b740%3B%2095%25%20CL%2C%200%5Cu00b731%2C0%5Cu00b750%20in%20EA%2C%20and%20sdHR%2C%200%5Cu00b741%3B%2095%25%20CL%2C%200%5Cu00b731%2C0%5Cu00b754%20in%20CA%29.%20Study%20limitations%20include%20potential%20misclassification%20of%20outcomes%20in%20real-world%20service%20delivery%20data%20and%20possible%20nonrepresentativeness%20of%20IeDEA%20sites%20and%20the%20population%20of%20HIV-exposed%20infants%20they%20serve.%5CnCONCLUSIONS%3A%20While%20there%20was%20marked%20regional%20and%20temporal%20heterogeneity%20in%20clinical%20and%20programmatic%20outcomes%2C%20infant%20LTFU%20was%20high%20across%20all%20regions%20and%20time%20periods.%20Further%20efforts%20are%20needed%20to%20keep%20HIV-exposed%20infants%20in%20care%20to%20receive%20essential%20services%20to%20reduce%20HIV%20infection%20and%20mortality.%22%2C%22date%22%3A%222022-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1004089%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236107857%22%2C%22PMCID%22%3A%22PMC9477260%22%2C%22ISSN%22%3A%221549-1676%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A21%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22LZEERED7%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Giraldo%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGiraldo%20L%2C%20Fink%20V%2C%20Cahn%20F%2C%20Aristegui%20I%2C%20Caceres%20B%2C%20Sued%20O%2C%20et%20al.%20Design%20and%20Development%20of%20an%20Electronic%20Health%20Record%20According%20to%20Argentine%20Gender%20Identity%20Law.%20Stud%20Health%20Technol%20Inform.%202022%20Jun%206%3B290%3A995%26%23×2013%3B6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220235%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220235%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035673173%3B%20PubMed%20Central%20PMCID%3A%20PMC9968499.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Design%20and%20Development%20of%20an%20Electronic%20Health%20Record%20According%20to%20Argentine%20Gender%20Identity%20Law%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liliana%22%2C%22lastName%22%3A%22Giraldo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florencia%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e9s%22%2C%22lastName%22%3A%22Aristegui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betiana%22%2C%22lastName%22%3A%22Caceres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Sued%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%5D%2C%22abstractNote%22%3A%22Health%20information%20systems%20face%20the%20challenge%20of%20collecting%20data%20on%20patients%26%23039%3B%20gender%20identity.%20The%20absence%20of%20this%20information%20may%20lead%20the%20patients%20to%20situations%20of%20vulnerability%20and%20discrimination.%20The%20objective%20of%20this%20study%20is%20to%20describe%20the%20process%20of%20designing%20and%20developing%20an%20Electronic%20Health%20Record%20according%20to%20the%20Argentine%20Gender%20Identity%20Law.%20This%20health%20record%20allows%20clinics%20to%20record%20legal%20names%20and%20surnames%2C%20other%20social%20names%2C%20gender%20identity%2C%20sex%20at%20birth%2C%20and%20legal%20sex.%22%2C%22date%22%3A%222022-06-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3233%5C%2FSHTI220235%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235673173%22%2C%22PMCID%22%3A%22PMC9968499%22%2C%22ISSN%22%3A%221879-8365%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A19%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22T6EA73R5%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Giraldo%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGiraldo%20L%2C%20Fink%20V%2C%20Cahn%20F%2C%20Caceres%20B%2C%20Sued%20O%2C%20Duda%20S%2C%20et%20al.%20Redesigning%20an%20Electronic%20Health%20Record%20in%20Argentina%20to%20Improve%20Comprehensive%20Health%20Care%20and%20Clinical%20Research.%20Stud%20Health%20Technol%20Inform.%202022%20Jun%206%3B290%3A993%26%23×2013%3B4.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220234%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FSHTI220234%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035673172%3B%20PubMed%20Central%20PMCID%3A%20PMC9943003.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Redesigning%20an%20Electronic%20Health%20Record%20in%20Argentina%20to%20Improve%20Comprehensive%20Health%20Care%20and%20Clinical%20Research%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liliana%22%2C%22lastName%22%3A%22Giraldo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florencia%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betiana%22%2C%22lastName%22%3A%22Caceres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Omar%22%2C%22lastName%22%3A%22Sued%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%5D%2C%22abstractNote%22%3A%22Updating%20electronic%20health%20record%20systems%20to%20meet%20new%20clinic%20needs%20and%20government%20regulations%20presents%20an%20ongoing%20challenge%20for%20health%20care%20organizations.%20To%20redesign%20an%20existing%20system%20for%20two%20HIV%20clinics%20in%20Argentina%2C%20we%20employed%20a%20three-phase%20approach%20of%20exploration%2C%20participatory%20design%2C%20and%20prototyping.%20The%20process%20and%20resulting%20architecture%20of%20the%20HIV-centered%20%26quot%3BRedClin%26quot%3B%20electronic%20health%20record%20may%20inform%20electronic%20health%20records%20at%20other%20clinics%20in%20Latin%20America%20and%20worldwide.%22%2C%22date%22%3A%222022-06-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3233%5C%2FSHTI220234%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235673172%22%2C%22PMCID%22%3A%22PMC9943003%22%2C%22ISSN%22%3A%221879-8365%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A20%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22CDVNLP47%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Eden%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BEden%20SK%2C%20Li%20C%2C%20Shepherd%20BE.%20Nonparametric%20estimation%20of%20Spearman%26%23×2019%3Bs%20rank%20correlation%20with%20bivariate%20survival%20data.%20Biometrics.%202022%20Jun%3B78%282%29%3A421%26%23×2013%3B34.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbiom.13453%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbiom.13453%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033704769%3B%20PubMed%20Central%20PMCID%3A%20PMC8453584.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nonparametric%20estimation%20of%20Spearman%27s%20rank%20correlation%20with%20bivariate%20survival%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Svetlana%20K.%22%2C%22lastName%22%3A%22Eden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22We%20study%20rank-based%20approaches%20to%20estimate%20the%20correlation%20between%20two%20right-censored%20variables.%20With%20end-of-study%20censoring%2C%20it%20is%20often%20impossible%20to%20nonparametrically%20identify%20the%20complete%20bivariate%20survival%20distribution%2C%20and%20therefore%20it%20is%20impossible%20to%20nonparametrically%20compute%20Spearman%26%23039%3Bs%20rank%20correlation.%20As%20a%20solution%2C%20we%20propose%20two%20measures%20that%20can%20be%20nonparametrically%20estimated.%20The%20first%20measure%20is%20Spearman%26%23039%3Bs%20correlation%20in%20a%20restricted%20region.%20The%20second%20measure%20is%20Spearman%26%23039%3Bs%20correlation%20for%20an%20altered%20but%20estimable%20joint%20distribution.%20We%20describe%20population%20parameters%20for%20these%20measures%20and%20illustrate%20how%20they%20are%20similar%20to%20and%20different%20from%20the%20overall%20Spearman%26%23039%3Bs%20correlation.%20We%20propose%20consistent%20estimators%20of%20these%20measures%20and%20study%20their%20performance%20through%20simulations.%20We%20illustrate%20our%20methods%20with%20a%20study%20assessing%20the%20correlation%20between%20the%20time%20to%20viral%20failure%20and%20the%20time%20to%20regimen%20change%20among%20persons%20living%20with%20HIV%20in%20Latin%20America%20who%20start%20antiretroviral%20therapy.%22%2C%22date%22%3A%222022-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fbiom.13453%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233704769%22%2C%22PMCID%22%3A%22PMC8453584%22%2C%22ISSN%22%3A%221541-0420%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A17%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22EEFGID3V%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Coelho%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCoelho%20LE%2C%20Jenkins%20CA%2C%20Shepherd%20BE%2C%20Pape%20JW%2C%20Mejia%20Cordero%20F%2C%20Padgett%20D%2C%20et%20al.%20Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America.%20Lancet%20Reg%20Health%20Am.%202022%20Apr%3B8%3A100173.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100173%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035528706%3B%20PubMed%20Central%20PMCID%3A%20PMC9070999.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight%20gain%20post-ART%20in%20HIV%2B%20Latinos%5C%2Fas%20differs%20in%20the%20USA%2C%20Haiti%2C%20and%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree%20Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20R.%22%2C%22lastName%22%3A%22Koethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%20C.%22%2C%22lastName%22%3A%22Marconi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Phyllis%20C.%22%2C%22lastName%22%3A%22Tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20L.%22%2C%22lastName%22%3A%22Willig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Colasanti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%20M.%22%2C%22lastName%22%3A%22Crane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Horberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angel%22%2C%22lastName%22%3A%22Mayor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20An%20obesity%20epidemic%20has%20been%20documented%20among%20adult%20Latinos%5C%2Fas%20in%20Latin%20America%20and%20the%20United%20States%20%28US%29%3B%20however%2C%20little%20is%20known%20about%20obesity%20among%20Latinos%5C%2Fas%20with%20HIV%20%28PWH%29.%20Moreover%2C%20Latinos%5C%2Fas%20PWH%20in%20the%20US%20may%20have%20different%20weight%20trajectories%20than%20those%20in%20Latin%20America%20due%20to%20the%20cultural%20and%20environmental%20contexts.%20We%20assessed%20weight%20and%20body%20mass%20index%20%28BMI%29%20trajectories%20among%20PWH%20initiating%20antiretroviral%20therapy%20%28ART%29%20across%205%20countries%20in%20Latin%20America%20and%20the%20Caribbean%20and%20the%20US.%5CnMETHODS%3A%20ART-na%5Cu00ffve%20PWH%20%5Cu226518%20years%20old%2C%20enrolled%20in%20Brazil%2C%20Honduras%2C%20Mexico%2C%20Peru%2C%20and%20Haiti%20%28sites%20within%20CCA-SAnet%29%20and%20the%20US%20%28NA-ACCORD%29%20starting%20ART%20between%202000%20and%202017%2C%20with%20at%20least%20one%20weight%20measured%20after%20ART%20initiation%20were%20included.%20Participants%20were%20classified%20according%20to%20site%5C%2Fethnicity%20as%3A%20Latinos%5C%2Fas%20in%20US%2C%20non-Latinos%5C%2Fas%20in%20US%2C%20Haitians%2C%20and%20Latinos%5C%2Fas%20in%20Latin%20America.%20Generalized%20least%20squares%20models%20were%20used%20to%20assess%20trends%20in%20weight%20and%20BMI.%20Models%20estimating%20probabilities%20of%20becoming%20overweight%5C%2Fobese%20%28BMI%20%5Cu226525%20kg%5C%2Fm2%29%20and%20of%20becoming%20obese%20%28BMI%20%5Cu226530%20kg%5C%2Fm2%29%20post%20ART%20initiation%20for%20males%20and%20females%20were%20fit%20using%20generalized%20estimating%20equations%20with%20a%20logit%20link%20and%20an%20independence%20working%20correlation%20structure.%5CnFINDINGS%3A%20Among%2059%2C207%20PWH%2C%209%25%20were%20Latinos%5C%2Fas%20from%20Latin%20America%2C%209%25%20Latinos%5C%2Fas%20from%20the%20US%2C%2068%25%20non-Latinos%5C%2Fas%20from%20the%20US%20and%2014%25%20were%20Haitian.%20At%20ART%20initiation%2C%2029%25%20were%20overweight%20and%2014%25%20were%20obese.%20Post-ART%20weight%20and%20BMI%20increases%20were%20steeper%20for%20Latinos%5C%2Fas%20in%20Latin%20America%20compared%20with%20other%20sites%5C%2Fethnicities%3B%20however%2C%20BMI%20at%203-years%20post%20ART%20remained%20lower%20compared%20to%20Latinos%5C%2Fas%20and%20non-Latinos%5C%2Fas%20in%20the%20US.%20Among%20females%2C%20at%203-years%20post%20ART%20initiation%20the%20greatest%20adjusted%20probability%20of%20obesity%20was%20found%20among%20non-Latinas%20in%20the%20US%20%2815%5Cu00b72%25%29%20and%20lowest%20among%20Latinas%20in%20Latin%20America%20%288.6%25%29.%20Among%20males%2C%20while%20starting%20with%20a%20lower%20BMI%2C%20Latinos%20in%20Latin%20America%20had%20the%20greatest%20adjusted%20probability%20of%20becoming%20overweight%20or%20obese%203-years%20post-ART%20initiation.%5CnINTERPRETATION%3A%20In%20the%20Americas%2C%20PWH%20gain%20substantial%20weight%20after%20ART%20initiation.%20Despite%20environmental%20and%20cultural%20differences%2C%20PWH%20in%20Latin%20America%2C%20Haiti%20and%20Latinos%20and%20non-Latinos%20in%20the%20US%20share%20similar%20BMI%20trajectories%20on%20ART%20and%20high%20probabilities%20of%20becoming%20overweight%20and%20obese%20over%20time.%20Multicohort%20studies%20are%20needed%20to%20better%20understand%20the%20burden%20of%20other%20metabolic%20syndrome%20components%20in%20PWH%20across%20different%20countries.%22%2C%22date%22%3A%222022-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100173%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235528706%22%2C%22PMCID%22%3A%22PMC9070999%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A18%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22I99FBBGX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Antimycobacterial%20Susceptibility%20Testing%20Group%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAntimycobacterial%20Susceptibility%20Testing%20Group.%20Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment.%20Eur%20Respir%20J.%202022%20Apr%3B59%284%29%3A2200166.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035422426%3B%20PubMed%20Central%20PMCID%3A%20PMC9059840.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Antimycobacterial%20Susceptibility%20Testing%20Group%22%7D%5D%2C%22abstractNote%22%3A%22Inappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%22%2C%22date%22%3A%222022-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235422426%22%2C%22PMCID%22%3A%22PMC9059840%22%2C%22ISSN%22%3A%221399-3003%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A19%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22WG3D4A6V%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Caro-Vega%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCaro-Vega%20Y%2C%20Rebeiro%20PF%2C%20Shepherd%20BE%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Crabtree-Ramirez%20B%2C%20Cesar%20C%2C%20et%20al.%20Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study.%20Lancet%20Reg%20Health%20Am.%202022%20Apr%3B8%3A100175.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lana.2021.100175%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035602655%3B%20PubMed%20Central%20PMCID%3A%20PMC9121860.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20effects%20of%20durability%20of%20immunosuppression%20in%20virologically%20suppressed%20ART-initiating%20persons%20with%20HIV%20in%20Latin%20America.%20A%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20Mendes%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padget%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Clinical%20outcomes%20are%20rarely%20studied%20in%20virologically%20suppressed%20people%20living%20with%20HIV%20%28PWH%29%20and%20incomplete%20CD4%20recovery.%20To%20explore%20whether%20time%20living%20with%20severe%20immunosuppression%20predict%20clinical%20outcomes%20better%20than%20baseline%20or%20time%20updated%20CD4%2C%20we%20estimated%20the%20association%20between%20cumulative%20percentage%20of%20time%20with%20CD4%20%26lt%3B200%20cells%5C%2F%5Cu03bcL%20during%20viral%20suppression%20%28VS%29%20%28%25tCD4%26lt%3B200%29%2C%20and%20mortality%20and%20comorbidities%20during%202000-2019.%5CnMETHODS%3A%20In%20a%20retrospective%20cohort%20analysis%2C%20we%20followed%20PWH%20initiating%20ART%20in%20Latin%20America%20from%20first%20VS%20%28HIV-RNA%26lt%3B200%20copies%5C%2F%5Cu03bcL%29%20to%20death%2C%20virological%20failure%20or%20loss%20to%20follow-up.%20We%20fit%20Cox%20models%20to%20estimate%20risk%20of%20death%20and%5C%2For%20AIDS-defining%20and%20serious%20non-AIDS-defining%20events%20%28ADE%20and%20SNADE%20-cancer%2C%20cardiovascular%2C%20liver%2C%20and%20renal%20diseases%29%20by%20%25tCD4%26lt%3B200%20%28continuous%20variable%29.%20We%20predicted%20survival%20probabilities%20for%20each%20event%20and%20calculated%20risks%20of%20hypothetical%20cases%20of%20different%20%25tCD4%26lt%3B200.%5CnFINDINGS%3A%20In%208%2C369%20patients%20with%2034%5Cu00b79%20months%20of%20follow-up%20%28median%2C%20IQR%3A%2016%5Cu00b77%2C%2069%5Cu00b71%29%2C%204%2C274%20%2851%25%29%20started%20ART%20with%20CD4%26lt%3B200%20cells%5C%2F%5Cu03bcL.%20Median%20%25tCD4%26lt%3B200%20was%200%25%20%28IQR%3A%200%2C%2015%25%29.%20We%20identified%20195%20%282%5Cu00b73%25%29%20deaths%20and%20584%20%287%5Cu00b72%25%29%20patients%20with%20ADE%5C%2FSNADE.%20For%20an%20increased%20%25tCD4%26lt%3B200%20of%2015%25%20%28e.g.%2C%2015%25%20vs.%200%25%29%2C%20the%20adjusted%20relative%20hazard%20%28aHR%29%20of%20death%20was%201%5Cu00b727%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%201%5Cu00b719%20-%201%5Cu00b735%29%2C%20of%20ADE%5C%2FSNADE%20was%201%5Cu00b713%20%2895%25CI%3A%201%5Cu00b709%20-%201%5Cu00b717%29%2C%20of%20SNADE%20was%200%5Cu00b796%20%2895%25CI%3A%200%5Cu00b789%20-%201%5Cu00b702%29%20and%20of%20death%5C%2FADE%5C%2FSNADE%20was%201%5Cu00b711%20%2895%25CI%3A%201%5Cu00b707%20-%201%5Cu00b714%29.%20Estimates%20were%20similar%20after%20adjusting%20for%20time%20updated%20CD4%20count.%5CnINTERPRETATION%3A%20In%20virologically%20suppressed%20PWH%2C%20increased%20time%20living%20with%20severe%20immunosuppression%20had%20an%20increased%20risk%20of%20death%20and%20ADE%5C%2FSNADE%20in%20this%20Latin%20American%20cohort%2C%20independently%20of%20time%20updated%20CD4%20count.%5CnFUNDING%3A%20This%20work%20was%20supported%20by%20the%20NIH-funded%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%2C%20U01AI069923%29%2C%20a%20member%20cohort%20of%20the%20International%20Epidemiologic%20Databases%20to%20Evaluate%20AIDS%20%28leDEA%29.%20This%20award%20is%20funded%20by%20the%20following%20institutes%3A%20Eunice%20Kennedy%20Shriver%20National%20Institute%20Of%20Child%20Health%20%26amp%3B%20Human%20Development%20%28NICHD%29%2C%20National%20Cancer%20Institute%20%28NCI%29%2C%20National%20Institute%20Of%20Allergy%20And%20Infectious%20Diseases%20%28NIAID%29%2C%20National%20Institute%20Of%20Mental%20Health%20%28NIMH%29%2C%20the%20National%20Heart%2C%20Lung%2C%20and%20Blood%20Institute%20%28NHLBI%29%2C%20the%20National%20Institute%20on%20Alcohol%20Abuse%20and%20Alcoholism%20%28NIAAA%29%2C%20the%20National%20Institute%20of%20Diabetes%20and%20Digestive%20and%20Kidney%20Diseases%20%28NIDDK%29%2C%20and%20the%20Fogarty%20International%20Center%20%28FIC%29.%20Specific%20funding%20was%20provided%20from%20the%20Fogarty%20International%20Center%20%28FIC%29%20for%20lead%20author%2C%20Yanink%20Caro-Vega%2C%20for%20the%20Fogarty-IeDEA%20Mentorship%20Program%20%28FIMP%29.%22%2C%22date%22%3A%222022-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lana.2021.100175%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235602655%22%2C%22PMCID%22%3A%22PMC9121860%22%2C%22ISSN%22%3A%222667-193X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A19%3A23Z%22%7D%7D%2C%7B%22key%22%3A%224D8B4PNE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Justice%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJustice%20AC%2C%20Goetz%20MB%2C%20Stewart%20CN%2C%20Hogan%20BC%2C%20Humes%20E%2C%20Luz%20PM%2C%20et%20al.%20Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem.%20Lancet%20HIV.%202022%20Apr%3B9%284%29%3Ae269%26%23×2013%3B80.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2822%2900003-0%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035218732%3B%20PubMed%20Central%20PMCID%3A%20PMC9128643.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20presentation%20of%20HIV%20among%20older%20individuals%3A%20a%20growing%20problem%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amy%20C.%22%2C%22lastName%22%3A%22Justice%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20B.%22%2C%22lastName%22%3A%22Goetz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cameron%20N.%22%2C%22lastName%22%3A%22Stewart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenna%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Humes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinei%22%2C%22lastName%22%3A%22Shamu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reena%22%2C%22lastName%22%3A%22Rajasuriar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%5D%2C%22abstractNote%22%3A%22Late%20presentation%20for%20care%20is%20a%20major%20impediment%20to%20the%20prevention%20and%20effective%20treatment%20of%20HIV%20infection.%20Older%20individuals%20are%20at%20increased%20risk%20of%20late%20presentation%2C%20represent%20a%20growing%20proportion%20of%20people%20with%20late%20presentation%2C%20and%20might%20require%20interventions%20tailored%20to%20their%20age%20group.%20We%20provide%20a%20summary%20of%20the%20literature%20published%20globally%20between%202016-21%20%28reporting%20data%20from%201984-2018%29%20and%20quantify%20the%20association%20of%20age%20with%20delayed%20presentation.%20Using%20the%20most%20common%20definitions%20of%20late%20presentation%20and%20older%20age%20from%20these%20earlier%20studies%2C%20we%20update%20this%20work%20with%20data%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%2C%20focusing%20on%20data%20from%202000-19%2C%20encompassing%20four%20continents.%20Finally%2C%20we%20consider%20how%20late%20presentation%20among%20older%20individuals%20might%20be%20more%20effectively%20addressed%20as%20electronic%20medical%20records%20become%20widely%20adopted.%22%2C%22date%22%3A%222022-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2822%2900003-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235218732%22%2C%22PMCID%22%3A%22PMC9128643%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A19%3A44Z%22%7D%7D%2C%7B%22key%22%3A%2252ERC49B%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Peetluk%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPeetluk%20LS%2C%20Rebeiro%20PF%2C%20Ridolfi%20FM%2C%20Andrade%20BB%2C%20Cordeiro-Santos%20M%2C%20Kritski%20A%2C%20et%20al.%20A%20Clinical%20Prediction%20Model%20for%20Unsuccessful%20Pulmonary%20Tuberculosis%20Treatment%20Outcomes.%20Clin%20Infect%20Dis.%202022%20Mar%2023%3B74%286%29%3A973%26%23×2013%3B82.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab598%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab598%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034214166%3B%20PubMed%20Central%20PMCID%3A%20PMC8946703.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Clinical%20Prediction%20Model%20for%20Unsuccessful%20Pulmonary%20Tuberculosis%20Treatment%20Outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%20M.%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Calvacante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20W.%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dandan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20Network%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Despite%20widespread%20availability%20of%20curative%20therapy%2C%20tuberculosis%20%28TB%29%20treatment%20outcomes%20remain%20suboptimal.%20Clinical%20prediction%20models%20can%20inform%20treatment%20strategies%20to%20improve%20outcomes.%20Using%20baseline%20clinical%20data%2C%20we%20developed%20a%20prediction%20model%20for%20unsuccessful%20TB%20treatment%20outcome%20and%20evaluated%20the%20incremental%20value%20of%20human%20immunodeficiency%20virus%20%28HIV%29-related%20severity%20and%20isoniazid%20acetylator%20status.%5CnMETHODS%3A%20Data%20originated%20from%20the%20Regional%20Prospective%20Observational%20Research%20for%20Tuberculosis%20Brazil%20cohort%2C%20which%20enrolled%20newly%20diagnosed%20TB%20patients%20in%20Brazil%20from%202015%20through%202019.%20This%20analysis%20included%20participants%20with%20culture-confirmed%2C%20drug-susceptible%20pulmonary%20TB%20who%20started%20first-line%20anti-TB%20therapy%20and%20had%20%5Cu226512%20months%20of%20follow-up.%20The%20end%20point%20was%20unsuccessful%20TB%20treatment%3A%20composite%20of%20death%2C%20treatment%20failure%2C%20regimen%20switch%2C%20incomplete%20treatment%2C%20or%20not%20evaluated.%20Missing%20predictors%20were%20imputed.%20Predictors%20were%20chosen%20via%20bootstrapped%20backward%20selection.%20Discrimination%20and%20calibration%20were%20evaluated%20with%20c-statistics%20and%20calibration%20plots%2C%20respectively.%20Bootstrap%20internal%20validation%20estimated%20overfitting%2C%20and%20a%20shrinkage%20factor%20was%20applied%20to%20improve%20out-of-sample%20prediction.%20Incremental%20value%20was%20evaluated%20with%20likelihood%20ratio-based%20measures.%5CnRESULTS%3A%20Of%20944%20participants%2C%20191%20%2820%25%29%20had%20unsuccessful%20treatment%20outcomes.%20The%20final%20model%20included%207%20baseline%20predictors%3A%20hemoglobin%2C%20HIV%20infection%2C%20drug%20use%2C%20diabetes%2C%20age%2C%20education%2C%20and%20tobacco%20use.%20The%20model%20demonstrated%20good%20discrimination%20%28c-statistic%5Cu2005%3D%5Cu20050.77%3B%2095%25%20confidence%20interval%2C%20.73-.80%29%20and%20was%20well%20calibrated%20%28optimism-corrected%20intercept%20and%20slope%2C%20-0.12%20and%200.89%2C%20respectively%29.%20HIV-related%20factors%20and%20isoniazid%20acetylation%20status%20did%20not%20improve%20prediction%20of%20the%20final%20model.%5CnCONCLUSIONS%3A%20Using%20information%20readily%20available%20at%20treatment%20initiation%2C%20the%20prediction%20model%20performed%20well%20in%20this%20population.%20The%20findings%20may%20guide%20future%20work%20to%20allocate%20resources%20or%20inform%20targeted%20interventions%20for%20high-risk%20patients.%22%2C%22date%22%3A%222022-03-23%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciab598%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234214166%22%2C%22PMCID%22%3A%22PMC8946703%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A16%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22A2V36D8V%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Hovhannisyan%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHovhannisyan%20L%2C%20Coelho%20LE%2C%20Velasque%20L%2C%20De%20Boni%20RB%2C%20Clark%20J%2C%20Cardoso%20SW%2C%20et%20al.%20Multilevel%20Analysis%20of%20Individual%20and%20Neighborhood%20Characteristics%20Associated%20with%20Viral%20Suppression%20Among%20Adults%20with%20HIV%20in%20Rio%20de%20Janeiro%2C%20Brazil.%20AIDS%20Behav.%202022%20Mar%3B26%283%29%3A947%26%23×2013%3B62.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-021-03450-2%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10461-021-03450-2%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034564777%3B%20PubMed%20Central%20PMCID%3A%20PMC8898026.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multilevel%20Analysis%20of%20Individual%20and%20Neighborhood%20Characteristics%20Associated%20with%20Viral%20Suppression%20Among%20Adults%20with%20HIV%20in%20Rio%20de%20Janeiro%2C%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lyolya%22%2C%22lastName%22%3A%22Hovhannisyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luciane%22%2C%22lastName%22%3A%22Velasque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%20B.%22%2C%22lastName%22%3A%22De%20Boni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesse%22%2C%22lastName%22%3A%22Clark%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20W.%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordan%22%2C%22lastName%22%3A%22Lake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22Understanding%20the%20impact%20of%20neighborhood%20context%20on%20viral%20suppression%20outcomes%20may%20help%20explain%20health%20disparities%20and%20identify%20future%20interventions.%20We%20assessed%20the%20relationship%20between%20individual%20characteristics%2C%20neighborhood%20socioeconomic%20context%2C%20and%20viral%20suppression%20using%20multilevel%20logistic%20regression%20models.%20Adults%20with%20HIV%20initiating%20antiretroviral%20therapy%20%28ART%29%20between%202000%20and%202017%2C%20who%20resided%20in%20Rio%20de%20Janeiro%20and%20had%20an%20HIV-1%20RNA%20level%20%28viral%20load%29%20measured%2090-270%20days%20after%20ART%20initiation%20were%20included.%20Overall%2C%2083.9%25%20achieved%20viral%20suppression.%20Participants%20who%20were%20older%2C%20had%20a%20higher%20level%20of%20education%2C%20and%20identified%20as%20heterosexual%20cisgender%20men%20and%20cisgender%20men-who-have-sex-with-men%20had%20increased%20odds%20of%20viral%20suppression.%20Later%20calendar%20year%20of%20ART%20initiation%20carried%20the%20strongest%20association%20with%20viral%20suppression%2C%20reflecting%20the%20increased%20effectiveness%20and%20tolerability%20of%20ART%20over%20time.%20Neighborhood%20socioeconomic%20indicators%20did%20not%20predict%20viral%20suppression%20in%20unadjusted%20or%20adjusted%20analyses%2C%20which%20may%20result%20from%20the%20integrated%20care%20provided%20in%20our%20health%20care%20facility%20together%20with%20Brazil%26%23039%3Bs%20universal%20treatment.%22%2C%22date%22%3A%222022-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10461-021-03450-2%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234564777%22%2C%22PMCID%22%3A%22PMC8898026%22%2C%22ISSN%22%3A%221573-3254%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A16%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22A232KDJD%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222022-02-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Nogueira%20B%2C%20Freire%20MVCNS%2C%20Queiroz%20ATL%2C%20et%20al.%20The%20Effect%20of%20Diabetes%20and%20Prediabetes%20on%20Antituberculosis%20Treatment%20Outcomes%3A%20A%20Multicenter%20Prospective%20Cohort%20Study.%20J%20Infect%20Dis.%202022%20Feb%2015%3B225%284%29%3A617%26%23×2013%3B26.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab427%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab427%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034651642%3B%20PubMed%20Central%20PMCID%3A%20PMC8844586.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Effect%20of%20Diabetes%20and%20Prediabetes%20on%20Antituberculosis%20Treatment%20Outcomes%3A%20A%20Multicenter%20Prospective%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Vit%5Cu00f3ria%20C.%20N.%20S.%22%2C%22lastName%22%3A%22Freire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Cristina%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29%5Cu2013Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20It%20is%20unclear%20whether%20diabetes%20or%20prediabetes%20affects%20unfavorable%20treatment%20outcomes%20and%20death%20in%20people%20with%20tuberculosis%20%28PWTB%29.%5CnMETHODS%3A%20Culture-confirmed%2C%20drug-susceptible%20PWTB%2C%20enrolled%20in%20the%20Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20cohort%20between%202015%20and%202019%20%28N%20%3D%20643%29%20were%20stratified%20based%20on%20glycemic%20status%20according%20to%20baseline%20glycated%20hemoglobin.%20Unfavorable%20tuberculosis%20%28TB%29%20outcome%20was%20defined%20as%20treatment%20failure%20or%20modification%2C%20recurrence%2C%20or%20death%3B%20favorable%20outcome%20was%20cure%20or%20treatment%20completion.%20We%20corroborated%20the%20findings%20using%20data%20from%20PWTB%20reported%20to%20the%20Brazilian%20National%20System%20of%20Diseases%20Notification%20%28SINAN%29%20during%202015-2019%20%28N%20%3D%2020%20989%29.%20Logistic%20regression%20models%20evaluated%20associations%20between%20glycemic%20status%20and%20outcomes.%5CnRESULTS%3A%20In%20both%20cohorts%2C%20in%20univariate%20analysis%2C%20unfavorable%20outcomes%20were%20more%20frequently%20associated%20with%20smoking%2C%20illicit%20drug%20use%2C%20and%20human%20immunodeficiency%20virus%20infection.%20Diabetes%2C%20but%20not%20prediabetes%2C%20was%20associated%20with%20unfavorable%20outcomes%20in%20the%20RePORT-Brazil%20%28adjusted%20relative%20risk%20%5BaRR%5D%2C%202.45%3B%20P%20%26lt%3B%20.001%29%20and%20SINAN%20%28aRR%2C%201.76%3B%20P%20%26lt%3B%20.001%29%20cohorts.%20Furthermore%2C%20diabetes%20was%20associated%20with%20high%20risk%20of%20death%20%28during%20TB%20treatment%29%20in%20both%20RePORT-Brazil%20%28aRR%2C%202.16%3B%20P%20%3D%20.040%29%20and%20SINAN%20%28aRR%2C%201.93%3B%20P%20%3D%20.001%29.%5CnCONCLUSIONS%3A%20Diabetes%20was%20associated%20with%20an%20increased%20risk%20of%20unfavorable%20outcomes%20and%20mortality%20in%20Brazilian%20PWTB.%20Interventions%20to%20improve%20TB%20treatment%20outcomes%20in%20persons%20with%20diabetes%20are%20needed.%22%2C%22date%22%3A%222022-02-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiab427%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234651642%22%2C%22PMCID%22%3A%22PMC8844586%22%2C%22ISSN%22%3A%221537-6613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A25%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22Q8LTF4R5%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Romo%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRomo%20ML%2C%20Patel%20RC%2C%20Edwards%20JK%2C%20Humphrey%20JM%2C%20Musick%20BS%2C%20Bernard%20C%2C%20et%20al.%20Disparities%20in%20Dolutegravir%20Uptake%20Affecting%20Females%20of%20Reproductive%20Age%20With%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%20After%20Initial%20Concerns%20About%20Teratogenicity%26%23x202F%3B%3A%20An%20Observational%20Study.%20Ann%20Intern%20Med.%202022%20Jan%3B175%281%29%3A84%26%23×2013%3B94.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3037%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7326%5C%2FM21-3037%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034843382%3B%20PubMed%20Central%20PMCID%3A%20PMC8808594.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disparities%20in%20Dolutegravir%20Uptake%20Affecting%20Females%20of%20Reproductive%20Age%20With%20HIV%20in%20Low-%20and%20Middle-Income%20Countries%20After%20Initial%20Concerns%20About%20Teratogenicity%20%3A%20An%20Observational%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20L.%22%2C%22lastName%22%3A%22Romo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rena%20C.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessie%20K.%22%2C%22lastName%22%3A%22Edwards%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caitlin%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mercy%20W.%22%2C%22lastName%22%3A%22Maina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Penner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katarzyna%22%2C%22lastName%22%3A%22Wyka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Penh%20Sun%22%2C%22lastName%22%3A%22Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cordelia%22%2C%22lastName%22%3A%22Kunzekwenyika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cort%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radoslaw%22%2C%22lastName%22%3A%22Panczak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20A.%22%2C%22lastName%22%3A%22Kelvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20transition%20to%20dolutegravir-containing%20antiretroviral%20therapy%20%28ART%29%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%20was%20complicated%20by%20an%20initial%20safety%20signal%20in%20May%202018%20suggesting%20that%20exposure%20to%20dolutegravir%20at%20conception%20was%20possibly%20associated%20with%20infant%20neural%20tube%20defects.%20On%20the%20basis%20of%20additional%20evidence%2C%20in%20July%202019%2C%20the%20World%20Health%20Organization%20recommended%20dolutegravir%20for%20all%20adults%20and%20adolescents%20living%20with%20HIV.%5CnOBJECTIVE%3A%20To%20describe%20dolutegravir%20uptake%20and%20disparities%20by%20sex%20and%20age%20group%20in%20LMICs.%5CnDESIGN%3A%20Observational%20cohort%20study.%5CnSETTING%3A%2087%20sites%20that%20began%20using%20dolutegravir%20in%2011%20LMICs%20in%20the%20Asia-Pacific%3B%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%3B%20and%20sub-Saharan%20African%20regions%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%5CnPATIENTS%3A%20134%5Cu00a0672%20patients%20aged%2016%20years%20or%20older%20who%20received%20HIV%20care%20from%20January%202017%20through%20March%202020.%5CnMEASUREMENTS%3A%20Sex%2C%20age%20group%2C%20and%20dolutegravir%20uptake%20%28that%20is%2C%20newly%20initiating%20ART%20with%20dolutegravir%20or%20switching%20to%20dolutegravir%20from%20another%20regimen%29.%5CnRESULTS%3A%20Differences%20in%20dolutegravir%20uptake%20among%20females%20of%20reproductive%20age%20%2816%20to%2049%20years%29%20emerged%20after%20the%20safety%20signal.%20By%20the%20end%20of%20follow-up%2C%20the%20cumulative%20incidence%20of%20dolutegravir%20uptake%20among%20females%2016%20to%2049%20years%20old%20was%2029.4%25%20%2895%25%20CI%2C%2029.0%25%20to%2029.7%25%29%20compared%20with%2057.7%25%20%28CI%2C%2057.2%25%20to%2058.3%25%29%20among%20males%2016%20to%2049%20years%20old.%20This%20disparity%20was%20greater%20in%20countries%20that%20began%20implementing%20dolutegravir%20before%20the%20safety%20signal%20and%20initially%20had%20highly%20restrictive%20policies%20versus%20countries%20with%20a%20later%20rollout.%20Dolutegravir%20uptake%20was%20similar%20among%20females%20and%20males%20aged%2050%20years%20or%20older.%5CnLIMITATION%3A%20Follow-up%20was%20limited%20to%206%20to%208%20months%20after%20international%20guidelines%20recommended%20expanding%20access%20to%20dolutegravir.%5CnCONCLUSION%3A%20Substantial%20disparities%20in%20dolutegravir%20uptake%20affecting%20females%20of%20reproductive%20age%20through%20early%202020%20are%20documented.%20Although%20this%20disparity%20was%20anticipated%20because%20of%20country-level%20restrictions%20on%20access%2C%20the%20results%20highlight%20its%20extent%20and%20initial%20persistence.%5CnPRIMARY%20FUNDING%20SOURCE%3A%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%222022-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.7326%5C%2FM21-3037%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234843382%22%2C%22PMCID%22%3A%22PMC8808594%22%2C%22ISSN%22%3A%221539-3704%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A17%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22KIY34VYK%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Karim%20F%2C%20Queiroz%20ATL%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Sales%20C%2C%20et%20al.%20Effect%20of%20Dysglycemia%20on%20Urinary%20Lipid%20Mediator%20Profiles%20in%20Persons%20With%20Pulmonary%20Tuberculosis.%20Front%20Immunol.%202022%3B13%3A919802.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.919802%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.919802%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035874781%3B%20PubMed%20Central%20PMCID%3A%20PMC9304990.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Dysglycemia%20on%20Urinary%20Lipid%20Mediator%20Profiles%20in%20Persons%20With%20Pulmonary%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farina%22%2C%22lastName%22%3A%22Karim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caio%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahomed-Yunus%20S.%22%2C%22lastName%22%3A%22Moosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matilda%22%2C%22lastName%22%3A%22Mazibuko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ginger%20L.%22%2C%22lastName%22%3A%22Milne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%20Henrique%22%2C%22lastName%22%3A%22Serezani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20R.%22%2C%22lastName%22%3A%22Koethe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alasdair%22%2C%22lastName%22%3A%22Leslie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Oxidized%20lipid%20mediators%20such%20as%20eicosanoids%20play%20a%20central%20role%20in%20the%20inflammatory%20response%20associated%20with%20tuberculosis%20%28TB%29%20pathogenesis.%20Diabetes%20mellitus%20%28DM%29%20leads%20to%20marked%20changes%20in%20lipid%20mediators%20in%20persons%20with%20TB.%20However%2C%20the%20associations%20between%20diabetes-related%20changes%20in%20lipid%20mediators%20and%20clearance%20of%20M.%20tuberculosis%20%28Mtb%29%20among%20persons%20on%20anti-TB%20treatment%20%28ATT%29%20are%20unknown.%20Quantification%20of%20urinary%20eicosanoid%20metabolites%20can%20provide%20insights%20into%20the%20circulating%20lipid%20mediators%20involved%20in%20Mtb%20immune%20responses.%5CnMETHODS%3A%20We%20conducted%20a%20multi-site%20prospective%20observational%20study%20among%20adults%20with%20drug-sensitive%20pulmonary%20TB%20and%20controls%20without%20active%20TB%3B%20both%20groups%20had%20sub-groups%20with%20or%20without%20dysglycemia%20at%20baseline.%20Participants%20were%20enrolled%20from%20RePORT-Brazil%20%28Salvador%20site%29%20and%20RePORT-South%20Africa%20%28Durban%20site%29%20and%20stratified%20according%20to%20TB%20status%20and%20baseline%20glycated%20hemoglobin%20levels%3A%20a%29%20TB-dysglycemia%20%28n%3D69%29%3B%20b%29%20TB-normoglycemia%20%28n%3D64%29%3B%20c%29%20non-TB%5C%2Fdysglycemia%20%28n%3D31%29%3B%20d%29%20non-TB%5C%2Fnon-dysglycemia%20%28n%3D29%29.%20We%20evaluated%20the%20following%20urinary%20eicosanoid%20metabolites%3A%2011%5Cu03b1-hydroxy-9%2C15-dioxo-2%2C3%2C4%2C5-tetranor-prostane-1%2C20-dioic%20acid%20%28major%20urinary%20metabolite%20of%20prostaglandin%20E2%2C%20PGE-M%29%2C%20tetranor-PGE1%20%28metabolite%20of%20PGE2%2C%20TN-E%29%2C%209%5Cu03b1-hydroxy-11%2C15-dioxo-2%2C3%2C4%2C5-tetranor-prostane-1%2C20-dioic%20acid%20%28metabolite%20of%20PGD2%2C%20PGD-M%29%2C%2011-dehydro-thromboxane%20B2%20%2811dTxB2%29%2C%202%2C3-dinor-6-keto-PGF1%5Cu03b1%20%28prostaglandin%20I%20metabolite%2C%20PGI-M%29%2C%20and%20leukotriene%20E4%20%28LTE4%29.%20Comparisons%20between%20the%20study%20groups%20were%20performed%20at%20three%20time%20points%3A%20before%20ATT%20and%202%20and%206%20months%20after%20initiating%20therapy.%5CnRESULTS%3A%20PGE-M%20and%20LTE4%20values%20were%20consistently%20higher%20at%20all%20three%20time-points%20in%20the%20TB-dysglycemia%20group%20compared%20to%20the%20other%20groups%20%28p%26lt%3B0.001%29.%20In%20addition%2C%20there%20was%20a%20significant%20decrease%20in%20PGI-M%20and%20LTE4%20levels%20from%20baseline%20to%20month%206%20in%20the%20TB-dysglycemia%20and%20TB-normoglycemia%20groups.%20Finally%2C%20TB-dysglycemia%20was%20independently%20associated%20with%20increased%20concentrations%20of%20PGD-M%2C%20PGI-M%2C%20and%20LTE4%20at%20baseline%20in%20a%20multivariable%20model%20adjusting%20for%20age%2C%20sex%2C%20BMI%2C%20and%20study%20site.%20These%20associations%20were%20not%20affected%20by%20HIV%20status.%5CnCONCLUSION%3A%20The%20urinary%20eicosanoid%20metabolite%20profile%20was%20associated%20with%20TB-dysglycemia%20before%20and%20during%20ATT.%20These%20observations%20can%20help%20identify%20the%20mechanisms%20involved%20in%20the%20pathogenesis%20of%20TB-dysglycemia%2C%20and%20potential%20biomarkers%20of%20TB%20treatment%20outcomes%2C%20including%20among%20persons%20with%20dysglycemia.%22%2C%22date%22%3A%222022%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2022.919802%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235874781%22%2C%22PMCID%22%3A%22PMC9304990%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A21%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22GIPKPZJL%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Ara%5Cu00fajo-Pereira%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BAra%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Arriaga%20MB%2C%20Musselwhite%20LW%2C%20Vinhaes%20CL%2C%20Belaunzaran-Zamudio%20PF%2C%20et%20al.%20Relationship%20Between%20Anemia%20and%20Systemic%20Inflammation%20in%20People%20Living%20With%20HIV%20and%20Tuberculosis%3A%20A%20Sub-Analysis%20of%20the%20CADIRIS%20Clinical%20Trial.%20Front%20Immunol.%202022%3B13%3A916216.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.916216%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.916216%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035812431%3B%20PubMed%20Central%20PMCID%3A%20PMC9260499.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relationship%20Between%20Anemia%20and%20Systemic%20Inflammation%20in%20People%20Living%20With%20HIV%20and%20Tuberculosis%3A%20A%20Sub-Analysis%20of%20the%20CADIRIS%20Clinical%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20W.%22%2C%22lastName%22%3A%22Musselwhite%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Rupert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20J.%22%2C%22lastName%22%3A%22Montaner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20M.%22%2C%22lastName%22%3A%22Lederman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irini%22%2C%22lastName%22%3A%22Sereti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%20Sierra%22%2C%22lastName%22%3A%22Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22People%20with%20HIV%20%28PWH%29%20are%20at%20increased%20risk%20of%20developing%20active%20tuberculosis%20%28TB%29%2C%20and%20anemia%20is%20a%20common%20complication%20in%20both%20conditions.%20Anemia%20in%20TB%20patients%20has%20been%20linked%20to%20immune%20activation%2C%20levels%20of%20inflammatory%20biomarkers%20in%20blood%2C%20and%20risk%20for%20HIV%20disease%20progression%20and%20death.%20In%20this%20study%20we%20show%20that%20anemia%20was%20associated%20with%20a%20more%20pronounced%20inflammatory%20profile%20in%20HIV-TB%20coinfected%20persons%20in%20a%20cohort%20of%20159%20individuals%20with%20advanced%20HIV%20disease%20%28CD4%20count%20%26lt%3B%20100%20cells%5C%2F%5Cu00b5L%29%20recruited%20as%20part%20of%20a%20randomized%20clinical%20trial%20%28NCT00988780%29.%20A%20panel%20of%20plasma%20biomarkers%20was%20assessed%20on%20plasma%20obtained%20prior%20to%20combination%20antiretroviral%20therapy%20%28cART%29%20initiation.%20We%20performed%20a%20series%20of%20multidimensional%20analyses%20including%20clinical%20variables%20and%20concentrations%20of%20inflammatory%20biomarkers%20to%20profile%20systemic%20inflammation%20of%20PWH%20with%20and%20without%20anemia.%20We%20observed%20that%20TB%20participants%20presented%20with%20moderately%20lower%20levels%20of%20hemoglobin%20than%20non-TB%20participants.%20These%20participants%20also%20presented%20a%20higher%20Degree%20of%20Inflammatory%20Perturbation%20%28DIP%29%20score%2C%20related%20to%20increased%20levels%20of%20IFN-%5Cu03b3%20and%20TNF.%20The%20DIP%20was%20associated%20with%20TB%20coinfection%20and%20anemia%20before%20cART%20initiation.%20Future%20mechanistic%20studies%20are%20warranted%20to%20assess%20the%20determinants%20of%20such%20associations%20and%20the%20implications%20on%20treatment%20outcomes.%22%2C%22date%22%3A%222022%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2022.916216%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235812431%22%2C%22PMCID%22%3A%22PMC9260499%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A21%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22888LDXIS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Villalva-Serra%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVillalva-Serra%20K%2C%20Barreto-Duarte%20B%2C%20Nunes%20VM%2C%20Menezes%20RC%2C%20Rodrigues%20MMS%2C%20Queiroz%20ATL%2C%20et%20al.%20Tuberculosis%20treatment%20outcomes%20of%20diabetic%20and%20non-diabetic%20TB%5C%2FHIV%20co-infected%20patients%3A%20A%20nationwide%20observational%20study%20in%20Brazil.%20Front%20Med%20%28Lausanne%29.%202022%3B9%3A972145.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2022.972145%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2022.972145%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036186793%3B%20PubMed%20Central%20PMCID%3A%20PMC9523014.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tuberculosis%20treatment%20outcomes%20of%20diabetic%20and%20non-diabetic%20TB%5C%2FHIV%20co-infected%20patients%3A%20A%20nationwide%20observational%20study%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klauss%22%2C%22lastName%22%3A%22Villalva-Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20M.%22%2C%22lastName%22%3A%22Nunes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%20C.%22%2C%22lastName%22%3A%22Menezes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20is%20a%20worldwide%20public%20health%20problem%2C%20especially%20in%20countries%20that%20also%20report%20high%20numbers%20of%20people%20living%20with%20HIV%20%28PLWH%29%20and%5C%2For%20diabetes%20mellitus%20%28DM%29.%20However%2C%20the%20unique%20features%20of%20persons%20with%20TB-HIV-DM%20are%20incompletely%20understood.%20This%20study%20compared%20anti-TB%20treatment%20%28ATT%29%20outcomes%20of%20diabetic%20and%20non-diabetic%20TB%5C%2FHIV%20co-infected%20patients.%5CnMETHODS%3A%20A%20nationwide%20retrospective%20observational%20investigation%20was%20performed%20with%20data%20from%20the%20Brazilian%20Tuberculosis%20Database%20System%20among%20patients%20reported%20to%20have%20TB-HIV%20co-infection%20between%202014%20and%202019.%20This%20database%20includes%20all%20reported%20TB%20cases%20in%20Brazil.%20Exploratory%20and%20association%20analyses%20compared%20TB%20treatment%20outcomes%20in%20DM%20and%20non-DM%20patients.%20Unfavorable%20outcomes%20were%20defined%20as%20death%2C%20treatment%20failure%2C%20loss%20to%20follow-up%20or%20recurrence.%20Multivariable%20stepwise%20logistic%20regressions%20were%20used%20to%20identify%20the%20variables%20associated%20with%20unfavorable%20ATT%20outcomes%20in%20the%20TB-HIV%20population.%5CnRESULTS%3A%20Of%20the%2031%2C070%20TB-HIV%20patients%20analyzed%2C%20999%20%283.2%25%29%20reported%20having%20DM.%20However%2C%20in%20these%20TB-HIV%20patients%2C%20DM%20was%20not%20associated%20with%20any%20unfavorable%20treatment%20outcome%20%5Badjusted%20Odds%20Ratio%20%28aOR%29%3A%200.97%2C%2095%25%20CI%3A%200.83-1.12%2C%20p%20%3D%200.781%5D.%20Furthermore%2C%20DM%20was%20also%20not%20associated%20with%20any%20specific%20type%20of%20unfavorable%20outcome%20in%20this%20study.%20In%20both%20the%20TB-HIV%20group%20and%20the%20TB-HIV-DM%20subpopulation%2C%20use%20of%20alcohol%2C%20illicit%20drugs%20and%20tobacco%2C%20as%20well%20as%20non-white%20ethnicity%20and%20prior%20TB%20were%20all%20characteristics%20more%20frequently%20observed%20in%20persons%20who%20experienced%20an%20unfavorable%20ATT%20outcome.%5CnCONCLUSION%3A%20DM%20is%20not%20associated%20with%20unfavorable%20TB%20treatment%20outcomes%20in%20persons%20with%20TB-HIV%2C%20including%20death%2C%20treatment%20failure%2C%20recurrence%20and%20loss%20to%20follow%20up.%20However%2C%20consumption%20habits%2C%20non-white%20ethnicity%20and%20prior%20TB%20are%20all%20more%20frequently%20detected%20in%20those%20with%20unfavorable%20outcomes%20in%20both%20TB-HIV%20and%20TB-HIV-DM%20patients.%22%2C%22date%22%3A%222022%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffmed.2022.972145%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236186793%22%2C%22PMCID%22%3A%22PMC9523014%22%2C%22ISSN%22%3A%222296-858X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A22%3A51Z%22%7D%7D%2C%7B%22key%22%3A%226MSKCTJU%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Z%5Cu00fcrcher%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZ%26%23xFC%3Brcher%20K%2C%20Cox%20SR%2C%20Ballif%20M%2C%20Enane%20LA%2C%20Marcy%20O%2C%20Yotebieng%20M%2C%20et%20al.%20Integrating%20services%20for%20HIV%20and%20multidrug-resistant%20tuberculosis%3A%20A%20global%20cross-sectional%20survey%20among%20ART%20clinics%20in%20low-%20and%20middle-income%20countries.%20PLOS%20Glob%20Public%20Health.%202022%3B2%283%29%3Ae0000180.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000180%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pgph.0000180%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2036778080%3B%20PubMed%20Central%20PMCID%3A%20PMC9910322.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Integrating%20services%20for%20HIV%20and%20multidrug-resistant%20tuberculosis%3A%20A%20global%20cross-sectional%20survey%20among%20ART%20clinics%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samyra%20R.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leslie%20A.%22%2C%22lastName%22%3A%22Enane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22Reubenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Worarat%22%2C%22lastName%22%3A%22Imsanguan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Larissa%22%2C%22lastName%22%3A%22Otero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nishi%22%2C%22lastName%22%3A%22Suryavanshi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20A.%22%2C%22lastName%22%3A%22Tornheim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20the%20leading%20cause%20of%20death%20among%20PLHIV%20and%20multidrug-resistant-TB%20%28MDR-TB%29%20is%20associated%20with%20high%20mortality.%20We%20examined%20the%20management%20for%20adult%20PLHIV%20coinfected%20with%20MDR-TB%20at%20ART%20clinics%20in%20lower%20income%20countries.%20Between%202019%20and%202020%2C%20we%20conducted%20a%20cross-sectional%20survey%20at%2029%20ART%20clinics%20in%20high%20TB%20burden%20countries%20within%20the%20global%20IeDEA%20network.%20We%20used%20structured%20questionnaires%20to%20collect%20clinic-level%20data%20on%20the%20TB%20and%20HIV%20services%20and%20the%20availability%20of%20diagnostic%20tools%20and%20treatment%20for%20MDR-TB.%20Of%2029%20ART%20clinics%2C%2025%20%2886%25%29%20were%20in%20urban%20areas%20and%2019%20%2866%25%29%20were%20tertiary%20care%20clinics.%20Integrated%20HIV-TB%20services%20were%20reported%20at%2025%20%2886%25%29%20ART%20clinics%20for%20pan-susceptible%20TB%2C%20and%2014%20%2848%25%29%20clinics%20reported%20full%20MDR-TB%20services%20on-site%2C%20i.e.%20drug%20susceptibility%20testing%20%5BDST%5D%20and%20MDR-TB%20treatment.%20Some%20form%20of%20DST%20was%20available%20on-site%20at%2022%20%2876%25%29%20clinics%2C%20while%20the%20remainder%20referred%20testing%20off-site.%20On-site%20DST%20for%20second-line%20drugs%20was%20available%20at%209%20%2831%25%29%20clinics.%20MDR-TB%20treatment%20was%20delivered%20on-site%20at%2015%20%2852%25%29%20clinics%2C%20with%2010%20individualizing%20treatment%20based%20on%20DST%20results%20and%20five%20using%20standardized%20regimens%20alone.%20Bedaquiline%20was%20routinely%20available%20at%205%20%2817%25%29%20clinics%20and%20delamanid%20at%203%20%2810%25%29%20clinics.%20Although%20most%20ART%20clinics%20reported%20having%20integrated%20HIV%20and%20TB%20services%2C%20few%20had%20fully%20integrated%20MDR-TB%20services.%20There%20is%20a%20continued%20need%20for%20increased%20access%20to%20diagnostic%20and%20treatment%20options%20for%20MDR-TB%20patients%20and%20better%20integration%20of%20MDR-TB%20services%20into%20the%20HIV%20care%20continuum.%22%2C%22date%22%3A%222022%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pgph.0000180%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2236778080%22%2C%22PMCID%22%3A%22PMC9910322%22%2C%22ISSN%22%3A%222767-3375%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A22%3A41Z%22%7D%7D%5D%7D
1.
Lotspeich SC, Shepherd BE, Amorim GGC, Shaw PA, Tao R. Efficient odds ratio estimation under two-phase sampling using error-prone data from a multi-national HIV research cohort. Biometrics. 2022 Dec;78(4):1674–85. http://doi.org/10.1111/biom.13512 PubMed PMID: 34213008; PubMed Central PMCID: PMC8720323.
1.
Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, et al. Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium. J Int AIDS Soc. 2022 Dec;25(12):e26036. http://doi.org/10.1002/jia2.26036 PubMed PMID: 36504431; PubMed Central PMCID: PMC9742047.
1.
Girardi E, Caro-Vega Y, Cozzi-Lepri A, Musaazi J, Carriquiry G, Castelnuovo B, et al. The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis. AIDS. 2022 Nov 15;36(14):2005–13. http://doi.org/10.1097/QAD.0000000000003321 PubMed PMID: 35848588.
1.
Sobral L, Arriaga MB, Souza AB, Araújo-Pereira M, Barreto-Duarte B, Sales C, et al. Determinants of losses in the tuberculosis infection cascade of care among children and adolescent contacts of pulmonary tuberculosis cases: A Brazilian multi-centre longitudinal study. Lancet Reg Health Am. 2022 Nov;15:100358. http://doi.org/10.1016/j.lana.2022.100358 PubMed PMID: 36438860; PubMed Central PMCID: PMC9696515.
1.
Wada PY, Kim A, Jayathilake K, Duda SN, Abo Y, Althoff KN, et al. Site-Level Comprehensiveness of Care Is Associated with Individual Clinical Retention Among Adults Living with HIV in International Epidemiology Databases to Evaluate AIDS, a Global HIV Cohort Collaboration, 2000-2016. AIDS Patient Care STDS. 2022 Sep;36(9):343–55. http://doi.org/10.1089/apc.2022.0042 PubMed PMID: 36037010; PubMed Central PMCID: PMC9514598.
1.
Núñez I, Crabtree-Ramirez B, Shepherd BE, Sterling TR, Cahn P, Veloso VG, et al. Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors. Int J Infect Dis. 2022 Sep;122:469–75. http://doi.org/10.1016/j.ijid.2022.06.041 PubMed PMID: 35768025; PubMed Central PMCID: PMC9851270.
1.
Wada PY, Costa AG, Araújo-Pereira M, Barreto-Duarte B, Souza AB, Rocha MS, et al. Possible sex difference in latent tuberculosis infection risk among close tuberculosis contacts. Int J Infect Dis. 2022 Sep;122:685–92. http://doi.org/10.1016/j.ijid.2022.07.031 PubMed PMID: 35843494; PubMed Central PMCID: PMC10041676.
1.
Edmonds A, Brazier E, Musick BS, Yotebieng M, Humphrey J, Abuogi LL, et al. Clinical and programmatic outcomes of HIV-exposed infants enrolled in care at geographically diverse clinics, 1997-2021: A cohort study. PLoS Med. 2022 Sep;19(9):e1004089. http://doi.org/10.1371/journal.pmed.1004089 PubMed PMID: 36107857; PubMed Central PMCID: PMC9477260.
1.
Giraldo L, Fink V, Cahn F, Aristegui I, Caceres B, Sued O, et al. Design and Development of an Electronic Health Record According to Argentine Gender Identity Law. Stud Health Technol Inform. 2022 Jun 6;290:995–6. http://doi.org/10.3233/SHTI220235 PubMed PMID: 35673173; PubMed Central PMCID: PMC9968499.
1.
Giraldo L, Fink V, Cahn F, Caceres B, Sued O, Duda S, et al. Redesigning an Electronic Health Record in Argentina to Improve Comprehensive Health Care and Clinical Research. Stud Health Technol Inform. 2022 Jun 6;290:993–4. http://doi.org/10.3233/SHTI220234 PubMed PMID: 35673172; PubMed Central PMCID: PMC9943003.
1.
Eden SK, Li C, Shepherd BE. Nonparametric estimation of Spearman’s rank correlation with bivariate survival data. Biometrics. 2022 Jun;78(2):421–34. http://doi.org/10.1111/biom.13453 PubMed PMID: 33704769; PubMed Central PMCID: PMC8453584.
1.
Coelho LE, Jenkins CA, Shepherd BE, Pape JW, Mejia Cordero F, Padgett D, et al. Weight gain post-ART in HIV+ Latinos/as differs in the USA, Haiti, and Latin America. Lancet Reg Health Am. 2022 Apr;8:100173. http://doi.org/10.1016/j.lana.2021.100173 PubMed PMID: 35528706; PubMed Central PMCID: PMC9070999.
1.
Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022 Apr;59(4):2200166. http://doi.org/10.1183/13993003.00166-2022 PubMed PMID: 35422426; PubMed Central PMCID: PMC9059840.
1.
Caro-Vega Y, Rebeiro PF, Shepherd BE, Belaunzarán-Zamudio PF, Crabtree-Ramirez B, Cesar C, et al. Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study. Lancet Reg Health Am. 2022 Apr;8:100175. http://doi.org/10.1016/j.lana.2021.100175 PubMed PMID: 35602655; PubMed Central PMCID: PMC9121860.
1.
Justice AC, Goetz MB, Stewart CN, Hogan BC, Humes E, Luz PM, et al. Delayed presentation of HIV among older individuals: a growing problem. Lancet HIV. 2022 Apr;9(4):e269–80. http://doi.org/10.1016/S2352-3018(22)00003-0 PubMed PMID: 35218732; PubMed Central PMCID: PMC9128643.
1.
Peetluk LS, Rebeiro PF, Ridolfi FM, Andrade BB, Cordeiro-Santos M, Kritski A, et al. A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. Clin Infect Dis. 2022 Mar 23;74(6):973–82. http://doi.org/10.1093/cid/ciab598 PubMed PMID: 34214166; PubMed Central PMCID: PMC8946703.
1.
Hovhannisyan L, Coelho LE, Velasque L, De Boni RB, Clark J, Cardoso SW, et al. Multilevel Analysis of Individual and Neighborhood Characteristics Associated with Viral Suppression Among Adults with HIV in Rio de Janeiro, Brazil. AIDS Behav. 2022 Mar;26(3):947–62. http://doi.org/10.1007/s10461-021-03450-2 PubMed PMID: 34564777; PubMed Central PMCID: PMC8898026.
1.
Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Nogueira B, Freire MVCNS, Queiroz ATL, et al. The Effect of Diabetes and Prediabetes on Antituberculosis Treatment Outcomes: A Multicenter Prospective Cohort Study. J Infect Dis. 2022 Feb 15;225(4):617–26. http://doi.org/10.1093/infdis/jiab427 PubMed PMID: 34651642; PubMed Central PMCID: PMC8844586.
1.
Romo ML, Patel RC, Edwards JK, Humphrey JM, Musick BS, Bernard C, et al. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study. Ann Intern Med. 2022 Jan;175(1):84–94. http://doi.org/10.7326/M21-3037 PubMed PMID: 34843382; PubMed Central PMCID: PMC8808594.
1.
Arriaga MB, Karim F, Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Sales C, et al. Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis. Front Immunol. 2022;13:919802. http://doi.org/10.3389/fimmu.2022.919802 PubMed PMID: 35874781; PubMed Central PMCID: PMC9304990.
1.
Araújo-Pereira M, Barreto-Duarte B, Arriaga MB, Musselwhite LW, Vinhaes CL, Belaunzaran-Zamudio PF, et al. Relationship Between Anemia and Systemic Inflammation in People Living With HIV and Tuberculosis: A Sub-Analysis of the CADIRIS Clinical Trial. Front Immunol. 2022;13:916216. http://doi.org/10.3389/fimmu.2022.916216 PubMed PMID: 35812431; PubMed Central PMCID: PMC9260499.
1.
Villalva-Serra K, Barreto-Duarte B, Nunes VM, Menezes RC, Rodrigues MMS, Queiroz ATL, et al. Tuberculosis treatment outcomes of diabetic and non-diabetic TB/HIV co-infected patients: A nationwide observational study in Brazil. Front Med (Lausanne). 2022;9:972145. http://doi.org/10.3389/fmed.2022.972145 PubMed PMID: 36186793; PubMed Central PMCID: PMC9523014.
1.
Zürcher K, Cox SR, Ballif M, Enane LA, Marcy O, Yotebieng M, et al. Integrating services for HIV and multidrug-resistant tuberculosis: A global cross-sectional survey among ART clinics in low- and middle-income countries. PLOS Glob Public Health. 2022;2(3):e0000180. http://doi.org/10.1371/journal.pgph.0000180 PubMed PMID: 36778080; PubMed Central PMCID: PMC9910322.
2021
76770
IP6F4TRX
2021
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22R7IPF6I8%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Costa%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCosta%20AG%2C%20Carvalho%20BKS%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Ibiapina%20HNS%2C%20Spener-Gomes%20R%2C%20Souza%20AB%2C%20et%20al.%20Lessons%20Learned%20from%20Implementation%20of%20an%20Interferon%20Gamma%20Release%20Assay%20to%20Screen%20for%20Latent%20Tuberculosis%20Infection%20in%20a%20Large%20Multicenter%20Observational%20Cohort%20Study%20in%20Brazil.%20Microbiol%20Spectr.%202021%20Dec%2022%3B9%283%29%3Ae0116321.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FSpectrum.01163-21%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FSpectrum.01163-21%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034851140%3B%20PubMed%20Central%20PMCID%3A%20PMC8635161.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lessons%20Learned%20from%20Implementation%20of%20an%20Interferon%20Gamma%20Release%20Assay%20to%20Screen%20for%20Latent%20Tuberculosis%20Infection%20in%20a%20Large%20Multicenter%20Observational%20Cohort%20Study%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allyson%20G.%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20K.%20S.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiochelson%20N.%20S.%22%2C%22lastName%22%3A%22Ibiapina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriano%22%2C%22lastName%22%3A%22Gomes-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisangela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22The%20interferon%20gamma%20release%20assay%20%28IGRA%29%20has%20emerged%20as%20a%20useful%20tool%20for%20identifying%20latent%20tuberculosis%20infection%20%28LTBI%29.%20This%20assay%20can%20be%20performed%20through%20testing%20platforms%20such%20as%20the%20QuantiFERON-TB%20Gold%20Plus%20%28QFT-Plus%29%20assay.%20This%20in%20vitro%20test%20has%20been%20incorporated%20into%20several%20guidelines%20worldwide%20and%20has%20recently%20been%20considered%20by%20the%20World%20Health%20Organization%20%28WHO%29%20for%20the%20diagnosis%20of%20LTBI.%20The%20possibility%20of%20systematically%20implementing%20IGRAs%20such%20as%20the%20QFT-Plus%20assay%20in%20centers%20that%20perform%20LTBI%20screening%20has%20been%20accelerated%20by%20the%20decreased%20availability%20of%20the%20tuberculin%20skin%20test%20%28TST%29%20in%20several%20countries.%20Nevertheless%2C%20the%20process%20to%20implement%20IGRA%20testing%20in%20routine%20clinical%20care%20has%20many%20gaps.%20The%20study%20utilized%20the%20expertise%20acquired%20by%20the%20laboratory%20teams%20of%20the%20Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20consortium%20during%20study%20protocol%20implementation%20of%20LTBI%20screening%20of%20tuberculosis%20%28TB%29%20close%20contacts.%20RePORT-Brazil%20includes%20clinical%20research%20sites%20from%20Brazilian%20cities%20and%20is%20the%20largest%20multicenter%20cohort%20of%20TB%20close%20contacts%20in%20the%20country%20to%20date.%20Operational%20and%20logistical%20challenges%20faced%20during%20IGRA%20implementation%20in%20all%20study%20laboratories%20are%20described%2C%20as%20well%20as%20the%20solutions%20that%20were%20developed%20and%20led%20to%20the%20successful%20establishment%20of%20IGRA%20testing%20in%20RePORT-Brazil.%20The%20descriptions%20of%20the%20problems%20identified%20and%20resolved%20in%20this%20study%20can%20assist%20laboratories%20implementing%20IGRAs%2C%20in%20addition%20to%20manufacturers%20of%20IGRAs%20providing%20effective%20technical%20support.%20This%20will%20facilitate%20the%20implementation%20of%20IGRA%20testing%20in%20countries%20with%20large%20TB%20burdens%2C%20such%20as%20Brazil.%20IMPORTANCE%20The%20IGRA%20has%20emerged%20as%20a%20useful%20tool%20for%20identifying%20persons%20with%20LTBI.%20Although%20the%20implementation%20of%20IGRAs%20is%20of%20utmost%20importance%2C%20to%20our%20knowledge%20there%20is%20scarce%20information%20on%20the%20identification%20of%20logistical%20and%20technical%20challenges%20for%20systematic%20screening%20for%20LTBI%20on%20a%20large%20scale.%20Thus%2C%20the%20descriptions%20of%20the%20problems%20identified%20and%20resolved%20in%20this%20study%20can%20assist%20laboratories%20implementing%20IGRAs%2C%20in%20addition%20to%20manufacturers%20of%20IGRAs%20providing%20effective%20technical%20support.%20This%20will%20facilitate%20the%20implementation%20of%20IGRA%20testing%20in%20countries%20with%20large%20TB%20burdens%2C%20such%20as%20Brazil.%22%2C%22date%22%3A%222021-12-22%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FSpectrum.01163-21%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234851140%22%2C%22PMCID%22%3A%22PMC8635161%22%2C%22ISSN%22%3A%222165-0497%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A16%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22A6TA7TWC%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222021-12-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Rocha%20MS%2C%20Nogueira%20BMF%2C%20Nascimento%20V%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Souza%20AB%2C%20et%20al.%20The%20Effect%20of%20Diabetes%20and%20Prediabetes%20on%20Mycobacterium%20tuberculosis%20Transmission%20to%20Close%20Contacts.%20J%20Infect%20Dis.%202021%20Dec%2015%3B224%2812%29%3A2064%26%23×2013%3B72.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab264%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiab264%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034008010%3B%20PubMed%20Central%20PMCID%3A%20PMC8672762.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Effect%20of%20Diabetes%20and%20Prediabetes%20on%20Mycobacterium%20tuberculosis%20Transmission%20to%20Close%20Contacts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Nascimento%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alysson%20G.%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriano%22%2C%22lastName%22%3A%22Gomes-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisangela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20It%20is%20unknown%20whether%20dysglycemia%20is%20associated%20with%20Mycobacterium%20tuberculosis%20transmission.%5CnMETHODS%3A%20We%20assessed%20epidemiological%20and%20clinical%20characteristics%20of%20patients%20with%20culture-confirmed%20pulmonary%20tuberculosis%20and%20their%20close%20contacts%2C%20enrolled%20in%20a%20multicenter%20prospective%20cohort%20in%20Brazil.%20Contacts%20were%20investigated%20at%20baseline%20and%206%20months%20after%20enrollment.%20QuantiFERON%20positivity%20at%20baseline%20and%20conversion%20%28from%20negative%20to%20positive%20at%20month%206%29%20were%20compared%20between%20subgroups%20of%20contacts%20according%20to%20glycemic%20status%20of%20persons%20with%20tuberculosis%20%28PWTB%29%20as%20diabetes%20mellitus%20%28DM%29%20or%20prediabetes.%20Multivariable%20mixed-effects%20logistic%20regression%20models%20were%20performed%20to%20test%20independent%20associations%20with%20baseline%20QuantiFERON%20positive%20and%20QuantiFERON%20conversion.%5CnRESULTS%3A%20There%20were%20592%20PWTB%20%28153%20DM%2C%20141%20prediabetes%2C%20211%20normoglycemic%29%20and%201784%20contacts%2C%20of%20whom%20658%20were%20QuantiFERON-positive%20at%20baseline%20and%20106%20converters.%20Multivariable%20analyses%20demonstrated%20that%20tuberculosis-prediabetes%20cases%2C%20acid-fast%20bacilli-positive%2C%20pulmonary%20cavities%2C%20and%20living%20with%20someone%20who%20smoked%20were%20independently%20associated%20with%20QuantiFERON%20positive%20in%20contacts%20at%20baseline.%20DM%2C%20persistent%20cough%2C%20acid-fast%20bacilli-positive%2C%20and%20pulmonary%20cavities%20in%20tuberculosis%20source%20cases%20were%20associated%20with%20QuantiFERON%20conversion.%5CnCONCLUSIONS%3A%20Contacts%20of%20persons%20with%20pulmonary%20tuberculosis%20and%20dysglycemia%20were%20at%20increased%20risk%20of%20being%20QuantiFERON%20positive%20at%20baseline%20or%20month%206.%20Increased%20focus%20on%20such%20close%20contacts%20could%20improve%20tuberculosis%20control.%22%2C%22date%22%3A%222021-12-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiab264%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234008010%22%2C%22PMCID%22%3A%22PMC8672762%22%2C%22ISSN%22%3A%221537-6613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A16%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22N2AYU9YE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Han%20et%20al.%22%2C%22parsedDate%22%3A%222021-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHan%20WM%2C%20Law%20MG%2C%20Egger%20M%2C%20Wools-Kaloustian%20K%2C%20Moore%20R%2C%20McGowan%20C%2C%20et%20al.%20Global%20estimates%20of%20viral%20suppression%20in%20children%20and%20adolescents%20and%20adults%20on%20antiretroviral%20therapy%20adjusted%20for%20missing%20viral%20load%20measurements%3A%20a%20multiregional%2C%20retrospective%20cohort%20study%20in%2031%20countries.%20Lancet%20HIV.%202021%20Dec%3B8%2812%29%3Ae766%26%23×2013%3B75.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2821%2900265-4%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2821%2900265-4%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034856180%3B%20PubMed%20Central%20PMCID%3A%20PMC8782625.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20estimates%20of%20viral%20suppression%20in%20children%20and%20adolescents%20and%20adults%20on%20antiretroviral%20therapy%20adjusted%20for%20missing%20viral%20load%20measurements%3A%20a%20multiregional%2C%20retrospective%20cohort%20study%20in%2031%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Win%20Min%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20G.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagalingesawaran%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thahira%20Jamal%22%2C%22lastName%22%3A%22Mohamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Euvrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Castelnuovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kate%22%2C%22lastName%22%3A%22Salters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20Esteves%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Eley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20As%20countries%20move%20towards%20the%20UNAIDS%26%23039%3Bs%2095-95-95%20targets%20and%20with%20strong%20evidence%20that%20undetectable%20equals%20untransmittable%2C%20it%20is%20increasingly%20important%20to%20assess%20whether%20those%20with%20HIV%20who%20are%20receiving%20antiretroviral%20therapy%20%28ART%29%20achieve%20viral%20suppression.%20We%20estimated%20the%20proportions%20of%20children%20and%20adolescents%20and%20adults%20with%20viral%20suppression%20at%201%2C%202%2C%20and%203%20years%20after%20initiating%20ART.%5CnMETHODS%3A%20In%20this%20retrospective%20cohort%20study%2C%20seven%20regional%20cohorts%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20contributed%20data%20from%20individuals%20initiating%20ART%20between%20Jan%201%2C%202010%2C%20and%20Dec%2031%2C%202019%2C%20at%20148%20sites%20in%2031%20countries%20with%20annual%20viral%20load%20monitoring.%20Only%20people%20with%20HIV%20who%20started%20ART%20after%20the%20time%20a%20site%20started%20routine%20viral%20load%20monitoring%20were%20included.%20Data%20up%20to%20March%2031%2C%202020%2C%20were%20analysed.%20We%20estimated%20the%20proportions%20of%20children%20and%20adolescents%20%28aged%20%26lt%3B18%20years%20at%20ART%20initiation%29%20and%20adults%20%28aged%20%5Cu226518%20years%20at%20ART%20initiation%29%20with%20viral%20suppression%20%28viral%20load%20%26lt%3B1000%20copies%20per%20mL%29%20at%201%2C%202%2C%20and%203%20years%20after%20ART%20initiation%20using%20an%20intention-to-treat%20approach%20and%20an%20adjusted%20approach%20that%20accounted%20for%20missing%20viral%20load%20measurements.%5CnFINDINGS%3A%2021%5Cu2008594%20children%20and%20adolescents%20%2811%5Cu2008812%20%5B55%25%5D%20female%2C%209782%20%5B45%25%5D%20male%29%20from%20106%20sites%20in%2022%20countries%20and%20255%5Cu2008662%20adults%20%28163%5Cu2008831%20%5B64%25%5D%20female%2C%2091%5Cu2008831%20%5B36%25%5D%20male%29%20from%20143%20sites%20in%2030%20countries%20were%20included.%20Using%20the%20intention-to-treat%20approach%2C%20the%20proportion%20of%20children%20and%20adolescents%20with%20viral%20suppression%20was%207303%20%2836%25%29%20of%2020%5Cu2008478%20at%201%20year%2C%205709%20%2830%25%29%20of%2019%5Cu2008135%20at%202%20years%2C%20and%204287%20%2824%25%29%20of%2017%5Cu2008589%20at%203%20years%20after%20ART%20initiation%3B%20the%20proportion%20of%20adults%20with%20viral%20suppression%20was%20106%5Cu2008541%20%2844%25%29%20of%20240%5Cu2008600%20at%201%20year%2C%2079%5Cu2008141%20%2836%25%29%20of%20220%5Cu2008925%20at%202%20years%2C%20and%2057%5Cu2008970%20%2829%25%29%20of%20201%5Cu2008124%20at%203%20years%20after%20ART%20initiation.%20After%20adjusting%20for%20missing%20viral%20load%20measurements%20among%20those%20who%20transferred%2C%20were%20lost%20to%20follow-up%2C%20or%20who%20were%20in%20follow-up%20without%20viral%20load%20testing%2C%20the%20proportion%20of%20children%20and%20adolescents%20with%20viral%20suppression%20was%2012%5Cu2008048%20%2864%25%20%5Bplausible%20range%2043-81%5D%29%20of%2018%5Cu2008835%20at%201%20year%2C%2010%5Cu2008796%20%2862%25%20%5B41-77%5D%29%20of%2017%5Cu2008553%20at%202%20years%2C%20and%209177%20%2859%25%20%5B38-91%5D%29%20of%2015%5Cu2008667%20at%203%20years%20after%20ART%20initiation%3B%20the%20proportion%20of%20adults%20with%20viral%20suppression%20was%20176%5Cu2008964%20%2879%25%20%5B53-80%5D%29%20of%20225%5Cu2008418%20at%201%20year%2C%20145%5Cu2008552%20%2872%25%20%5B48-79%5D%29%20of%20201%5Cu2008238%20at%202%20years%2C%20and%20115%5Cu2008260%20%2865%25%20%5B43-69%5D%29%20of%20178%5Cu2008458%20at%203%20years%20after%20ART%20initiation.%5CnINTERPRETATION%3A%20Although%20adults%20with%20HIV%20are%20approaching%20the%20global%20target%20of%2095%25%20viral%20suppression%2C%20progress%20among%20children%20and%20adolescents%20is%20much%20slower.%20Substantial%20efforts%20are%20still%20needed%20to%20reach%20the%20viral%20suppression%20target%20for%20children%20and%20adolescents.%5CnFUNDING%3A%20US%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%222021-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2821%2900265-4%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234856180%22%2C%22PMCID%22%3A%22PMC8782625%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A15%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22X6FH6GUQ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22McMahon%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMcMahon%20DE%2C%20Semeere%20A%2C%20Laker-Oketta%20M%2C%20Byakwaga%20H%2C%20Mugglin%20C%2C%20Duda%20SN%2C%20et%20al.%20Global%20Disparities%20in%20Skin%20Cancer%20Services%20at%20HIV%20Treatment%20Centers%20across%2029%20Countries.%20J%20Invest%20Dermatol.%202021%20Oct%3B141%2810%29%3A2533-2536.e2.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jid.2021.02.758%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jid.2021.02.758%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033864771%3B%20PubMed%20Central%20PMCID%3A%20PMC8464481.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20Disparities%20in%20Skin%20Cancer%20Services%20at%20HIV%20Treatment%20Centers%20across%2029%20Countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Devon%20E.%22%2C%22lastName%22%3A%22McMahon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aggrey%22%2C%22lastName%22%3A%22Semeere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Laker-Oketta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Byakwaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catrina%22%2C%22lastName%22%3A%22Mugglin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iskandar%22%2C%22lastName%22%3A%22Azwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%20E.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jid.2021.02.758%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233864771%22%2C%22PMCID%22%3A%22PMC8464481%22%2C%22ISSN%22%3A%221523-1747%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A10%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22IQTJMWZJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Tymejczyk%20O%2C%20Zaniewski%20E%2C%20Egger%20M%2C%20Wools-Kaloustian%20K%2C%20Yiannoutsos%20CT%2C%20et%20al.%20Effects%20of%20National%20Adoption%20of%20Treat-All%20Guidelines%20on%20Pre-Antiretroviral%20Therapy%20%28ART%29%20CD4%20Testing%20and%20Viral%20Load%20Monitoring%20After%20ART%20initiation%3A%20A%20Regression%20Discontinuity%20Analysis.%20Clin%20Infect%20Dis.%202021%20Sep%2015%3B73%286%29%3Ae1273%26%23×2013%3B81.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab222%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciab222%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033693517%3B%20PubMed%20Central%20PMCID%3A%20PMC8442775.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20National%20Adoption%20of%20Treat-All%20Guidelines%20on%20Pre-Antiretroviral%20Therapy%20%28ART%29%20CD4%20Testing%20and%20Viral%20Load%20Monitoring%20After%20ART%20initiation%3A%20A%20Regression%20Discontinuity%20Analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Tymejczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Jaquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20S.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junko%22%2C%22lastName%22%3A%22Tanuma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Th%5Cu00e9odore%22%2C%22lastName%22%3A%22Niyongabo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20World%20Health%20Organization%26%23039%3Bs%20Treat-All%20guidance%20recommends%20CD4%20testing%20before%20initiating%20antiretroviral%20therapy%20%28ART%29%2C%20and%20routine%20viral%20load%20%28VL%29%20monitoring%20%28over%20CD4%20monitoring%29%20for%20patients%20on%20ART.%5CnMETHODS%3A%20We%20used%20regression%20discontinuity%20analyses%20to%20estimate%20changes%20in%20CD4%20testing%20and%20VL%20monitoring%20among%20547%20837%20ART-naive%20patients%20enrolling%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20care%20during%202006-2018%20at%20225%20clinics%20in%2026%20countries%20where%20Treat-All%20policies%20were%20adopted.%20We%20examined%20CD4%20testing%20within%2012%20months%20before%20and%20VL%20monitoring%206%20months%20after%20ART%20initiation%20among%20adults%20%28%5Cu226520%20years%29%2C%20adolescents%20%2810-19%20years%29%2C%20and%20children%20%280-9%20years%29%20in%20low%5C%2Flower-middle-income%20countries%20%28L%5C%2FLMICs%29%20and%20high%5C%2Fupper-middle-income%20countries%20%28H%5C%2FUMICs%29.%5CnRESULTS%3A%20Treat-All%20adoption%20led%20to%20an%20immediate%20decrease%20in%20pre-ART%20CD4%20testing%20among%20adults%20in%20L%5C%2FLMICs%2C%20from%2057.0%25%20to%2048.1%25%20%28-8.9%20percentage%20points%20%5Bpp%5D%3B%2095%25%20CI%3A%20-11.0%2C%20-6.8%29%2C%20and%20a%20small%20increase%20in%20H%5C%2FUMICs%2C%20from%2090.1%25%20to%2091.7%25%20%28%2B1.6pp%3B%2095%25%20CI%3A%200.2%2C%203.0%29%2C%20with%20no%20changes%20among%20adolescents%20or%20children%3B%20decreases%20in%20pre-ART%20CD4%20testing%20accelerated%20after%20Treat-All%20adoption%20in%20L%5C%2FLMICs.%20In%20L%5C%2FLMICs%2C%20VL%20monitoring%20after%20ART%20initiation%20was%20low%20among%20all%20patients%20in%20L%5C%2FLMICs%20before%20Treat-All%3B%20while%20there%20was%20no%20immediate%20change%20at%20Treat-All%20adoption%2C%20VL%20monitoring%20trends%20significantly%20increased%20afterwards.%20VL%20monitoring%20increased%20among%20adults%20immediately%20after%20Treat-All%20adoption%2C%20from%2058.2%25%20to%2061.1%25%20%28%2B2.9pp%3B%2095%25%20CI%3A%200.5%2C%205.4%29%2C%20with%20no%20significant%20changes%20among%20adolescents%5C%2Fchildren.%5CnCONCLUSIONS%3A%20While%20on-ART%20VL%20monitoring%20has%20improved%20in%20L%5C%2FLMICs%2C%20Treat-All%20adoption%20has%20accelerated%20and%20disparately%20worsened%20suboptimal%20pre-ART%20CD4%20monitoring%2C%20which%20may%20compromise%20care%20outcomes%20for%20individuals%20with%20advanced%20HIV.%22%2C%22date%22%3A%222021-09-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciab222%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233693517%22%2C%22PMCID%22%3A%22PMC8442775%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A12%3A33Z%22%7D%7D%2C%7B%22key%22%3A%224VXFUYEV%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Kassanjee%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKassanjee%20R%2C%20Johnson%20LF%2C%20Zaniewski%20E%2C%20Ballif%20M%2C%20Christ%20B%2C%20Yiannoutsos%20CT%2C%20et%20al.%20Global%20HIV%20mortality%20trends%20among%20children%20on%20antiretroviral%20treatment%20corrected%20for%20under-reported%20deaths%3A%20an%20updated%20analysis%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20collaboration.%20J%20Int%20AIDS%20Soc.%202021%20Sep%3B24%20Suppl%205%28Suppl%205%29%3Ae25780.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25780%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25780%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034546646%3B%20PubMed%20Central%20PMCID%3A%20PMC8454681.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20HIV%20mortality%20trends%20among%20children%20on%20antiretroviral%20treatment%20corrected%20for%20under-reported%20deaths%3A%20an%20updated%20analysis%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reshma%22%2C%22lastName%22%3A%22Kassanjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benedikt%22%2C%22lastName%22%3A%22Christ%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patience%22%2C%22lastName%22%3A%22Nyakato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tavitiya%22%2C%22lastName%22%3A%22Sudjaritruk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%5Cu00e9sir%5Cu00e9%20Lucien%22%2C%22lastName%22%3A%22Dahourou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christelle%22%2C%22lastName%22%3A%22Twizere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Kasozi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20Joint%20United%20Nations%20Programme%20on%20HIV%5C%2FAIDS%20%28UNAIDS%29%20projections%20of%20paediatric%20HIV%20prevalence%20and%20deaths%20rely%20on%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20for%20mortality%20estimates%20among%20children%20living%20with%20HIV%20%28CHIV%29%20receiving%20antiretroviral%20therapy%20%28ART%29.%20Previous%20estimates%2C%20based%20on%20data%20through%202014%2C%20may%20no%20longer%20be%20accurate%20due%20to%20expanded%20paediatric%20HIV%20care%20and%20treatment%20eligibility%2C%20and%20the%20possibility%20of%20unreported%20deaths%20in%20CHIV%20considered%20lost%20to%20follow-up%20%28LTFU%29.%20We%20therefore%20estimated%20all-cause%20mortality%20and%20its%20trends%20in%20CHIV%20%28%26lt%3B15%5Cu00a0years%20old%29%20on%20ART%20using%20extended%20and%20new%20IeDEA%20data.%5CnMETHODS%3A%20We%20analysed%20%28i%29%20IeDEA%20observational%20data%20from%20CHIV%20in%20routine%20care%20globally%2C%20and%20%28ii%29%20novel%20data%20from%20an%20IeDEA%20tracing%20study%20that%20determined%20outcomes%20in%20a%20sample%20of%20CHIV%20after%20being%20LTFU%20in%20southern%20Africa.%20We%20included%2045%2C711%20CHIV%20on%20ART%20during%202004%20to%202017%20at%2072%20programmes%20in%20Africa%2C%20Asia-Pacific%20and%20Latin%20America.%20We%20used%20mixed%20effects%20Poisson%20regression%20to%20estimate%20mortality%20by%20age%2C%20sex%2C%20CD4%20at%20ART%20start%2C%20time%20on%20ART%2C%20region%20and%20calendar%20year.%20For%20Africa%2C%20in%20an%20adjusted%20analysis%20that%20accounts%20for%20unreported%20deaths%20among%20those%20LTFU%2C%20we%20first%20modified%20the%20routine%20data%20by%20simulating%20mortality%20outcomes%20within%20six%20months%20after%20LTFU%2C%20based%20on%20a%20Gompertz%20survival%20model%20fitted%20to%20the%20tracing%20data%20%28n%20%3D%20221%29.%5CnRESULTS%3A%20Observed%20mortality%20rates%20were%201.8%20%2895%25%20CI%3A%201.7%20to%201.9%29%20and%209.4%20%286.3%20to%2013.4%29%20deaths%20per%20100%5Cu00a0person-years%20in%20the%20routine%20and%20tracing%20data%2C%20respectively.%20We%20found%20strong%20evidence%20of%20higher%20mortality%20at%20shorter%20ART%20durations%2C%20lower%20CD4%20values%2C%20and%20in%20infancy.%20Averaging%20over%20covariate%20patterns%2C%20the%20adjusted%20mortality%20rate%20was%2054%25%20higher%20than%20the%20unadjusted%20rate.%20In%20unadjusted%20analyses%2C%20mortality%20reduced%20by%20an%20average%2060%25%20and%2073%25%20from%202005%20to%202017%2C%20within%20and%20outside%20of%20Africa%2C%20respectively.%20In%20the%20adjusted%20analysis%20for%20Africa%2C%20this%20temporal%20reduction%20was%2042%25.%5CnCONCLUSIONS%3A%20Mortality%20rates%20among%20CHIV%20have%20decreased%20substantially%20over%20time.%20However%2C%20when%20accounting%20for%20worse%20outcomes%20among%20those%20LTFU%2C%20mortality%20estimates%20increased%20and%20temporal%20improvements%20were%20slightly%20reduced%2C%20suggesting%20caution%20in%20interpreting%20analyses%20based%20only%20on%20programme%20data.%20The%20improved%20and%20updated%20IeDEA%20estimates%20on%20mortality%20among%20CHIV%20on%20ART%20support%20UNAIDS%20efforts%20to%20accurately%20model%20global%20HIV%20statistics.%22%2C%22date%22%3A%222021-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25780%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234546646%22%2C%22PMCID%22%3A%22PMC8454681%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A11%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22QEPFHCUN%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Souza%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSouza%20AB%2C%20Arriaga%20MB%2C%20Amorim%20G%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Nogueira%20BMF%2C%20Queiroz%20ATL%2C%20et%20al.%20Determinants%20of%20losses%20in%20the%20latent%20tuberculosis%20infection%20cascade%20of%20care%20in%20Brazil.%20BMJ%20Glob%20Health.%202021%20Sep%3B6%289%29%3Ae005969.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-005969%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjgh-2021-005969%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034518204%3B%20PubMed%20Central%20PMCID%3A%20PMC8438757.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determinants%20of%20losses%20in%20the%20latent%20tuberculosis%20infection%20cascade%20of%20care%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20Brito%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Factors%20associated%20with%20losses%20in%20the%20latent%20tuberculosis%20infection%20%28LTBI%29%20cascade%20of%20care%20in%20contacts%20of%20patients%20with%20tuberculosis%20%28TB%29%20were%20investigated%20in%20a%20multicentre%20prospective%20cohort%20from%20highly%20endemic%20regions%20in%20Brazil.%5CnMETHODS%3A%20Close%20contacts%20of%201187%20patients%20with%20culture-confirmed%20pulmonary%20TB%20were%20prospectively%20studied%20between%202015%20and%202019%2C%20with%20follow-up%20of%206-24%20months.%20Data%20on%20TB%20screening%20by%20clinical%20investigation%2C%20radiographic%20examination%20and%20interferon-gamma%20release%20assay%20%28IGRA%29%20were%20collected.%20Multivariable%20regressions%20were%20used%20to%20identify%20determinants%20of%20losses%20in%20the%20LTBI%20cascade.%5CnRESULTS%3A%20Among%204145%20TB%20contacts%20initially%20identified%2C%201901%20were%20examined%20%2854%25%20loss%29.%20Among%20those%20examined%2C%20933%20were%20people%20living%20with%20HIV%2C%20%5Cu22645%20years%20old%20and%5C%2For%20had%20positive%20IGRA%20results%2C%20and%20therefore%20had%20a%20recommendation%20to%20start%20TB%20preventive%20treatment%20%28TPT%29.%20Of%20those%2C%20454%20%2823%25%29%20initiated%20treatment%2C%20and%20247%20%2854%25%20of%20those%20initiating%3B%2026%25%20of%20those%20in%20whom%20treatment%20was%20recommended%29%20completed%20TPT.%20Multivariable%20regression%20analysis%20revealed%20that%20living%20with%20HIV%2C%20illiteracy%20and%20black%5C%2Fpardo%20%28brown%29%20race%20were%20independently%20associated%20with%20losses%20in%20the%20cascade.%5CnCONCLUSION%3A%20There%20were%20losses%20at%20all%20LTBI%20cascade%20stages%2C%20but%20particularly%20at%20the%20initial%20screening%20and%20examination%20steps.%20Close%20contacts%20of%20low%20socioeconomic%20status%20and%20living%20with%20HIV%20were%20at%20heightened%20risk%20of%20not%20completing%20the%20LTBI%20cascade%20of%20care%20in%20Brazil.%22%2C%22date%22%3A%222021-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjgh-2021-005969%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234518204%22%2C%22PMCID%22%3A%22PMC8438757%22%2C%22ISSN%22%3A%222059-7908%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A12%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22PFHLVF3T%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Johnson%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJohnson%20LF%2C%20Kariminia%20A%2C%20Trickey%20A%2C%20Yiannoutsos%20CT%2C%20Ekouevi%20DK%2C%20Minga%20AK%2C%20et%20al.%20Achieving%20consistency%20in%20measures%20of%20HIV-1%20viral%20suppression%20across%20countries%3A%20derivation%20of%20an%20adjustment%20based%20on%20international%20antiretroviral%20treatment%20cohort%20data.%20J%20Int%20AIDS%20Soc.%202021%20Sep%3B24%20Suppl%205%28Suppl%205%29%3Ae25776.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25776%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25776%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034546623%3B%20PubMed%20Central%20PMCID%3A%20PMC8454679.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Achieving%20consistency%20in%20measures%20of%20HIV-1%20viral%20suppression%20across%20countries%3A%20derivation%20of%20an%20adjustment%20based%20on%20international%20antiretroviral%20treatment%20cohort%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Trickey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Albert%20K.%22%2C%22lastName%22%3A%22Minga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Roberta%20Pati%22%2C%22lastName%22%3A%22Pascom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Win%20Min%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lei%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gad%22%2C%22lastName%22%3A%22Murenzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nei-Yuan%22%2C%22lastName%22%3A%22Hsiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberly%22%2C%22lastName%22%3A%22Marsh%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20The%20third%20of%20the%20Joint%20United%20Nations%20Programme%20on%20HIV%5C%2FAIDS%20%28UNAIDS%29%2090-90-90%20targets%20is%20to%20achieve%20a%2090%25%20rate%20of%20viral%20suppression%20%28HIV%20viral%20load%20%26lt%3B1000%20HIV-1%20RNA%20copies%5C%2Fml%29%20in%20patients%20on%20antiretroviral%20treatment%20%28ART%29%20by%202020.%20However%2C%20some%20countries%20use%20different%20thresholds%20when%20reporting%20viral%20suppression%2C%20and%20there%20is%20thus%20a%20need%20for%20an%20adjustment%20to%20standardize%20estimates%20to%20the%20%26lt%3B1000%20threshold.%20We%20aim%20to%20propose%20such%20an%20adjustment%2C%20to%20support%20consistent%20monitoring%20of%20progress%20towards%20the%20%26quot%3Bthird%2090%26quot%3B%20target.%5CnMETHODS%3A%20We%20considered%20three%20possible%20distributions%20for%20viral%20loads%20in%20ART%20patients%3A%20Weibull%2C%20Pareto%20and%20reverse%20Weibull%20%28imposing%20an%20upper%20limit%20but%20no%20lower%20limit%20on%20the%20log%20scale%29.%20The%20models%20were%20fitted%20to%20data%20on%20viral%20load%20distributions%20in%20ART%20patients%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20collaboration%20%28representing%20seven%20global%20regions%29%20and%20the%20ART%20Cohort%20Collaboration%20%28representing%20Europe%29%2C%20using%20separate%20random%20effects%20models%20for%20adults%20and%20children.%20The%20models%20were%20validated%20using%20data%20from%20the%20World%20Health%20Organization%20%28WHO%29%20HIV%20drug%20resistance%20report%20and%20the%20Brazilian%20national%20ART%20programme.%5CnRESULTS%3A%20Models%20were%20calibrated%20using%20921%2C157%20adult%20and%2037%2C431%20paediatric%20viral%20load%20measurements%2C%20over%202010-2019.%20The%20Pareto%20and%20reverse%20Weibull%20models%20provided%20the%20best%20fits%20to%20the%20data%2C%20but%20for%20all%20models%2C%20the%20%26quot%3Bshape%26quot%3B%20parameters%20for%20the%20viral%20load%20distributions%20differed%20significantly%20between%20regions.%20The%20Weibull%20model%20performed%20best%20in%20the%20validation%20against%20the%20WHO%20drug%20resistance%20survey%20data%2C%20while%20the%20Pareto%20model%20produced%20uncertainty%20ranges%20that%20were%20too%20narrow%2C%20relative%20to%20the%20validation%20data.%20Based%20on%20these%20analyses%2C%20we%20recommend%20using%20the%20reverse%20Weibull%20model.%20For%20example%2C%20if%20a%20country%20reports%20an%2080%25%20rate%20of%20viral%20suppression%20at%20%26lt%3B200%20copies%5C%2Fml%2C%20this%20model%20estimates%20the%20proportion%20virally%20suppressed%20at%20%26lt%3B1000%20copies%5C%2Fml%20is%2088.3%25%20%280.800.56%20%29%2C%20with%20uncertainty%20range%2085.5-90.6%25%20%280.800.70%20-0.800.44%20%29.%5CnCONCLUSIONS%3A%20Estimates%20of%20viral%20suppression%20can%20change%20substantially%20depending%20on%20the%20threshold%20used%20in%20defining%20viral%20suppression.%20It%20is%2C%20therefore%2C%20important%20that%20viral%20suppression%20rates%20are%20standardized%20to%20the%20same%20threshold%20for%20the%20purpose%20of%20assessing%20progress%20towards%20UNAIDS%20targets.%20We%20have%20proposed%20a%20simple%20adjustment%20that%20allows%20this%2C%20and%20this%20has%20been%20incorporated%20into%20UNAIDS%20modelling%20software.%22%2C%22date%22%3A%222021-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25776%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234546623%22%2C%22PMCID%22%3A%22PMC8454679%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A12%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22UP8RQPXJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Somerville%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSomerville%20K%2C%20Jenkins%20CA%2C%20Carlucci%20JG%2C%20Person%20AK%2C%20Machado%20DM%2C%20Luque%20MT%2C%20et%20al.%20Outcomes%20After%20Second-Line%20Antiretroviral%20Therapy%20in%20Children%20Living%20With%20HIV%20in%20Latin%20America.%20J%20Acquir%20Immune%20Defic%20Syndr.%202021%20Jul%201%3B87%283%29%3A993%26%23×2013%3B1001.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002678%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAI.0000000000002678%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033675618%3B%20PubMed%20Central%20PMCID%3A%20PMC8192432.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20After%20Second-Line%20Antiretroviral%20Therapy%20in%20Children%20Living%20With%20HIV%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kayla%22%2C%22lastName%22%3A%22Somerville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20G.%22%2C%22lastName%22%3A%22Carlucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20M.%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20T.%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%20K.%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Little%20is%20known%20about%20the%20long-term%20outcomes%20of%20children%20living%20with%20HIV%20in%20Latin%20America.%20Few%20studies%20have%20examined%20antiretroviral%20therapy%20%28ART%29%20regimen%20switches%20in%20the%20years%20after%20the%20introduction%20of%20ART%20in%20this%20population.%20This%20study%20aimed%20to%20assess%20clinical%20outcomes%20among%20children%20who%20started%20second-line%20ART%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology.%5CnMETHODS%3A%20Children%20%28%26lt%3B18%20years%20old%29%20with%20HIV%20who%20switched%20to%20second-line%20ART%20at%20sites%20within%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20were%20included.%20The%20cumulative%20incidence%20and%20relative%20hazards%20of%20virologic%20failure%20while%20on%20second-line%20ART%2C%20loss%20to%20follow-up%2C%20additional%20major%20ART%20regimen%20changes%2C%20and%20all-cause%20mortality%20were%20evaluated%20using%20competing%20risks%20methods%20and%20Cox%20models.%5CnRESULTS%3A%20A%20total%20of%20672%20children%20starting%20second-line%20ART%20were%20included.%20Three%20years%20after%20starting%20second-line%20ART%2C%20the%20cumulative%20incidence%20of%20death%20was%200.10%20%5B95%25%20confidence%20interval%20%28CI%29%200.08%20to%200.13%5D%2C%20loss%20to%20follow-up%20was%200.14%20%2895%25%20CI%3A%200.11%20to%200.17%29%2C%20and%20major%20regimen%20change%20was%200.19%20%2895%25%20CI%3A%200.15%20to%200.22%29.%20Of%20those%20changing%20regimens%2C%2035%25%20were%20due%20to%20failure%20and%2011%25%20due%20to%20toxicities%5C%2Fside%20effects.%20Among%20the%20312%20children%20with%20viral%20load%20data%2C%20the%20cumulative%20incidence%20of%20virologic%20failure%20at%203%20years%20was%200.62%20%2895%25%20CI%3A%200.56%20to%200.68%29%3B%20time%20to%20virologic%20failure%20and%20regimen%20change%20were%20uncorrelated%20%28rank%20correlation%20-0.001%3B%2095%25%20CI%20-0.18%20to%200.17%29.%5CnCONCLUSIONS%3A%20Poor%20outcomes%20after%20starting%20second-line%20ART%20in%20Latin%20America%20were%20common.%20The%20high%20incidence%20of%20virologic%20failure%20and%20its%20poor%20correlation%20with%20changing%20regimens%20was%20particularly%20worrisome.%20Additional%20efforts%20are%20needed%20to%20ensure%20children%20receive%20optimal%20ART%20regimens.%22%2C%22date%22%3A%222021-07-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAI.0000000000002678%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233675618%22%2C%22PMCID%22%3A%22PMC8192432%22%2C%22ISSN%22%3A%221944-7884%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A11%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22L98KN9ML%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Joseph%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJoseph%20Y%2C%20Yao%20Z%2C%20Dua%20A%2C%20Severe%20P%2C%20Collins%20SE%2C%20Bang%20H%2C%20et%20al.%20Long-term%20mortality%20after%20tuberculosis%20treatment%20among%20persons%20living%20with%20HIV%20in%20Haiti.%20J%20Int%20AIDS%20Soc.%202021%20Jul%3B24%287%29%3Ae25721.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25721%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25721%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034235862%3B%20PubMed%20Central%20PMCID%3A%20PMC8264404.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20mortality%20after%20tuberculosis%20treatment%20among%20persons%20living%20with%20HIV%20in%20Haiti%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yvetot%22%2C%22lastName%22%3A%22Joseph%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhiwen%22%2C%22lastName%22%3A%22Yao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akanksha%22%2C%22lastName%22%3A%22Dua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Severe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20E.%22%2C%22lastName%22%3A%22Collins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heejung%22%2C%22lastName%22%3A%22Bang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Antoine%20Jean-Juste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oksana%22%2C%22lastName%22%3A%22Ocheretina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Apollon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaret%20L.%22%2C%22lastName%22%3A%22McNairy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Dupnik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Cremieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Byrne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serena%20P.%22%2C%22lastName%22%3A%22Koenig%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Long-term%20mortality%20among%20TB%20survivors%20appears%20to%20be%20higher%20than%20control%20populations%20without%20TB%20in%20many%20settings.%20However%2C%20data%20are%20limited%20among%20persons%20with%20HIV%20%28PWH%29.%20We%20assessed%20the%20association%20between%20cured%20TB%20and%20long-term%20mortality%20among%20persons%20with%20PWH%20in%20Haiti.%5CnMETHODS%3A%20A%20prospective%20cohort%20of%20PWH%20from%20the%20CIPRA%20HT-001%20trial%20was%20followed%20from%20study%20enrolment%20%28August%202005%20to%20July%202008%29%20to%20study%20closure%20%28December%202018%29%20to%20compare%20mortality%20between%20participants%20with%20and%20without%20TB.%20The%20index%20date%20for%20the%20survival%20analysis%20was%20defined%20as%20240%5Cu00a0days%20after%20TB%20diagnosis%20or%20randomization%20date.%20Time%20to%20death%20was%20described%20using%20Kaplan-Meier%20curves%2C%20and%20log-rank%20tests%20were%20used%20to%20compare%20time%20to%20death%20between%20the%20TB%20and%20no-TB%20cohorts.%20The%20association%20between%20TB%20and%20long-term%20mortality%20was%20estimated%20with%20multivariable%20Cox%20models.%5CnRESULTS%3A%20Of%20the%20816%20participants%20in%20the%20CIPRA%20HT-001%20trial%2C%2077%20were%20excluded%20for%20a%20history%20of%20TB%20prior%20to%20study%20enrolment%20and%2031%20were%20excluded%20due%20to%20death%20or%20attrition%20prior%20to%20the%20index%20date%2C%20leaving%20574%20in%20the%20no-TB%20and%20134%20in%20the%20TB%20cohort.%20Twenty-four%20%2817.9%25%29%20participants%20in%20the%20TB%20and%2048%20%288.4%25%29%20in%20the%20no-TB%20cohort%20died%20during%20follow-up.%20Five%20and%2010-year%20mortality%20rates%20were%2014.2%25%20and%2017.9%25%20respectively%2C%20in%20the%20TB%20cohort%2C%20and%206.1%25%20and%208.4%25%20in%20the%20no-TB%20cohort.%20In%20Kaplan-Meier%20analysis%2C%20participants%20in%20the%20TB%20cohort%20had%20a%20significantly%20shorter%20time%20to%20death%20%28log-rank%20p%5Cu00a0%26lt%3B%5Cu00a00.001%29.%20In%20multivariable%20analysis%2C%20TB%20treatment%20was%20the%20only%20predictor%20of%20mortality%20%28HR%3A%202.78%3B%2095%25%20CI%3A%201.61%2C%204.79%29.%20Sensitivity%20analyses%2C%20which%20included%20only%20baseline%20TB%20cases%2C%20an%20index%20date%20of%20two%20years%20after%20TB%20diagnosis%2C%20and%20study%20enrolment%20and%20case-control%20matching%20yielded%20results%20that%20were%20consistent%20with%20primary%20analyses.%5CnCONCLUSIONS%3A%20PWH%20who%20are%20successfully%20treated%20for%20TB%20have%20higher%20long-term%20mortality%20than%20those%20who%20are%20never%20diagnosed%20with%20TB%2C%20even%20after%20accounting%20for%20acute%20TB-related%20mortality.%20A%20better%20understanding%20of%20the%20underlying%20mechanisms%20associated%20with%20TB%20sequelae%20is%20critically%20needed%20to%20guide%20specific%20interventions.%20Until%20then%2C%20more%20aggressive%20measures%20for%20health%20promotion%20and%20disease%20prevention%20are%20essential%20to%20improve%20long-term%20survival%20for%20PWH%20after%20TB%20treatment.%22%2C%22date%22%3A%222021-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25721%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234235862%22%2C%22PMCID%22%3A%22PMC8264404%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A11%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22CNW2CY6C%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Z%5Cu00fcrcher%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZ%26%23xFC%3Brcher%20K%2C%20Reichmuth%20ML%2C%20Ballif%20M%2C%20Loiseau%20C%2C%20Borrell%20S%2C%20Reinhard%20M%2C%20et%20al.%20Mortality%20from%20drug-resistant%20tuberculosis%20in%20high-burden%20countries%20comparing%20routine%20drug%20susceptibility%20testing%20with%20whole-genome%20sequencing%3A%20a%20multicentre%20cohort%20study.%20Lancet%20Microbe.%202021%20Jul%3B2%287%29%3Ae320%26%23×2013%3B30.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900044-6%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2821%2900044-6%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035252901%3B%20PubMed%20Central%20PMCID%3A%20PMC8896764.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mortality%20from%20drug-resistant%20tuberculosis%20in%20high-burden%20countries%20comparing%20routine%20drug%20susceptibility%20testing%20with%20whole-genome%20sequencing%3A%20a%20multicentre%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Borrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Reinhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronika%22%2C%22lastName%22%3A%22Skrivankova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rico%22%2C%22lastName%22%3A%22H%5Cu00f6mke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Sander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alash%27le%20G.%22%2C%22lastName%22%3A%22Abimiku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jimena%22%2C%22lastName%22%3A%22Collantes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Jane%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Huebner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Drug%20resistance%20threatens%20global%20tuberculosis%20control.%20We%20aimed%20to%20examine%20mortality%20in%20patients%20with%20tuberculosis%20from%20high-burden%20countries%2C%20according%20to%20concordance%20or%20discordance%20of%20results%20from%20drug%20susceptibility%20testing%20done%20locally%20and%20whole-genome%20sequencing%20%28WGS%29.%5CnMETHODS%3A%20In%20this%20multicentre%20cohort%20study%2C%20we%20collected%20pulmonary%20Mycobacterium%20tuberculosis%20isolates%20and%20clinical%20data%20from%20individuals%20with%20tuberculosis%20from%20antiretroviral%20therapy%20programmes%20and%20tuberculosis%20clinics%20in%20C%5Cu00f4te%20d%26%23039%3BIvoire%2C%20Democratic%20Republic%20of%20the%20Congo%2C%20Kenya%2C%20Nigeria%2C%20Peru%2C%20South%20Africa%2C%20and%20Thailand%2C%20stratified%20by%20HIV%20status%20and%20drug%20resistance.%20Sites%20tested%20drug%20susceptibility%20using%20routinely%20available%20methods.%20WGS%20was%20done%20on%20Illumina%20HiSeq%202500%20in%20the%20USA%20and%20Switzerland%2C%20and%20TBprofiler%20was%20used%20to%20analyse%20the%20genomes.%20We%20included%20individuals%20aged%2016%20years%20or%20older%20with%20pulmonary%20tuberculosis%20%28bacteriologically%20confirmed%20or%20clinically%20diagnosed%29.%20We%20analysed%20mortality%20in%20multivariable%20logistic%20regression%20models%20adjusted%20for%20sex%2C%20age%2C%20HIV%20status%2C%20history%20of%20tuberculosis%2C%20and%20sputum%20positivity.%5CnFINDINGS%3A%20Between%20Sept%201%2C%202014%2C%20and%20July%204%2C%202016%2C%20of%20634%20patients%20included%20in%20our%20previous%20analysis%2C%20we%20included%20582%20patients%20with%20tuberculosis%20%28median%20age%2033%20years%20%5BIQR%2027-43%5D%2C%20225%20%5B39%25%5D%20women%2C%20and%20247%20%5B42%25%5D%20HIV-positive%29.%20Based%20on%20WGS%2C%20339%20%2858%25%29%20isolates%20were%20pan-susceptible%2C%2035%20%286%25%29%20monoresistant%2C%20146%20%2825%25%29%20multidrug-resistant%2C%20and%2024%20%284%25%29%20pre-extensively%20drug-resistant%20%28pre-XDR%29%20or%20XDR.%20The%20analysis%20of%20mortality%20was%20based%20on%20530%20patients%3B%2063%20%2812%25%29%20died%20and%2077%20%2815%25%29%20patients%20received%20inappropriate%20treatment.%20Mortality%20ranged%20from%206%25%20%2818%20of%20310%29%20in%20patients%20with%20pan-susceptible%20tuberculosis%20to%2039%25%20%28nine%20of%2023%29%20in%20patients%20with%20pre-XDR%20or%20XDR%20tuberculosis.%20The%20adjusted%20odds%20ratio%20for%20mortality%20was%204%5Cu00b792%20%2895%25%20CI%202%5Cu00b747-9%5Cu00b778%29%20among%20undertreated%20patients%2C%20compared%20with%20appropriately%20treated%20patients.%5CnINTERPRETATION%3A%20In%20seven%20countries%20with%20a%20high%20burden%20of%20tuberculosis%2C%20we%20observed%20discrepancies%20between%20drug%20resistance%20patterns%20obtained%20locally%20and%20WGS.%20The%20underdiagnosis%20of%20drug%20resistance%20resulted%20in%20inappropriate%20treatment%20and%20higher%20mortality.%20WGS%20can%20provide%20accurate%20and%20detailed%20drug%20resistance%20information%20required%20to%20improve%20the%20outcomes%20of%20drug-resistant%20tuberculosis%20in%20high-burden%20settings.%20Our%20results%20support%20WHO%26%23039%3Bs%20call%20for%20point-of-care%20tests%20based%20on%20WGS.%5CnFUNDING%3A%20National%20Institutes%20of%20Allergy%20and%20Infectious%20Diseases%2C%20Swiss%20National%20Science%20Foundation%2C%20and%20Swiss%20National%20Center%20for%20Mycobacteria.%22%2C%22date%22%3A%222021-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2666-5247%2821%2900044-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235252901%22%2C%22PMCID%22%3A%22PMC8896764%22%2C%22ISSN%22%3A%222666-5247%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A16%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22IASSXK9M%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Chiao%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BChiao%20EY%2C%20Coghill%20A%2C%20Kizub%20D%2C%20Fink%20V%2C%20Ndlovu%20N%2C%20Mazul%20A%2C%20et%20al.%20The%20effect%20of%20non-AIDS-defining%20cancers%20on%20people%20living%20with%20HIV.%20Lancet%20Oncol.%202021%20Jun%3B22%286%29%3Ae240%26%23×2013%3B53.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1470-2045%2821%2900137-6%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1470-2045%2821%2900137-6%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034087151%3B%20PubMed%20Central%20PMCID%3A%20PMC8628366.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20non-AIDS-defining%20cancers%20on%20people%20living%20with%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20Y.%22%2C%22lastName%22%3A%22Chiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Coghill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darya%22%2C%22lastName%22%3A%22Kizub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ntokozo%22%2C%22lastName%22%3A%22Ndlovu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Mazul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Sigel%22%7D%5D%2C%22abstractNote%22%3A%22Non-AIDS-defining%20cancers%20are%20a%20growing%20source%20of%20morbidity%20for%20people%20with%20HIV%20globally.%20Although%20people%20living%20with%20HIV%20have%20a%20disproportionately%20increased%20risk%20of%20developing%20virally%20mediated%20cancers%2C%20cancer%20burden%20for%20common%20non-AIDS-defining%20cancers%20that%20are%20not%20virally%20associated%20and%20are%20linked%20to%20ageing%2C%20such%20as%20prostate%20cancer%2C%20is%20becoming%20higher%20than%20for%20virally%20mediated%20cancers.%20Ageing%2C%20behavioural%2C%20and%20HIV-specific%20factors%20drive%20the%20incidence%20and%20affect%20the%20outcomes%20of%20non-AIDS-defining%20cancers%2C%20presenting%20different%20challenges%20for%20addressing%20global%20morbidity%20and%20mortality%20from%20non-AIDS-defining%20cancer.%20Although%20large%20population-based%20studies%20have%20shown%20that%20people%20living%20with%20HIV%20with%20non-AIDS-defining%20cancers%20have%20poorer%20cancer%20outcomes%20than%20do%20people%20without%20HIV%2C%20current%20guidelines%20emphasise%20that%20people%20living%20with%20HIV%20with%20non-AIDS-defining%20cancers%20should%20receive%20standard%2C%20guideline-based%20treatment%2C%20and%20infectious%20disease%20and%20oncology%20providers%20should%20work%20closely%20to%20address%20potential%20drug%20interactions%20between%20antiretroviral%20therapy%20and%20antineoplastic%20treatment.%20Most%20trials%20target%20preventive%20measures%20focusing%20on%20non-AIDS-defining%20cancers.%20However%2C%20treatment%20trials%20for%20the%20optimal%20management%20of%20people%20living%20with%20HIV%20and%20non-AIDS-defining%20cancer%2C%20including%20interventions%20such%20as%20immunotherapies%2C%20are%20needed%20to%20improve%20non-AIDS-defining%20cancer%20outcomes.%22%2C%22date%22%3A%222021-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS1470-2045%2821%2900137-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234087151%22%2C%22PMCID%22%3A%22PMC8628366%22%2C%22ISSN%22%3A%221474-5488%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A10%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22ZP39EHCR%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Oh%20et%20al.%22%2C%22parsedDate%22%3A%222021-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BOh%20EJ%2C%20Shepherd%20BE%2C%20Lumley%20T%2C%20Shaw%20PA.%20Improved%20generalized%20raking%20estimators%20to%20address%20dependent%20covariate%20and%20failure-time%20outcome%20error.%20Biom%20J.%202021%20Jun%3B63%285%29%3A1006%26%23×2013%3B27.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202000187%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fbimj.202000187%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033709462%3B%20PubMed%20Central%20PMCID%3A%20PMC8211389.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improved%20generalized%20raking%20estimators%20to%20address%20dependent%20covariate%20and%20failure-time%20outcome%20error%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20J.%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%5D%2C%22abstractNote%22%3A%22Biomedical%20studies%20that%20use%20electronic%20health%20records%20%28EHR%29%20data%20for%20inference%20are%20often%20subject%20to%20bias%20due%20to%20measurement%20error.%20The%20measurement%20error%20present%20in%20EHR%20data%20is%20typically%20complex%2C%20consisting%20of%20errors%20of%20unknown%20functional%20form%20in%20covariates%20and%20the%20outcome%2C%20which%20can%20be%20dependent.%20To%20address%20the%20bias%20resulting%20from%20such%20errors%2C%20generalized%20raking%20has%20recently%20been%20proposed%20as%20a%20robust%20method%20that%20yields%20consistent%20estimates%20without%20the%20need%20to%20model%20the%20error%20structure.%20We%20provide%20rationale%20for%20why%20these%20previously%20proposed%20raking%20estimators%20can%20be%20expected%20to%20be%20inefficient%20in%20failure-time%20outcome%20settings%20involving%20misclassification%20of%20the%20event%20indicator.%20We%20propose%20raking%20estimators%20that%20utilize%20multiple%20imputation%2C%20to%20impute%20either%20the%20target%20variables%20or%20auxiliary%20variables%2C%20to%20improve%20the%20efficiency.%20We%20also%20consider%20outcome-dependent%20sampling%20designs%20and%20investigate%20their%20impact%20on%20the%20efficiency%20of%20the%20raking%20estimators%2C%20either%20with%20or%20without%20multiple%20imputation.%20We%20present%20an%20extensive%20numerical%20study%20to%20examine%20the%20performance%20of%20the%20proposed%20estimators%20across%20various%20measurement%20error%20settings.%20We%20then%20apply%20the%20proposed%20methods%20to%20our%20motivating%20setting%2C%20in%20which%20we%20seek%20to%20analyze%20HIV%20outcomes%20in%20an%20observational%20cohort%20with%20EHR%20data%20from%20the%20Vanderbilt%20Comprehensive%20Care%5Cu00a0Clinic.%22%2C%22date%22%3A%222021-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fbimj.202000187%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233709462%22%2C%22PMCID%22%3A%22PMC8211389%22%2C%22ISSN%22%3A%221521-4036%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A10%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22HUWU5LPS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Tsondai%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTsondai%20PR%2C%20Davies%20MA%2C%20Singtoroj%20T%2C%20Maxwell%20N%2C%20McGowan%20CC%2C%20Songtaweesin%20WN%2C%20et%20al.%20Improving%20Methods%20to%20Classify%20Perinatal%20versus%20Nonperinatal%20HIV%20Acquisition%20in%20Young%20Adolescents%2010-14%20Years%20of%20Age.%20Pediatr%20Infect%20Dis%20J.%202021%20May%201%3B40%285%29%3A453%26%23×2013%3B6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000003059%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FINF.0000000000003059%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033538538%3B%20PubMed%20Central%20PMCID%3A%20PMC8043971.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improving%20Methods%20to%20Classify%20Perinatal%20versus%20Nonperinatal%20HIV%20Acquisition%20in%20Young%20Adolescents%2010-14%20Years%20of%20Age%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priscilla%20Ruvimbo%22%2C%22lastName%22%3A%22Tsondai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thida%22%2C%22lastName%22%3A%22Singtoroj%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wipaporn%20N.%22%2C%22lastName%22%3A%22Songtaweesin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karl-G%5Cu00fcnter%22%2C%22lastName%22%3A%22Technau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleophas%22%2C%22lastName%22%3A%22Chimbetete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20C.%20M.%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22Mode%20of%20HIV%20acquisition%20for%20adolescents%20with%20HIV%20is%20often%20not%20recorded%20within%20routine%20healthcare%20databases.%20Hence%2C%20age%20at%20enrollment%20in%20HIV%20care%20is%20often%20used%20as%20a%20proxy%20for%20perinatal%20versus%20nonperinatal%20infection.%20Using%20routine%20cohort%20data%20from%20adolescents%20presenting%20for%20HIV%20care%2010-14%20years%20of%20age%2C%20we%20developed%20logistic%20regression%20models%20to%20predict%20likely%20mode%20of%20infection.%22%2C%22date%22%3A%222021-05-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FINF.0000000000003059%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233538538%22%2C%22PMCID%22%3A%22PMC8043971%22%2C%22ISSN%22%3A%221532-0987%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A06%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22C56JT5TS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Yohannes%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BYohannes%20NT%2C%20Jenkins%20CA%2C%20Clouse%20K%2C%20Cort%26%23xE9%3Bs%20CP%2C%20Mej%26%23xED%3Ba%20Cordero%20F%2C%20Padgett%20D%2C%20et%20al.%20Timing%20of%20HIV%20diagnosis%20relative%20to%20pregnancy%20and%20postpartum%20HIV%20care%20continuum%20outcomes%20among%20Latin%20American%20women%2C%202000%20to%202017.%20J%20Int%20AIDS%20Soc.%202021%20May%3B24%285%29%3Ae25740.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25740%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25740%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034021715%3B%20PubMed%20Central%20PMCID%3A%20PMC8140191.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Timing%20of%20HIV%20diagnosis%20relative%20to%20pregnancy%20and%20postpartum%20HIV%20care%20continuum%20outcomes%20among%20Latin%20American%20women%2C%202000%20to%202017%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathaniel%20T.%22%2C%22lastName%22%3A%22Yohannes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kate%22%2C%22lastName%22%3A%22Clouse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cort%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mej%5Cu00eda%20Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%20K.%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20HIV%20incidence%20among%20women%20of%20reproductive%20age%20and%20vertical%20HIV%20transmission%20rates%20remain%20high%20in%20Latin%20America.%20We%2C%20therefore%2C%20quantified%20HIV%20care%20continuum%20barriers%20and%20outcomes%20among%20pregnant%20women%20living%20with%20HIV%20%28WLWH%29%20in%20Latin%20America.%5CnMETHODS%3A%20WLWH%20%28aged%20%5Cu226516%5Cu00a0years%29%20enrolling%20at%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20sites%20from%202000%20to%202017%20who%20had%20HIV%20diagnosis%2C%20pregnancy%20and%20delivery%20dates%20contributed.%20Logistic%20regression%20produced%20adjusted%20odds%20ratios%20%28aOR%29%20and%2095%25%20confidence%20intervals%20%28CI%29%20for%20retention%20in%20care%20%28%5Cu22652%20visits%20%5Cu22653%5Cu00a0months%20apart%29%20and%20virological%20suppression%20%28viral%20load%20%26lt%3B200%20copies%5C%2FmL%29%2012%5Cu00a0months%20after%20pregnancy%20outcome.%20Cumulative%20incidences%20of%20loss%20to%20follow-up%20%28LTFU%29%20postpartum%20were%20estimated%20using%20Cox%20regression.%20Evidence%20of%20HIV%20status%20at%20pregnancy%20confirmation%20was%20the%20exposure.%20Covariates%20included%20pregnancy%20outcome%20%28born%20alive%20vs.%20others%29%3B%20AIDS%20diagnosis%20prior%20to%20delivery%3B%20CD4%2C%20age%2C%20HIV-1%20RNA%20and%20cART%20regimen%20at%20first%20delivery%20and%20CCASAnet%20country.%5CnRESULTS%3A%20Among%20579%20WLWH%2C%20median%20postpartum%20follow-up%20was%204.34%5Cu00a0years%20%28IQR%201.91%2C%207.35%29%3B%20459%20%2879%25%29%20were%20HIV-diagnosed%20before%20pregnancy%20confirmation%2C%20445%20%2877%25%29%20retained%20in%20care%20and%20259%20%2845%25%29%20virologically%20suppressed%20at%2012%5Cu00a0months%20of%20postpartum.%20Cumulative%20incidence%20of%20LTFU%20was%2021%25%20by%2012%5Cu00a0months%20and%2040%25%20by%20five%20years%20postpartum.%20Those%20HIV-diagnosed%20during%20pregnancy%20had%20lower%20odds%20of%20retention%20%28aOR%5Cu00a0%3D%5Cu00a00.58%2C%2095%25%20CI%3A%200.35%20to%200.97%29%20and%20virological%20suppression%20%28aOR%5Cu00a0%3D%5Cu00a00.50%2C%2095%25%20CI%3A%200.31%20to%200.82%29%20versus%20those%20HIV-diagnosed%20before.%5CnCONCLUSION%3A%20HIV%20diagnosis%20during%20pregnancy%20was%20associated%20with%20poorer%2012-month%20retention%20and%20virological%20suppression.%20Young%20women%20should%20be%20tested%20and%20linked%20to%20HIV%20care%20earlier%20to%20narrow%20these%20disparities.%22%2C%22date%22%3A%222021-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25740%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234021715%22%2C%22PMCID%22%3A%22PMC8140191%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A10%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22FBH28KWD%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Smiley%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSmiley%20CL%2C%20Rebeiro%20PF%2C%20Cesar%20C%2C%20Belaunzaran-Zamudio%20PF%2C%20Crabtree-Ramirez%20B%2C%20Padgett%20D%2C%20et%20al.%20Estimated%20life%20expectancy%20gains%20with%20antiretroviral%20therapy%20among%20adults%20with%20HIV%20in%20Latin%20America%20and%20the%20Caribbean%3A%20a%20multisite%20retrospective%20cohort%20study.%20Lancet%20HIV.%202021%20May%3B8%285%29%3Ae266%26%23×2013%3B73.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930358-1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930358-1%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033891877%3B%20PubMed%20Central%20PMCID%3A%20PMC8171816.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Estimated%20life%20expectancy%20gains%20with%20antiretroviral%20therapy%20among%20adults%20with%20HIV%20in%20Latin%20America%20and%20the%20Caribbean%3A%20a%20multisite%20retrospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Casey%20L.%22%2C%22lastName%22%3A%22Smiley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20There%20are%20few%20data%20on%20life%20expectancy%20gains%20among%20people%20living%20with%20HIV%20in%20low-income%20and%20middle-income%20settings%20where%20antiretroviral%20therapy%20%28ART%29%20is%20increasingly%20available.%20We%20aimed%20to%20analyse%20life%20expectancy%20trends%20from%202003%20to%202017%20among%20people%20with%20HIV%20beginning%20treatment%20with%20ART%20within%20the%20Caribbean%2C%20central%20America%2C%20and%20South%20America.%5CnMETHODS%3A%20We%20did%20a%20multisite%20retrospective%20cohort%20study%20and%20included%20people%20with%20HIV%20who%20had%20started%20treatment%20with%20ART%20and%20were%20aged%2016%20years%20or%20older%20between%20Jan%201%2C%202003%2C%20and%20Dec%2031%2C%202017%2C%20from%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%20sites%20in%20Argentina%2C%20Brazil%2C%20Chile%2C%20Haiti%2C%20Honduras%2C%20Mexico%2C%20and%20Peru%2C%20who%20contributed%20person-time%20data%20from%20the%20age%20of%2020%20years%20until%20date%20of%20death%2C%20last%20contact%2C%20database%20closure%2C%20or%20Dec%2031%2C%202017.%20We%20used%20the%20Chiang%20method%20of%20abridged%20life%20tables%20to%20estimate%20life%20expectancy%20at%20age%2020%20years%20for%20three%20eras%20%282003-08%2C%202009-12%2C%20and%202013-17%29%20overall%20and%20by%20demographic%20and%20clinical%20characteristics%20at%20ART%20initiation.%20We%20used%20Poisson%20regression%20models%20to%20weight%20mortality%20rates%20to%20account%20for%20informative%20censoring.%5CnFINDINGS%3A%2030%5Cu2009688%20people%20with%20HIV%20were%20included%20in%20the%20study%3B%2017%5Cu2009491%20%2857%5Cu00b70%25%29%20were%20from%20the%20Haiti%20site%20and%2013%5Cu2009197%20%2843%5Cu00b70%25%29%20were%20from%20all%20other%20sites.%20There%20were%202637%20deaths%20during%20the%20study%20period%3A%201470%20in%20Haiti%20and%201167%20in%20other%20sites.%20Crude%20and%20weighted%20mortality%20rates%20decreased%20among%20all%20age%20groups%20over%20calendar%20eras.%20From%202003-08%20to%202013-17%2C%20overall%20life%20expectancy%20for%20people%20with%20HIV%20at%20age%2020%20years%20increased%20from%2013%5Cu00b79%20years%20%2895%25%20CI%2012%5Cu00b75-15%5Cu00b72%29%20to%2061%5Cu00b72%20years%20%2859%5Cu00b70-63%5Cu00b74%29%20in%20Haiti%20and%20from%2031%5Cu00b70%20years%20%2829%5Cu00b73-32%5Cu00b78%29%20to%2069%5Cu00b75%20years%20%2867%5Cu00b72-71%5Cu00b78%29%20in%20other%20sites.%20Life%20expectancies%20at%20the%20end%20of%20the%20study%20period%20were%20within%2010%20years%20of%20those%20of%20the%20general%20population%20%2869%5Cu00b79%20years%20in%20Haiti%20and%2078%5Cu00b70%20years%20in%20all%20other%20sites%20in%202018%29.%20Disparities%20in%20life%20expectancy%20among%20people%20with%20HIV%20by%20sex%20or%20HIV%20transmission%20risk%20factor%2C%20CD4%20cell%20count%2C%20level%20of%20education%2C%20and%20history%20of%20tuberculosis%20at%20or%20before%20ART%20initiation%20persisted%20across%20calendar%20eras.%5CnINTERPRETATION%3A%20Life%20expectancy%20among%20people%20with%20HIV%20receiving%20ART%20has%20significantly%20improved%20in%20Latin%20America%20and%20the%20Caribbean.%20Persistent%20disparities%20in%20life%20expectancy%20among%20people%20with%20HIV%20by%20demographic%20and%20clinical%20factors%20at%20ART%20initiation%20highlight%20vulnerable%20populations%20in%20the%20region.%5CnFUNDING%3A%20National%20Institutes%20of%20Health.%5CnTRANSLATION%3A%20For%20the%20Spanish%20translation%20of%20the%20abstract%20see%20Supplementary%20Materials%20section.%22%2C%22date%22%3A%222021-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2820%2930358-1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233891877%22%2C%22PMCID%22%3A%22PMC8171816%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A09%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22E5T9PBLV%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Nascimento-Carvalho%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BNascimento-Carvalho%20GC%2C%20Nascimento-Carvalho%20EC%2C%20Ramos%20CL%2C%20Vilas-Boas%20AL%2C%20Moreno-Carvalho%20OA%2C%20Vinhaes%20CL%2C%20et%20al.%20Zika-exposed%20microcephalic%20neonates%20exhibit%20higher%20degree%20of%20inflammatory%20imbalance%20in%20cerebrospinal%20fluid.%20Sci%20Rep.%202021%20Apr%2019%3B11%281%29%3A8474.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-87895-4%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-87895-4%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033875756%3B%20PubMed%20Central%20PMCID%3A%20PMC8055905.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Zika-exposed%20microcephalic%20neonates%20exhibit%20higher%20degree%20of%20inflammatory%20imbalance%20in%20cerebrospinal%20fluid%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%20C.%22%2C%22lastName%22%3A%22Nascimento-Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20C.%22%2C%22lastName%22%3A%22Nascimento-Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%20L.%22%2C%22lastName%22%3A%22Ramos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana-Luisa%22%2C%22lastName%22%3A%22Vilas-Boas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ot%5Cu00e1vio%20A.%22%2C%22lastName%22%3A%22Moreno-Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristiana%20M.%22%2C%22lastName%22%3A%22Nascimento-Carvalho%22%7D%5D%2C%22abstractNote%22%3A%22Not%20every%20neonate%20with%20congenital%20Zika%20virus%20%28ZIKV%29%20infection%20%28CZI%29%20is%20born%20with%20microcephaly.%20We%20compared%20inflammation%20mediators%20in%20CSF%20%28cerebrospinal%20fluid%20obtained%20from%20lumbar%20puncture%29%20between%20ZIKV-exposed%20neonates%20with%5C%2Fwithout%20microcephaly%20%28cases%29%20and%20controls.%20In%20Brazil%2C%20in%20the%20same%20laboratory%2C%20we%20identified%2014%20ZIKV-exposed%20neonates%20during%20the%20ZIKV%20epidemic%20%282015-2016%29%2C%207%2850%25%29%20with%20and%207%2850%25%29%20without%20microcephaly%2C%20without%20any%20other%20congenital%20infection%2C%20and%2014%20neonates%20%282017-2018%29%20eligible%20to%20be%20controls%20and%20to%20match%20cases.%2029%20inflammation%20mediators%20were%20measured%20using%20Luminex%20immunoassay%20and%20multidimensional%20analyses%20were%20employed.%20Neonates%20with%20ZIKV-associated%20microcephaly%20presented%20substantially%20higher%20degree%20of%20inflammatory%20perturbation%2C%20associated%20with%20uncoupled%20inflammatory%20response%20and%20decreased%20correlations%20between%20concentrations%20of%20inflammatory%20biomarkers.%20The%20groups%20of%20microcephalic%20and%20non-microcephalic%20ZIKV-exposed%20neonates%20were%20distinguished%20from%20the%20control%20group%20%28area%20under%20curve%20%5BAUC%5D%5Cu2009%3D%5Cu20091%3B%20P%5Cu2009%26lt%3B%5Cu20090.0001%29.%20Between%20controls%20and%20those%20non-microcephalic%20exposed%20to%20ZIKV%2C%20IL-1%5Cu03b2%2C%20IL-3%2C%20IL-4%2C%20IL-7%20and%20EOTAXIN%20were%20the%20top%20CSF%20markers.%20By%20comparing%20the%20microcephalic%20cases%20with%20controls%2C%20the%20top%20discriminant%20scores%20were%20for%20IL-1%5Cu03b2%2C%20IL-3%2C%20EOTAXIN%20and%20IL-12p70.%20The%20degree%20of%20inflammatory%20imbalance%20may%20be%20associated%20with%20microcephaly%20in%20CZI%20and%20it%20may%20aid%20additional%20investigations%20in%20experimental%20pre-clinical%20models%20testing%20immune%20modulators%20in%20preventing%20extensive%20damage%20of%20the%20Central%20Nervous%20System.%22%2C%22date%22%3A%222021-04-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-87895-4%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233875756%22%2C%22PMCID%22%3A%22PMC8055905%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A09%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22VGW9BUYP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Spener-Gomes%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSpener-Gomes%20R%2C%20Costa%20AG%2C%20Melo%20HF%20de%2C%20Souza%20AB%20de%2C%20Beraldi-Magalh%26%23xE3%3Bes%20F%2C%20Jesus%20JS%2C%20et%20al.%20Examination%20of%20respiratory%20specimens%20improves%20microbiological%20diagnosis%20of%20patients%20with%20presumptive%20extrapulmonary%20tuberculosis.%20Int%20J%20Infect%20Dis.%202021%20Apr%3B105%3A743%26%23×2013%3B5.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2021.03.022%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2021.03.022%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033722683%3B%20PubMed%20Central%20PMCID%3A%20PMC8941595.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Examination%20of%20respiratory%20specimens%20improves%20microbiological%20diagnosis%20of%20patients%20with%20presumptive%20extrapulmonary%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allyson%20Guimar%5Cu00e3es%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hilda%20Ferreira%20de%22%2C%22lastName%22%3A%22Melo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20Brito%20de%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Beraldi-Magalh%5Cu00e3es%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaquelane%20Silva%22%2C%22lastName%22%3A%22Jesus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Izabella%22%2C%22lastName%22%3A%22Safe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anete%22%2C%22lastName%22%3A%22Trajman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Bacteriological%20confirmation%20of%20extrapulmonary%20tuberculosis%20%28EPTB%29%20is%20challenging%20for%20several%20reasons%3A%20the%20paucibacillary%20nature%20of%20the%20sample%3B%20scarce%20resources%2C%20mainly%20in%20middle%20and%20low-income%20countries%3B%20the%20need%20for%20hospitalization%3B%20and%20unfavorable%20outcomes.%20We%20evaluated%20the%20diagnostic%20role%20of%20respiratory%20specimen%20examination%20prospectively%20in%20a%20cohort%20of%20patients%20with%20presumptive%20EPTB.%5CnMETHODS%3A%20From%20July%202018%20to%20January%202019%2C%20in%20a%20tuberculosis%20%28TB%29%5C%2FHIV%20reference%20hospital%2C%20a%20cohort%20of%20157%20patients%20with%20presumed%20EPTB%20was%20evaluated.%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20Ultra%20or%20a%20culture-positive%20result%20was%20considered%20for%20bacteriologically%20confirmed%20TB.%5CnRESULTS%3A%20Out%20of%20157%20patients%20with%20presumptive%20EPTB%2C%2097%20%2862%25%29%20provided%20extrapulmonary%20and%20respiratory%20specimens%20and%2060%20%2838%25%29%20extrapulmonary%20specimens%20only.%20Of%20the%2060%20patients%20with%20extrapulmonary%20samples%2C%205%20%288%25%29%20were%20positive.%20Of%20those%20with%20respiratory%20and%20extrapulmonary%20samples%2C%2027%20%2828%25%29%20were%20positive%3A%2010%20in%20both%20the%20respiratory%20and%20extrapulmonary%20samples%2C%206%20in%20the%20extrapulmonary%20sample%20only%2C%20and%2011%20in%20the%20respiratory%20sample%20only.%20A%20respiratory%20specimen%20examination%20increased%20by%206-fold%20the%20chance%20of%20bacteriological%20confirmation%20of%20TB%20%28odds%20ratio%20%3D%205.97%20%5B1.11-47.17%5D%29.%5CnCONCLUSION%3A%20We%20conclude%20that%20respiratory%20samples%20should%20be%20examined%20in%20patients%20with%20presumptive%20EPTB.%22%2C%22date%22%3A%222021-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2021.03.022%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233722683%22%2C%22PMCID%22%3A%22PMC8941595%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A09%3A35Z%22%7D%7D%2C%7B%22key%22%3A%227S6QCLVA%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Peetluk%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPeetluk%20LS%2C%20Ridolfi%20FM%2C%20Rebeiro%20PF%2C%20Liu%20D%2C%20Rolla%20VC%2C%20Sterling%20TR.%20Systematic%20review%20of%20prediction%20models%20for%20pulmonary%20tuberculosis%20treatment%20outcomes%20in%20adults.%20BMJ%20Open.%202021%20Mar%202%3B11%283%29%3Ae044687.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-044687%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fbmjopen-2020-044687%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033653759%3B%20PubMed%20Central%20PMCID%3A%20PMC7929865.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Systematic%20review%20of%20prediction%20models%20for%20pulmonary%20tuberculosis%20treatment%20outcomes%20in%20adults%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%20M.%22%2C%22lastName%22%3A%22Ridolfi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dandan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20systematically%20review%20and%20critically%20evaluate%20prediction%20models%20developed%20to%20predict%20tuberculosis%20%28TB%29%20treatment%20outcomes%20among%20adults%20with%20pulmonary%20TB.%5CnDESIGN%3A%20Systematic%20review.%5CnDATA%20SOURCES%3A%20PubMed%2C%20Embase%2C%20Web%20of%20Science%20and%20Google%20Scholar%20were%20searched%20for%20studies%20published%20from%201%20January%201995%20to%209%20January%202020.%5CnSTUDY%20SELECTION%20AND%20DATA%20EXTRACTION%3A%20Studies%20that%20developed%20a%20model%20to%20predict%20pulmonary%20TB%20treatment%20outcomes%20were%20included.%20Study%20screening%2C%20data%20extraction%20and%20quality%20assessment%20were%20conducted%20independently%20by%20two%20reviewers.%20Study%20quality%20was%20evaluated%20using%20the%20Prediction%20model%20Risk%20Of%20Bias%20Assessment%20Tool.%20Data%20were%20synthesised%20with%20narrative%20review%20and%20in%20tables%20and%20figures.%5CnRESULTS%3A%2014%5Cu2009739%20articles%20were%20identified%2C%20536%20underwent%20full-text%20review%20and%2033%20studies%20presenting%2037%20prediction%20models%20were%20included.%20Model%20outcomes%20included%20death%20%28n%3D16%2C%2043%25%29%2C%20treatment%20failure%20%28n%3D6%2C%2016%25%29%2C%20default%20%28n%3D6%2C%2016%25%29%20or%20a%20composite%20outcome%20%28n%3D9%2C%2025%25%29.%20Most%20models%20%28n%3D30%2C%2081%25%29%20measured%20discrimination%20%28median%20c-statistic%3D0.75%3B%20IQR%3A%200.68-0.84%29%2C%20and%2017%20%2846%25%29%20reported%20calibration%2C%20often%20the%20Hosmer-Lemeshow%20test%20%28n%3D13%29.%20Nineteen%20%2851%25%29%20models%20were%20internally%20validated%2C%20and%20six%20%2816%25%29%20were%20externally%20validated.%20Eighteen%20%2854%25%29%20studies%20mentioned%20missing%20data%2C%20and%20of%20those%2C%20half%20%28n%3D9%29%20used%20complete%20case%20analysis.%20The%20most%20common%20predictors%20included%20age%2C%20sex%2C%20extrapulmonary%20TB%2C%20body%20mass%20index%2C%20chest%20X-ray%20results%2C%20previous%20TB%20and%20HIV.%20Risk%20of%20bias%20varied%20across%20studies%2C%20but%20all%20studies%20had%20high%20risk%20of%20bias%20in%20their%20analysis.%5CnCONCLUSIONS%3A%20TB%20outcome%20prediction%20models%20are%20heterogeneous%20with%20disparate%20outcome%20definitions%2C%20predictors%20and%20methodology.%20We%20do%20not%20recommend%20applying%20any%20in%20clinical%20settings%20without%20external%20validation%2C%20and%20encourage%20future%20researchers%20adhere%20to%20guidelines%20for%20developing%20and%20reporting%20of%20prediction%20models.%5CnTRIAL%20REGISTRATION%3A%20The%20study%20was%20registered%20on%20the%20international%20prospective%20register%20of%20systematic%20reviews%20PROSPERO%20%28CRD42020155782%29.%22%2C%22date%22%3A%222021-03-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fbmjopen-2020-044687%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233653759%22%2C%22PMCID%22%3A%22PMC7929865%22%2C%22ISSN%22%3A%222044-6055%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A08%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22BVWWK3WC%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rodrigues%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRodrigues%20A%2C%20Struchiner%20CJ%2C%20Coelho%20LE%2C%20Veloso%20VG%2C%20Grinsztejn%20B%2C%20Luz%20PM.%20Late%20initiation%20of%20antiretroviral%20therapy%3A%20inequalities%20by%20educational%20level%20despite%20universal%20access%20to%20care%20and%20treatment.%20BMC%20Public%20Health.%202021%20Feb%2019%3B21%281%29%3A389.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10421-8%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-021-10421-8%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033607975%3B%20PubMed%20Central%20PMCID%3A%20PMC7893724.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Late%20initiation%20of%20antiretroviral%20therapy%3A%20inequalities%20by%20educational%20level%20despite%20universal%20access%20to%20care%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20J.%22%2C%22lastName%22%3A%22Struchiner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lara%20E.%22%2C%22lastName%22%3A%22Coelho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Late%20antiretroviral%20treatment%20initiation%20for%20HIV%20disease%20worsens%20health%20outcomes%20and%20contributes%20to%20ongoing%20transmission.%20We%20investigated%20whether%20socioeconomic%20inequalities%20exist%20in%20access%20to%20treatment%20in%20a%20setting%20with%20universal%20access%20to%20care%20and%20treatment.%5CnMETHODS%3A%20This%20study%20investigated%20the%20association%20of%20educational%20level%2C%20used%20as%20a%20proxy%20for%20socioeconomic%20status%2C%20with%20late%20treatment%20initiation%20and%20treatment%20initiation%20with%20advanced%20disease.%20Study%20participants%20included%20adults%20%28%5Cu226525%5Cu2009years%29%20who%20started%20treatment%20from%202005%20to%202018%20at%20Instituto%20Nacional%20de%20Infectologia%20Evandro%20Chagas%20of%20Funda%5Cu00e7%5Cu00e3o%20Oswaldo%20Cruz%20%28INI%5C%2FFIOCRUZ%29%2C%20Rio%20de%20Janeiro%2C%20Brazil.%20Educational%20level%20was%20categorized%20following%20UNESCO%26%23039%3Bs%20International%20Standard%20Classification%20of%20Education%3A%20incomplete%20basic%20education%2C%20basic%20education%2C%20secondary%20level%2C%20and%20tertiary%20level.%20We%20defined%20late%20treatment%20initiation%20as%20those%20initiating%20treatment%20with%20a%20CD4%5Cu2009%26lt%3B%5Cu2009350%20cells%5C%2FmL%20or%20an%20AIDS-defining%20event%2C%20and%20treatment%20initiation%20with%20advanced%20disease%20as%20those%20initiating%20treatment%20with%20a%20CD4%5Cu2009%26lt%3B%5Cu2009200%20cells%5C%2FmL%20or%20an%20AIDS-defining%20event.%20A%20directed%20acyclic%20graph%20%28DAG%29%20was%20constructed%20to%20represent%20the%20theoretical-operational%20model%20and%20to%20understand%20the%20involvement%20of%20covariates.%20Logistic%20regression%20models%20were%20used%20to%20estimate%20the%20adjusted%20odds%20ratios%20%28aOR%29%20and%2095%25%20confidence%20intervals%20%2895%25CI%29.%20Multiple%20imputation%20using%20a%20chained%20equations%20approach%20was%20used%20to%20treat%20missing%20values%20and%20non-linear%20terms%20for%20continuous%20variables%20were%20tested.%5CnRESULTS%3A%20In%20total%2C%203226%20individuals%20composed%20the%20study%20population%3A%20876%20%2827.4%25%29%20had%20incomplete%20basic%20education%2C%20540%20%2816.9%25%29%20basic%2C%201251%20%2839.2%25%29%20secondary%20level%2C%20and%20525%20%2816.4%25%29%20tertiary%20level.%20Late%20treatment%20initiation%20was%20observed%20for%202076%20%2864.4%25%29%20while%20treatment%20initiation%20with%20advanced%20disease%20was%20observed%20for%201423%20%2844.1%25%29.%20Compared%20to%20tertiary%20level%20of%20education%2C%20incomplete%20basic%2C%20basic%20and%20secondary%20level%20increased%20the%20odds%20of%20late%20treatment%20initiation%20by%2089%25%20%28aOR%3A1.89%2095%25CI%3A1.47-2.43%29%2C%2061%25%20%28aOR%3A1.61%2095%25CI%3A1.23-2.10%29%2C%20and%2035%25%20%28aOR%3A1.35%2095%25CI%3A1.09-1.67%29.%20Likewise%2C%20the%20odds%20of%20treatment%20initiation%20with%20advanced%20disease%20was%202.5-fold%20%28aOR%3A2.53%2095%25CI%3A1.97-3.26%29%2C%202-fold%20%28aOR%3A2.07%2095%25CI%3A1.59-2.71%29%2C%201.5-fold%20%28aOR%3A1.51%2095%25CI%3A1.21-1.88%29%20higher%20for%20those%20with%20incomplete%20basic%2C%20basic%20and%20secondary%20level%20education%20compared%20to%20tertiary%20level.%5CnCONCLUSION%3A%20Despite%20universal%20access%20to%20HIV%20care%20and%20antiretroviral%20treatment%2C%20late%20treatment%20initiation%20and%20social%20inequalities%20persist.%20Lower%20educational%20level%20significantly%20increased%20the%20odds%20of%20both%20outcomes%2C%20reinforcing%20the%20existence%20of%20barriers%20to%20%26quot%3Buniversal%26quot%3B%20antiretroviral%20treatment.%22%2C%22date%22%3A%222021-02-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-021-10421-8%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233607975%22%2C%22PMCID%22%3A%22PMC7893724%22%2C%22ISSN%22%3A%221471-2458%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A08%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22AMDG3GK4%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Oh%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BOh%20EJ%2C%20Shepherd%20BE%2C%20Lumley%20T%2C%20Shaw%20PA.%20Raking%20and%20regression%20calibration%3A%20Methods%20to%20address%20bias%20from%20correlated%20covariate%20and%20time-to-event%20error.%20Stat%20Med.%202021%20Feb%2010%3B40%283%29%3A631%26%23×2013%3B49.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.8793%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.8793%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033140432%3B%20PubMed%20Central%20PMCID%3A%20PMC7874496.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Raking%20and%20regression%20calibration%3A%20Methods%20to%20address%20bias%20from%20correlated%20covariate%20and%20time-to-event%20error%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20J.%22%2C%22lastName%22%3A%22Oh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Lumley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%5D%2C%22abstractNote%22%3A%22Medical%20studies%20that%20depend%20on%20electronic%20health%20records%20%28EHR%29%20data%20are%20often%20subject%20to%20measurement%20error%2C%20as%20the%20data%20are%20not%20collected%20to%20support%20research%20questions%20under%20study.%20These%20data%20errors%2C%20if%20not%20accounted%20for%20in%20study%20analyses%2C%20can%20obscure%20or%20cause%20spurious%20associations%20between%20patient%20exposures%20and%20disease%20risk.%20Methodology%20to%20address%20covariate%20measurement%20error%20has%20been%20well%20developed%3B%20however%2C%20time-to-event%20error%20has%20also%20been%20shown%20to%20cause%20significant%20bias%2C%20but%20methods%20to%20address%20it%20are%20relatively%20underdeveloped.%20More%20generally%2C%20it%20is%20possible%20to%20observe%20errors%20in%20both%20the%20covariate%20and%20the%20time-to-event%20outcome%20that%20are%20correlated.%20We%20propose%20regression%20calibration%20%28RC%29%20estimators%20to%20simultaneously%20address%20correlated%20error%20in%20the%20covariates%20and%20the%20censored%20event%20time.%20Although%20RC%20can%20perform%20well%20in%20many%20settings%20with%20covariate%20measurement%20error%2C%20it%20is%20biased%20for%20nonlinear%20regression%20models%2C%20such%20as%20the%20Cox%20model.%20Thus%2C%20we%20additionally%20propose%20raking%20estimators%20which%20are%20consistent%20estimators%20of%20the%20parameter%20defined%20by%20the%20population%20estimating%20equation.%20Raking%20can%20improve%20upon%20RC%20in%20certain%20settings%20with%20failure-time%20data%2C%20require%20no%20explicit%20modeling%20of%20the%20error%20structure%2C%20and%20can%20be%20utilized%20under%20outcome-dependent%20sampling%20designs.%20We%20discuss%20features%20of%20the%20underlying%20estimation%20problem%20that%20affect%20the%20degree%20of%20improvement%20the%20raking%20estimator%20has%20over%20the%20RC%20approach.%20Detailed%20simulation%20studies%20are%20presented%20to%20examine%20the%20performance%20of%20the%20proposed%20estimators%20under%20varying%20levels%20of%20signal%2C%20error%2C%20and%20censoring.%20The%20methodology%20is%20illustrated%20on%20observational%20EHR%20data%20on%20HIV%20outcomes%20from%20the%20Vanderbilt%20Comprehensive%20Care%20Clinic.%22%2C%22date%22%3A%222021-02-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fsim.8793%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233140432%22%2C%22PMCID%22%3A%22PMC7874496%22%2C%22ISSN%22%3A%221097-0258%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A05%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22N3AA3HUL%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Tao%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTao%20R%2C%20Lotspeich%20SC%2C%20Amorim%20G%2C%20Shaw%20PA%2C%20Shepherd%20BE.%20Efficient%20semiparametric%20inference%20for%20two-phase%20studies%20with%20outcome%20and%20covariate%20measurement%20errors.%20Stat%20Med.%202021%20Feb%2010%3B40%283%29%3A725%26%23×2013%3B38.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.8799%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fsim.8799%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033145800%3B%20PubMed%20Central%20PMCID%3A%20PMC8214478.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficient%20semiparametric%20inference%20for%20two-phase%20studies%20with%20outcome%20and%20covariate%20measurement%20errors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ran%22%2C%22lastName%22%3A%22Tao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22In%20modern%20observational%20studies%20using%20electronic%20health%20records%20or%20other%20routinely%20collected%20data%2C%20both%20the%20outcome%20and%20covariates%20of%20interest%20can%20be%20error-prone%20and%20their%20errors%20often%20correlated.%20A%20cost-effective%20solution%20is%20the%20two-phase%20design%2C%20under%20which%20the%20error-prone%20outcome%20and%20covariates%20are%20observed%20for%20all%20subjects%20during%20the%20first%20phase%20and%20that%20information%20is%20used%20to%20select%20a%20validation%20subsample%20for%20accurate%20measurements%20of%20these%20variables%20in%20the%20second%20phase.%20Previous%20research%20on%20two-phase%20measurement%20error%20problems%20largely%20focused%20on%20scenarios%20where%20there%20are%20errors%20in%20covariates%20only%20or%20the%20validation%20sample%20is%20a%20simple%20random%20sample%20of%20study%20subjects.%20Herein%2C%20we%20propose%20a%20semiparametric%20approach%20to%20general%20two-phase%20measurement%20error%20problems%20with%20a%20quantitative%20outcome%2C%20allowing%20for%20correlated%20errors%20in%20the%20outcome%20and%20covariates%20and%20arbitrary%20second-phase%20selection.%20We%20devise%20a%20computationally%20efficient%20and%20numerically%20stable%20expectation-maximization%20algorithm%20to%20maximize%20the%20nonparametric%20likelihood%20function.%20The%20resulting%20estimators%20possess%20desired%20statistical%20properties.%20We%20demonstrate%20the%20superiority%20of%20the%20proposed%20methods%20over%20existing%20approaches%20through%20extensive%20simulation%20studies%2C%20and%20we%20illustrate%20their%20use%20in%20an%20observational%20HIV%20study.%22%2C%22date%22%3A%222021-02-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fsim.8799%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233145800%22%2C%22PMCID%22%3A%22PMC8214478%22%2C%22ISSN%22%3A%221097-0258%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A05%3A34Z%22%7D%7D%2C%7B%22key%22%3A%225SIFTFW2%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Amorim%20G%2C%20Queiroz%20ATL%2C%20Rodrigues%20MMS%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Nogueira%20BMF%2C%20et%20al.%20Novel%20stepwise%20approach%20to%20assess%20representativeness%20of%20a%20large%20multicenter%20observational%20cohort%20of%20tuberculosis%20patients%3A%20The%20example%20of%20RePORT%20Brazil.%20Int%20J%20Infect%20Dis.%202021%20Feb%3B103%3A110%26%23×2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2020.11.140%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2020.11.140%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033197582%3B%20PubMed%20Central%20PMCID%3A%20PMC7959330.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Novel%20stepwise%20approach%20to%20assess%20representativeness%20of%20a%20large%20multicenter%20observational%20cohort%20of%20tuberculosis%20patients%3A%20The%20example%20of%20RePORT%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betania%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20Brito%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kleydson%22%2C%22lastName%22%3A%22Alves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20A%20major%20goal%20of%20tuberculosis%20%28TB%29%20epidemiological%20studies%20is%20to%20obtain%20results%20that%20can%20be%20generalized%20to%20the%20larger%20population%20with%20TB.%20The%20ability%20to%20extrapolate%20findings%20on%20the%20determinants%20of%20TB%20treatment%20outcomes%20is%20also%20important.%5CnMETHODS%3A%20We%20compared%20baseline%20clinical%20and%20demographic%20characteristics%20and%20determinants%20of%20anti-TB%20treatment%20outcomes%20between%20persons%20enrolled%20in%20the%20Regional%20Prospective%20Observational%20Research%20in%20Tuberculosis%20%28RePORT%29-Brazil%20cohort%20between%20June%202015%20and%20June%202019%2C%20and%20the%20registry%20of%20TB%20cases%20reported%20to%20the%20Brazilian%20National%20TB%20Program%20%28Information%20System%20for%20Notifiable%20Diseases%20%5BSINAN%5D%29%20during%20the%20same%20time%20period.%20Multivariable%20regression%20models%20adjusted%20for%20the%20study%20site%20were%20performed%20using%20second-generation%20p-values%2C%20a%20novel%20statistical%20approach.%20Associations%20with%20unfavorable%20treatment%20outcomes%20were%20tested%20for%20both%20RePORT-Brazil%20and%20SINAN%20cohorts.%5CnFINDINGS%3A%20A%20total%20of%201%2C060%20culture-confirmed%20TB%20patients%20were%20enrolled%20in%20RePORT-Brazil%20and%20455%2C873%20TB%20cases%20were%20reported%20to%20SINAN.%20Second-generation%20p-value%20analyses%20revealed%20that%20the%20cohorts%20were%20strikingly%20similar%20with%20regard%20to%20sex%2C%20age%2C%20use%20of%20antiretroviral%20therapy%20and%20positive%20initial%20smear%20sputum%20microscopy.%20However%2C%20diabetes%2C%20HIV%20infection%2C%20and%20smoking%20were%20more%20frequently%20documented%20in%20RePORT-Brazil.%20Illicit%20drug%20use%2C%20the%20presence%20of%20diabetes%2C%20and%20history%20of%20prior%20TB%20were%20associated%20with%20unfavorable%20TB%20treatment%20outcomes%3B%20illicit%20drug%20use%20was%20associated%20with%20such%20outcomes%20in%20both%20cohorts.%5CnCONCLUSIONS%3A%20There%20were%20important%20similarities%20in%20demographic%20characteristics%20and%20determinants%20of%20clinical%20outcomes%20between%20the%20RePORT-Brazil%20cohort%20and%20the%20Brazilian%20National%20registry%20of%20TB%20cases.%22%2C%22date%22%3A%222021-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2020.11.140%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233197582%22%2C%22PMCID%22%3A%22PMC7959330%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A06%3A33Z%22%7D%7D%2C%7B%22key%22%3A%223EGF6982%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pereira%20et%20al.%22%2C%22parsedDate%22%3A%222021-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPereira%20GFM%2C%20Kim%20A%2C%20Jalil%20EM%2C%20Fernandes%20Fonseca%20F%2C%20Shepherd%20BE%2C%20Veloso%20VG%2C%20et%20al.%20Dolutegravir%20and%20pregnancy%20outcomes%20in%20women%20on%20antiretroviral%20therapy%20in%20Brazil%3A%20a%20retrospective%20national%20cohort%20study.%20Lancet%20HIV.%202021%20Jan%3B8%281%29%3Ae33%26%23×2013%3B41.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930268-X%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2820%2930268-X%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033387477%3B%20PubMed%20Central%20PMCID%3A%20PMC7869891.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dolutegravir%20and%20pregnancy%20outcomes%20in%20women%20on%20antiretroviral%20therapy%20in%20Brazil%3A%20a%20retrospective%20national%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerson%20Fernando%20Mendes%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%20M.%22%2C%22lastName%22%3A%22Jalil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Fernandes%20Fonseca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Rick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Cristina%22%2C%22lastName%22%3A%22Pimenta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Beber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%20Girade%22%2C%22lastName%22%3A%22Corr%5Cu00eaa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renato%22%2C%22lastName%22%3A%22Lima%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adele%22%2C%22lastName%22%3A%22Schwartz%20Benzaken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22National%20Cohort%20Study%20of%20Dolutegravir%20and%20Pregnancy%20Outcomes%20in%20Brazil%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Dolutegravir%20has%20been%20widely%20available%20in%20Brazil%20since%202017.%20Following%20the%20signal%20that%20infants%20born%20to%20women%20with%20dolutegravir%20exposure%20at%20conception%20in%20Botswana%20had%20a%20higher%20risk%20of%20neural%20tube%20defects%20%28NTDs%29%2C%20public%20health%20leaders%20initiated%20a%20national%20investigation%20to%20evaluate%20periconception%20dolutegravir%20exposure%20among%20all%20pregnant%20Brazilian%20women%20with%20HIV%20and%20its%20potential%20association%20with%20risk%20of%20NTDs%2C%20stillbirth%2C%20or%20miscarriage%20before%2022%20weeks%20%28also%20called%20spontaneous%20abortion%29.%5CnMETHODS%3A%20In%20this%20retrospective%2C%20observational%2C%20national%2C%20cohort%20study%2C%20we%20identified%20all%20women%20with%20pregnancies%20and%20possible%20dolutegravir%20exposure%20within%208%20weeks%20of%20estimated%20date%20of%20conception%20between%20Jan%201%2C%202017%2C%20and%20May%2031%2C%202018%2C%20and%20approximately%203%3A1%20matched%20pregnant%20women%20exposed%20to%20efavirenz%20between%20Jan%201%2C%202015%2C%20and%20May%2031%2C%202018%2C%20using%20the%20Brazilian%20antiretroviral%20therapy%20database.%20We%20did%20detailed%20chart%20reviews%20for%20identified%20women.%20The%20primary%20outcomes%20were%20NTD%20and%20a%20composite%20measure%20of%20NTD%2C%20stillbirth%2C%20or%20miscarriage.%20NTD%20incidences%20were%20calculated%20with%2095%25%20CI.%20The%20composite%20outcome%20was%20examined%20with%20logistic%20regression%20using%20propensity%20score%20matching%20weights%20to%20balance%20confounders.%5CnFINDINGS%3A%20Of%201427%20included%20women%2C%20382%20were%20exposed%20to%20dolutegravir%20within%208%20weeks%20of%20estimated%20date%20of%20conception.%20During%20pregnancy%2C%20183%20%2848%25%29%20of%20382%20dolutegravir-exposed%20and%20465%20%2844%25%29%20of%201045%20efavirenz-exposed%20women%20received%20folic%20acid%20supplementation.%20There%20were%201452%20birth%20outcomes.%20There%20were%20no%20NTDs%20in%20either%20dolutegravir-exposed%20%280%2C%2095%25%20CI%200-0%5Cu00b70010%29%20or%20efavirenz-exposed%20groups%20%280%2C%2095%25%20CI%200-0%5Cu00b70036%29.%20There%20were%2023%20%286%25%29%20stillbirths%20or%20miscarriages%20in%20384%20dolutegravir-exposed%20fetuses%20and%2028%20%283%25%29%20in%20the%201068%20efavirenz-exposed%20fetuses%20%28p%3D0%5Cu00b70037%29.%20Logistic%20regression%20models%20did%20not%20consistently%20indicate%20an%20association%20between%20dolutegravir%20exposure%20and%20risk%20of%20stillbirths%20or%20miscarriages.%20After%20study%20closure%2C%20two%20confirmed%20NTD%20outcomes%20in%20fetuses%20with%20periconception%20dolutegravir%20exposure%20were%20reported%20to%20public%20health%20officials.%20An%20updated%20estimate%20of%20NTD%20incidence%20incorporating%20these%20cases%20and%20the%20estimated%20number%20of%20additional%20dolutegravir-exposed%20pregnancies%20between%20Jan%201%2C%202015%20and%20Feb%2028%2C%202019%2C%20is%200%5Cu00b70018%20%2895%25%20CI%200%5Cu00b70005-0%5Cu00b70067%29.%5CnINTERPRETATION%3A%20Neither%20dolutegravir%20nor%20efavirenz%20exposure%20was%20associated%20with%20NTDs%20in%20our%20national%20cohort%3B%20incidence%20of%20NTDs%20is%20probably%20well%20under%201%25%20in%20dolutegravir-exposed%20HIV-positive%20women%20but%20still%20slightly%20above%20HIV-uninfected%20women%20%280%5Cu00b706%25%29%20in%20Brazil.%5CnFUNDING%3A%20The%20Brazilian%20Ministry%20of%20Health%20and%20the%20United%20States%26%23039%3B%20National%20Institutes%20of%20Health.%22%2C%22date%22%3A%222021-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2820%2930268-X%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233387477%22%2C%22PMCID%22%3A%22PMC7869891%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A05%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22XGZKIDL8%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castilho%20et%20al.%22%2C%22parsedDate%22%3A%222021-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastilho%20JL%2C%20Kim%20A%2C%20Jenkins%20CA%2C%20Grinsztejn%20B%2C%20Gotuzzo%20E%2C%20Fink%20V%2C%20et%20al.%20Antiretroviral%20therapy%20and%20Kaposi%26%23×2019%3Bs%20sarcoma%20trends%20and%20outcomes%20among%20adults%20with%20HIV%20in%20Latin%20America.%20J%20Int%20AIDS%20Soc.%202021%20Jan%3B24%281%29%3Ae25658.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25658%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25658%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033405281%3B%20PubMed%20Central%20PMCID%3A%20PMC7787071.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Antiretroviral%20therapy%20and%20Kaposi%27s%20sarcoma%20trends%20and%20outcomes%20among%20adults%20with%20HIV%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%22%2C%22lastName%22%3A%22Fink%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Mercedes%22%2C%22lastName%22%3A%22Escuder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosa%20Alencar%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%20B.%22%2C%22lastName%22%3A%22Tenore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidnei%20R.%22%2C%22lastName%22%3A%22Pimentel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Let%5Cu00edcia%20Rodrigues%22%2C%22lastName%22%3A%22Ikeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20R.%22%2C%22lastName%22%3A%22de%20Alencastro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Unai%22%2C%22lastName%22%3A%22Tupinanbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Brites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estela%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliana%22%2C%22lastName%22%3A%22Netto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Grangeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%2C%20South%20America%20network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Kaposi%26%23039%3Bs%20sarcoma%20%28KS%29%20remains%20the%20most%20frequent%20malignancy%20in%20persons%20living%20with%20HIV%20%28PWH%29%20in%20Latin%20America.%20We%20examined%20KS%20trends%20and%20outcomes%20from%20Latin%20American%20clinical%20sites%20in%20the%20era%20of%20increased%20access%20to%20antiretroviral%20therapy%20%28ART%29.%5CnMETHODS%3A%20Cohorts%20in%20Brazil%2C%20Peru%2C%20Mexico%2C%20Honduras%2C%20Argentina%20and%20Chile%20contributed%20clinical%20data%20of%20PWH%20%5Cu226516%5Cu00a0years%20old%20from%202000%20to%202017%2C%20excluding%20patients%20with%20KS%20diagnosed%20before%20clinic%20enrolment.%20We%20compared%20KS%20incidence%20over%20time%20using%20multivariable%20incidence%20rate%20ratios.%20Predictors%20of%20KS%20before%5C%2Fat%20or%20after%20ART%20initiation%20and%20of%20mortality%20after%20KS%20were%20examined%20using%20Cox%20regression.%5CnRESULTS%3A%20Of%2025%5Cu00a0981%20PWH%2C%20481%20had%20incident%20KS%2C%20including%20200%20ART-na%5Cu00efve%20and%20281%20ART-treated%20patients.%20From%202000%20to%202017%2C%20the%20incidence%20of%20KS%20decreased%20from%2055.1%20to%203.0%20per%201000%20person-years.%20In%20models%20adjusting%20for%20CD4%20and%20other%20factors%2C%20the%20relative%20risk%20for%20KS%20decreased%20from%202000%20to%202008.%20Since%202010%2C%20the%20adjusted%20risk%20of%20KS%20increased%20in%20the%20periods%20before%20and%20%5Cu226490%5Cu00a0days%20after%20ART%20initiation%20but%20decreased%20%26gt%3B90%5Cu00a0days%20after%20ART.%20In%20addition%20to%20low%20CD4%20and%20male-to-male%20sex%2C%20KS%20risk%20after%20ART%20was%20associated%20with%20age%20and%20history%20of%20other%20AIDS-defining%20illnesses.%20Mortality%20after%20KS%20%28approximately%2025%25%20after%20five%20years%29%20was%20not%20associated%20with%20either%20year%20of%20KS%20diagnosis%20nor%20timing%20of%20diagnosis%20relative%20to%20ART%20initiation.%5CnCONCLUSIONS%3A%20KS%20incidence%20in%20Latin%20America%20has%20remained%20stable%20in%20recent%20years%20and%20risk%20is%20highest%20before%20and%20shortly%20after%20ART%20initiation.%20Early%20diagnosis%20of%20HIV%20and%20ART%20initiation%20remain%20critical%20priorities%20in%20the%20region.%22%2C%22date%22%3A%222021-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25658%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233405281%22%2C%22PMCID%22%3A%22PMC7787071%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A06%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22QTJUW8B4%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Carvalho%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCarvalho%20ACC%2C%20Amorim%20G%2C%20Melo%20MGM%2C%20Silveira%20AKA%2C%20Vargas%20PHL%2C%20Moreira%20ASR%2C%20et%20al.%20Pre-Treatment%20Neutrophil%20Count%20as%20a%20Predictor%20of%20Antituberculosis%20Therapy%20Outcomes%3A%20A%20Multicenter%20Prospective%20Cohort%20Study.%20Front%20Immunol.%202021%3B12%3A661934.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.661934%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2021.661934%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2034276654%3B%20PubMed%20Central%20PMCID%3A%20PMC8284392.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pre-Treatment%20Neutrophil%20Count%20as%20a%20Predictor%20of%20Antituberculosis%20Therapy%20Outcomes%3A%20A%20Multicenter%20Prospective%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Cristina%20C.%22%2C%22lastName%22%3A%22Carvalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Amorim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayla%20G.%20M.%22%2C%22lastName%22%3A%22Melo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Karla%20A.%22%2C%22lastName%22%3A%22Silveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20H.%20L.%22%2C%22lastName%22%3A%22Vargas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisangela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Neutrophils%20have%20been%20associated%20with%20lung%20tissue%20damage%20in%20many%20diseases%2C%20including%20tuberculosis%20%28TB%29.%20Whether%20neutrophil%20count%20can%20serve%20as%20a%20predictor%20of%20adverse%20treatment%20outcomes%20is%20unknown.%5CnMETHODS%3A%20We%20prospectively%20assessed%20936%20patients%20%28172%20HIV-seropositive%29%20with%20culture-confirmed%20pulmonary%20TB%2C%20enrolled%20in%20a%20multicenter%20prospective%20cohort%20study%20from%20different%20regions%20in%20Brazil%2C%20from%20June%202015%20to%20June%202019%2C%20and%20were%20followed%20up%20to%20two%20years.%20TB%20patients%20had%20a%20baseline%20visit%20before%20treatment%20%28month%200%29%20and%20visits%20at%20month%202%20and%206%20%28or%20at%20the%20end%20of%20TB%20treatment%29.%20Smear%20microscopy%2C%20and%20culture%20for%20Mycobacterium%20tuberculosis%20%28MTB%29%20were%20performed%20at%20TB%20diagnosis%20and%20during%20follow-up.%20Complete%20blood%20counts%20were%20measured%20at%20baseline.%20Treatment%20outcome%20was%20defined%20as%20either%20unfavorable%20%28death%2C%20treatment%20failure%20or%20TB%20recurrence%29%20or%20favorable%20%28cure%20or%20treatment%20completion%29.%20We%20performed%20multivariable%20logistic%20regression%2C%20with%20propensity%20score%20regression%20adjustment%2C%20to%20estimate%20the%20association%20between%20neutrophil%20count%20with%20MTB%20culture%20result%20at%20month%202%20and%20unfavorable%20treatment%20outcome.%20We%20used%20a%20propensity%20score%20adjustment%20instead%20of%20a%20fully%20adjusted%20regression%20model%20due%20to%20the%20relatively%20low%20number%20of%20outcomes.%5CnRESULTS%3A%20Among%20682%20patients%20who%20had%20MTB%20culture%20results%20at%20month%202%2C%2040%20%285.9%25%29%20had%20a%20positive%20result.%20After%20regression%20with%20propensity%20score%20adjustment%2C%20no%20significant%20association%20between%20baseline%20neutrophil%20count%20%28103%5C%2Fmm3%29%20and%20positive%20MTB%20culture%20at%20month%202%20was%20found%20among%20either%20HIV-seronegative%20%28OR%20%3D%201.06%2C%2095%25%20CI%20%3D%20%5B0.95%3B1.19%5D%20or%20HIV-seropositive%20patients%20%28OR%20%3D%200.77%2C%2095%25%20CI%20%3D%20%5B0.51%3B%201.20%5D%29.%20Of%20691%20TB%20patients%20followed%20up%20for%20at%20least%2018%20months%20and%20up%20to%2024%20months%2C%20635%20%2891.9%25%29%20were%20either%20cured%20or%20completed%20treatment%2C%20and%2056%20%288.1%25%29%20had%20an%20unfavorable%20treatment%20outcome.%20A%20multivariable%20regression%20with%20propensity%20score%20adjustment%20found%20an%20association%20between%20higher%20neutrophil%20count%20%28103%5C%2Fmm3%29%20at%20baseline%20and%20unfavorable%20outcome%20among%20HIV-seronegative%20patients%20%5BOR%3D%201.17%20%2895%25%20CI%3D%20%5B1.06%3B1.30%5D%29.%20In%20addition%2C%20adjusted%20Cox%20regression%20found%20that%20higher%20baseline%20neutrophil%20count%20%28103%5C%2Fmm3%29%20was%20associated%20with%20unfavorable%20treatment%20outcomes%20overall%20and%20among%20HIV-seronegative%20patients%20%28HR%3D%201.16%20%2895%25%20CI%20%3D%20%5B1.05%3B1.27%5D%29.%5CnCONCLUSION%3A%20Increased%20neutrophil%20count%20prior%20to%20anti-TB%20treatment%20initiation%20was%20associated%20with%20unfavorable%20treatment%20outcomes%2C%20particularly%20among%20HIV-seronegative%20patients.%20Further%20prospective%20studies%20evaluating%20neutrophil%20count%20in%20response%20to%20drug%20treatment%20and%20association%20with%20TB%20treatment%20outcomes%20are%20warranted.%22%2C%22date%22%3A%222021%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2021.661934%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2234276654%22%2C%22PMCID%22%3A%22PMC8284392%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A11%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22HK5SS97G%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Arriaga%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BArriaga%20MB%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Barreto-Duarte%20B%2C%20Sales%20C%2C%20Miguez-Pinto%20JP%2C%20Nogueira%20EB%2C%20et%20al.%20Prevalence%20and%20Clinical%20Profiling%20of%20Dysglycemia%20and%20HIV%20Infection%20in%20Persons%20With%20Pulmonary%20Tuberculosis%20in%20Brazil.%20Front%20Med%20%28Lausanne%29.%202021%3B8%3A804173.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2021.804173%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2021.804173%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035127760%3B%20PubMed%20Central%20PMCID%3A%20PMC8814308.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20and%20Clinical%20Profiling%20of%20Dysglycemia%20and%20HIV%20Infection%20in%20Persons%20With%20Pulmonary%20Tuberculosis%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caio%22%2C%22lastName%22%3A%22Sales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00e3o%20Pedro%22%2C%22lastName%22%3A%22Miguez-Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Evelyn%20B.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bet%5Cu00e2nia%20M.%20F.%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20S.%22%2C%22lastName%22%3A%22Rocha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Benjamin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%20G.%22%2C%22lastName%22%3A%22de%20Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Moreno%20M.%20S.%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Cavalcante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20R.%22%2C%22lastName%22%3A%22Lapa-E-Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kristki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT-Brazil%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20There%20are%20scarce%20data%20on%20the%20prevalence%20and%20disease%20presentation%20of%20HIV%20in%20patients%20with%20tuberculosis%20%28TB%29%20and%20dysglycemia%20%28diabetes%20%5BDM%5D%20and%20prediabetes%20%5BPDM%5D%29%2C%20especially%20in%20TB-endemic%20countries.%5CnMETHODS%3A%20We%20assessed%20the%20baseline%20epidemiological%20and%20clinical%20characteristics%20of%20patients%20with%20culture-confirmed%20pulmonary%20TB%2C%20enrolled%20in%20a%20multicenter%20prospective%20cohort%20in%20Brazil%20%28RePORT-Brazil%29%20during%202015-2019.%20Dysglycemia%20was%20defined%20by%20elevated%20glycated%20hemoglobin%20and%20stratified%20as%20PDM%20or%20DM.%20Additionally%2C%20we%20used%20data%20from%20TB%20cases%20obtained%20through%20the%20Brazilian%20National%20Notifiable%20Diseases%20Information%20System%20%28SINAN%29%2C%20during%202015-2019.%20In%20SINAN%2C%20diagnosis%20of%20diabetes%20was%20based%20on%20self-report.%20Logistic%20regression%20models%20were%20performed%20to%20test%20independent%20associations%20between%20HIV%2C%20dysglycemia%20status%2C%20and%20other%20baseline%20characteristics%20in%20both%20cohorts.%5CnRESULTS%3A%20In%20the%20RePORT-Brazil%20cohort%2C%20the%20prevalence%20of%20DM%20and%20of%20PDM%20was%2023.7%20and%2037.8%25%2C%20respectively.%20Furthermore%2C%20the%20prevalence%20of%20HIV%20was%2021.4%25%20in%20the%20group%20of%20persons%20with%20TB-dysglycemia%20and%2020.5%25%20in%20that%20of%20patients%20with%20TBDM.%20In%20the%20SINAN%20cohort%2C%20the%20prevalence%20of%20DM%20was%209.2%25%2C%20and%20among%20the%20TBDM%20group%20the%20prevalence%20of%20HIV%20was%204.1%25.%20Logistic%20regressions%20demonstrated%20that%20aging%20was%20independently%20associated%20with%20PDM%20or%20DM%20in%20both%20the%20RePORT-Brazil%20and%20SINAN%20cohorts.%20In%20RePORT-Brazil%2C%20illicit%20drug%20use%20was%20associated%20with%20PDM%2C%20whereas%20a%20higher%20body%20mass%20index%20%28BMI%29%20was%20associated%20with%20DM%20occurrence.%20Of%20note%2C%20HIV%20was%20not%20associated%20with%20an%20increased%20risk%20of%20PDM%20or%20DM%20in%20patients%20with%20pulmonary%20TB%20in%20both%20cohorts.%20Moreover%2C%20in%20both%20cohorts%2C%20the%20TBDM-HIV%20group%20presented%20with%20a%20lower%20proportion%20of%20positive%20sputum%20smear%20and%20a%20higher%20frequency%20of%20tobacco%20and%20alcohol%20users.%5CnCONCLUSION%3A%20There%20is%20a%20high%20prevalence%20of%20dysglycemia%20in%20patients%20with%20pulmonary%20TB%20in%20Brazil%2C%20regardless%20of%20the%20HIV%20status.%20This%20reinforces%20the%20idea%20that%20DM%20should%20be%20systematically%20screened%20in%20persons%20with%20TB.%20Presence%20of%20HIV%20does%20not%20substantially%20impact%20clinical%20presentation%20in%20persons%20with%20TBDM%2C%20although%20it%20is%20associated%20with%20more%20frequent%20use%20of%20recreational%20drugs%20and%20smear%20negative%20sputum%20samples%20during%20TB%20screening.%22%2C%22date%22%3A%222021%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffmed.2021.804173%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235127760%22%2C%22PMCID%22%3A%22PMC8814308%22%2C%22ISSN%22%3A%222296-858X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A17%3A49Z%22%7D%7D%5D%7D
1.
Costa AG, Carvalho BKS, Araújo-Pereira M, Ibiapina HNS, Spener-Gomes R, Souza AB, et al. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. Microbiol Spectr. 2021 Dec 22;9(3):e0116321. http://doi.org/10.1128/Spectrum.01163-21 PubMed PMID: 34851140; PubMed Central PMCID: PMC8635161.
1.
Arriaga MB, Rocha MS, Nogueira BMF, Nascimento V, Araújo-Pereira M, Souza AB, et al. The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. J Infect Dis. 2021 Dec 15;224(12):2064–72. http://doi.org/10.1093/infdis/jiab264 PubMed PMID: 34008010; PubMed Central PMCID: PMC8672762.
1.
Han WM, Law MG, Egger M, Wools-Kaloustian K, Moore R, McGowan C, et al. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV. 2021 Dec;8(12):e766–75. http://doi.org/10.1016/S2352-3018(21)00265-4 PubMed PMID: 34856180; PubMed Central PMCID: PMC8782625.
1.
McMahon DE, Semeere A, Laker-Oketta M, Byakwaga H, Mugglin C, Duda SN, et al. Global Disparities in Skin Cancer Services at HIV Treatment Centers across 29 Countries. J Invest Dermatol. 2021 Oct;141(10):2533-2536.e2. http://doi.org/10.1016/j.jid.2021.02.758 PubMed PMID: 33864771; PubMed Central PMCID: PMC8464481.
1.
Brazier E, Tymejczyk O, Zaniewski E, Egger M, Wools-Kaloustian K, Yiannoutsos CT, et al. Effects of National Adoption of Treat-All Guidelines on Pre-Antiretroviral Therapy (ART) CD4 Testing and Viral Load Monitoring After ART initiation: A Regression Discontinuity Analysis. Clin Infect Dis. 2021 Sep 15;73(6):e1273–81. http://doi.org/10.1093/cid/ciab222 PubMed PMID: 33693517; PubMed Central PMCID: PMC8442775.
1.
Kassanjee R, Johnson LF, Zaniewski E, Ballif M, Christ B, Yiannoutsos CT, et al. Global HIV mortality trends among children on antiretroviral treatment corrected for under-reported deaths: an updated analysis of the International epidemiology Databases to Evaluate AIDS collaboration. J Int AIDS Soc. 2021 Sep;24 Suppl 5(Suppl 5):e25780. http://doi.org/10.1002/jia2.25780 PubMed PMID: 34546646; PubMed Central PMCID: PMC8454681.
1.
Souza AB, Arriaga MB, Amorim G, Araújo-Pereira M, Nogueira BMF, Queiroz ATL, et al. Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. BMJ Glob Health. 2021 Sep;6(9):e005969. http://doi.org/10.1136/bmjgh-2021-005969 PubMed PMID: 34518204; PubMed Central PMCID: PMC8438757.
1.
Johnson LF, Kariminia A, Trickey A, Yiannoutsos CT, Ekouevi DK, Minga AK, et al. Achieving consistency in measures of HIV-1 viral suppression across countries: derivation of an adjustment based on international antiretroviral treatment cohort data. J Int AIDS Soc. 2021 Sep;24 Suppl 5(Suppl 5):e25776. http://doi.org/10.1002/jia2.25776 PubMed PMID: 34546623; PubMed Central PMCID: PMC8454679.
1.
Somerville K, Jenkins CA, Carlucci JG, Person AK, Machado DM, Luque MT, et al. Outcomes After Second-Line Antiretroviral Therapy in Children Living With HIV in Latin America. J Acquir Immune Defic Syndr. 2021 Jul 1;87(3):993–1001. http://doi.org/10.1097/QAI.0000000000002678 PubMed PMID: 33675618; PubMed Central PMCID: PMC8192432.
1.
Joseph Y, Yao Z, Dua A, Severe P, Collins SE, Bang H, et al. Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti. J Int AIDS Soc. 2021 Jul;24(7):e25721. http://doi.org/10.1002/jia2.25721 PubMed PMID: 34235862; PubMed Central PMCID: PMC8264404.
1.
Zürcher K, Reichmuth ML, Ballif M, Loiseau C, Borrell S, Reinhard M, et al. Mortality from drug-resistant tuberculosis in high-burden countries comparing routine drug susceptibility testing with whole-genome sequencing: a multicentre cohort study. Lancet Microbe. 2021 Jul;2(7):e320–30. http://doi.org/10.1016/S2666-5247(21)00044-6 PubMed PMID: 35252901; PubMed Central PMCID: PMC8896764.
1.
Chiao EY, Coghill A, Kizub D, Fink V, Ndlovu N, Mazul A, et al. The effect of non-AIDS-defining cancers on people living with HIV. Lancet Oncol. 2021 Jun;22(6):e240–53. http://doi.org/10.1016/S1470-2045(21)00137-6 PubMed PMID: 34087151; PubMed Central PMCID: PMC8628366.
1.
Oh EJ, Shepherd BE, Lumley T, Shaw PA. Improved generalized raking estimators to address dependent covariate and failure-time outcome error. Biom J. 2021 Jun;63(5):1006–27. http://doi.org/10.1002/bimj.202000187 PubMed PMID: 33709462; PubMed Central PMCID: PMC8211389.
1.
Tsondai PR, Davies MA, Singtoroj T, Maxwell N, McGowan CC, Songtaweesin WN, et al. Improving Methods to Classify Perinatal versus Nonperinatal HIV Acquisition in Young Adolescents 10-14 Years of Age. Pediatr Infect Dis J. 2021 May 1;40(5):453–6. http://doi.org/10.1097/INF.0000000000003059 PubMed PMID: 33538538; PubMed Central PMCID: PMC8043971.
1.
Yohannes NT, Jenkins CA, Clouse K, Cortés CP, Mejía Cordero F, Padgett D, et al. Timing of HIV diagnosis relative to pregnancy and postpartum HIV care continuum outcomes among Latin American women, 2000 to 2017. J Int AIDS Soc. 2021 May;24(5):e25740. http://doi.org/10.1002/jia2.25740 PubMed PMID: 34021715; PubMed Central PMCID: PMC8140191.
1.
Smiley CL, Rebeiro PF, Cesar C, Belaunzaran-Zamudio PF, Crabtree-Ramirez B, Padgett D, et al. Estimated life expectancy gains with antiretroviral therapy among adults with HIV in Latin America and the Caribbean: a multisite retrospective cohort study. Lancet HIV. 2021 May;8(5):e266–73. http://doi.org/10.1016/S2352-3018(20)30358-1 PubMed PMID: 33891877; PubMed Central PMCID: PMC8171816.
1.
Nascimento-Carvalho GC, Nascimento-Carvalho EC, Ramos CL, Vilas-Boas AL, Moreno-Carvalho OA, Vinhaes CL, et al. Zika-exposed microcephalic neonates exhibit higher degree of inflammatory imbalance in cerebrospinal fluid. Sci Rep. 2021 Apr 19;11(1):8474. http://doi.org/10.1038/s41598-021-87895-4 PubMed PMID: 33875756; PubMed Central PMCID: PMC8055905.
1.
Spener-Gomes R, Costa AG, Melo HF de, Souza AB de, Beraldi-Magalhães F, Jesus JS, et al. Examination of respiratory specimens improves microbiological diagnosis of patients with presumptive extrapulmonary tuberculosis. Int J Infect Dis. 2021 Apr;105:743–5. http://doi.org/10.1016/j.ijid.2021.03.022 PubMed PMID: 33722683; PubMed Central PMCID: PMC8941595.
1.
Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021 Mar 2;11(3):e044687. http://doi.org/10.1136/bmjopen-2020-044687 PubMed PMID: 33653759; PubMed Central PMCID: PMC7929865.
1.
Rodrigues A, Struchiner CJ, Coelho LE, Veloso VG, Grinsztejn B, Luz PM. Late initiation of antiretroviral therapy: inequalities by educational level despite universal access to care and treatment. BMC Public Health. 2021 Feb 19;21(1):389. http://doi.org/10.1186/s12889-021-10421-8 PubMed PMID: 33607975; PubMed Central PMCID: PMC7893724.
1.
Oh EJ, Shepherd BE, Lumley T, Shaw PA. Raking and regression calibration: Methods to address bias from correlated covariate and time-to-event error. Stat Med. 2021 Feb 10;40(3):631–49. http://doi.org/10.1002/sim.8793 PubMed PMID: 33140432; PubMed Central PMCID: PMC7874496.
1.
Tao R, Lotspeich SC, Amorim G, Shaw PA, Shepherd BE. Efficient semiparametric inference for two-phase studies with outcome and covariate measurement errors. Stat Med. 2021 Feb 10;40(3):725–38. http://doi.org/10.1002/sim.8799 PubMed PMID: 33145800; PubMed Central PMCID: PMC8214478.
1.
Arriaga MB, Amorim G, Queiroz ATL, Rodrigues MMS, Araújo-Pereira M, Nogueira BMF, et al. Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil. Int J Infect Dis. 2021 Feb;103:110–8. http://doi.org/10.1016/j.ijid.2020.11.140 PubMed PMID: 33197582; PubMed Central PMCID: PMC7959330.
1.
Pereira GFM, Kim A, Jalil EM, Fernandes Fonseca F, Shepherd BE, Veloso VG, et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021 Jan;8(1):e33–41. http://doi.org/10.1016/S2352-3018(20)30268-X PubMed PMID: 33387477; PubMed Central PMCID: PMC7869891.
1.
Castilho JL, Kim A, Jenkins CA, Grinsztejn B, Gotuzzo E, Fink V, et al. Antiretroviral therapy and Kaposi’s sarcoma trends and outcomes among adults with HIV in Latin America. J Int AIDS Soc. 2021 Jan;24(1):e25658. http://doi.org/10.1002/jia2.25658 PubMed PMID: 33405281; PubMed Central PMCID: PMC7787071.
1.
Carvalho ACC, Amorim G, Melo MGM, Silveira AKA, Vargas PHL, Moreira ASR, et al. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Front Immunol. 2021;12:661934. http://doi.org/10.3389/fimmu.2021.661934 PubMed PMID: 34276654; PubMed Central PMCID: PMC8284392.
1.
Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Miguez-Pinto JP, Nogueira EB, et al. Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. Front Med (Lausanne). 2021;8:804173. http://doi.org/10.3389/fmed.2021.804173 PubMed PMID: 35127760; PubMed Central PMCID: PMC8814308.
2020
76770
IP6F4TRX
2020
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%224UMMEW8L%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Giganti%20and%20Shepherd%22%2C%22parsedDate%22%3A%222020-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGiganti%20MJ%2C%20Shepherd%20BE.%20Multiple-Imputation%20Variance%20Estimation%20in%20Studies%20With%20Missing%20or%20Misclassified%20Inclusion%20Criteria.%20Am%20J%20Epidemiol.%202020%20Dec%201%3B189%2812%29%3A1628%26%23×2013%3B32.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwaa153%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwaa153%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032685964%3B%20PubMed%20Central%20PMCID%3A%20PMC7705600.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multiple-Imputation%20Variance%20Estimation%20in%20Studies%20With%20Missing%20or%20Misclassified%20Inclusion%20Criteria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Giganti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22In%20observational%20studies%20using%20routinely%20collected%20data%2C%20a%20variable%20with%20a%20high%20level%20of%20missingness%20or%20misclassification%20may%20determine%20whether%20an%20observation%20is%20included%20in%20the%20analysis.%20In%20settings%20where%20inclusion%20criteria%20are%20assessed%20after%20imputation%2C%20the%20popular%20multiple-imputation%20variance%20estimator%20proposed%20by%20Rubin%20%28%26quot%3BRubin%26%23039%3Bs%20rules%26quot%3B%20%28RR%29%29%20is%20biased%20due%20to%20incompatibility%20between%20imputation%20and%20analysis%20models.%20While%20alternative%20approaches%20exist%2C%20most%20analysts%20are%20not%20familiar%20with%20them.%20Using%20partially%20validated%20data%20from%20a%20human%20immunodeficiency%20virus%20cohort%2C%20we%20illustrate%20the%20calculation%20of%20an%20imputation%20variance%20estimator%20proposed%20by%20Robins%20and%20Wang%20%28RW%29%20in%20a%20scenario%20where%20the%20study%20exclusion%20criteria%20are%20based%20on%20a%20variable%20that%20must%20be%20imputed.%20In%20this%20motivating%20example%2C%20the%20corresponding%20imputation%20variance%20estimate%20for%20the%20log%20odds%20was%2029%25%20smaller%20using%20the%20RW%20estimator%20than%20using%20the%20RR%20estimator.%20We%20further%20compared%20these%202%20variance%20estimators%20with%20a%20simulation%20study%20which%20showed%20that%20coverage%20probabilities%20of%2095%25%20confidence%20intervals%20based%20on%20the%20RR%20estimator%20were%20too%20high%20and%20became%20worse%20as%20more%20observations%20were%20imputed%20and%20more%20subjects%20were%20excluded%20from%20the%20analysis.%20The%20RW%20imputation%20variance%20estimator%20performed%20much%20better%20and%20should%20be%20employed%20when%20there%20is%20incompatibility%20between%20imputation%20and%20analysis%20models.%20We%20provide%20analysis%20code%20to%20aid%20future%20analysts%20in%20implementing%20this%20method.%22%2C%22date%22%3A%222020-12-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwaa153%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232685964%22%2C%22PMCID%22%3A%22PMC7705600%22%2C%22ISSN%22%3A%221476-6256%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A04%3A41Z%22%7D%7D%2C%7B%22key%22%3A%223MI446PI%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Reichmuth%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BReichmuth%20ML%2C%20H%26%23xF6%3Bmke%20R%2C%20Z%26%23xFC%3Brcher%20K%2C%20Sander%20P%2C%20Avihingsanon%20A%2C%20Collantes%20J%2C%20et%20al.%20Natural%20Polymorphisms%20in%20Mycobacterium%20tuberculosis%20Conferring%20Resistance%20to%20Delamanid%20in%20Drug-Naive%20Patients.%20Antimicrob%20Agents%20Chemother.%202020%20Oct%2020%3B64%2811%29%3Ae00513-20.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00513-20%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00513-20%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032868333%3B%20PubMed%20Central%20PMCID%3A%20PMC7577131.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Natural%20Polymorphisms%20in%20Mycobacterium%20tuberculosis%20Conferring%20Resistance%20to%20Delamanid%20in%20Drug-Naive%20Patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20L.%22%2C%22lastName%22%3A%22Reichmuth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rico%22%2C%22lastName%22%3A%22H%5Cu00f6mke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Sander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jimena%22%2C%22lastName%22%3A%22Collantes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Borrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Reinhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%5D%2C%22abstractNote%22%3A%22Mutations%20in%20the%20genes%20of%20the%20F420%20signaling%20pathway%20of%20Mycobacterium%20tuberculosis%20complex%2C%20including%20dnn%2C%20fgd1%2C%20fbiA%2C%20fbiB%2C%20fbiC%2C%20and%20fbiD%2C%20can%20lead%20to%20delamanid%20resistance.%20We%20searched%20for%20such%20mutations%20among%20129%20M.%20tuberculosis%20strains%20from%20Asia%2C%20South%20America%2C%20and%20Africa%20using%20whole-genome%20sequencing%3B%2070%20%2854%25%29%20strains%20had%20at%20least%20one%20mutation%20in%20one%20of%20the%20genes.%20For%2010%20strains%20with%20mutations%2C%20we%20determined%20the%20MIC%20of%20delamanid.%20We%20found%20one%20strain%20from%20a%20delamanid-naive%20patient%20carrying%20the%20natural%20polymorphism%20Tyr29del%20%28ddn%29%20that%20was%20associated%20with%20a%20critical%20delamanid%20MIC.%22%2C%22date%22%3A%222020-10-20%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00513-20%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232868333%22%2C%22PMCID%22%3A%22PMC7577131%22%2C%22ISSN%22%3A%221098-6596%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A04%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22FFXWGDNJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rebeiro%20et%20al.%22%2C%22parsedDate%22%3A%222020-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRebeiro%20PF%2C%20Duda%20SN%2C%20Wools-Kaloustian%20KK%2C%20Nash%20D%2C%20Althoff%20KN%2C%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29.%20Implications%20of%20COVID-19%20for%20HIV%20Research%3A%20data%20sources%2C%20indicators%20and%20longitudinal%20analyses.%20J%20Int%20AIDS%20Soc.%202020%20Oct%3B23%2810%29%3Ae25627.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25627%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25627%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033047483%3B%20PubMed%20Central%20PMCID%3A%20PMC7550555.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Implications%20of%20COVID-19%20for%20HIV%20Research%3A%20data%20sources%2C%20indicators%20and%20longitudinal%20analyses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%20K.%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25627%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233047483%22%2C%22PMCID%22%3A%22PMC7550555%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A04%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22DCF4JDC5%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Desmonde%20et%20al.%22%2C%22parsedDate%22%3A%222020-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BDesmonde%20S%2C%20Neilan%20AM%2C%20Musick%20B%2C%20Patten%20G%2C%20Chokephaibulkit%20K%2C%20Edmonds%20A%2C%20et%20al.%20Time-varying%20age-%20and%20CD4-stratified%20rates%20of%20mortality%20and%20WHO%20stage%203%20and%20stage%204%20events%20in%20children%2C%20adolescents%20and%20youth%200%20to%2024%20years%20living%20with%20perinatally%20acquired%20HIV%2C%20before%20and%20after%20antiretroviral%20therapy%20initiation%20in%20the%20paediatric%20IeDEA%20Global%20Cohort%20Consortium.%20J%20Int%20AIDS%20Soc.%202020%20Oct%3B23%2810%29%3Ae25617.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25617%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25617%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033034417%3B%20PubMed%20Central%20PMCID%3A%20PMC7545918.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Time-varying%20age-%20and%20CD4-stratified%20rates%20of%20mortality%20and%20WHO%20stage%203%20and%20stage%204%20events%20in%20children%2C%20adolescents%20and%20youth%200%20to%2024%20years%20living%20with%20perinatally%20acquired%20HIV%2C%20before%20and%20after%20antiretroviral%20therapy%20initiation%20in%20the%20paediatric%20IeDEA%20Global%20Cohort%20Consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20M.%22%2C%22lastName%22%3A%22Neilan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kulkanya%22%2C%22lastName%22%3A%22Chokephaibulkit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Edmonds%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%20L.%22%2C%22lastName%22%3A%22Ciaranello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Evaluating%20outcomes%20of%20paediatric%20patients%20with%20HIV%20provides%20crucial%20data%20for%20clinicians%20and%20policymakers.%20We%20analysed%20mortality%20and%20clinical%20events%20rates%20among%20children%2C%20adolescents%2C%20and%20youth%20with%20perinatally%20acquired%20HIV%20%28PHIV%29%20aged%200%20to%2024%5Cu00a0years%20stratified%20by%20time-varying%20age%20and%20CD4%2C%20before%20and%20after%20antiretroviral%20therapy%20%28ART%29%2C%20in%20the%20paediatric%20IeDEA%20multiregional%20collaboration%20%28East%2C%20West%2C%20Central%20and%20Southern%20Africa%2C%20Asia-Pacific%2C%20and%20Central%5C%2FSouth%20America%20and%20the%20Caribbean%29.%5CnMETHODS%3A%20ART-na%5Cu00efve%20children%20with%20HIV%20enrolled%20before%20age%2010%20%28proxy%20for%20perinatal%20infection%29%20at%20IeDEA%20sites%20between%202004%20and%202016%2C%20with%20%5Cu22651%20CD4%20measurement%20during%20follow-up%20were%20included.%20We%20estimated%20incidence%20rates%20%28IR%29%20and%2095%25%20confidence%20intervals%20%2895%25%20CI%29%20of%20mortality%20and%20first%20occurrence%20of%20WHO-4%20and%20WHO-3%20events%2C%20excluding%20tuberculosis%2C%20during%20person-years%20%28PY%29%20spent%20within%20different%20age%20%28%26lt%3B2%2C%202%20to%204%2C%205%20to%209%2C%2010%20to%2014%2C%2015%20to%2019%2C%2020%20to%2024%29%20and%20CD4%20%28percent%20when%20%26lt%3B5%5Cu00a0years%20%5B%26lt%3B15%25%2C%2015%25%20to%2024%25%2C%20%5Cu226525%25%5D%3B%20count%20when%20%5Cu22655%5Cu00a0years%20%5B%26lt%3B200%2C%20200%20to%20499%2C%20%5Cu2265500%5Cu00a0cells%5C%2F%5Cu00b5L%5D%29%20strata.%20We%20used%20linear%20mixed%20models%20to%20predict%20CD4%20evolution%2C%20with%20trends%20modelled%20by%20region.%5CnRESULTS%3A%20In%20the%20pre-ART%20period%2C%2049%5Cu00a0137%20participants%20contributed%2051%5Cu00a0966%5Cu00a0PY%20of%20follow-up%20%28median%20enrolment%20age%3A%203.9%5Cu00a0years%29.%20The%20overall%20pre-ART%20IRs%20were%202.8%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%202.7%20to%202.9%29%20for%20mortality%2C%203.3%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%203.0%20to%203.5%29%20for%20first%20occurrence%20of%20a%20WHO-4%20event%2C%20and%207.0%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%206.7%20to%207.4%29%20for%20first%20occurrence%20of%20a%20WHO-3%20event.%20Lower%20CD4%20and%20younger%20age%20strata%20were%20associated%20with%20increased%20rates%20of%20both%20mortality%20and%20first%20occurrence%20of%20a%20clinical%20event.%20In%20the%20post-ART%20period%2C%2052%5Cu00a0147%20PHIVY%20contributed%20207%5Cu00a0945%20PY%20%28ART%20initiation%20median%20age%3A%204.5%5Cu00a0years%29.%20Overall%20mortality%20IR%20was%201.4%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%201.4%20to%201.5%29%20and%20higher%20in%20low%20CD4%20strata%3B%20patients%20at%20each%20end%20of%20the%20age%20spectrum%20%28%26lt%3B2%20and%20%26gt%3B19%29%20had%20increased%20mortality%20post-ART.%20IRs%20for%20first%20occurrence%20of%20WHO-4%20and%20WHO-3%20events%20were%201.3%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%201.2%20to%201.4%29%20and%202.1%5C%2F100%5Cu00a0PY%20%2895%25%20CI%3A%202.0%20to%202.2%29%20respectively.%20These%20were%20also%20associated%20with%20lower%20CD4%20and%20younger%20age%20strata.%5CnCONCLUSIONS%3A%20Mortality%20and%20incidence%20of%20clinical%20events%20were%20highest%20in%20both%20younger%20%28%26lt%3B2%5Cu00a0years%29%20and%20older%20%28%26gt%3B19%5Cu00a0years%29%20youth%20with%20PHIV.%20Scaling-up%20services%20for%20%26lt%3B2%5Cu00a0years%20%28early%20access%20to%20HIV%20diagnosis%20and%20care%29%20and%20%26gt%3B19%5Cu00a0years%20%28adolescent-%20and%20youth-focused%20health%20services%29%20is%20critical%20to%20improve%20outcomes%20among%20PHIVY.%22%2C%22date%22%3A%222020-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25617%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233034417%22%2C%22PMCID%22%3A%22PMC7545918%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A01%3A08Z%22%7D%7D%2C%7B%22key%22%3A%228935IIPV%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Loiseau%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLoiseau%20C%2C%20Brites%20D%2C%20Reinhard%20M%2C%20Z%26%23xFC%3Brcher%20K%2C%20Borrell%20S%2C%20Ballif%20M%2C%20et%20al.%20HIV%20Coinfection%20Is%20Associated%20with%20Low-Fitness%20rpoB%20Variants%20in%20Rifampicin-Resistant%20Mycobacterium%20tuberculosis.%20Antimicrob%20Agents%20Chemother.%202020%20Sep%2021%3B64%2810%29%3Ae00782-20.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00782-20%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.00782-20%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032718966%3B%20PubMed%20Central%20PMCID%3A%20PMC7508592.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV%20Coinfection%20Is%20Associated%20with%20Low-Fitness%20rpoB%20Variants%20in%20Rifampicin-Resistant%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Brites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Reinhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Borrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liliana%20K.%22%2C%22lastName%22%3A%22Rutaihwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Jane%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alash%27le%22%2C%22lastName%22%3A%22Abimiku%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%22%2C%22lastName%22%3A%22Zetola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Basra%22%2C%22lastName%22%3A%22Doulla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%5D%2C%22abstractNote%22%3A%22We%20analyzed%20312%20drug-resistant%20genomes%20of%20Mycobacterium%20tuberculosis%20isolates%20collected%20from%20HIV-coinfected%20and%20HIV-negative%20TB%20patients%20from%20nine%20countries%20with%20a%20high%20tuberculosis%20burden.%20We%20found%20that%20rifampicin-resistant%20M.%20tuberculosis%20strains%20isolated%20from%20HIV-coinfected%20patients%20carried%20disproportionally%20more%20resistance-conferring%20mutations%20in%20rpoB%20that%20are%20associated%20with%20a%20low%20fitness%20in%20the%20absence%20of%20the%20drug%2C%20suggesting%20these%20low-fitness%20rpoB%20variants%20can%20thrive%20in%20the%20context%20of%20reduced%20host%20immunity.%22%2C%22date%22%3A%222020-09-21%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.00782-20%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232718966%22%2C%22PMCID%22%3A%22PMC7508592%22%2C%22ISSN%22%3A%221098-6596%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A03%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22LF3CD2MW%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Shepherd%20and%20Shaw%22%2C%22parsedDate%22%3A%222020-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BShepherd%20BE%2C%20Shaw%20PA.%20Errors%20in%20multiple%20variables%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20cohort%20and%20electronic%20health%20record%20data%3A%20statistical%20challenges%20and%20opportunities.%20Stat%20Commun%20Infect%20Dis.%202020%20Sep%201%3B12%28Suppl1%29%3A20190015.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fscid-2019-0015%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fscid-2019-0015%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2035880997%3B%20PubMed%20Central%20PMCID%3A%20PMC9204761.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Errors%20in%20multiple%20variables%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20cohort%20and%20electronic%20health%20record%20data%3A%20statistical%20challenges%20and%20opportunities%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%3A%20Observational%20data%20derived%20from%20patient%20electronic%20health%20records%20%28EHR%29%20data%20are%20increasingly%20used%20for%20human%20immunodeficiency%20virus%5C%2Facquired%20immunodeficiency%20syndrome%20%28HIV%5C%2FAIDS%29%20research.%20There%20are%20challenges%20to%20using%20these%20data%2C%20in%20particular%20with%20regards%20to%20data%20quality%3B%20some%20are%20recognized%2C%20some%20unrecognized%2C%20and%20some%20recognized%20but%20ignored.%20There%20are%20great%20opportunities%20for%20the%20statistical%20community%20to%20improve%20inference%20by%20incorporating%20validation%20subsampling%20into%20analyses%20of%20EHR%20data.Methods%3A%20Methods%20to%20address%20measurement%20error%2C%20misclassification%2C%20and%20missing%20data%20are%20relevant%2C%20as%20are%20sampling%20designs%20such%20as%20two-phase%20sampling.%20However%2C%20many%20of%20the%20existing%20statistical%20methods%20for%20measurement%20error%2C%20for%20example%2C%20only%20address%20relatively%20simple%20settings%2C%20whereas%20the%20errors%20seen%20in%20these%20datasets%20span%20multiple%20variables%20%28both%20predictors%20and%20outcomes%29%2C%20are%20correlated%2C%20and%20even%20affect%20who%20is%20included%20in%20the%20study.Results%5C%2FConclusion%3A%20We%20will%20discuss%20some%20preliminary%20methods%20in%20this%20area%20with%20a%20particular%20focus%20on%20time-to-event%20outcomes%20and%20outline%20areas%20of%20future%20research.%22%2C%22date%22%3A%222020-09-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1515%5C%2Fscid-2019-0015%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2235880997%22%2C%22PMCID%22%3A%22PMC9204761%22%2C%22ISSN%22%3A%222194-6310%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A05%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22TSFYJ5TX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Duda%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BDuda%20SN%2C%20Musick%20BS%2C%20Davies%20MA%2C%20Sohn%20AH%2C%20Ledergerber%20B%2C%20Wools-Kaloustian%20K%2C%20et%20al.%20The%20IeDEA%20Data%20Exchange%20Standard%3A%20a%20common%20data%20model%20for%20global%20HIV%20cohort%20collaboration%20%5BInternet%5D.%20medRxiv%3B%202020%20%5Bcited%202023%20Jun%2016%5D.%20Available%20from%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fwww.medrxiv.org%5C%2Fcontent%5C%2F10.1101%5C%2F2020.07.22.20159921v1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fwww.medrxiv.org%5C%2Fcontent%5C%2F10.1101%5C%2F2020.07.22.20159921v1%26lt%3B%5C%2Fa%26gt%3B%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2020.07.22.20159921%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2020.07.22.20159921%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22preprint%22%2C%22title%22%3A%22The%20IeDEA%20Data%20Exchange%20Standard%3A%20a%20common%20data%20model%20for%20global%20HIV%20cohort%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Ledergerber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicola%20J.%22%2C%22lastName%22%3A%22Maxwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cam%20Ha%20Dao%22%2C%22lastName%22%3A%22Ostinelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenna%20C.%22%2C%22lastName%22%3A%22Hogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qiuhu%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruth%20L.%22%2C%22lastName%22%3A%22Goodall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dennis%20Karsten%22%2C%22lastName%22%3A%22Kristensen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20V.%22%2C%22lastName%22%3A%22Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolyn%20F.%20M.%22%2C%22lastName%22%3A%22Williams%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judith%20T.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%5D%2C%22abstractNote%22%3A%22Objective%20To%20describe%20content%20domains%20and%20applications%20of%20the%20IeDEA%20Data%20Exchange%20Standard%2C%20its%20development%20history%2C%20governance%20structure%2C%20and%20relationships%20to%20other%20established%20data%20models%2C%20as%20well%20as%20to%20share%20open%20source%2C%20reusable%2C%20scalable%2C%20and%20adaptable%20implementation%20tools%20with%20the%20informatics%20community.%5CnMethods%20In%202012%2C%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20collaboration%20began%20development%20of%20a%20data%20exchange%20standard%2C%20the%20IeDEA%20DES%2C%20to%20support%20collaborative%20global%20HIV%20epidemiology%20research.%20With%20the%20HIV%20Cohorts%20Data%20Exchange%20Protocol%20as%20a%20template%2C%20a%20global%20group%20of%20data%20managers%2C%20statisticians%2C%20clinicians%2C%20informaticians%2C%20and%20epidemiologists%20reviewed%20existing%20data%20schemas%20and%20clinic%20data%20procedures%20to%20develop%20the%20HIV%20data%20exchange%20model.%20The%20model%20received%20a%20substantial%20update%20in%202017%2C%20with%20annual%20updates%20thereafter.%5CnFindings%20The%20resulting%20IeDEA%20DES%20is%20a%20patient-centric%20common%20data%20model%20designed%20for%20HIV%20research%20that%20has%20been%20informed%20by%20established%20data%20models%20from%20US-based%20electronic%20health%20records%2C%20broad%20experience%20in%20data%20collection%20in%20resource-limited%20settings%2C%20and%20informatics%20best%20practices.%20The%20IeDEA%20DES%20is%20inherently%20flexible%20and%20continues%20to%20grow%20based%20on%20the%20ongoing%20stewardship%20of%20the%20IeDEA%20Data%20Harmonization%20Working%20Group%20with%20input%20from%20external%20collaborators.%20Use%20of%20the%20IeDEA%20DES%20has%20improved%20multiregional%20collaboration%20within%20and%20beyond%20IeDEA%2C%20expediting%20over%2095%20multiregional%20research%20projects%20using%20data%20from%20more%20than%20400%20HIV%20care%20and%20treatment%20sites%20across%20seven%20global%20regions.%20A%20detailed%20data%20model%20specification%20and%20REDCap%20data%20entry%20templates%20that%20implement%20the%20IeDEA%20DES%20are%20publicly%20available%20on%20GitHub.%5CnConclusions%20The%20IeDEA%20common%20data%20model%20and%20related%20resources%20are%20powerful%20tools%20to%20foster%20collaboration%20and%20accelerate%20science%20across%20research%20networks.%20While%20currently%20directed%20towards%20observational%20HIV%20research%20and%20data%20from%20resource-limited%20settings%2C%20this%20model%20is%20flexible%20and%20extendable%20to%20other%20areas%20of%20health%20research.%5CnHighlightsThe%20IeDEA%20Data%20Exchange%20Standard%20is%20a%20data%20model%20for%20HIV%20epidemiology%20research.The%20model%20has%20expedited%2095%20projects%20using%20data%20from%20%26gt%3B400%20HIV%20clinics%20worldwide.A%20browsable%20and%20adaptable%20version%20and%20data%20collection%20templates%20are%20available%20online.%22%2C%22genre%22%3A%22%22%2C%22repository%22%3A%22medRxiv%22%2C%22archiveID%22%3A%22%22%2C%22date%22%3A%222020-07-25%22%2C%22DOI%22%3A%2210.1101%5C%2F2020.07.22.20159921%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.medrxiv.org%5C%2Fcontent%5C%2F10.1101%5C%2F2020.07.22.20159921v1%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A01%3A49Z%22%7D%7D%2C%7B%22key%22%3A%226R8AQ3EA%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Oliveira-de-Souza%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BOliveira-de-Souza%20D%2C%20Vinhaes%20CL%2C%20Arriaga%20MB%2C%20Kumar%20NP%2C%20Queiroz%20ATL%2C%20Fukutani%20KF%2C%20et%20al.%20Aging%20increases%20the%20systemic%20molecular%20degree%20of%20inflammatory%20perturbation%20in%20patients%20with%20tuberculosis.%20Sci%20Rep.%202020%20Jul%209%3B10%281%29%3A11358.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-68255-0%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-68255-0%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032647178%3B%20PubMed%20Central%20PMCID%3A%20PMC7347549.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Aging%20increases%20the%20systemic%20molecular%20degree%20of%20inflammatory%20perturbation%20in%20patients%20with%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deivide%22%2C%22lastName%22%3A%22Oliveira-de-Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathella%20Pavan%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Artur%20T.%20L.%22%2C%22lastName%22%3A%22Queiroz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subash%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20a%20chronic%20infection%20that%20can%20affect%20individuals%20of%20all%20ages.%20The%20description%20of%20determinants%20of%20immunopathogenesis%20in%20TB%20is%20of%20tremendous%20interest%20due%20to%20the%20perspective%20of%20finding%20a%20reliable%20host-directed%20therapy%20to%20reduce%20disease%20burden.%20The%20association%20between%20specific%20biomarker%20profiles%20related%20to%20inflammation%20and%20the%20diverse%20clinical%20disease%20presentations%20in%20TB%20has%20been%20extensively%20studied%20in%20adults.%20However%2C%20relatively%20scarce%20data%20on%20profiling%20the%20inflammatory%20responses%20in%20pediatric%20TB%20are%20available.%20Here%2C%20we%20employed%20the%20molecular%20degree%20of%20perturbation%20%28MDP%29%20score%20adapted%20to%20plasma%20biomarkers%20in%20two%20distinct%20databanks%20from%20studies%20that%20examined%20either%20adults%20or%20children%20presenting%20with%20pulmonary%20or%20extrapulmonary%20disease.%20We%20used%20multidimensional%20statistical%20analyses%20to%20characterize%20the%20impact%20of%20age%20on%20the%20overall%20changes%20in%20the%20systemic%20inflammation%20profiles%20in%20subpopulation%20of%20TB%20patients.%20Our%20findings%20indicate%20that%20TB%20results%20in%20significant%20increases%20in%20molecular%20perturbation%2C%20with%20the%20highest%20values%20being%20detected%20in%20adult%20patients.%20Furthermore%2C%20there%20were%20unique%20differences%20in%20the%20biomarker%20perturbation%20patterns%20and%20the%20overall%20degree%20of%20inflammation%20according%20to%20disease%20site%20and%20age.%20Importantly%2C%20the%20molecular%20degree%20of%20perturbation%20was%20not%20influenced%20by%20sex.%20Our%20results%20revealed%20that%20aging%20is%20an%20important%20determinant%20of%20the%20differences%20in%20quality%20and%20magnitude%20of%20systemic%20inflammatory%20perturbation%20in%20distinct%20clinical%20forms%20of%20TB.%22%2C%22date%22%3A%222020-07-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-68255-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232647178%22%2C%22PMCID%22%3A%22PMC7347549%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A02%3A58Z%22%7D%7D%2C%7B%22key%22%3A%22RF3KDUC5%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Boettiger%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBoettiger%20DC%2C%20Escuder%20MM%2C%20Law%20MG%2C%20Veloso%20V%2C%20Souza%20RA%2C%20Ikeda%20MLR%2C%20et%20al.%20Cardiovascular%20disease%20among%20people%20living%20with%20HIV%20in%20Brazil.%20Trop%20Med%20Int%20Health.%202020%20Jul%3B25%287%29%3A886%26%23×2013%3B96.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.13405%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Ftmi.13405%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032306480.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cardiovascular%20disease%20among%20people%20living%20with%20HIV%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20C.%22%2C%22lastName%22%3A%22Boettiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Mercedes%22%2C%22lastName%22%3A%22Escuder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20G.%22%2C%22lastName%22%3A%22Law%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosa%20A.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20L.%20R.%22%2C%22lastName%22%3A%22Ikeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20R.%22%2C%22lastName%22%3A%22de%20Alencastro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Unai%22%2C%22lastName%22%3A%22Tupinamb%5Cu00e1s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Brites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackeline%20O.%22%2C%22lastName%22%3A%22Ggomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayonara%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karu%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Grangeiro%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20There%20is%20a%20paucity%20of%20data%20on%20cardiovascular%20disease%20%28CVD%29%20among%20people%20living%20with%20HIV%20%28PLHIV%29%20in%20resource-limited%20countries.%20We%20assessed%20factors%20associated%20with%20CVD%20and%20the%20impact%20of%20prevalent%20CVD%20on%20all-cause%20mortality%20in%20PLHIV%20on%20antiretroviral%20therapy%20in%20Brazil.%5CnMETHODS%3A%20Competing%20risk%20regression%20to%20assess%20factors%20associated%20with%20CVD%20and%20all-cause%20mortality%20in%20the%20HIV-Brazil%20Cohort%20Study%20between%202003%20and%202014.%5CnRESULTS%3A%20Among%205614%20patients%2C%20the%20rate%20of%20CVD%20was%203.5%20%2895%25%20confidence%20interval%20%5B95%25%20CI%5D%202.9-4.3%29%20per%201000%20person-years.%20CVD%20was%20associated%20with%20older%20age%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%206.4%20for%20%5Cu226555%5Cu00a0years%20vs.%20%26lt%3B35%5Cu00a0years%2C%2095%25%20CI%3A%202.5-16.3%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.01%29%2C%20black%20race%20%28aHR%201.8%20vs.%20white%20race%2C%2095%25%20CI%3A%201.0-3.1%2C%20P%5Cu00a0%3D%5Cu00a00.04%29%2C%20past%20CVD%20%28aHR%203.0%20vs.%20no%20past%20CVD%2C%2095%25%20CI%3A%201.4-6.2%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.01%29%2C%20hypertension%20%28aHR%201.8%20vs.%20no%20hypertension%2C%2095%25%20CI%3A%201.0-3.1%2C%20P%5Cu00a0%3D%5Cu00a00.04%29%2C%20high-grade%20dyslipidemia%20%28aHR%209.3%20vs.%20no%20high-grade%20dyslipidemia%2C%2095%25%20CI%3A%206.0-14.6%2C%20P%5Cu00a0%26lt%3B%5Cu00a00.01%29%2C%20ever%20smoking%20%28aHR%202.4%20vs.%20never%2C%2095%25%20CI%3A%201.2-5.0%2C%20P%5Cu00a0%3D%5Cu00a00.02%29%20and%20low%20nadir%20CD4%20cell%20count%20%28aHR%201.8%20for%20100-250%5Cu00a0cells%5C%2Fmm3%20vs.%20%26gt%3B250%5Cu00a0cells%5C%2Fmm3%20%2C%2095%25%20CI%3A%201.0-3.2%2C%20P%5Cu00a0%3D%5Cu00a00.05%29.%20The%20rate%20of%20death%20was%2016.6%20%2895%25%20CI%3A%2015.1-18.3%29%20per%201000%20person-years.%20Death%20was%20strongly%20associated%20with%20having%20had%20a%20past%20CVD%20event%20%28aHR%201.7%20vs.%20no%20past%20CVD%20event%2C%2095%25%20CI%3A%201.1-2.7%2C%20P%5Cu00a0%3D%5Cu00a00.01%29.%5CnCONCLUSIONS%3A%20Traditional%20and%20HIV-specific%20factors%20associated%20with%20CVD%20among%20PLHIV%20in%20Brazil%20are%20similar%20to%20those%20identified%20among%20PLHIV%20in%20high-income%20countries.%20PLHIV%20in%20Brazil%20with%20a%20history%20of%20CVD%20have%20a%20high%20risk%20of%20death.%20CVD%20care%20and%20treatment%20remain%20priorities%20for%20PLHIV%20in%20Brazil%20as%20this%20population%20ages%20and%20antiretroviral%20therapy%20use%20expands.%22%2C%22date%22%3A%22Jul%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Ftmi.13405%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232306480%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221365-3156%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A11%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22N7VW7429%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Patten%20et%20al.%22%2C%22parsedDate%22%3A%222020-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPatten%20G%2C%20Puthanakit%20T%2C%20McGowan%20CC%2C%20Wools-Kaloustian%20K%2C%20Hazra%20R%2C%20Pinto%20JA%2C%20et%20al.%20Raltegravir%20use%20and%20outcomes%20among%20children%20and%20adolescents%20living%20with%20HIV%20in%20the%20IeDEA%20global%20consortium.%20J%20Int%20AIDS%20Soc.%202020%20Jul%3B23%287%29%3Ae25580.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25580%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25580%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032722897%3B%20PubMed%20Central%20PMCID%3A%20PMC7387110.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Raltegravir%20use%20and%20outcomes%20among%20children%20and%20adolescents%20living%20with%20HIV%20in%20the%20IeDEA%20global%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thanyawee%22%2C%22lastName%22%3A%22Puthanakit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rohan%22%2C%22lastName%22%3A%22Hazra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20A.%22%2C%22lastName%22%3A%22Pinto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helena%22%2C%22lastName%22%3A%22Rabie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20As%20integrase%20inhibitors%20become%20available%20in%20low-%20and%20middle-income%20countries%20%28LMICs%29%2C%20they%20offer%20the%20potential%20to%20expand%20extremely%20limited%20treatment%20options%20available%20to%20children%20and%20adolescents.%20In%20LMICs%2C%20only%20small%20numbers%20have%20used%20raltegravir%2C%20primarily%20as%20part%20of%20third-line%20regimens.%20Using%20data%20from%20the%20IeDEA%20global%20consortium%2C%20we%20aimed%20to%20describe%20the%20characteristics%20of%20children%20on%20raltegravir-containing%20regimens%20and%20their%20outcomes.%5CnMETHODS%3A%20We%20included%20data%20from%201994%20to%202017%20from%20children%20%28age%20%26lt%3B18%5Cu00a0years%29%2C%20from%20East%20and%20Southern%20Africa%2C%20Asia%20and%20South%20America%2C%20who%20received%20cART%20regimens%20containing%20raltegravir%20for%20%5Cu226590%5Cu00a0days.%20We%20describe%20their%20characteristics%20at%20raltegravir%20start%2C%20and%20their%20immunological%20and%20virological%20outcomes.%5CnRESULTS%20AND%20DISCUSSION%3A%20In%20total%2C%2062%20children%20were%20included%2C%20with%20median%20age%20at%20raltegravir%20initiation%20of%2014.3%5Cu00a0years%20%28IQR%2011.2%20to%2015.8%29%20and%20median%20CD4%20count%20of%20276%5Cu00a0cells%5C%2F%5Cu00b5L%20%28IQR%2068%20to%20494%29.%20Among%2040%20%2865%25%29%20with%20drug%20resistance%20testing%20prior%20to%20raltegravir%2C%2071%25%20were%20resistant%20to%20at%20least%20one%20protease%20inhibitor%20%28PI%29%2C%20and%2032%25%20had%20high-level%20resistance%20to%20at%20least%20one%20drug%20class.%20Most%20%28n%5Cu00a0%3D%5Cu00a050%3B%2081%25%29%20received%20raltegravir%20as%20part%20of%20third-line%20cART%20following%20PI-based%20regimens%2C%20and%20were%20on%20regimens%20containing%20four%20or%20more%20drugs%20%28n%5Cu00a0%3D%5Cu00a047%2C%2076%25%29.%20By%20database%20closure%2C%20median%20duration%20on%20raltegravir%20was%202.0%5Cu00a0years%20%28IQR%200.8%20to%203.0%29%2C%201%20%281.6%25%29%20patient%20had%20died%2C%206%20%289.7%25%29%20were%20lost%20to%20follow-up%20and%2021%20%2834%25%29%20had%20discontinued%20raltegravir.%20Among%2015%20patients%20reporting%20reasons%20for%20stopping%20raltegravir%2C%20six%20discontinued%20because%20it%20was%20no%20longer%20available.%20Within%20one%20year%20of%20starting%20raltegravir%2C%20among%2053%20patients%20with%20VL%20measures%2C%2040%20%2875%25%29%20had%20VL%5Cu00a0%26lt%3B%5Cu00a01000%5Cu00a0copies%5C%2FmL%2C%20and%20among%2054%20with%20a%20reported%20CD4%20count%2C%2045%20%2883%25%29%20and%2036%20%2867%25%29%20were%20%5Cu2265350%20and%20%5Cu2265500%5Cu00a0cells%5C%2F%5Cu00b5L%2C%20respectively%2C%20with%20median%20CD4%20count%20increasing%20to%20517.5%5Cu00a0cells%5C%2F%5Cu00b5L%20%28IQR%20288%20to%20810%29.%5CnCONCLUSIONS%3A%20Among%20children%20in%20LMICs%2C%20the%20initial%20use%20of%20raltegravir%20has%20been%20primarily%20for%20post%20PI-based%20cART.%20We%20found%20good%20virological%20and%20immunological%20outcomes%20despite%20frequent%20prior%20triple-class%20failure%20and%20high%20levels%20of%20drug%20resistance.%20Both%20access%20to%20raltegravir%20and%20long-term%20adherence%20to%20regimens%20with%20large%20pill-burdens%20remain%20challenging.%20Policies%20which%20promote%20earlier%20access%20to%20new%20drugs%20and%20simplify%20daily%20regimens%20for%20children%20and%20adolescents%20in%20LMICs%20are%20needed.%22%2C%22date%22%3A%22Jul%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25580%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232722897%22%2C%22PMCID%22%3A%22PMC7387110%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A12%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22HPP832HE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Koenig%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BKoenig%20SP%2C%20Kim%20A%2C%20Shepherd%20BE%2C%20Cesar%20C%2C%20Veloso%20V%2C%20Cortes%20CP%2C%20et%20al.%20Increased%20Mortality%20After%20Tuberculosis%20Treatment%20Completion%20in%20Persons%20Living%20With%20Human%20Immunodeficiency%20Virus%20in%20Latin%20America.%20Clin%20Infect%20Dis.%202020%20Jun%2024%3B71%281%29%3A215%26%23×2013%3B7.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciz1032%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciz1032%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031629369%3B%20PubMed%20Central%20PMCID%3A%20PMC7312222.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20Mortality%20After%20Tuberculosis%20Treatment%20Completion%20in%20Persons%20Living%20With%20Human%20Immunodeficiency%20Virus%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serena%20P.%22%2C%22lastName%22%3A%22Koenig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahra%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%5D%2C%22abstractNote%22%3A%22We%20assessed%20the%20association%20between%20cured%20tuberculosis%20%28TB%29%20and%20mortality%20among%20persons%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29%20in%20Latin%20America.%20We%20compared%20survival%20among%20persons%20with%20and%20without%20TB%20at%20enrollment%20in%20HIV%20care%2C%20starting%209%20months%20after%20clinic%20enrollment.%20In%20multivariable%20analysis%2C%20TB%20was%20associated%20with%20higher%20long-term%20mortality%20%28hazard%20ratio%2C%201.57%3B%2095%25%20confidence%20interval%2C%201.25-1.99%29.%22%2C%22date%22%3A%22Jun%2024%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciz1032%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231629369%22%2C%22PMCID%22%3A%22PMC7312222%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A08%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22XGGCU9VH%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rebeiro%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-09%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRebeiro%20PF%2C%20Cohen%20MJ%2C%20Ewing%20HM%2C%20Figueiredo%20MC%2C%20Peetluk%20LS%2C%20Andrade%20KB%2C%20et%20al.%20Knowledge%20and%20stigma%20of%20latent%20tuberculosis%20infection%20in%20Brazil%3A%20implications%20for%20tuberculosis%20prevention%20strategies.%20BMC%20Public%20Health.%202020%20Jun%209%3B20%281%29%3A897.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-020-09053-1%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-020-09053-1%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032517671%3B%20PubMed%20Central%20PMCID%3A%20PMC7285569.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Knowledge%20and%20stigma%20of%20latent%20tuberculosis%20infection%20in%20Brazil%3A%20implications%20for%20tuberculosis%20prevention%20strategies%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mollie%20J.%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heather%20M.%22%2C%22lastName%22%3A%22Ewing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20Cruvinel%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20Saag%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kleydson%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marshall%22%2C%22lastName%22%3A%22Eakin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%20J.%22%2C%22lastName%22%3A%22Zechmeister%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20elimination%20requires%20treatment%20of%20millions%20of%20persons%20with%20latent%20M.%20tuberculosis%20infection%20%28LTBI%29.%20LTBI%20treatment%20acceptance%20depends%20on%20population-wide%20TB%20knowledge%20and%20low%20stigma%2C%20but%20limited%20data%20are%20available%20on%20the%20relationship%20between%20stigma%20and%20knowledge.%20We%20assessed%20knowledge%20of%20TB%20disease%20and%20LTBI%20throughout%20Brazil%20and%20examined%20their%20association%20with%20TB%20stigma%20and%20incidence.%5CnMETHODS%3A%20We%20performed%20a%20nationwide%20survey%20with%20multi-stage%20probability%20design%20through%20AmericasBarometer%20from%20April-May%202017%3B%20the%20sample%20was%20representative%20of%20Brazil%20at%20regional%20and%20national%20levels.%20Knowledge%20of%20and%20stigma%20toward%20TB%20were%20assessed%20by%20validated%20survey%20questions.%5CnRESULTS%3A%20Survey-weighted%20responses%20of%201532%20individuals%20suggest%20that%2057%25%20of%20the%20population%20knew%20LTBI%20can%20occur%2C%20and%2090%25%20would%20seek%20treatment%20for%20it.%20Regarding%20active%20TB%2C%2085%25%20knew%20TB%20symptoms%2C%2070%25%20reported%20they%20should%20avoid%20contact%20with%20someone%20with%20active%20TB%2C%20and%2024%25%20had%20stigma%20toward%20persons%20with%20TB%20%28i.e.%2C%20thought%20persons%20with%20tuberculosis%20should%20feel%20ashamed%2C%20or%20deserved%20their%20illness%29.%20In%20regression%20models%20adjusting%20for%20clinical%20and%20demographic%20variables%2C%20knowledge%20of%20LTBI%20was%20associated%20with%20increased%20stigma%20toward%20persons%20with%20TB%20%28adjusted%20odds%20ratio%20%5BOR%5D%5Cu2009%3D%5Cu20092.13%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%201%5Cu00b725-3.63%2C%20for%20%26quot%3Bshould%20feel%20ashamed%26quot%3B%3B%20OR%5Cu2009%3D%5Cu20091%5Cu00b782%2C%2095%25%20CI%3A%201%5Cu00b715-2%5Cu00b789%2C%20for%20%26quot%3Bdeserve%20illness%26quot%3B%29.%20Adjusting%20for%20regional%20TB%20incidence%20did%20not%20affect%20this%20association.%5CnCONCLUSIONS%3A%20High%20proportions%20of%20this%20representative%20Brazilian%20population%20had%20knowledge%20of%20LTBI%20and%20were%20willing%20to%20seek%20treatment%20for%20it.%20However%2C%20such%20knowledge%20was%20associated%20with%20TB-specific%20stigma.%20Strategies%20to%20educate%20and%20implement%20treatment%20of%20latent%20tuberculosis%20must%20include%20efforts%20to%20decrease%20TB%20stigma.%22%2C%22date%22%3A%22Jun%2009%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-020-09053-1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232517671%22%2C%22PMCID%22%3A%22PMC7285569%22%2C%22ISSN%22%3A%221471-2458%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A12%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22C283XGQT%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Belaunzar%5Cu00e1n-Zamudio%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBelaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Caro-Vega%20YN%2C%20Shepherd%20BE%2C%20Rebeiro%20PF%2C%20Crabtree-Ram%26%23xED%3Brez%20BE%2C%20Cortes%20CP%2C%20et%20al.%20The%20Population%20Impact%20of%20Late%20Presentation%20With%20Advanced%20HIV%20Disease%20and%20Delayed%20Antiretroviral%20Therapy%20in%20Adults%20Receiving%20HIV%20Care%20in%20Latin%20America.%20Am%20J%20Epidemiol.%202020%20Jun%201%3B189%286%29%3A564%26%23×2013%3B72.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwz252%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Faje%5C%2Fkwz252%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031667488%3B%20PubMed%20Central%20PMCID%3A%20PMC7443201.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Population%20Impact%20of%20Late%20Presentation%20With%20Advanced%20HIV%20Disease%20and%20Delayed%20Antiretroviral%20Therapy%20in%20Adults%20Receiving%20HIV%20Care%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%20N.%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Rouzier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%20Wagner%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22Late%20presentation%20to%20care%20and%20antiretroviral%20therapy%20%28ART%29%20initiation%20with%20advanced%20human%20immunodeficiency%20virus%20%28HIV%29%20disease%20are%20common%20in%20Latin%20America.%20We%20estimated%20the%20impact%20of%20these%20conditions%20on%20mortality%20in%20the%20region.%20We%20included%20adults%20enrolled%20during%202001-2014%20at%20HIV%20care%20clinics.%20We%20estimated%20the%20adjusted%20attributable%20risk%20%28AR%29%20and%20population%20attributable%20fraction%20%28PAF%29%20for%20all-cause%20mortality%20of%20presentation%20to%20care%20with%20advanced%20HIV%20disease%20%28advanced%20LP%29%2C%20ART%20initiation%20with%20advanced%20HIV%20disease%2C%20and%20not%20initiating%20ART.%20Advanced%20HIV%20disease%20was%20defined%20as%20CD4%5Cu00a0of%20%26lt%3B200%20cells%5C%2F%5Cu03bcL%20or%20acquired%20immune%20deficiency%20syndrome.%20AR%20and%20PAF%20were%20derived%20using%20marginal%20structural%20models.%20Of%209%2C229%20patients%2C%2056%25%20presented%20with%20advanced%20HIV%20disease.%20ARs%20of%20death%20for%20advanced%20LP%20were%2086%25%2C%2071%25%2C%20and%2058%25%2C%20and%20PAFs%20were%2078%25%2C%2058%25%2C%20and%2043%25%20at%201%2C%205%2C%20and%2010%20years%20after%20enrollment.%20Among%20people%20without%20advanced%20LP%2C%20ARs%20of%20death%20for%20delaying%20ART%20were%2039%25%2C%2032%25%2C%20and%2037%25%20at%201%2C%205%2C%20and%2010%20years%20post-enrollment%20and%20PAFs%20were%2020%25%2C%2014%25%2C%20and%2015%25.%20Among%20people%20with%20advanced%20LP%2C%20ART%20decreased%20the%20hazard%20of%20death%20by%2063%25%20in%20the%20first%20year%20after%20enrollment%2C%20but%2093%25%20of%20these%20started%20ART%3B%20thus%20universal%20ART%20among%20them%20would%20reduce%20mortality%20by%20only%2010%25.%20Earlier%20presentation%20to%20care%20and%20earlier%20ART%20initiation%20would%20prevent%20most%20HIV%20deaths%20in%20Latin%20America.%22%2C%22date%22%3A%22Jun%2001%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Faje%5C%2Fkwz252%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231667488%22%2C%22PMCID%22%3A%22PMC7443201%22%2C%22ISSN%22%3A%221476-6256%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A08%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22W4Z9IKZJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Penn-Nicholson%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPenn-Nicholson%20A%2C%20Mbandi%20SK%2C%20Thompson%20E%2C%20Mendelsohn%20SC%2C%20Suliman%20S%2C%20Chegou%20NN%2C%20et%20al.%20RISK6%2C%20a%206-gene%20transcriptomic%20signature%20of%20TB%20disease%20risk%2C%20diagnosis%20and%20treatment%20response.%20Sci%20Rep.%202020%20May%2025%3B10%281%29%3A8629.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-65043-8%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-65043-8%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032451443%3B%20PubMed%20Central%20PMCID%3A%20PMC7248089.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22RISK6%2C%20a%206-gene%20transcriptomic%20signature%20of%20TB%20disease%20risk%2C%20diagnosis%20and%20treatment%20response%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adam%22%2C%22lastName%22%3A%22Penn-Nicholson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%20Kimbung%22%2C%22lastName%22%3A%22Mbandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ethan%22%2C%22lastName%22%3A%22Thompson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%20C.%22%2C%22lastName%22%3A%22Mendelsohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Suliman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Novel%20N.%22%2C%22lastName%22%3A%22Chegou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanus%20T.%22%2C%22lastName%22%3A%22Malherbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatoumatta%22%2C%22lastName%22%3A%22Darboe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mzwandile%22%2C%22lastName%22%3A%22Erasmus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Willem%20A.%22%2C%22lastName%22%3A%22Hanekom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Bilek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Fisher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%20H.%20E.%22%2C%22lastName%22%3A%22Kaufmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jill%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melissa%22%2C%22lastName%22%3A%22Murphy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Wood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carl%22%2C%22lastName%22%3A%22Morrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ildiko%22%2C%22lastName%22%3A%22Van%20Rhijn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Branch%22%2C%22lastName%22%3A%22Moody%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Murray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jayne%22%2C%22lastName%22%3A%22Sutherland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kogieleum%22%2C%22lastName%22%3A%22Naidoo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesri%22%2C%22lastName%22%3A%22Padayatchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerhard%22%2C%22lastName%22%3A%22Walzl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Hatherill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Zak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20J.%22%2C%22lastName%22%3A%22Scriba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Adolescent%20Cohort%20Study%20team%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22GC6-74%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22SATVI%20Clinical%20and%20Laboratory%20Team%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ScreenTB%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22AE-TBC%20Consortium%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22RePORT%20Brazil%20Team%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Peruvian%20Household%20Contacts%20Cohort%20Team%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CAPRISA%20IMPRESS%20team%22%7D%5D%2C%22abstractNote%22%3A%22Improved%20tuberculosis%20diagnostics%20and%20tools%20for%20monitoring%20treatment%20response%20are%20urgently%20needed.%20We%20developed%20a%20robust%20and%20simple%2C%20PCR-based%20host-blood%20transcriptomic%20signature%2C%20RISK6%2C%20for%20multiple%20applications%3A%20identifying%20individuals%20at%20risk%20of%20incident%20disease%2C%20as%20a%20screening%20test%20for%20subclinical%20or%20clinical%20tuberculosis%2C%20and%20for%20monitoring%20tuberculosis%20treatment.%20RISK6%20utility%20was%20validated%20by%20blind%20prediction%20using%20quantitative%20real-time%20%28qRT%29%20PCR%20in%20seven%20independent%20cohorts.%20Prognostic%20performance%20significantly%20exceeded%20that%20of%20previous%20signatures%20discovered%20in%20the%20same%20cohort.%20Performance%20for%20diagnosing%20subclinical%20and%20clinical%20disease%20in%20HIV-uninfected%20and%20HIV-infected%20persons%2C%20assessed%20by%20area%20under%20the%20receiver-operating%20characteristic%20curve%2C%20exceeded%2085%25.%20As%20a%20screening%20test%20for%20tuberculosis%2C%20the%20sensitivity%20at%2090%25%20specificity%20met%20or%20approached%20the%20benchmarks%20set%20out%20in%20World%20Health%20Organization%20target%20product%20profiles%20for%20non-sputum-based%20tests.%20RISK6%20scores%20correlated%20with%20lung%20immunopathology%20activity%2C%20measured%20by%20positron%20emission%20tomography%2C%20and%20tracked%20treatment%20response%2C%20demonstrating%20utility%20as%20treatment%20response%20biomarker%2C%20while%20predicting%20treatment%20failure%20prior%20to%20treatment%20initiation.%20Performance%20of%20the%20test%20in%20capillary%20blood%20samples%20collected%20by%20finger-prick%20was%20noninferior%20to%20venous%20blood%20collected%20in%20PAXgene%20tubes.%20These%20results%20support%20incorporation%20of%20RISK6%20into%20rapid%2C%20capillary%20blood-based%20point-of-care%20PCR%20devices%20for%20prospective%20assessment%20in%20field%20studies.%22%2C%22date%22%3A%22May%2025%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-65043-8%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232451443%22%2C%22PMCID%22%3A%22PMC7248089%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A11%3A29Z%22%7D%7D%2C%7B%22key%22%3A%227UK9LY25%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Jesson%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJesson%20J%2C%20Desmonde%20S%2C%20Yiannoutsos%20CT%2C%20Patten%20G%2C%20Malateste%20K%2C%20Duda%20SN%2C%20et%20al.%20Weight-for-age%20distributions%20among%20children%20with%20HIV%20on%20antiretroviral%20therapy%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20multiregional%20consortium.%20BMC%20Res%20Notes.%202020%20May%2024%3B13%281%29%3A249.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13104-020-05081-7%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13104-020-05081-7%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032448379%3B%20PubMed%20Central%20PMCID%3A%20PMC7245795.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Weight-for-age%20distributions%20among%20children%20with%20HIV%20on%20antiretroviral%20therapy%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20multiregional%20consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Desmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malateste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nagalingeswaran%22%2C%22lastName%22%3A%22Kumarasamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeriane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Ciaranello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Pediatric%20antiretroviral%20therapy%20%28ART%29%20for%20children%20with%20HIV%20%28CHIV%29%20must%20be%20dosed%20appropriately%20for%20children%26%23039%3Bs%20changing%20weights%20as%20they%20grow.%20To%20inform%20accurate%20estimates%20of%20ART%20formulations%20and%20doses%20needed%2C%20we%20described%20weight-for-age%20distributions%20among%20CHIV%20on%20ART%20in%20the%20IeDEA%20global%20pediatric%20collaboration%20between%202004%20and%202016%2C%20using%20data%20from%20six%20regions%20%28East%2C%20West%2C%20Central%2C%20and%20Southern%20Africa%2C%20Asia-Pacific%2C%20and%20Central%5C%2FSouth%20America%20and%20the%20Caribbean%29.%5CnRESULTS%3A%20Overall%2C%2059%2C862%20children%20contributed%20to%20the%20analysis.%20Age%20and%20weight%20data%20were%20available%20from%20530%2C080%20clinical%20encounters%20for%20girls%20and%20537%2C894%20for%20boys.%20For%20each%20one-year%20age%20stratum%20from%200%20to%2015%5Cu00a0years%2C%20we%20calculated%20the%20proportion%20of%20children%20in%20each%20of%20the%20weight%20bands%20designated%20by%20the%20World%20Health%20Organization%20as%20relevant%20to%20pediatric%20ART%20formulations%3A%200%20to%20%5Cu2009%26lt%3B%5Cu20093%5Cu00a0kg%2C%203%20to%20%5Cu2009%26lt%3B%5Cu20096%5Cu00a0kg%2C%206%20to%20%5Cu2009%26lt%3B%5Cu200910%5Cu00a0kg%2C%2010%20to%20%5Cu2009%26lt%3B%5Cu200914%5Cu00a0kg%2C%2014%20to%20%5Cu2009%26lt%3B%5Cu200920%5Cu00a0kg%2C%2020%20to%20%5Cu2009%26lt%3B%5Cu200925%5Cu00a0kg%2C%2025%20to%20%5Cu2009%26lt%3B%5Cu200930%5Cu00a0kg%2C%2030%20to%20%5Cu2009%26lt%3B%5Cu200935%5Cu00a0kg%2C%2035%20to%20%5Cu2009%26lt%3B%5Cu200940%5Cu00a0kg%2C%2040%20to%20%5Cu2009%26lt%3B%5Cu200945%5Cu00a0kg%2C%2045%20to%20%5Cu2009%26lt%3B%5Cu200950%5Cu00a0kg%2C%2050%20to%20%5Cu2009%26lt%3B%5Cu200955%5Cu00a0kg%2C%2055%20to%20%5Cu2009%26lt%3B%5Cu200960%5Cu00a0kg%2C%20and%5Cu2009%5Cu2265%5Cu200960%5Cu00a0kg.%20Data%20are%20reported%20for%20the%20entire%20cohort%2C%20as%20well%20as%20stratified%20by%20sex%20and%20IeDEA%20region%2C%20calendar%20year%20of%20ART%20use%2C%20and%20duration%20on%20ART%20at%20time%20of%20assessment%20%28%26lt%3B%5Cu200912%20or%5Cu2009%5Cu2265%5Cu200912%5Cu00a0months%29%2C%20provided%20in%20data%20tables.%20These%20data%20are%20critical%20to%20improve%20the%20accuracy%20of%20forecasting%20and%20procurement%20of%20pediatric%20ART%20formulations%20as%20the%20pediatric%20HIV%20epidemic%20and%20pediatric%20HIV%20treatment%20strategies%20evolve.%22%2C%22date%22%3A%222020-05-24%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13104-020-05081-7%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232448379%22%2C%22PMCID%22%3A%22PMC7245795%22%2C%22ISSN%22%3A%221756-0500%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A02%3A38Z%22%7D%7D%2C%7B%22key%22%3A%227SUA9UKZ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Peetluk%20et%20al.%22%2C%22parsedDate%22%3A%222020-04-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPeetluk%20LS%2C%20Rebeiro%20PF%2C%20Cordeiro-Santos%20M%2C%20Kritski%20A%2C%20Andrade%20BB%2C%20Durovni%20B%2C%20et%20al.%20Lack%20of%20Weight%20Gain%20During%20the%20First%202%20Months%20of%20Treatment%20and%20Human%20Immunodeficiency%20Virus%20Independently%20Predict%20Unsuccessful%20Treatment%20Outcomes%20in%20Tuberculosis.%20J%20Infect%20Dis.%202020%20Apr%207%3B221%289%29%3A1416%26%23×2013%3B24.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiz595%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Finfdis%5C%2Fjiz595%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031724035%3B%20PubMed%20Central%20PMCID%3A%20PMC7137883.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lack%20of%20Weight%20Gain%20During%20the%20First%202%20Months%20of%20Treatment%20and%20Human%20Immunodeficiency%20Virus%20Independently%20Predict%20Unsuccessful%20Treatment%20Outcomes%20in%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauren%20S.%22%2C%22lastName%22%3A%22Peetluk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afranio%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betina%22%2C%22lastName%22%3A%22Durovni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solange%22%2C%22lastName%22%3A%22Calvacante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Weight%20change%20may%20inform%20tuberculosis%20treatment%20response%2C%20but%20its%20predictive%20power%20may%20be%20confounded%20by%20human%20immunodeficiency%20virus%20%28HIV%29.%5CnMETHODS%3A%20We%20prospectively%20followed%20up%20adults%20with%20culture-confirmed%2C%20drug-susceptible%2C%20pulmonary%20tuberculosis%20receiving%20standard%204-drug%20therapy%20%28isoniazid%2C%20rifampin%2C%20pyrazinamide%2C%20and%20ethambutol%29%20in%20Brazil.%20We%20examined%20median%20weight%20change%202%20months%20after%20treatment%20initiation%20by%20HIV%20status%2C%20using%20quantile%20regression%2C%20and%20unsuccessful%20tuberculosis%20treatment%20outcome%20%28treatment%20failure%2C%20tuberculosis%20recurrence%2C%20or%20death%29%20by%20HIV%20and%20weight%20change%20status%2C%20using%20Cox%20regression.%5CnRESULTS%3A%20Among%20547%20participants%2C%20102%20%2819%25%29%20were%20HIV%20positive%2C%20and%2035%20%286%25%29%20had%20an%20unsuccessful%20outcome.%20After%20adjustment%20for%20confounders%2C%20persons%20living%20with%20HIV%20%28PLWH%29%20gained%20a%20median%20of%201.3%20kg%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%20-2.8%20to%20.1%29%20less%20than%20HIV-negative%20individuals%20during%20the%20first%202%20months%20of%20tuberculosis%20treatment.%20PLWH%20were%20at%20increased%20risk%20of%20an%20unsuccessful%20outcome%20%28adjusted%20hazard%20ratio%2C%204.8%3B%2095%25%20CI%2C%202.1-10.9%29.%20Weight%20change%20was%20independently%20associated%20with%20outcome%2C%20with%20risk%20of%20unsuccessful%20outcome%20decreasing%20by%2012%25%20%2895%25%20CI%2C%20.81%25-.95%25%29%20per%201-kg%20increase.%5CnCONCLUSIONS%3A%20PLWH%20gained%20less%20weight%20during%20the%20first%202%20months%20of%20tuberculosis%20treatment%2C%20and%20lack%20of%20weight%20gain%20and%20HIV%20independently%20predicted%20unsuccessful%20tuberculosis%20treatment%20outcomes.%20Weight%2C%20an%20easily%20collected%20biomarker%2C%20may%20identify%20patients%20who%20would%20benefit%20from%20alternative%20treatment%20strategies.%22%2C%22date%22%3A%22Apr%2007%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Finfdis%5C%2Fjiz595%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231724035%22%2C%22PMCID%22%3A%22PMC7137883%22%2C%22ISSN%22%3A%221537-6613%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A09%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22J8RKRBUT%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Lotspeich%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BLotspeich%20SC%2C%20Giganti%20MJ%2C%20Maia%20M%2C%20Vieira%20R%2C%20Machado%20DM%2C%20Succi%20RC%2C%20et%20al.%20Self-audits%20as%20alternatives%20to%20travel-audits%20for%20improving%20data%20quality%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology.%20J%20Clin%20Transl%20Sci.%202020%20Apr%3B4%282%29%3A125%26%23×2013%3B32.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2Fcts.2019.442%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2Fcts.2019.442%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032313702%3B%20PubMed%20Central%20PMCID%3A%20PMC7159809.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Self-audits%20as%20alternatives%20to%20travel-audits%20for%20improving%20data%20quality%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20epidemiology%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20C.%22%2C%22lastName%22%3A%22Lotspeich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Giganti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelle%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renalice%22%2C%22lastName%22%3A%22Vieira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daisy%20Maria%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Regina%20C%5Cu00e9lia%22%2C%22lastName%22%3A%22Succi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayonara%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%20Sergio%22%2C%22lastName%22%3A%22Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Fernanda%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetane%22%2C%22lastName%22%3A%22Julmiste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20Tulio%22%2C%22lastName%22%3A%22Luque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%3A%20Audits%20play%20a%20critical%20role%20in%20maintaining%20the%20integrity%20of%20observational%20cohort%20data.%20While%20previous%20work%20has%20validated%20the%20audit%20process%2C%20sending%20trained%20auditors%20to%20sites%20%28%26quot%3Btravel-audits%26quot%3B%29%20can%20be%20costly.%20We%20investigate%20the%20efficacy%20of%20training%20sites%20to%20conduct%20%26quot%3Bself-audits.%26quot%3B%5CnMethods%3A%20In%202017%2C%20eight%20research%20groups%20in%20the%20Caribbean%2C%20Central%2C%20and%20South%20America%20network%20for%20HIV%20Epidemiology%20each%20audited%20a%20subset%20of%20their%20patient%20records%20randomly%20selected%20by%20the%20data%20coordinating%20center%20at%20Vanderbilt.%20Designated%20investigators%20at%20each%20site%20compared%20abstracted%20research%20data%20to%20the%20original%20clinical%20source%20documents%20and%20captured%20audit%20findings%20electronically.%20Additionally%2C%20two%20Vanderbilt%20investigators%20performed%20on-site%20travel-audits%20at%20three%20randomly%20selected%20sites%20%28one%20adult%20and%20two%20pediatric%29%20in%20late%20summer%202017.%5CnResults%3A%20Self-%20and%20travel-auditors%2C%20respectively%2C%20reported%20that%2093%25%20and%2092%25%20of%208919%20data%20entries%2C%20captured%20across%2028%20unique%20clinical%20variables%20on%2065%20patients%2C%20were%20entered%20correctly.%20Across%20all%20entries%2C%208409%20%2894%25%29%20received%20the%20same%20assessment%20from%20self-%20and%20travel-auditors%20%287988%20correct%20and%20421%20incorrect%29.%20Of%20421%20entries%20mutually%20assessed%20as%20%26quot%3Bincorrect%2C%26quot%3B%20304%20%2882%25%29%20were%20corrected%20by%20both%20self-%20and%20travel-auditors%20and%20250%20of%20these%20%2872%25%29%20received%20the%20same%20corrections.%20Reason%20for%20changing%20antiretroviral%20therapy%20%28ART%29%20regimen%2C%20ART%20end%20date%2C%20viral%20load%20value%2C%20CD4%25%2C%20and%20HIV%20diagnosis%20date%20had%20the%20most%20mismatched%20corrections.%5CnConclusions%3A%20With%20similar%20overall%20error%20rates%2C%20findings%20suggest%20that%20data%20audits%20conducted%20by%20trained%20local%20investigators%20could%20provide%20an%20alternative%20to%20on-site%20audits%20by%20external%20auditors%20to%20ensure%20continued%20data%20quality.%20However%2C%20discrepancies%20observed%20between%20corrections%20illustrate%20challenges%20in%20determining%20correct%20values%20even%20with%20audits.%22%2C%22date%22%3A%22Apr%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1017%5C%2Fcts.2019.442%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232313702%22%2C%22PMCID%22%3A%22PMC7159809%22%2C%22ISSN%22%3A%222059-8661%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A10%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22PXM7B56Z%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCollaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration.%20Outcomes%20of%20second-line%20antiretroviral%20therapy%20among%20children%20living%20with%20HIV%3A%20a%20global%20cohort%20analysis.%20J%20Int%20AIDS%20Soc.%202020%20Apr%3B23%284%29%3Ae25477.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25477%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25477%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032297485%3B%20PubMed%20Central%20PMCID%3A%20PMC7160415.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20second-line%20antiretroviral%20therapy%20among%20children%20living%20with%20HIV%3A%20a%20global%20cohort%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Limited%20data%20describe%20outcomes%20on%20second-line%20antiretroviral%20therapy%20%28ART%29%20among%20children%20globally.%20Our%20objective%20was%20to%20contribute%20data%20on%20outcomes%20among%20children%20living%20with%20HIV%20after%20initiation%20of%20second-line%20ART%20in%20the%20context%20of%20routine%20care%20within%20a%20large%20global%20cohort%20collaboration.%5CnMETHODS%3A%20Patient-level%20data%20from%201993%20through%202015%20from%2011%20paediatric%20HIV%20cohorts%20were%20pooled.%20Characteristics%20at%20switch%20and%20through%20two%20years%20of%20follow-up%20were%20summarized%20for%20children%20who%20switched%20to%20second-line%20ART%20after%20starting%20a%20standard%20first-line%20regimen%20in%20North%20America%2C%20Latin%20America%2C%20Europe%2C%20Asia%2C%20Southern%20Africa%20%28South%20Africa%20%26amp%3B%20Botswana%29%20and%20the%20rest%20of%20sub-Saharan%20Africa%20%28SSA%29.%20Cumulative%20incidences%20of%20mortality%20and%20loss%20to%20follow-up%20%28LTFU%29%20were%20estimated%20using%20a%20competing%20risks%20framework.%5CnRESULTS%3A%20Of%20the%2085%2C389%20children%20on%20first-line%20ART%2C%203%2C555%20%284%25%29%20switched%20to%20second-line%20after%20a%20median%20of%202.8%5Cu00a0years%20on%20ART%20%28IQR%3A%201.6%2C%204.7%29%3B%2069%25%20were%20from%20Southern%20Africa%20or%20SSA%20and%2086%25%20of%20second-line%20regimens%20were%20protease%20inhibitor-based.%20At%20switch%2C%20median%20age%20was%208.4%5Cu00a0years%20and%2050%25%20had%20a%20prior%20AIDS%20diagnosis.%20Median%20follow-up%20after%20switch%20to%20second-line%20ranged%20from%201.8%5Cu00a0years%20in%20SSA%20to%205.3%5Cu00a0years%20in%20North%20America.%20Median%20CD4%20counts%20at%20switch%20to%20second-line%20ranged%20from%20235%5Cu00a0cells%5C%2Fmm3%20in%20SSA%20to%20828%5Cu00a0cells%5C%2Fmm3%20in%20North%20America.%20Improvements%20in%20CD4%20counts%20were%20observed%20over%20two%20years%20of%20follow-up%2C%20particularly%20in%20regions%20with%20lower%20CD4%20counts%20at%20second-line%20switch.%20Improvements%20in%20weight-for-age%20z-scores%20were%20not%20observed%20during%20follow-up.%20Cumulative%20incidence%20of%20LTFU%20at%20two%20years%20was%20%26lt%3B5%25%20in%20all%20regions%20except%20SSA%20%287.1%25%29%20and%20Southern%20Africa%20%287.4%25%29.%20Risk%20of%20mortality%20was%20%26lt%3B3%25%20at%20two%20years%20of%20follow-up%20in%20all%20regions%2C%20except%20Latin%20America%20%284.9%25%29%20and%20SSA%20%285.5%25%29.%5CnCONCLUSIONS%3A%20Children%20switched%20to%20second-line%20ART%20experience%20CD4%20count%20increases%20as%20well%20as%20low%20to%20moderate%20rates%20of%20LTFU%20and%20mortality%20within%20two%20years%20after%20switch.%20Severe%20immune%20deficiency%20at%20time%20of%20switch%20in%20some%20settings%20suggests%20need%20for%20improved%20recognition%20and%20management%20of%20treatment%20failure%20in%20children.%22%2C%22date%22%3A%22Apr%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25477%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232297485%22%2C%22PMCID%22%3A%22PMC7160415%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A11%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22Z8393DEX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Cubillos-Angulo%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCubillos-Angulo%20JM%2C%20Arriaga%20MB%2C%20Melo%20MGM%2C%20Silva%20EC%2C%20Alvarado-Arnez%20LE%2C%20de%20Almeida%20AS%2C%20et%20al.%20Polymorphisms%20in%20interferon%20pathway%20genes%20and%20risk%20of%20Mycobacterium%20tuberculosis%20infection%20in%20contacts%20of%20tuberculosis%20cases%20in%20Brazil.%20Int%20J%20Infect%20Dis.%202020%20Mar%3B92%3A21%26%23×2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2019.12.013%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2019.12.013%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031843671%3B%20PubMed%20Central%20PMCID%3A%20PMC7197195.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Polymorphisms%20in%20interferon%20pathway%20genes%20and%20risk%20of%20Mycobacterium%20tuberculosis%20infection%20in%20contacts%20of%20tuberculosis%20cases%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Manuel%22%2C%22lastName%22%3A%22Cubillos-Angulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayla%20G.%20M.%22%2C%22lastName%22%3A%22Melo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisangela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucia%20Elena%22%2C%22lastName%22%3A%22Alvarado-Arnez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%20S.%22%2C%22lastName%22%3A%22de%20Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milton%20O.%22%2C%22lastName%22%3A%22Moraes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20R.%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20R.%22%2C%22lastName%22%3A%22Hawn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martha%20M.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Host%20genetic%20polymorphisms%20may%20be%20important%20in%20determining%20susceptibility%20to%20Mycobacterium%20tuberculosis%20%28Mtb%29%20infection%2C%20but%20their%20role%20is%20not%20fully%20understood.%20Detection%20of%20microbial%20DNA%20and%20activation%20of%20type%20I%20interferon%20%28IFN%29%20pathways%20regulate%20macrophage%20responses%20to%20Mtb%20infection.%5CnMETHODS%3A%20We%20examined%20whether%20seven%20candidate%20gene%20SNPs%20were%20associated%20with%20tuberculin%20skin%20test%20%28TST%29%20positivity%20in%20close%20contacts%20of%20microbiologically%20confirmed%20pulmonary%20TB%20patients%20in%20Brazil.%20Independent%20associations%20with%20TST%20positivity%20were%20tested%20using%20multivariable%20logistic%20regression%20%28using%20genotypes%20and%20clinical%20variables%29%20and%20genetic%20models.%5CnRESULTS%3A%20Among%20482%20contacts%20of%20145%20TB%20index%20cases%2C%20296%20contacts%20were%20TST%20positive.%20Multivariable%20regression%20analysis%20adjusted%20for%20population%20admixture%2C%20age%2C%20family%20relatedness%2C%20sex%20and%20clinical%20variables%20related%20to%20increased%20TB%20risk%20demonstrated%20that%20SNPs%20in%20PYHIN1-IFI16-AIM2%20rs1101998%20%28adjusted%20OR%20%5BaOR%5D%3A%203.72%3B%2095%25CI%3D1.15-12.0%3B%20p%3D0.028%29%20and%20in%20PYHIN1-IFI16-AIM2%20rs1633256%20%28aOR%3D24.84%3B%2095%25CI%3D2.26-272.95%3B%20p%3D0.009%29%20were%20associated%20with%20TST%20positivity%20in%20a%20recessive%20model.%20Furthermore%2C%20an%20IRF7%20polymorphism%20%28rs11246213%29%20was%20associated%20with%20reduced%20odds%20of%20TST%20positivity%20in%20a%20dominant%20model%20%28aOR%3A%200.50%2C%2095%25CI%3A%200.26-0.93%3B%20p%3D0.029%29.%5CnCONCLUSIONS%3A%20Polymorphisms%20in%20PYHIN1-IFI16-AIM2%20rs1633256%2C%20rs1101998%20and%20in%20IRF7%20rs11246213%20were%20associated%20with%20altered%20susceptibility%20to%20Mtb%20infection%20in%20this%20Brazilian%20cohort.%22%2C%22date%22%3A%222020-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2019.12.013%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231843671%22%2C%22PMCID%22%3A%22PMC7197195%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-14T20%3A16%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22TVFE865Y%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Cubillos-Angulo%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCubillos-Angulo%20JM%2C%20Arriaga%20MB%2C%20Melo%20MGM%2C%20Silva%20EC%2C%20Alvarado-Arnez%20LE%2C%20de%20Almeida%20AS%2C%20et%20al.%20Polymorphisms%20in%20interferon%20pathway%20genes%20and%20risk%20of%20Mycobacterium%20tuberculosis%20infection%20in%20contacts%20of%20tuberculosis%20cases%20in%20Brazil.%20Int%20J%20Infect%20Dis.%202020%20Mar%3B92%3A21%26%23×2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2019.12.013%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ijid.2019.12.013%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031843671%3B%20PubMed%20Central%20PMCID%3A%20PMC7197195.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Polymorphisms%20in%20interferon%20pathway%20genes%20and%20risk%20of%20Mycobacterium%20tuberculosis%20infection%20in%20contacts%20of%20tuberculosis%20cases%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Manuel%22%2C%22lastName%22%3A%22Cubillos-Angulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mayla%20G.%20M.%22%2C%22lastName%22%3A%22Melo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisangela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucia%20Elena%22%2C%22lastName%22%3A%22Alvarado-Arnez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%20S.%22%2C%22lastName%22%3A%22de%20Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milton%20O.%22%2C%22lastName%22%3A%22Moraes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20R.%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20R.%22%2C%22lastName%22%3A%22Hawn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martha%20M.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Host%20genetic%20polymorphisms%20may%20be%20important%20in%20determining%20susceptibility%20to%20Mycobacterium%20tuberculosis%20%28Mtb%29%20infection%2C%20but%20their%20role%20is%20not%20fully%20understood.%20Detection%20of%20microbial%20DNA%20and%20activation%20of%20type%20I%20interferon%20%28IFN%29%20pathways%20regulate%20macrophage%20responses%20to%20Mtb%20infection.%5CnMETHODS%3A%20We%20examined%20whether%20seven%20candidate%20gene%20SNPs%20were%20associated%20with%20tuberculin%20skin%20test%20%28TST%29%20positivity%20in%20close%20contacts%20of%20microbiologically%20confirmed%20pulmonary%20TB%20patients%20in%20Brazil.%20Independent%20associations%20with%20TST%20positivity%20were%20tested%20using%20multivariable%20logistic%20regression%20%28using%20genotypes%20and%20clinical%20variables%29%20and%20genetic%20models.%5CnRESULTS%3A%20Among%20482%20contacts%20of%20145%20TB%20index%20cases%2C%20296%20contacts%20were%20TST%20positive.%20Multivariable%20regression%20analysis%20adjusted%20for%20population%20admixture%2C%20age%2C%20family%20relatedness%2C%20sex%20and%20clinical%20variables%20related%20to%20increased%20TB%20risk%20demonstrated%20that%20SNPs%20in%20PYHIN1-IFI16-AIM2%20rs1101998%20%28adjusted%20OR%20%5BaOR%5D%3A%203.72%3B%2095%25CI%3D1.15-12.0%3B%20p%3D0.028%29%20and%20in%20PYHIN1-IFI16-AIM2%20rs1633256%20%28aOR%3D24.84%3B%2095%25CI%3D2.26-272.95%3B%20p%3D0.009%29%20were%20associated%20with%20TST%20positivity%20in%20a%20recessive%20model.%20Furthermore%2C%20an%20IRF7%20polymorphism%20%28rs11246213%29%20was%20associated%20with%20reduced%20odds%20of%20TST%20positivity%20in%20a%20dominant%20model%20%28aOR%3A%200.50%2C%2095%25CI%3A%200.26-0.93%3B%20p%3D0.029%29.%5CnCONCLUSIONS%3A%20Polymorphisms%20in%20PYHIN1-IFI16-AIM2%20rs1633256%2C%20rs1101998%20and%20in%20IRF7%20rs11246213%20were%20associated%20with%20altered%20susceptibility%20to%20Mtb%20infection%20in%20this%20Brazilian%20cohort.%22%2C%22date%22%3A%222020-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ijid.2019.12.013%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231843671%22%2C%22PMCID%22%3A%22PMC7197195%22%2C%22ISSN%22%3A%221878-3511%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-07T21%3A25%3A50Z%22%7D%7D%2C%7B%22key%22%3A%223W3RIAX6%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Humphrey%20et%20al.%22%2C%22parsedDate%22%3A%222020-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BHumphrey%20JM%2C%20Mpofu%20P%2C%20Pettit%20AC%2C%20Musick%20B%2C%20Carter%20EJ%2C%20Messou%20E%2C%20et%20al.%20Mortality%20Among%20People%20With%20HIV%20Treated%20for%20Tuberculosis%20Based%20on%20Positive%2C%20Negative%2C%20or%20No%20Bacteriologic%20Test%20Results%20for%20Tuberculosis%3A%20The%20IeDEA%20Consortium.%20Open%20Forum%20Infect%20Dis.%202020%20Jan%3B7%281%29%3Aofaa006.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofaa006%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofaa006%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032010735%3B%20PubMed%20Central%20PMCID%3A%20PMC6984675.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mortality%20Among%20People%20With%20HIV%20Treated%20for%20Tuberculosis%20Based%20on%20Positive%2C%20Negative%2C%20or%20No%20Bacteriologic%20Test%20Results%20for%20Tuberculosis%3A%20The%20IeDEA%20Consortium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20M.%22%2C%22lastName%22%3A%22Humphrey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philani%22%2C%22lastName%22%3A%22Mpofu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20C.%22%2C%22lastName%22%3A%22Pettit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Jane%22%2C%22lastName%22%3A%22Carter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eug%5Cu00e8ne%22%2C%22lastName%22%3A%22Messou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Anastos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20In%20resource-constrained%20settings%2C%20many%20people%20with%20HIV%20%28PWH%29%20are%20treated%20for%20tuberculosis%20%28TB%29%20without%20bacteriologic%20testing.%20Their%20mortality%20compared%20with%20those%20with%20bacteriologic%20testing%20is%20uncertain.%5CnMethods%3A%20We%20conducted%20an%20observational%20cohort%20study%20among%20PWH%5Cu2005%5Cu226515%20years%20of%20age%20initiating%20TB%20treatment%20at%20sites%20affiliated%20with%204%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20consortium%20regions%20from%202012%20to%202014%3A%20Caribbean%2C%20Central%20and%20South%20America%2C%20and%20Central%2C%20East%2C%20and%20West%20Africa.%20The%20exposure%20of%20interest%20was%20the%20TB%20bacteriologic%20test%20status%20at%20TB%20treatment%20initiation%3A%20positive%2C%20negative%2C%20or%20no%20test%20result.%20The%20hazard%20of%20death%20in%20the%2012%20months%20after%20TB%20treatment%20initiation%20was%20estimated%20using%20a%20Cox%20proportional%20hazard%20model.%20Missing%20covariate%20values%20were%20multiply%20imputed.%5CnResults%3A%20In%202091%20PWH%2C%20median%20age%2036%20years%2C%2053%25%20had%20CD4%20counts%5Cu2005%5Cu2264200%20cells%5C%2Fmm3%2C%20and%2052%25%20were%20on%20antiretroviral%20therapy%20%28ART%29%20at%20TB%20treatment%20initiation.%20The%20adjusted%20hazard%20of%20death%20was%20higher%20in%20patients%20with%20no%20test%20compared%20with%20those%20with%20positive%20test%20results%20%28hazard%20ratio%20%5BHR%5D%2C%201.56%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.08-2.26%29.%20The%20hazard%20of%20death%20was%20also%20higher%20among%20those%20with%20negative%20compared%20with%20positive%20tests%20but%20was%20not%20statistically%20significant%20%28HR%2C%201.28%3B%2095%25%20CI%2C%200.91-1.81%29.%20Being%20on%20ART%2C%20having%20a%20higher%20CD4%20count%2C%20and%20tertiary%20facility%20level%20were%20associated%20with%20a%20lower%20hazard%20for%20death.%5CnConclusions%3A%20There%20was%20some%20evidence%20that%20PWH%20treated%20for%20TB%20with%20no%20bacteriologic%20test%20results%20were%20at%20higher%20risk%20of%20death%20than%20those%20with%20positive%20tests.%20Research%20is%20needed%20to%20understand%20the%20causes%20of%20death%20in%20PWH%20treated%20for%20TB%20without%20bacteriologic%20testing.%22%2C%22date%22%3A%22Jan%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofaa006%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232010735%22%2C%22PMCID%22%3A%22PMC6984675%22%2C%22ISSN%22%3A%222328-8957%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A11%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22VG84HGCJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Giganti%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGiganti%20MJ%2C%20Shaw%20PA%2C%20Chen%20G%2C%20Bebawy%20SS%2C%20Turner%20MM%2C%20Sterling%20TR%2C%20et%20al.%20Accounting%20for%20dependent%20errors%20in%20predictors%20and%20time-to-event%20outcomes%20using%20electronic%20health%20records%2C%20validation%20samples%20and%20multiple%20imputation.%20Ann%20Appl%20Stat.%202020%3B14%282%29%3A1045%26%23×2013%3B61.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1214%5C%2F20-AOAS1343%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1214%5C%2F20-AOAS1343%26lt%3B%5C%2Fa%26gt%3B%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Accounting%20for%20dependent%20errors%20in%20predictors%20and%20time-to-event%20outcomes%20using%20electronic%20health%20records%2C%20validation%20samples%20and%20multiple%20imputation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Giganti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20A.%22%2C%22lastName%22%3A%22Shaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guanhua%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sally%20S.%22%2C%22lastName%22%3A%22Bebawy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%20M.%22%2C%22lastName%22%3A%22Turner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2206%5C%2F2020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1214%5C%2F20-AOAS1343%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fprojecteuclid.org%5C%2Feuclid.aoas%5C%2F1593449337%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221932-6157%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A16%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22UFWDNVZP%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rohner%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRohner%20E%2C%20B%26%23xFC%3Btikofer%20L%2C%20Schmidlin%20K%2C%20Sengayi%20M%2C%20Maskew%20M%2C%20Giddy%20J%2C%20et%20al.%20Cervical%20cancer%20risk%20in%20women%20living%20with%20HIV%20across%20four%20continents%3A%20A%20multicohort%20study.%20Int%20J%20Cancer.%202020%2001%3B146%283%29%3A601%26%23×2013%3B9.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.32260%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.32260%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031215037%3B%20PubMed%20Central%20PMCID%3A%20PMC6898726.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cervical%20cancer%20risk%20in%20women%20living%20with%20HIV%20across%20four%20continents%3A%20A%20multicohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Rohner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22B%5Cu00fctikofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kurt%22%2C%22lastName%22%3A%22Schmidlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mazvita%22%2C%22lastName%22%3A%22Sengayi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mhairi%22%2C%22lastName%22%3A%22Maskew%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janet%22%2C%22lastName%22%3A%22Giddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katayoun%22%2C%22lastName%22%3A%22Taghavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20D.%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20J.%22%2C%22lastName%22%3A%22Goedert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20John%22%2C%22lastName%22%3A%22Gill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20J.%22%2C%22lastName%22%3A%22Silverberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gypsyamber%22%2C%22lastName%22%3A%22D%27Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pragna%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Firouze%22%2C%22lastName%22%3A%22Bani-Sadr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ninon%22%2C%22lastName%22%3A%22Taylor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vassilios%22%2C%22lastName%22%3A%22Paparizos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%22%2C%22lastName%22%3A%22Verbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00f6rg%20Janne%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20A.%22%2C%22lastName%22%3A%22Post%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Sabin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%22%2C%22lastName%22%3A%22Mocroft%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Dronda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niels%22%2C%22lastName%22%3A%22Obel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Grabar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincenzo%22%2C%22lastName%22%3A%22Spagnuolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eugenia%22%2C%22lastName%22%3A%22Quiros-Roldan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Mussini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20M.%22%2C%22lastName%22%3A%22Miro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Hasse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deborah%22%2C%22lastName%22%3A%22Konopnicki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernardino%22%2C%22lastName%22%3A%22Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Barger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%20M.%22%2C%22lastName%22%3A%22Clifford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Franceschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Bohlius%22%7D%5D%2C%22abstractNote%22%3A%22We%20compared%20invasive%20cervical%20cancer%20%28ICC%29%20incidence%20rates%20in%20Europe%2C%20South%20Africa%2C%20Latin%20and%20North%20America%20among%20women%20living%20with%20HIV%20who%20initiated%20antiretroviral%20therapy%20%28ART%29%20between%201996%20and%202014.%20We%20analyzed%20cohort%20data%20from%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20and%20the%20Collaboration%20of%20Observational%20HIV%20Epidemiological%20Research%20in%20Europe%20%28COHERE%29%20in%20EuroCoord.%20We%20used%20flexible%20parametric%20survival%20models%20to%20determine%20regional%20ICC%20rates%20and%20risk%20factors%20for%20incident%20ICC.%20We%20included%2064%2C231%20women%20from%2045%20countries.%20During%20320%2C141%20person-years%20%28pys%29%2C%20356%20incident%20ICC%20cases%20were%20diagnosed%20%28Europe%20164%2C%20South%20Africa%20156%2C%20North%20America%2019%20and%20Latin%20America%2017%29.%20Raw%20ICC%20incidence%20rates%20per%20100%2C000%20pys%20were%20447%20in%20South%20Africa%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%20382-523%29%2C%20136%20in%20Latin%20America%20%2895%25%20CI%3A%2085-219%29%2C%2076%20in%20North%20America%20%2895%25%20CI%3A%2048-119%29%20and%2066%20in%20Europe%20%2895%25%20CI%3A%2057-77%29.%20Compared%20to%20European%20women%20ICC%20rates%20at%205%20years%20after%20ART%20initiation%20were%20more%20than%20double%20in%20Latin%20America%20%28adjusted%20hazard%20ratio%20%5BaHR%5D%3A%202.43%2C%2095%25%20CI%3A%201.27-4.68%29%20and%2011%20times%20higher%20in%20South%20Africa%20%28aHR%3A%2010.66%2C%2095%25%20CI%3A%206.73-16.88%29%2C%20but%20similar%20in%20North%20America%20%28aHR%3A%200.79%2C%2095%25%20CI%3A%200.37-1.71%29.%20Overall%2C%20ICC%20rates%20increased%20with%20age%20%28%26gt%3B50%5Cu2009years%20vs.%2016-30%5Cu2009years%2C%20aHR%3A%201.57%2C%2095%25%20CI%3A%201.03-2.40%29%20and%20lower%20CD4%20cell%20counts%20at%20ART%20initiation%20%28per%20100%20cell%5C%2F%5Cu03bcl%20decrease%2C%20aHR%3A%201.25%2C%2095%25%20CI%3A%201.15-1.36%29.%20Improving%20access%20to%20early%20ART%20initiation%20and%20effective%20cervical%20cancer%20screening%20in%20women%20living%20with%20HIV%20should%20be%20key%20parts%20of%20global%20efforts%20to%20reduce%20cancer-related%20health%20inequities.%22%2C%22date%22%3A%2202%2001%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.32260%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231215037%22%2C%22PMCID%22%3A%22PMC6898726%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A07%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22TQP3QRJX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22IeDEA%20and%20COHERE%20in%20EuroCoord%20Cohort%20Collaboration%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BIeDEA%20and%20COHERE%20in%20EuroCoord%20Cohort%20Collaboration.%20All-cause%20mortality%20after%20antiretroviral%20therapy%20initiation%20in%20HIV-positive%20women%20from%20Europe%2C%20Sub-Saharan%20Africa%20and%20the%20Americas.%20AIDS.%202020%2001%3B34%282%29%3A277%26%23×2013%3B89.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002399%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002399%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031876592%3B%20PubMed%20Central%20PMCID%3A%20PMC6948801.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22All-cause%20mortality%20after%20antiretroviral%20therapy%20initiation%20in%20HIV-positive%20women%20from%20Europe%2C%20Sub-Saharan%20Africa%20and%20the%20Americas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20and%20COHERE%20in%20EuroCoord%20Cohort%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Women%20account%20for%20over%20half%20of%20persons%20living%20with%20HIV%5C%2FAIDS%20globally.%20We%20examined%20geographic%20variation%20in%20all-cause%20mortality%20after%20antiretroviral%20therapy%20%28ART%29%20for%20women%20living%20with%20HIV%20%28WLWH%29%20worldwide.%5CnMETHODS%3A%20We%20pooled%20data%20from%20WLWH%20at%20least%2018%20years%20initiating%20ART%202000-2014%20within%20COHERE%20%28Europe%29%20and%20IeDEA%20regions%20%28East%20Africa%2C%20West%20Africa%2C%20South%20Africa%2C%20North%20America%2C%20Latin%20America%5C%2FCaribbean%29.%20Mortality%20rates%20were%20calculated%20at%200-3%2C%203-6%2C%206-12%2C%2012-24%20and%2024-48%20months%20after%20ART%2C%20and%20mortality%20rate%20ratios%20were%20compared%20with%20European%20rates%20with%20piecewise%20exponential%20parametric%20survival%20models%20based%20on%20Poisson%20regression.%5CnFINDINGS%3A%20One%20hundred%20ninety%20thousand%2C%20one%20hundred%20and%20seventy-five%20WLWH%20%2816%25%20Europe%2C%2047%25%20East%20Africa%2C%2013%25%20West%20Africa%2C%2019%25%20South%20Africa%2C%201%25%20South%20America%2C%203%25%20North%20America%20and%202%25%20Central%20America%5C%2FCaribbean%29%20were%20included.%20The%20highest%20death%20rates%20occurred%200-3%20months%20after%20ART%20%5B1.51%20%2895%25%20CI%201.25-1.82%29%20per%20100%20person-years%20in%20Europe%2C%2012.45%20%2811.30-13.73%29%2C%2014.03%20%2813.12-15.02%29%20and%209.44%20%288.80-10.11%29%20in%20East%2C%20West%20and%20South%20Africa%2C%20and%201.53%20%280.97-2.43%29%2C%207.83%20%285.44-11.27%29%20and%2017.02%20%2814.62-19.81%29%20in%20North%2C%20South%20America%20and%20Central%20America%5C%2FCaribbean%2C%20respectively%5D%20and%20declined%20thereafter.%20Mortality%20in%20Europe%20was%20the%20lowest%2C%20with%20regional%20differences%20greatest%20in%20the%20first%203%20months%20and%20smaller%20at%20longer%20ART%20durations%20%5Badjusted%20rate%20ratios%2024-48%20months%20after%20ART%3A%203.63%20%2895%25%20CI%203.04-4.33%29%2C%205.61%20%284.84-6.51%29%20and%203.47%20%282.97-4.06%29%20for%20East%2C%20West%20and%20South%20Africa%3B%202.86%20%282.26-3.62%29%2C%202.42%20%281.65-3.55%29%20and%202.50%20%281.92-3.26%29%20for%20North%2C%20South%20America%20and%20Central%20America%5C%2FCaribbean%2C%20respectively%5D.%5CnCONCLUSION%3A%20Global%20variations%20in%20short-term%20and%20long-term%20mortality%20among%20WLWH%20initiating%20ART%20may%20inform%20context-specific%20interventions.%22%2C%22date%22%3A%2202%2001%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000002399%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231876592%22%2C%22PMCID%22%3A%22PMC6948801%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A14%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22YY72BJV9%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Musay%5Cu00f3n-Oblitas%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BMusay%26%23xF3%3Bn-Oblitas%20FY%2C%20C%26%23xE1%3Brcamo%20CP%2C%20Gimbel%20S%2C%20Zarate%20JIE%2C%20Espinoza%20ABG.%20Validation%20of%20a%20counseling%20guide%20for%20adherence%20to%20antiretroviral%20therapy%20using%20implementation%20science.%20Rev%20Lat%20Am%20Enfermagem.%202020%3B28%3Ae3228.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1590%5C%2F1518-8345.3117.3228%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1590%5C%2F1518-8345.3117.3228%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032022148%3B%20PubMed%20Central%20PMCID%3A%20PMC7000190.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20a%20counseling%20guide%20for%20adherence%20to%20antiretroviral%20therapy%20using%20implementation%20science%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flor%20Yesenia%22%2C%22lastName%22%3A%22Musay%5Cu00f3n-Oblitas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cesar%20Paul%22%2C%22lastName%22%3A%22C%5Cu00e1rcamo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Gimbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Ignacio%20Echevarria%22%2C%22lastName%22%3A%22Zarate%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Beatriz%20Gra%5Cu00f1a%22%2C%22lastName%22%3A%22Espinoza%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20to%20determine%20the%20contents%20that%20must%20be%20included%20in%20the%20usual%20counseling%20to%20improve%20the%20adherence%20to%20antiretroviral%20therapy%20%28ART%29%20of%20HIV%20patients%2C%20according%20to%20their%20different%20levels%20of%20alcohol%20consumption%2C%20and%20to%20determine%20the%20validity%20of%20the%20Counseling%20Guide%20in%20improving%20the%20adherence%20to%20ART%20in%20patients%20who%20consume%20alcohol%20using%20Implementation%20Science.%5CnMETHOD%3A%20this%20is%20an%20observational%20study%20with%20formative%20and%20validation%20phases.%20The%20formative%20phase%20defined%20the%20content%2C%20approach%20and%20structure%20of%20the%20counseling.%20Validation%20included%20focus%20groups%20with%20patients%20and%20nurses%2C%20trial%20process%20by%20an%20expert%20and%20a%20pilot%20test.%20The%20criteria%20evaluated%20based%20on%20Implementation%20Science%20were%3A%20intervention%20source%2C%20evidence%20strength%20and%20quality%2C%20relative%20advantage%2C%20and%20complexity.%20The%20following%20criteria%20were%20also%20evaluated%3A%20usefulness%2C%20practicality%2C%20acceptability%2C%20sustainability%2C%20effectiveness%3B%20content%20consistency%20and%20congruence%3B%20procedural%20compliance%20and%20difficulties%2C%20and%20time%20spent%20in%20counseling.%5CnRESULTS%3A%20the%20strength%20of%20evidence%20of%20the%20counseling%20is%20High-IIA%2C%20with%20strong%20level%20of%20recommendation%20and%20presenting%20usefulness%2C%20practicality%2C%20acceptability%2C%20sustainability%20and%20effectiveness.%20Eight%20in%2011%20experts%20argued%20that%20the%20Guide%20is%20clear%2C%20consistent%20and%20congruent.%20Initial%20counseling%20takes%20around%2024%20minutes%3B%20and%20follow-up%20counseling%2C%2021.%20The%20instruments%20of%20the%20Guide%20present%20reliability%20levels%20between%20good%20and%20high%20%280.65%20%5Cu2265%20alpha%20%5Cu2264%200.92%29.%5CnCONCLUSION%3A%20the%20Counseling%20Guide%20is%20valid%20to%20improve%20the%20adherence%20to%20antiretroviral%20therapy%20in%20patients%20who%20consume%20alcohol.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1590%5C%2F1518-8345.3117.3228%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232022148%22%2C%22PMCID%22%3A%22PMC7000190%22%2C%22ISSN%22%3A%221518-8345%22%2C%22language%22%3A%22eng%2C%20por%2C%20spa%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A02%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22CV4Z4X6M%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Demitto%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BDemitto%20FO%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Schmaltz%20CA%2C%20Sant%26%23×2019%3BAnna%20FM%2C%20Arriaga%20MB%2C%20Andrade%20BB%2C%20et%20al.%20Impact%20of%20Persistent%20Anemia%20on%20Systemic%20Inflammation%20and%20Tuberculosis%20Outcomes%20in%20Persons%20Living%20With%20HIV.%20Front%20Immunol.%202020%3B11%3A588405.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.588405%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.588405%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033072136%3B%20PubMed%20Central%20PMCID%3A%20PMC7541849.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Persistent%20Anemia%20on%20Systemic%20Inflammation%20and%20Tuberculosis%20Outcomes%20in%20Persons%20Living%20With%20HIV%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%20O.%22%2C%22lastName%22%3A%22Demitto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carolina%20A.%22%2C%22lastName%22%3A%22Schmaltz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fl%5Cu00e1via%20M.%22%2C%22lastName%22%3A%22Sant%27Anna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valeria%20C.%22%2C%22lastName%22%3A%22Rolla%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20associated%20with%20systemic%20inflammation%20and%20anemia%2C%20which%20are%20aggravated%20in%20persons%20living%20with%20HIV%20%28PLWH%29.%20Here%2C%20we%20characterized%20the%20dynamics%20of%20hemoglobin%20levels%20in%20PLWH%20coinfected%20with%20TB%20undergoing%20antitubercular%20therapy%20%28ATT%29.%20We%20also%20examined%20the%20relationships%20between%20anemia%20and%20systemic%20inflammatory%20disturbance%20as%20well%20as%20the%20association%20between%20persistent%20anemia%20and%20unfavorable%20clinical%20outcomes.%20Data%20on%20several%20blood%20biochemical%20parameters%20and%20on%20blood%20cell%20counts%20were%20retrospectively%20analyzed%20in%20a%20cohort%20of%20256%20TB%5C%2FHIV%20patients%20from%20Brazil%20during%20180%20days%20of%20ATT.%20Multidimensional%20statistical%20analyses%20were%20employed%20to%20profile%20systemic%20inflammation%20of%20patients%20stratified%20by%20anemia%20status%20%28hemoglobin%20levels%20%26lt%3B12%20g%5C%2FdL%20for%20female%20and%20%26lt%3B13.5%20g%5C%2FdL%20for%20male%20individuals%29%20prior%20to%20treatment%20and%20to%20perform%20prediction%20of%20unfavorable%20outcomes%2C%20such%20as%20treatment%20failure%2C%20loss%20to%20follow%20up%20and%20death.%20We%20found%20that%20101%20%2863.63%25%29%20of%20patients%20with%20anemia%20at%20pre-ATT%20persisted%20with%20such%20condition%20until%20day%20180.%20Such%20individuals%20exhibited%20heightened%20degree%20of%20inflammatory%20perturbation%20%28DIP%29%2C%20which%20in%20turn%20was%20inversely%20correlated%20with%20hemoglobin%20levels.%20Recovery%20from%20anemia%20was%20associated%20with%20increased%20pre-ATT%20albumin%20levels%20whereas%20persistent%20anemia%20was%20related%20to%20higher%20total%20protein%20levels%20in%20serum.%20Multivariable%20regression%20analysis%20revealed%20that%20lower%20baseline%20hemoglobin%20levels%20was%20the%20major%20determinant%20of%20the%20unfavorable%20outcomes.%20Our%20findings%20demonstrate%20that%20persistent%20anemia%20in%20PLWH%20during%20the%20course%20of%20ATT%20is%20closely%20related%20with%20chronic%20inflammatory%20perturbation.%20Early%20intervention%20to%20promote%20recovery%20from%20anemia%20may%20improve%20ATT%20outcomes.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.588405%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233072136%22%2C%22PMCID%22%3A%22PMC7541849%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A03%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22IQH4U8Q8%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Barreto-Duarte%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBarreto-Duarte%20B%2C%20Sterling%20TR%2C%20Fiske%20CT%2C%20Almeida%20A%2C%20Nochowicz%20CH%2C%20Smith%20RM%2C%20et%20al.%20Increased%20Frequency%20of%20Memory%20CD4%2B%20T-Cell%20Responses%20in%20Individuals%20With%20Previously%20Treated%20Extrapulmonary%20Tuberculosis.%20Front%20Immunol.%202020%3B11%3A605338.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.605338%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.605338%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033391271%3B%20PubMed%20Central%20PMCID%3A%20PMC7774017.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20Frequency%20of%20Memory%20CD4%2B%20T-Cell%20Responses%20in%20Individuals%20With%20Previously%20Treated%20Extrapulmonary%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%20T.%22%2C%22lastName%22%3A%22Fiske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cynthia%20H.%22%2C%22lastName%22%3A%22Nochowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%20M.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Barnett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amondrea%22%2C%22lastName%22%3A%22Blackman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Roberto%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%20A.%22%2C%22lastName%22%3A%22Kalams%22%7D%5D%2C%22abstractNote%22%3A%22Extrapulmonary%20TB%20%28EPTB%29%20occurs%20with%20increased%20frequency%20in%20persons%20with%20underlying%20immunodeficiency.%20Even%20after%20recovery%20from%20acute%20illness%2C%20differences%20in%20immune%20phenotype%20and%20activation%20persist.%20Studies%20defining%20characteristics%20of%20immune%20responses%20after%20recovery%20from%20extrapulmonary%20TB%20may%20provide%20insights%20into%20factors%20that%20increase%20TB%20risk.%20We%20performed%20two%20case-control%20studies%20%28in%20the%20United%20States%20and%20Brazil%29%20among%20HIV-seronegative%20adults%20with%20previous%20EPTB%20%28n%20%3D%209%3B%2025%29%2C%20previous%20pulmonary%20TB%20%28n%20%3D%207%3B%2025%29%2C%20latent%20M.%20tuberculosis%20%28Mtb%29%20infection%20%28n%20%3D%2011%3B%2025%29%2C%20and%20uninfected%20TB%20contacts%20%28n%20%3D%2010%3B%2025%29.%20We%20assessed%20the%20frequency%20of%20dual%20CD4%2B%20interferon-%5Cu03b3%20and%20tumor%20necrosis%20factor-%5Cu03b1%20responses%20after%20stimulation%20with%20overlapping%20Mtb%20peptides%20from%20ESAT-6%20or%20CFP-10%2C%20or%20gamma-irradiated%20Mtb%20H37Rv%2C%20proliferative%20responses%20to%20Mtb%20antigens%2C%20T-regulatory%20cell%20%28Treg%29%20frequency%20and%20phenotype.%20In%20both%20study%20populations%2C%20individuals%20with%20prior%20EPTB%20had%20the%20highest%20frequency%20of%20intracellular%20cytokine-producing%20cells%20in%20response%20to%20Mtb%20antigens%20%28p%20%26lt%3B%200.05%3B%20p%20%26lt%3B.0001%29.%20Persons%20with%20prior%20EPTB%20in%20Brazil%20had%20the%20highest%20levels%20of%20CD4%20proliferation%20to%20Mtb%20antigens%20%28p%20%26lt%3B%200.0001%29%2C%20and%20the%20highest%20expression%20of%20CD39%20on%20Tregs%20%28p%20%26lt%3B%200.0001%29.%20Individuals%20with%20treated%20EPTB%20maintained%20high%20frequencies%20of%20Mtb-specific%20memory%20responses%20and%20active%20Treg%20cells%2C%20suggesting%20that%20susceptibility%20to%20EPTB%20occurs%20despite%20the%20ability%20to%20develop%20and%20maintain%20enhanced%20adaptive%20immune%20responses.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.605338%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233391271%22%2C%22PMCID%22%3A%22PMC7774017%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A05%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22AKVZ9WPF%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Barreto-Duarte%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBarreto-Duarte%20B%2C%20Sterling%20TR%2C%20Fiske%20CT%2C%20Almeida%20A%2C%20Nochowicz%20CH%2C%20Smith%20RM%2C%20et%20al.%20Increased%20Frequency%20of%20Memory%20CD4%2B%20T-Cell%20Responses%20in%20Individuals%20With%20Previously%20Treated%20Extrapulmonary%20Tuberculosis.%20Front%20Immunol.%202020%3B11%3A605338.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.605338%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.605338%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033391271%3B%20PubMed%20Central%20PMCID%3A%20PMC7774017.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20Frequency%20of%20Memory%20CD4%2B%20T-Cell%20Responses%20in%20Individuals%20With%20Previously%20Treated%20Extrapulmonary%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christina%20T.%22%2C%22lastName%22%3A%22Fiske%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Almeida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cynthia%20H.%22%2C%22lastName%22%3A%22Nochowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rita%20M.%22%2C%22lastName%22%3A%22Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Barnett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amondrea%22%2C%22lastName%22%3A%22Blackman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Roberto%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%20A.%22%2C%22lastName%22%3A%22Kalams%22%7D%5D%2C%22abstractNote%22%3A%22Extrapulmonary%20TB%20%28EPTB%29%20occurs%20with%20increased%20frequency%20in%20persons%20with%20underlying%20immunodeficiency.%20Even%20after%20recovery%20from%20acute%20illness%2C%20differences%20in%20immune%20phenotype%20and%20activation%20persist.%20Studies%20defining%20characteristics%20of%20immune%20responses%20after%20recovery%20from%20extrapulmonary%20TB%20may%20provide%20insights%20into%20factors%20that%20increase%20TB%20risk.%20We%20performed%20two%20case-control%20studies%20%28in%20the%20United%20States%20and%20Brazil%29%20among%20HIV-seronegative%20adults%20with%20previous%20EPTB%20%28n%20%3D%209%3B%2025%29%2C%20previous%20pulmonary%20TB%20%28n%20%3D%207%3B%2025%29%2C%20latent%20M.%20tuberculosis%20%28Mtb%29%20infection%20%28n%20%3D%2011%3B%2025%29%2C%20and%20uninfected%20TB%20contacts%20%28n%20%3D%2010%3B%2025%29.%20We%20assessed%20the%20frequency%20of%20dual%20CD4%2B%20interferon-%5Cu03b3%20and%20tumor%20necrosis%20factor-%5Cu03b1%20responses%20after%20stimulation%20with%20overlapping%20Mtb%20peptides%20from%20ESAT-6%20or%20CFP-10%2C%20or%20gamma-irradiated%20Mtb%20H37Rv%2C%20proliferative%20responses%20to%20Mtb%20antigens%2C%20T-regulatory%20cell%20%28Treg%29%20frequency%20and%20phenotype.%20In%20both%20study%20populations%2C%20individuals%20with%20prior%20EPTB%20had%20the%20highest%20frequency%20of%20intracellular%20cytokine-producing%20cells%20in%20response%20to%20Mtb%20antigens%20%28p%20%26lt%3B%200.05%3B%20p%20%26lt%3B.0001%29.%20Persons%20with%20prior%20EPTB%20in%20Brazil%20had%20the%20highest%20levels%20of%20CD4%20proliferation%20to%20Mtb%20antigens%20%28p%20%26lt%3B%200.0001%29%2C%20and%20the%20highest%20expression%20of%20CD39%20on%20Tregs%20%28p%20%26lt%3B%200.0001%29.%20Individuals%20with%20treated%20EPTB%20maintained%20high%20frequencies%20of%20Mtb-specific%20memory%20responses%20and%20active%20Treg%20cells%2C%20suggesting%20that%20susceptibility%20to%20EPTB%20occurs%20despite%20the%20ability%20to%20develop%20and%20maintain%20enhanced%20adaptive%20immune%20responses.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.605338%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233391271%22%2C%22PMCID%22%3A%22PMC7774017%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A04%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22CQQJNR7W%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Safe%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSafe%20IP%2C%20Amaral%20EP%2C%20Ara%26%23xFA%3Bjo-Pereira%20M%2C%20Lacerda%20MVG%2C%20Printes%20VS%2C%20Souza%20AB%2C%20et%20al.%20Adjunct%20N-Acetylcysteine%20Treatment%20in%20Hospitalized%20Patients%20With%20HIV-Associated%20Tuberculosis%20Dampens%20the%20Oxidative%20Stress%20in%20Peripheral%20Blood%3A%20Results%20From%20the%20RIPENACTB%20Study%20Trial.%20Front%20Immunol.%202020%3B11%3A602589.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.602589%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2020.602589%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2033613521%3B%20PubMed%20Central%20PMCID%3A%20PMC7889506.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adjunct%20N-Acetylcysteine%20Treatment%20in%20Hospitalized%20Patients%20With%20HIV-Associated%20Tuberculosis%20Dampens%20the%20Oxidative%20Stress%20in%20Peripheral%20Blood%3A%20Results%20From%20the%20RIPENACTB%20Study%20Trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Izabella%20P.%22%2C%22lastName%22%3A%22Safe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20P.%22%2C%22lastName%22%3A%22Amaral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Ara%5Cu00fajo-Pereira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcus%20V.%20G.%22%2C%22lastName%22%3A%22Lacerda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vitoria%20S.%22%2C%22lastName%22%3A%22Printes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%20B.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Beraldi-Magalh%5Cu00e3es%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wuelton%20M.%22%2C%22lastName%22%3A%22Monteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanderson%20S.%22%2C%22lastName%22%3A%22Sampaio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%20M.%20S.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Renata%22%2C%22lastName%22%3A%22Spener-Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Allyson%20Guimar%5Cu00e3es%22%2C%22lastName%22%3A%22Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Cordeiro-Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20still%20causes%20significant%20morbidity%20and%20mortality%20worldwide%2C%20especially%20in%20persons%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29.%20This%20disease%20is%20hallmarked%20by%20persistent%20oxidative%20stress%20and%20systemic%20inflammation.%20N-acetylcysteine%20%28NAC%29%2C%20a%20glutathione%20%28GSH%29%20precursor%2C%20has%20been%20shown%20in%20experimental%20models%20to%20limit%20Mycobacterium%20tuberculosis%20infection%20and%20disease%20both%20by%20suppression%20of%20the%20host%20oxidative%20response%20and%20through%20direct%20antimicrobial%20activity.%20In%20a%20recent%20phase%20II%20randomized%20clinical%20trial%20%28RIPENACTB%20study%29%2C%20use%20of%20NAC%20as%20adjunct%20therapy%20during%20the%20first%20two%20months%20of%20anti-TB%20treatment%20was%20safe.%20Whether%20adjunct%20NAC%20therapy%20of%20patients%20with%20TB-HIV%20coinfection%20in%20the%20context%20of%20anti-TB%20treatment%20could%20directly%20affect%20pro-oxidation%20and%20systemic%20inflammation%20has%20not%20been%20yet%20formally%20demonstrated.%20To%20test%20this%20hypothesis%2C%20we%20leveraged%20existing%20data%20and%20biospecimens%20from%20the%20RIPENACTB%20trial%20to%20measure%20a%20number%20of%20surrogate%20markers%20of%20oxidative%20stress%20and%20of%20immune%20activation%20in%20peripheral%20blood%20of%20the%20participants%20at%20pre-treatment%20and%20at%20the%20day%2060%20of%20anti-TB%20treatment.%20Upon%20initiation%20of%20therapy%2C%20we%20found%20that%20the%20group%20of%20patients%20undertaking%20NAC%20exhibited%20significant%20increase%20in%20GSH%20levels%20and%20in%20total%20antioxidant%20status%20while%20displaying%20substantial%20reduction%20in%20lipid%20peroxidation%20compared%20to%20the%20control%20group.%20Only%20small%20changes%20in%20plasma%20concentrations%20of%20cytokines%20were%20noted.%20Pharmacological%20improvement%20of%20the%20host%20antioxidant%20status%20appears%20to%20be%20a%20reasonable%20strategy%20to%20reduce%20TB-associated%20immunopathology.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2020.602589%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2233613521%22%2C%22PMCID%22%3A%22PMC7889506%22%2C%22ISSN%22%3A%221664-3224%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222023-06-16T16%3A07%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22X8FUEHA2%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Parcesepe%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BParcesepe%20AM%2C%20Lancaster%20K%2C%20Edelman%20EJ%2C%20DeBoni%20R%2C%20Ross%20J%2C%20Atwoli%20L%2C%20et%20al.%20Substance%20use%20service%20availability%20in%20HIV%20treatment%20programs%3A%20Data%20from%20the%20global%20IeDEA%20consortium%2C%202014-2015%20and%202017.%20PLoS%20ONE.%202020%3B15%288%29%3Ae0237772.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0237772%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0237772%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032853246%3B%20PubMed%20Central%20PMCID%3A%20PMC7451518.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Substance%20use%20service%20availability%20in%20HIV%20treatment%20programs%3A%20Data%20from%20the%20global%20IeDEA%20consortium%2C%202014-2015%20and%202017%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%20M.%22%2C%22lastName%22%3A%22Parcesepe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathryn%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%20Jennifer%22%2C%22lastName%22%3A%22Edelman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22DeBoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukoye%22%2C%22lastName%22%3A%22Atwoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mpho%22%2C%22lastName%22%3A%22Tlali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Judica%5Cu00ebl%22%2C%22lastName%22%3A%22Tine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Substance%20use%20is%20common%20among%20people%20living%20with%20HIV%20and%20has%20been%20associated%20with%20suboptimal%20HIV%20treatment%20outcomes.%20Integrating%20substance%20use%20services%20into%20HIV%20care%20is%20a%20promising%20strategy%20to%20improve%20patient%20outcomes.%5CnMETHODS%3A%20We%20report%20on%20substance%20use%20education%2C%20screening%2C%20and%20referral%20practices%20from%20two%20surveys%20of%20HIV%20care%20and%20treatment%20sites%20participating%20in%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium.%20HIV%20care%20and%20treatment%20sites%20participating%20in%20IeDEA%20are%20primarily%20public-sector%20health%20facilities%20and%20include%20both%20academic%20and%20community-based%20hospitals%20and%20health%20facilities.%20A%20total%20of%20286%20sites%20in%2045%20countries%20participated%20in%20the%202014-2015%20survey%20and%20237%20sites%20in%2044%20countries%20participated%20in%20the%202017%20survey.%20We%20compared%20changes%20over%20time%20for%20147%20sites%20that%20participated%20in%20both%20surveys.%5CnRESULTS%3A%20In%202014-2015%2C%20most%20sites%20%2875%25%29%20reported%20providing%20substance%20use-related%20education%20on-site%20%28i.e.%2C%20at%20the%20HIV%20clinic%20or%20the%20same%20health%20facility%29.%20Approximately%20half%20reported%20on-site%20screening%20for%20substance%20use%20%2852%25%29%20or%20referrals%20for%20substance%20use%20treatment%20%2851%25%29.%20In%202017%2C%20the%20proportion%20of%20sites%20providing%20on-site%20substance%20use-related%20education%2C%20screening%2C%20or%20referrals%20increased%20by%209%25%2C%2016%25%2C%20and%208%25%2C%20respectively.%20In%202017%2C%20on-site%20substance%20use%20screening%20and%20referral%20were%20most%20commonly%20reported%20at%20sites%20serving%20only%20adults%20%28compared%20to%20only%20children%5C%2Fadolescents%20or%20adults%20and%20children%5C%2Fadolescents%3B%20screening%3A%2086%25%2C%2037%25%2C%20and%2059%25%2C%20respectively%3B%20referral%3A%2076%25%2C%2047%25%2C%20and%2046%25%2C%20respectively%29%20and%20at%20sites%20in%20high-income%20countries%20%28compared%20to%20upper%20middle%20income%2C%20lower%20middle%20income%20or%20low-income%20countries%3B%20screening%3A%2089%25%2C%2076%25%2C%2068%25%2C%20and%2045%25%2C%20respectively%3B%20referral%3A%2082%25%2C%2071%25%2C%2057%25%2C%20and%2034%25%2C%20respectively%29.%5CnCONCLUSION%3A%20Although%20there%20have%20been%20increases%20in%20the%20proportion%20of%20sites%20reporting%20substance%20use%20education%2C%20screening%2C%20and%20referral%20services%20across%20IeDEA%20sites%2C%20gaps%20persist%20in%20the%20integration%20of%20substance%20use%20services%20into%20HIV%20care%2C%20particularly%20in%20relation%20to%20screening%20and%20referral%20practices%2C%20with%20reduced%20availability%20for%20children%5C%2Fadolescents%20and%20those%20receiving%20care%20within%20resource-constrained%20settings.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0237772%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232853246%22%2C%22PMCID%22%3A%22PMC7451518%22%2C%22ISSN%22%3A%221932-6203%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A12%3A55Z%22%7D%7D%2C%7B%22key%22%3A%2276J2KQJJ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Belaunzaran-Zamudio%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBelaunzaran-Zamudio%20PF%2C%20Caro-Vega%20Y%2C%20Giganti%20MJ%2C%20Castilho%20JL%2C%20Crabtree-Ramirez%20BE%2C%20Shepherd%20BE%2C%20et%20al.%20Frequency%20of%20non-communicable%20diseases%20in%20people%2050%20years%20of%20age%20and%20older%20receiving%20HIV%20care%20in%20Latin%20America.%20PLoS%20ONE.%202020%3B15%286%29%3Ae0233965.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0233965%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0233965%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2032555607%3B%20PubMed%20Central%20PMCID%3A%20PMC7299309.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Frequency%20of%20non-communicable%20diseases%20in%20people%2050%20years%20of%20age%20and%20older%20receiving%20HIV%20care%20in%20Latin%20America%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzaran-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Giganti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ramirez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernando%22%2C%22lastName%22%3A%22Mej%5Cu00eda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Cesar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%20C.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelo%22%2C%22lastName%22%3A%22Wolff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%20and%20South%20American%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20A%20growing%20population%20of%20older%20adults%20with%20HIV%20will%20increase%20demands%20on%20HIV-related%20healthcare.%20Nearly%20a%20quarter%20of%20people%20receiving%20care%20for%20HIV%20in%20Latin%20America%20are%20currently%2050%20years%20or%20older%2C%20yet%20little%20is%20known%20about%20the%20frequency%20of%20comorbidities%20in%20this%20population.%20We%20estimated%20the%20prevalence%20and%20incidence%20of%20non-communicable%20diseases%20%28NCDs%29%20among%20people%2050%20years%20of%20age%20or%20older%20%28%5Cu226550yo%29%20receiving%20HIV%20care%20during%202000-2015%20in%20six%20centers%20affiliated%20with%20the%20Caribbean%2C%20Central%20and%20South%20American%20network%20for%20HIV%20epidemiology%20%28CCASAnet%29.%5CnMETHODS%3A%20We%20estimated%20the%20annual%20prevalence%2C%20and%20overall%20prevalence%20and%20incidence%20of%20cardiovascular%20diseases%2C%20diabetes%2C%20hypertension%2C%20dyslipidemia%2C%20psychiatric%20disorders%2C%20chronic%20liver%20and%20renal%20diseases%2C%20and%20non-AIDS-defining%20cancers%2C%20and%20multimorbidity%20%28more%20than%20one%20NCD%29%20of%20people%20%5Cu226550yo%20receiving%20care%20for%20HIV.%20Analyses%20were%20performed%20according%20to%20age%20at%20enrollment%20into%20HIV%20care%20%28%26lt%3B50yo%20and%20%5Cu226550yo%29.%5CnRESULTS%3A%20We%20included%203%2C415%20patients%20%5Cu226550yo%2C%20of%20whom%201%2C487%2843%25%29%20were%20enrolled%20at%20age%20%5Cu226550%20years.%20The%20annual%20prevalence%20of%20NCDs%20increased%20from%2032%25%20to%2068%25%20and%20multimorbidity%20from%2030%25%20to%2040%25%20during%202000-2015.%20At%20the%20last%20registered%20visit%2C%2053%25%20of%20patients%20enrolled%20%26lt%3B50yo%20and%2050%25%20of%20those%20enrolled%20%5Cu226550yo%20had%20at%20least%20one%20NCD.%20Most%20common%20NCDs%20at%20the%20last%20visit%20in%20each%20age-group%20at%20enrollment%20were%20dyslipidemia%20%2836%25%20in%20%26lt%3B50yo%20and%2028%25%20in%20%5Cu226550yo%29%2C%20hypertension%20%2817%25%20and%2018%25%29%2C%20psychiatric%20disorders%20%2815%25%20and%2010%25%29%2C%20and%20diabetes%20%2811%25%20and%2012%25%29.%5CnCONCLUSIONS%3A%20The%20prevalence%20of%20NCDs%20and%20multimorbidity%20in%20people%20%5Cu226550%20years%20receiving%20care%20for%20HIV%20in%20CCASAnet%20centers%20in%20Latin%20America%20increased%20substantially%20in%20the%20last%2015%20years.%20Our%20results%20make%20evident%20the%20need%20of%20planning%20for%20provision%20of%20complex%2C%20primary%20care%20for%20aging%20adults%20living%20with%20HIV.%22%2C%22date%22%3A%222020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0233965%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2232555607%22%2C%22PMCID%22%3A%22PMC7299309%22%2C%22ISSN%22%3A%221932-6203%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A12%3A08Z%22%7D%7D%5D%7D
1.
Giganti MJ, Shepherd BE. Multiple-Imputation Variance Estimation in Studies With Missing or Misclassified Inclusion Criteria. Am J Epidemiol. 2020 Dec 1;189(12):1628–32. http://doi.org/10.1093/aje/kwaa153 PubMed PMID: 32685964; PubMed Central PMCID: PMC7705600.
1.
Reichmuth ML, Hömke R, Zürcher K, Sander P, Avihingsanon A, Collantes J, et al. Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e00513-20. http://doi.org/10.1128/AAC.00513-20 PubMed PMID: 32868333; PubMed Central PMCID: PMC7577131.
1.
Rebeiro PF, Duda SN, Wools-Kaloustian KK, Nash D, Althoff KN, International epidemiology Databases to Evaluate AIDS (IeDEA). Implications of COVID-19 for HIV Research: data sources, indicators and longitudinal analyses. J Int AIDS Soc. 2020 Oct;23(10):e25627. http://doi.org/10.1002/jia2.25627 PubMed PMID: 33047483; PubMed Central PMCID: PMC7550555.
1.
Desmonde S, Neilan AM, Musick B, Patten G, Chokephaibulkit K, Edmonds A, et al. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium. J Int AIDS Soc. 2020 Oct;23(10):e25617. http://doi.org/10.1002/jia2.25617 PubMed PMID: 33034417; PubMed Central PMCID: PMC7545918.
1.
Loiseau C, Brites D, Reinhard M, Zürcher K, Borrell S, Ballif M, et al. HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00782-20. http://doi.org/10.1128/AAC.00782-20 PubMed PMID: 32718966; PubMed Central PMCID: PMC7508592.
1.
Shepherd BE, Shaw PA. Errors in multiple variables in human immunodeficiency virus (HIV) cohort and electronic health record data: statistical challenges and opportunities. Stat Commun Infect Dis. 2020 Sep 1;12(Suppl1):20190015. http://doi.org/10.1515/scid-2019-0015 PubMed PMID: 35880997; PubMed Central PMCID: PMC9204761.
1.
Duda SN, Musick BS, Davies MA, Sohn AH, Ledergerber B, Wools-Kaloustian K, et al. The IeDEA Data Exchange Standard: a common data model for global HIV cohort collaboration [Internet]. medRxiv; 2020 [cited 2023 Jun 16]. Available from: https://www.medrxiv.org/content/10.1101/2020.07.22.20159921v1 http://doi.org/10.1101/2020.07.22.20159921
1.
Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Queiroz ATL, Fukutani KF, et al. Aging increases the systemic molecular degree of inflammatory perturbation in patients with tuberculosis. Sci Rep. 2020 Jul 9;10(1):11358. http://doi.org/10.1038/s41598-020-68255-0 PubMed PMID: 32647178; PubMed Central PMCID: PMC7347549.
1.
Boettiger DC, Escuder MM, Law MG, Veloso V, Souza RA, Ikeda MLR, et al. Cardiovascular disease among people living with HIV in Brazil. Trop Med Int Health. 2020 Jul;25(7):886–96. http://doi.org/10.1111/tmi.13405 PubMed PMID: 32306480.
1.
Patten G, Puthanakit T, McGowan CC, Wools-Kaloustian K, Hazra R, Pinto JA, et al. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. J Int AIDS Soc. 2020 Jul;23(7):e25580. http://doi.org/10.1002/jia2.25580 PubMed PMID: 32722897; PubMed Central PMCID: PMC7387110.
1.
Koenig SP, Kim A, Shepherd BE, Cesar C, Veloso V, Cortes CP, et al. Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. Clin Infect Dis. 2020 Jun 24;71(1):215–7. http://doi.org/10.1093/cid/ciz1032 PubMed PMID: 31629369; PubMed Central PMCID: PMC7312222.
1.
Rebeiro PF, Cohen MJ, Ewing HM, Figueiredo MC, Peetluk LS, Andrade KB, et al. Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health. 2020 Jun 9;20(1):897. http://doi.org/10.1186/s12889-020-09053-1 PubMed PMID: 32517671; PubMed Central PMCID: PMC7285569.
1.
Belaunzarán-Zamudio PF, Caro-Vega YN, Shepherd BE, Rebeiro PF, Crabtree-Ramírez BE, Cortes CP, et al. The Population Impact of Late Presentation With Advanced HIV Disease and Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin America. Am J Epidemiol. 2020 Jun 1;189(6):564–72. http://doi.org/10.1093/aje/kwz252 PubMed PMID: 31667488; PubMed Central PMCID: PMC7443201.
1.
Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, et al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Sci Rep. 2020 May 25;10(1):8629. http://doi.org/10.1038/s41598-020-65043-8 PubMed PMID: 32451443; PubMed Central PMCID: PMC7248089.
1.
Jesson J, Desmonde S, Yiannoutsos CT, Patten G, Malateste K, Duda SN, et al. Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium. BMC Res Notes. 2020 May 24;13(1):249. http://doi.org/10.1186/s13104-020-05081-7 PubMed PMID: 32448379; PubMed Central PMCID: PMC7245795.
1.
Peetluk LS, Rebeiro PF, Cordeiro-Santos M, Kritski A, Andrade BB, Durovni B, et al. Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. J Infect Dis. 2020 Apr 7;221(9):1416–24. http://doi.org/10.1093/infdis/jiz595 PubMed PMID: 31724035; PubMed Central PMCID: PMC7137883.
1.
Lotspeich SC, Giganti MJ, Maia M, Vieira R, Machado DM, Succi RC, et al. Self-audits as alternatives to travel-audits for improving data quality in the Caribbean, Central and South America network for HIV epidemiology. J Clin Transl Sci. 2020 Apr;4(2):125–32. http://doi.org/10.1017/cts.2019.442 PubMed PMID: 32313702; PubMed Central PMCID: PMC7159809.
1.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. J Int AIDS Soc. 2020 Apr;23(4):e25477. http://doi.org/10.1002/jia2.25477 PubMed PMID: 32297485; PubMed Central PMCID: PMC7160415.
1.
Cubillos-Angulo JM, Arriaga MB, Melo MGM, Silva EC, Alvarado-Arnez LE, de Almeida AS, et al. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. Int J Infect Dis. 2020 Mar;92:21–8. http://doi.org/10.1016/j.ijid.2019.12.013 PubMed PMID: 31843671; PubMed Central PMCID: PMC7197195.
1.
Cubillos-Angulo JM, Arriaga MB, Melo MGM, Silva EC, Alvarado-Arnez LE, de Almeida AS, et al. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. Int J Infect Dis. 2020 Mar;92:21–8. http://doi.org/10.1016/j.ijid.2019.12.013 PubMed PMID: 31843671; PubMed Central PMCID: PMC7197195.
1.
Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, et al. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infect Dis. 2020 Jan;7(1):ofaa006. http://doi.org/10.1093/ofid/ofaa006 PubMed PMID: 32010735; PubMed Central PMCID: PMC6984675.
1.
Giganti MJ, Shaw PA, Chen G, Bebawy SS, Turner MM, Sterling TR, et al. Accounting for dependent errors in predictors and time-to-event outcomes using electronic health records, validation samples and multiple imputation. Ann Appl Stat. 2020;14(2):1045–61. http://doi.org/10.1214/20-AOAS1343
1.
Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, et al. Cervical cancer risk in women living with HIV across four continents: A multicohort study. Int J Cancer. 2020 01;146(3):601–9. http://doi.org/10.1002/ijc.32260 PubMed PMID: 31215037; PubMed Central PMCID: PMC6898726.
1.
IeDEA and COHERE in EuroCoord Cohort Collaboration. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas. AIDS. 2020 01;34(2):277–89. http://doi.org/10.1097/QAD.0000000000002399 PubMed PMID: 31876592; PubMed Central PMCID: PMC6948801.
1.
Musayón-Oblitas FY, Cárcamo CP, Gimbel S, Zarate JIE, Espinoza ABG. Validation of a counseling guide for adherence to antiretroviral therapy using implementation science. Rev Lat Am Enfermagem. 2020;28:e3228. http://doi.org/10.1590/1518-8345.3117.3228 PubMed PMID: 32022148; PubMed Central PMCID: PMC7000190.
1.
Demitto FO, Araújo-Pereira M, Schmaltz CA, Sant’Anna FM, Arriaga MB, Andrade BB, et al. Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV. Front Immunol. 2020;11:588405. http://doi.org/10.3389/fimmu.2020.588405 PubMed PMID: 33072136; PubMed Central PMCID: PMC7541849.
1.
Barreto-Duarte B, Sterling TR, Fiske CT, Almeida A, Nochowicz CH, Smith RM, et al. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. Front Immunol. 2020;11:605338. http://doi.org/10.3389/fimmu.2020.605338 PubMed PMID: 33391271; PubMed Central PMCID: PMC7774017.
1.
Barreto-Duarte B, Sterling TR, Fiske CT, Almeida A, Nochowicz CH, Smith RM, et al. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. Front Immunol. 2020;11:605338. http://doi.org/10.3389/fimmu.2020.605338 PubMed PMID: 33391271; PubMed Central PMCID: PMC7774017.
1.
Safe IP, Amaral EP, Araújo-Pereira M, Lacerda MVG, Printes VS, Souza AB, et al. Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial. Front Immunol. 2020;11:602589. http://doi.org/10.3389/fimmu.2020.602589 PubMed PMID: 33613521; PubMed Central PMCID: PMC7889506.
1.
Parcesepe AM, Lancaster K, Edelman EJ, DeBoni R, Ross J, Atwoli L, et al. Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017. PLoS ONE. 2020;15(8):e0237772. http://doi.org/10.1371/journal.pone.0237772 PubMed PMID: 32853246; PubMed Central PMCID: PMC7451518.
1.
Belaunzaran-Zamudio PF, Caro-Vega Y, Giganti MJ, Castilho JL, Crabtree-Ramirez BE, Shepherd BE, et al. Frequency of non-communicable diseases in people 50 years of age and older receiving HIV care in Latin America. PLoS ONE. 2020;15(6):e0233965. http://doi.org/10.1371/journal.pone.0233965 PubMed PMID: 32555607; PubMed Central PMCID: PMC7299309.
2019
76770
IP6F4TRX
2019
1
nlm
50
date
desc
161
https://www.ccasanet.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22E5J4VXQT%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Giganti%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGiganti%20MJ%2C%20Shepherd%20BE%2C%20Caro-Vega%20Y%2C%20Luz%20PM%2C%20Rebeiro%20PF%2C%20Maia%20M%2C%20et%20al.%20The%20impact%20of%20data%20quality%20and%20source%20data%20verification%20on%20epidemiologic%20inference%3A%20a%20practical%20application%20using%20HIV%20observational%20data.%20BMC%20Public%20Health.%202019%20Dec%2030%3B19%281%29%3A1748.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-019-8105-2%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12889-019-8105-2%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031888571%3B%20PubMed%20Central%20PMCID%3A%20PMC6937856.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20impact%20of%20data%20quality%20and%20source%20data%20verification%20on%20epidemiologic%20inference%3A%20a%20practical%20application%20using%20HIV%20observational%20data%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20J.%22%2C%22lastName%22%3A%22Giganti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paula%20M.%22%2C%22lastName%22%3A%22Luz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcelle%22%2C%22lastName%22%3A%22Maia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetane%22%2C%22lastName%22%3A%22Julmiste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Data%20audits%20are%20often%20evaluated%20soon%20after%20completion%2C%20even%20though%20the%20identification%20of%20systematic%20issues%20may%20lead%20to%20additional%20data%20quality%20improvements%20in%20the%20future.%20In%20this%20study%2C%20we%20assess%20the%20impact%20of%20the%20entire%20data%20audit%20process%20on%20subsequent%20statistical%20analyses.%5CnMETHODS%3A%20We%20conducted%20on-site%20audits%20of%20datasets%20from%20nine%20international%20HIV%20care%20sites.%20Error%20rates%20were%20quantified%20for%20key%20demographic%20and%20clinical%20variables%20among%20a%20subset%20of%20records%20randomly%20selected%20for%20auditing.%20Based%20on%20audit%20results%2C%20some%20sites%20were%20tasked%20with%20targeted%20validation%20of%20high-error-rate%20variables%20resulting%20in%20a%20post-audit%20dataset.%20We%20estimated%20the%20times%20from%20antiretroviral%20therapy%20initiation%20until%20death%20and%20first%20AIDS-defining%20event%20using%20the%20pre-audit%20data%2C%20the%20audit%20data%2C%20and%20the%20post-audit%20data.%5CnRESULTS%3A%20The%20overall%20discrepancy%20rate%20between%20pre-audit%20and%20audit%20data%20%28n%5Cu2009%3D%5Cu2009250%29%20across%20all%20audited%20variables%20was%2017.1%25.%20The%20estimated%20probability%20of%20mortality%20and%20an%20AIDS-defining%20event%20over%20time%20was%20higher%20in%20the%20audited%20data%20relative%20to%20the%20pre-audit%20data.%20Among%20patients%20represented%20in%20both%20the%20post-audit%20and%20pre-audit%20cohorts%20%28n%5Cu2009%3D%5Cu200918%2C999%29%2C%20AIDS%20and%20mortality%20estimates%20also%20were%20higher%20in%20the%20post-audit%20data.%5CnCONCLUSION%3A%20Though%20some%20changes%20may%20have%20occurred%20independently%2C%20our%20findings%20suggest%20that%20improved%20data%20quality%20following%20the%20audit%20may%20impact%20epidemiological%20inferences.%22%2C%22date%22%3A%22Dec%2030%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12889-019-8105-2%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231888571%22%2C%22PMCID%22%3A%22PMC6937856%22%2C%22ISSN%22%3A%221471-2458%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A10%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22NRNNS2GX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Silveira-Mattos%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-30%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BSilveira-Mattos%20PS%2C%20Barreto-Duarte%20B%2C%20Vasconcelos%20B%2C%20Fukutani%20KF%2C%20Vinhaes%20CL%2C%20Oliveira-de-Souza%20D%2C%20et%20al.%20Differential%20expression%20of%20activation%20markers%20by%20Mycobacterium%20tuberculosis-specific%20CD4%2B%20T-cell%20distinguishes%20extrapulmonary%20from%20pulmonary%20tuberculosis%20and%20latent%20infection.%20Clin%20Infect%20Dis.%202019%20Oct%2030.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciz1070%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciz1070%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031665254.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Differential%20expression%20of%20activation%20markers%20by%20Mycobacterium%20tuberculosis-specific%20CD4%2B%20T-cell%20distinguishes%20extrapulmonary%20from%20pulmonary%20tuberculosis%20and%20latent%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20S.%22%2C%22lastName%22%3A%22Silveira-Mattos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Barreto-Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Vasconcelos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deivide%22%2C%22lastName%22%3A%22Oliveira-de-Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%20C.%22%2C%22lastName%22%3A%22Ibegbu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%20C.%22%2C%22lastName%22%3A%22Figueiredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jyothi%22%2C%22lastName%22%3A%22Rengarajan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Diagnosis%20of%20active%20tuberculosis%20%28ATB%29%20currently%20relies%20on%20detection%20of%20M.%20tuberculosis%20%28Mtb%29.%20Identifying%20patients%20with%20extrapulmonary%20TB%20%28EPTB%29%20remains%20challenging%20because%20microbiological%20confirmation%20is%20often%20not%20possible.%20Highly%20accurate%20blood-based%20tests%20could%20improve%20diagnosis%20of%20both%20EPTB%20and%20pulmonary%20TB%20%28PTB%29%2C%20and%20timely%20initiation%20of%20anti-TB%20therapy.%5CnMETHODS%3A%20A%20case-control%20study%20was%20performed%20using%20discriminant%20analyses%20to%20validate%20an%20approach%20using%20Mtb-specific%20CD4%2BT-cell%20activation%20markers%20in%20blood%20to%20discriminate%20PTB%20and%20EPTB%20from%20latent%20TB%20infection%20%28LTBI%29%20as%20well%20as%20EPTB%20from%20PTB%20in%20270%20Brazilian%20individuals.%20We%20further%20tested%20the%20effect%20of%20HIV%20co-infection%20on%20diagnostic%20performance.%20Frequencies%20of%20IFN%5Cu03b3%2BCD4%2BT-cells%20expressing%20CD38%2C%20HLADR%2C%20and%5C%2For%20Ki67%20were%20assessed%20by%20flow%20cytometry.%5CnRESULTS%3A%20EPTB%20and%20PTB%20were%20associated%20with%20higher%20frequencies%20of%20CD4%2BT-cells%20expressing%20CD38%2C%20HLADR%20or%20Ki67%20compared%20to%20LTBI%20%28all%20p-values%20%26lt%3B%20.001%29.%20Moreover%2C%20frequencies%20of%20HLADR%2B%20%28p%3D%20.03%29%20or%20Ki67%2B%20%28p%26lt%3B%20.001%29%20cells%20accurately%20distinguished%20EPTB%20from%20PTB.%20HIV%20infection%20did%20not%20affect%20the%20capacity%20of%20these%20markers%20to%20distinguish%20ATB%20from%20LTBI%20or%20EPTB%20from%20PTB.%5CnCONCLUSION%3A%20Cell%20activation%20markers%20in%20Mtb-specific%20CD4%2BT-cells%20distinguished%20ATB%20from%20LTBI%2C%20and%20EPTB%20from%20PTB%2C%20regardless%20of%20HIV%20infection%20status.%20These%20parameters%20provide%20an%20attractive%20approach%20for%20developing%20blood-based%20diagnostic%20tests%20for%20both%20active%20and%20latent%20TB.%22%2C%22date%22%3A%22Oct%2030%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciz1070%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231665254%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A08%3A26Z%22%7D%7D%2C%7B%22key%22%3A%2272GR3VZF%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration%22%2C%22parsedDate%22%3A%222019-02%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCollaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration.%20Incidence%20of%20switching%20to%20second-line%20antiretroviral%20therapy%20and%20associated%20factors%20in%20children%20with%20HIV%3A%20an%20international%20cohort%20collaboration.%20Lancet%20HIV.%202019%20Feb%3B6%282%29%3Ae105%26%23×2013%3B15.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2818%2930319-9%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2352-3018%2818%2930319-9%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030723008%3B%20PubMed%20Central%20PMCID%3A%20PMC7093820.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Incidence%20of%20switching%20to%20second-line%20antiretroviral%20therapy%20and%20associated%20factors%20in%20children%20with%20HIV%3A%20an%20international%20cohort%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Estimates%20of%20incidence%20of%20switching%20to%20second-line%20antiretroviral%20therapy%20%28ART%29%20among%20children%20with%20HIV%20are%20necessary%20to%20inform%20the%20need%20for%20paediatric%20second-line%20formulations.%20We%20aimed%20to%20quantify%20the%20cumulative%20incidence%20of%20switching%20to%20second-line%20ART%20among%20children%20in%20an%20international%20cohort%20collaboration.%5CnMETHODS%3A%20In%20this%20international%20cohort%20collaboration%20study%2C%20we%20pooled%20individual%20patient-level%20data%20for%20children%20younger%20than%2018%20years%20who%20initiated%20ART%20%28two%20or%20more%20nucleoside%20reverse-transcriptase%20inhibitors%20%5BNRTI%5D%20plus%20a%20non-NRTI%20%5BNNRTI%5D%20or%20boosted%20protease%20inhibitor%29%20between%201993%20and%202015%20from%2012%20observational%20cohort%20networks%20in%20the%20Collaborative%20Initiative%20for%20Paediatric%20HIV%20Education%20and%20Research%20%28CIPHER%29%20Global%20Cohort%20Collaboration.%20Patients%20who%20were%20reported%20to%20be%20horizontally%20infected%20with%20HIV%20and%20those%20who%20were%20enrolled%20in%20trials%20of%20treatment%20monitoring%2C%20switching%2C%20or%20interruption%20strategies%20were%20excluded.%20Switch%20to%20second-line%20ART%20was%20defined%20as%20change%20of%20one%20or%20more%20NRTI%20plus%20either%20change%20in%20drug%20class%20%28NNRTI%20to%20protease%20inhibitor%20or%20vice%20versa%29%20or%20protease%20inhibitor%20change%2C%20change%20from%20single%20to%20dual%20protease%20inhibitor%2C%20or%20addition%20of%20a%20new%20drug%20class.%20We%20used%20cumulative%20incidence%20curves%20to%20assess%20time%20to%20switching%2C%20and%20multivariable%20proportional%20hazards%20models%20to%20explore%20patient-level%20and%20cohort-level%20factors%20associated%20with%20switching%2C%20with%20death%20and%20loss%20to%20follow-up%20as%20competing%20risks.%5CnFINDINGS%3A%20At%20the%20data%20cutoff%20of%20Sept%2016%2C%202015%2C%20182%5Cu2008747%20children%20with%20HIV%20were%20included%20in%20the%20CIPHER%20dataset%2C%20of%20whom%2093%5Cu2008351%20were%20eligible%2C%20with%2083%5Cu2008984%20%2890%5Cu00b70%25%29%20from%20sub-Saharan%20Africa.%20At%20ART%20initiation%2C%20the%20median%20patient%20age%20was%203%5Cu00b79%20years%20%28IQR%201%5Cu00b76-6%5Cu00b79%29%20and%2082%5Cu2008885%20%2888%5Cu00b78%25%29%20patients%20initiated%20NNRTI-based%20and%2010%20466%20%2811%5Cu00b72%25%29%20initiated%20protease%20inhibitor-based%20regimens.%20Median%20duration%20of%20follow-up%20after%20ART%20initiation%20was%2026%20months%20%28IQR%209-52%29.%203883%20%284%5Cu00b72%25%29%20patients%20switched%20to%20second-line%20ART%20after%20a%20median%20of%2035%20months%20%28IQR%2020-57%29%20of%20ART.%20The%20cumulative%20incidence%20of%20switching%20at%203%20years%20was%203%5Cu00b71%25%20%2895%25%20CI%203%5Cu00b70-3%5Cu00b72%29%2C%20but%20this%20estimate%20varied%20widely%20depending%20on%20the%20cohort%20monitoring%20strategy%2C%20from%206%5Cu00b78%25%20%286%5Cu00b75-7%5Cu00b72%29%20in%20settings%20with%20routine%20monitoring%20of%20CD4%20%28CD4%25%20or%20CD4%20count%29%20and%20viral%20load%20to%200%5Cu00b78%25%20%280%5Cu00b76-1%5Cu00b70%29%20in%20settings%20with%20clinical%20only%20monitoring.%20In%20multivariable%20analyses%2C%20patient-level%20factors%20associated%20with%20an%20increased%20likelihood%20of%20switching%20were%20male%20sex%2C%20older%20age%20at%20ART%20initiation%2C%20and%20initial%20NNRTI-based%20regimen%20%28p%26lt%3B0%5Cu00b70001%29.%20Cohort-level%20factors%20that%20increased%20the%20likelihood%20of%20switching%20were%20higher-income%20country%20%28p%3D0%5Cu00b70017%29%20and%20routine%20or%20targeted%20monitoring%20of%20CD4%20and%20viral%20load%20%28p%26lt%3B0%5Cu00b70001%29%2C%20which%20was%20associated%20with%20a%20166%25%20increase%20in%20likelihood%20of%20switching%20compared%20with%20CD4%20only%20monitoring%20%28subdistributional%20hazard%20ratio%202%5Cu00b766%2C%2095%25%20CI%202%5Cu00b722-3%5Cu00b719%29.%5CnINTERPRETATION%3A%20Our%20global%20paediatric%20analysis%20found%20wide%20variations%20in%20the%20incidence%20of%20switching%20to%20second-line%20ART%20across%20monitoring%20strategies.%20These%20findings%20suggest%20the%20scale-up%20of%20viral%20load%20monitoring%20would%20probably%20increase%20demand%20for%20paediatric%20second-line%20ART%20formulations.%5CnFUNDING%3A%20International%20AIDS%20Society-CIPHER.%22%2C%22date%22%3A%22Feb%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2FS2352-3018%2818%2930319-9%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230723008%22%2C%22PMCID%22%3A%22PMC7093820%22%2C%22ISSN%22%3A%222352-3018%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A05%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22EPAK82BX%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Pettit%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPettit%20AC%2C%20Jenkins%20CA%2C%20Blevins%20Peratikos%20M%2C%20Yotebieng%20M%2C%20Diero%20L%2C%20Do%20CD%2C%20et%20al.%20Directly%20observed%20therapy%20and%20risk%20of%20unfavourable%20tuberculosis%20treatment%20outcomes%20among%20an%20international%20cohort%20of%20people%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries.%20J%20Int%20AIDS%20Soc.%202019%3B22%2812%29%3Ae25423.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25423%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25423%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031814312%3B%20PubMed%20Central%20PMCID%3A%20PMC6900483.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Directly%20observed%20therapy%20and%20risk%20of%20unfavourable%20tuberculosis%20treatment%20outcomes%20among%20an%20international%20cohort%20of%20people%20living%20with%20HIV%20in%20low-%20and%20middle-income%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20C.%22%2C%22lastName%22%3A%22Pettit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%20A.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meridith%22%2C%22lastName%22%3A%22Blevins%20Peratikos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lameck%22%2C%22lastName%22%3A%22Diero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cuong%20D.%22%2C%22lastName%22%3A%22Do%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%20G.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denise%22%2C%22lastName%22%3A%22Hawerlander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Marcy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Identification%20of%20persons%20living%20with%20human%20immunodeficiency%20virus%20%28HIV%29-associated%20tuberculosis%20%28TB%29%20at%20increased%20risk%20for%20unfavourable%20TB%20outcomes%20would%20inform%20efforts%20to%20improve%20such%20outcomes.%20We%20sought%20to%20identify%20factors%20associated%20with%20a%20decreased%20risk%20of%20unfavourable%20TB%20treatment%20outcomes%20among%20people%20living%20with%20HIV-infection%20%28PLHIV%29%20in%20low-%20and%20middle-income%20countries%20%28LMIC%29%2C%20with%20a%20specific%20focus%20on%20directly%20observed%20therapy%20%28DOT%29%20compared%20with%20self-administered%20therapy%20%28SAT%29%20during%20the%20continuation%20phase%20of%20anti-TB%20therapy.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20cohort%20study%20among%20adults%20diagnosed%20with%20HIV-associated%20TB%20in%20Africa%2C%20Asia%20and%20the%20Americas%20from%202012%20to%202013%3B%20data%20were%20collected%20from%202012%20to%202016.%20Unfavourable%20TB%20treatment%20outcomes%20%28death%20during%20TB%20treatment%2C%20and%20TB%20treatment%20failure%20or%20recurrence%29%20were%20defined%20according%20to%20World%20Health%20Organization%20criteria.%20Receipt%20of%20DOT%20was%20obtained%20at%20the%20site%20level%20and%20defined%20as%20%5Cu22655%5Cu00a0days%20of%20DOT%20per%20week.%20The%20person%20administering%20DOT%20and%20treatment%20location%20varied%20by%20site.%20Lack%20of%20receipt%20of%20DOT%20was%20defined%20as%20SAT.%20Multivariable%20logistic%20regression%20estimated%20the%20adjusted%20odds%20of%20unfavourable%20TB%20treatment%20outcomes.%5CnRESULTS%3A%20Among%201862%20adults%20with%20HIV-associated%20TB%20included%2C%20252%20%2813.5%25%29%20had%20unfavourable%20TB%20outcomes%20%28226%20deaths%2C%2026%20recurrences%5C%2Ffailures%29.%20Overall%2C%201825%20%2898%25%29%20received%20DOT%20in%20the%20intensive%20phase%20and%201617%20%2887%25%29%20received%20DOT%20in%20the%20continuation%20phase.%20DOT%20in%20the%20continuation%20phase%20was%20not%20significantly%20associated%20with%20unfavourable%20TB%20outcomes%20%28aOR%201.43%2C%2095%25%20CI%200.86%20to%202.38%29%20compared%20to%20SAT.%20Body%20mass%20index%20%28BMI%29%20change%20during%20anti-TB%20treatment%20%28per%202%20units%20increase%2C%20aOR%200.74%2C%2095%25%20CI%200.68%20to%200.82%29%20and%20CD4%2B%20count%20at%20TB%20diagnosis%20%28200%20vs.%2050%20%5Cu00a0cells%5C%2F%5Cu00b5L%2C%20aOR%200.54%2C%2095%25%20CI%200.39%20to%200.73%29%20were%20both%20independently%20associated%20with%20decreased%20odds%20of%20unfavourable%20TB%20treatment%20outcomes.%5CnCONCLUSIONS%3A%20In%20this%20large%2C%20international%20cohort%20of%20people%20living%20with%20HIV-associated%20TB%20in%20LMIC%20who%20received%20intensive%20phase%20DOT%2C%20DOT%20during%20the%20continuation%20phase%20of%20anti-TB%20therapy%20was%20not%20associated%20with%20a%20decreased%20odds%20of%20unfavourable%20TB%20treatment%20outcomes%20compared%20to%20SAT.%20Randomized%20trials%20evaluating%20the%20effect%20of%20continuation-phase%20DOT%20on%20TB%20outcomes%20among%20PLHIV%20are%20needed.%22%2C%22date%22%3A%2212%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25423%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231814312%22%2C%22PMCID%22%3A%22PMC6900483%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A10%3A05Z%22%7D%7D%2C%7B%22key%22%3A%228DCVCGJD%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Crabtree-Ram%5Cu00edrez%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCrabtree-Ram%26%23xED%3Brez%20BE%2C%20Caro-Vega%20Y%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Shepherd%20BE%2C%20Rebeiro%20PF%2C%20Veloso%20V%2C%20et%20al.%20Temporal%20changes%20in%20ART%20initiation%20in%20adults%20with%20high%20CD4%20counts%20in%20Latin%20America%3A%20a%20cohort%20study.%20J%20Int%20AIDS%20Soc.%202019%3B22%2812%29%3Ae25413.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25413%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25413%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031855320%3B%20PubMed%20Central%20PMCID%3A%20PMC6922020.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Temporal%20changes%20in%20ART%20initiation%20in%20adults%20with%20high%20CD4%20counts%20in%20Latin%20America%3A%20a%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brenda%20E.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanink%22%2C%22lastName%22%3A%22Caro-Vega%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdilea%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20P.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20K.%22%2C%22lastName%22%3A%22Person%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Caribbean%2C%20Central%2C%20South%20America%20Network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20In%202013%2C%20the%20World%20Health%20Organization%20%28WHO%29%20recommended%20initiating%20combination%20ART%20%28cART%29%20in%20all%20adults%20with%20HIV%20and%20CD4%2B%20lymphocyte%20counts%20%28CD4%29%20%26lt%3B500%5Cu00a0cells%5C%2Fmm3%20.%20In%202015%2C%20this%20was%20updated%20to%20recommend%20cART%20initiation%20in%20all%20patients%20with%20HIV%2C%20regardless%20of%20CD4%20count.%20Implementation%20of%20these%20guidelines%20in%20real-world%20settings%20has%20not%20been%20evaluated%20in%20Latin%20America.%20To%20assess%20changes%20in%20time%20to%20cART%20initiation%20during%20routine%20care%2C%20we%20estimated%20trends%20in%20time%20from%20enrolment%20in%20care%20to%20cART%20initiation%20in%20HIV-positive%20adults%20with%20high%20CD4%20counts%20in%20the%20Caribbean%2C%20Central%20and%20South%20America%20network%20for%20HIV%20Epidemiology%20%28CCASAnet%29%20during%202003%20to%202017.%5CnMETHODS%3A%20All%20cART-naive%20individuals%20%5Cu226518%5Cu00a0years%20of%20age%20from%202003%20to%202017%20with%20CD4%20%5Cu2265350%5Cu00a0cells%5C%2Fmm3%20and%20without%20AIDS%20at%20enrolment%20at%20five%20CCASAnet%20sites%20%28Brazil%2C%20Chile%2C%20Honduras%2C%20Mexico%20and%20Peru%29%20were%20included.%20Patients%20without%20information%20regarding%20AIDS-defining%20events%20were%20excluded.%20We%20estimated%20unadjusted%20median%20time%20from%20enrolment%20to%20cART%20initiation%20by%20calendar%20year%20using%20Kaplan-Meier%20methods%20and%20calculated%20adjusted%20hazard%20ratios%20%28HR%29%20and%2095%25%20confidence%20intervals%20%2895%25%20CI%29%20for%20trends%20in%20cART%20initiation%20using%20Cox%20models%20and%20restricted%20cubic%20splines%20for%20continuous%20variables%2C%20accounting%20for%20age%2C%20sex%2C%20CD4%20at%20enrolment%2C%20route%20of%20HIV%20transmission%20and%20clinic%20site.%5CnRESULTS%3A%20Of%20the%203171%20patients%20included%2C%201%2C650%20%2852%25%29%20had%20CD4%20%5Cu2265500%5Cu00a0cells%5C%2Fmm3%20at%20enrolment.%20Median%20time%20to%20cART%20initiation%20after%202013%20was%206.21%5Cu00a0weeks%20%28interquartile%20range%20%28IQR%29%3A%201.89%2C%2023.21%29%2C%20and%204.71%5Cu00a0weeks%20%28IQR%3A%201.43%2C%209.57%29%20after%202015.%20Among%20763%20%2824%25%29%20patients%20who%20never%20initiated%20cART%2C%2033%20%284.3%25%29%20were%20reported%20as%20deceased%2C%20481%20%2863%25%29%20were%20lost%20to%20follow-up%2C%20and%20249%20%2833%25%29%20were%20administratively%20censored%20before%20initiation.%20Adjusted%20probability%20of%20cART%20initiation%20greatly%20increased%20in%20recent%20years%2C%20in%20particular%20after%202013%20and%202015%20%282013%20vs.%202003%3A%20HR%5Cu00a0%3D%5Cu00a07.14%3B%2095%25%20CI%3A%205.84%20to%208.73%2C%20and%202015%20vs.%202003%3A%20HR%5Cu00a0%3D%5Cu00a012.60%3B%2095%25%20CI%3A%2010.37%20to%2015.32%29.%5CnCONCLUSIONS%3A%20Time%20to%20cART%20initiation%20decreased%20substantially%2C%20roughly%20following%20changes%20in%20WHO%20guidelines%20in%20this%20real-world%20setting%20in%20Latin%20America.%20However%2C%20a%20very%20high%20proportion%20of%20patients%20never%20started%20cART%2C%20compromising%20retention%20in%20care%20and%20survival%2C%20as%20shown%20by%20their%20higher%20proportion%20of%20LTFU%20and%20death%2C%20which%20reinforce%20the%20notion%20that%20earlier%20treatment%20implementation%20strategies%20are%20needed.%22%2C%22date%22%3A%2212%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25413%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231855320%22%2C%22PMCID%22%3A%22PMC6922020%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A15%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22KBWACZVE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Stover%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BStover%20J%2C%20Glaubius%20R%2C%20Mofenson%20L%2C%20Dugdale%20CM%2C%20Davies%20MA%2C%20Patten%20G%2C%20et%20al.%20Updates%20to%20the%20Spectrum%5C%2FAIM%20model%20for%20estimating%20key%20HIV%20indicators%20at%20national%20and%20subnational%20levels.%20AIDS.%202019%2015%3B33%20Suppl%203%3AS227%26%23×2013%3B34.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002357%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002357%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031805028%3B%20PubMed%20Central%20PMCID%3A%20PMC6919230.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updates%20to%20the%20Spectrum%5C%2FAIM%20model%20for%20estimating%20key%20HIV%20indicators%20at%20national%20and%20subnational%20levels%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Stover%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Glaubius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lynne%22%2C%22lastName%22%3A%22Mofenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caitlin%20M.%22%2C%22lastName%22%3A%22Dugdale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Patten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20Spectrum%5C%2FAIM%20model%20is%20used%20by%20national%20programs%20and%20UNAIDS%20to%20prepare%20annual%20estimates%20of%20the%20status%20of%20the%20HIV%20epidemic%20in%20170%20countries.%20The%20model%20and%20assumptions%20are%20updated%20regularly%20under%20the%20guidance%20of%20the%20UNAIDS%20Reference%20Group%20on%20Estimates%2C%20Modelling%20and%20Projections%20in%20response%20to%20new%20data%2C%20studies%20and%20program%20needs.%20This%20article%20describes%20the%20most%20recent%20updates%20for%20the%202018%20round%20of%20estimates.%5CnMETHODS%3A%20New%20data%20on%20AIDS-related%20mortality%20from%20Europe%20and%20Brazil%20have%20been%20used%20to%20update%20mortality%20rates%20of%20those%20not%20on%20antiretroviral%20therapy%20%28ART%29.%20Household%20survey%20data%20and%20new%20studies%20of%20pregnant%20women%2C%20mothers%2C%20and%20children%20have%20been%20used%20to%20improve%20estimates%20of%20the%20number%20of%20HIV-positive%20pregnant%20and%20breastfeeding%20women%20and%20pediatric%20ART%20initiation.%20New%20tools%20to%20estimate%20geographic%20variation%20in%20HIV%20prevalence%20have%20been%20used%20to%20prepare%20district%20estimates%20of%20key%20indicators.%5CnRESULTS%3A%20The%202018%20version%20of%20Spectrum%20includes%3A%20new%20estimates%20of%20non-ART%20AIDS-related%20mortality%20by%20CD4%20count%20that%20depend%20on%20ART%20coverage%3B%20a%20procedure%20to%20estimate%20country-specific%20patterns%20of%20HIV%20incidence%20by%20age%20by%20fitting%20to%20prevalence%20by%20age%20from%20household%20surveys%3B%20an%20updated%20estimate%20of%20postpartum%20transmission%20with%20ART%20started%20before%20pregnancy%20of%200.023%25%20per%20month%3B%20an%20updated%20estimate%20of%20retention%20on%20treatment%20at%20delivery%20of%2080%25%20for%20all%20women%20on%20ART%3B%20a%20somewhat%20older%20pattern%20of%20ART%20initiation%20by%20age%20that%20has%2026%25%20of%20new%20pediatric%20patients%20initiating%20ART%20at%2010-14%20years%20of%20age%2C%2018%25%20at%202-4%20years%20of%20age%2C%20and%2026%25%20at%205-9%20years%20of%20age%3B%20and%20a%20new%20tool%20for%20estimating%20key%20HIV%20indicators%20at%20the%20district%20level.%5CnCONCLUSION%3A%20The%20new%20methods%20and%20data%20implemented%20in%20the%202018%20version%20of%20Spectrum%20allow%20national%20programs%20more%20flexibility%20in%20describing%20their%20programs%20and%20are%20intended%20to%20improve%20the%20estimates%20of%20adult%20mortality%20and%20pediatric%20HIV%20indicators.%22%2C%22date%22%3A%2212%2015%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000002357%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231805028%22%2C%22PMCID%22%3A%22PMC6919230%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A10%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22964ATDZ6%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Johnson%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJohnson%20LF%2C%20Anderegg%20N%2C%20Zaniewski%20E%2C%20Eaton%20JW%2C%20Rebeiro%20PF%2C%20Carriquiry%20G%2C%20et%20al.%20Global%20variations%20in%20mortality%20in%20adults%20after%20initiating%20antiretroviral%20treatment%3A%20an%20updated%20analysis%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20cohort%20collaboration.%20AIDS.%202019%2015%3B33%20Suppl%203%3AS283%26%23×2013%3B94.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002358%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FQAD.0000000000002358%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031800405%3B%20PubMed%20Central%20PMCID%3A%20PMC6919233.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20variations%20in%20mortality%20in%20adults%20after%20initiating%20antiretroviral%20treatment%3A%20an%20updated%20analysis%20of%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20cohort%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leigh%20F.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanina%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20W.%22%2C%22lastName%22%3A%22Eaton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%20K.%22%2C%22lastName%22%3A%22Ekouevi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20B.%22%2C%22lastName%22%3A%22Holmes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%20Y.%22%2C%22lastName%22%3A%22Choi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Awachana%22%2C%22lastName%22%3A%22Jiamsakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giorgos%22%2C%22lastName%22%3A%22Bakoyannis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annette%20H.%22%2C%22lastName%22%3A%22Sohn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20Collaboration%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20UNAIDS%20models%20use%20data%20from%20the%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20collaboration%20in%20setting%20assumptions%20about%20mortality%20rates%20after%20antiretroviral%20treatment%20%28ART%29%20initiation.%20This%20study%20aims%20to%20update%20these%20assumptions%20with%20new%20data%2C%20to%20quantify%20the%20extent%20of%20regional%20variation%20in%20ART%20mortality%20and%20to%20assess%20trends%20in%20ART%20mortality.%5CnMETHODS%3A%20Adult%20ART%20patients%20from%20Africa%2C%20Asia%20and%20the%20Americas%20were%20included%20if%20they%20had%20a%20known%20date%20of%20ART%20initiation%20during%202001-2017%20and%20a%20baseline%20CD4%20cell%20count.%20In%20cohorts%20that%20relied%20only%20on%20passive%20follow-up%20%28no%20patient%20tracing%20or%20linkage%20to%20vital%20registration%20systems%29%2C%20mortality%20outcomes%20were%20imputed%20in%20patients%20lost%20to%20follow-up%20based%20on%20a%20meta-analysis%20of%20tracing%20study%20data.%20Poisson%20regression%20models%20were%20fitted%20to%20the%20mortality%20data.%5CnRESULTS%3A%20464%20048%20ART%20patients%20were%20included.%20In%20multivariable%20analysis%2C%20mortality%20rates%20were%20lowest%20in%20Asia%20and%20highest%20in%20Africa%2C%20with%20no%20significant%20differences%20between%20African%20regions.%20Adjusted%20mortality%20rates%20varied%20significantly%20between%20programmes%20within%20regions.%20Mortality%20rates%20in%20the%20first%2012%20months%20after%20ART%20initiation%20were%20significantly%20higher%20during%202001-2006%20than%20during%202010-2014%2C%20although%20the%20difference%20was%20more%20substantial%20in%20Asia%20and%20the%20Americas%20%5Badjusted%20incidence%20rate%20ratio%20%28aIRR%29%201.43%2C%2095%25%20CI%3A%201.22-1.66%5D%20than%20in%20Africa%20%28aIRR%201.07%2C%2095%25%20CI%3A%201.04-1.11%29.%5CnCONCLUSION%3A%20There%20is%20substantial%20variation%20in%20ART%20mortality%20between%20and%20within%20regions%2C%20even%20after%20controlling%20for%20differences%20in%20mortality%20by%20age%2C%20sex%2C%20baseline%20CD4%20category%20and%20calendar%20period.%20ART%20mortality%20rates%20have%20declined%20substantially%20over%20time%2C%20although%20declines%20have%20been%20slower%20in%20Africa.%22%2C%22date%22%3A%2212%2015%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FQAD.0000000000002358%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231800405%22%2C%22PMCID%22%3A%22PMC6919233%22%2C%22ISSN%22%3A%221473-5571%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A10%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22XNGPMT99%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Jesson%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BJesson%20J%2C%20Schomaker%20M%2C%20Malasteste%20K%2C%20Wati%20DK%2C%20Kariminia%20A%2C%20Sylla%20M%2C%20et%20al.%20Stunting%20and%20growth%20velocity%20of%20adolescents%20with%20perinatally%20acquired%20HIV%3A%20differential%20evolution%20for%20males%20and%20females.%20A%20multiregional%20analysis%20from%20the%20IeDEA%20global%20paediatric%20collaboration.%20J%20Int%20AIDS%20Soc.%202019%3B22%2811%29%3Ae25412.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25412%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25412%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031702088%3B%20PubMed%20Central%20PMCID%3A%20PMC6839428.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Stunting%20and%20growth%20velocity%20of%20adolescents%20with%20perinatally%20acquired%20HIV%3A%20differential%20evolution%20for%20males%20and%20females.%20A%20multiregional%20analysis%20from%20the%20IeDEA%20global%20paediatric%20collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Jesson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Schomaker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%22%2C%22lastName%22%3A%22Malasteste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dewi%20K.%22%2C%22lastName%22%3A%22Wati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Azar%22%2C%22lastName%22%3A%22Kariminia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariam%22%2C%22lastName%22%3A%22Sylla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kouakou%22%2C%22lastName%22%3A%22Kouadio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shobna%22%2C%22lastName%22%3A%22Sawry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mwangelwa%22%2C%22lastName%22%3A%22Mubiana-Mbewe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Ayaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Vreeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9riane%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20global%20cohort%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Stunting%20is%20a%20key%20issue%20for%20adolescents%20with%20perinatally%20acquired%20HIV%20%28APH%29%20that%20needs%20to%20be%20better%20understood.%20As%20part%20of%20the%20IeDEA%20multiregional%20consortium%2C%20we%20described%20growth%20evolution%20during%20adolescence%20for%20APH%20on%20antiretroviral%20therapy%20%28ART%29.%5CnMETHODS%3A%20We%20included%20data%20from%20sub-Saharan%20Africa%2C%20the%20Asia-Pacific%2C%20and%20the%20Caribbean%2C%20Central%20and%20South%20America%20regions%20collected%20between%202003%20and%202016.%20Adolescents%20on%20ART%2C%20reporting%20perinatally%20acquired%20infection%20or%20entering%20HIV%20care%20before%2010%5Cu00a0years%20of%20age%2C%20with%20at%20least%20one%20height%20measurement%20between%2010%20and%2016%5Cu00a0years%20of%20age%2C%20and%20followed%20in%20care%20until%20at%20least%2014%5Cu00a0years%20of%20age%20were%20included.%20Characteristics%20at%20ART%20initiation%20and%20at%2010%5Cu00a0years%20of%20age%20were%20compared%20by%20sex.%20Correlates%20of%20growth%20defined%20by%20height-for-age%20z-scores%20%28HAZ%29%20between%20ages%2010%20and%2019%5Cu00a0years%20were%20studied%20separately%20for%20males%20and%20females%2C%20using%20linear%20mixed%20models.%5CnRESULTS%3A%20Overall%2C%208737%20APH%20were%20included%2C%20with%2046%25%20from%20Southern%20Africa.%20Median%20age%20at%20ART%20initiation%20was%208.1%5Cu00a0years%20%28interquartile%20range%20%28IQR%29%206.1%20to%209.6%29%2C%2050%25%20were%20females%2C%20and%2041%25%20were%20stunted%20%28HAZ%26lt%3B-2%5Cu00a0SD%29%20at%20ART%20initiation.%20Males%20and%20females%20did%20not%20differ%20by%20age%20and%20stunting%20at%20ART%20initiation%2C%20CD4%20count%20over%20time%20or%20retention%20in%20care.%20At%2010%5Cu00a0years%20of%20age%2C%2034%25%20of%20males%20were%20stunted%20versus%2039%25%20of%20females%20%28p%5Cu00a0%26lt%3B%5Cu00a00.001%29.%20Females%20had%20better%20subsequent%20growth%2C%20resulting%20in%20a%20higher%20prevalence%20of%20stunting%20for%20males%20compared%20to%20females%20by%20age%2015%20%2848%25%20vs.%2025%25%29%20and%2018%5Cu00a0years%20%2831%25%20vs.%2015%25%29.%20In%20linear%20mixed%20models%2C%20older%20age%20at%20ART%20initiation%20and%20low%20CD4%20count%20were%20associated%20with%20poor%20growth%20over%20time%20%28p%5Cu00a0%26lt%3B%5Cu00a00.001%29.%20Those%20stunted%20at%2010%5Cu00a0years%20of%20age%20or%20at%20ART%20initiation%20had%20the%20greatest%20growth%20improvement%20during%20adolescence.%5CnCONCLUSIONS%3A%20Prevalence%20of%20stunting%20is%20high%20among%20APH%20worldwide.%20Substantial%20sex-based%20differences%20in%20growth%20evolution%20during%20adolescence%20were%20observed%20in%20this%20global%20cohort%2C%20which%20were%20not%20explained%20by%20differences%20in%20age%20of%20access%20to%20HIV%20care%2C%20degree%20of%20immunosuppression%20or%20region.%20Other%20factors%20influencing%20growth%20differences%20in%20APH%2C%20such%20as%20differences%20in%20pubertal%20development%2C%20should%20be%20better%20documented%2C%20to%20guide%20further%20research%20and%20inform%20interventions%20to%20optimize%20growth%20and%20health%20outcomes%20among%20APH.%22%2C%22date%22%3A%2211%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25412%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231702088%22%2C%22PMCID%22%3A%22PMC6839428%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A09%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22R7A5I7V4%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Vinhaes%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BVinhaes%20CL%2C%20Oliveira-de-Souza%20D%2C%20Silveira-Mattos%20PS%2C%20Nogueira%20B%2C%20Shi%20R%2C%20Wei%20W%2C%20et%20al.%20Changes%20in%20inflammatory%20protein%20and%20lipid%20mediator%20profiles%20persist%20after%20antitubercular%20treatment%20of%20pulmonary%20and%20extrapulmonary%20tuberculosis%3A%20A%20prospective%20cohort%20study.%20Cytokine.%202019%3B123%3A154759.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cyto.2019.154759%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cyto.2019.154759%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031226436%3B%20PubMed%20Central%20PMCID%3A%20PMC6739167.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Changes%20in%20inflammatory%20protein%20and%20lipid%20mediator%20profiles%20persist%20after%20antitubercular%20treatment%20of%20pulmonary%20and%20extrapulmonary%20tuberculosis%3A%20A%20prospective%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deivide%22%2C%22lastName%22%3A%22Oliveira-de-Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20S.%22%2C%22lastName%22%3A%22Silveira-Mattos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betania%22%2C%22lastName%22%3A%22Nogueira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruiru%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wang%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xing%22%2C%22lastName%22%3A%22Yuan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guolong%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ying%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clifton%20E.%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20E.%22%2C%22lastName%22%3A%22Via%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%20D.%22%2C%22lastName%22%3A%22Mayer-Barber%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20identification%20of%20meaningful%20biomarkers%20of%20tuberculosis%20%28TB%29%20has%20potential%20to%20improve%20diagnosis%2C%20disease%20staging%20and%20prediction%20of%20treatment%20outcomes.%20It%20has%20been%20shown%20that%20active%20pulmonary%20TB%20%28PTB%29%20is%20associated%20with%20qualitative%20and%20quantitative%20changes%20in%20systemic%20immune%20profile%2C%20suggesting%20a%20chronic%20inflammatory%20imbalance.%20Here%20we%20characterized%20the%20profile%20of%20PTB%20and%20extrapulmonary%20TB%20%28EPTB%29%20in%20a%20prospective%20cohort%20study.%5CnMETHODS%3A%20We%20measured%20a%20panel%20of%2027%20inflammatory%20cytokines%2C%20soluble%20receptors%2C%20and%20lipid%20mediators%20in%20peripheral%20blood%20from%20patients%20with%20PTB%20or%20EPTB%20from%20a%20prospective%20clinical%20study%20in%20China.%20Multidimensional%20analyses%20were%20performed%20to%20describe%20associations%20between%20plasma%20levels%20of%20biomarkers%20and%20different%20TB%20disease%20presentation%20profiles.%5CnRESULTS%3A%20Mycobacterium%20tuberculosis%20infection%20induced%20changes%20in%20both%20the%20expression%20and%20correlation%20profiles%20of%20plasma%20mediators%20of%20inflammation%20in%20patients%20with%20PTB%20compared%20to%20those%20with%20EPTB.%20Increases%20in%20mycobacterial%20loads%20in%20sputum%20smears%20were%20associated%20with%20rises%20in%20concentrations%20of%20several%20molecules%20involved%20in%20TB%20pathogenesis%2C%20such%20as%20IL-1%5Cu03b2%2C%20IFN-%5Cu03b1%2C%20IL-10%20and%20PGF2%5Cu03b1.%20Moreover%2C%20PTB%20patients%20presenting%20with%20severe%20disease%20exhibited%20a%20distinct%20inflammatory%20profile%20hallmarked%20by%20heightened%20levels%20of%20TNF-%5Cu03b1%2C%20IL-1%5Cu03b2%2C%20IL17%2C%20IL-18%20and%20IL-27.%20Interestingly%2C%20while%20antitubercular%20treatment%20%28ATT%29%20resulted%20in%20early%20changes%20of%20plasma%20concentrations%20of%20markers%20in%20PTB%2C%20changes%20were%20delayed%20in%20EPTB%20patients.%20Exploratory%20analyses%20of%20the%20molecular%20degree%20of%20perturbation%20%28MDP%29%20of%20the%20inflammatory%20mediators%20before%20and%20during%20ATT%20suggested%20the%20occurrence%20of%20infection%20and%5C%2For%20treatment-induced%20long%20lasting%20%26quot%3Binflammatory%20imprinting%26quot%3B%20of%20biomarker%20profiles%20in%20TB.%20At%2024%5Cu202fweeks%20post%20ATT%20commencement%2C%20markers%20underlying%20the%20observed%20increases%20in%20MDP%20scores%20were%20IL-27%20in%20PTB%20and%20IL-1%5Cu03b2%20in%20EPTB%20patients.%5CnCONCLUSION%3A%20Our%20findings%20describe%20systemic%20and%20durable%20changes%20in%20the%20concentrations%20of%20inflammatory%20cytokines%20and%20lipid%20mediators%20in%20both%20PTB%20and%20EPTB%20and%20emphasize%20the%20role%20of%20M.%20tuberculosis%20bacterial%20burden%20and%20site%20of%20disease%20in%20modulating%20patient%20immune%20biomarkers.%22%2C%22date%22%3A%2211%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cyto.2019.154759%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231226436%22%2C%22PMCID%22%3A%22PMC6739167%22%2C%22ISSN%22%3A%221096-0023%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A09%3A49Z%22%7D%7D%2C%7B%22key%22%3A%228P9E2G4E%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Rivera%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BRivera%20VR%2C%20Lu%20L%2C%20Ocheretina%20O%2C%20Jean%20Juste%20MA%2C%20Julma%20P%2C%20Archange%20D%2C%20et%20al.%20Diagnostic%20yield%20of%20active%20case%20finding%20for%20tuberculosis%20at%20human%20immunodeficiency%20virus%20testing%20in%20Haiti.%20Int%20J%20Tuberc%20Lung%20Dis.%202019%2001%3B23%2811%29%3A1217%26%23×2013%3B22.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0835%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0835%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031718759.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20yield%20of%20active%20case%20finding%20for%20tuberculosis%20at%20human%20immunodeficiency%20virus%20testing%20in%20Haiti%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%20R.%22%2C%22lastName%22%3A%22Rivera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Ocheretina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20A.%22%2C%22lastName%22%3A%22Jean%20Juste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Julma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Archange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20G.%22%2C%22lastName%22%3A%22Moise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Homeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20D.%22%2C%22lastName%22%3A%22Phanor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Peti%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.-Y.%22%2C%22lastName%22%3A%22Cremieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20W.%22%2C%22lastName%22%3A%22Fitzgerald%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20W.%22%2C%22lastName%22%3A%22Pape%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20P.%22%2C%22lastName%22%3A%22Koenig%22%7D%5D%2C%22abstractNote%22%3A%22SETTING%3A%20The%20Groupe%20Ha%5Cu00eftien%20d%26%23039%3B%5Cu00e9tude%20du%20Sarcome%20de%20Kaposi%20et%20des%20Infections%20Opportunistes%20%28GHESKIO%29%20Centres%2C%20Port-au-Prince%2C%20Haiti%2C%20facilitate%20%26quot%3Btest%20and%20treat%26quot%3B%20strategies%20by%20screening%20all%20patients%20for%20tuberculosis%20%28TB%29%20at%20human%20immunodeficiency%20virus%20%28HIV%29%20testing.OBJECTIVE%3A%201%29%20To%20determine%20the%20proportion%20of%20patients%20with%20chronic%20cough%20at%20HIV%20testing%20diagnosed%20with%20TB%2C%20stratified%20by%20HIV%20test%20results%3B%20and%202%29%20to%20evaluate%20the%20additional%20diagnostic%20yield%20of%20Xpert%5Cu00ae%20MTB%5C%2FRIF%20vs.%20sputum%20microscopy.DESIGN%3A%20We%20conducted%20a%20retrospective%20cohort%20analysis%20including%20all%20adults%20tested%20for%20HIV%20at%20GHESKIO%20from%20August%202014%20to%20July%202015.RESULTS%3A%20Of%2029%5Cu2009233%20adult%20patients%20tested%20for%20HIV%2C%202953%20%2810%25%29%20were%20diagnosed%20as%20HIV-positive.%20Chronic%20cough%20lasting%20%5Cu22652%20weeks%20was%20reported%20by%201116%20%2838%25%29%20HIV-positive%20patients%3B%20984%20%2888%25%29%20were%20tested%20and%20265%20%2827%25%29%20were%20diagnosed%20with%20TB.%20Chronic%20cough%20was%20reported%20by%205985%20%2823%25%29%20HIV-negative%20patients%3B%205654%20%2894%25%29%20were%20tested%20and%201179%20%2821%25%29%20were%20diagnosed%20with%20TB.%20Of%20all%20bacteriologically%20confirmed%20cases%2C%2027%25%20were%20smear-negative%20and%20Xpert-positive.%20Among%20all%20TB%20patients%2C%2081%25%20were%20HIV-negative.CONCLUSIONS%3A%20Screening%20for%20TB%20at%20HIV%20testing%20was%20high-yield%2C%20among%20both%20HIV-infected%20and%20HIV-negative%20individuals.%20Testing%20for%20both%20diseases%20should%20be%20conducted%20among%20patients%20who%20present%20with%20chronic%20cough%20at%20HIV%20testing.%22%2C%22date%22%3A%2211%2001%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.18.0835%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231718759%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221815-7920%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A08%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22P78M9WDS%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Z%5Cu00fcrcher%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BZ%26%23xFC%3Brcher%20K%2C%20Ballif%20M%2C%20Kiertiburanakul%20S%2C%20Chenal%20H%2C%20Yotebieng%20M%2C%20Grinsztejn%20B%2C%20et%20al.%20Diagnosis%20and%20clinical%20outcomes%20of%20extrapulmonary%20tuberculosis%20in%20antiretroviral%20therapy%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multicohort%20study.%20J%20Int%20AIDS%20Soc.%202019%3B22%289%29%3Ae25392.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25392%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25392%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031507083%3B%20PubMed%20Central%20PMCID%3A%20PMC6737289.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnosis%20and%20clinical%20outcomes%20of%20extrapulmonary%20tuberculosis%20in%20antiretroviral%20therapy%20programmes%20in%20low-%20and%20middle-income%20countries%3A%20a%20multicohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kathrin%22%2C%22lastName%22%3A%22Z%5Cu00fcrcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sasisopin%22%2C%22lastName%22%3A%22Kiertiburanakul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Chenal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denna%22%2C%22lastName%22%3A%22Michael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kapella%20M.%22%2C%22lastName%22%3A%22Ngonyani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20M.%22%2C%22lastName%22%3A%22Mandalakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20C.%22%2C%22lastName%22%3A%22Pettit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Fenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Extrapulmonary%20tuberculosis%20%28EPTB%29%20is%20difficult%20to%20confirm%20bacteriologically%20and%20requires%20specific%20diagnostic%20capacities.%20Diagnosis%20can%20be%20especially%20challenging%20in%20under-resourced%20settings.%20We%20studied%20diagnostic%20modalities%20and%20clinical%20outcomes%20of%20EPTB%20compared%20to%20pulmonary%20tuberculosis%20%28PTB%29%20among%20HIV-positive%20adults%20in%20antiretroviral%20therapy%20%28ART%29%20programmes%20in%20low-%20and%20middle-income%20countries%20%28LMIC%29.%5CnMETHODS%3A%20We%20collected%20data%20from%20HIV-positive%20TB%20patients%20%28%5Cu226516%5Cu00a0years%29%20in%2022%20ART%20programmes%20participating%20in%20the%20International%20Epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%20in%20sub-Saharan%20Africa%2C%20Asia-Pacific%2C%20and%20Caribbean%2C%20Central%20and%20South%20America%20regions%20between%202012%20and%202014.%20We%20categorized%20TB%20as%20PTB%20or%20EPTB%20%28EPTB%20included%20mixed%20PTB%5C%2FEPTB%29.%20We%20used%20multivariable%20logistic%20regression%20to%20assess%20associations%20with%20clinical%20outcomes.%5CnRESULTS%20AND%20DISCUSSION%3A%20We%20analysed%202695%20HIV-positive%20TB%20patients.%20Median%20age%20was%2036%5Cu00a0years%20%28interquartile%20range%20%28IQR%29%2030%20to%2043%29%2C%201102%20were%20female%20%2841%25%29%2C%20and%20the%20median%20CD4%20count%20at%20TB%20treatment%20start%20was%20114%20cells%5C%2F%5Cu03bcL%20%28IQR%2040%20to%20248%29.%20Overall%2C%201930%20had%20PTB%20%2872%25%29%2C%20and%20765%20EPTB%20%2828%25%29.%20Among%20EPTB%20patients%2C%20the%20most%20frequently%20involved%20sites%20were%20the%20lymph%20nodes%20%2824%25%29%2C%20pleura%20%2815%25%29%2C%20abdomen%20%2811%25%29%20and%20meninges%20%286%25%29.%20The%20majority%20of%20PTB%20%281123%20of%201930%2C%2058%25%29%20and%20EPTB%20%28582%20of%20765%2C%2076%25%29%20patients%20were%20diagnosed%20based%20on%20clinical%20criteria.%20Bacteriological%20confirmation%20%28using%20positive%20smear%20microscopy%2C%20culture%2C%20Xpert%20MTB%5C%2FRIF%2C%20or%20other%20nucleic%20acid%20amplification%20tests%20result%29%20was%20obtained%20in%20897%20of%201557%20PTB%20%2852%25%29%20and%20183%20of%20438%20EPTB%20%2842%25%29%20patients.%20EPTB%20was%20not%20associated%20with%20higher%20mortality%20compared%20to%20PTB%20%28adjusted%20odd%20ratio%20%28aOR%29%201.0%2C%2095%25%20CI%200.8%20to%201.3%29%2C%20but%20TB%20meningitis%20was%20%28aOR%201.9%2C%2095%25%20CI%201.0%20to%203.1%29.%20Bacteriological%20confirmation%20was%20associated%20with%20reduced%20mortality%20among%20PTB%20patients%20%28aOR%200.7%2C%2095%25%20CI%200.6%20to%200.8%29%20and%20EPTB%20patients%20%28aOR%200.3%2095%25%20CI%200.1%20to%200.8%29%20compared%20to%20TB%20patients%20with%20a%20negative%20test%20result.%5CnCONCLUSIONS%3A%20Diagnosis%20of%20EPTB%20and%20PTB%20at%20ART%20programmes%20in%20LMIC%20was%20mainly%20based%20on%20clinical%20criteria.%20Greater%20availability%20and%20usage%20of%20TB%20diagnostic%20tests%20would%20improve%20the%20diagnosis%20and%20clinical%20outcomes%20of%20both%20EPTB%20and%20PTB.%22%2C%22date%22%3A%2209%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25392%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231507083%22%2C%22PMCID%22%3A%22PMC6737289%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A07%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22G5KI737Z%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Cubillos-Angulo%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCubillos-Angulo%20JM%2C%20Arriaga%20MB%2C%20Silva%20EC%2C%20M%26%23xFC%3Bller%20BLA%2C%20Ramalho%20DMP%2C%20Fukutani%20KF%2C%20et%20al.%20Polymorphisms%20in%20TLR4%20and%20TNFA%20and%20Risk%20of%20Mycobacterium%20tuberculosis%20Infection%20and%20Development%20of%20Active%20Disease%20in%20Contacts%20of%20Tuberculosis%20Cases%20in%20Brazil%3A%20A%20Prospective%20Cohort%20Study.%20Clin%20Infect%20Dis.%202019%2030%3B69%286%29%3A1027%26%23×2013%3B35.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciy1001%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciy1001%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030481307%3B%20PubMed%20Central%20PMCID%3A%20PMC6735688.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Polymorphisms%20in%20TLR4%20and%20TNFA%20and%20Risk%20of%20Mycobacterium%20tuberculosis%20Infection%20and%20Development%20of%20Active%20Disease%20in%20Contacts%20of%20Tuberculosis%20Cases%20in%20Brazil%3A%20A%20Prospective%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Manuel%22%2C%22lastName%22%3A%22Cubillos-Angulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mar%5Cu00eda%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elis%5Cu00e2ngela%20C.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%20L.%20A.%22%2C%22lastName%22%3A%22M%5Cu00fcller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%20P.%22%2C%22lastName%22%3A%22Ramalho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pryscila%20F.%20C.%22%2C%22lastName%22%3A%22Miranda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%20S.%20R.%22%2C%22lastName%22%3A%22Moreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Ruffino-Netto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20R.%22%2C%22lastName%22%3A%22Lapa%20E%20Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Afr%5Cu00e2nio%20L.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martha%20M.%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20role%20of%20genetic%20polymorphisms%20in%20latent%20tuberculosis%20%28TB%29%20infection%20and%20progression%20to%20active%20TB%20is%20not%20fully%20understood.%5CnMETHODS%3A%20We%20tested%20the%20single-nucleotide%20polymorphisms%20%28SNPs%29%20rs5743708%20%28TLR2%29%2C%20rs4986791%20%28TLR4%29%2C%20rs361525%20%28TNFA%29%2C%20rs2430561%20%28IFNG%29%20rs1143627%20%28IL1B%29%20as%20risk%20factors%20for%20tuberculin%20skin%20test%20%28TST%29%20conversion%20or%20development%20of%20active%20TB%20in%20contacts%20of%20active%20TB%20cases.%20Contacts%20of%20microbiologically%20confirmed%20pulmonary%20TB%20cases%20were%20initially%20screened%20for%20longitudinal%20evaluation%20up%20to%2024%20months%2C%20with%20clinical%20examination%20and%20serial%20TST%2C%20between%201998%20and%202004%20at%20a%20referral%20center%20in%20Brazil.%20Data%20and%20biospecimens%20were%20collected%20from%20526%20individuals%20who%20were%20contacts%20of%20177%20active%20TB%20index%20cases.%20TST%20conversion%20was%20defined%20as%20induration%20%5Cu22655%20mm%20after%20a%20negative%20TST%20result%20%280%20mm%29%20at%20baseline%20or%20month%204%20visit.%20Independent%20associations%20were%20tested%20using%20logistic%20regression%20models.%5CnRESULTS%3A%20Among%20the%20526%20contacts%2C%2060%20had%20TST%20conversion%20and%2044%20developed%20active%20TB%20during%20follow-up.%20Multivariable%20regression%20analysis%20demonstrated%20that%20male%20sex%20%28odds%20ratio%20%5BOR%5D%3A%202.3%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%201.1-4.6%29%2C%20as%20well%20as%20SNPs%20in%20TLR4%20genes%20%28OR%3A%2062.8%2C%2095%25%20CI%3A%207.5-525.3%29%20and%20TNFA%20%28OR%3A%204.2%2C%2095%25%20CI%3A%201.9-9.5%29%20were%20independently%20associated%20with%20TST%20conversion.%20Moreover%2C%20a%20positive%20TST%20at%20baseline%20%28OR%3A%204.7%2C%2095%25%20CI%3A%202.3-9.7%29%20and%20SNPs%20in%20TLR4%20%28OR%3A%206.5%2C%2095%25%20CI%3A%201.1-36.7%29%20and%20TNFA%20%28OR%3A%2012.4%2C%2095%25%20CI%3A5.1-30.1%29%20were%20independently%20associated%20with%20incident%20TB.%5CnCONCLUSIONS%3A%20SNPs%20in%20TLR4%20and%20TNFA%20predicted%20both%20TST%20conversion%20and%20active%20TB%20among%20contacts%20of%20TB%20cases%20in%20Brazil.%22%2C%22date%22%3A%2208%2030%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciy1001%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230481307%22%2C%22PMCID%22%3A%22PMC6735688%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A13%3A56Z%22%7D%7D%2C%7B%22key%22%3A%2292KWTWTE%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Brazier%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BBrazier%20E%2C%20Maruri%20F%2C%20Duda%20SN%2C%20Tymejczyk%20O%2C%20Wester%20CW%2C%20Somi%20G%2C%20et%20al.%20Implementation%20of%20%26%23x201C%3BTreat-all%26%23x201D%3B%20at%20adult%20HIV%20care%20and%20treatment%20sites%20in%20the%20Global%20IeDEA%20Consortium%3A%20results%20from%20the%20Site%20Assessment%20Survey.%20J%20Int%20AIDS%20Soc.%202019%3B22%287%29%3Ae25331.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25331%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25331%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031623428%3B%20PubMed%20Central%20PMCID%3A%20PMC6625339.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Implementation%20of%20%5C%22Treat-all%5C%22%20at%20adult%20HIV%20care%20and%20treatment%20sites%20in%20the%20Global%20IeDEA%20Consortium%3A%20results%20from%20the%20Site%20Assessment%20Survey%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fernanda%22%2C%22lastName%22%3A%22Maruri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephany%20N.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Tymejczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20William%22%2C%22lastName%22%3A%22Wester%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Somi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Ross%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aimee%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morna%22%2C%22lastName%22%3A%22Cornell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armel%22%2C%22lastName%22%3A%22Poda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beverly%20S.%22%2C%22lastName%22%3A%22Musick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fujie%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keri%20N.%22%2C%22lastName%22%3A%22Althoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catrina%22%2C%22lastName%22%3A%22Mugglin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22April%20D.%22%2C%22lastName%22%3A%22Kimmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Since%202015%2C%20the%20World%20Health%20Organization%20%28WHO%29%20has%20recommended%20that%20all%20people%20living%20with%20HIV%20%28PLHIV%29%20initiate%20antiretroviral%20treatment%20%28ART%29%2C%20irrespective%20of%20CD4%2B%20count%20or%20clinical%20stage.%20National%20adoption%20of%20universal%20treatment%20has%20accelerated%20since%20WHO%26%23039%3Bs%202015%20%26quot%3BTreat%20All%26quot%3B%20recommendation%3B%20however%2C%20little%20is%20known%20about%20the%20translation%20of%20this%20guidance%20into%20practice.%20This%20study%20aimed%20to%20assess%20the%20status%20of%20Treat%20All%20implementation%20across%20regions%2C%20countries%2C%20and%20levels%20of%20the%20health%20care%20delivery%20system.%5CnMETHODS%3A%20Between%20June%20and%20December%202017%2C%20201%5C%2F221%20%2891%25%29%20adult%20HIV%20treatment%20sites%20that%20participate%20in%20the%20global%20IeDEA%20research%20consortium%20completed%20a%20survey%20on%20capacity%20and%20practices%20related%20to%20HIV%20care.%20Located%20in%2041%20countries%20across%20seven%20geographic%20regions%2C%20sites%20provided%20information%20on%20the%20status%20and%20timing%20of%20site-level%20introduction%20of%20Treat%20All%2C%20as%20well%20as%20site-level%20practices%20related%20to%20ART%20initiation.%5CnRESULTS%3A%20Almost%20all%20sites%20%2893%25%29%20reported%20that%20they%20had%20begun%20implementing%20Treat%20All%2C%20and%20there%20were%20no%20statistically%20significant%20differences%20in%20site-level%20Treat%20All%20introduction%20by%20health%20facility%20type%2C%20urban%5C%2Frural%20location%2C%20sector%20%28public%5C%2Fprivate%29%20or%20country%20income%20level.%20The%20median%20time%20between%20national%20policy%20adoption%20and%20site-level%20introduction%20was%20one%20month.%20In%20countries%20where%20Treat%20All%20was%20not%20yet%20adopted%20in%20national%20guidelines%2C%2069%25%20of%20sites%20reported%20initiating%20all%20patients%20on%20ART%2C%20regardless%20of%20clinical%20criteria%2C%20and%20these%20sites%20had%20been%20implementing%20Treat%20All%20for%20a%20median%20period%20of%20seven%20months%20at%20the%20time%20of%20the%20survey.%20The%20majority%20of%20sites%20%2877%25%29%20reported%20typically%20initiating%20patients%20on%20ART%20within%2014%5Cu00a0days%20of%20confirming%20diagnosis%2C%20with%2060%25%20to%2062%25%20of%20sites%20implementing%20Treat%20All%20in%20East%2C%20Southern%20and%20West%20Africa%20reporting%20same-day%20ART%20initiation%20for%20most%20patients.%5CnCONCLUSIONS%3A%20By%20mid-%20to%20late-2017%2C%20the%20Treat%20All%20strategy%20was%20the%20standard%20of%20care%20at%20almost%20all%20IeDEA%20sites%2C%20including%20rural%2C%20primary-level%20health%20facilities%20in%20low-resource%20settings.%20While%20further%20assessments%20of%20site-level%20capacity%20to%20provide%20high-quality%20HIV%20care%20under%20Treat%20All%20and%20to%20support%20sustained%20viral%20suppression%20after%20ART%20initiation%20are%20needed%2C%20the%20widespread%20introduction%20of%20Treat%20All%20at%20the%20service%20delivery%20level%20is%20a%20critical%20step%20towards%20global%20targets%20for%20ending%20the%20HIV%20epidemic%20as%20a%20public%20health%20threat.%22%2C%22date%22%3A%2207%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25331%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231623428%22%2C%22PMCID%22%3A%22PMC6625339%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A07%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22G764QWME%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Tymejczyk%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BTymejczyk%20O%2C%20Brazier%20E%2C%20Yiannoutsos%20CT%2C%20Vinikoor%20M%2C%20van%20Lettow%20M%2C%20Nalugoda%20F%2C%20et%20al.%20Changes%20in%20rapid%20HIV%20treatment%20initiation%20after%20national%20%26%23x201C%3Btreat%20all%26%23x201D%3B%20policy%20adoption%20in%206%20sub-Saharan%20African%20countries%3A%20Regression%20discontinuity%20analysis.%20PLoS%20Med.%202019%3B16%286%29%3Ae1002822.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1002822%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pmed.1002822%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031181056%3B%20PubMed%20Central%20PMCID%3A%20PMC6557472.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Changes%20in%20rapid%20HIV%20treatment%20initiation%20after%20national%20%5C%22treat%20all%5C%22%20policy%20adoption%20in%206%20sub-Saharan%20African%20countries%3A%20Regression%20discontinuity%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Tymejczyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellen%22%2C%22lastName%22%3A%22Brazier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Constantin%20T.%22%2C%22lastName%22%3A%22Yiannoutsos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Vinikoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monique%22%2C%22lastName%22%3A%22van%20Lettow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fred%22%2C%22lastName%22%3A%22Nalugoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Urassa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20d%27Amour%22%2C%22lastName%22%3A%22Sinayobye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20F.%22%2C%22lastName%22%3A%22Rebeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kara%22%2C%22lastName%22%3A%22Wools-Kaloustian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary-Ann%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Zaniewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nanina%22%2C%22lastName%22%3A%22Anderegg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grace%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathan%22%2C%22lastName%22%3A%22Ford%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Nash%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22IeDEA%20consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Most%20countries%20have%20formally%20adopted%20the%20World%20Health%20Organization%26%23039%3Bs%202015%20recommendation%20of%20universal%20HIV%20treatment%20%28%26quot%3Btreat%20all%26quot%3B%29.%20However%2C%20there%20are%20few%20rigorous%20assessments%20of%20the%20real-world%20impact%20of%20treat%20all%20policies%20on%20antiretroviral%20treatment%20%28ART%29%20uptake%20across%20different%20contexts.%5CnMETHODS%20AND%20FINDINGS%3A%20We%20used%20longitudinal%20data%20for%20814%2C603%20patients%20enrolling%20in%20HIV%20care%20between%201%20January%202004%20and%2010%20July%202018%20in%206%20countries%20participating%20in%20the%20global%20International%20epidemiology%20Databases%20to%20Evaluate%20AIDS%20%28IeDEA%29%20consortium%3A%20Burundi%20%28N%20%3D%2011%2C176%29%2C%20Kenya%20%28N%20%3D%20179%2C941%29%2C%20Malawi%20%28N%20%3D%2084%2C558%29%2C%20Rwanda%20%28N%20%3D%2017%2C396%29%2C%20Uganda%20%28N%20%3D%2096%2C286%29%2C%20and%20Zambia%20%28N%20%3D%20425%2C246%29.%20Using%20a%20quasi-experimental%20regression%20discontinuity%20design%2C%20we%20assessed%20the%20change%20in%20the%20proportion%20initiating%20ART%20within%2030%20days%20of%20enrollment%20in%20HIV%20care%20%28rapid%20ART%20initiation%29%20after%20country-level%20adoption%20of%20the%20treat%20all%20policy.%20A%20modified%20Poisson%20model%20was%20used%20to%20identify%20factors%20associated%20with%20failure%20to%20initiate%20ART%20rapidly%20under%20treat%20all.%20In%20each%20of%20the%206%20countries%2C%20over%2060%25%20of%20included%20patients%20were%20female%2C%20and%20median%20age%20at%20enrollment%20ranged%20from%2032%20to%2036%20years.%20In%20all%20countries%20studied%2C%20national%20adoption%20of%20treat%20all%20was%20associated%20with%20large%20increases%20in%20rapid%20ART%20initiation.%20Significant%20increases%20in%20rapid%20ART%20initiation%20immediately%20after%20treat%20all%20policy%20adoption%20were%20observed%20in%20Rwanda%2C%20from%2044.4%25%20to%2078.9%25%20of%20patients%20%2834.5%20percentage%20points%20%5Bpp%5D%2C%2095%25%20CI%2027.2%20to%2041.7%3B%20p%20%26lt%3B%200.001%29%2C%20Kenya%20%2825.7%20pp%2C%2095%25%20CI%2021.8%20to%2029.5%3B%20p%20%26lt%3B%200.001%29%2C%20Burundi%20%2817.7%20pp%2C%2095%25%20CI%206.5%20to%2028.9%3B%20p%20%3D%200.002%29%2C%20and%20Malawi%20%2812.5%20pp%2C%2095%25%20CI%207.5%20to%2017.5%3B%20p%20%26lt%3B%200.001%29%2C%20while%20no%20immediate%20increase%20was%20observed%20in%20Zambia%20%280.4%20pp%2C%2095%25%20CI%20-2.9%20to%203.8%3B%20p%20%3D%200.804%29%20and%20Uganda%20%28-4.2%20pp%2C%2095%25%20CI%20-9.0%20to%200.7%3B%20p%20%3D%200.090%29.%20The%20rate%20of%20rapid%20ART%20initiation%20accelerated%20sharply%20following%20treat%20all%20policy%20adoption%20in%20Malawi%2C%20Uganda%2C%20and%20Zambia%3B%20slowed%20in%20Kenya%3B%20and%20did%20not%20change%20in%20Rwanda%20and%20Burundi.%20In%20post%20hoc%20analyses%20restricted%20to%20patients%20enrolling%20under%20treat%20all%2C%20young%20adults%20%2816-24%20years%29%20and%20men%20were%20at%20increased%20risk%20of%20not%20rapidly%20initiating%20ART%20%28compared%20to%20older%20patients%20and%20women%2C%20respectively%29.%20However%2C%20rapid%20ART%20initiation%20following%20enrollment%20increased%20for%20all%20groups%20as%20more%20time%20elapsed%20since%20treat%20all%20policy%20adoption.%20Study%20limitations%20include%20incomplete%20data%20on%20potential%20ART%20eligibility%20criteria%2C%20such%20as%20clinical%20status%2C%20pregnancy%2C%20and%20enrollment%20CD4%20count%2C%20which%20precluded%20the%20assessment%20of%20rapid%20ART%20initiation%20specifically%20among%20patients%20known%20to%20be%20eligible%20for%20ART%20before%20treat%20all.%5CnCONCLUSIONS%3A%20Our%20analysis%20indicates%20that%20adoption%20of%20treat%20all%20policies%20had%20a%20strong%20effect%20on%20increasing%20rates%20of%20rapid%20ART%20initiation%2C%20and%20that%20these%20increases%20followed%20different%20trajectories%20across%20the%206%20countries.%20Young%20adults%20and%20men%20still%20require%20additional%20attention%20to%20further%20improve%20rapid%20ART%20initiation.%22%2C%22date%22%3A%2206%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pmed.1002822%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231181056%22%2C%22PMCID%22%3A%22PMC6557472%22%2C%22ISSN%22%3A%221549-1676%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A06%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22KIA7K7CQ%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Oliveira-de-Souza%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BOliveira-de-Souza%20D%2C%20Vinhaes%20CL%2C%20Arriaga%20MB%2C%20Kumar%20NP%2C%20Cubillos-Angulo%20JM%2C%20Shi%20R%2C%20et%20al.%20Molecular%20degree%20of%20perturbation%20of%20plasma%20inflammatory%20markers%20associated%20with%20tuberculosis%20reveals%20distinct%20disease%20profiles%20between%20Indian%20and%20Chinese%20populations.%20Sci%20Rep.%202019%2029%3B9%281%29%3A8002.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-019-44513-8%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-019-44513-8%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2031142816%3B%20PubMed%20Central%20PMCID%3A%20PMC6541651.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20degree%20of%20perturbation%20of%20plasma%20inflammatory%20markers%20associated%20with%20tuberculosis%20reveals%20distinct%20disease%20profiles%20between%20Indian%20and%20Chinese%20populations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deivide%22%2C%22lastName%22%3A%22Oliveira-de-Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caian%20L.%22%2C%22lastName%22%3A%22Vinhaes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20B.%22%2C%22lastName%22%3A%22Arriaga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathella%20Pavan%22%2C%22lastName%22%3A%22Kumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20M.%22%2C%22lastName%22%3A%22Cubillos-Angulo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ruiru%22%2C%22lastName%22%3A%22Shi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wang%22%2C%22lastName%22%3A%22Wei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xing%22%2C%22lastName%22%3A%22Yuan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guolong%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ying%22%2C%22lastName%22%3A%22Cai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clifton%20E.%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20E.%22%2C%22lastName%22%3A%22Via%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alan%22%2C%22lastName%22%3A%22Sher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subash%22%2C%22lastName%22%3A%22Babu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katrin%20D.%22%2C%22lastName%22%3A%22Mayer-Barber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helder%20I.%22%2C%22lastName%22%3A%22Nakaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyoshi%20F.%22%2C%22lastName%22%3A%22Fukutani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%20B.%22%2C%22lastName%22%3A%22Andrade%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20a%20chronic%20inflammatory%20disease%20caused%20by%20Mycobacterium%20tuberculosis%20infection%20which%20causes%20tremendous%20morbidity%20and%20mortality%20worldwide.%20Clinical%20presentation%20of%20TB%20patients%20is%20very%20diverse%20and%20disease%20heterogeneity%20is%20associated%20with%20changes%20in%20biomarker%20signatures.%20Here%2C%20we%20compared%20at%20the%20molecular%20level%20the%20extent%20of%20individual%20inflammatory%20perturbation%20of%20plasma%20protein%20and%20lipid%20mediators%20associated%20with%20TB%20in%20patients%20in%20China%20versus%20India.%20We%20performed%20a%20cross-sectional%20study%20analyzing%20the%20overall%20degree%20of%20inflammatory%20perturbation%20in%20treatment-na%5Cu00efve%20pulmonary%20TB%20patients%20and%20uninfected%20individuals%20from%20India%20%28TB%3A%20n%5Cu2009%3D%5Cu200997%2C%20healthy%3A%20n%5Cu2009%3D%5Cu200920%29%20and%20China%20%28TB%3A%20n%5Cu2009%3D%5Cu2009100%2C%20healthy%3A%20n%5Cu2009%3D%5Cu200911%29.%20We%20employed%20the%20molecular%20degree%20of%20perturbation%20%28MDP%29%20adapted%20to%20plasma%20biomarkers%20to%20examine%20the%20overall%20changes%20in%20inflammation%20between%20these%20countries.%20M.%20tuberculosis%20infection%20caused%20a%20significant%20degree%20of%20molecular%20perturbation%20in%20patients%20from%20both%20countries%2C%20with%20higher%20perturbation%20detected%20in%20India.%20Interestingly%2C%20there%20were%20differences%20in%20biomarker%20perturbation%20patterns%20and%20the%20overall%20degree%20of%20inflammation.%20Patients%20with%20severe%20TB%20exhibited%20increased%20MDP%20values%20and%20Indian%20patients%20with%20this%20condition%20exhibited%20even%20higher%20degree%20of%20perturbation%20compared%20to%20Chinese%20patients.%20Network%20analyses%20identified%20IFN-%5Cu03b1%2C%20IFN-%5Cu03b2%2C%20IL-1RI%20and%20TNF-%5Cu03b1%20as%20combined%20biomarkers%20that%20account%20for%20the%20overall%20molecular%20perturbation%20in%20the%20entire%20study%20population.%20Our%20results%20delineate%20the%20magnitude%20of%20the%20systemic%20inflammatory%20perturbation%20in%20pulmonary%20TB%20and%20reveal%20qualitative%20changes%20in%20inflammatory%20profiles%20between%20two%20countries%20with%20high%20disease%20prevalence.%22%2C%22date%22%3A%2205%2029%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-019-44513-8%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2231142816%22%2C%22PMCID%22%3A%22PMC6541651%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A06%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22R6JTWXTG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Perez-Patrigeon%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BPerez-Patrigeon%20S%2C%20Camiro-Z%26%23xFA%3B%26%23xF1%3Biga%20A%2C%20Jaramillo-Jante%20MR%2C%20Belaunzar%26%23xE1%3Bn-Zamudio%20PF%2C%20Crabtree-Ram%26%23xED%3Brez%20B%2C%20Soto-Ram%26%23xED%3Brez%20LE%2C%20et%20al.%20Immediate%20treatment%20of%20acute%20HIV%20in%20a%20tertiary%20healthcare%20center%3A%20bridging%20gaps%20in%20communication%20using%20smartphones.%20HIV%20Med.%202019%3B20%285%29%3A308%26%23×2013%3B16.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.12713%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.12713%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030924588%3B%20PubMed%20Central%20PMCID%3A%20PMC6640641.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immediate%20treatment%20of%20acute%20HIV%20in%20a%20tertiary%20healthcare%20center%3A%20bridging%20gaps%20in%20communication%20using%20smartphones%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Perez-Patrigeon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Camiro-Z%5Cu00fa%5Cu00f1iga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20R.%22%2C%22lastName%22%3A%22Jaramillo-Jante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%20F.%22%2C%22lastName%22%3A%22Belaunzar%5Cu00e1n-Zamudio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20E.%22%2C%22lastName%22%3A%22Soto-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20J.%22%2C%22lastName%22%3A%22Calva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez-Le%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20L.%22%2C%22lastName%22%3A%22Mosqueda-G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Navarro-Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20G.%22%2C%22lastName%22%3A%22Sierra-Madero%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Early%20initiation%20of%20antiretroviral%20therapy%20%28ART%29%20during%20acute%20HIV%20infection%20is%20associated%20with%20favourable%20clinical%20and%20epidemiological%20outcomes.%20Barriers%20to%20prompt%20treatment%20initiation%20limit%20the%20benefits%20of%20universal%20access%20to%20ART%20in%20Mexico.%20We%20sought%20to%20create%20an%20algorithm%20for%20the%20immediate%20detection%20and%20treatment%20of%20patients%20with%20acute%20HIV%20infection.%5CnMETHODS%3A%20A%20nationwide%20cohort%20of%20patients%20with%20acute%20HIV%20infection%20was%20created%20in%202015.%20In%20order%20to%20identify%20cases%20and%20treat%20them%20promptly%20at%20our%20centre%2C%20an%20interdisciplinary%20group%20coordinated%20through%20an%20instant-messaging%20tool%20using%20smart%20phones%20was%20established.%20When%20a%20probable%20case%20was%20detected%2C%20a%20discussion%20was%20initiated%20to%20confirm%20the%20diagnosis%20and%20facilitate%20the%20administrative%20processes%20to%20initiate%20ART%20as%20soon%20as%20possible.%20We%20compared%20time%20to%20ART%20initiation%20with%20that%20in%20a%20comparison%20group%20of%20patients%20with%20chronic%20HIV%20infection%20enrolled%20during%20the%20same%20period%20%28May%202015%20to%20February%202017%29%20through%20routine%20care%2C%20using%20survival%20analysis%20estimators%20and%20log-rank%20tests.%5CnRESULTS%3A%20We%20recruited%2029%20patients%20with%20acute%20HIV%20infection.%20The%20median%20time%20to%20ART%20initiation%20was%202%5Cu00a0days%20in%20these%20patients%2C%20in%20contrast%20to%2021%5Cu00a0days%20for%20patients%20with%20chronic%20infection.%20There%20were%20no%20significant%20differences%20in%20the%20percentages%20of%20patients%20engaged%20in%20care%2C%20on%20treatment%20or%20virologically%20suppressed%20at%201%5Cu00a0year%20of%20follow-up.%5CnCONCLUSIONS%3A%20Implementing%20immediate%20ART%20initiation%20programmes%20is%20feasible%20in%20Mexico%2C%20in%20spite%20of%20the%20substantial%20administrative%20barriers%20that%20exist%20in%20the%20country.%20More%20extensive%20replication%20of%20this%20model%20in%20other%20centres%20and%20in%20patients%20with%20chronic%20infection%20is%20warranted%20to%20evaluate%20its%20effect%20on%20the%20continuum%20of%20care.%22%2C%22date%22%3A%2205%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fhiv.12713%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230924588%22%2C%22PMCID%22%3A%22PMC6640641%22%2C%22ISSN%22%3A%221468-1293%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A06%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22ZMB3V67B%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Gygli%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BGygli%20SM%2C%20Keller%20PM%2C%20Ballif%20M%2C%20Bl%26%23xF6%3Bchliger%20N%2C%20H%26%23xF6%3Bmke%20R%2C%20Reinhard%20M%2C%20et%20al.%20Whole-Genome%20Sequencing%20for%20Drug%20Resistance%20Profile%20Prediction%20in%20Mycobacterium%20tuberculosis.%20Antimicrob%20Agents%20Chemother.%202019%3B63%284%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.02175-18%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FAAC.02175-18%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030718257%3B%20PubMed%20Central%20PMCID%3A%20PMC6496161.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Whole-Genome%20Sequencing%20for%20Drug%20Resistance%20Profile%20Prediction%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20M.%22%2C%22lastName%22%3A%22Gygli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bl%5Cu00f6chliger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rico%22%2C%22lastName%22%3A%22H%5Cu00f6mke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miriam%22%2C%22lastName%22%3A%22Reinhard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Ritter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Sander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonia%22%2C%22lastName%22%3A%22Borrell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jimena%22%2C%22lastName%22%3A%22Collantes%20Loo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anchalee%22%2C%22lastName%22%3A%22Avihingsanon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joachim%22%2C%22lastName%22%3A%22Gnokoro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Yotebieng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Gagneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%5D%2C%22abstractNote%22%3A%22Whole-genome%20sequencing%20allows%20rapid%20detection%20of%20drug-resistant%20Mycobacterium%20tuberculosis%20isolates.%20However%2C%20the%20availability%20of%20high-quality%20data%20linking%20quantitative%20phenotypic%20drug%20susceptibility%20testing%20%28DST%29%20and%20genomic%20data%20have%20thus%20far%20been%20limited.%20We%20determined%20drug%20resistance%20profiles%20of%20176%20genetically%20diverse%20clinical%20M.%20tuberculosis%20isolates%20from%20the%20Democratic%20Republic%20of%20the%20Congo%2C%20Ivory%20Coast%2C%20Peru%2C%20Thailand%2C%20and%20Switzerland%20by%20quantitative%20phenotypic%20DST%20for%2011%20antituberculous%20drugs%20using%20the%20BD%20Bactec%20MGIT%20960%20system%20and%207H10%20agar%20dilution%20to%20generate%20a%20cross-validated%20phenotypic%20DST%20readout.%20We%20compared%20DST%20results%20with%20predicted%20drug%20resistance%20profiles%20inferred%20by%20whole-genome%20sequencing.%20Classification%20of%20strains%20by%20the%20two%20phenotypic%20DST%20methods%20into%20resistotype%5C%2Fwild-type%20populations%20was%20concordant%20in%2073%20to%2099%25%20of%20cases%2C%20depending%20on%20the%20drug.%20Our%20data%20suggest%20that%20the%20established%20critical%20concentration%20%285%5Cu2009mg%5C%2Fliter%29%20for%20ethambutol%20resistance%20%28MGIT%20960%20system%29%20is%20too%20high%20and%20misclassifies%20strains%20as%20susceptible%2C%20unlike%207H10%20agar%20dilution.%20Increased%20minimal%20inhibitory%20concentrations%20were%20explained%20by%20mutations%20identified%20by%20whole-genome%20sequencing.%20Using%20whole-genome%20sequences%2C%20we%20were%20able%20to%20predict%20quantitative%20drug%20resistance%20levels%20for%20the%20majority%20of%20drug%20resistance%20mutations.%20Predicting%20quantitative%20levels%20of%20drug%20resistance%20by%20whole-genome%20sequencing%20was%20partially%20limited%20due%20to%20incompletely%20understood%20drug%20resistance%20mechanisms.%20The%20overall%20sensitivity%20and%20specificity%20of%20whole-genome-based%20DST%20were%2086.8%25%20and%2094.5%25%2C%20respectively.%20Despite%20some%20limitations%2C%20whole-genome%20sequencing%20has%20the%20potential%20to%20infer%20resistance%20profiles%20without%20the%20need%20for%20time-consuming%20phenotypic%20methods.%22%2C%22date%22%3A%2204%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1128%5C%2FAAC.02175-18%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230718257%22%2C%22PMCID%22%3A%22PMC6496161%22%2C%22ISSN%22%3A%221098-6596%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A06%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22E884HPVF%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Crabtree-Ram%5Cu00edrez%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCrabtree-Ram%26%23xED%3Brez%20B%2C%20Jenkins%20C%2C%20Jayathilake%20K%2C%20Carriquiry%20G%2C%20Veloso%20V%2C%20Padgett%20D%2C%20et%20al.%20HIV-related%20tuberculosis%3A%20mortality%20risk%20in%20persons%20without%20vs.%20with%20culture-confirmed%20disease.%20Int%20J%20Tuberc%20Lung%20Dis.%202019%2001%3B23%283%29%3A306%26%23×2013%3B14.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0111%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0111%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030871661%3B%20PubMed%20Central%20PMCID%3A%20PMC6537600.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22HIV-related%20tuberculosis%3A%20mortality%20risk%20in%20persons%20without%20vs.%20with%20culture-confirmed%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Crabtree-Ram%5Cu00edrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Carriquiry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Padgett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Gotuzzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Cortes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Duda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20E.%22%2C%22lastName%22%3A%22Shepherd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tuberculosis%20%28TB%29%20diagnosis%20in%20human%20immunodeficiency%20virus%20%28HIV%29%20positive%20persons%20is%20difficult%2C%20particularly%20in%20resource-limited%20settings.%20The%20relationship%20between%20TB%20culture%20status%20and%20mortality%20in%20HIV-positive%20persons%20treated%20for%20TB%20is%20unclear.%5CnMETHODS%3A%20We%20evaluated%20HIV-positive%20adults%20treated%20for%20TB%20at%20or%20after%20their%20first%20HIV%20clinic%20visit%20in%20Argentina%2C%20Brazil%2C%20Chile%2C%20Honduras%2C%20Mexico%20or%20Peru%20from%202000%20to%202015.%20Anti-tuberculosis%20treatment%20included%202%20months%20of%20isoniazid%2C%20rifampicin%20%28RMP%29%5C%2Frifabutin%20%28RBT%29%2C%20pyrazinamide%20%5Cu00b1%20ethambutol%2C%20followed%20by%20continuation%20phase%20treatment%20with%20isoniazid%20%2B%20RMP%5C%2FRBT.%5CnRESULTS%3A%20Of%20759%20TB-HIV%20patients%2C%20238%20%2831%25%29%20were%20culture-negative%2C%20228%20%2830%25%29%20had%20unknown%20culture%20status%20or%20did%20not%20undergo%20culture%20and%20293%20%2839%25%29%20were%20culture-positive.%20The%20median%20CD4%20at%20TB%20diagnosis%20was%2096%20%28interquartile%20range%2040-228%29%3B%20636%20%2884%25%29%20received%20concurrent%20antiretroviral%20therapy%20%28ART%29%20and%20anti-tuberculosis%20treatment.%20There%20were%20123%20%2816%25%29%20deaths%3A%2090%5C%2F466%20%2819%25%29%20with%20TB%20culture-negative%2C%20unknown%20or%20not%20performed%20vs.%2033%5C%2F293%20%2811%25%29%20who%20were%20TB%20culture-positive%20%28P%20%3D%200.005%29.%20In%20Kaplan-Meier%20analysis%2C%20mortality%20in%20TB%20patients%20without%20culture-confirmed%20disease%20was%20higher%20%28P%20%3D%200.002%29.%20In%20a%20Cox%20model%20adjusted%20for%20age%2C%20sex%2C%20CD4%2C%20ART%20timing%2C%20disease%20site%20and%20stratified%20by%20study%20site%2C%20mortality%20in%20persons%20without%20culture-confirmed%20TB%20was%20not%20significantly%20increased%20compared%20to%20those%20with%20culture-positive%20TB%20%28hazard%20ratio%201.39%2C%2095%25CI%200.89-2.16%2C%20P%20%3D%200.15%29.%5CnCONCLUSION%3A%20Most%20HIV-positive%20patients%20treated%20for%20TB%20did%20not%20have%20culture-confirmed%20TB%2C%20and%20mortality%20tended%20to%20be%20higher%20in%20patients%20without%20culture-confirmed%20disease%2C%20although%20the%20association%20was%20not%20statistically%20different%20after%20adjusting%20for%20other%20variables.%20Accurate%20TB%20diagnosis%20in%20HIV-positive%20persons%20is%20crucial.%22%2C%22date%22%3A%2203%2001%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.18.0111%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230871661%22%2C%22PMCID%22%3A%22PMC6537600%22%2C%22ISSN%22%3A%221815-7920%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A05%3A55Z%22%7D%7D%2C%7B%22key%22%3A%229W7JF8IG%22%2C%22library%22%3A%7B%22id%22%3A76770%7D%2C%22meta%22%3A%7B%22lastModifiedByUser%22%3A%7B%22id%22%3A414120%2C%22username%22%3A%22sndu%22%2C%22name%22%3A%22Steph%22%2C%22links%22%3A%7B%22alternate%22%3A%7B%22href%22%3A%22https%3A%5C%2F%5C%2Fwww.zotero.org%5C%2Fsndu%22%2C%22type%22%3A%22text%5C%2Fhtml%22%7D%7D%7D%2C%22creatorSummary%22%3A%22Castilho%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%20style%3D%26quot%3Bclear%3A%20left%3B%20%26quot%3B%26gt%3B%5Cn%20%20%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-left-margin%26quot%3B%20style%3D%26quot%3Bfloat%3A%20left%3B%20padding-right%3A%200.5em%3B%20text-align%3A%20right%3B%20width%3A%201em%3B%26quot%3B%26gt%3B1.%26lt%3B%5C%2Fdiv%26gt%3B%26lt%3Bdiv%20class%3D%26quot%3Bcsl-right-inline%26quot%3B%20style%3D%26quot%3Bmargin%3A%200%20.4em%200%201.5em%3B%26quot%3B%26gt%3BCastilho%20JL%2C%20Escuder%20MM%2C%20Veloso%20V%2C%20Gomes%20JO%2C%20Jayathilake%20K%2C%20Ribeiro%20S%2C%20et%20al.%20Trends%20and%20predictors%20of%20non-communicable%20disease%20multimorbidity%20among%20adults%20living%20with%20HIV%20and%20receiving%20antiretroviral%20therapy%20in%20Brazil.%20J%20Int%20AIDS%20Soc.%202019%3B22%281%29%3Ae25233.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25233%26%23039%3B%26gt%3Bhttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjia2.25233%26lt%3B%5C%2Fa%26gt%3B%20PubMed%20PMID%3A%2030697950%3B%20PubMed%20Central%20PMCID%3A%20PMC6351749.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%20%20%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Trends%20and%20predictors%20of%20non-communicable%20disease%20multimorbidity%20among%20adults%20living%20with%20HIV%20and%20receiving%20antiretroviral%20therapy%20in%20Brazil%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%20L.%22%2C%22lastName%22%3A%22Castilho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20M.%22%2C%22lastName%22%3A%22Escuder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valdil%5Cu00e9a%22%2C%22lastName%22%3A%22Veloso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jackeline%20O.%22%2C%22lastName%22%3A%22Gomes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karu%22%2C%22lastName%22%3A%22Jayathilake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sayonara%22%2C%22lastName%22%3A%22Ribeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosa%20A.%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20L.%22%2C%22lastName%22%3A%22Ikeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paulo%20R.%22%2C%22lastName%22%3A%22de%20Alencastro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Unai%22%2C%22lastName%22%3A%22Tupinanbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Brites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20C.%22%2C%22lastName%22%3A%22McGowan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Grangeiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatriz%22%2C%22lastName%22%3A%22Grinsztejn%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20People%20living%20with%20HIV%20%28PLHIV%29%20on%20antiretroviral%20therapy%20%28ART%29%20experience%20high%20rates%20of%20non-communicable%20diseases%20%28NCDs%29.%20These%20co-morbidities%20often%20accumulate%20and%20older%20adults%20may%20suffer%20from%20multimorbidity.%20Multimorbidity%20has%20been%20associated%20with%20loss%20of%20quality%20of%20life%2C%20polypharmacy%2C%20and%20increased%20risk%20of%20frailty%20and%20mortality.%20Little%20is%20known%20of%20the%20trends%20or%20predictors%20NCD%20multimorbidity%20in%20PLHIV%20in%20low-%20and%20middle-income%20countries.%5CnMETHODS%3A%20We%20examined%20NCD%20multimorbidity%20in%20adult%20PLHIV%20initiating%20ART%20between%202003%20and%202014%20using%20a%20multi-site%2C%20observational%20cohort%20in%20Brazil.%20NCDs%20included%20cardiovascular%20artery%20disease%2C%20hyperlipidemia%20%28HLD%29%2C%20diabetes%2C%20chronic%20kidney%20disease%2C%20cirrhosis%2C%20osteoporosis%2C%20osteonecrosis%2C%20venous%20thromboembolism%20and%20non-AIDS-defining%20cancers.%20Multimorbidity%20was%20defined%20as%20the%20incident%20accumulation%20of%20two%20or%20more%20unique%20NCDs.%20We%20used%20Poisson%20regression%20to%20examine%20trends%20and%20Cox%20proportional%20hazard%20models%20to%20examine%20predictors%20of%20multimorbidity.%5CnRESULTS%3A%20Of%20the%206206%20adults%2C%20332%20%285%25%29%20developed%20multimorbidity%20during%20the%20study%20period.%20Parallel%20to%20the%20ageing%20of%20the%20cohort%2C%20the%20prevalence%20of%20multimorbidity%20rose%20from%203%25%20to%2011%25%20during%20the%20study%20period.%20Older%20age%2C%20female%20sex%20%28adjusted%20hazard%20ratio%20%28aHR%29%5Cu00a0%3D%5Cu00a01.30%20%2895%25%20confidence%20interval%20%28CI%29%201.03%20to%201.65%29%29%20and%20low%20CD4%20nadir%20%28%26lt%3B100%20vs.%20%5Cu2265200%5Cu00a0cells%5C%2Fmm3%20aHR%5Cu00a0%3D%5Cu00a01.52%20%2895%25%20CI%3A%201.15%20to%202.01%29%29%20at%20cohort%20entry%20were%20significantly%20associated%20with%20increased%20risk%20of%20multimorbidity.%20Among%20patients%20with%20incident%20multimorbidity%2C%20the%20most%20common%20NCDs%20were%20HLD%20and%20diabetes%3B%20however%2C%20osteoporosis%20was%20also%20frequent%20in%20women%20%2816%20vs.%2035%25%20of%20men%20and%20women%20with%20multimorbidity%20respectively%29.%5CnCONCLUSIONS%3A%20Among%20adult%20PLHIV%20in%20Brazil%2C%20NCD%20multimorbidity%20increased%20from%202003%20to%202014.%20Females%20and%20adults%20with%20low%20CD4%20nadir%20were%20at%20increased%20risk%20in%20adjusted%20analyses.%20Further%20studies%20examining%20prevention%2C%20screening%20and%20management%20of%20NCDs%20in%20PLHIV%20in%20low-%20and%20middle-income%20countries%20are%20needed.%22%2C%22date%22%3A%2201%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fjia2.25233%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%2230697950%22%2C%22PMCID%22%3A%22PMC6351749%22%2C%22ISSN%22%3A%221758-2652%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22IP6F4TRX%22%5D%2C%22dateModified%22%3A%222020-09-15T16%3A05%3A24Z%22%7D%7D%5D%7D
1.
Giganti MJ, Shepherd BE, Caro-Vega Y, Luz PM, Rebeiro PF, Maia M, et al. The impact of data quality and source data verification on epidemiologic inference: a practical application using HIV observational data. BMC Public Health. 2019 Dec 30;19(1):1748. http://doi.org/10.1186/s12889-019-8105-2 PubMed PMID: 31888571; PubMed Central PMCID: PMC6937856.
1.
Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-de-Souza D, et al. Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection. Clin Infect Dis. 2019 Oct 30. http://doi.org/10.1093/cid/ciz1070 PubMed PMID: 31665254.
1.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV. 2019 Feb;6(2):e105–15. http://doi.org/10.1016/S2352-3018(18)30319-9 PubMed PMID: 30723008; PubMed Central PMCID: PMC7093820.
1.
Pettit AC, Jenkins CA, Blevins Peratikos M, Yotebieng M, Diero L, Do CD, et al. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries. J Int AIDS Soc. 2019;22(12):e25423. http://doi.org/10.1002/jia2.25423 PubMed PMID: 31814312; PubMed Central PMCID: PMC6900483.
1.
Crabtree-Ramírez BE, Caro-Vega Y, Belaunzarán-Zamudio PF, Shepherd BE, Rebeiro PF, Veloso V, et al. Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study. J Int AIDS Soc. 2019;22(12):e25413. http://doi.org/10.1002/jia2.25413 PubMed PMID: 31855320; PubMed Central PMCID: PMC6922020.
1.
Stover J, Glaubius R, Mofenson L, Dugdale CM, Davies MA, Patten G, et al. Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. AIDS. 2019 15;33 Suppl 3:S227–34. http://doi.org/10.1097/QAD.0000000000002357 PubMed PMID: 31805028; PubMed Central PMCID: PMC6919230.
1.
Johnson LF, Anderegg N, Zaniewski E, Eaton JW, Rebeiro PF, Carriquiry G, et al. Global variations in mortality in adults after initiating antiretroviral treatment: an updated analysis of the International epidemiology Databases to Evaluate AIDS cohort collaboration. AIDS. 2019 15;33 Suppl 3:S283–94. http://doi.org/10.1097/QAD.0000000000002358 PubMed PMID: 31800405; PubMed Central PMCID: PMC6919233.
1.
Jesson J, Schomaker M, Malasteste K, Wati DK, Kariminia A, Sylla M, et al. Stunting and growth velocity of adolescents with perinatally acquired HIV: differential evolution for males and females. A multiregional analysis from the IeDEA global paediatric collaboration. J Int AIDS Soc. 2019;22(11):e25412. http://doi.org/10.1002/jia2.25412 PubMed PMID: 31702088; PubMed Central PMCID: PMC6839428.
1.
Vinhaes CL, Oliveira-de-Souza D, Silveira-Mattos PS, Nogueira B, Shi R, Wei W, et al. Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study. Cytokine. 2019;123:154759. http://doi.org/10.1016/j.cyto.2019.154759 PubMed PMID: 31226436; PubMed Central PMCID: PMC6739167.
1.
Rivera VR, Lu L, Ocheretina O, Jean Juste MA, Julma P, Archange D, et al. Diagnostic yield of active case finding for tuberculosis at human immunodeficiency virus testing in Haiti. Int J Tuberc Lung Dis. 2019 01;23(11):1217–22. http://doi.org/10.5588/ijtld.18.0835 PubMed PMID: 31718759.
1.
Zürcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, Grinsztejn B, et al. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. J Int AIDS Soc. 2019;22(9):e25392. http://doi.org/10.1002/jia2.25392 PubMed PMID: 31507083; PubMed Central PMCID: PMC6737289.
1.
Cubillos-Angulo JM, Arriaga MB, Silva EC, Müller BLA, Ramalho DMP, Fukutani KF, et al. Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. Clin Infect Dis. 2019 30;69(6):1027–35. http://doi.org/10.1093/cid/ciy1001 PubMed PMID: 30481307; PubMed Central PMCID: PMC6735688.
1.
Brazier E, Maruri F, Duda SN, Tymejczyk O, Wester CW, Somi G, et al. Implementation of “Treat-all” at adult HIV care and treatment sites in the Global IeDEA Consortium: results from the Site Assessment Survey. J Int AIDS Soc. 2019;22(7):e25331. http://doi.org/10.1002/jia2.25331 PubMed PMID: 31623428; PubMed Central PMCID: PMC6625339.
1.
Tymejczyk O, Brazier E, Yiannoutsos CT, Vinikoor M, van Lettow M, Nalugoda F, et al. Changes in rapid HIV treatment initiation after national “treat all” policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Med. 2019;16(6):e1002822. http://doi.org/10.1371/journal.pmed.1002822 PubMed PMID: 31181056; PubMed Central PMCID: PMC6557472.
1.
Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Cubillos-Angulo JM, Shi R, et al. Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations. Sci Rep. 2019 29;9(1):8002. http://doi.org/10.1038/s41598-019-44513-8 PubMed PMID: 31142816; PubMed Central PMCID: PMC6541651.
1.
Perez-Patrigeon S, Camiro-Zúñiga A, Jaramillo-Jante MR, Belaunzarán-Zamudio PF, Crabtree-Ramírez B, Soto-Ramírez LE, et al. Immediate treatment of acute HIV in a tertiary healthcare center: bridging gaps in communication using smartphones. HIV Med. 2019;20(5):308–16. http://doi.org/10.1111/hiv.12713 PubMed PMID: 30924588; PubMed Central PMCID: PMC6640641.
1.
Gygli SM, Keller PM, Ballif M, Blöchliger N, Hömke R, Reinhard M, et al. Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2019;63(4). http://doi.org/10.1128/AAC.02175-18 PubMed PMID: 30718257; PubMed Central PMCID: PMC6496161.
1.
Crabtree-Ramírez B, Jenkins C, Jayathilake K, Carriquiry G, Veloso V, Padgett D, et al. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. Int J Tuberc Lung Dis. 2019 01;23(3):306–14. http://doi.org/10.5588/ijtld.18.0111 PubMed PMID: 30871661; PubMed Central PMCID: PMC6537600.
1.
Castilho JL, Escuder MM, Veloso V, Gomes JO, Jayathilake K, Ribeiro S, et al. Trends and predictors of non-communicable disease multimorbidity among adults living with HIV and receiving antiretroviral therapy in Brazil. J Int AIDS Soc. 2019;22(1):e25233. http://doi.org/10.1002/jia2.25233 PubMed PMID: 30697950; PubMed Central PMCID: PMC6351749.